<SEC-DOCUMENT>0000950170-24-033482.txt : 20240319
<SEC-HEADER>0000950170-24-033482.hdr.sgml : 20240319
<ACCEPTANCE-DATETIME>20240319161503
ACCESSION NUMBER:		0000950170-24-033482
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240319
DATE AS OF CHANGE:		20240319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		24763399

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>acet-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-19T15:33:34.1355+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:acet="http://www.adicetbio.com/20231231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_78e26d3a-28ba-443c-9f3a-713342ae37b0" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d">FY</ix:nonNumeric><ix:nonFraction id="F_b105355c-88f2-4bb0-9587-2ecb45059c3c" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="C_4e336b74-cdf0-4074-a710-6ea06894b567" unitRef="U_USDollarShare" decimals="INF">0</ix:nonFraction><ix:nonNumeric id="F_49ae315d-b10b-4413-bf96-d7282eb25f7e" name="dei:EntityCentralIndexKey" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d">0001720580</ix:nonNumeric><ix:nonNumeric id="F_f30c709a-76e3-4145-b103-2ca8c4ebcfe6" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_bf683366-266e-49d4-80ac-b860fd1c30bd">2037-12-31</ix:nonNumeric><ix:nonNumeric id="F_1fe11b76-4e54-4945-809b-fff21b239652" name="dei:CurrentFiscalYearEndDate" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d">--12-31</ix:nonNumeric><ix:nonNumeric id="F_02c8489a-6506-4289-ab9f-6643a1cc30cf" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_861cf2db-c8b6-4b71-8308-dd9637a42ef6">2035-12-31</ix:nonNumeric><ix:nonNumeric id="F_af856426-4501-4430-80e2-08edda63f4be" name="dei:AmendmentFlag" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_8355ddf8-e507-406d-9614-b01702d73d24" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="C_25598d97-d78f-4397-9197-66cd5cdbf8ef" unitRef="U_USDollarShare" decimals="INF">0</ix:nonFraction><ix:nonFraction id="F_3f165358-ac84-4432-ab5b-1a2e7c4a487f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_6a2aed98-a0c1-4bfc-9ae8-b9b0b7443017" name="us-gaap:CommitmentsAndContingencies" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_15175557-fa82-4f42-8860-de5b090ee079" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric id="F_7c070633-44bd-4104-9d0e-d47392d30bc3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2" xsi:nil="true"></ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8c149222-bc5e-4c16-ad97-efbf7c1789f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36cb52c2-306e-4caa-b3ac-f865a14de66a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5962f55e-c424-4534-bcc2-208837c6f318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42ffbc28-8797-4c9a-88db-e5d89d2b4738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec965417-7244-4e77-bb2e-c305534384cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06b4ae69-f76e-476a-824f-b50f46053d25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e25f46c-a94c-4ebc-b2ae-28925638d603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_521621f6-cd1f-43e6-8b46-e9d3d9f8d92c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9348b37e-6b12-4d6f-ae6c-a16de43632b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c7df557-b405-497e-9c20-e9d91070c1c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e336b74-cdf0-4074-a710-6ea06894b567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9574821a-e3a7-4169-a889-41b0f5866c4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc080d41-4d34-4968-8ee6-17defa00e2d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:BlackScholesOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58d02c2b-7ab3-4be5-b6e6-472220ca82b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0fd947b-427a-49bf-b248-d4fd92ea0354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a623b912-7fdc-45eb-b768-963c9acc0e80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_347a9bbd-5136-4186-a21c-9d1306e004b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dce953e-d2b7-435c-8ac4-abae82da8350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_861cf2db-c8b6-4b71-8308-dd9637a42ef6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10c7a5a5-e785-4aa8-b13b-b70c7914a426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf683366-266e-49d4-80ac-b860fd1c30bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03b04d41-2a70-46cc-b31d-d9c911eb2cda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0c69718-cc5e-49e4-a0e8-bdc77ac5c987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_733a8089-51c5-4d2f-ba06-56a474b671db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5315a26-1d42-4c2a-88a8-f9074dbbcfc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebaf029a-2dfd-4e74-9c11-5aaa7f157e14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_567c498c-9118-465c-999b-374820f503df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc363f47-13e1-4ded-8501-89b95420f66d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d5312ec-a7ba-4ea9-806a-0f9c38c43ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b31a2fd-9ce2-44b0-ae61-2ba25f62ea40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3211074-499b-46e0-bac9-fdef2d5b6a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AdicetTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_241fa14f-5fcb-4423-8601-15153c2f69e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84848db9-118f-4390-b78f-e0b308c9a192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4e3d6b0-f801-44dd-b98a-08f6aee1758f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:InducementGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57f55a55-f9b7-41ed-98a9-192b9feeae13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f44dae87-630e-4f43-926e-3a7d2b0185c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3839044c-67c3-4761-9d07-88d8d945f812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46cd3449-6f00-448a-a65c-df577e2a664f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a819e95-0893-45bf-809c-89c052bcc2bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af2ebdd0-26c4-43a6-a4ca-3aa3d01aa585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50941431-c7dd-4f38-8678-4027d202f1e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f148e6a6-cf77-4216-bdf2-c79ea3d192a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7c9f079-510c-48e3-b00d-988277978714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2934718-edb2-47e5-ae88-69ff951335ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_941f1480-af5e-406b-8c0f-c6265ac70511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da045486-c2fe-4b90-ab00-21eab7441f0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af925b6c-d225-4763-b22a-b3974a3e23db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_120ea2d3-27e2-495d-b032-85ee8a4225d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e485415b-bfa6-4e68-b402-10c45a238a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cbd04fa-00ff-47cb-b761-f69bdbaecf25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0981498-005c-4ad0-9192-bd130ea10fe8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e885ea3-80a2-45de-abec-f29848bb6275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_869bf6a3-58bc-465a-b7da-4f80fdac6a75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_530cfa2e-3440-4246-a577-8979ecb76ea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e312fee1-4691-4e86-92c4-5ce4a346c5df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28bf845e-d84a-43e5-867a-584ae32a962a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe26f58a-9036-43d0-abc5-d86be0b9ef22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff7e4a68-2391-4c50-aaba-76ac9387247f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f218b6be-cd0a-49e1-8525-a5eb02ac8f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_311e49e6-e6fe-465d-83fb-e37ac0ea7ce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d264861-044d-454d-9a46-2ea594afdb73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-28</xbrli:startDate><xbrli:endDate>2022-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4019755-11ed-4ad5-8299-f0d1cfdef0eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_596f1ec4-c26f-47d8-873a-09b6b3910e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c4301bd-829f-4113-9dfb-fc7cb0d08261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1caa1e3e-b49b-4099-b413-9f91f7e43341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c123cd80-5380-4099-a3a4-c9250a72e19d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b4a7d79-358a-4bf6-8b1a-17f8afc3527a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-23</xbrli:startDate><xbrli:endDate>2024-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd112089-6f8c-421a-b580-9551aa752b5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40665ebd-fd67-4d04-97c7-45124e5c850b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91bff28d-648d-4207-9e94-2523616823eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcd33f2a-27fd-406a-827c-58b453fc673e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e7400b2-991e-4baa-bd6d-1b6d5cc20a11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:BlackScholesOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11fc1a2e-6bbc-4957-8f50-7b077832e3e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_747dc985-0918-4eea-aab1-03ff0d433f81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3230b6d3-1bf9-4181-a9f1-7031157a8914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac9c8951-310f-4055-8d6a-dd9b592bf973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f58078b6-76be-474e-a1ef-f5d1e47368bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7944d0b-f730-4427-b995-a253e5c8fac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd6622b0-707b-4b92-a039-abb383da1129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_301d7c2e-336e-4386-a679-d09592f8589f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_254f47ef-7aad-45a0-af9a-05ffb52efd9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_119167b2-4bd2-41bc-bc2b-7272a38298f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b748401-3bad-4b8b-a340-f66ff9129682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_916c0314-0614-4526-9283-d8a045dc95a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a65afde-d201-475c-b3b9-224c530f5ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d422142-c5e5-4b57-97a3-51fb1b8cf885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cecd4cc3-7caa-450f-a101-f3b58059d74a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:FederalAndStateResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dde8aec-c602-4c92-b003-83bf44a811d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25598d97-d78f-4397-9197-66cd5cdbf8ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edc6bfee-a0a7-4dbb-a2f0-2d9cb5654b09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e5442b4-b4a0-4661-aeb9-e32534abdac2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b17d8234-ba90-441b-b4a7-b13d05bda5b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84de4e02-9bcb-4587-b4c2-9ad91bf61ddc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14728681-e228-429d-9c6d-e288fc904418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10e00936-04f7-40bc-8922-30c108c241ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9b5d182-d438-4385-8651-fad8f690a69d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8e06b97-dcd0-4935-82a5-621e10a35a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54fb6a03-848a-42a9-a84c-0292032c99c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f239a655-77af-476f-8413-e0d33ef6a09e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_017e9e60-0f49-41f5-a465-41847cfbef4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ace4969-2a3a-4174-850a-95de252b6cec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1127a611-ccab-4753-9b4a-ad14202f612e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57732136-14ea-4518-80b2-de77d352b723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2ca41eb-0eab-49bb-971f-56952843d4a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_734eb96f-caad-4eb8-9771-349750199d0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4cf6be1-4f2c-4f83-bfd3-9d9edf02216a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbf4e63c-86b1-47fc-8dda-dad71e1a42cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dfe4ff4-baa6-4df7-adb9-4800a2eebae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f65238a-1a42-43ff-a87b-7cac1f995a5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_897945e8-d886-4a9a-afe5-8e849b01fa66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30421e9-e302-416b-8491-76859aa72b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d8568b6-257d-4933-9f8c-8954426bbed7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b3a4007-846a-4910-997b-c91ad41987d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20687195-6562-483c-b3ff-ff5be6c897ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a1f48c1-61ea-48ac-83cf-0496c0da44fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d1c290-a6a5-4ca0-a3ab-96d98d887372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d48a06f-dbae-4fc5-8ffb-b637076720b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_516b6271-7ed7-4039-97f5-4296694a6d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88454f42-8fdc-4021-91ce-b4d6b6330c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bbcb4a0-03ec-4fec-b751-f0405cc986d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Customer"><xbrli:measure>acet:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>acet:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f" fromRefs="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789 F_fad817cb-52dd-4a37-aa97-a437d3c1006a F_a4cf4f7d-863d-4f43-b627-e3f1271563ae F_162cb483-d00e-4d08-84e7-64fe8ccb19fc F_eb235763-2049-4536-89f0-a95a1e624a98 F_32cc67c2-c20b-4110-8ee5-573adde35339 F_66bfc669-7f11-4299-bdfe-2fa260b91fd3 F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b8155da4-ace1-4e3d-9591-49c7404454de" fromRefs="F_fad817cb-52dd-4a37-aa97-a437d3c1006a F_162cb483-d00e-4d08-84e7-64fe8ccb19fc F_32cc67c2-c20b-4110-8ee5-573adde35339 F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1" fromRefs="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789 F_a4cf4f7d-863d-4f43-b627-e3f1271563ae F_eb235763-2049-4536-89f0-a95a1e624a98 F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d612eae3-79b2-4c1e-bffb-1fef370f9dab" fromRefs="F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b52f8333-ac77-4d14-a73d-eda21bab3138" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_01f65c5d-2a08-4622-bd3a-4830f7d431c9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_237ec7de-955c-4e3b-904a-58f391d9d8df" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">December 31, </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85ced808-82c3-45f8-ae78-abf8dbd9ec63" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_fc6174bc-19f5-4396-94e4-1660c15c5604" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Commission File No. </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5487efb0-e011-4dfe-a731-92d399b589a1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_895f722b-a426-414d-b53e-281fc85757da" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"/>
    <td style="width:1%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_4370ed9a-8447-4403-8142-2026be019dea" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_1d279dfc-a083-47ec-96d2-257c22438ff7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c8097dd-1b13-4984-bdea-4e6b6155dd40" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">131 Dartmouth Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ff46ed4-4537-453e-89ac-d080a2b2fee2" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">3rd Floor</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06ee9583-5e64-47b7-85a4-d7f262e08d63" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a5e1c41-d8ec-4c7d-923b-446353b27acd" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">MA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2e8b506-fe70-4438-b7db-bd9d66208c00" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">02116</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bb7696a-e9d9-4e8e-bd0f-938c4bd7b19c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="font-size:7pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22fd7ddc-a223-47e2-97ce-7ce438cbd0fc" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> 503-9095</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"/>
    <td style="width:20%;"/>
    <td style="width:40%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_0fa302e5-e4d1-4a85-b711-f6b489c648de" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_f79caa2e-8782-4e69-8014-d05a2f6868bb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:middle;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7pt;"><ix:nonNumeric id="F_6abf3361-7415-481d-b9c1-8d10969bd5d4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    &#9744;  Yes    &#9746;  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f777f323-b717-4618-b14f-97c869220884" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    &#9744;  Yes    &#9746;  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd08f763-07dc-40a8-a1b9-6b1e120e377f" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    &#9746;  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34f4f070-4b65-42e3-9318-2b62a1879d16" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">    &#9744;   No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    &#9746;  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d4c1616-7a92-4e66-9379-2576438e83a7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">   &#9744;  No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.7%;"/>
    <td style="width:3.14%;"/>
    <td style="width:52.16%;"/>
    <td style="width:2.38%;"/>
    <td style="width:19.04%;"/>
    <td style="width:3.58%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ea21a242-d382-4052-9f27-6e8640851e69" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c293ff81-e895-45f1-831b-bcc2e75011d4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ef2c22f6-c502-4035-953a-d9c217b44dd9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a1d0098-bdb0-4eb4-a77a-d7006cfb6b21" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_998e3a19-8fb8-4880-bece-ff08b3f24ec5" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_469ca882-3f02-4a2f-8635-8b93ec42fc7d" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> Yes    &#9746; No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2023, the aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a11ddc0-4832-4843-aa6b-464274af95f5" contextRef="C_42ffbc28-8797-4c9a-88db-e5d89d2b4738" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million based on a closing price of $2.43 per share as quoted by The Nasdaq Global Market as of such date. In determining the market value of non-affiliate common stock, shares of the registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">March 14, 2024 there were </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c32cab7-4008-4ae6-90a2-8ad047812ef4" contextRef="C_28bf845e-d84a-43e5-867a-584ae32a962a" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">82,153,984</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> sha</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">res of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fbe7d63-cd48-4daa-9100-a687e3e8a302" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2024 annual meeting of shareholders, scheduled to be held on June 5, 2024, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We have a limited operating history and face significant challenges and expenses as we build our capabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on the success of ADI-001. If we are unable to obtain regulatory approval for ADI-001 in one or more indications and effectively commercialize ADI-001 for the treatment of patients in indications for which we receive approval (if any), our business would be significantly harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our gamma delta T cell candidates represent a novel approach to the treatment of autoimmune diseases and cancer indications that creates significant challenges for us.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of such product candidates and the time and cost of product candidate development and obtaining regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to file Investigational New Drug (IND) applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the U.S. Food and Drug Administration (FDA) may not permit us to proceed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We have not yet commenced manufacturing operations at our manufacturing facility and currently depend on the ability of our third-party suppliers and manufacturers with whom we contract to perform adequately, particularly with respect to the timely production and delivery of our product candidates, including ADI-001. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Global conflicts may increase the likelihood of supply interruptions which could impact our ability to find the materials we need to make our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Failure to achieve and maintain effective internal control over financial reporting could harm our business and negatively impact the value of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If our collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock is highly volatile, which could result in substantial losses for purchasers of our common stock. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;"/>
    <td style="width:1%;"/>
    <td style="width:82%;"/>
    <td style="width:1%;"/>
    <td style="width:6%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forwardlooking_st"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART I</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART II</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of <br/>Equity Securities</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[</span><a href="#item_6"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">]</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART III</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PART IV</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item16_updated"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_regarding_forwardlooking_st"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements include, among other things, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of and our ability to execute our clinical trials for ADI-001 in autoimmune indications and non-Hodgkin&#8217;s lymphoma (NHL), including the ability to successfully complete our Phase 1 clinical trial in NHL and initiate a Phase 1 clinical trial in lupus nephritis (LN) and additional potential autoimmune indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our additional internal gamma delta T cell therapy programs in preclinical development, including ADI-270, and our ability to develop other product candidates in our research pipeline;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the availability, timing and announcement of data from our Phase 1 clinical trials for ADI-001;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations for ADI-270 as a treatment for renal cell carcinoma (RCC) and other CD70+ solid tumor and hematological malignancies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) of a potential path to support Biologics License Application (BLA) and Marketing Authorization Application (MAA) for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the anticipated timing of our submission of Investigational New Drug (IND) applications or equivalent regulatory filings and initiation of future clinical trials, including the timing of the anticipated results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the impact of unstable market and economic conditions, including impacts of inflation and adverse developments affecting the financial services industry, on our business, results of operations or financial conditions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of acceptance and clinical utility of any products for which we receive regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the manufacturing of our product candidates and any products for which we receive regulatory approval by us or by our third-party suppliers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify additional product candidates with significant commercial potential;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to enter into collaborations for the development and commercialization of product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential benefits of any current and future collaboration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain the continued service of our key professionals and to identify, hire, and retain additional qualified professionals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations related to the use of cash and cash equivalents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain effective internal control over financial reporting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of government laws and regulations; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk Factors&#8221; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this Annual Report on Form 10-K, and we believe these industry publications and third-party research, surveys and studies are reliable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to &#8220;Adicet Bio,&#8221; &#8220;Adicet,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Adicet Bio, Inc. and its subsidiaries, as applicable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. We are advancing a pipeline of &#8220;off-the-shelf&#8221; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach to activate, engineer and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows us to generate new product candidates in a rapid and cost-efficient manner. Our allogeneic "off-the-shelf" manufacturing process is designed to allow product from unrelated donors to be stored and sold on demand to treat patients without inducing a graft versus host immune response. This is in contrast to products based on alpha beta T cells, which either must be manufactured for each patient from his or her own T cells, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Our pipeline also includes our lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Our pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors. We expect to continue to develop product candidates in autoimmune diseases and cancer based on our gamma delta T cell platform using either previously validated antigens or those that we identify and target using CAR and other technology. We plan to file one new Investigational New Drug (IND) application every 12-18 months, including an IND for ADI-270 in the first half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADI-001</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the U.S. Food and Drug Administration (FDA) cleared our IND application for ADI-001 in lupus nephritis, an autoimmune disease caused by systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of SLE which affects approximately 40% of the estimated 325,000 patients with SLE in the U.S. We expect to initiate a Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024 and expand development of the candidate into one to two additional autoimmune indications in the second and third quarters of 2024, subject to clearance of INDs in those indications. We believe the potential market opportunity for ADI-001 in B cell mediated autoimmune diseases is substantial based on the prevalence in the U.S., EU5, China and Japan of greater than 1.7 million patients with autoimmune diseases where CAR-T cell therapy has demonstrated clinical proof-of-concept, including SLE (which includes lupus nephritis), systemic sclerosis and idiopathic inflammatory myopathies.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate providing preliminary clinical data from our Phase 1 clinical trial of ADI-001 in lupus nephritis in the fourth quarter of 2024 or first quarter of 2025, subject to study site activation and enrollment, and to begin to provide preliminary clinical data in the additional autoimmune indications starting in the fourth quarter of 2024 or first half of 2025, subject to clearance of INDs in those indications as well as successful site initiation and patient enrollment in the relevant clinical protocols.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Relapsed or Refractory Aggressive B cell NHL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we initiated the first-in-human Phase 1 (GLEAN) trial to assess safety and efficacy of ADI-001 in patients with relapsed or refractory aggressive B cell NHL. The study includes a dose escalation portion followed by dose expansion cohorts to explore the activity of ADI-001 in multiple subtypes of NHL. In April 2022, the FDA granted fast track designation for ADI-001 for NHL. As of the May 4, 2023 cutoff date, of the 24 evaluable subjects in the GLEAN trial, 18 had large B cell lymphoma (LBCL), five had mantle cell lymphoma (MCL), and one patient had follicular lymphoma. Most patients were heavily pre-treated, with a median four lines of prior therapy, and twelve patients (50%) had previously</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">progressed following CAR T cell therapy. Despite the advanced nature of patients at baseline, we observed a high complete response (CR) rate and favorable durability in MCL patients. Across all doses of MCL patients, we observed an 80% (4/5 patients) overall response rate (ORR), an 80% CR rate (4/5 patients) and a 60% CR rate (3/5 patients) at six months. As of May 4, 2023, the safety profile of ADI-001 was generally favorable, with no significant risk of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or T cell malignancy observed. In November 2023, we initiated an expansion cohort, EXPAND, in post-CAR T LBCL. In January 2024, we announced our decision to deprioritize enrolling LBCL patients in the GLEAN trial in order to focus on advancing MCL enrollment.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to provide a clinical update from the Phase 1 study in NHL patients which will include efficacy data, including six-month CR rate, and safety data from additional MCL patients in the second half of 2024. Subject to clinical data and regulatory feedback, in the first half of 2025, we plan to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL and provide a further clinical update in the second half of 2025.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have expanded manufacturing capabilities of ADI-001 by transferring the manufacturing process to an additional contract development and manufacturing organization (CDMO) that is capable of operating at a larger scale of production.</span></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADI-270</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-270 is an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of renal cell carcinoma (RCC) and with potential in other solid tumor indications. ADI-270 is designed to home to solid tumors, with a highly specific targeting moiety for CD70 and an armoring technology of transforming growth factor (TGF) beta dominant-negative receptor to address immunosuppressive factors in the tumor microenvironment.  Building on gamma delta 1 tissue tropism to solid tumors and three mechanisms of anti-tumor activity (CAR, innate and adaptive), CAR gamma delta 1 T cells may be well positioned to address solid tumors. We plan to file an IND application for ADI-270 in RCC in the second quarter of 2024 and provide clinical data in the first half of 2025, subject to regulatory clearance and study initiation activities. We are also considering potential expansion into additional CD70+ tumor indications in the first half of 2025, with potential clinical data from such studies in the second half of 2025, subject to regulatory clearance and study initiation activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently developing a pipeline of allogeneic &#8220;off-the-shelf&#8221; gamma delta T cell therapies, using either previously validated antigens or those that we identify and target using our CAR and other technology. Our most advanced product candidate in development, ADI-001, is in an ongoing Phase 1 clinical trial for relapsed or refractory aggressive B NHL targeting B cell antigen CD20 and we expect to initiate a Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024. We are also developing a pipeline to advance the research and development of allogeneic CAR T cell product candidates in autoimmune diseases, hematological malignancies and solid tumor indications. We expect to continue to develop product candidates in autoimmune diseases and cancer based on our gamma delta T cell platform using either previously validated antigens or those that we identify and target using CAR and other technologies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pipeline is represented in the diagram below:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img104831930_0.jpg" alt="img104831930_0.jpg" style="width:681px;height:303px;"/>&#160;</p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">           * - Phase 3 may not be required if Phase 2 is registrational</span></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">           1 - Adicet is focused on advancing MCL enrollment in the GLEAN trial and has deprioritized  enrolling large B-cell lymphoma patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1. Company Pipeline</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our objective is to be the leading biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Key elements of our strategy include our plans to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to advance clinical development of ADI-001.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ADI-001, our lead  product candidate, is in Phase 1 clinical development for autoimmune diseases and relapsed or refractory B cell NHL. CD20 is a well validated target for immunotherapy for NHL and has emerged as an important target for autoimmune diseases. In December 2023, the FDA cleared our IND application for ADI-001 in lupus nephritis. We expect to initiate a Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024.  We expect to provide a clinical update from the Phase 1 study in NHL patients which will include efficacy data, including 6-month complete response rate, and safety data from additional MCL patients in the second half of 2024. Subject to clinical data and regulatory feedback, in the first half of 2025, we plan to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL and provide a further clinical update in the second half of 2025.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance ADI-270 into clinical development for renal cell carcinoma. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Building on gamma delta 1 tissue tropism to solid tumors and three mechanisms of anti-tumor activity (CAR, innate and adaptive), CAR gamma delta 1 T cells may be well positioned to address solid tumors. We expect to file an IND application for ADI-270 in the second quarter of 2024 and advance the product candidate into Phase 1 clinical development for the treatment of renal cell carcinoma.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continue to innovate and invest in the gamma delta T cell platform and pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We expect to continue to develop product candidates in autoimmune diseases and cancer based on the gamma delta T cell platform using either previously validated antigens or those that we identify and target.  We also expect to continue to develop product candidates in autoimmune diseases and cancer based on our allogeneic gamma delta T cell platform using CAR and other technologies. We may utilize genetic engineering, editing technologies or other technologies with the goal of further improving the activity and tolerability profile of our product candidates. A key strength of our gamma delta T cell therapy platform lies in our ability to target antigens of both known and unknown potential and devote our clinical development resources to those antigens that show the most promise in preclinical in vivo analyses and early human trials. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exploit the potential for outpatient administration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. While we expect that the initial subjects receiving our allogeneic gamma delta T cell-based therapies in clinical studies will be hospitalized for a minimum of 24-hours for observation after infusion, a favorable tolerability profile may allow administration of such investigational therapies </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in an outpatient setting. We believe this would represent a significant competitive advantage for our gamma delta T cell-based therapies as compared to existing approved CAR T-cell therapy or other therapies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand and protect our intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We will continue to aggressively protect the allogeneic gamma delta T cell production methodology we have developed as well as specific product candidates based on proprietary antigen-binding domains. For more information on our intellectual property, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; section of this Annual Report on Form 10-K.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Background</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Diseases and Relapsed or Refractory Aggressive B cell NHL</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAR T therapy, originally developed as a cancer treatment, has recently been the subject of increased interest for autoimmune diseases, due to its potential to remove disease causing immune cells with a single dose or treatment over a short period of time. Currently approved therapies for autoimmune indications treat only the symptoms with a chronic treatment regimen and are not considered curative. There are currently no FDA approved CAR T therapies for autoimmune indications. Initial support for and increased interest in the use of CAR T therapies for autoimmune indications was based on durable proof of concept data presented by Dr. Georg Schett at the American College of Rheumatology and the 2023 American Society of Hematology Meeting showing that CD19-targeted CAR T cells induced persistent, drug-free remission in three distinct autoantibody dependent autoimmune diseases with good tolerability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical data for ADI-001 in NHL have shown B cell depletion that mirrors the B cell depletion by autologous alpha beta CD19-targeted CAR T in academic clinical studies in systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathy patients.&#8239;Given that gamma delta 1 T cells preferentially traffic to organs and tissues, ADI-001 is designed to target and deplete B cells in the periphery, secondary lymphoid organs, kidneys and other organs, which is highly desirable in autoimmune diseases. We believe ADI-001's off-the-shelf availability and favorable safety profile in the cancer setting support the potential for outpatient administration.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Relapsed or Refractory Aggressive B cell NHL</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, immuno-oncology has advanced many therapies for cancer treatment. Immuno-oncology deploys the immune system to attack and, in some cases, to eliminate cancer. One of the key breakthroughs in immuno-oncology involved using T cells, a key element of the immune system, and turning them into even more potent, tumor-cell-specific killers. Researchers have achieved this improvement and targeting by loading the T cells with a gene encoding a CAR. These engineered receptors represent a powerful combination of, first, a region that binds to a target on a cancer cell and tethers the T cell to it; and second, a signal that activates the T cell to eliminate the tethered cancer cell. To our knowledge, all marketed CAR T cells contain predominantly alpha beta T cells. While we believe the use of CAR T-cell therapies is promising, conventional CAR T-cell therapies also have some key flaws that, we believe, can potentially be addressed by using a cell population, specifically, gamma delta T cells rather than alpha beta T cells.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Existing Approved CAR T Cell Therapies in Cancer</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, four CD19-targeting CAR T-cell therapies have been approved by the FDA for the treatment of B cell lymphomas: axicabtagene ciloleucel (Yescarta&#174;) and brexucabtagene autoleucel (Tecartus&#153;) developed by Kite Pharma, now Gilead Sciences, Inc. (Gilead); tisagenlecleucel (Kymriah&#174;), developed by Novartis; and lisocabtagene maraleucel (Breyanzi&#174;) developed by Juno Therapeutics, Inc. (now Bristol Myers Squibb Company). We believe that, despite their progress to date, currently available CAR T-cell therapies have not reached their full promise, and our allogeneic gamma delta CAR T-cell approach has the potential to be a significant improvement.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current generation of approved CAR T-cell therapies for B cell lymphomas represented by Yescarta&#174;, Tecartus&#153;, Breyanzi&#174;, and Kymriah&#174; are autologous cell therapies, that is, they are based on immune cells isolated from a patient, modified and expanded in a laboratory and then reintroduced into the same patient. One key reason for taking this autologous approach is that the cytotoxic, or, cell-killing, cells are predominantly alpha beta T cells that are used to generate these therapies and are cells that the immune system uses to recognize and attack foreign cells. If these types of T cells were to be introduced into a patient from an unrelated donor, the donor T cells would attack healthy tissues throughout the patient in a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">process known as graft versus host disease (GvHD) potentially causing multiple organ failure and death.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The T cells used for first-generation CAR T-cell therapies were derived from a highly abundant subclass of T cells known as alpha beta T cells. Alpha beta T cells, which comprise approximately 95% of the T cells in circulation in the body, are able to distinguish whether cells that they encounter are either normal cells that belong in the body or foreign or damaged cells that need to be destroyed. Alpha beta T cells have naturally occurring T cell receptors (TCRs) which is made up of alpha and beta protein chains. These TCRs recognize targets, also known as antigens, on cells that are presented by antigen-presenting molecules encoded by the major histocompatibility complex (MHC). The MHC contains genes that encode a number of proteins with multiple variants, such that most individuals have a distinct MHC profile. During normal T cell development, those T cells that recognize the combination of the specific MHC profile and antigens that are presented by healthy cells of the specific individual are eliminated, resulting in a population of T cells that circulate throughout the body, vigilantly checking for abnormal antigens or foreign cells, including from another individual.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In one type of cellular immunotherapy known as adoptive cell therapy, naturally occurring immune cells from a patient are isolated and are activated using cytokines and tumor-specific antigens to stimulate the growth and expansion of antitumor T cells that already exist at low abundance in the patient. After activation and expansion in the laboratory, large numbers of T cells that are primed to recognize the tumor are reintroduced into the same patient.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAR T-cell therapies are a variant of this adoptive cell therapy in which, instead of trying to activate T cells based on the ability of TCRs to recognize tumor antigens, a CAR designed to recognize a specific tumor antigen is genetically introduced into T cells. These CAR T cells are then able to destroy any cells expressing the appropriate antigen completely independent of MHC. However, without further genetic engineering, CAR T cells derived from alpha beta T cells still have endogenous TCRs which restrict their use to the original patient.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations of Autologous Cell Therapies</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Autologous cell therapies, such as those developed by Kite Pharma and Novartis, have a number of limitations, including but not limited to the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment delays imposed by individualized manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Due to the individualized manufacturing process, patients must wait up to three to four weeks for the individualized products to be manufactured and administered. In the registrational trials for Yescarta&#174; and Kymriah&#174;, up to 31% of intended patients ultimately did not receive treatment primarily due to complications from the underlying disease that occurred during manufacturing or due to manufacturing failures.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing variability and failure</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. It was reported by Novartis in 2018 that variability in product specifications had been observed in the production of Kymriah&#174;. In addition, in approximately 9% of the cases, no product could be shipped to patients at all due to out-of-specification issues or from manufacturing failures.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">High costs limit patient access</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The high cost of therapy and payer policies can limit access to autologous CAR T-cell therapies. According to a 2019 article published in the journal </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Managed Care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, treating physicians estimate that the costs of autologous CAR T-cell therapies combined with patient care services are approximately $1 million per patient, generating reluctance of payers to approve these therapies for patients before they have exhausted other options. These therapies are then relegated to the most heavily pretreated patients who may be unable to withstand the severe side effects.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scalability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because each patient requires a custom manufacturing batch, the production of autologous CAR T cells at the scale needed to meet commercial demand and anticipated label and geographic expansions may be challenging.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Autologous cell therapies, such as CAR T cells derived from alpha beta T cells, have been successful in their initial use in hematological malignancies. Furthermore, they have provided critical data that demonstrates the potential of immunocellular cancer therapies. However, manufacturing of these cells imposes some critical limitations that could be minimized if similar allogeneic cell therapies that can be given to any patient, regardless of the donor of cells, are developed. We believe that allogeneic cell therapies offer great promise for optimizing the access to therapy, overcoming manufacturing-related and cost-related limitations of autologous cell therapies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential Advantages of Gamma Delta T Cell-Based Therapies</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immunotherapies developed using gamma delta T cells have a number of potential or anticipated advantages over other therapies developed using other cell types, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exposure. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exposure, measured by Cmax, D28 persistence and AUC with ADI-001 is consistent with values reported for approved autologous CD19 CAR T. This property differentiates our CAR gamma-delta1 allogeneic T cell therapies from other allogeneic therapies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential for superior cytotoxic activity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. T cells from some patients, for example those with chronic lymphocytic leukemia, often display an exhausted, or otherwise dysfunctional, phenotype and CAR T-cell products from these cells may perform poorly. Our allogeneic cell therapy is manufactured from unrelated donors whose T cells have been shown to generate highly active CAR T-cells.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical B-cell depletion data from our ADI-001 in lymphoma, mirrors the B-cell depletion reported in academic studies by Shett et.al.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of autologous CD19 CAR-T in lupus patients who experienced robust efficacy associated with an immune reset of the B cell compartment. Similarly, in lymphoma patients, ADI-001 has demonstrated deep cytoreductive complete responses that surpass the depth of response demonstrated by autologous CAR T therapy in the same patient.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tissue and tumor localization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition to being present in the circulation at low frequency, gamma delta T cells have an inherent propensity to home to tissues and tumors. Their ability to be activated in tissue environments less perfused with oxygen, such as those found in the tumor microenvironment, has the potential to increase the activity of gamma delta T cells in solid tumors and in tissues. Similarly, this tissue homing may be ideally suited to deplete B-cell nests located in peripheral tissues including secondary lymphoid organs and kidneys associated with autoimmune disease, which may better enable an effective reset of the immune system.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MHC-independent antigen recognition for tissue homeostasis and tumor targeting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gamma delta TCR can recognize antigens associated with dysfunctional cells, associated with tumorigenic or dysregulated functions, in a MHC-independent manner. This further facilitates the use of products derived from donors who are unrelated to patients which may avoid the need to match the human leukocyte antigen (HLA)-type of the donor to the patient.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limited ability for antigen escape</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Although the initial responses to immunotherapies such as antibodies and CAR T cells are often impressive, many patients become refractory or relapse. A common mechanism for the relapse to these therapies is loss of the expression of the CAR-targeted antigen such as CD19 from target cells. Because gamma delta T cells also express innate cytotoxic immune receptors, they can recognize and kill dysfunctional cells even in the absence of the CAR-targeted tumor antigen.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ability to manufacture more efficiently and cost-effectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Unlike alpha beta T cells, therapies based on gamma delta T cells can potentially be manufactured in bulk and used in the allogeneic or "off-the-shelf" setting, addressing many of the shortcomings of conventional alpha beta T cell therapy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lack of GvHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> A body of published evidence, mainly in the field of </span><span style="color:#202124;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">haematopoietic stem cell transplantation</span><span style="color:#202124;white-space:pre-wrap;font-size:10pt;font-family:'Roboto',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (HSCT), supports the safety profile of transfer of allogeneic gamma delta T cells to patient recipients from unrelated donors. HSCT procedures containing significant numbers of gamma delta T cells were able to proceed with no signs of acute or chronic GvHD. In many cases, the presence of gamma delta T cells in the HSCT products correlated with improved clinical outcomes, indicating the antitumor potential of gamma delta T cells. Additionally, a study performed by Martin Wilhelm and colleagues in 2014 indicated that gamma delta T cells from haploidentical donors could be successfully expanded and infused in large numbers (2.17x10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cells / kg (range, 0.9-3.84)), followed by further expansion (mean, 68-fold) in the patients without any observed GvHD.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limited cytokine secretion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Unlike alpha beta T cells, gamma delta T cells can be made to secrete lower levels of certain cytokines such as interleukin 6 (IL-6). This, combined with lack of recognition of normal, non-malignant, cells by of gamma delta T cells, may lower the risk of life-threatening cytokine release syndrome.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential for re-dosing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Along with increased availability of material due to the ability to utilize "off-the-shelf" donor-derived starting material from unrelated donors compared to conventional CAR T-cell therapies, the lack of MHC-dependent GvHD also opens up the possibility of being able to re-dose patients to achieve further clinical activity if they do not obtain an adequate clinical response from initial treatment or if they relapse. A number of studies with other CAR T-cell therapies have linked the development of cytokine release syndrome with high numbers of circulating CAR T cells following rapid alpha beta T cell proliferation. Having the option to retreat patients with gamma delta T cells provides the option of starting with a low dose and re-dosing if required.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Safety Potential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ADI-001 has shown to be well tolerated with no significant CRS, ICANS and an inherently lower risk of T-cell malignancies compared to autologous CAR-Ts. This profile and ADI-001 off-the-shelf availability makes it suitable for the treatment of autoimmune diseases and provides the potential to those patients in the community setting.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Allogeneic Gamma Delta T Cell Technology</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human gamma delta T cells can be divided into three main subsets based on their TCR delta chain usage: V&#948;1, V&#948;2 and V&#948;3. The most abundant subset of gamma delta T cells in the circulatory system, the V&#948;2 cells, is also the most well-studied. However, it is the V&#948;1 subset which primarily resides in tissues and presents a favorable cytotoxic profile against target cells that we are activating and manufacturing using our proprietary platform technology.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">V</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#948;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1 Gamma Delta T Cells</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">V&#948;1 cells have properties of both the innate and adaptive immune system, meaning that they can be activated by tumor-specific antigens as well as by general activators common to damaged or otherwise abnormal cells. Similar to other T cells, they express TCRs, but also express cytotoxicity receptors that are found on innate immune cells such as natural killer (NK) cells. These gamma delta T cells can induce tumor cell death through multiple mechanisms including the secretion of cytotoxic proteins such as granzymes and perforin as well as through the secretion of cytokines such as interferon gamma (IFN&#947;), and tumor necrosis factor alpha (TNF&#945;).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In in vitro and in vivo preclinical models, V&#948;1 cells are more cytotoxic and may have a longer durability than V&#948;2 cells. V&#948;1 cells are also more resistant to activation induced cell death (AICD), which has posed significant problems in clinical trials following chronic stimulation of V&#948;2 cells. V&#948;1 cells normally reside within tissues and they are able to adapt to lower nutrient availability and decreased oxygen levels, conditions which are similar to those in the microenvironments or localized areas associated with certain solid tumors. Incubation of these gamma delta T cells in conditions of low oxygen (hypoxia) that are typical of tumors has been shown to enhance their cytotoxicity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anticipated Advantages of V</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#948;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1 Gamma Delta T Cells Over NK Cell Based Therapies</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An alternate approach to the development of allogeneic CAR T cells consists of engineered NK cell-based therapy. While both gamma delta T cell and NK cell therapy generally are not expected to cause GvHD, NK cells express a broad repertoire of both inhibitory and activating receptors and have more limited tumor induced secretion of multiple cytokines. We believe that the gamma delta T cell technology we are developing has several advantages over this approach. Unlike engineered NK cells, V&#948;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The presence of cytotoxic gamma delta cells in tumors and disease-associated tissues is strongly correlated with positive clinical outcomes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Can secrete multiple cytokines associated with potent cytotoxicity including expressing high levels of interferon-gamma;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Can be produced as highly homogeneous cell populations that display potent non-clinical anti-tumor activity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Express activating receptors more predominantly; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Display features of adaptive immunity including, TCR-mediated, but MHC-independent, antigen recognition against those commonly displayed on malignant and abnormal cells, a long lifespan and persistence for protracted periods of time.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe these advantages position gamma delta T cell-based therapies to become an attractive alternative to NK based therapies for many autoimmune and cancer indications and lines of therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anticipated Advantages of V</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#948;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1 Gamma Delta T Cells Over Other Approaches to Generate Allogeneic CAR T Cells</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An alternative approach to the development of allogeneic gamma delta CAR T cells consists of introducing genetic modifications that disable the TCR in alpha beta T cells derived from donors that are unrelated to the patient. This process prevents these cells from attacking the patient&#8217;s healthy cells. We believe that the unrelated donor-derived gamma delta T cell</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technology, which lacks the ability to attack healthy cells from unrelated individuals, has a number of advantages over this approach. In an allogeneic paradigm, unlike alpha beta T cells, V&#948;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Do not rely on genetic manipulations to inactivate the alpha beta TCR;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Display properties of both adaptive and innate immune systems and are capable of killing cells even if their specifically targeted CAR antigen is expressed at low levels or not present;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May not be prone to exhaustion and are likely to persist longer;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May maintain the capacity to home to tissues and tumors rather than predominantly residing in circulation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May be less likely to induce cytokine release syndrome due to more limited endogenous IL-6 secretion by activated cells.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe these advantages position gamma delta T cell based therapies to become an attractive alternative to alpha beta T cell based therapies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anticipated Advantages of V</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#948;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1 Gamma Delta T Cells Over Bispecific Antibody T Cell Recruitment for Tumor Immunotherapy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An alternative approach to the development of allogeneic CAR T cells consists of bispecific antibodies that are designed to crosslink T cells to specific targets on the tumor. This approach generally requires healthy and functional T cells able to attack the tumor when guided to the tumor expressing the target antigen. We believe that the unrelated donor-derived gamma delta T cell technology has a number of potential advantages over this approach. Unlike bispecific antibodies, V&#948;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Do not rely on functional T cells derived from the patient for clinical activity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Display properties of both adaptive and innate immune systems and are capable of killing cells even if their specifically targeted CAR antigen is not present;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maintain the capacity to home to tissues and tumors rather than predominantly residing in circulation and can actively distribute into localized tumors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May be less likely to induce cytokine release syndrome due to more limited endogenous IL-6 secretion by activated cells.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe these advantages position gamma delta T cell-based therapies to become an attractive alternative to bispecific-based therapies for many autoimmune and cancer indications and lines of therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Key Anticipated Differentiation from Gamma Delta T Cell Competitors</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the gamma delta T cell technology that we are developing has a number of potential advantages over the technology of gamma delta T cell competitor companies, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Robust and practical proprietary antibody-based manufacturing method for gamma delta T cells;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Large-scale expansion of blood-derived gamma delta T cells;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ability to selectively expand multiple gamma delta T cell subpopulations including highly potent V&#948;1 cells;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No potentially pro-tumorigenic or pro-autoimmune Th17-type responses in our V&#948;1 subpopulation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In-house CAR target identification and verification process; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ability to effectively target tumor-specific intracellular protein-derived peptides using proprietary T cell receptor-like (TCRL) antibodies.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe these advantages position our gamma delta T cell based therapies to become an attractive approach to the technologies used by other gamma delta T cell competitor companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Production of Gamma Delta T Cells</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To produce gamma delta T cell-based product candidates, we isolate peripheral blood mononuclear cells from unrelated donors that meet all the safety criteria for human cells, tissues, and cellular and tissue-based products (HCT/P) for donors as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">outlined by the FDA in Title 21 of the Code of Federal Regulations (CFR), Part 1271. We then activate V&#948;1 gamma delta T cells using a proprietary agonistic antibody and cytokines which expands these cells before transduction with replication-incompetent retroviral vectors containing the coding sequence for CAR constructs. These CAR-modified cells are further expanded at significant orders of magnitude, routinely greater than 6,000-fold at clinical scale, resulting in cell cultures that primarily consist of the desired gamma delta T cells. To reduce the chance of a patient developing GvHD, the remaining alpha beta T cells are then depleted using alpha-beta-specific, antibody-based techniques. The resulting gamma delta T cells are then formulated in an infusible solution to form the final drug product, which is filled into vials and then frozen to enable delivery of a post-thaw cell dose of CAR-T cells.  A schematic of our large-scale manufacturing process is summarized in the diagram below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img104831930_1.jpg" alt="img104831930_1.jpg" style="width:682px;height:352px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2. Production of Gamma Delta T Cells</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001, an Anti-CD20 CAR Gamma Delta T Cell  Product Candidate Targeting Autoimmune Diseases and Aggressive Relapsed/Refractory NHL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Solution, ADI-001</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 is our gamma delta CAR T-cell product candidate that is designed to target malignant B cells via an anti-CD20 CAR and via the gamma delta T cell endogenous receptors, which we are developing as an allogeneic immunocellular therapy for the treatment of B cell NHL. ADI-001 is created from V&#948;1 gamma delta T cells isolated from unrelated donors. It is manufactured in bulk under current Good Manufacturing Practices (cGMP) -compliant conditions and is intended to be supplied as an immediately available "off-the-shelf" anti-CD20 CAR T-cell therapy.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Similar to other CAR-Ts cells including the one used to create Kymriah&#174;, our CAR T cells contain the clinically validated costimulatory domain from 4-1BB and the CD3&#950;.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADI-001 Development Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Diseases</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Phase 1 study of ADI-001 in lupus nephritis will perform a 3+3 dose escalation starting at 100 million CAR+ cells flat dose. Subject to safety findings, higher doses will be explored up to one billion CAR+ cells. Before ADI-001 infusion, each patient will be conditioned with cyclophosphamide and fludarabine lymphodepletion. The dose limiting toxicity reporting window is set to 42 days; safety events during this period will be driving dose escalation decisions. The first safety assessment is scheduled on Day 28 after infusion, and then on months 3-6-9-12-18 and 24 thereafter. Once the maximum tolerated dose is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determined, a dose expansion cohort will be opened to further characterize the safety and efficacy of ADI-001 in lupus nephritis patients. Primary endpoints will be focused on safety. For an illustration of our ADI-001 Phase 1 study design in lupus nephritis, please refer to Figure 3 below.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img104831930_2.jpg" alt="img104831930_2.jpg" style="width:681px;height:350px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3. Planned ADI-001 Phase 1 Study Design: Lupus Nephritis</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Aggressive Relapsed and Refractory NHL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the FDA cleared our IND application for ADI-001 for the treatment of NHL. The active IND enabled us to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients in the first quarter of 2021. The ongoing Phase 1 study for ADI-001 will enroll up to 80 late-stage NHL patients at a number of cancer centers across the United States. The study includes a dose finding portion followed by dose expansion cohorts to explore the activity of ADI-001 in multiple subtypes of NHL. Included in this trial will be previously treated patients who were not able to receive approved autologous CAR T-cell therapies due to medical, technical, logistical, or financial reasons, as well as patients who relapsed after receiving autologous CAR T-cell therapies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MCL patients enrolled in the trial will undergo chemotherapy-based lymphodepletion for three days followed by ADI-001 dosing by infusion on day five. Patients will be evaluated at four weeks, 12 weeks and then every three months for the first year and at months 18 and 24 after treatment. Once a recommended dose has been selected, patients experiencing clinical benefit with ADI-001 may be eligible for retreatment. Refer to Figure 4. for the Phase 1 ADI-001 study patient flow.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img104831930_3.jpg" alt="img104831930_3.jpg" style="width:681px;height:355px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 4. Phase 1 ADI-001 study patient flow</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment in the Phase 1 clinical study of ADI-001 is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory NHL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; for information regarding recent interim results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory NHL</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On June 26, 2023, we announced interim results from the ongoing Phase 1 study of ADI-001 in relapsed or refractory NHL. Data highlights from the study as of the May 4, 2023 cut-off date are summarized below.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the 24 efficacy-evaluable patients, three received ADI-001 at dose level 1 (DL1) (30 million CAR+ cells), three received ADI-001 at dose level 2 (DL2) (100 million CAR+ cells), six received ADI-001 at dose level 3 (DL3) (300 million CAR+ cells), four received two infusions of ADI-001 at DL3 (two doses of 300 million CAR+ cells, one on day one and the second dose on day seven following a single lymphodepletion), and eight received ADI-001 at dose level 4 (DL4) (1 billion CAR+ cells).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients were heavily pretreated with a median of four prior lines of therapy (range: 2 to 9), had relatively high tumor burden, and had a poor prognostic outlook based on their median International Prognostic Index (IPI) score. 50% of patients enrolled in the study had progressed on prior CAR T cell therapy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients receiving ADI-001 demonstrated a 71% ORR and 63% CR rate in the study across all dose levels.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 demonstrated an 83% ORR and 67% CR rate in heavily pre-treated patients (four median prior lines of therapy) who had progressed on prior CAR T cell therapy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 demonstrated a 6-month CR rate consistent with autologous CAR T cell therapy when factoring number of prior lines of therapy and percent of patients enrolled in the study who progressed on prior CAR T cell therapy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We selected the recommended Phase 2 dose (RP2D) as 1 billion CAR positive cells (DL4).</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the RP2D (DL4) (with four median prior lines of therapy, 38% post- CAR T cell therapy) the six-month CR rate was 25%. At this dose level, in patients who had progressed on prior CAR T cell therapy, the CR rate was 67% and the six-month CR rate was 33%.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expansion and persistence of ADI-001 at the RP2D exceeded values reported for approved autologous CD19 CAR T cell therapy. DL4 demonstrated a mean Cmax of 483 cells/ul with a mean time-to-peak at approximately day 9 and demonstrated persistence through day 28 with a mean concentration of 21 cells/ul.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-001 was generally well-tolerated in the study and there were no occurrences of dose-limiting toxicities or GvHD. Of the 24 patients evaluable for safety, there was one report of Grade 3 or higher CRS and one report of Grade 3 or higher ICANS.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to focus on the MCL patient population in our ongoing Phase 1 GLEAN study (at dose level 4), based on the results observed in the June 2023 update. Subject to clinical data and regulatory feedback, in the first half of 2025, we plan to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL and provide a further clinical update in the second half of 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-270 is an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC, with potential in other solid tumor indications. ADI-270 is designed to home to solid tumors, with a highly specific targeting moiety for CD70 and an armoring technology of a dominant-negative TGF beta receptor to address immunosuppressive factors in the tumor microenvironment.&#8239; Building on gamma delta 1 tissue tropism to solid tumors and three mechanisms of anti-tumor activity (CAR, innate and adaptive) observed in preclinical models, CAR gamma delta 1 T cells may be well positioned to address solid tumors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to file an IND application for ADI-270 in RCC in the second quarter of 2024 and provide clinical data in the first half of 2025, subject to regulatory clearance and study initiation activities. We are also considering potential expansion into additional CD70+ tumor indications in the first half of 2025, with potential clinical data from such studies in the second half of 2025, subject to regulatory clearance and study initiation activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#8239;</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional Preclinical Programs (CAR and Other Technologies)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for autoimmune diseases, hematological malignancies and solid tumors. These pipeline programs were selected by integrating aspects of gamma delta one tissue homing, differentiated mechanisms of action, targeting enhancement and engineered armoring. We believe that the combination of our gamma delta T cells engineered with CAR or other technology provides the basis for a new generation of gamma delta T cell therapies that have the potential to transform the treatment of solid tumors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-002, an Anti-GPC3 CAR Gamma Delta T Cell Product Candidate</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an anti-GPC3 allogeneic CAR gamma delta T cell product candidate, pursuant to our agreement signed in 2016. In conjunction with the exercise of its option, Regeneron paid us an exercise fee of $20.0 million. We elected not to exercise our option to co-fund the further development of ADI-002. Accordingly, Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and we are entitled to royalties of any future sales of such products by Regeneron. See Note 8. Third Party Agreements to our consolidated financial statements in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategic Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into multiple strategic agreements and collaborations, including our License and Collaboration Agreement with Regeneron as well as our Antibody Discovery Agreement with Twist Bioscience Corporation. We have also entered into amendments to these original agreements. For additional information regarding our significant agreements, refer to Note 8. Third Party Agreements to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Intellectual Property</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our gamma delta T cell-based product candidates and substantially all of our intellectual property have been developed by us, with certain antigen binding domains derived from our collaboration with Regeneron. Additional intellectual portfolio assets were acquired in 2016 via acquisition of Applied Immune Technologies Ltd. (AIT), which is now our wholly owned</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subsidiary, Adicet Bio Israel, Ltd. We strive to protect and enhance proprietary technology, inventions and improvements that are commercially material to our business, including seeking, maintaining and defending our patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing United States and foreign patents and applications related to our technology, inventions, and improvements that are material to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patent portfolio includes composition of matter, method of treatment and manufacturing process protection for our lead product candidates, ADI-001 and ADI-270, as well as for our partnered program ADI-002 and several additional research-stage candidates. As of March 14, 2024, there are multiple patent families comprising four pending United States non-provisional applications and over 50 corresponding granted foreign patents and pending foreign patent applications in such jurisdictions as Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico, Russia, Singapore and South Africa with claims directed to particular reagents and related protocols for gamma delta T cell expansion and resulting gamma delta T cell compositions of matter, including engineered gamma delta CAR T cells which, if issued, are expected to expire between 2035 and 2038. The first U.S. non-provisional application in our original patent family was granted as U.S. Patent No. 11,135,245, expiring on May 19, 2038, and the first U.S. non-provisional application in our second patent family was granted as U.S. Patent No. 11,299,708, expiring on December 26, 2037. Additional U.S. non-provisional applications are pending in both of these patent families.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our ADI-001 program in particular, there is one patent family comprising one U.S. non-provisional application and corresponding foreign patent applications pending in such jurisdictions as Australia, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa, with claims directed to CAR constructs and antigen binding domains relating to ADI-001, as well as their methods of use for certain indications, preconditioning methods, and dosing regimens, which, if issued, would expire in 2039. Additionally, we have one pending international Patent Cooperation Treaty (PCT) application directed to certain methods of treatment using ADI-001, where subsequent national stage applications claiming the benefit of this PCT application would expire in 2042 assuming they are filed and issued in due course.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our research-stage programs, we have three pending international PCT applications focusing on CD70, prostate specific member antigen and B7-H6, respectively, where any subsequent national stage applications claiming the benefit of these PCT applications would expire in 2043 assuming they are filed and issued in due course. We also have two pending U.S. provisional patent applications directed to certain improvements in T cell engineering, and one pending U.S. provisional patent application directed to a companion diagnostic and related adjunctive therapy for use in adoptive cell therapies in general, where applications claiming the benefit of these provisional applications would expire in 2044 assuming they are converted, prosecuted and issued in due course.  There are also multiple granted patents and pending patent applications in the United States and internationally directed to our TCRL platform technology expiring between 2023 and 2037, including three pending patent families directed to certain carcinoma, melanoma and glioblastoma targets expiring between 2036 and 2037.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our ADI-002 program, partnered with Regeneron, there is one patent family comprising one U.S. non-provisional application and corresponding foreign patent applications pending in such jurisdictions as Australia, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa, with claims directed to CAR constructs and antigen binding domains relating to ADI-002, as well as their methods of use for certain indications, preconditioning methods, and dosing regimens, which, if issued, would expire in 2039. We also have one patent family comprising one U.S. non-provisional application and corresponding foreign patent applications pending in such jurisdictions as Australia, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Singapore and South Africa directed to certain proprietary antibodies to GPC3 and methods of use thereof, where the national stage applications claiming the benefit of this PCT application will expire in 2042 if issued in due course.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the U.S., patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office (USPTO) in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, core technologies, and know-how, as well as our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of companies like us are generally uncertain and involve complex legal, scientific, and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents or will be commercially useful in protecting our commercial products and methods of using and manufacturing the same. We also cannot predict whether the patent applications it is currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold, or control may be challenged, circumvented or invalidated by third parties. In addition, while we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. Further, our trade secrets may otherwise become known or independently discovered by competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have licensed various intellectual property and trade secrets to third parties for purposes of collaboration, product development and research and development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are developing and enabling scalable and proprietary current Good Manufacturing Practice (cGMP)-compliant manufacturing processes. We have invested resources to optimize our manufacturing process and plan to maintain that investment to continuously improve our production and supply chain capabilities over time.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We manufacture cell-based immunotherapy products based on gamma delta T cells obtained from the blood of donors who are unrelated to the patients that will be treated. These products are classed as allogeneic cell therapy products. Donor-derived blood product is fractionated and the fraction containing gamma delta T cells is frozen prior to use in future manufacturing campaigns. We believe that our freezing and storing of the donor blood products allows us to efficiently schedule subsequent manufacturing steps. After obtaining blood products from unrelated donors the manufacturing process begins with the activation of a subpopulation of gamma delta T cells, referred to as Vd1 T-cells, using an antibody that is proprietary to us. This antibody, in combination with other factors including the cytokine, IL-2, induces gamma delta T cells to proliferate, whereupon we expose the cells to a viral vector that transfers a gene sequence encoding a CAR or other gene sequences, to the proliferating cells. This step is referred to as the transduction step. Following the transduction step gamma delta T cells are induced to proliferate further with IL-2 before an enrichment step that increases the proportion of gamma delta T cells, removes unwanted residual alpha beta T cells and results in the CAR-modified gamma delta T cell drug product. CAR-modified gamma delta T cell products are then frozen in single-use vials for long-term storage at cryogenic temperatures. These storage conditions are designed to ensure stability of the cell-based drug products for protracted periods of time. The storage in single use vials is designed to simplify the handling and treatment administration. Just prior to administration of treatment, the vials will be thawed and then the contents infused into the patient. We believe that the single manufacturing process we are developing will be able to be completed in approximately two weeks and will result in sufficient quantities of drug product to treat numerous patients.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and any products that we may develop. We have chosen to partner with a number of CDMOs in the United States to access specific capabilities to ensure that the manufacturing process is highly scalable, and fully cGMP compliant. This strategy allows us to maintain a more flexible infrastructure while focusing our expertise on developing our products. In addition to the quality management systems utilized by strategic manufacturing partners, we have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we currently engage multiple third-party manufacturers for both viral vector and drug product across our pipeline. We also will have internal GMP cell processing and vector manufacturing operations at our 1000 Bridge Parkway, Redwood City, California facility (1000 Bridge Parkway) for the production of drug products intended for Phase 1/2 clinical trials. We also utilize separate third-party contractors to manufacture cGMP-compliant starting and critical materials that are used for the manufacturing of our product candidates, such as donor blood products, gamma delta T cell activating antibody and viral vectors that are used to deliver the applicable CAR gene into the T cells. We believe all materials and components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">utilized in the production of the activating antibody producing cell line, viral vector and final gamma delta T cell product are available from qualified suppliers and suitable for pivotal process development in readiness for registration and commercialization. Going forward, we intend to continue to expand our manufacturing capability through agreements with leading cell therapy and viral vector CDMOs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If there is a setback or delay with third-party manufacturing, or our own internal cell or vector manufacturing, we believe that there are a number of potential replacements, although we would likely incur some delay in identifying and qualifying such replacements. We plan to continue to create a robust supply chain with redundant sources of supply comprised of both internal and external infrastructure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including existing and novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Novartis and Kite Pharma (now Gilead) were the first to achieve FDA approval for autologous T cell therapies. In August 2017, Novartis obtained FDA approval to commercialize Kymriah&#174;, for the treatment of children and young adults with B cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. In May 2018, Kymriah&#174; received FDA approval for adults with relapsed or refractory (R/R) large B cell lymphoma. In October 2017, Kite Pharma obtained FDA approval to commercialize Yescarta&#174;, the first CAR T-cell product candidate for the treatment of adult patients with R/R large B cell lymphoma. In July 2020, Gilead obtained FDA approval to commercialize Tecartus&#153;, the first CAR T-cell product candidate for the treatment of adult patients with R/R MCL. In February 2021, Bristol Myers Squibb obtained FDA approval to commercialize Breyanzi&#174; for the treatment of adults with R/R large B cell lymphoma. In 2022, both Yescarta and Breyanzi were approved by the FDA for treating a subset of adult patients with LBCL in the second line, representing a line-expansion from the earlier third-line approvals.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the promising therapeutic effect of T cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogeneic T cell therapies generally. Potential T cell therapy competitors include, but are not limited to:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Competition</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Allogeneic T-cell therapy competition:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Sana Biotechnology, Inc., CRISPR Therapeutics AG, Fate Therapeutics, Inc., Nkarta, Inc., and Century Therapeutics, Inc.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autologous T-cell therapy competition: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Novartis AG, Bristol-Myers Squibb Company, Autolus Therapeutics PLC, Cartesian Therapeutics, Inc., iCell Gene Therapeutics Inc., Cabaletta Bio, Inc., Gracell Biotechnologies Inc., and Kyverna Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cancer Competition</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Allogeneic T-cell therapy competition:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Allogene Therapeutics, Inc., Caribou Biosciences, Inc., Century Therapeutics, Inc., Cellectis, S.A., Celyad S.A., CRISPR Therapeutics AG, Fate Therapeutics Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc., Immatics Biotechnologies GmbH, Takeda, TC BioPharm Limited, Incysus Therapeutics, Inc., and Gadeta BV.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autologous T-cell therapy competition:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Adaptimmune Therapeutics PLC, Autolus Therapeutics plc, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson &amp; Johnson, Iovance Biotherapeutics, Inc., Mustang Bio, Inc., and Novartis International AG.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe our development of proprietary processes for engineering and manufacturing gamma delta T cells expressing CARs is unique due to what we believe is the enormous potential of these cells, it is likely that additional competition may arise from existing companies currently focusing on development of alpha beta or gamma delta T cell therapies, or from new entrants in the field.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition may also arise from non-cell based immune cancer platforms. For instance, we may experience competition from companies, such as Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, MacroGenics, Inc., Merus N.V., Regeneron Pharmaceuticals, Inc., and Xencor Inc., that are pursuing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bispecific antibodies, which target both the cancer antigen and T cell receptor, thus bringing both cancer cells and T cells in close proximity to maximize the likelihood of an immune response to the cancer cells. Further, companies such as Novartis AG, F. Hoffmann-La Roche AG, Biogen Inc., and GSK plc are developing antibody-based therapies targeting B cell antigens and other targets for the treatment of autoimmune diseases. Additionally, companies, such as Amgen Inc., AbbVie Inc., Daiichi Sankyo Company, Limited, GSK plc, Immunomedics, Inc., and Pfizer Inc., are pursuing antibody drug conjugates, which utilize the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Further competition in MCL may arise from Bruton&#8217;s tyrosine kinase inhibitors, including those approved and under development by AstraZeneca plc, BeiGene Ltd., Merck KGaA and Eli Lilly and Company.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our own products, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and tolerability profile, convenience, price, reimbursement and cost of manufacturing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, and investor capital, as well as for technologies complementary to, or necessary for, our programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA to the FDA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them. Generally, before a new drug or biologic can be marketed, considerable data demonstrating our quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States (at the federal, state, and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States Product Development Process</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act (the FDCA), the Public Health Service Act (the PHSA), and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of nonclinical laboratory tests and key animal studies according to good laboratory practices (GLPs), and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND application, which is subject to a waiting period of 30 calendar days, must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent Institutional Review Board (IRB) or ethics committee for each clinical site before the trial is commenced;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (GCPs) and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for our intended use;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of a Biologics License Application (BLA) for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices (cGTPs) for the use of human cellular and tissue products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval, or licensure, of the BLA prior to any commercial marketing or sale of the biologic in the U.S.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the key preclinical tests must comply with federal regulations and requirements including GLPs. An IND application is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND application is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and requests additional information and or places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND application will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators at independent clinical sites/hospitals, physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. A clinical trial outside the United States may also be conducted under the authorization of similar regulatory authorities of the country/region. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1. The biological product is typically introduced into healthy human subjects and tested for safety. However, in the case of some products for severe or life-threatening diseases, such as cancer or the hematological malignancies that we aspire to treat, initial human testing is routinely conducted directly in ill patients with the approval of relevant ethics committee(s) under the supervision of a licensed physician.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. In case of an accelerated BLA approval based on limited clinical data, FDA may mandate a Phase 4 clinical trial prior to full approval. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within 7 calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product according to the requirements of the phase of clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States Review and Approval Processes</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product safety, efficacy, development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance or guarantee that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For cellular immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with cGTPs, to the extent applicable. These are FDA regulations and guidance documents that in part govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the cGTPs is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, cGTPs and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (PSP), within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, priority review designation, accelerated approval, Regenerative Medicine Advanced Therapy (RMAT) designation, and breakthrough therapy designation. Additionally, under the Food and Drug Omnibus Reform Act of 2022 (FDORA), sponsors of designated platform technologies may receive expedited development and review of any subsequent application for a drug or biologic that uses or incorporates the platform technology.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies and, under FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RMAT designation was established by the FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or regulatory approval process for our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, under FDORA, a platform technology incorporated within or utilized by a biological product is eligible for designation as a designated platform technology if (1) the platform technology is incorporated in, or utilized by, a biological product approved under a BLA; (2) preliminary evidence submitted by the sponsor of the licensed biological product, or a sponsor that has been granted a right of reference to data submitted in the application for such biological product, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one biological product without an adverse effect on quality, manufacturing, or safety; and (3) data or information submitted by the applicable person indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring significant efficiencies to the biological product development or manufacturing process and to the review process. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND for a biological product that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original BLA for a biological product that uses or incorporates the platform technology. Designated platform technology status does not ensure that a biological product will be developed more quickly or receive FDA approval. In addition, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as off-label use), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physician deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product&#8217;s approved labeling.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, additional FDA limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and may also require the implementation of other risk management measures, including a REMS, or the conduct of post-marketing studies to assess a newly discovered safety issue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the adequate stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.  Under FDORA, sponsors of approved drugs and biologics must provide 6 months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a product, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to produce clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Marketing Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA), amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. BPCIA, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our United States patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States Pediatric exclusivity that, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the biologic. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services (CMS), other divisions of the United States Department of Health and Human Services (HHS) (e.g., the Office of Inspector General, the United States Department of Justice (DOJ), and individual United States Attorney offices within the DOJ, and state and local governments). For example, our business practices, including any of our research and future sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), transparency requirements, and similar state, local and foreign laws, each as amended.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and other individuals and entities on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of the facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the ACA codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the United States government. For example, pharmaceutical and other healthcare companies have been, and continue to be, investigated or prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, many states have similar fraud and abuse statutes or regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor. These laws are enforced by various state agencies and through private actions. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures. In addition, certain state and local laws require the registration of pharmaceutical sales representatives.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, impose requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. State and foreign laws,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including for example the European Union General Data Protection Regulation also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities that potentially harm consumers.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians, as defined by such law, certain other licensed health care practitioners and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the U.S., third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the European Union (EU), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the ACA has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created a Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extended manufacturers&#8217; Medicaid rebate liability under the Medicaid Drug Rebate Program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded eligibility criteria for Medicaid programs, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded the entities eligible for discounts under the 340B Drug Discount Program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expanded healthcare fraud and abuse laws, including the Anti-Kickback Statute and the Foreign Corrupt Practices Act (FCPA), created new government investigative powers, and enhanced penalties for noncompliance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required reporting of certain financial arrangements with physicians and teaching hospitals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to physicians;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">created a licensure framework for follow on biologic products.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the ACA was enacted:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2031 unless additional Congressional action is taken. Subsequent legislation extended the 2% payment reduction which remains in effect through 2030. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#242424;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation, and delay the rebate rule that would limit the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.  If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Individual states in the United States have also been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that these and other healthcare reform efforts will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could materially harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Foreign Corrupt Practices Act</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FCPA prohibits any United States individual or business from offering, paying, promising to pay, or authorizing payment of money or anything of value, to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to any foreign official, political party or candidate to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist the individual or business in obtaining or retaining business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are owned and operated by the government, and doctors and other hospital employees are considered foreign officials for the purposes of the statute. Certain payments made in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, if we expand our presence outside of the United States, we will need to dedicate additional resources to complying with the laws and regulations in each jurisdiction in which it plans to operate. Therefore, this may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Packaging and Distribution in the United States</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the United States Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. We maintain workers&#8217; compensation insurance to cover costs and expenses it may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against it. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Europe / Rest of World Government Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014 (Regulation), which replaced the Clinical Trials Directive 2001/20/EC (Directive), on January 31, 2022. The new Regulation overhauls the current system of approvals for clinical trials in the EU. Specifically, the new Regulation, which is directly applicable in all EU member states (meaning that no national implementing legislation in each EU member state is required), aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System (CTIS); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of a medicinal product under EU regulatory systems, we must submit an MAA. The centralized procedure provides for the grant of a single marketing authorization by the European Commission (EC) that is valid across all of the EU, and in the additional member states of the European Economic Area (Iceland, Liechtenstein and Norway). The scientific evaluation of MAAs for Advanced Therapy Medicinal Product (ATMPS) (which comprise gene therapy, somatic cell therapy and tissue engineered medicines) is primarily performed by a specialized scientific committee called the Committee for Advanced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therapies (CAT). The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use (CHMP). The CHMP recommendation is then sent to the EC, which adopts a decision binding in all EU Member States. The maximum timeframe for the evaluation of an MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the EC, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major public health interest, particularly from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products with an orphan designation in the EU can receive ten years of market exclusivity, during which time &#8220;no similar medicinal product&#8221; for the same indication may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two years of market exclusivity in the EU where an agreed pediatric investigation plan for pediatric studies has been complied with. The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (2) either (i) the prevalence of such condition must not be more than five in 10,000 persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Otherwise, orphan medicine marketing exclusivity may be revoked only in very select cases, such as if: (i) a second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder of the authorized orphan product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union General Data Protection Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, ensuring a legal basis or condition applies to the processing of personal data, rules relating to for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contracts with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the EU, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, following the United Kingdom&#8217;s (UK) exit from the EU, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the UK GDPR into UK law. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the EC has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the European Economic Area (EEA) remain free flowing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The UK is not subject to the EC&#8217;s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which will enable transfers from the UK (the International Data Transfer Addendum). We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Data Privacy Law</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020, created comprehensive individual privacy rights for consumers (as that word is broadly defined in the law) and placed increased privacy and security obligations on entities handling the personal data of consumers or households. The CCPA required covered companies to provide new disclosures to California consumers, provided such consumers new ways to opt-out of certain sales of personal information, and allowed for a new private cause of action for data breaches. The CCPA was amended by the California Privacy Rights Act (CPRA) which became effective on January 1, 2023 and imposed additional obligations on companies covered by the legislation. The CPRA significantly modified the CCPA and created a state agency that is vested with authority to implement and enforce the CCPA. As our business progresses, the CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar laws have been passed and proposed in numerous other states. These laws are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and limited obligations for entities regulated by HIPAA. There are also states that are specifically regulating health information. For example, Washington state recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such enacted and proposed legislation may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 143 full-time employees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have built a strong culture by collaboratively creating company values, a Mission and Vision. We seek input from employees on our culture through regular employee engagement surveys. We offer attractive benefits, including competitive salaries, excellent health insurance, and a 401K match. We are committed to pay equity, regardless of gender, race/ethnicity, or sexual orientation and conduct comprehensive pay equity analyses on a semi-annual basis. During the pay equity reviews we assess and ensure equality in pay for various groups to ensure fairness.  In addition to providing strong benefits packages to employees, we believe in fostering individual and organizational effectiveness by offering our employees various professional development opportunities. We believe that investing in our employees&#8217; career growth provides individuals and the organization with the knowledge and skills to respond effectively to current and future business demands and support the organization&#8217;s development efforts. Our culture is one that actively supports the application of new knowledge and skills on the job. In addition, we recognize several cultural holidays during the year in support of our diverse workforce. In 2024, we plan to continue add to our human capital resources as we grow. We are also monitoring the current landscape of wage inflation and labor shortages in connection with our employees' overall compensation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#153; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Internet address is www.adicetbio.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC). Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">www.sec.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. In evaluating the Company and our business, you should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other filings with the SEC, before investing in our common stock. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment in our common stock. The risks and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties that we currently do not know about or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements and Industry Data&#8221; section in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business and Industry</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Operating History</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history and face significant challenges and expenses as we build our capabilities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We began operations in November 2014. We have a limited operating history upon which someone can evaluate our business and prospects and is subject to the risks inherent in any early stage company, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. We currently do not have complete in-house resources to enable our gamma delta T cell platform. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred net losses since our inception and anticipate that we will incur substantial net losses in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an early clinical stage biopharmaceutical company. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses since our inception. To date, we have financed our operations primarily with proceeds from our license and collaboration agreements and the issuance and sale of our capital stock, including most recently: (i) net proceeds of approximately $19.3 million, after deducting sales agent commissions, but before deducting any expenses related to such sales, from sales of our common stock under our &#8220;at-the-market&#8221; program in January 2024 and (ii) net proceeds of approximately $91.8 million, after deducting the underwriting discount and commissions and other estimated offering expenses, from the sale of our common stock and pre-funded warrants in an underwritten public offering in January 2024. For the year ended December 31, 2023, we recorded net loss of $142.7 million. As of December 31, 2023, we had an accumulated deficit of $380.8 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our gamma delta T cell platform, including ADI-001 and ADI-270. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations, any of which could have a material adverse effect on our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business, financial condition, results of operations, and prospects and cause investors to lose all or part of their investments.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our history of recurring losses and anticipated expenditures could raise substantial doubts about our ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  As of the date of this Annual Report on Form 10-K, we believe that with $159.7 million in cash and cash equivalents as of December 31, 2023, as well as the proceeds raised subsequent to year end through our ATM program and underwritten public offering, we are capitalized into the second half of 2026. Our ability to continue as a going concern beyond this point will require us to obtain additional funding. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, limit, reduce or terminate our product development or future commercialization efforts of one or more of our product candidates, or may be forced to reduce or terminate our operations. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. In our future required quarterly assessments, we may again conclude that there is substantial doubt about our ability to continue as a going concern, and future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there exists substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of ADI-001. If we are unable to obtain regulatory approval for ADI-001 in one or more indications and effectively commercialize ADI-001 for the treatment of patients in indications for which we receive approval (if any), our business would be significantly harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced product candidate, ADI-001. ADI-001 is in the early stages of development with an ongoing Phase 1 study to assess the safety and efficacy of ADI-001 in patients with relapsed or refractory aggressive non-Hodgkin&#8217;s lymphoma (NHL) that commenced in March 2021, and we plan to initiate a Phase 1 study of ADI-001 in lupus nephritis (LN) in the second quarter of 2024.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical results or clinical results to date may not predict results for our planned or ongoing trials or any future studies of ADI-001 or any other allogeneic gamma delta T cell product candidate. Because of the lack of evaluation of allogeneic products and gamma delta T cell therapy products in the clinic to date, any such product&#8217;s failure, or the failure of other allogeneic T cell therapies or gamma delta T cell therapies, may significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies, which could have a material adverse effect on our reputation. If our gamma delta T cell therapy is viewed as less safe or effective than autologous therapies or other allogeneic T cell therapies, our ability to develop other allogeneic gamma delta T cell therapies may be significantly harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our product candidates, including ADI-001, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because ADI-001 is our most advanced product candidate, and because our other product candidates are based on similar technology, if ADI-001 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed, which could have a material adverse effect on our business, reputation and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our gamma delta T cell candidates represent a novel approach to the treatment of autoimmune diseases and cancer indications that creates significant challenges for us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a pipeline of gamma delta T cell product candidates and a novel antibody platform that are intended for use in patients with certain autoimmune diseases and cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon a program;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrolling or inability to enroll subjects in our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing our product candidates to our specifications and in a timely manner to support our current and future clinical trials, and, if approved, commercialization;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sourcing current and future clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to achieve efficacy in autoimmune disease and cancer patients following treatment with our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving a side effect profile from our product candidates in autoimmune diseases and cancer indications that makes them clinically and commercially attractive for further development;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of our product candidates, if approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">using medicines to manage adverse side effects of our product candidates which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditioning patients with chemotherapy or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with development of allogeneic T cell therapies for autoimmune diseases and cancer; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our business, including our ability to obtain financing and generate any revenue in the future, will primarily depend on the positive efficacy and safety profile and durability of our product candidates in our clinical trials, regulatory approval, successful development and commercialization of our novel product candidates, and our ability to build out our manufacturing capabilities, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety or durability for any of our product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business, which could have a material adverse effect on our results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of such product candidates and the time and cost of product candidate development and obtaining regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated our research and development efforts on our allogeneic gamma delta T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and product candidates and there can be no assurance that any development problems we have experienced or may experience in the future will not cause significant delays or result in unforeseen issues or unanticipated costs, or that any such development problems or issues can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our future clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, our expectations with regard to the advantages of an allogeneic gamma delta T cell therapy platform relative to other therapies may not materialize or materialize to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">degree we anticipate. Further, our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the clinical study requirements of the FDA, the European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR T cell therapies, such as Kymriah&#174; and Yescarta&#174;, as well as other pathways to approval, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our product candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may also not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T-cell therapies that have previously been approved or alpha beta T cell therapies that may be approved in the future. Unexpected clinical outcomes could materially and adversely affect our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could halt our clinical development, prevent our regulatory approval, limit our commercial potential or result in significant negative consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T-cell therapies and those under development have shown frequent rates of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. Additionally, in November 2023, the FDA announced an investigation into reports of T-cell malignancies in patients who had received BCMA-directed or CD19-directed autologous CAR T cell immunotherapies. In January 2024, the FDA determined that new boxed warning language related to T-cell malignancies should be included in the labeling for all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. While we believe our gamma delta T cell approach may lessen such results, similar or other adverse events for our allogeneic gamma delta T cell product candidates may occur and could result in increased government regulation, unfavorable public perception and publicity, potential impacts on enrollment in our clinical trials, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates . In addition, while we anticipate our focus on gamma delta T cells may lessen the likelihood of GvHD relative to therapies relying on unrelated alpha beta T cells, similar or other adverse events for our allogeneic gamma delta T cell product candidates may occur.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. A data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Novel therapeutic candidates, such as those we are developing, may result in novel side effect profiles that may not be appropriately recognized or managed by the treating medical staff. We anticipate having to train medical personnel using our product candidates to understand the side effect profile of our product candidates for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in serious adverse events including patient deaths. Based on available preclinical data and clinical experience with other cell therapy agents, the safety profile of our pipeline product candidates is expected to include cytokine release syndrome, neurotoxicity, and possibly additional adverse events. Any of these occurrences may have a material adverse effect our business, financial condition and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to side effects and adverse events caused by any product candidates we may develop, the conditioning, administration process or related procedures that may be used with our product candidates may also cause adverse side effects. A T cell therapy patient is generally administered cytotoxic drugs to remove stem cells from the bone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marrow to create sufficient space in the bone marrow for the modified stem cells to engraft and produce new cells. This procedure causes side effects and, among other potential risks, can transiently compromise the patient&#8217;s immune system, known as neutropenia, and reduce blood clotting, known as thrombocytopenia. If we are unable to demonstrate that such adverse events were caused by the conditioning regimens used, administration process or related procedure, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we may develop for any or all target indications. Even if we are able to demonstrate that adverse events are not related to our product candidate, such occurrences could affect patient recruitment, the ability of enrolled patients to complete the clinical trial or the commercial viability of any product candidates that obtain regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Clinical Trials</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, for the ongoing Phase 1 study of ADI-001 and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Any of the foregoing could have a material adverse effect on our business, prospects and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to file Investigational New Drug (IND) applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the IND for our lead product candidate, ADI-001, to treat patients with NHL was cleared by the FDA for a clinical trial in patients with NHL. In December 2023, the FDA cleared our IND for a clinical trial of ADI-001 in LN patients. Our pipeline also includes ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70+ cancers. We have several additional internal gamma delta T cell therapy programs in preclinical development. We previously announced our plan to file one new IND every 12-18 months, including an IND for ADI-270 in the first half of 2024. We may not be able to make these filings on the timelines we expect, which may cause delays in commencing additional clinical trials. Even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND application or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. Moreover, we cannot be sure that submission of an IND application for any of our other product candidates will result in the FDA allowing trials to begin, or that, once begun, issues will not arise that result in a decision by us, by independent institutional review boards (IRBs) or independent ethics committees, or by the FDA, the EMA or other regulatory authorities to suspend or terminate clinical trials. For example, we may experience manufacturing delays or other delays with IND-enabling studies or the FDA, the EMA or other regulatory authorities may require additional preclinical studies that we did not anticipate. Moreover, we cannot be assured that submission of an IND application will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that result in a decision by us, by IRBs, or independent ethics committees or by the FDA, the EMA or other regulatory authorities to suspend or terminate clinical trials, including as a result of a clinical hold. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND application or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. The inability to initiate clinical trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any of our product candidates on the timeline currently anticipated or at all could have a material adverse effect on our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching an agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in obtaining required IRB approval at each clinical study site;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in recruiting suitable patients to participate in our clinical studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty collaborating with patient groups and investigators;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by our CROs or other third parties to adhere to clinical study requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s Good Clinical Practices (GCPs) requirements or applicable regulatory guidelines in other countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges in transferring manufacturing processes to any new contract development and manufacturing organizations (CDMOs) or our manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients&#8217; complete participation in a study or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients dropping out of a study;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">political conditions or conflicts in regions where we conduct or may seek to conduct our clinical trials; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing challenges, including delays in testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our timing of filing INDs for our product candidates is dependent on further preclinical and manufacturing success, which we work on with various third parties. We cannot be sure that we will be able to submit our INDs in a timely manner, if at all, or that submission of an IND application or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Monitoring safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our current and planned clinical trials of our product candidates, we have contracted with and expect to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. Medicines used at centers to help manage adverse side effects of ADI-001 may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates, any of which could have a material adverse effect on our ability to obtain regulatory approval and commercialize on the timelines anticipated or at all, which could have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with the protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until the conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to study sites;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because our product candidates represent unproven methods for the treatment of autoimmune diseases and cancer, potential patients and their doctors may be inclined to use conventional therapies rather than enroll in our clinical trial. For cancer, they may use chemotherapy and hematopoietic cell transplantation or autologous CAR T cell therapies. Patients eligible for allogeneic CAR T cell therapies but ineligible for autologous CAR T cell therapies due to aggressive cancer and inability to wait for autologous CAR T cell therapies may be at greater risk for complications and death from therapy. For autoimmune diseases, potential patients may use therapies that focus on symptomatic relief.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our gamma delta T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, &#8220;off-the-shelf&#8221; products, we expect that we will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with autoimmune diseases and cancer and to treat potential side effects that may result from our product candidates can be significant. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products, which is expected to have a material adverse effect on our financial position and ability to achieve profitability.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. For example, in November 2023, we announced that we paused preclinical development of ADI-925 to prioritize corporate resources on ADI-270 and in January 2024, we announced we had deprioritized enrollment of LBCL patients in our Phase 1 clinical trial of ADI-001 in NHL. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to globally develop our product candidates. Accordingly, we expect that our development programs will be subject to additional risks related to operating in foreign countries, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">import and export requirements and restrictions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act or comparable foreign regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war, such as the ongoing conflicts in the Ukraine and the Middle East, and terrorism.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with our potential international operations may materially adversely affect our ability to develop our product candidates and attain or maintain profitable operations, which could have a material adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Marketing Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA often approves new therapies initially only for use in patients who are currently not adequately treated with currently approved therapies. We expect to initially seek approval of ADI-001 and our other product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T-cell product candidates, including approved autologous CAR T-cell products. Our therapies may not be as safe and effective as autologous CAR T-cell therapies and may only be approved for patients who are ineligible for autologous CAR T-cell therapy.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have the indications we are targeting, as well as the subset of people with these indications in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these indications. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of our core strategies is to pursue clinical development of additional product candidates beyond ADI-001. Our pipeline also includes ADI-270, an armored gamma delta CAR T-cell product candidate targeting CD70+ cancers, in the preclinical development stage. In addition, we have several additional internal gamma delta T cell therapy programs in preclinical development. We plan to submit one new IND to the FDA every 12-18 months, including an IND for ADI-270 in the first half of 2024. Developing, obtaining regulatory approval for and commercializing additional gamma delta T cell product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we receive FDA approval to market our product candidates for the treatment of our targeted indications, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate which could have a material adverse effect on our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We may develop a marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that it will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or overseas. If we are unable to successfully market and distribute our products, our business, results of operations and prospects could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, engineered T cells face significant competition in both the CAR and T cell receptor (TCR) technology space from multiple companies. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is affected by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Manufacturing</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have not yet commenced manufacturing operations at our manufacturing facility and currently depend on the ability of our third-party suppliers and manufacturers with whom we contract to perform adequately, particularly with respect to the timely production and delivery of our product candidates, including ADI-001. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we built out manufacturing capabilities at our Redwood City facility in the fourth quarter of 2022, we rely and expect to continue to rely to a significant extent on third parties for the manufacture of our product candidates for preclinical and clinical development. We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or through our CDMOs, including timely supply of &#8220;off-the-shelf&#8221; product to satisfy demands to support clinical trials of any of our product candidates. To the extent we are not able to obtain timely supply of &#8220;off-the-shelf&#8221; product, the anticipated timing for our clinical trials and the development of our product candidates could be adversely impacted. Very few companies have experience in manufacturing gamma delta T cell therapy derived from blood of unrelated donors, and gamma delta T cells require several complex manufacturing steps before being available as a mass-produced, &#8220;off-the-shelf&#8221; product. We have limited experience in managing the allogeneic gamma delta T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by or on our behalf will result in T cells that will be safe and effective.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations remain subject to review and oversight by the FDA and the FDA could object to our use of any manufacturing facilities. Even if our product candidates are approved, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with current Good Manufacturing Practices (cGMPs) and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The occurrence of any of such problems could adversely impact the availability of products for our clinical trials and commercial sale. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We have experienced manufacturing delays due to these issues in the past and cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also experience both internal and external manufacturing difficulties due to resource constraints or as a result of labor disputes. We have experienced external manufacturing difficulties in the past; if we were to continue to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized, which could have a material adverse effect on our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Operations</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct substantially all of our operations at our facilities in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in this market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock units that vest over time. The value to employees of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel. To provide added incentives to retain and motivate key contributors, our board of directors recently approved a stock option repricing in August 2023. Despite this, we may have difficulty retaining key personnel, which could adversely affect our business and further development of our product candidates. See the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Recent Developments &#8211; Option Repricing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; elsewhere in this Annual Report on Form 10-K for information about the stock option repricing.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to spend a substantial amount of capital in the clinical development of our product candidates, including the ongoing Phase 1 clinical trial for ADI-001, the potential pivotal Phase 2 study for ADI-001 and the preclinical development of additional internal gamma delta T cell therapy programs, including ADI-270. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the date of this Annual Report on Form 10-K, we believe that with $159.7 million in cash and cash equivalents as of December 31, 2023, as well as the proceeds raised subsequent to year end through our ATM program and underwritten public offering, we are capitalized into the second half of 2026. However, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities and may need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Other than the funding agreement and our Loan Agreement (as defined below) with Banc of California (formerly known as Pacific Western Bank), we have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Additionally, United States and global economic uncertainty, higher interest rates and diminished credit availability may limit our ability to incur indebtedness on favorable terms. Furthermore, the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the United States and China, an escalation in conflict between Russia and Ukraine or the ongoing armed conflict in Israel and the Gaza strip, including any resulting sanctions, export controls or other restrictive actions, also could lead to disruption, instability and volatility in the global markets, which may have an impact on our ability to obtain additional funding.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have grown rapidly and will need to continue to grow the size of our organization, and it may experience difficulties in managing this growth.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our development and commercialization plans and strategies develop, and as we have transitioned into operating as a public company, we have rapidly expanded our employee base and expect to continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants, pursuant to arrangements which expire after a certain period of time, to provide certain services, including certain research and development as well as general and administrative support. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals, which could have a material adverse effect on our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our License and Collaboration Agreement (the Regeneron Agreement) with Regeneron Pharmaceuticals, Inc. (Regeneron) requires significant research and development commitments that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction, which could have a material adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Business Disruptions</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our CDMO, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, such as public health crises or other natural or man-made disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster, the severity and frequency of which may be amplified by global climate change, or other business interruptions. We have facilities located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Global conflicts may increase the likelihood of supply interruptions which could impact our ability to find the materials we need to make our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ongoing conflicts, including conflicts between Russia and Ukraine and Israel and Hamas, may increase the likelihood of supply interruptions and hinder our ability to find the materials we need to make our product candidates. Supply disruptions make it more difficult for us to find favorable pricing and reliable sources for the materials we need, which increases pressure on our costs and increases the risk that we may be unable to acquire the necessary goods and services to successfully manufacture our product candidates. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical studies or clinical trials, such as our ongoing or planned clinical trials of ADI-001, could be delayed or suspended. Any delay or interruption in the supply of trial materials could delay the completion of such trials, increase the costs associated with maintaining these research and development activities and, depending upon the period of delay, require us to commence new preclinical studies or clinical trials at additional expense or terminate such trials completely.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the approval of our product candidates rely, which would negatively impact our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, adequate staffing, furloughs, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved, which would adversely affect our business. For example, over the past decade, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, including our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue to fund our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Healthcare Regulation</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with customers, physicians including clinical investigators, clinical research organizations and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, transparency laws, government price reporting and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, vendors, or other agents violate these laws, we could face substantial penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information. For further</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discussion on U.S. healthcare regulations, see the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8211;Government Regulation and Product Approval&#8212;Other U.S. Healthcare Laws and Compliance Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending themselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes in these laws could materially and adversely harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to federal and state data privacy and security laws and regulations, and laws and expectations relating to privacy continue to evolve. Changes in these laws may limit our data access, use and disclosure, and may require increased expenditures. In addition, data protection, privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business contact information, provider information, and other information relating to identifiable individuals. For example, the California Consumer Privacy Act (CCPA) requires covered businesses to, among other things, provide notices to California consumers regarding the collection, use and disclosure of such consumers&#8217; personal information and afford such consumers new rights with respect to their personal information, including the right to opt out of certain sales of personal information. In addition, the California Privacy Rights Act (CPRA), which amended the CCPA, became effective on January 1, 2023 and imposed additional obligations on companies covered by the legislation. The CPRA modified the CCPA and has created a state agency that is vested with authority to implement and enforce the CCPA. There are also states that are specifically regulating health information. For example, Washington state recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Since then, similar laws have been passed in numerous other states and other states have proposed similar new privacy laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that increased regulation in additional jurisdictions is likely in the area of data privacy. Any of the foregoing may have a material adverse effect on our ability to provide services to patients and, in turn, our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection and use of personal health data in the European Economic Area (EEA) is governed by the General Data Protection Regulation (GDPR). The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for controllers of personal data, including stringent requirements relating to ensuring an appropriate legal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">basis or condition applies to the processing of personal data, stricter requirements relating to obtaining consent from data subjects, stricter requirements around the collection of sensitive data (such as health data), expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, implementing safeguards to protect the security and confidentiality of personal data and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the United Kingdom&#8217;s (UK) exit from the European Union (EU), the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the European Union&#8217;s data protection regime. Although the GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the GDPR. The UK Government has also now introduced a Data Protection and Digital Information Bill (the UK Bill) into the UK legislative process with the intention for this bill to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EU data protection regime. This may lead to additional compliance costs and could increase our overall risk. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of EU personal information and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EU. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the European Union&#8217;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The UK government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. The European Commission has issued forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The UK is not subject to the EC&#8217;s new standard contractual clauses but has published the UK International Data Transfer Agreement and International Data Transfer Addendum to the new standard contractual clauses (the IDTA), which enable transfers from the UK. For new transfers, the IDTA already needs to be in place, and must be in place for all existing transfers from the UK from March 21, 2024. Following a ruling from the Court of Justice of the EU, in Data Protection Commissioner v Facebook Ireland Limited and Maximillian Schrems, Case C-311/18 (Schrems II), companies relying on standard contractual clauses to govern transfers of personal data to third countries (in particular the United States) will need to assess whether the data importer can ensure sufficient guarantees for safeguarding the personal data under GDPR. This assessment includes assessing whether third party vendors can also ensure these guarantees. The same assessment is required for transfers governed by the IDTA. Further, the EU and United States have adopted its adequacy decision for the EU-U.S. Data Privacy Framework (Framework), which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to the United States are carried out in line with GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. We will be required to implement these new safeguards when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with the requirements of the GDPR or UK GDPR and the related national data protection laws of the EEA Member States may result in fines up to &#8364;20 million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR and UK GDPR grant data subjects the right to claim material and non-material damages resulting from infringement of the GDPR or UK GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR and UK GDPR, will require significant time, resources and expense, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many other jurisdictions outside of Europe are also considering and/or enacting new and/or amended comprehensive data protection legislation. We also continue to see jurisdictions imposing data localization laws. These regulations may interfere with our intended business activities, inhibit our ability to expand into those markets or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit us from continuing to offer services in those markets without significant additional costs. Because the interpretation and application of many privacy and data protection laws (including the GDPR), commercial frameworks, and standards are uncertain, it is possible that these laws, frameworks, and standards may be interpreted and applied in a manner that is inconsistent with our existing data management practices and policies. If so, in addition to the possibility of fines, lawsuits, breach of contract claims, and other claims and penalties, we could be required to fundamentally change our business activities and practices or modify our solutions, which could have an adverse effect on our business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable privacy and security or data security laws, regulations, and policies, could result in additional cost and liability to us, damage our reputation, inhibit our ability to conduct trials, and adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data protection, privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business contact information, provider information, and other information relating to identifiable individuals. Failure to comply with these laws may result in, among other things, civil and criminal liability, negative publicity, damage to our reputation, and liability under contractual provisions. In addition, compliance with such laws may require increased costs to us or may dictate that wet not offer certain types of services in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EU&#8217;s Artificial Intelligence Act (AI Act) &#8212; the world&#8217;s first comprehensive AI law &#8212; is anticipated to enter into force in Spring 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes significant obligations on providers and deployers of high risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems.  If we develop or use AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, transparency, and human oversight, as well as adhering to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising funds through lending arrangements may restrict our operations or produce other adverse results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current Loan and Security Agreement with Banc of California, as amended on July 8, 2020, September 14, 2020, September 15, 2020, October 21, 2021, December 2, 2022 and May 30, 2023 (the Loan Agreement), sets the interest rate of the term loans under the Loan Agreement at the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%. The Loan Agreement contains a variety of affirmative and negative covenants, including required financial reporting, requirements to maintain certain balances at Banc of California, limitations on certain dispositions of assets, limitations on the incurrence of additional debt and other requirements. To secure our performance of our obligations under this Loan Agreement, we granted a security interest in substantially all of our assets, other than certain intellectual property assets, to Banc of California and issued a warrant to purchase our capital stock.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 13, 2023, we executed a letter agreeing that, notwithstanding the covenants included in the Fifth Amendment to the Loan Agreement, dated as of December 2, 2022 (the 2022 Loan Amendment), until June 30, 2023 (i) we and our subsidiaries will not be required to maintain the lesser of $200 million or seventy percent (70%) of our combined balances in demand deposit accounts, money market funds and/or insured cash sweep (ICS) accounts with Banc of California and (ii) we must maintain our combined balances at Banc of California or its affiliates, including Pacific Western Asset Management (the Letter). Upon executing the Letter, we wired $187.2 million from our ICS accounts at Banc of California to Pacific Western Asset Management who subsequently invested the funds into money market funds held in custody with U.S. Bank National Association.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2023, we entered into the Sixth Amendment to the Loan Agreement, dated as of May 30, 2023 (the 2023 Loan Amendment). Pursuant to the 2023 Loan Amendment, we must maintain the lesser of (i) $35.0 million or (ii) all of the Company&#8217;s combined balances in demand deposit accounts, money market accounts, and/or insured cash sweep accounts with Banc of California. If our total cash and investments drop to less than $35.0 million, the 2023 Loan Amendment permits us to maintain cash and/or investments in one or more accounts outside of Banc of California up to a total of $2.5 million. As of December 31, 2023, we were in compliance with such covenants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to comply with the covenants in the Loan Agreement, including as a result of changing the position of certain of our accounts, failure to transfer funds back to Banc of California at expiration of the Letter, the occurrence of a material impairment in our prospect of repayment operations, business or financial condition, our ability to repay the loan, or in the value, perfection or priority of Banc of California&#8217;s lien on our assets, as determined by PacWest, or the occurrence of certain other specified events could result in an event of default that, if not cured or waived, could result in the acceleration of all or a substantial portion of our debt, potential foreclosure on our assets and other adverse results. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent of Banc of California, including, without limitation, incurring certain additional indebtedness, making certain asset dispositions, entering into certain mergers, acquisitions or other business combination transactions or incurring any non-permitted lien or other encumbrance on our assets. The foregoing prohibitions and constraints on our operations could result in our inability to: (a) acquire promising intellectual property or other assets on desired timelines or terms; (b) reduce costs by disposing of assets or business segments no longer deemed advantageous to retain; (c) reallocate certain of our cash deposits and money market accounts depending on various global banking events; (d) stimulate further corporate growth or development through the assumption of additional debt; or (e) enter into other arrangements that necessitate the imposition of a lien on corporate assets. Moreover, if the conditions set forth in the consent provided by Banc of California are not satisfied, or if we do not comply with the terms of the Letter, we would effectively need to terminate the Loan Agreement and repay any outstanding loan funds or refinance the facility with another lender. As of the date of this Annual Report on Form 10-K, no amounts have been drawn under the Loan Agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC stated all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. Although we are not a borrower or party to any such instruments with SVB, Signature or any other financial institution currently in receivership, if any of our lenders or counterparties to any such instruments, including Banc of California or its affiliates, were to be placed into receivership, we may be unable to access such funds. In addition, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">d</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">elayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of access to revolving existing credit facilities or other working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential or actual breach of contractual obligations that require us to maintain letters or credit or other credit support arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential or actual breach of financial covenants in our credit agreements or credit arrangements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing agreements; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to achieve and maintain effective internal control over financial reporting could harm our business and negatively impact the value of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended. We will remain a non-accelerated filer as long as we qualify to be a &#8220;smaller reporting company&#8221; under Rule 12b-2 of the Exchange Act, which will be for as long as either (i) the market value of our common stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million as of the prior June 30. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue our efforts to improve our control processes, though there can be no assurance that our efforts will ultimately be successful or avoid potential future material weaknesses, and we expect to continue incurring additional costs as a result of these efforts. If we are unable to successfully remediate any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities, which could harm our reputation and our financial condition, or divert financial and management resources from our core business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Taxation</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Section 382 and Section 383 of the Internal Revenue Code of 1986 (IRC), as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as one or more shareholders or groups of shareholders who own at least 5 percent of the corporation&#8217;s equity increasing their equity ownership in the aggregate by a greater than 50 percentage point change (by value) over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2023, we had federal net operating loss carryforwards of approximately $294.8 million, and our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above or subject to other limitations, which could potentially result in increased future tax liability to us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (IRS) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made and changes are likely to continue to occur in the future. For example, under Section 174 of the code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional changes to U.S. federal income tax law are currently being contemplated, and future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. You are urged to consult your tax advisor regarding the implications of potential changes in tax laws on an investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Third Parties</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our collaboration with Regeneron is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial performance may be significantly affected by our Regeneron collaboration that we have entered into to develop next-generation engineered immune-cell therapeutics with fully human CARs and TCRs directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. Under the Regeneron Agreement, Regeneron paid us a non-refundable upfront payment of $25.0 million and an aggregate of $20.0 million of additional payments for research funding as of December 31, 2023, and we will collaborate with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regeneron to identify and validate targets and develop a pipeline of engineered immune-cell therapeutics for selected targets. Regeneron has the option to obtain development and commercial rights for a certain number of the product candidates developed by the parties, subject to an option payment for each product candidate. On January 28, 2022, we received a payment of $20.0 million from Regeneron for exercise of its option to license exclusive rights to ADI-002, and we completed the transfer of the associated license rights to Regeneron in the first quarter of 2022. If Regeneron exercises its option on a given product candidate, we then have an option to participate in the development and commercialization for such product. If we do not exercise our option, we will be entitled to royalties on any future sales of such products by Regeneron. We did not exercise our option to participate in the development and commercialization of ADI-002. In addition to developing CARs and TCRs for use in novel immune-cell therapies as part of the collaboration, Regeneron will have the right to use these CARs and TCRs in our other antibody programs outside of the collaboration. Regeneron will also be entitled to royalties on any future sales of products developed and commercialized by us under the agreement. If Regeneron were to terminate our collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek additional funding or another collaboration that might not be available on favorable terms or at all, and could cause significant delays in development and/or commercialization efforts and result in substantial additional costs to us. Termination of such collaboration agreement or the loss of rights provided to us under such agreement may create substantial new and additional risks to the successful development and commercialization of our products and could materially harm our financial condition and operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regeneron may change its strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us under the agreement. Regeneron has a variety of marketed products and product candidates either by itself or under collaboration with other companies, including some of our competitors, and the corporate objectives of Regeneron may not be consistent with our best interests. Regeneron may change its position regarding its participation and funding of our and Regeneron joint activities, which may impact our ability to successfully pursue the program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our existing and future collaborations will be important to our business. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered, and plan to enter, into collaborations with other companies, including our collaboration agreement with Regeneron and discovery agreement with Twist Bioscience Corporation (Twist), that we believe can provide us with additional capabilities beneficial to our business. The collaboration with Regeneron has provided us with important technologies, expertise and funding for our programs and technology. Under our discovery agreement with Twist, Twist will utilize its proprietary platform technology to assist us with the discovery of novel antibodies related to our gamma delta T cell therapy programs. We may receive additional technologies, expertise and funding under other collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may dispute the amounts of payments owed;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could develop independently, or with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with our own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may dispute ownership or rights in jointly developed technologies or intellectual property;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may fail to comply with applicable legal and regulatory requirements regarding the development, manufacture, sale, distribution or marketing of a product candidate or product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators with sales, marketing, manufacturing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the sale, marketing, manufacturing and distribution of such product or products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, payment obligations or the preferred course of discovery, development, sales or marketing, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional and burdensome responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend their or our relevant intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation and liability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a collaborator of ours is involved in a business combination or cessation, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates, or potentially lose access to the collaborator&#8217;s intellectual property.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> our therapeutic collaborations do not result in the successful discovery, development and commercialization of products or if one of our collaborators terminates our agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development and commercialization of our technology and product candidates could be delayed and we may need additional resources to develop product candidates and our technology. All of the risks relating to product discovery, development, regulatory approval and commercialization described in these risk factors also apply to the activities of our therapeutic collaborators.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the Regeneron collaboration described above, for some of our programs, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for discovery, development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators because, for example, third parties also have rights to allogeneic T cell technologies. For example, in April 2020, Johnson &amp; Johnson entered into a collaboration agreement with Fate Therapeutics, a company that is also using allogeneic T cell technologies, for up to four CAR Natural Killer (NK) and CAR T-cell therapies. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail discovery efforts or the development of a product candidate, reduce or delay our development program or one or more of our other development programs, delay our potential manufacture or commercialization, or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our expense. If we elect to fund and undertake discovery, development, manufacturing or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary discovery, development, manufacturing and commercialization activities, we may not be able to further develop our product</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">candidates, manufacture the product candidates, bring them to market or continue to develop our technology and our business may be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to certain exclusivity obligations under our agreement with Regeneron.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the five-year period following the effective date of the Regeneron Agreement, with certain limited exceptions, we may not directly or indirectly research, develop, manufacture or commercialize a gamma delta immune cell product (ICP) or grant a license to do the foregoing, except pursuant to the terms of the Regeneron Agreement. Both parties also have obligations not to research, develop, manufacture or commercialize an ICP with the same target as one being developed under a research program or commercialized by a party (and royalty bearing under the agreement), for so long as such activities are occurring. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in cancer. If our collaboration with Regeneron is not successful, including any failure caused by the risks listed in the preceding paragraphs, and the agreement and research programs are not terminated, we may not be able to enter into collaborations with other companies with respect to ICPs and our business could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exclusivity obligations under the Regeneron Agreement expired on July 29, 2021. Prior to this expiration date, our ability to advance any gamma delta immune cell therapeutics outside of the scope of the research plan agreed on with Regeneron was limited. The restrictions on internal development under the Regeneron Agreement could lead to delays in our ability to discover and develop gamma delta immune cell therapeutics for targets not covered by the collaboration with Regeneron and loss of opportunities to obtain additional research funding and advance our own technologies separately from the Regeneron collaboration. If we are delayed in our ability to advance our technologies due to the Regeneron Agreement, our business could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials will involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently utilize, and expect to continue to utilize, third parties to manufacture our product candidates. If the field of cell therapy continues to expand, we may encounter increasing competition and costs for these materials and services. Demand for third-party manufacturing in cell therapy may grow at a faster rate than existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of our product candidates at an acceptable cost or at all. We have also not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing at a commercial scale and therefore may be unable to create an inventory of mass-produced, "off-the-shelf" product to satisfy demands for any of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we anticipate reliance on a limited number of third-party manufacturers may adversely affect our operations and exposes us to the following risks:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third-party manufacturers could breach or terminate their agreement(s) with us.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any CDMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CDMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original CDMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CDMOs for any reason, we will be required to verify that the new CDMO maintains facilities and procedures that comply with quality standards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CDMO may possess technology related to the manufacture of our product candidates that such CDMO owns independently. This would increase our reliance on such CDMO or require us to obtain a license from such CDMO in order to have another CDMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates require many specialty raw materials, including viral vectors that deliver the targeting moiety and other genes to the product candidate. We currently manufacture through contract manufacturers, some of which have limited resources and experience supporting a commercial product, and such suppliers may not be able to deliver raw materials to our specifications. Those suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, some raw materials utilized in the manufacture of our candidates are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. Further, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. We may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our internal computer systems and the systems of our CROs, contractors and consultants are vulnerable to cybersecurity threats. Additionally, we operate in a hybrid work environment. As our employees and our business partners&#8217; employees work from home and access our systems remotely, we may be subject to heightened security and privacy risks, including the risks of cyberattacks and privacy incidents. Cybersecurity threats may include, but are not limited to, social-engineering attacks (including through phishing attacks), business email compromise, online and offline fraud, malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, access attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, and telecommunications failures among other cybersecurity risks. Threat actors and their techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. We may expend significant resources to try to protect against these threats to our systems. Certain data privacy and security laws, as well as industry best practice standards, may require us to implement and maintain security measures. While we have implemented security measures designed to protect our systems and confidential and sensitive data, there can be no assurance that these measures will be effective.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. Other consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Further, our insurance coverage may not be adequate or sufficient in type or amount to protect us from or to mitigate liabilities arising out of our privacy and security practices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits of acquired assets or other strategic transactions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, and any future strategic transactions depends on the risks and uncertainties involved including:</span></p>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated liabilities related to acquired companies or joint ventures;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties integrating acquired personnel, technologies, and operations into our existing business;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.424326795639711%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could have a material adverse effect on our financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Government Regulation</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to the EMA or comparable foreign authorities. A BLA must include extensive preclinical and clinical data and sufficient supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for autoimmune diseases and cancer. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also experience delays in obtaining regulatory approvals, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory authorization to begin a trial, if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">redesigning our study protocols and need to conduct additional studies as may be required by a regulator;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">governmental or regulatory delays and changes in regulation or policy relating to the development and commercialization of our product candidate by the FDA, EMA or other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiating the terms of any collaboration agreements we may choose to initiate or conclude;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of third-party contractors, such as CROs, or investigators to comply with regulatory requirements, including GCP standards;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to recruit and enroll suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty in having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any patient safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to add new clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">varying interpretations of the data generated from our preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of establishing, expanding and scaling manufacturing capabilities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to manufacture, or obtain from third parties, sufficient quantities of qualified materials under cGMPs, for the completion in preclinical and clinical studies; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">problems with biopharmaceutical product candidate storage, stability and distribution resulting in global supply chain disruptions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential unforeseen business disruptions or market fluctuations that delay our product development or clinical trials and increase our costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import or export restrictions, or public health crises.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA, EMA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition from biosimilar products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any of our product candidates that are approved in the United States as a biological product under a BLA should qualify for the 12-year period of reference product exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors, including under state laws, that are still developing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy and durability of effect must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we are developing novel allogeneic cell immunotherapy product candidates, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the category of cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in the regulation of existing cell therapy products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complex regulatory environments also exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include somatic cell therapy products and tissue engineered products. These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our gamma delta CAR T-cell product candidates is new, we may face even more cumbersome and complex regulations than those emerging for cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for our product candidates to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative, two-stage, pivotal, multicenter, single-arm clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. Subject to clinical data and regulatory feedback, in the first half of 2025, we plan to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 and provide a further clinical update in the second half of 2025. However, the process of clinical development is inherently uncertain and we do not have any agreement or guidance from the FDA that our future regulatory development plans are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptable or will be sufficient to support submission of a BLA. For example, we may seek an accelerated approval pathway for our one or more of our product candidates from the FDA, EMA or comparable foreign regulatory authorities. If we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may grant accelerated approval for our product candidates that meet the criteria for accelerated approval. As a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of accelerated approval was granted. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. Even if we seek to utilize the accelerated approval pathway, we may not be able to obtain accelerated approval and, even if we do, we may not experience a faster development, regulatory review or approval process for that product. In addition, receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval. Further, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, EMA or other regulatory agencies requesting additional studies to evaluate our product candidate relative to the new products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities will inspect our manufacturing facility (or our CDMO's facility) and may not find it acceptable; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations. Further, the FDA may further reevaluate its regulations and policies under the Orphan Drug Act. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received fast track designation for ADI-001 for the treatment of NHL. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical needs for this condition, the product candidate sponsor may apply for fast track designation for a particular indication. We may seek fast track designation for certain of our product candidates, but there is no assurance that the FDA will grant this status to any of our product candidates. Marketing applications filed by sponsors of product candidate with fast track designation may qualify for priority review under the policies and procedures offered by the FDA, but the fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a fast track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any fast track designation at any time.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RMAT designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek RMAT designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Positive results from early preclinical studies and clinical trials are not necessarily predictive of the results of any future clinical trials of our product candidates, and may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data. If we cannot replicate the positive results from our earlier preclinical studies and clinical trials of our product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publish interim, top-line or preliminary results from our preclinical studies or clinical trials. Such clinical results are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. As a result, interim, &#8220;top-line,&#8221; and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. It is also difficult to predict the timing of announcing interim results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, any positive results from our preclinical studies and ongoing and future clinical trials of our product candidates may not necessarily be predictive of the results from required later clinical trials. Similarly, even if we are able to complete our planned preclinical studies or any future clinical trials according to our current development timeline, the positive results from such preclinical studies and clinical trials may not be replicated in subsequent preclinical studies or clinical trial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidate performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or similar regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our ongoing clinical trial utilizes an &#8220;open-label&#8221; trial design, as may be the case in planned future clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in a controlled environment with a placebo or active control.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the clinical updates, or the interim, "top-line", or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, on June 23, 2016, the UK held a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement (TCA) which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. For example, the new Clinical Trials Regulation, which became effective in the EU on January 31, 2022 and provides for a streamlined clinical trial application and assessment procedure covering multiple EU Member States, has not been implemented into UK law, and a separate application will need to be submitted for clinical trial authorization in the UK. The separate, and potentially diverging, regulatory regimes between Great Britain and the EU may increase our regulatory burden of applying for and obtaining authorization in Great Britain and the EU.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates will require post-market surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy (REMS), in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials that we conduct post-approval. As such, we and our contract manufacturers are required to register establishments with the FDA and certain state agencies, and will be subject to continual review and unannounced inspections by the FDA and state agencies to assess compliance with cGMPs and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. We will also be required to comply with FDA's promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturers' communications on the subject of off-label use of their products. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community, adversely affecting our ability to achieve our commercial and financial projections.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of engineered gamma delta T cells as potential treatments for autoimmune diseases and cancer is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We expect physicians, including rheumatologists, nephrologists and oncologists, to be particularly important to the market acceptance of our products and we may not be able to educate them on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">benefits of using our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product labeling or product insert requirements of the FDA, EMA or other regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of autoimmune diseases and cancer, we cannot accurately estimate the potential revenue from our product candidates. For further discussion on coverage and reimbursement matters, see the section entitled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Business&#8211;Government Regulation and Product Approval&#8211;Coverage, Pricing and Reimbursement&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, Centers for Medicare and Medicaid Services (CMS) revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers and reduce the willingness of physicians to use our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Because our product candidate may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidate. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. Specifically, there have been several United States Congressional inquiries and federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. Increased efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidate. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. For further discussion on healthcare reform matters, see the section entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business &#8211; Government Regulation and Product Approval &#8211; Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical and biologics pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in various congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for our product candidates if we obtain regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that it believes is fair for our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if and when patents will issue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that it was the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may require access to additional intellectual property to develop our current or future product candidates. Accordingly, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patient&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Third Party Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We depend substantially on our license agreements with Regeneron. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on us avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are aware of United States and foreign patents held by a third parties relating to gamma delta T cell expansion protocols and related compositions which, on information and belief, are invalid and/or not infringed. In the event that these patents are successfully asserted against our product candidates, such as ADI-001, ADI-270 and ADI-002, or the use of our precursor cells in manufacture of these product candidates, such litigation may negatively impact our ability to commercialize these product candidates in such jurisdictions. We are also aware of several United States and foreign patents held by third parties relating to certain CAR compositions of matter, methods of making and methods of use which, on information and belief, are invalid and/or not infringed. Nevertheless, third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when ADI-001, ADI-270, ADI-002 or another CAR-based product candidate is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid and/or not infringed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Intellectual Property Laws</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent United States Court of Appeals for the Federal Circuit and Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our intellectual property rights outside the United States Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions outside of the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or licenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership Generally</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The trading price of our common stock is highly volatile, which could result in substantial losses for purchasers of our common stock. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial condition and results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price is highly volatile. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In addition, if the market for pharmaceutical and biotechnology stocks or the broader stock market continues to experience a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition or results of operations. As a result of this volatility, you may not be able to sell your common stock at or above the purchase price and you may lose some or all of your investment. The market price for our common stock may be influenced by many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of existing or new competitive products or technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of clinical trials of ADI-001; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain FDA clearance of additional INDs for ADI-001 in autoimmune indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of preclinical studies of ADI-270;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commencement or termination of collaborations for our development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure or discontinuation of any of our development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials of product candidates of our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to develop additional product candidates or products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issues or delays regarding the manufacturing of our product candidates and, if approved, products by us or by our third-party suppliers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results or development timelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders or other stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. We have been, and may in the future be, subject to securities litigation related to corporate governance matters determined in good faith by our board of directors, including the stock option repricing in August 2023 in accordance with the terms of our 2015 Plan and 2018 Plan. Even if the allegations against us are unfounded or we ultimately are not held liable, we may experience related negative publicity resulting in damage to our reputation. Further, the costs to defend ourselves may be significant and the litigation may subject us to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial settlements, fines, penalties or judgments against us and may consume management&#8217;s bandwidth and attention, some or all of which may negatively impact our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not be sustained. If an active trading market is not sustained, our ability to raise capital in the future may be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock began trading on The Nasdaq Global Select Market on January 26, 2018 and now trades on The Nasdaq Global Market under the symbol &#8220;ACET.&#8221; Given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not be sustained, which could put downward pressure on the market price of our common stock and thereby affect your ability to sell shares you purchased. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and impair our ability to acquire other companies or technologies by using our shares as consideration.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers, directors, and 5% stockholders beneficially owned, in the aggregate, approximately 56.9% of our outstanding voting common stock as of December 31, 2023. Accordingly, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Market Uncertainties</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, volatile interest rates, rising and fluctuating inflation rates, reduced corporate profitability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the United States. Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the United States. The impact of this or any further downgrades to the U.S. government&#8217;s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. In addition, inflation rates in the U.S. have recently increased to levels not seen in decades.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the state of global economic conditions are particularly volatile and uncertain and may negatively impact our ability to conduct clinical trials on the scale and timelines anticipated. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business or political environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make obtaining any necessary debt or equity financing more difficult, more costly and more dilutive. For example, as a result of political, social, and economic instability abroad, including as a result of armed conflict, war or threat of war, in particular, the current conflict between Russia and Ukraine, including resulting sanctions, terrorist activity and other security concerns in general, there could be a significant disruption of global financial markets, impairing our ability to raise capital when needed on acceptable terms, if at all. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. To the extent that our profitability and strategies are negatively affected by downturns or volatility in general economic conditions, our business and results of operations may be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets. For instance, rising interest rates have impacted our net income. Recent supply chain constraints have led to higher inflation, which, if sustained, could have a negative impact on our product development and operations. If inflation or other factors were to significantly increase our business costs, our ability to develop our current pipeline and new therapeutic products may be negatively affected. Current capital market conditions, including the impact of inflation, have increased borrowing rates and can be expected to significantly increase our cost of capital as compared to prior periods and could also affect our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers and manufacturers to manufacture clinical trial materials for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Charter and Bylaws</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our third amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our director, officer or other employee to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim against us governed by the internal affairs doctrine (Delaware Forum Provision); provided, however, that the Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. This choice of forum provision contained in our amended and restated bylaws will not apply to any causes of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated bylaws described above; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies&#8217; bylaws or certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a SRC and the reduced disclosure requirements applicable to SRCs may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are considered a SRC under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company for as long as (i) the market value of our common stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million as of the prior June 30.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the future clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend themselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exhaustion of any available insurance and our capital resources; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any product candidate.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceeds our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle it to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market price of our common stock. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act of 1933, as amended (Securities Act) would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 15, 2022, we filed a registration statement on Form S-3 (File No. 333-263587) with the SEC, which was amended by the Amendment No. 1 to the Registration Statement on Form S-3, as filed with the SEC on March 16, 2022, declared effective on May 9, 2022 (2022 Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. Under the 2022 Shelf Registration Statement and a prospectus supplement filed on January 22, 2024, on January 25, 2024, we completed an underwritten public offering of 32,379,667 shares of our common stock, which included 5,325,000 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of our common stock, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. The shares of common stock were sold at a public offering price of $2.40 per share and the pre-funded warrants were sold at a public offering price of $2.3999 per pre-funded warrant, which represents the per share public offering price of each share of common stock minus the $0.0001 per share exercise price for each pre-funded warrant. We received $98.0 million in aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses. As a result of this offering, our stockholders experienced significant dilution. If we sell, or the market perceives that we intend to sell, substantial amounts of our common stock under the 2022 Shelf Registration Statement or otherwise, the market price of our common stock could decline significantly.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also filed registration statements on Form S-8 registering the issuance of shares of common stock issued or reserved for future issuance under our equity compensation plans. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain of our employees, executive officers, and directors may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule 10b5-1 trading plan may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule 10b5-1 trading plan when they are not in possession of material, nonpublic information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unresolved Staff Comments.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cyber Risk Management and Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies on electronic systems and information technologies to conduct its operations. We have adopted and maintain a cybersecurity risk management program, in accordance with our risk profile and business, that is informed by industry standards.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We leverage the support of third-party information technology and security providers, including to perform penetration testing and threat intelligence analysis. We have previously conducted a cybersecurity risk assessment that was intended to take into account the evolving cyber threat landscape and industry best practices, and we have endeavored to adapt our cyber risk strategy to mitigate emerging cybersecurity risks. We implement a multi-layered approach to cybersecurity that includes, for example, employee security awareness training, various security tools and technologies, and incident response planning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although risks from cybersecurity threats have to date not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations or financial condition, we could, from time to time, experience threats and security incidents relating to our, and our third party vendors&#8217;, information systems. For more information, please see the section entitled &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Senior Director of Information Technology (&#8220;IT&#8221;) reports directly to our Chief Financial Officer and is responsible for the strategic leadership and direction of our cybersecurity program, with support from our Associate Director of Information Security and Senior Manager of IT. With over 20 years of experience in IT and cybersecurity risk management, our Senior Director of IT works alongside individuals across other Company management functions to establish and implement our cybersecurity risk management strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee, which reports directly to the board of directors, is responsible for overseeing our cybersecurity risk management program pursuant to the audit committee&#8217;s charter. The audit committee receives periodic updates on cybersecurity risks, mitigation strategies, and, if necessary, incident response activities from our Senior Director of IT. The audit committee may update the full board of directors on matters relating to cybersecurity risk management as needed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have offices in Boston, Massachusetts, and Redwood City, California. Our principal executive offices are located at 131 Dartmouth Street, 3rd Floor, Boston, Massachusetts. On January 31, 2024, our Boston, Massachusetts lease at 200 Berkeley Street was terminated by the landlord due to closing of the office space. On January 19, 2024, we entered into a membership agreement with Industrious Bos 131 Dartmouth Street LLC for office space at 131 Dartmouth Street, Boston, Massachusetts (the Dartmouth Street Agreement). The Dartmouth Street Agreement commenced on February 1, 2024 and expires on January 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also lease office and laboratory space located at 1000 Bridge Parkway, Redwood City, California. The lease commenced on March 31, 2020 and expires on February 28, 2030. In addition, we lease office space at 1200 Bridge Parkway, Redwood City, California. This lease commenced on June 17, 2022 and expires on June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently subject to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock trades on The Nasdaq Global Market under the symbol &#8220;ACET&#8221;. Trading of our common stock commenced on January 26, 2018, in connection with our initial public offering of resTORbio. Prior to that time, there was no established public trading market for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 14, 2024, we had approximately 16 holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Compensation Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 5 of Form 10&#8209;K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10&#8209;K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [Reserved].</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. We are advancing a pipeline of &#8220;off-the-shelf&#8221; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach to activate, engineer and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows us to generate new product candidates in a rapid and cost-efficient manner. Our allogeneic "off-the-shelf" manufacturing process is designed to allow product from unrelated donors to be stored and sold on demand to treat patients without inducing a graft versus host immune response. This is in contrast to products based on alpha beta T cells, which either must be manufactured for each patient from his or her own T cells, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Our pipeline also includes our lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Our pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors. We expect to continue to develop product candidates in autoimmune diseases and cancer based on our gamma delta T cell platform using either previously validated antigens or those that we identify and target using CAR and other technology. We plan to file one new Investigational New Drug (IND) application every 12-18 months, including an IND for ADI-270 in the first half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADI-001</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Autoimmune Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the U.S. Food and Drug Administration (FDA) cleared our IND application for ADI-001 in lupus nephritis, an autoimmune disease caused by systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of SLE which affects approximately 40% of the estimated 325,000 patients with SLE in the U.S. We expect to initiate a Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024 and expand development of the candidate into one to two additional autoimmune indications in the second and third quarters of 2024, subject to clearance of INDs in those indications. We believe the potential market opportunity for ADI-001 in B cell mediated autoimmune diseases is substantial based on the prevalence in the U.S., EU5, China and Japan of greater than 1.7 million patients with autoimmune diseases where CAR-T cell therapy has demonstrated clinical proof-of-concept, including SLE (which includes lupus nephritis), systemic sclerosis and idiopathic inflammatory myopathies.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate providing preliminary clinical data from our Phase 1 clinical trial of ADI-001 in lupus nephritis in the fourth quarter of 2024 or first quarter of 2025, subject to study site activation and enrollment, and to begin to provide preliminary clinical data in the additional autoimmune indications starting in the fourth quarter of 2024 or first half of 2025, subject to clearance of INDs in those indications as well as successful site initiation and patient enrollment in the relevant clinical protocols.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Relapsed or Refractory Aggressive B cell NHL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we initiated the first-in-human Phase 1 (GLEAN) trial to assess safety and efficacy of ADI-001 in patients with relapsed or refractory aggressive B cell NHL. The study includes a dose escalation portion followed by dose expansion cohorts to explore the activity of ADI-001 in multiple subtypes of NHL. In April 2022, the FDA granted fast track designation for ADI-001 for NHL. As of the May 4, 2023 cutoff date, of the 24 evaluable subjects in the GLEAN trial, 18 had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">large B cell lymphoma (LBCL), five had mantle cell lymphoma (MCL), and one patient had follicular lymphoma. Most patients were heavily pre-treated, with a median four lines of prior therapy, and twelve patients (50%) had previously progressed following CAR T cell therapy. Despite the advanced nature of patients at baseline, we observed a high complete response (CR) rate and favorable durability in MCL patients. Across all doses of MCL patients, we observed an 80% (4/5 patients) overall response rate (ORR), an 80% CR rate (4/5 patients) and a 60% CR rate (3/5 patients) at six months. As of May 4, 2023, the safety profile of ADI-001 was generally favorable, with no significant risk of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or T cell malignancy observed. In November 2023, we initiated an expansion cohort, EXPAND, in post-CAR T LBCL. In January 2024, we announced our decision to deprioritize enrolling LBCL patients in the GLEAN trial in order to focus on advancing MCL enrollment.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to provide a clinical update from the Phase 1 study in NHL patients which will include efficacy data, including six-month CR rate, and safety data from additional MCL patients in the second half of 2024. Subject to clinical data and regulatory feedback, in the first half of 2025, we plan to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL and provide a further clinical update in the second half of 2025.</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have expanded manufacturing capabilities of ADI-001 by transferring the manufacturing process to an additional contract development and manufacturing organization (CDMO) that is capable of operating at a larger scale of production.</span></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ADI-270</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADI-270 is an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of renal cell carcinoma (RCC) and with potential in other solid tumor indications. ADI-270 is designed to home to solid tumors, with a highly specific targeting moiety for CD70 and an armoring technology of transforming growth factor (TGF) beta dominant-negative receptor to address immunosuppressive factors in the tumor microenvironment.  Building on gamma delta 1 tissue tropism to solid tumors and three mechanisms of anti-tumor activity (CAR, innate and adaptive), CAR gamma delta 1 T cells may be well positioned to address solid tumors. We plan to file an IND application for ADI-270 in RCC in the second quarter of 2024 and provide clinical data in the first half of 2025, subject to regulatory clearance and study initiation activities. We are also considering potential expansion into additional CD70+ tumor indications in the first half of 2025, with potential clinical data from such studies in the second half of 2025, subject to regulatory clearance and study initiation activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Developments</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1000 Bridge Parkway Lease and Letter of Credit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2023, we entered into a third lease amendment (the Third Amendment) with Westport Office Park, LLC (Westport). The Third Amendment further amends the Redwood City Lease and increases the tenant improvement allowance as of January 1, 2023 by an additional $3.0 million. We expect to utilize the full allowance for the continued buildout of office and laboratory space at 1000 Bridge Parkway. Per the terms of this amendment, this additional allowance will be repaid through equal monthly payments of principal amortization and interest on a monthly basis over the term of the lease at an interest rate of eight percent (8%) per annum. We received the allowance on February 21, 2023.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, we entered into a fourth lease amendment (the Fourth Amendment) with Westport. The Fourth Amendment amended the period over which the tenant improvement allowance received in the Third Amendment will be amortized and identified our monthly amortization payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 1, 2023, we amended our letter of credit with Westport. The amendment reduced the amount of the letter of credit associated with our 1000 Bridge Parkway facility by $2.1 million resulting in an updated letter of credit amount of $2.1 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option Repricing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2023, our board of directors approved a stock option repricing (the Option Repricing) to be effective on August 14, 2023 (the Effective Date) in accordance with the terms of our 2015 Stock Incentive Plan and 2018 Plan (together, the Plans). Pursuant to the Option Repricing and subject to a one year cliff period,  the exercise price of each stock option previously granted under the Plans, totaling 6,431,910 options, was amended to reduce the exercise price of such options to $2.14 per share, the closing price of our common stock on the Nasdaq Global Market on the Effective Date. Under the terms of the Option Repricing, a repriced option will revert to its original exercise price if, prior to the one-year anniversary of the Effective Date, (a) the option holder&#8217;s employment is terminated by us with cause or by the option holder or (b) the option is exercised. The repriced options otherwise retained their existing terms and conditions as set forth in the Plans and applicable award agreements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of the Effective Date, we issued 1,418,042 options to purchase shares of common stock under the 2018 Plan to eligible employees who held inducement awards as of August 8, 2023. These new options were issued to eligible employees because their inducement awards granted under Nasdaq Listing Rule 5635(c)(4) are not eligible for repricing. The prior inducement awards remain outstanding under their original terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Underwritten Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, we entered into an Underwriting Agreement (the Underwriting Agreement) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the underwriters (the Underwriters), related to an underwritten public offering (the Offering) of 32,379,667 shares of our common stock, which included 5,325,000 shares sold and issued upon the exercise in full by the Underwriters of their option to purchase additional shares of common stock, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. The shares of common stock were sold at a public offering price of $2.40 per share and the pre-funded warrants were sold at a public offering price of $2.3999 per pre-funded warrant, which represents the per share public offering price of each share of common stock minus the $0.0001 per share exercise price for each pre-funded warrant. We received net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses, of approximately $91.8 million. We may receive nominal proceeds, if any, from the exercise of the pre-funded warrants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-the-Market (ATM) Offering</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we sold an aggregate of 6,350,000 shares of common stock in a series of sales in accordance with our &#8220;at-the-market&#8221; offering program (ATM Program) with JonesTrading Institutional Services LLC (Sales Agent), at an average price of $3.13 per share, for aggregate net proceeds of approximately $19.3 million, after deducting sales agent commissions, but before deducting any expenses related to such sales. As of the date of this Annual Report on Form 10-K, up to $80.1 million of our common stock remains available for sale from time to time under our ATM Program. In March 2024, we terminated our ATM Program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products approved for commercial sale and do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for our product candidates, which we expect will not be for at least several years, if ever. Our revenues to date have been generated from our License and Collaboration Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) and the agreement referred to as the &#8220;Regeneron Agreement.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received a non-refundable upfront payment of $25.0 million from Regeneron upon execution of the Regeneron Agreement on July 29, 2016 and have received an aggregate of $20.0 million of additional payments for research funding from Regeneron as of December 31, 2023. Our obligations under the Regeneron Agreement were completed during the first quarter of 2022. Regeneron may have to pay us additional amounts in the future consisting of up to an aggregate of $80.0 million of option exercise fees for a certain number of Interprofessional Collaboration Practices (ICPs). On January 28, 2022, we received a payment of $20.0 million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other Collaboration ICP targets under the Regeneron Agreement. We declined to exercise our option to co-fund the development of ADI-002 with Regeneron, and accordingly, Regeneron must also pay us high single digit royalties as a percentage of net sales for ADI-002 or any other optioned ICPs to targets for which it has exclusive rights and low single digit royalties as a percentage of net sales on any non-ICP product comprising a target generated by us through the use of Regeneron&#8217;s proprietary mice. We must pay Regeneron mid-single to low double digit royalties as a percentage of net sales of Collaboration ICPs to targets for which we have exercised exclusive rights, and low to mid-single digit royalties as a percentage of net sales of targeting moieties generated from our license to use Regeneron&#8217;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or 12 years from first commercial sale.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We used a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize under the Regeneron Agreement. In applying the cost-based input method of revenue recognition, we used actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. Revenue was recognized based on actual costs incurred as a percentage of total budgeted costs as we completed our performance obligations over the research term. A cost-based input method of revenue recognition requires us to estimate costs to complete our performance obligations, which requires significant judgment to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete our performance obligations is recorded in the period in which changes are identified and amounts can be reasonably estimated.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expenses</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses, which consist primarily of costs incurred in connection with the development of our product candidates, are expensed as incurred. Research and development expenses consist primarily of:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee related costs, including salaries, benefits and stock-based compensation expenses for research and development employees;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs incurred under agreements with consultants, CDMOs and contract research organizations (CROs);</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lab materials, supplies and maintenance of equipment used for research and development activities; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and amortization, information technology costs and general support services.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not allocate our costs by product candidate, as a significant amount of research and development expenses are not tracked by product candidate, and we believe the allocation of such costs would be arbitrary and would not provide a meaningful assessment as we have used our employee and infrastructure resources across multiple product candidate research and development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are focusing substantially all of our resources on the development of our product candidates. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress and expense of clinical trials and other research and development activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial results;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainties in clinical trial enrollment rate or design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant and changing government regulation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and receipt of any regulatory approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA&#8217;s or other regulatory authority&#8217;s influence on clinical trial design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continued applicable safety profiles of the products following approval; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key research and development personnel.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to other rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock based compensation expenses, professional fees for legal, consulting, accounting and tax services, allocated overhead expenses, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our general and administrative expenses will increase for the foreseeable future due to expenses related to operating as a public company, including expenses related to personnel costs, expanded infrastructure and higher consulting, legal and accounting services costs associated with complying with the applicable Nasdaq and SEC requirements, investor relations costs and director and officer insurance premiums.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill Impairment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in our merger with resTORbio, Inc. in September 2020. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value. If the fair value of the reporting unit is less than the carrying value, we measure the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. This amount is recognized as a goodwill impairment charge for the period. The Company performed an interim test for goodwill impairment in the third quarter of 2023 and determined that the entire balance of goodwill was impaired.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists primarily of interest earned on our cash and cash equivalents.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense consists primarily of the non-cash amortization of costs incurred in connection with the Loan Agreement (as defined below).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Expense, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expense, net primarily consists of state franchise and capital taxes not related to income.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.11%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:9.442%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:9.442%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:9.242%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.922%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">% Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue &#8211; related party</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24,990</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,043</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,797</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,295</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">152,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,541</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,497</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(152,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,551</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(79,487</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,978</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,760</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,218</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(80</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(573</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(919</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">346</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income tax benefit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(142,658</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(69,790</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,868</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(142,658</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(69,790</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,868</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue decreased by $25.0 million, or 100%, for the year ended December 31, 2023 compared to the year ended December 31, 2022. The decrease was due to no revenue recognized under the Regeneron Agreement in the current period. Our obligations under the combined performance obligation with Regeneron were completed during the first quarter of 2022, resulting in revenue fully recognized under the agreement as of March 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:65.847%;"/>
    <td style="width:1.78%;"/>
    <td style="width:1%;"/>
    <td style="width:13.297%;"/>
    <td style="width:1%;"/>
    <td style="width:1.78%;"/>
    <td style="width:1%;"/>
    <td style="width:13.297%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payroll and personnel expenses(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,744</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Costs incurred under agreements with consultants, CDMOs, and CROs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,963</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,233</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab materials, supplies and maintenance of equipment<br/>used for research and development activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,065</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,929</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other research and development expenses(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,271</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,883</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,043</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  Employee related costs, including salaries, benefits, bonuses, and stock-based compensation expenses for research and development employees.</span></p>
  <p style="margin-left:4.533%;text-indent:-2.874%;padding-left:2.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  Allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and amortization, information technology costs and general support services.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $34.8 million, or 49%, during the year ended December 31, 2023 compared to the year ended December 31, 2022. The increase in research and development expenses was primarily due to a $10.7 million increase in expenses related to CDMOs and other externally conducted research and development and a $11.5 million increase in payroll and personnel expenses resulting from an increase in overall headcount. In addition, there was an $8.5 million increase in allocated facility expenses and a $4.1 million increase in laboratory expenses for the period. This increase was partially offset by a $0.2 million decrease in professional fees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses increased by $0.2 million, or 1%, during the year ended December 31, 2023 compared to the year ended December 31, 2022. The increase in general and administrative expenses was primarily due to a $3.3 million increase in payroll and personnel expenses, which includes an increase in salaries and benefits of $1.0 million, contractor fees of $0.9 million, stock-based compensation of $1.2 million and recruiting fees of $0.3 million. These increases were the result of increased headcount for the period. The increase was partially offset by a $2.6 million decrease in allocated facility expenses. There was also a $0.5 million decrease in professional fees for the period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill Impairment</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill impairment charges increased by $19.5 million, or 100%, during the year ended December 31, 2023 compared to the year ended December 31, 2022. Beginning in the third quarter of 2023, we experienced a significant decline in our stock price. We concluded that the decrease in stock price was sustained and that it was more likely than not that the fair value of our single reporting unit was less than its carrying amount. As such, we performed an interim goodwill impairment test as of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023. Based on our interim impairment test, we recorded a goodwill impairment charge of $19.5 million during the year ended December 31, 2023, representing the entire balance of goodwill.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income increased by $6.2 million, or 165%, during the year ended December 31, 2023 compared to the year ended December 31, 2022, which was primarily due to higher interest rates as well as our investments in treasury securities and money market funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Expense, Net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other expense decreased by $0.3 million, or 38%, during the year ended December 31, 2023 compared to the year ended December 31, 2022, which was primarily due to a decrease in franchise and capital taxes for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Benefit</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no income tax expense or benefit for the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have historically funded our operations primarily through a collaboration and licensing arrangement, public and private placements of equity securities and debt, and cash received in our merger with resTORbio, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, we received net proceeds of $43.6 million from the sale of shares of our common stock under our ATM Program with the Sales Agent and, in January 2024, we received net proceeds of $19.3 million from the sale of shares of our common stock under our ATM Program. Up to $80.1 million of shares of our common stock remains available for sale under our ATM Program, providing us with an additional source of liquidity, subject to market conditions. In March 2024, we terminated our ATM Program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in January 2024, we completed the Offering, which resulted in net proceeds to us, after deducting the underwriting discount and commissions and other estimated offering expenses, of approximately $91.8 million. We may also receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $159.7 million. We expect that our cash and cash equivalents, together with the proceeds raised subsequent to year-end through our ATM Program and the Offering, will be sufficient to fund our forecasted operating expenses, capital expenditure requirements and debt service payments for at least the next twelve months from the issuance of the consolidated financial statements included in this Annual Report on Form 10-K.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2020, we entered into a Loan and Security Agreement, as amended on July 8, 2020, September 14, 2020, September 15, 2020, October 21, 2021, December 2, 2022 and May 30, 2023 (the Loan Agreement), with Banc of California (formerly known as Pacific Western Bank) to finance leasehold improvements for our facilities in Redwood City, California and other purposes permitted under the Loan Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2023, we amended our Loan Agreement with Banc of California (the 2023 Loan Amendment). Pursuant to the 2023 Loan Amendment, we must maintain the lesser of (i) $35.0 million or (ii) all of our combined balances in demand deposit accounts, money market accounts, and/or insured cash sweep accounts with Banc of California. If our total cash and investments drop to less than $35.0 million, the 2023 Loan Amendment permits us to maintain cash and/or investments in one or more accounts outside of Banc of California up to a total of $2.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have $12.7 million available under the Loan Agreement. As of the date of this Annual Report on Form 10-K, we were in compliance with such covenants and had no indebtedness outstanding under the Loan Agreement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses since inception and have incurred losses of $142.7 million and $69.8 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $380.8 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $159.7 million. Subsequent to December 31, 2023, we raised aggregate net proceeds of approximately $19.3 million through our ATM Program and approximately $91.8 million through the Offering. We believe that our cash and cash equivalents, together with the proceeds raised subsequent to year-end through our ATM Program and the Offering, will be sufficient for us to fund our operations for at least 12 months from the issuance date of our consolidated financial statements as of, and for the year ended, December 31, 2023 included elsewhere in this Annual Report on Form 10-K. We have based these estimates on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we expect. Because of the risks and uncertainties associated with research, development, and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our revenue to date has been generated from the Regeneron Agreement, which is a collaboration and license agreement. We do not expect to generate any significant product revenue until we obtain regulatory approval of and commercialize any of our product candidates or enter into additional collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, number and scope of clinical programs we decide to pursue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope and costs of development and commercial manufacturing activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our implementation of operational, financial and management systems;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of potential health emergencies on United States and global economic conditions that may impact our ability to access capital on terms anticipated, or at all; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the post-merger costs associated with being a public company.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. Adequate funding may not be available to us on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to other rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See the section of this Annual Report on Form 10-K titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary Statement of Cash Flows</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the primary sources and uses of our cash, cash equivalents, and restricted cash for each of the periods presented below (in thousands):</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.72%;"/>
    <td style="width:1.68%;"/>
    <td style="width:1%;"/>
    <td style="width:12.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1.68%;"/>
    <td style="width:1%;"/>
    <td style="width:12.96%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(93,717</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(44,765</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(16,782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">236</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,509</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(97,945</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities was $93.7 million for the year ended December 31, 2023. Cash used in operating activities consisted of net loss offset by non-cash adjustments of $48.7 million and a net increase in operating assets and liabilities of $0.3 million. Non-cash items primarily included goodwill impairment of $19.5 million, stock-based compensation expense of $20.3 million, depreciation and amortization of $6.1 million and non-cash lease expense of $2.8 million. The net increase in assets and liabilities was primarily due to an increase of $0.9 million in prepaid expenses and other current assets and an increase of $0.4 million in other non-current assets accounts. There was also an increase in accrued and other current and non-current liabilities of $0.8 million. The increase was partially offset by a decrease in accounts payable of $1.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities was $44.8 million for the year ended December 31, 2022. Cash used in operating activities consisted of net loss and non-cash adjustments of $22.3 million as well as an increase in assets and liabilities of $2.7 million. Non-cash items primarily included stock-based compensation expense of $17.1 million, non-cash lease expense of $2.4 million and depreciation and amortization of $2.6 million. The net change in assets and liabilities was primarily due to an increase in accrued and other current and non-current liabilities of $5.8 million, an increase in accounts payable of $1.7 million and an increase in prepaid expenses and other current assets of $1.3 million. The increase was partially offset by a decrease in deferred revenue of $4.8 million related to the Regeneron Agreement and a decrease in operating lease liability of $2.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $4.5 million for the year ended December 31, 2023, which consisted of purchases of property and equipment related to the construction of our facilities in Redwood City, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $16.8 million for the year ended December 31, 2022, which consisted of purchases of property and equipment related to the construction of our facilities in Redwood City, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities was $0.2 million for the year ended December 31, 2023, which was primarily related to $0.4 million in net proceeds from the issuance of common stock in connection with our employee stock purchase plan. This was partially offset by $0.2 million of cash paid for taxes withheld on the net share settlement of equity awards.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities was $41.5 million for the year ended December 31, 2022, which primarily consisted of $43.4 million in proceeds from the issuance of common stock pursuant to our ATM Program and $1.7 million in cash proceeds from the exercise of stock options and purchases under our Employee Stock Purchase Plan. Net cash provided by financing activities was partially offset by $3.2 million of taxes withheld and paid related to net share settlement of employee equity awards and $0.4 million related to deferred issuance costs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting practices (GAAP). The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in our consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. While our significant accounting policies are more fully described in the Notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued CDMO, CRO, and Research and Development Expenses</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into various agreements with CDMOs and CROs. Our research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. To date, our estimated accruals have not differed materially from the actual costs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a fair value-based method to account for all stock-based compensation arrangements with employees and non-employees, including stock options and restricted stock awards. Our determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option pricing model. The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting period. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period. We account for forfeitures as they occur. In determining fair value of the stock options granted, we use the Black&#8211;Scholes option-pricing model, which requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of our common stock price over the expected term (expected volatility), risk-free interest rate and expected dividends. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized; and the resulting change in fair value, if any, is recognized in our consolidated statements of operations during the period the related services are rendered. These inputs are subjective and generally require significant analysis and judgment to develop. Changes in the following assumptions can materially affect the estimate of the fair value of stock-based compensation:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected Term &#8212; The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected Volatility &#8212; The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of our expected future stock price volatility. For purposes of identifying these peer companies, we consider the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measure historical volatility over a period equivalent to the expected term. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk-Free Interest Rate &#8212; The risk-free interest rate is based on the implied yield currently available on United States Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expected Dividend Rate &#8212; We have not paid and do not anticipate paying dividends in the near future. Accordingly, we estimate the dividend yield to be zero.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. We have determined that we operate in a single operating segment and have a single reporting unit.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to performing the impairment test, we assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, we were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, we would perform a quantitative impairment test.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, we measure the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. We performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023 and determined that goodwill was impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Smaller Reporting Company</span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. As a smaller reporting company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not smaller reporting companies. These provisions include (i) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act of 2002, as amended; (ii) scaled executive compensation disclosures; and (iii) the option to provide only two years of audited financial statements, instead of three years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to be a smaller reporting company for as long as we continue to have (i) less than $250 million in market value of our shares held by non-affiliates as of the last business day of our second fiscal quarter or (ii) less than $100 million of annual revenues in our most recent fiscal year completed before the last business day of our second fiscal quarter and a market value of our shares held by non-affiliates of less than $700 million as of the last business day of our second fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.133%;text-indent:4.545%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to take advantage of some but not all of these exemptions. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. We have elected to avail ourselves of the exemption for the delayed adoption of certain accounting standards and, therefore, are not subject to the same new or revised accounting standards as other public companies that are not smaller reporting companies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in Note 2 to our financial statements included elsewhere in this Annual Report on Form 10-K for additional information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ive Disclosures About Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash and cash equivalents of $159.7 million, which consisted of cash and treasury securities. Interest income is sensitive to general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a material impact on our cash and cash equivalents, financial position, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Exchange Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters are located in the United States, where a majority of our general and administrative expenses and research and development costs are incurred in U.S. Dollars. As we grow our business, our results of operations and cash flows may be subject to fluctuations due to foreign currency exchange rates. To date, we do not believe foreign currency exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assets are primarily monetary, consisting of cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our equipment, furniture, fixtures and office equipment, computer hardware and software and leasehold improvements, we believe that the incremental inflation related to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">replacement costs of such items will not materially affect our operations. Inflation generally affects us by increasing our cost of labor, clinical trial and manufacturing costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statemen</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ts and Supplementary Data.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All financial statements and supplementary data required to be filed hereunder are filed as listed under Item 15(a) of this Annual Report on Form 10-K and are incorporated herein by this reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of disclosure controls and procedures</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. These limitations include the possibility of human error, the circumvention or overriding of the controls and procedures and reasonable resource constraints. In addition, because we have designed our system of controls based on certain assumptions, which we believe are reasonable, about the likelihood of future events, our system of controls may not achieve its desired purpose under all possible future conditions. Accordingly, our disclosure controls and procedures provide reasonable assurance, but not absolute assurance, of achieving their objectives.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management's Annual Report on Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of our consolidated financial statements in accordance with U.S. GAAP, and includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, assessed our internal control over financial reporting as of December 31, 2023. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting. As we are a non-accelerated filer, management&#8217;s report is not subject to attestation by our registered public accounting firm.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that material weaknesses or significant deficiencies will not occur in the future or that we will be able to remediate such weaknesses or deficiencies in a timely manner, which could impair our ability to accurately and timely report our financial position, results of operations or cash flows. For additional information, see the related risks in the section titled "Risk Factors" of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than as stated above, no change in our internal control over our financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the year ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) None.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed, on March 12, 2021, we entered into a Capital On Demand&#153; Sales Agreement (Sales Agreement) with JonesTrading Institutional Services LLC (Sales Agent), pursuant to which we may sell from time to time, at our option, up to an aggregate of $75,000,000 of shares of the our common stock (ATM Shares), through our Sales Agent (ATM Program). On November 8, 2022, we filed a new prospectus supplement covering the offer and sale of up to $100.0 million of shares of our common stock under the ATM Program, which included the $30.0 million of shares of our common stock not sold pursuant to the existing prospectus and up to an additional $70.0 million of shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 13, 2024, we delivered written notice to our Sales Agent to terminate the Sales Agreement, effective as of March 15, 2024, pursuant to Section 12(b) thereof. We are not subject to any termination penalties related to the termination of the Sales Agreement. Prior to termination, $64.9 million of the ATM Shares had been sold and $80.1 million of the ATM Shares remained available for sale pursuant to the Sales Agreement. As a result of the termination of the Sales Agreement, we will not offer or sell any additional shares under the ATM Program.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ficers and Corporate Governance.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding directors, executive officers and corporate governance will be included in our 2024 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference (excluding pay versus performance disclosure).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a code of business conduct and ethics for directors, officers, and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at https://investor.adicetbio.com/corporate-governance/governance-highlights. We will promptly disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver. Shareholders may request a free copy of the Code of Business Conduct and Ethics from our Compliance Officer, c/o Adicet Bio, Inc., 131 Dartmouth Street, 3rd Floor, Boston, Massachusetts 02116.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding executive compensation will be included in our 2024 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference (excluding pay versus performance disclosure).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Ow</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding security ownership of certain beneficial owners and management and securities authorized for issuance under equity compensation plans will be included in our 2024 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding certain relationships and related transactions and director independence will be included in our 2024 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tant Fees and Services.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our independent public accounting firm is KPMG LLP, Boston, Massachusetts (PCAOB Auditor ID: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bca20154-3a7a-4a90-92fe-7c0d5222cc9d" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item regarding principal accounting fees and services will be included in our 2024 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits and Finan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cial Statement Schedules.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) The following documents are included in this Annual Report on Form 10-K:</span></p>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following Report and Consolidated Financial Statements of the Company are included in this Annual Report:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div></div>
  <div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits. The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The Exhibit Index is incorporated herein by reference.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92%;"/>
    <td style="width:8%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (KPMG LLP, Boston, MA, Auditor Firm ID: 185)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Consolidated Financial Statements</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:24.5pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:24.5pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:24.5pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:24.5pt;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:33.85pt;vertical-align:top;"><p style="margin-left:24.85pt;text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Adicet Bio, Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57d911dd-5f8c-4998-b332-25c680ab7913" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29245981-29bc-4e39-b52a-ddc74853e198" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 19, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">alance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:69.566%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:11.678%;"/>
    <td style="width:1%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:11.678%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_530d0756-2ac2-4372-a443-ef42e84da6ad" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,711</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d4af636-37bb-4148-953a-953b14bb7100" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,656</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89554672-39d0-4da9-856d-c65b04cf2f02" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eecfa28-f48d-4504-9418-a7e25449f46b" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f57fa17-fa78-4a00-9b85-e69af5398f76" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_854817e4-a5d6-4563-a346-6f00d2328c65" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac91906c-4d9b-4bed-8ac6-85c760e66da3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,777</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_961dc87f-2e45-4a77-ba31-3fc828bb576d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,710</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e1a035-c350-4d48-8e23-c23768451820" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56a66b60-3c8b-403e-9505-81373e9966c2" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f7f135-1820-4fc9-bfb8-a9067e85ab15" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa9a9835-9647-4a19-844c-5b8935dab11b" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b8dfcc2-386d-40ab-b80d-9525ddd05e6c" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">822</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115bf040-ec2e-4133-a3b3-3fd0755cb92d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d2fff31-710f-48a2-90e9-5f7d5f079bb3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,295</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a126345-2bb4-447f-951f-5c841206b368" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c4cc242-cbcb-46a7-9ca8-36921af7cc42" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,625</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17e180a8-8c4e-4891-85fb-8f0be1761916" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2e78ab2-1b9c-4db5-ad3f-62c4d4c461c1" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25eeca35-3865-4d6c-9bce-e59c902ecbaa" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51d132e5-826a-4e1f-bd05-e604c3a787b5" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,221</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f584735-72a6-4063-a5c4-b9c61fb1b17a" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53f36560-c95e-4247-8993-be32231da942" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,287</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c1efe05-e558-44b8-ab4b-ee033a20416d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,707</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e4d96a7-5f06-4ed2-9fce-e25c96f829c9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,703</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1139f58f-b114-4756-9d88-c2a6c29aa5e4" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,531</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e9a9b04-b85c-4132-b95d-7d3b7c126b32" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf625e61-878b-4277-a0a5-f03faa52e155" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bda9113-600f-44e3-9550-3ecce2b29c05" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,120</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54ef1874-832f-46f8-b2cf-d1a7ddd50295" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_3f165358-ac84-4432-ab5b-1a2e7c4a487f;"><span style="-sec-ix-hidden:F_6a2aed98-a0c1-4bfc-9ae8-b9b0b7443017;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Preferred stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c87772f7-cc0d-4a88-93f8-fb9d2cc50a7d" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_808c095c-00e3-4f9d-903f-55d5eac8a9fe" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value, </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62069b0f-3356-4ac1-bf9e-b5b78dc3f060" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_70da6ea6-ac38-45a7-ab4e-c1ce7947711c" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized as of December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edca7554-a9f0-41d8-9ba3-0eb65e63f3b8" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e64b9457-102b-4288-aa14-0cd818119013" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_78ecff4f-63d5-4913-bd82-51f0b19c1f65" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_39b49483-2f60-49bb-b8e9-e6d2d7bbda78" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff08f3c-a0e1-4f36-891e-f91c2db42820" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d135f376-ee5b-41de-94c4-db27b3d6bacd" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Common stock, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1941e927-1783-42f5-b11f-466c84add8d4" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_82cd0326-f946-47a0-b72c-26bfe215f652" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;par value, </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c185c71-e951-4f20-ad0b-f1a8f57e3199" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b93ae9bf-4446-4f94-98ba-b2da27e57b3d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares authorized as of December 31, 2023 and December 31, 2022, respectively; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_457d5cab-1cbe-4db6-b4ac-171ee3ef59e4" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fce7ca27-c3cf-4b93-bcb5-5a945ba490da" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,270,386</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_742bdd2d-d96d-4017-94e5-be6a0677f043" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5651a4b0-5d3f-48e8-97ac-5b4d6c451c70" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">42,954,820</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f427be9-277d-48e2-baf3-da12fcccbef3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9e35d1b-90ec-4f45-aafe-d4b283f08c1d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d982ec5d-e68d-4166-b759-43013c8440fb" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,943</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f85c8fbe-6ad9-45c3-93c4-10ed04b6c5a8" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_443fe3a0-a13e-4fa3-9d27-6478e215896c" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">380,772</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1ef68ae-bb6c-40fc-90a1-37fc6acaba20" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238,114</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93fa33b4-bead-431e-b590-42cdc1353bce" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa7041ca-b069-43d9-9e28-a99252ef35bc" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_903b4ca4-901f-4d13-b6fa-71c9be1de2f9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,295</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab08bce2-cc43-4f71-b22c-ab9d67591bfc" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">330,690</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_operations_compr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Ope</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.607%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:13.077%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:13.077%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">related party</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_095a7c54-6207-42c6-8902-79e626a7c9a7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c376a72-3e08-4451-bb35-294a2feecd93" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_757a4c75-7da0-440c-8c23-34ba5acec58b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,043</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fa7807c-6995-4e63-89ca-78323e159465" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_678cffe5-8ecf-4142-b48e-c1523801f7c6" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccdf3f48-cdeb-44ae-835e-3ba6895df26e" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,295</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1257019-a5f5-4642-9c3b-e945684e7d93" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:GoodwillImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef798215-53d0-484e-9a6e-d5778c0d963a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:GoodwillImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48bb6bdf-6108-4243-865d-420170166a6b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b5f7ef0-986b-457f-8348-7befd8143712" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,541</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7e3a974-416c-4056-9617-076a13b27b95" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8844c480-a16d-4617-abed-bb1c89bc98b9" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">72,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_297a96b2-d10d-4cb4-a847-81dc132e9a41" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,978</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfcf1f68-17c4-4022-9805-388a3f0a9b9e" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,760</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9896ee8c-0809-4138-a990-fb73b48d2e0e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d19befe7-ca22-4b3c-8dd9-a7f1800c91e6" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1382a9b-5ff5-40da-8c54-0fa9eeda2385" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">573</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_585209e9-f3dd-4d7c-9602-31cac30edd8f" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income tax provision</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8455b887-18f1-4a4b-8d22-bf3e207ec890" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e49f2045-aa04-4c2d-b663-541ef877b49f" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbe33acc-22fd-4845-8d92-7fdbf52ca865" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a64d136e-6752-44a9-9398-33906e01fc3a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2536bac1-3640-40d9-937f-1d87e2f41294" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e161ae0-db67-4933-8b73-6b003138acf4" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5936ce69-9d3e-4091-8923-3e13d2a7390c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_020897d0-892d-460c-b3c4-7fa51a892fc8" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.31</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae2258f1-93e5-4eee-9b16-83e6448adc31" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_789b91ec-c0b9-4b8b-83c8-5bd732a39662" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.70</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares used in computing net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30081f3e-7765-42b6-9e8b-999fc0123ad9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77b4c982-ccfc-491b-8bcc-142e89f25533" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,042,405</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7f9007a-0cac-42bf-92ae-ba0ca8333e53" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0344bd9d-1d17-4917-a748-2114fbf9294e" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,080,286</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_redeemable_conve"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.703%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:9.468%;"/>
    <td style="width:1%;"/>
    <td style="width:1.221%;"/>
    <td style="width:1%;"/>
    <td style="width:8.986999999999998%;"/>
    <td style="width:1%;"/>
    <td style="width:1.221%;"/>
    <td style="width:1%;"/>
    <td style="width:8.986999999999998%;"/>
    <td style="width:1%;"/>
    <td style="width:1.221%;"/>
    <td style="width:1%;"/>
    <td style="width:8.986999999999998%;"/>
    <td style="width:1%;"/>
    <td style="width:1.221%;"/>
    <td style="width:1%;"/>
    <td style="width:8.986999999999998%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d21b79f-926f-4854-8e91-a3c447adf476" contextRef="C_6dce953e-d2b7-435c-8ac4-abae82da8350" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,736,914</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0368a475-4978-4bfe-a074-2f062d36b976" contextRef="C_6dce953e-d2b7-435c-8ac4-abae82da8350" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e57ab629-08eb-4efb-b867-6f94d904a848" contextRef="C_f218b6be-cd0a-49e1-8525-a5eb02ac8f27" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42c98d5e-6dfe-452f-aa90-1c0b1d2fe085" contextRef="C_3839044c-67c3-4761-9d07-88d8d945f812" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">168,324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21f459a2-fbb6-463e-ab5e-ab54df069233" contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd4065d-b2f8-472b-a339-0e3a1bf1e298" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">126,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_344fb7a6-9865-4108-9a4a-42d37dfdcad8" contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_554f84c7-f279-47fa-ac78-cb6f174c74bd" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon vesting of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79df30e3-8c77-460a-a334-b2c8f24a419e" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">548,580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3cf67ef-98c5-459d-8162-b00a5650e089" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,731</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares withheld for taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4e4054c-d77d-48ac-822a-68c8ba096e68" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">215,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a80f39-bd7f-4af6-9b48-174fdd3030b8" contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5902606-8abf-41a1-bee4-16c23feba29b" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ef92196-8655-40d5-ba5a-87beb8b0db5b" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">46,597</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b91d80d5-066e-4dfd-8d6d-9e3abbd8adfd" contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54521517-f0ed-4bf0-9c0d-0a738c2af6f4" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f8ab82f-d93e-4294-b703-48d1dfee797c" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;million</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_907d6a28-6cfb-4bdc-8d0c-7e1cc091be17" contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe" name="acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,611,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb4d40be-e9a6-4ee8-9c8e-bfc11200d46e" contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd" name="acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a423d4fa-7664-4eb3-ac32-a7175af848de" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5377bdcb-e5d1-426f-8d0d-872d33c57c7f" contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4dbde40-fbde-444b-872e-4ece18c86e8a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6f29f3-313d-4ddd-b438-a39350466cf6" contextRef="C_8ace4969-2a3a-4174-850a-95de252b6cec" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bccfe20-1bb8-4ff2-8f02-d85f620fde35" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99795ac4-67d6-48de-91a5-03fc5d20db28" contextRef="C_e312fee1-4691-4e86-92c4-5ce4a346c5df" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">42,954,820</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63fe387f-7e0e-49c8-bff5-4813c9ed670e" contextRef="C_e312fee1-4691-4e86-92c4-5ce4a346c5df" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ef38651-34e6-4c2c-a510-5d785ae5ef40" contextRef="C_57f55a55-f9b7-41ed-98a9-192b9feeae13" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7f9748b-28ed-4e06-ba25-798a64aff08f" contextRef="C_869bf6a3-58bc-465a-b7da-4f80fdac6a75" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238,114</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe938a7-8da8-4580-9310-774b84e11293" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292,338</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_833443ab-6a7e-43e4-9aae-63314d0b9438" contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">946</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a54b9e29-c3e8-4ace-afc9-bb57fcd9e022" contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bead084-418e-4417-9767-ea84e9895c2c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon vesting of restricted stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a79e80-aa68-4690-bc5b-51dc0b3bec6f" contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">194,455</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares withheld for taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ae15424-791e-490c-a5f4-167f17a8cf5a" contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">86,145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f620f31-434f-499b-a8ef-28cda4fd3e43" contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0feaa598-4035-4747-bacd-771bc67de378" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of common stock under Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_159b8c83-70e3-4958-a2c4-062b9b4ccec3" contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">206,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40c6440a-8d37-433f-8526-599b40cc7e9f" contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_284dc7a2-8489-48d2-8f08-bdc4678f950e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cadfe79-009a-4fdb-be8c-bbb2fd97ca0a" contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8dc0197-cd12-412d-baf3-d7df0b34f938" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c84d031d-7212-4c86-8d7e-48075bb6a386" contextRef="C_ff7e4a68-2391-4c50-aaba-76ac9387247f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ad36d9-ad9c-4e47-b140-4b4f97e301a4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3923e7d4-cea4-426a-b7f7-8e684edd35b8" contextRef="C_20687195-6562-483c-b3ff-ff5be6c897ac" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,270,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66b8148a-d166-454e-94c1-d3966f038897" contextRef="C_20687195-6562-483c-b3ff-ff5be6c897ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cba09608-b874-40c2-9b5e-3e91ea52724b" contextRef="C_fe26f58a-9036-43d0-abc5-d86be0b9ef22" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,943</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69b2e9ea-76c9-42dc-bf09-520c98a7889c" contextRef="C_8dfe4ff4-baa6-4df7-adb9-4800a2eebae6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">380,772</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93574348-7503-49fc-91db-04b78fe9e0fb" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ents of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.8%;"/>
    <td style="width:1.42%;"/>
    <td style="width:1%;"/>
    <td style="width:10.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.42%;"/>
    <td style="width:1%;"/>
    <td style="width:10.68%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef82b4b2-915f-4dd4-8277-701b2bbdc541" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd93dfb-121d-4d75-ae93-c407b2aab607" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d016486-da84-45c2-a10c-2363601c5fb9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb335d83-202b-4640-8c69-256edc9546fc" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04c8740d-487c-4ca9-951b-1c7d234f6591" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OtherNoncashExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,844</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54d0122c-f439-4a85-89d6-4a81844b4db8" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:OtherNoncashExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ae884d8-1165-4846-8572-60d47ce622b1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc0188ce-e5ad-42c5-9ce0-aff62f60ddb6" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of property, plant, and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d159cafd-8b50-4790-bf1d-388d5b88ec1a" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_821d76cc-38c1-4f68-8989-47f3b1af7ecf" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill impairment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a665040-24b3-4b67-b98b-58cc28340862" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07bae918-479f-47d9-b4a1-d59dca587895" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of lease assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1427b788-01cb-465b-9237-0d849bc7fd03" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:LossOnDisposalOfLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3243922b-13e4-4009-a9e7-12cd398e3f2b" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:LossOnDisposalOfLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of deferred debt issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46852efa-935b-4337-9e5e-21c22a12b8e8" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:AmortizationOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c050bbfd-080c-4337-8b51-1e087461e3eb" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:AmortizationOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71c98e3-78f4-477b-a68e-ee30be54c23e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">926</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd36ed37-8d71-4fec-aaec-294f7df837a2" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f4958d-7663-4125-8f2b-310fc112e9b7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">358</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09c15454-9ddd-4b3d-86c6-0a0b6575a9bd" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f2b9edf-d5b4-4d6c-9387-4d18df052bc5" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,683</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbbf747e-76ea-4693-b015-26fdf5812bfb" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,710</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities &#8212; related party</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cb64f94-09ba-443a-9a98-4a022771f466" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82d127f3-37a2-43ee-8c6e-dd841b0d0b0b" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,805</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af9585b0-7795-45a6-a103-7c30e0291dcf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7c874ca-e7c9-4195-a6f9-e013cea1acdb" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and other current and non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e92c8a52-d7f2-4861-88aa-c575c801edf1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cac94148-5962-40e9-af97-a28b760da3de" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29dd1ea4-dba0-4eb6-b921-37119b16c9af" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,717</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c460ead1-35a6-4902-869d-810300636845" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,765</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c6397fe-254e-4c3d-b18c-55d34df45a13" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dfbba70-8a4b-41e4-8d9f-686f1ba1e1bf" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,782</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11d41570-91ce-4a4d-8d0c-5b49073adcaf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_820669ba-1e4e-4d74-9193-f03ef7ded340" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,782</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a2e903d-118a-403d-9eb5-4ba6976c87a5" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1b8273c-a92a-4292-be3b-2fd6f25ba8f7" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28c8644-17e9-4f01-834d-c5c562eefd8f" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8903ee6-c139-4e22-af99-522478573e79" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from Employee Stock Purchase Plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7b79e86-1a39-4ad9-8255-f70d5b96c537" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f93ee81-6b15-48ec-aa86-54b216e1762e" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Taxes withheld and paid related to net share settlement of equity awards</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6633365e-04b6-4be8-8951-04e28908ec46" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e45ec692-1b46-4104-a03d-585eb17de7f2" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7022d4f-b392-47a3-a21d-f6040c8768ee" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa18cdb-e24d-478e-a206-71e522c9d4cf" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f76ddc85-1773-47ed-8d6c-0d5c1089fad7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cfa4337-d3c6-4b0d-8f6f-a587fe70a8cc" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net change in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfb465e5-6c30-4d12-b323-5d276142b545" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b100b8f-9c98-4915-8b52-eb08b641095b" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at the beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc5da96b-f0cb-402a-9c21-7cb26839d25f" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,656</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4f355ec-6cee-4c29-ac6d-1fa71ff17599" contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, at the end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50e14436-576a-4f99-b251-412458d2ce5f" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,711</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ded5ccf-4bd7-472e-8089-8031a7d6c892" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,656</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosures of noncash investing and financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment included in accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bc81ced-a015-44b5-9628-9c9e1f41e833" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">279</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73c7ffd3-4f2e-4789-97b6-786472126d45" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right-of-use assets obtained in exchange for operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a547734b-f269-44af-8585-a14a4bed6a58" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_345d5da2-8771-4cd4-be2a-91864593dd5c" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,329</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a01d79c-a37c-4752-ae5a-01b9f5ec6abf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:OrganizationAndNatureOfBusinessTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Nature of the Business</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The Company is advancing a pipeline of &#8220;off-the-shelf&#8221; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost-efficient manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. (when referred to prior to the merger, Former Adicet) was incorporated in November 2014 in Delaware. On September 15, 2020, Former Adicet completed a merger (Merger) with resTORbio, pursuant to which Former Adicet merged with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#8220;Adicet Therapeutics, Inc.&#8221; (Adicet Therapeutics). In connection with the Merger, the Company changed its name from &#8220;resTORbio, Inc.&#8221; to &#8220;Adicet Bio, Inc.&#8221; The Company&#8217;s principal executive offices are located in Boston, Massachusetts. The Company also has offices in Redwood City, California.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of the Company and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, the Company consolidated its operations, including research and development activities, in the United States and as a result, substantially reduced its operations in Israel.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant net operating losses and negative cash flows from operations and has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_4dc0ad4e-c334-43d7-b54c-ea6ba9c38d21" contextRef="C_b3211074-499b-46e0-bac9-fdef2d5b6a7c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">380.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, public and private placements of equity securities and debt, and cash received in the Merger with resTORbio. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2021, the Company entered into a Capital On Demand&#153; Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as sales agent, to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a7ac6ff-5b5b-4edd-8cc0-6a2d2e2eb52f" contextRef="C_f148e6a6-cf77-4216-bdf2-c79ea3d192a2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock from time to time in &#8220;at-the-market&#8221; (ATM) offerings under a registration statement on Form S-3 (File No. 333-254193) (2021 Shelf Registration Statement) filed with the U.S. Securities and Exchange Commission (the SEC), which was declared effective on March 30, 2021. In August 2022, pursuant to the Sales Agreement and subject to the limitations thereof, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_718a5da2-d16f-4608-8593-04c017730b77" contextRef="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,611,723</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_951ef926-56f8-49e4-867f-f66a1ffbef84" contextRef="C_e7c9f079-510c-48e3-b00d-988277978714" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share resulting in net proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39a3ee2b-1189-4709-adb0-8df69c7b8a90" contextRef="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7" name="acet:SalesAgentCommissionsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting sales agent commissions and expenses. In November 2022, the Company filed a new prospectus supplement to the 2021 Shelf Registration Statement for the offer and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89a293d0-7317-4d88-b48e-903fe89d7972" contextRef="C_5962f55e-c424-4534-bcc2-208837c6f318" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock from time to time through the sales agent, which includes the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58455675-68a5-4d1c-9e83-deb5eda8abea" contextRef="C_8c7df557-b405-497e-9c20-e9d91070c1c9" name="acet:CommonStockNotSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock not sold under the original prospectus and up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c328a700-0dba-43c2-8b9e-cd13649d3024" contextRef="C_8c7df557-b405-497e-9c20-e9d91070c1c9" name="acet:AdditionalCommonStockNotSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock (the ATM Program). During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6e34a87-4b80-4084-bd6e-00065e07b674" contextRef="C_84de4e02-9bcb-4587-b4c2-9ad91bf61ddc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were sold under the ATM Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to December 31, 2023, the Company raised aggregate net proceeds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef2a562-76be-4bc6-87ca-ae1b3b8af05d" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:AggregateNetProceed" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through its ATM Program and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_def8567e-01bd-4c50-935f-c9a78f06b67a" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:UnderwrittenPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through an underwritten public offering (the Offering). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 19. Subsequent Events for additional details on these financings subsequent to December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that its cash and cash equivalents, together with the proceeds raised subsequent to year-end through our ATM Program and the Offering, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements and debt service payments for at least the next twelve months from the issuance of these consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s revenue to date has been generated from a collaboration and license agreement with Regeneron Pharmaceuticals Inc, (Regeneron). The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercializes any of the Company&#8217;s product candidates or enters into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seeks regulatory approvals for, its product candidates and begins to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), the regulatory approval process, market acceptance of the Company&#8217;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#8217;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24885e85-af31-4030-aec2-0857fe64182a" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_964165cc-9d0c-4ecd-9f45-c46e5f7c8784" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae49c962-8dba-48d8-8acf-a2be426f882c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7489c76-fa9f-4def-8e37-f6ef4be2bee4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#8217;s incremental borrowing rate. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08c1ff5c-d043-4b44-94af-706a05526c8d" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and determined that goodwill was impaired. For additional information regarding this assessment, refer to Note 16. Goodwill to our consolidated financial statements.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01131c88-8418-48df-87bf-4acde2b6fd97" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec8c61ab-2749-4021-9c08-e7912ce9ed66" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable and operating segment, which is the business of research and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allogeneic gamma delta T cell therapies for autoimmune diseases and cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bd6eed2-c22b-4bbf-a5fb-f9d9217619d7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds and treasury securities. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3658ddc3-617f-4a30-8018-9b2563e092e0" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:NumberOfCustomer" unitRef="U_Customer" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer, Regeneron, which represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b387d197-8816-4f4b-b586-84094d601137" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:CustomersPercentageOfTotalRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5a4b3dcb-a4c1-4918-8b1f-3d1512e51fef" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:CustomersPercentageOfTotalRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s total revenue during the year ended December 31, 2022 (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fdb48d4-9d78-46c5-be1a-010259d21be0" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b5b9586-f0e9-4fa5-b2c2-f991f40e11fd" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, cash and cash equivalents consist of cash deposited with banks, investments in money market funds with maturities of three months or less from the date of purchase, and overnight treasury securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f292a89-281b-40a6-a062-0b71c8814cab" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56628d6f-3a28-4299-b479-4bfefad37fec" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the lesser of the assets&#8217; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accumulated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8eedb956-417a-4f81-8408-9b9602cf55f0" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. The Company performed a long-lived asset impairment test in conjunction with its goodwill impairment test in the third quarter of 2023 and concluded that there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19527f36-af6d-42f8-8fb9-10d9718f8816" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets. There was also </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b08047-c46e-42a9-b325-fa69ff7fbf6d" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f86015c6-a3b1-47c7-9d88-3587ba2d0972" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#8217;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s revenues for the year ended December 31, 2022 are derived through a license and collaboration agreement with Regeneron (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue under the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments or reimbursements for the Company&#8217;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#8217;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b969bd3a-b9f4-404e-a244-eab0a151ab01" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CDMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd0b4e60-43ac-4cf4-bb68-f82e31ee017b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:AccruedResearchAndDevelopmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued CRO, CDMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various agreements with CDMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2ba0302-37bb-4d47-aab3-1d47c6a9ea03" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material adjustments to the Company&#8217;s prior period estimates of accrued research and development expenses.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_829a7009-d692-498b-bbb9-10ad861652fb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2016-02), the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8847191-029b-4741-a44a-af8c61a7a2f9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_246e783f-33d5-4808-beb0-ddb75c156308" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25d06cbb-5aab-4a02-94d0-e9642e5293ab" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per common share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan (ESPP) awards and unvested restricted stock units (RSUs), are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Since the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b3d7320-9530-471c-8a3e-00f4d1e2c1c4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events Considerations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements. Refer to Note 17. Subsequent Events.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c12a6f87-ea99-4679-acef-c4264460b96c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-13 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. SEC filers that are eligible to be smaller reporting companies should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which enhances the transparency and usefulness of income tax disclosures. This amendment requires public issuers to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income, or loss, by the applicable statutory income tax rate. Additionally, this amendment requires issuers to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes as well as the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact the adoption that this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ef1c869-365b-4ce0-9ef3-3ab245399dcf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8212; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8212; Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8c20c02-8d00-4c72-b4d5-aabfec8d198f" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Treasury securities (1) (2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32cc67c2-c20b-4110-8ee5-573adde35339" contextRef="C_516b6271-7ed7-4039-97f5-4296694a6d53" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fad817cb-52dd-4a37-aa97-a437d3c1006a" contextRef="C_9348b37e-6b12-4d6f-ae6c-a16de43632b1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_162cb483-d00e-4d08-84e7-64fe8ccb19fc" contextRef="C_dc363f47-13e1-4ded-8501-89b95420f66d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6" contextRef="C_dbf4e63c-86b1-47fc-8dda-dad71e1a42cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_167fe1f9-4f4c-4c5a-879c-32bf788d2134" contextRef="C_530cfa2e-3440-4246-a577-8979ecb76ea6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_289c2d77-3f07-48b1-b05e-14aa2a3b8ff3" contextRef="C_e0981498-005c-4ad0-9192-bd130ea10fe8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6afd780f-687b-487f-a47b-9e5865ac07f6" contextRef="C_c4019755-11ed-4ad5-8299-f0d1cfdef0eb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_772ba258-d3cf-4fa6-876e-614691315b0a" contextRef="C_14728681-e228-429d-9c6d-e288fc904418" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1%;"/>
        <td style="width:9.282%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (1) (3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789" contextRef="C_301d7c2e-336e-4386-a679-d09592f8589f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb235763-2049-4536-89f0-a95a1e624a98" contextRef="C_f239a655-77af-476f-8413-e0d33ef6a09e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4cf4f7d-863d-4f43-b627-e3f1271563ae" contextRef="C_edc6bfee-a0a7-4dbb-a2f0-2d9cb5654b09" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66bfc669-7f11-4299-bdfe-2fa260b91fd3" contextRef="C_62d1c290-a6a5-4ca0-a3ab-96d98d887372" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_264ec5a1-634e-4019-be8c-8b3a13b4fb14" contextRef="C_521621f6-cd1f-43e6-8b46-e9d3d9f8d92c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1066aed2-2284-433a-b20e-fe482fc66b5c" contextRef="C_a0fd947b-427a-49bf-b248-d4fd92ea0354" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f24151e0-4a05-4fc7-a789-e1079a26dbaa" contextRef="C_120ea2d3-27e2-495d-b032-85ee8a4225d9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1443a2fd-5bd6-442e-a399-63df5ee36b1f" contextRef="C_8c149222-bc5e-4c16-ad97-efbf7c1789f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents in the consolidated balance sheets.</span></ix:footnote></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_b8155da4-ace1-4e3d-9591-49c7404454de" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.</span></ix:footnote></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. </span></ix:footnote></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf470113-99d4-4a03-b61c-d123b0688597" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e567a99-f0d2-460f-bcd3-21f26e545f1b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20385f06-e2a4-4b4c-82a7-af66ccb64ce9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17bcd837-cc00-4077-b2f9-44469abcd00f" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software subscription and licensing fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2da595be-c179-41e1-abaa-59ed5b7a9a9b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:PrepaidSoftwareSubscriptionAndLicensingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b4f5119-30b5-499f-bc54-2dd99d5d4911" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:PrepaidSoftwareSubscriptionAndLicensingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid maintenance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca001244-7609-473c-b629-d7d01dee5fb9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">373</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2388ecdb-b365-4191-9ca6-b5b63ffe020a" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54c55ca7-a4a2-46a3-89bc-b45477cd2c2d" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:PrepaidProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d83f2f54-8c86-416e-8480-ac4e2e208fa8" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:PrepaidProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepayments to CROs and CDMOs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a42c906-3fad-4ac6-9ed7-56d9d1c6e801" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:PrepaymentsToCros" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57e4581d-7bc3-4d3c-a94f-fce33bca8d1b" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:PrepaymentsToCros" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">492</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6503f15-3f49-412d-9f56-133db837bb90" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20c63534-a916-4e2e-9e0f-4f1c904bf704" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a9fc24-4326-4a76-ac36-2e3f6e8ef83b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a43e3001-2ae4-44b6-9ab9-48b3a27d2cc8" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7742b82-a74a-4e1f-83ba-a6249d8d291e" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1077d7e5-a823-4855-a911-0744f91fc9e3" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,382</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2482fe7-734b-4227-b310-90be74589489" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Property and Equipment, net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d261f10-1bef-4e36-987c-99f097c9b144" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.64%;"/>
        <td style="width:1.68%;"/>
        <td style="width:18.32%;"/>
        <td style="width:1.64%;"/>
        <td style="width:1%;"/>
        <td style="width:12.54%;"/>
        <td style="width:1%;"/>
        <td style="width:1.64%;"/>
        <td style="width:1%;"/>
        <td style="width:12.54%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful life<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_15175557-fa82-4f42-8860-de5b090ee079;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of useful life or lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e106f5f2-37b9-4b77-bb9b-d0b200fdc5bc" contextRef="C_b7944d0b-f730-4427-b995-a253e5c8fac0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be59a930-45c8-4867-9bdf-f62415366700" contextRef="C_2bbcb4a0-03ec-4fec-b751-f0405cc986d4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d7e31791-88b0-4ba4-81f9-acc39b105225" contextRef="C_a8e06b97-dcd0-4935-82a5-621e10a35a16" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_538b09da-5d3b-42c6-85fc-1f9203548da6" contextRef="C_a8e06b97-dcd0-4935-82a5-621e10a35a16" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe521b4f-7212-41f4-8928-919cac67f4df" contextRef="C_1caa1e3e-b49b-4099-b413-9f91f7e43341" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,503</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8d04f061-4eac-4921-b2f6-35fbdfaa97a0" contextRef="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_910d3ade-29a6-4ab3-8471-0df0e755727a" contextRef="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">951</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5170f904-1863-4ec4-9a24-6b3841db53ae" contextRef="C_254f47ef-7aad-45a0-af9a-05ffb52efd9a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e938855e-ce4d-4a17-af25-5c2b3ea05a06" contextRef="C_c123cd80-5380-4099-a3a4-c9250a72e19d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd7e3e9c-294c-41f8-a362-3b414513254d" contextRef="C_c123cd80-5380-4099-a3a4-c9250a72e19d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_531a1911-25f7-46e6-ad2f-1f05807ccffe" contextRef="C_4cbd04fa-00ff-47cb-b761-f69bdbaecf25" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_7c070633-44bd-4104-9d0e-d47392d30bc3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0ed4a04-ce81-4de3-8b09-5c0b432ff35b" contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0bd065c-4d5e-47b9-a402-2142714fa2a4" contextRef="C_9dde8aec-c602-4c92-b003-83bf44a811d5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,292</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3f97280e-e8d6-40b0-9952-e733da209cff" contextRef="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e0bb82-b8f0-4f77-ade7-777eadb5c74e" contextRef="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_270cd59f-d75f-4cfb-a0c7-1ab11a3a2e40" contextRef="C_b17d8234-ba90-441b-b4a7-b13d05bda5b4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc1bc77d-5e76-487a-bf34-dd3af7be4490" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da3a541a-b480-4f6b-8ee4-6511f6b92ab2" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,463</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54c389b1-b672-46f0-b10e-caaa68589271" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_102654d2-8733-4221-933b-0f8b19e196fc" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,753</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862317cd-5182-4cd7-8f6e-26ece30cabb7" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,777</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22209d40-9789-4558-9d37-80bb46a4230e" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,710</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s property and equipment as of December 31, 2023 and 2022 is located in the U.S. Depreciation and amortization expense for the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75701812-f4b6-4b0e-b1e3-a6070ff21480" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e2ed1a-69be-40e6-af57-cfc4ee1ba11d" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in expense is primarily due to the completion and subsequent depreciation of the Company's good manufacturing practice (GMP) cell processing and vector manufacturing suite at the Company's office in Redwood City, California (1000 Bridge Parkway) which was completed in February 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction in progress has decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_621af8ad-d633-4054-b999-679a0da35bf2" contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2" name="us-gaap:ConstructionInProgressGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, compared to the balance at December 31, 2022, due to the Company's completion of the Company's GMP cell processing and vector manufacturing suite in February 2023. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5b8fc17-fd89-41b0-824b-755e84338e0f" contextRef="C_af925b6c-d225-4763-b22a-b3974a3e23db" name="acet:ConstructionInProgressNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in construction in progress as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is primarily related to lab and computer equipment not yet placed into service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16499ac8-2664-4e73-9706-802226079cda" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Accrued and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a67de1f9-c93c-44aa-a57b-7aca1d1177e1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1.68%;"/>
        <td style="width:1%;"/>
        <td style="width:12.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dccefd1-3ac8-4642-af9a-b5241ab3e064" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51e74b17-e2ff-41c6-a6c3-80b15ce2b4d3" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CDMO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0f87815-813b-4f15-8674-6a2d69f59856" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:AccruedCmoCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,679</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05a7e9a1-5cdc-468b-aee2-593279913a48" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:AccruedCmoCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,390</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df86ba1-e3c9-485c-9502-09e302f06489" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19efcf3b-ecec-4f22-8ac5-2986bb3997f0" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,356</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77b291b1-9533-4658-92b2-dd750fbb6717" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b51caaa7-bd39-469c-9424-6466056910f0" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CRO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12793fc9-61f2-4aef-bbc1-4cdf3ea2765d" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:AccruedCroCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a582ecd-769e-482c-87d7-b3d9de2f121a" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:AccruedCroCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ffb083f-863d-4f3a-8ea4-870dc2e120f4" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d98bb6-6899-4038-9038-26759c640e42" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aed0691-3091-4a8d-a757-1f20dd677f8f" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_955654ba-7f97-48a7-8c59-79f6e306935b" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,811</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d60cfe7-0b19-418e-b596-00f6187417e9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Term Loan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2020, the Company entered into a Loan and Security Agreement (the Loan Agreement) as amended on July 8, 2020, September 14, 2020, September 15, 2020, October 21, 2021, December 2, 2022 (the 2022 Loan Amendment) and May 30, 2023 with Banc of California (formerly known as Pacific Western Bank) to finance leasehold improvements for the facilities in Redwood City, CA and other purposes permitted under the Loan Agreement. Under the October 21, 2021 amendment, Banc of California will provide one or more Term Loans (as defined in the 2021 Loan Amendment), as well as Non-Formula Ancillary Services which shall not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3c94a60-ddc1-4c1a-b778-3bd7668ca0ca" contextRef="C_8b31a2fd-9ce2-44b0-ae61-2ba25f62ea40" name="acet:TermLoanToFinanceLeaseholdImprovements1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_516e8dc9-c542-492c-bd35-1a5d19d5f8fb" contextRef="C_897945e8-d886-4a9a-afe5-8e849b01fa66" name="acet:TermLoanToFinanceLeaseholdImprovements1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which each Term Loan to be in an amount of not less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3137f882-27d6-44d6-aa44-22f742edde03" contextRef="C_54fb6a03-848a-42a9-a84c-0292032c99c7" name="acet:TermLoanToFinanceLeaseholdImprovements1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 13, 2023, the Company and Banc of California executed a letter agreeing that, notwithstanding the covenants included in the 2022 Loan Amendment, until June 30, 2023 (i) the Company and its subsidiaries will not be required to maintain the lesser of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a418351-d317-45c7-9c81-cad1d59b1e11" contextRef="C_7e25f46c-a94c-4ebc-b2ae-28925638d603" name="acet:CombinedBalancesInDemandDepositAccounts" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or seventy percent (70%) of its combined balances in demand deposit accounts, money</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">funds and/or insured cash sweep (ICS) accounts with Banc of California and (ii) the Company must maintain its combined balances at Banc of California or its affiliates, including Pacific Western Asset Management (the Letter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2023, the Company further amended its Loan Agreement with Banc of California (the 2023 Loan Amendment). Pursuant to the 2023 Loan Amendment, the Company must maintain the lesser of (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_133ab3fd-d960-46a9-ba9a-80d98988bb6f" contextRef="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8" name="us-gaap:DemandDepositAccounts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or (ii) all of the Company&#8217;s combined balances in demand deposit accounts, money market accounts, and/or insured cash sweep accounts with Banc of California. If the Company&#8217;s total cash and investments drop to less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3268abd-9660-4aaa-a11d-a3e341d08d99" contextRef="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8" name="acet:TermLoanCashMaintain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the 2023 Loan Amendment permits the Company to maintain cash and/or investments in one or more accounts outside of Banc of California up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11f7fe30-a287-4d08-bc11-0cf0511c8362" contextRef="C_ec965417-7244-4e77-bb2e-c305534384cf" name="acet:TotalLoanAccountsOutside" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_362eb9ab-e791-4a67-9fb5-618f63852fd0" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:AvailableUnderTheLoanAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available under the Loan Agreement. Additionally, as of December 31, 2023, the Company is in compliance with such covenants as stated in the 2023 Loan Amendment and had no indebtedness outstanding under the Loan Agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07d5ed00-b085-46a6-bf9b-1869257c4e7d" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Third Party Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regeneron</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#8217;s investment in the Company&#8217;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company received a non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_379fa577-a723-45f0-9545-15f1d31ef4ac" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="acet:NonRefundableUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Regeneron upon execution of the Regeneron Agreement and an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c40c5404-c7ba-4c9c-9673-509fa76dac80" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of additional payments for research funding from Regeneron as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53e85266-8917-4001-a71c-7a462da83a78" contextRef="C_a623b912-7fdc-45eb-b768-963c9acc0e80" name="acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of option exercise fees, as specified in the Regeneron Agreement. Per the terms of the agreement, Regeneron must pay the Company high single digit royalties as a percentage of net sales for immune cell products (ICPs) to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#8217;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#8217;s license to use Regeneron&#8217;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_487441de-56a2-4f98-9f87-18069e8ea7fb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:LicenseAgreementTerminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve (12) years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from first commercial sale. No royalties have been earned or paid under the Regeneron Agreement through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta CAR T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement. In conjunction with the exercise of the option, Regeneron paid an exercise fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40e7f430-e8cb-4df2-8b72-91d63a5ecf3a" contextRef="C_1d264861-044d-454d-9a46-2ea594afdb73" name="acet:ExerciseFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Company on January 28, 2022, and the Company completed the transfer of the associated license rights to Regeneron during the first quarter of 2022. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2398b078-be33-4228-964b-fc5b8f27a9fa" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="acet:ExerciseFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million option exercise fee, plus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0348938e-2426-40fb-bed6-37d24831b216" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized relating to the combined performance obligation, resulted in an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36cf082f-9cd2-4fef-ae77-7307e80c878f" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="acet:LicenceAgreementAdditionalRevenueRecognised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million recorded as revenue for the year ended December 31, 2022. The Company's obligations under the combined performance obligation were completed during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d982ae9-6d89-4791-9227-b07b37ea2cb2" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true" continuedAt="F_4d982ae9-6d89-4791-9227-b07b37ea2cb2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, there were no contract assets related to the Regeneron Agreement. The following tables present changes in the Company&#8217;s contract liabilities for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:14.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:13.903%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:14.643%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f8e9191-ba39-4d05-a2df-1b8307466686" contextRef="C_40665ebd-fd67-4d04-97c7-45124e5c850b" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cfed16c-3f5a-4ca3-85a5-e8dec2ce67ea" contextRef="C_50941431-c7dd-4f38-8678-4027d202f1e1" name="acet:ContractAssetsAndLiabilitiesAdditionsDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98ea76df-a187-491a-8a38-47443cd457ce" contextRef="C_8f65238a-1a42-43ff-a87b-7cac1f995a5c" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:14.463%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:13.903%;"/>
        <td style="width:1%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:14.643%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions<br/>(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b98d36a4-e09f-4d8d-8e93-484bd6ae61ba" contextRef="C_e30421e9-e302-416b-8491-76859aa72b91" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,805</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6" contextRef="C_bd6622b0-707b-4b92-a039-abb383da1129" name="acet:ContractAssetsAndLiabilitiesAdditionsDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,805</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e46f4c1-bcc0-426b-81d4-81778adabcb9" contextRef="C_40665ebd-fd67-4d04-97c7-45124e5c850b" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span><ix:continuation id="F_4d982ae9-6d89-4791-9227-b07b37ea2cb2_1"><ix:footnote id="FNT_d612eae3-79b2-4c1e-bffb-1fef370f9dab" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Twist Bioscience</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into an Antibody Discovery Agreement (the Twist Agreement) with Twist Bioscience Corporation (Twist). Under the terms of the Twist Agreement, Twist will utilize its proprietary platform technology to assist the Company with the discovery of novel antibodies related to target antigens selected by the Company. The Company maintains the sole and exclusive rights to any program antibodies discovered under the Twist Agreement and has the right to patent, assign, license or transfer any work product under the agreement. Furthermore, the Company has the right to sublicense its rights to program antibodies to third parties. The Company may terminate the Twist Agreement at any time, with or without cause, upon a specified period advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per the terms of the agreement, the Company will pay Twist an upfront, non-refundable project initiation fee, a technology access fee, as well as a project fee for each project entered into under the agreement. Additionally, the Company will pay fees for development and regulatory milestones in the tens of millions of dollars and low single digit royalties on net sales to Twist for programs initiated under the agreement. In November 2022, the Company entered into an amendment to the Twist Agreement (the Twist Amendment). The Twist Amendment updates the language associated with Twist's audit rights as well as the amounts associated with technology access fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On a cumulative basis as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has incurred and expensed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eac18e41-3a0a-43c5-a21f-b8046170bba1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:ResearchAndDevelopmentInProcess1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to project initiation fees, technology access fees and projects fees as research and development expense related to this agreement.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_bb55f8b4-9672-4095-a4be-46cbc31c6067" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office and laboratory space in Redwood City, California, and Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redwood City</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, Adicet Therapeutics executed a non-cancelable lease agreement, as amended in 2022, pursuant to which the Company leases office and laboratory facility at 1000 Bridge Parkway and a portion of 1200 Bridge Parkway in Redwood City, California (the Redwood City Lease).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2023, Adicet Therapeutics entered into a third lease amendment with Westport Office Park, LLC (the Third Amendment). The Third Amendment further amends the Redwood City Lease and increases the tenant improvement allowance as of January 1, 2023 by an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5597909-80a6-4c0a-9788-812824c63676" contextRef="C_916c0314-0614-4526-9283-d8a045dc95a2" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company fully utilized the allowance for the continued buildout of office and laboratory space at 1000 Bridge Parkway in 2023. Per the terms of this amendment, this additional allowance will be repaid through equal monthly payments of principal amortization and interest on a monthly basis over the term of the lease at an interest rate of eight percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b5d0385-ccbe-4557-86e3-21f74e5b11a7" contextRef="C_af2ebdd0-26c4-43a6-a4ca-3aa3d01aa585" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) per annum. The Company received the allowance on February 21, 2023 and increased the operating lease liability accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, Adicet Therapeutics entered into a fourth lease amendment with Westport Office Park, LLC (the Fourth Amendment). The Fourth Amendment amends the period over which the tenant improvement allowance received in the Third Amendment will be amortized and identifies the monthly amortization payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 1, 2023, Adicet Therapeutics amended its letter of credit with Westport Office Park, LLC. The amendment reduced the amount of the letter of credit associated with 1000 Bridge Parkway by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c2ee79c-47e0-4fcd-84ba-672809e49c30" contextRef="C_e0c69718-cc5e-49e4-a0e8-bdc77ac5c987" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million resulting in an updated letter of credit amount of $2.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Boston</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, the Company entered into a lease agreement, as amended in 2019, for office space at 500 Boylston St, Boston, Massachusetts (500 Boylston Lease). Under the terms of the 500 Boylston Lease, the Company was permitted to assign, sublease or transfer this lease, with the consent of the landlord.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 19, 2021, the Company entered into a sublease agreement with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cd698f0-6f38-4614-892f-b3b0e250de14" contextRef="C_9574821a-e3a7-4169-a889-41b0f5866c4c" name="acet:AreaOfSublease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">9,501</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rentable square feet of 500 Boylston St. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55d652a8-eeb0-4ece-a1f4-52b7175157a3" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:ScheduleOfSubleaseIncomeTableTextBlock" escape="true" continuedAt="F_55d652a8-eeb0-4ece-a1f4-52b7175157a3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected undiscounted cash flows to be received from the sublease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_55d652a8-eeb0-4ece-a1f4-52b7175157a3_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:28.7%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc8da30e-76f7-4e62-bb0d-3b0131917c1c" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57712be8-0d19-42d4-8d4f-8897ea20fc04" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cd84adf-02c8-4952-8ba0-384976127ee2" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62d99ac0-4b03-4406-9366-b5719a94e649" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,896</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized rent expense, net of sublease income, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8514bc7a-03b4-4c34-a3fd-2206b44d308f" contextRef="C_03b04d41-2a70-46cc-b31d-d9c911eb2cda" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11559be6-d4e0-47d8-9f6d-d3e8ad7d2a88" contextRef="C_91bff28d-648d-4207-9e94-2523616823eb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the Company remains liable for the remaining lease payments under the 500 Boylston Lease, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b7a8f2d-0868-4611-826a-1257ce0eaf10" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is included in the future minimum lease payments table below.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c5b295e-ece9-474c-9ad0-75f00c5923d6" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments under all non-cancelable operating lease obligations as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:28.7%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f60cac49-8322-4690-99d7-6f11c6573d00" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,015</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31369049-acb8-4f9f-8c58-163f37122872" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,662</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd3a384a-5ad0-4c32-ba53-8d64d961699f" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,009</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_190a4f01-6b70-4b11-aa14-5136f505ebc0" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,090</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_092929f7-9e07-4f12-ab62-3692341228f2" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,776</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_157e2ed9-916d-4d7b-a3d1-e07a109331d6" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,852</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c820531d-4c0f-4640-afcf-2df0ba7bc665" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_664c8645-a570-48ae-b674-fd3b51a1ee18" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,221</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, net of current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276b8e67-dab4-4860-b2ea-bfaeb3cb38d3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b66bb551-cc38-482f-9e40-01e32e3735f7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.16%;"/>
        <td style="width:1.46%;"/>
        <td style="width:21.52%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:26.86%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Locations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IBR</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Terms<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1000 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07f26da0-7483-4ebc-98f7-2bf3e3d185c3" contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_83388a2c-0dcc-4da7-a847-7b91085cd296" contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1200 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dbddaec-0755-490b-a409-25b4e82d372f" contextRef="C_2e885ea3-80a2-45de-abec-f29848bb6275" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_08580194-e1c5-49a3-b928-9c0f1d8cbfe4" contextRef="C_2e885ea3-80a2-45de-abec-f29848bb6275" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.50</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Boston, MA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b88be579-1a0a-4db2-81a1-14ea3ba5b5e3" contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0fff927e-83b0-4d73-ad52-6f7c5289c8d5" contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.60</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57970bb9-9c9f-40e6-9772-110707908bbe" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9b58cf41-6ba1-45ff-9494-d05945a00514" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.70</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4695a3fa-6a87-4db8-be00-b3ff1c42c43c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the operating lease cost and information related to the operating lease right-of-use assets, net and operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.63%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:21.124%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:21.124%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbdedbde-20ed-436b-b8d5-2e3c0249ab99" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,510</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05e1a57d-808a-480e-a2ed-3fe26fcc5922" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,508</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be82e5b6-aa89-48d7-a603-e3771928084e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8ebcbda-d1e6-40d6-98f2-3232b1c0cfb7" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33562ed6-6ee0-452a-8889-f5a2b1b10396" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">714</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d59edfc-fa65-4899-8666-cf5700f5cf98" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c75c86bc-1fc5-4136-97b8-b9aeb656a3ab" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,991</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d06d0155-ef58-463d-bea7-3f5441a32661" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,937</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d76afb2a-c0eb-4494-88cb-0e79d8c37094" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:OperatingLeaseProceedsPaymentsUse" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60c03100-9519-48f9-ac08-aceb3d3d271a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:OperatingLeaseProceedsPaymentsUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e3689723-aa18-4ed2-8d09-2934fb7999d4" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a793b8c4-35bc-4d52-b3cb-eba4d5d5d2aa" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee8e796-4d8a-4df6-b240-ab8f06c7fa8c" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4edf305a-19ab-427a-b075-524e3e9c8a30" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, operating right-of-use assets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeb4e8f4-d8ee-40f7-ab10-b91886cf453e" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease liabilities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_678d0123-51b8-40b4-836e-2d6c0db3bfad" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has no material finance leases.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains letters of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7789f59-97a9-4301-8f26-8dc726cb223f" contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c965289f-0760-49aa-87e1-bb10a22e68e0" contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in connection with the Company&#8217;s office leases in Redwood City, CA and Boston, MA, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; liability insurance.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83afc251-8983-4efa-8d81-10b320e5b30b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders' Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Certificate of Incorporation, as amended, authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e666c07-ba5c-46ad-b223-5926e994e897" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3aceaa-63eb-4406-a04a-0856ef486eb6" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value common stock as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stockholders are entitled to dividends if and when declared by the Board of Directors of the Company subject to the prior rights of the preferred stockholders. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b0f4cdd-9ee5-4823-bb7f-8ab2ae153dd9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DividendsPayableCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends on common stock had been declared by the Board of Directors.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1265920d-e9e3-4461-8320-889755b6fa57" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:13.44%;"/>
        <td style="width:1%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:13.44%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units available for future grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_357c8f11-b474-4983-884b-6e3f0ae7b4d3" contextRef="C_0e5442b4-b4a0-4661-aeb9-e32534abdac2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,473,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df2f215f-6af7-4b62-8110-57bce3933451" contextRef="C_4d422142-c5e5-4b57-97a3-51fb1b8cf885" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,871,705</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f97094ab-9cf1-429e-a78a-af339dda4ee3" contextRef="C_8c4301bd-829f-4113-9dfb-fc7cb0d08261" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,383,105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0811e1f2-92aa-44ad-945f-e76722a27967" contextRef="C_311e49e6-e6fe-465d-83fb-e37ac0ea7ce6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,203,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bf40953-0066-456a-9139-a8810b5b28c0" contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">454,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a66693a-064d-45b1-9124-6a4bd4a87cfb" contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4541ee9-e384-49c6-a542-90716791d22d" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,310,790</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_852981fd-f476-4c6b-9eb0-83c1f9295e52" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,272,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a18efdd-d7ec-4cfa-8a3a-1653e2d890f8" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c1e949b-a96d-4fb2-9b49-9042d22de06a" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.236%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.236%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60d21f4c-b52d-41b5-9742-e67cce8e8396" contextRef="C_f58078b6-76be-474e-a1ef-f5d1e47368bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c012c85-63b1-4544-bec9-ce2700d7c422" contextRef="C_7d48a06f-dbae-4fc5-8ffb-b637076720b8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_858c1955-6150-4511-a917-bf576fecb570" contextRef="C_88454f42-8fdc-4021-91ce-b4d6b6330c65" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9cae74d-180c-4ed3-8735-7f9786c338a8" contextRef="C_733a8089-51c5-4d2f-ba06-56a474b671db" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,901</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eed7ab63-313a-4c46-bc99-86bc3f9440cd" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,259</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2267e981-c3fe-4974-896c-4e114ed8455f" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,126</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.236%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:21.236%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_390ea28b-e174-4e16-8626-d99839c0e8f4" contextRef="C_b4cf6be1-4f2c-4f83-bfd3-9d9edf02216a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,060</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_056f23df-1d86-41d1-9d63-fbe9cfd063eb" contextRef="C_9d5312ec-a7ba-4ea9-806a-0f9c38c43ee2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b7e45ab-9e15-449e-9164-e94a9ed3a5a7" contextRef="C_596f1ec4-c26f-47d8-873a-09b6b3910e9a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f32bef3-80ab-430d-9ba2-56514901c9ef" contextRef="C_241fa14f-5fcb-4423-8601-15153c2f69e7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,878</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c66c849-b540-43d2-ad25-77ef1abef579" contextRef="C_e485415b-bfa6-4e68-b402-10c45a238a24" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ad7f00d-3567-4982-9a11-35afa9a9dd21" contextRef="C_dd112089-6f8c-421a-b580-9551aa752b5e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1549e207-823c-40b2-b050-924ffb9faf45" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,259</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_088fbb61-c944-4fc5-8993-a218ee2aed8d" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,126</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c3d2bb5-4962-47c2-8bf7-09d392bdfe44" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below (in thousands, except share and per share data):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.747%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.934%;"/>
        <td style="width:1%;"/>
        <td style="width:1.319%;"/>
        <td style="width:1%;"/>
        <td style="width:13.295%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.934%;"/>
        <td style="width:1%;"/>
        <td style="width:1.319%;"/>
        <td style="width:1%;"/>
        <td style="width:13.455%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14d9d8f-78cf-4bd1-a29a-571141a58876" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,203,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a4485a7-26f1-43af-8186-94f51d81b531" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e1e33338-a1f3-4b73-b65a-2d5a1c725ffd" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a26b9ab-ee04-4a84-a194-52cc2210482f" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92970713-8e97-49f5-a609-b452d128c5bf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,293,442</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df324e7c-c7e7-4855-9dd4-101b8a88d56c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbab6298-d834-470f-99fb-afa5bce6b74a" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">946</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ec1a99-3f7f-4bdf-add8-403a522a03c7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.76</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited or cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fff9293-12a4-41d3-8779-efbb805a29d3" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,112,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70f46aae-f68b-41a7-ac6e-622a6e034ef8" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d182ffa-21c5-41ab-aeb8-579086ce82bb" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,383,105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6f46572-e0c3-4336-babc-3cfa85bf4647" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.64</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_bd774236-1e34-42a0-986c-7b95844f08bd" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9342299-e9ac-458e-8f3d-2c368a4c27d6" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eca386bb-de02-401a-9b82-d3702d17857f" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,984,821</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c126b5a9-b0c3-4ebf-b93b-667e342c5861" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.65</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fea7fabf-1534-4009-9327-d450b5f49f33" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0fa659d-d446-4da8-9915-a3414c02c326" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1cbe082b-107f-40d2-9af5-43e9cb84a2f3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,383,105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c8808e6-fca7-4ea0-88b2-2edc70c0f26f" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.64</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7692d494-dd21-4e6f-b4ac-d2c53547d294" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1ad513c-76e5-405b-b7a4-bf0b4b31a1e0" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e818314f-42a6-45cc-98ac-bedcff5d9ed7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions used in the Black Scholes Model to calculate stock-based compensation are as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"/>
        <td style="width:2.04%;"/>
        <td style="width:23.195%;"/>
        <td style="width:2.04%;"/>
        <td style="width:23.195%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d01ab6e-c8d2-41dc-8dea-90398039f502" contextRef="C_da045486-c2fe-4b90-ab00-21eab7441f0a" name="acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f695e4f-f278-4c04-84f0-4aa16ceba200" contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9" name="acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.15</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47927b0a-4dbc-4910-a716-becbb6f1c579" contextRef="C_cecd4cc3-7caa-450f-a101-f3b58059d74a" name="acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82f6839d-fdc5-4a2a-a535-cad834625f3e" contextRef="C_57732136-14ea-4518-80b2-de77d352b723" name="acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.97</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_407d48d9-8817-45c3-8b68-363c08455c41" contextRef="C_da045486-c2fe-4b90-ab00-21eab7441f0a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_d8ad00b5-ee83-4bbd-a70c-b4f14913d511" contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_abc27536-e0ad-4cfa-b65b-0dde5e9b6637" contextRef="C_cecd4cc3-7caa-450f-a101-f3b58059d74a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_f416037e-e5f3-4451-a7ef-d261a13b646f" contextRef="C_57732136-14ea-4518-80b2-de77d352b723" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37c9b69f-5907-4285-8c7f-a166d8625d62" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">83.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bf13a8d-a8b6-4e8b-b635-a022bf1b87ba" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">92.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e78d3e-7f86-4906-b9fa-7dd95e1cedd9" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">77.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa1c12e7-db5c-48e8-9e72-13c65fe64d2a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">81.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free rates</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e747f30-f7f9-4e32-8a08-2cfde039bf8f" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30b22238-24b6-4e5a-90a4-ebe3270ae070" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22d723fa-c746-4bf3-ab42-d7bfa236a97f" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec0650a5-7eec-44f7-84f5-be118704f4ed" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab48b1f6-61c5-4859-90f6-86a89482585e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99b6dfbb-bba7-4e05-9807-e7d1164d581a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions are as follows:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#8217;s industry peers.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money at December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2023 and 2022 was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8388e93-4f64-452b-aa6e-b75617b1201a" contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0194fefd-6cd7-4d5e-98e6-2601c80619da" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of options that vested during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab65c3e8-c361-4762-9396-ac08bd3d651c" contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dcbcdc0-557f-4ada-969d-a0873f07f495" contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The options granted during the years ended December 31, 2023 and 2022 had a weighted-average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc17a1c2-eafe-44ac-941d-1a3b3bfae57c" contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d0106c6-07b6-41b0-b8f0-516fc1b61ef3" contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the total unrecognized stock-based compensation expense related to unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cba97280-871a-4add-88b2-e49729bb5c20" contextRef="C_747dc985-0918-4eea-aab1-03ff0d433f81" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9607b7c-1122-497b-96cb-f3e2979a2114" contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_208bf39a-606c-47c9-9f33-e444df603ada" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of RSU activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:21.72%;"/>
        <td style="width:1%;"/>
        <td style="width:2.04%;"/>
        <td style="width:1%;"/>
        <td style="width:21.18%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77b94e07-46c6-45d6-bb66-753bfed1471a" contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">197,580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11227600-a00c-4be6-8a0c-e7f050650e7a" contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab547956-5dd6-42ca-a1e2-b2da566e161a" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">513,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d544e8db-6b6d-4124-9a17-793ac9c0f3b1" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c04e77d0-7ac5-4875-be74-e760826d48ac" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">194,455</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9138131-9597-424c-9e1c-31d6eb5a6e44" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38783f80-b772-495d-9d92-9c060d42f931" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">62,625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2558018a-de0b-4f7a-acec-452277a5e93d" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c362d2b6-cd6f-4ed2-8a7f-723860705e9f" contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">454,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de97ea0c-2656-4bb6-91b8-366e5a3bd84e" contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.69</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80356415-15ba-4857-a3a2-3017bfdca160" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">513,700</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSU's in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcbc4e2b-d7af-4237-abde-b33c2346c68e" contextRef="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t grant any RSU's in the year ended December 31, 2022. The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2468e4a0-ddc9-44d9-84fd-5efbd0d2688b" contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5da0787d-2db0-4bcd-807c-71327f858be6" contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56ee6cdf-b471-4366-bc64-99e3c563a80c" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option repricing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 8, 2023, the board of directors approved a stock option repricing (the Option Repricing) to be effective on August 14, 2023 (the Effective Date) in accordance with the terms of the Company&#8217;s 2015 Stock Incentive Plan and 2018 Plan (together, the Plans). Pursuant to the Option Repricing, and subject to a one year cliff period, the exercise price of each stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">previously granted under the Plans, totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90c7a6aa-eb17-4504-9e63-08823c6440d2" contextRef="C_347a9bbd-5136-4186-a21c-9d1306e004b8" name="acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,431,910</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options, was amended to reduce the exercise price of such options to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9e98ba0-0a75-4c53-b6f8-a60aa85c3170" contextRef="C_567c498c-9118-465c-999b-374820f503df" name="acet:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the Effective Date. Under the terms of the Option Repricing, a repriced option will revert to its original exercise price if, prior to the one year anniversary of the Effective Date, (a) the option holder&#8217;s employment is terminated by the Company with cause or by the option holder or (b) the option is exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The repriced options otherwise retained their existing terms and conditions as set forth in the Plans and applicable award agreements. The stock option modification resulted in an incremental compensation cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_653316eb-e0ed-40d8-a42a-d7a6843d8132" contextRef="C_3e7400b2-991e-4baa-bd6d-1b6d5cc20a11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was calculated based on the difference between the fair value of the stock options before the repricing and the fair value as of the Effective Date, using the Black-Scholes option-pricing model. Of the incremental compensation cost, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d25eae2-6d79-4a53-a315-ece6f4d73541" contextRef="C_dc080d41-4d34-4968-8ee6-17defa00e2d7" name="acet:ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, and the remaining amount, less any employee terminations, will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of the Effective Date, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99facc77-3ab7-45d5-b428-49dd1aed47ab" contextRef="C_b4e3d6b0-f801-44dd-b98a-08f6aee1758f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,418,042</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to purchase shares of common stock under the 2018 Plan to eligible employees who held inducement awards as of August 8, 2023. These new options were issued to eligible employees because their inducement awards granted under Nasdaq Listing Rule 5635(c)(4) are not eligible for repricing. The prior inducement awards remain outstanding under their original terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_258c0ce7-9c4c-4a07-a222-0eaf43e7d0bb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0114e57f-c5fc-4d5e-b42b-52ff484f5ec9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.854%;"/>
        <td style="width:2.099%;"/>
        <td style="width:1%;"/>
        <td style="width:13.974%;"/>
        <td style="width:1%;"/>
        <td style="width:2.099%;"/>
        <td style="width:1%;"/>
        <td style="width:13.974%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63bf2469-76df-4409-9339-1bc9fdaefeac" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca01993c-8fad-4c6c-bd2e-6d3c136e0d65" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,790</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1424a39f-cc47-492f-a47c-0787c140b694" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a254f150-00d3-4be9-a796-f56edb0f6034" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,042,405</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fee951f-6a8e-4ebf-b8c1-46097c0e2e9d" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e8570035-8512-45d2-a0a4-4925e1d18afd" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">41,080,286</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d60b5315-3d1e-4e93-89a6-70c43199642d" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8b0b794a-3213-495e-8b7d-ed8cb0728ed2" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.31</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c39f2d5-4057-42f4-bcc0-6c2847e473a5" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1c751ad7-3165-4d07-aa26-0374d079a3f2" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.70</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's potentially dilutive shares as of December 31, 2023 and 2022, which include outstanding stock options and unvested RSUs, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98d5a8be-8e77-4df5-a22f-f79dff8508e1" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:14.44%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:14.44%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a8c64b7-9dfa-40ab-9240-cdc1f771dddd" contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,383,105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_982ed2f6-6cb5-437e-b88f-e7a2b5fe34cd" contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,203,020</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b298e2c-493f-4980-b07e-c3cbb072eb4f" contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">454,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfa01e22-d05a-47cf-aeea-00bd681abbcf" contextRef="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">197,580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c28592e-a983-4ee1-9d15-9a70ed7ec5bb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,837,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deb4a4af-fbc4-4248-ad3c-bc95b8b5cfd0" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,400,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52a5c437-ef37-4cc2-baff-11db01fb0103" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c30c5b4c-624a-4475-b349-f2369cc3fa40" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4920332-dd11-4e9d-acc0-0d93a5341fdb" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_578e1135-5d2d-4185-94a3-e8b7496fcc32" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd4bd504-44ed-44a6-82dd-24e57b774da0" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c6d6ad9-c7c7-451a-b145-5814d50364f9" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54e184c3-78fd-4636-b60e-3abe5a5b9889" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f094b1dc-9fae-4eb8-9c63-2b694c8f74a2" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e43394d-098a-4bbf-8e0f-44e1cdee6a8c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d8c6413-7963-4858-b9ed-8c23e8789f42" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d0e6f1e-4170-46b0-b5af-00c758e8235e" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4db91092-f032-4ba0-a066-925d739dd85b" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65572815-9807-4e90-bc73-c7f8dce6044c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1025de46-1226-459b-a047-691e9053a091" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24e8e8aa-4ab4-45bf-808d-93f4450ccf88" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_072f92bd-4d23-493f-b1ae-942115cacea0" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6ed073b-904b-4a9c-a889-8d403ee90187" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae967139-d036-49df-b28e-ce850748c881" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for (benefit from) income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36f359d1-66f4-412c-88c0-e4dc35c3a6a4" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c308ea68-b602-4b11-89a2-7ca74445bf3d" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a495cbba-c70c-46bf-b60b-29ce6fa6fae0" contextRef="C_58d02c2b-7ab3-4be5-b6e6-472220ca82b1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e98771df-5759-4a41-9fd6-e0c06c13772b" contextRef="C_bcd33f2a-27fd-406a-827c-58b453fc673e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax expense nor benefit for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e9dcfd5-0efb-4fc9-9f73-cdbf40176152" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"/>
        <td style="width:1.96%;"/>
        <td style="width:1%;"/>
        <td style="width:14.040000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.96%;"/>
        <td style="width:1%;"/>
        <td style="width:14.040000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b81149-0c3f-4653-b6ed-9c0fef6a5336" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c36fbe4-7f79-44c8-b7c6-433c8095c432" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_622d8d12-f6fd-434f-a1ee-bd707bd33aac" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dded7af-078c-4572-a2b0-b3ad58a23073" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e2a91cb-1819-4680-b332-e984ec76dbcd" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58c02f2f-ecfa-4bc8-9f72-f55e5bbbe198" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a96dcc1d-b152-4f60-a975-c03dd3f96f0b" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16fa261d-4ace-4cf4-b48a-4f2860664804" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">23.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">162m limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5f48a8c-2b3c-465c-832f-12ab3d114a3f" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:MLimitation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce41bbf8-3c3a-4209-830b-82b63ccd0668" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0256d7f-de04-4333-a12d-e9ef1f2feb90" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bda6d5b-ecbf-4cbd-a9df-818d0ea03d88" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cbb3918-798a-4bb6-8202-aee1e3a09af3" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5bbb536-e15f-4aa6-a635-e1e7c1a9ce83" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e8951bd-5043-48c2-a918-cad928cd27e9" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52bd7f83-6ec5-4299-a7cd-ea02c6a5e4e8" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffce8181-b76b-4f3b-8267-5eec002d2875" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05f8dcc-199f-4a45-abbc-0c8ffd84176c" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26471871-898f-439a-b6ac-12d2fa604fa7" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18ea3bb3-2476-4a3c-b711-71ceb930699b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,601</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5316668b-b868-40eb-9b6d-8c9714ec254d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,499</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7daf5bab-32ad-425a-a1cf-bffa78a17f74" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,414</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29b8cd1f-6c00-482d-a547-5784963949cd" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,641</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60199e97-1836-4b22-91ee-0dbffdad0dc0" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_290542d8-6c6d-4fe0-843d-94d00f6041d2" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_335285d2-2834-4164-a9d3-96ec902f9f6b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a3ee984-1081-4705-b6b5-9803beef222d" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_634038cf-ef7f-48aa-9612-92d8d7d7f2d9" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_034cd5c5-d2b2-4140-a903-8b6a092323a1" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6ad1579-b691-43db-91e7-643d5c2ac2e1" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:DeferredTaxAssetsFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_467cde21-17b9-4633-a8b1-7d472f64b526" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:DeferredTaxAssetsFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2abfa51e-c2d8-4988-8f80-2ac74aa17566" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02f3e559-7a32-4fd2-9746-d325ea48c3ec" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sec 174 Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276386bc-9ffa-4b35-9693-0e5b7eb72a09" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:Sec174CapitalizedRD" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,871</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d21a204-2656-4e39-88cf-1afae86418f8" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:Sec174CapitalizedRD" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,803</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1281dc0-fc5d-4d06-9bad-964e03e28e6e" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f099297-eddc-4a7c-aab5-68838dd74a14" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aac7f75b-3c9f-4299-a591-3b7700445fc3" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,745</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_119c82a1-db43-4ae5-a352-8651f301e5aa" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61ee369d-b588-455c-96f1-96c3677d1a4b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,069</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc701ae1-8c54-4ccf-b38a-1b6cbc98e37f" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd883db6-f411-4708-86ba-c31dab85610a" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82658894-1f87-455d-ae84-166c9966ab13" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92c9e49f-579e-40ff-876c-edc85025e01b" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_665cab43-911d-4253-a583-06e93bf6b6ef" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basis Difference IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_303d38a4-0417-42c6-a345-fc8655a17412" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:DeferredTaxBasisDifferenceIPRD" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e6a1d64-6df1-4a0e-9665-0b9314d6675a" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:DeferredTaxBasisDifferenceIPRD" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4480f10b-39dc-4479-8867-72a80f3c7a36" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="acet:DeferredTaxOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,676</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_996b0079-0811-4814-aa9a-059c322f47ca" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="acet:DeferredTaxOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cae59781-0c64-4e21-9702-b9b560dc9861" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca6ba3ac-9db3-4a8b-a9c8-9b55e21828bb" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. IRC Section 174, as modified by the Tax Cuts and Jobs Act of 2017, no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. As a result the Company capitalized such costs in its 2023 income tax provision, resulting in an increase in deferred tax assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97c8d497-8a6b-4921-b7be-cf2811ec2621" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:DeferredTaxAssetsValuationAllowanceIncrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa16ff58-4a58-4e64-ae1f-84b2679bcc2a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="acet:DeferredTaxAssetsValuationAllowanceIncrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_138c7da5-7ac4-4725-8d99-2d2da0bb7947" contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">294.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff0dd16-ed57-43d1-936b-07801c1a2d43" contextRef="C_36cb52c2-306e-4caa-b3ac-f865a14de66a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34ac8196-50ae-4e39-b93c-ae537403b2f1" contextRef="C_ebaf029a-2dfd-4e74-9c11-5aaa7f157e14" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0744e4d6-d148-4a52-9590-9041f7eecfb5" contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will begin to expire in 2036 if not utilized, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c517da68-d22f-458d-8924-9d8166c5fb74" contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914" name="acet:OperatingLossCarryforwardsIndefinitely" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">287.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f30b300c-ccf2-4818-b80e-5c93a1af2d03" contextRef="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9c34ce0-d6ec-4794-bb34-dd14c4888727" contextRef="C_d5315a26-1d42-4c2a-88a8-f9074dbbcfc7" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of California research and development tax credit carryforwards available to offset future taxable income as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c159000-a667-4be9-8b74-fbb1df252c21" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="acet:OwnershipChangePlanDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  If the Company has experienced an ownership change, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. As of December 31, 2023, the ownership change analysis has not been completed, however no material tax attributes are expected to be limited for full use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before their respective carryforward periods expires.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts and Israel. The tax years 2016 to 2023 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers. Additionally, the Company is currently undergoing an audit with California&#8217;s Franchise Tax Board (FTB) regarding the apportionment of revenue for the tax year 2017 and may be obligated to make future payments to the state related to this tax year depending on the outcome of the examination. The Company is evaluating the FTB's proposal and assessing its course of action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d55c2a96-9087-465b-9226-d2423e985728" contextRef="C_017e9e60-0f49-41f5-a465-41847cfbef4a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed46bc69-27a8-4812-9984-395ecacbefa5" contextRef="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the federal and state research and development credits as a result of no formal research credit study performed.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3af2629e-0baa-489a-9ddd-7e7f35672538" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1%;"/>
        <td style="width:13.56%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4663ef72-cd00-4206-9f26-b614ddd8be74" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25193600-792b-47da-8b45-acc5d79945f1" contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,040</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25306f78-d007-4ee5-8cec-1dcb88936cdf" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a63dc3c5-2546-45b2-992a-89c93937742a" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97b6271c-cc90-4641-802a-a3f482dbdc39" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_501e6810-dc87-428a-8185-18fe3b6611d8" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,721</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32be0ae5-6d9b-426e-8571-c704d5dcfede" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_244f47c3-7a97-45f2-b4e3-7f519e03c22a" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0adc0309-42f7-4702-8481-9f1f5ddeb255" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Regeneron owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f4aac5-afe6-4cf7-8e50-40901e5c1b6d" contextRef="C_10e00936-04f7-40bc-8922-30c108c241ea" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">883,568</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing which was subsequently converted into common stock. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e8a3478-c9da-4647-bf21-b703cce3cb55" contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from the Regeneron Agreement. See Note 8 for a discussion of the Regeneron Agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e45aaa00-c79a-478f-9c36-d27bdcc54ada" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Defined Contribution Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company made aggregate matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bda7b6f-0942-47d5-a227-fbde61ed4915" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1c5aeed-f9c2-4805-b54e-e9de12c91731" contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2e5758d-c205-4b9b-97ee-5576f137dec8" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Goodwill</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the annual goodwill impairment analysis performed during the fourth quarter of 2022, the Company determined that the fair value of its sole reporting unit exceeded its book value, and therefore </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6f9e44e-a9c6-4d68-b1d6-a4bad8785a0f" contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill impairment charge was recorded in 2022. During the first and second quarters of 2023, the Company concluded that no events or changes in circumstances had occurred that indicated goodwill was more likely than not impaired.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the third quarter of 2023, the Company experienced a significant decline in its stock price. As of September 30, 2023, the Company&#8217;s stock price declined </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a59ed779-4cdb-4e51-8d93-37bf81a37e51" contextRef="C_9a1f48c1-61ea-48ac-83cf-0496c0da44fb" name="acet:StockPriceDecrease" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% from its closing stock price on June 30, 2023, and the decline in stock price was sustained. The Company determined that this decline in stock price and market capitalization of the Company constituted a substantive change in circumstances that would more likely than not reduce the fair value of the Company&#8217;s single reporting unit below its carrying amount. Accordingly, the Company tested its goodwill for impairment as of September 30, 2023 (the Interim Testing Date).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the fair value of the Company&#8217;s sole reporting unit for the interim impairment analysis as of the Interim Testing Date, the Company used a market-based approach, and the primary input in this approach was a quoted market price in an active market. To determine the estimated fair value of the Company&#8217;s single reporting unit, the Company calculated its market capitalization based on its stock price. Based on the Company&#8217;s interim impairment analysis as of the Interim Testing Date, the carrying value of the Company&#8217;s single reporting unit exceeded its fair value. Accordingly, step two of the goodwill impairment test was performed. In performing step two of the goodwill impairment test, the Company utilized observable inputs and concluded that an impairment charge was necessary for the full amount of goodwill. As a result of the step two evaluation, the Company recorded a goodwill impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65bea098-5ec4-4a59-8b78-4ebce3b9cd37" contextRef="C_1127a611-ccab-4753-9b4a-ad14202f612e" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the three month period ended September 30, 2023. This impairment charge reduced the balance of goodwill to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e35c9ad-c544-42d7-8290-2030f5dad4d6" contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_426c20fb-561c-4743-8b38-ccc80332ad8c" contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Subsequent Events</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abd0cad6-1a25-4191-8c8d-c62c25d3bb60" contextRef="C_8b748401-3bad-4b8b-a340-f66ff9129682" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued in a series of sales in accordance with the ATM Program, at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f316112d-3120-497e-bad4-856d2b3ed66c" contextRef="C_8b748401-3bad-4b8b-a340-f66ff9129682" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for aggregate net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a29b772d-f7f1-45c7-8d30-8cdf0f1cd646" contextRef="C_941f1480-af5e-406b-8c0f-c6265ac70511" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting sales agent commissions, but before deducting any expenses related to such sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Underwritten Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, Adicet entered into an Underwriting Agreement (the Underwriting Agreement) with Jefferies LLC and Guggenheim Securities, LLC (the Underwriters) related to an underwritten public offering (the Offering) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2644e0ca-0d2d-48c8-bcd3-861e0f737f22" contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,054,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Shares) of common stock of the Company, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_962307c5-5df7-4032-9c4b-3fdecd96b376" contextRef="C_2b3a4007-846a-4910-997b-c91ad41987d4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the Common Stock), and, in lieu of Common Stock to an investor, pre-funded warrants (the Pre-Funded Warrants) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15ea346-317d-400e-9db1-881938fcd5d1" contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,445,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock (the Warrant Shares). The Shares were sold at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6661593d-512f-4a59-8a0f-d771c501eff1" contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the Pre-Funded Warrants were sold at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd2171db-864a-4038-819f-3cde3d56cf9b" contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.3999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per underlying share, which represents the per share public offering price of each share of common stock minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fa9436d-56dd-4297-a4d9-4b04ee133cc7" contextRef="C_06b4ae69-f76e-476a-824f-b50f46053d25" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share exercise price for each pre-funded warrant. The purchase price paid by the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Underwriters </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the Company was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa696e8-e95b-4615-b704-5541fa09dad1" contextRef="C_ac9c8951-310f-4055-8d6a-dd9b592bf973" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.256</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6a6e839-7223-4dc3-b696-269b6218a244" contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.2559</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant, representing a discount to the Underwriters of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e08e5dcc-9dee-4634-b310-f9b9bc40eea1" contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4" name="acet:DiscountOnUnderwritersWarrant" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. In addition, the Company granted the Underwriters an option exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fc7fd52-4b4a-4bd1-9f56-75a93b717315" contextRef="C_11fc1a2e-6bbc-4957-8f50-7b077832e3e6" name="us-gaap:UnderwritingCommitments"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days from the date of the Underwriting Agreement to purchase, at the public offering price less underwriting discounts and commissions, up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_897531d6-7f2f-40a5-a1a0-8feca14524de" contextRef="C_10c7a5a5-e785-4aa8-b13b-b70c7914a426" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,325,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock. On January 23, 2024, the Underwriters exercised this option in full. The Company received net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74066459-ac2f-43a2-aca8-eebab634bbd8" contextRef="C_8b4a7d79-358a-4bf6-8b1a-17f8afc3527a" name="us-gaap:NoninterestExpenseOfferingCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.7%;"/>
    <td style="width:1.14%;"/>
    <td style="width:90.16%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:0.05pt;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:0.05pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Exhibit</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518025718/d483880dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant (as currently in effect) (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 30, 2018).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of resTORbio, Inc. related to the Reverse Stock Split, dated September 15, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of resTORbio, Inc. related to the Name Change, dated September 15, 2020 (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;3.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518025718/d483880dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (as currently in effect) (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 30, 2018)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459020010474/torc-ex43_235.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 12, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001720580/000119312517383712/d475892dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated as of November 29, 2017, among the Registrant and the other parties thereto (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form S-1 (File No. 333-222373) filed with the SEC on December 29, 2017).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017024007011/acet-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 24, 2024).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1026.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement, dated as of April 28, 2020, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.26 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1032.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Loan and Security Agreement, dated as of July 8, 2020, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Loan and Security Agreement, dated as of September 14, 2020, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Loan and Security Agreement, dated as of September 15, 2020, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022004583/acet-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change Order No. 1, dated September 23, 2021, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022004583/acet-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change Order No. 2, dated March 18, 2022, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.7</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022004583/acet-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Change Order No. 3, dated March 18, 2022, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022011916/acet-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Lease, dated as of June 16, 2022, between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC, as Landlord (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 21, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.7%;"/>
    <td style="width:1.14%;"/>
    <td style="width:90.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.9+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022023230/acet-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Antibody Discovery Agreement, dated as of March 23, 2021, by and between the Registrant and Twist Bioscience Corporation (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on November 8, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.10+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017023008130/acet-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Antibody Discovery Agreement, dated as of November 8, 2022, by and between the Registrant and Twist Bioscience Corporation (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.11+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021002279/acet-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amendment to Loan and Security Agreement, dated as of October 21, 2021, between Adicet Therapeutics, Inc. and Banc of California, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on October 25, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.12</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022026232/acet-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fifth Amendment to Loan and Security Agreement, dated as of December 2, 2022, between Adicet Therapeutics, Inc. and Banc of California, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on December 8, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.13</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex107.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unconditional Secured Guaranty, dated September 15, 2020 (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.14+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021002279/acet-ex10_2.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Affirmation and Amendment of Guaranty, dated as of October 21, 2021, between the Registrant and Banc of California, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on October 25, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.15#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amended and Restated 2018 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 5, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.16#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312517383712/d475892dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2017 Stock Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended, (File No. 333-222373) filed with the SEC on January 16, 2018)</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.17#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1013.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2015 Stock Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.18#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.19#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_15.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2022 Inducement Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.20#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017023008130/acet-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to the 2022 Inducement Plan (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.21#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_16.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Employment Agreement (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.22</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_17.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.23#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_18.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on May 9, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;">  </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.24#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017022003753/acet-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.25</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1023.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement, dated as of October 31, 2018, by and between Adicet Bio, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.26</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312521001980/d105716dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Lease, dated as of December 30, 2020, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 5, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.7%;"/>
    <td style="width:1.14%;"/>
    <td style="width:90.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.27</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021000417/acet-20210625ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Lease, dated as of January 9, 2023, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.28</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518010514/d475892dex1015.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office Lease Agreement, dated as of January 8, 2018, by and between resTORbio, Inc. and 500 Boylston and 222 Berkeley Owner (DE) LLC (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1, as amended, (File No. 333-222373) filed with the SEC on January 16, 2018).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.29</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459019019433/torc-ex102_58.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Office Lease, dated as of April 1, 2019, by and between resTORbio, Inc. and 500 Boylston and 222 Berkeley Owner (DE) LLC (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on May 15, 2019).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.30</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459021037772/acet-ex101_8.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sublease Agreement, dated as of July 19, 2021, by and between Adicet Bio, Inc. and RFS Opco LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on July 23, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.31</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312521111629/d44496dex101.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Standard Form of Agreement between Owner and Contractor Where the Basis for Payment is a Stipulated Sum, effective as of April 2, 2021, by and between Adicet Therapeutics, Inc., as Owner, and CP Enterprises, Inc. d/b/a CP Construction, as Contractor (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on April 9, 2021)</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.32+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1027.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated License Agreement, dated as of May 21, 2014, by and between Technion Research and Development Foundation Ltd., acting on behalf of itself and the Technion-Israel Institute of Technology, and Adicet Therapeutics, Inc. as successor in interest to Applied Immune Technology, Ltd. (incorporated by reference to Exhibit 10.27 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.33+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1028.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to Amended and Restated License Agreement, dated as of June 30, 2015, by and between Technion Research and Development Foundation Ltd., acting on behalf of itself and the Technion-Israel Institute of Technology, and Applied Immune Technology, Ltd. (incorporated by reference to Exhibit 10.28 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.34+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1029.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 2 to Amended and Restated License Agreement, dated as of January 13, 2016, by and between Technion Research and Development Foundation Ltd., Applied Immune Technology, Ltd., and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.29 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.35+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1030.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License and Collaboration Agreement, dated as of July 29, 2016, by and between Adicet Bio, Inc. and Regeneron Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.36+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1031.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to License and Collaboration Agreement, dated as of April 24, 2019, by and between Adicet Bio, Inc. and Regeneron Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.37</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017023026406/acet-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sixth Amendment to Loan and Security Agreement, dated as of May 30, 2023, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 5, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.38</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017023040631/acet-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fourth Amendment to Lease, dated as of August 7, 2023, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on August 9, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;10.39*+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex10_39.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Membership Agreements, dated January 19, 2024 and March 12, 2024, by and between the Registrant and Industrious Bos 131 Dartmouth Street LLC.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;19.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adicet Bio, Inc. Insider Trading Policy.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459021012664/acet-ex211_341.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 12, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;23.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.7%;"/>
    <td style="width:1.14%;"/>
    <td style="width:90.16%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;24.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_a_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on signature page).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;32.1**</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;97.1#*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adicet Bio, Inc. Compensation Recovery Policy.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_v3"><span id="item_16"></span><span id="item_16_v2"></span><span id="tenk_summary"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span id="item16_updated"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 16. 10-K Summary</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.7in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52%;"/>
    <td style="width:4%;"/>
    <td style="width:44%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adicet Bio, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 19, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chen Schor</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chen Schor</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Director</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_a_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span><span id="powerofattorney"></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Chen Schor and Nick Harvey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27%;"/>
    <td style="width:1%;"/>
    <td style="width:48.3%;"/>
    <td style="width:1%;"/>
    <td style="width:22.7%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chen Schor</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chen Schor</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nick Harvey</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nick Harvey</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer (principal financial officer and principal accounting officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jeffrey Chodakewitz</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:16.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jeffrey Chodakewitz, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Steve Dubin</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:17.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Steve Dubin</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Carl L. Gordon</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carl L. Gordon, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Aya Jakobovits</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:18.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aya Jakobovits, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Kauffman</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Kauffman, M.D., Ph.D</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Katie Peng</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Katie Peng</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Andrew Sinclair</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Andrew Sinclair, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 19, 2024</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>2
<FILENAME>acet-ex10_39.htm
<DESCRIPTION>EX-10.39
<TEXT>
<html>
 <head>
  <title>EX-10.39</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:35.347%;text-indent:24.862%;font-size:10pt;margin-top:10.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:36.176%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious: MEMBERSHIP AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.028%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Contract Date: January 19, 2024</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Membership Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) is made by and between the Industrious entity or entities (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and the member (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) set forth below:</font></p>
  <p style="font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.333%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.062%;"></td>
    <td style="width:42.669%;"></td>
    <td style="width:15.063%;"></td>
    <td style="width:31.206%;"></td>
   </tr>
   <tr style="height:21.6pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="2" style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:0.75pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.75pt;text-indent:0;font-size:10pt;margin-top:4.85pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Industrious</font></p></td>
    <td colspan="2" style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:0.8pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.8pt;text-indent:0;font-size:10pt;margin-top:4.85pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Member</font></p></td>
   </tr>
   <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:14.15pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:14.15pt;text-indent:0;font-size:10pt;margin-top:11.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:75.4pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:17.55pt;text-indent:-57.85pt;padding-left:57.85pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">INDUSTRIOUS BOS 131 DARTMOUTH STREET LLC</font></p></td>
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:24.15pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:15pt;text-indent:-9.15pt;padding-left:9.15pt;font-size:10pt;margin-top:5.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Company Name</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.8pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.8pt;text-indent:0;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.029166666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Adicet Bio</font></p></td>
   </tr>
   <tr style="height:46.1pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="background-color:#d9d9d9;border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.9pt;text-indent:-0.85pt;padding-left:0.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08055555555555555in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Location Address</font></p></td>
    <td rowspan="2" style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:53.2pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7444444444444445in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">131 Dartmouth Street 3rd Floor</font></p><p style="margin-left:53.4pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7444444444444445in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Boston, MA 02116</font></p></td>
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:24.15pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:19.2pt;text-indent:-4.95pt;padding-left:4.95pt;font-size:10pt;margin-top:11.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Contact Name</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:2.1pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.018055555555555557in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:22.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:24.55pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:24.55pt;text-indent:0;font-size:10pt;margin-top:5.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Email</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1.9pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:1.9pt;text-indent:0;font-size:10pt;margin-top:5.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.018055555555555557in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">nharvey@adicetbio.com</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">for access to and services relating to the following office space (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), at the following terms:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.22%;"></td>
    <td style="width:16.08%;"></td>
    <td style="width:20.54%;"></td>
    <td style="width:17.86%;"></td>
    <td style="width:22.3%;"></td>
   </tr>
   <tr style="height:39.6pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:0.9pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:10.25pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Office No(s).</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:23.75pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:14.8pt;text-indent:-8.95pt;padding-left:8.95pt;font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1909722222222222in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Office Size (Seats)</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:43.1pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:7.9pt;text-indent:-35.2pt;padding-left:35.2pt;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.09097222222222222in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Monthly Licensing Fee</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:26.65pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:25.3pt;text-indent:-1.35pt;padding-left:1.35pt;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Security Deposit</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:31.7pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:13.3pt;text-indent:-18.4pt;padding-left:18.4pt;font-size:10pt;margin-top:4.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.16180555555555556in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Conference Room Allowance</font></p></td>
   </tr>
   <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0020833333333333333in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">BOSCOP059</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.95pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.95pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$3,668.25</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$5,502.38</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1.4pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:1.4pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8 hours per month</font></p></td>
   </tr>
   <tr style="height:24.5pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0020833333333333333in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">BOSCOP076</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.95pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.95pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$1,799.00</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$2,698.50</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1.4pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:1.4pt;text-indent:0;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7 hours per month</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.38%;"></td>
    <td style="width:26.76%;"></td>
    <td style="width:17.7%;"></td>
    <td style="width:21.24%;"></td>
    <td style="width:15.92%;"></td>
   </tr>
   <tr style="height:78.5pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:15.3pt;text-indent:-20.55pt;padding-left:20.55pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1951388888888889in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">License Start Date</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.6pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.944444444444445E-4in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Earliest Expiration Date</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.8pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Month-to-Month Agreement</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:7.8pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:7.8pt;text-indent:0.15pt;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.09583333333333334in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">One Month Termination Option</font></p><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(Month-to-Month Agreements Only)</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.65pt;text-indent:3.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06736111111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Autopay Opt- Out Surcharge</font></p></td>
   </tr>
   <tr style="height:44.65pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;text-indent:0.85pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.85pt;text-indent:0;font-size:10pt;margin-top:10.75pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.002777777777777778in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">February 01,</font></p><p style="margin-left:0.85pt;text-indent:0;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.6pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">January 31, 2025</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.75pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.001388888888888889in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:26.55pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:8.15pt;text-indent:-18.4pt;padding-left:18.4pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$45 per month (USD)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">* PLEASE NOTE THAT THIS AGREEMENT CONTAINS AUTO-RENEWAL TERMS AS SET FORTH BELOW AND IN SECTION 7(M). PLEASE REVIEW THIS LANGUAGE CAREFULLY BEFORE SIGNING THIS AGREEMENT.</font></p>
  <p style="font-size:10pt;margin-top:1.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Agreement comprises this signature page and the Industrious Membership Terms and Conditions, together with any attached or referenced authorizations exhibits, and schedules. Optional services are available, as set forth on the attached initial fee schedule, which fees are subject to change from time to time with reasonable advance notice to Member.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.009%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The initial Agreement term (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) will commence on the License Start Date and end on the Earliest Expiration Date (each as specified above). Upon expiration of the Initial Term, this Agreement shall automatically renew (each a &#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Renewal Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#34;) for an additional successive term equal in length to the Initial Term, unless Member provides written notice of non-renewal (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-Renewal Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) to Industrious at least two (2) calendar months prior to the end of the then-current term, or unless sooner terminated as provided in Section 2. As used in this Agreement, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; will include the Initial Term and any Renewal Term.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the Term is renewed for any Renewal Terms pursuant to this Section, the terms and conditions of this Agreement during each such Renewal Term shall be the same as the terms and conditions in effect immediately prior to such renewal, subject to any change in the Licensing Fees and other fees payable hereunder by Member during the applicable Renewal Term as set forth in Section 7(m). If Member provides timely notice of its intent not to renew this Agreement, then, unless otherwise sooner terminated in accordance with its terms, this Agreement shall terminate on the expiration of the then-current Term.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Month-to-Month Agreements Only</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: Notwithstanding the foregoing, if the One Month Termination Option has been selected by Member, as specified on page one of this Agreement, upon Industrious&#x2019;s receipt of Member&#x2019;s Non-Renewal Notice, the Agreement will terminate effective as of the last day of the first (1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">) full calendar month following Industrious&#x2019;s receipt of the Non-Renewal Notice. For example, if Member gives notice of termination on February 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or 25</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, the last day of Member&#x2019;s membership will be March 31</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">All Other Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: For all Agreements with an Initial Term other than month-to-month, unless Industrious receives a timely Non-Renewal Notice, the Term of this Agreement will automatically renew as set forth above.</font></div></div>
  <p style="font-size:10pt;margin-top:2.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Simultaneously with Member&#x2019;s execution of this Agreement, Member will deliver to Industrious a security deposit in the amount described above (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;); provided that if the Premises (as defined hereunder) has not yet opened for business as of the Contract Date, and if the License Start Date is more than thirty (30) days after the Contract Date, Twenty (20) % of the Security Deposit must be paid upon execution of this Agreement by Member and the balance of the Security Deposit must be paid no later than thirty (30) days prior to the License Start Date.</font></p>
  <p style="font-size:10pt;margin-top:1.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Agreement may be executed in counterparts, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Signatures to this Agreement transmitted by electronic means will be valid and effective to bind the party so signing. This Agreement will not be valid until approved and signed by an authorized representative of each party hereto.</font></p>
  <p style="margin-left:0.413%;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">[Signature Page to Follow]</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">By signing below, each party acknowledges that it has read and understood this Agreement and agrees to be bound by its terms, effective as of the Contract Date set forth above.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Industrious:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Member:</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">&#160;/s/ Liza Greenberg</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">&#160;/s/ Nick Harvey</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Name: Liza Greenberg</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Company Name: Adicet Bio</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Industrious Team</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Contact Name: Nick Harvey</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Title: CFO</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Membership Agreement Signature Page</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:37.867%;text-indent:1.626%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:39.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious OPTIONAL SERVICES</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(additional fees required)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additional conference room hours:$25/half hour</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dedicated internet (100% fiber dedicated bandwidth):$10.00 per Mbs/company/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Public IP Address:$20.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone service (without phone):$40.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone service (with phone):$60.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone tree (basic):$40/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone tree (enhanced):$120/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Call recording:$50/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Port in a number (transfer existing number to your new Industrious phone):$15/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Port out a number (transfer an Industrious number to a new line/phone):$30</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Conference bridge:$20.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fax to email:$30.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Logo:$250 / logo</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">MEMBERSHIP TERMS AND CONDITIONS</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These Membership Terms and Conditions are incorporated into and made part of the Membership Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) entered into by and between the Industrious entity or entities (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and the member (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) set forth on the Agreement signature page. Capitalized terms not otherwise defined herein have the meanings ascribed to them on the Agreement signature page.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 1. Office Space and Services</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Subject to these terms and conditions and payment of all applicable fees, Industrious will permit Member to access and use the number and configuration of furnished workspaces and workstations specified on the Agreement signature page (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), located at the property, building, or space owned, leased, or otherwise controlled by Industrious indicated on the Agreement signature page (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will use commercially reasonable efforts to make the Office Space available to Member as of the date specified on the Agreement signature page as the License Start Date, provided that if </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Industrious </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">is unable to make the Office Space available on the date specified, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; will mean the date Member actually receives access to the Office Space. Member&#x2019;s payment obligations hereunder will begin on the License Start Date. Industrious reserves the right to relocate, reduce or increase the size, number, or configuration of the Office Space from time to time, in which case the applicable fees will be proportionately reduced or increased, as determined in Industrious&#x2019;s sole discretion; provided that no such relocation or increase shall result in an increase of the monthly License Fee by more than 10% of the then-current monthly License Fee without Member&#x2019;s prior written consent. Industrious will provide Member with reasonable advance written notice should changes to the Office Space or License Start Date be necessary.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Premises will include standard power outlets, common area restrooms and a common area kitchen. For common use within the Premises, Industrious will use good faith efforts to provide certain services (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), such as access to and use of shared internet connection and printers/scanners and other services as may be described in the Member handbook provided to Member. Any or all of the Services may be provided by Industrious, an affiliate of Industrious, or any third party service provider designated by Industrious from time to time in its sole discretion. All Services, other than shared internet connection and printers/scanners, that may be provided by or on behalf of Industrious may be added, deleted, or changed at any time at the sole discretion of Industrious, with or without prior notice to Member.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Business Hours</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Business hours for the Premises may vary by location&#x2014;the hours of operation in effect will be posted at the Premises or otherwise made available to Member. Industrious reserves the right to close the Premises on national holidays and on days with inclement weather at the discretion of Industrious. Certain Services may be available only during regular business hours, excluding holidays. The Premises may be accessible outside of business hours using the key card assigned to Member, in accordance with the procedures set forth in the Member handbook or other policy documents applicable to the particular Industrious location.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In order to receive certain Services (including but not limited to access to the network, shared printing, etc.), Member may be required to install on Member&#x2019;s computer device certain drivers or software tools (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member acknowledges and agrees that Software may be owned, controlled, or provided by third parties, and that the installation or use of any Software may be subject to separate licenses, terms, conditions, or restrictions. Industrious provides no warranties with respect to the Software (even if provided by or through Industrious), and as a condition of use of the Software, Member, on behalf of itself and its employees, agents, and invitees, waives any claim against Industrious, its affiliates, and any</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">person acting on behalf of Industrious or its affiliates arising from or in conjunction with the installation or use of such Software.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Specific Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will accept mail on behalf of Members. However, Industrious will not be responsible for any items received on behalf of Member. If Member expects a special delivery or package, Member must provide Industrious with reasonable notice and instructions, if necessary, in order for Industrious to accept such delivery. If Member&#x2019;s membership package includes a monthly allowance of conference room hours, such monthly allowance will not be rolled over from one month to the next. If Member has added Parking to its suite of Services, Member agrees to follow any and all rules and requirements for parking set forth by the Landlord or Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Maintenance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will use commercially reasonable efforts to maintain the Premises in good functional condition; provided that Member is and will remain responsible for, and will indemnify, defend and hold harmless Industrious, Landlord (as defined hereunder), and their respective affiliates for any and all damage to the Office Space, Premises and/or the building in which the Premises is located, exceeding normal wear and tear, caused by Member or its agents, employees and invitees, and for the acts and omissions of Member and its employees, agents, or invitees. Member shall take good care of all parts of the Office Space, Premises and/or the Building, including any equipment, fixtures and furnishings, which Member is permitted to use hereunder. Member shall not alter any part of the Office Space, Premises and/or building or Industrious&#x2019;s equipment, fixtures or furnishings.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Access</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that Industrious and its designees will at all times have access to the Office Space, upon at least 24 hours&#x2019; notice to Member (except in case of an emergency, which shall be determined in Industrious&#x2019;s sole discretion, and for routine janitorial or similar access), for purposes including but not limited to the maintenance and safety of the same and any emergency situations. Industrious may temporarily move and/or replace parts and components of the Office Space in Industrious&#x2019;s sole discretion. Notwithstanding the foregoing, except in the case of emergency, Industrious will use commercially reasonable efforts not to disrupt Member&#x2019;s business in or use of the Office Space.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Only</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding anything herein to the contrary, this Agreement is a revocable license to access the Office Space and receive certain Services, upon the terms and conditions set forth herein. The relationship between Industrious and Member is that of a licensor and licensee only, and not a landlord- tenant or lessor-lessee relationship. This Agreement will not be construed to grant Member any right, title, interest, easement, or lien in or to Industrious&#x2019;s business, the Office Space, the Premises, or anything contained therein, nor will this Agreement be interpreted or construed as a lease. Member acknowledges that this Agreement creates no tenancy interest, leasehold estate, or other real property interest in Member&#x2019;s favor and Member hereby waives any and all claims and/or defenses based upon any such interest.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 2. Term and Termination of Agreement</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Term of this Agreement is set forth on the Agreement signature page.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:8.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Termination for Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may terminate this Agreement in its sole discretion, effective immediately if Member or any of its agents, employees, or invitees breaches any provision in this Agreement or violates any Industrious rules, policies, or codes of conduct. Provided that, if Member fails to pay any fee when due (or an Autopay (as defined in Section 3) payment is returned, declined or otherwise rejected), if it is Member&#x2019;s first delinquency in any twelve (12)-month period, Industrious will send Member written notice of the delinquency, and Member will have five (5) days from the date of such notice to cure the delinquency by paying all amounts owed (including late fees and finance charges, as applicable). Member is only entitled to one notice and cure period per twelve (12)-month period, and for any subsequent delinquency Industrious may terminate Member&#x2019;s license and membership immediately, in Industrious&#x2019;s sole discretion. Additionally, Industrious shall charge Member the Autopay Opt-Out Surcharge, in the event that Member</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cancels Autopay and does not provide an alternative payment credential to be used for future Autopay payments as part of the cancellation procedure.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Termination for Convenience</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may terminate this Agreement (i) immediately in the event that Industrious&#x2019;s rights in the Premises terminate or expire for any reason; or (ii) upon thirty (30) days&#x2019; written notice to Member in Industrious&#x2019;s sole and absolute discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Removal of Property upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. On or prior to the termination or expiration of this Agreement, Member will remove all of its property from the Office Space and Premises, leaving them in the same condition as they were in when Member moved in, reasonable wear and tear excepted, it being understood and agreed that member has no right to continue to use and/or access the Office Space or any Services after the expiration or termination of this Agreement. In addition to any other rights and remedies Industrious has hereunder, Industrious will be entitled to remove and dispose of any of such property remaining in or at the Office Space or the Premises after the termination of this Agreement in any way that Industrious chooses, without notice to Member (whether belonging to Member or its employees, agents, or invitees), and without waiving its right to claim from Member all expenses and damages caused by Member's failure to remove such property, and Member and any other person or entity shall have no right to compensation from or any other claim against Industrious as a result</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Effect of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Following the termination or expiration of this Agreement for any reason, Member will remain liable for all amounts due or owing as of the effective date of such termination or expiration (regardless of the date Member vacates any or all of the Office Space or the Premises). Without limiting the foregoing, if this Agreement is terminated for breach pursuant to Section 2(b) above, Member will remain liable for (x) all License Fees and any other fees owed through the remainder of the Term, and (y) the full amount of any fees that Industrious paid to a broker in connection with this Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Broker Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). All such License Fees and Broker Fees will be due and payable immediately upon such termination pursuant to Section 2(b). In the event this Agreement is terminated for convenience pursuant to Section 2(c) above, Industrious will within a reasonable time following the effective date of the termination return to Member any pre-paid License Fees or other fees applicable to the post-termination period. This Section 2 and Sections 4 through 7 of this Agreement will survive the termination or expiration of this Agreement for any reason, as will all other provisions of this Agreement that may be reasonably expected to survive such termination or expiration.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 3. Fees</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Beginning on the License Start Date, and continuing during the Initial Term of this Agreement, Member will pay, in advance, the monthly license fee specified on the Agreement signature page (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). The License Fee is due on or before the 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">of each month during the Term, provided that if the License Start Date falls on a date that is not the 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">day of the month, then on the License Start Date Member will pay the pro rata portion of the monthly License Fee for the remainder of that month. All License Fees must be paid in U.S. dollars. All amounts paid under this Agreement are nonrefundable and noncancellable, except as expressly provided herein. When Industrious receives funds from Member, such funds will be applied first to any past-due balances, oldest to newest, then to any current monthly fees due and owing. License Fees are subject to change during the Renewal Term (if any) as set forth in Section 7(m) hereunder.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Other Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Where permitted under state law, Industrious may assess an extra charge (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Surcharge</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in an amount that is commensurate with Industrious&#x2019;s cost to accept and process credit card transactions in the event the Member has opted out of Autopay. Such Surcharge will only be applicable to non-Autopay credit card transactions. Any such Surcharge will be identified on the Agreement signature page and on the Member&#x2019;s monthly invoice. Payments made by Autopay will not be subject to a Surcharge. A ten percent (10%) late fee will be charged on any outstanding balance existing on the 5th day of any month. Additionally, Member may be subject to additional fees for declined or returned payments due to insufficient</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">funds, as set forth in fee schedules published or posted by Industrious from time to time. Member acknowledges that all fees are subject to change from time to time at the discretion of Industrious. Any late fees or charges are in addition to any other rights and remedies Industrious may have for Member&#x2019;s breach of this Agreement.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Security Deposit must be paid in the amount and at the time set forth on the Agreement signature page. The Security Deposit will be refunded to Member within forty-five (45) days after termination of this Agreement, subject to the complete satisfaction of Member&#x2019;s obligations under this Agreement, as determined by Industrious in its sole discretion. The Security Deposit will be held by Industrious, without liability for interest, as security for the performance by Member of Member&#x2019;s covenants and obligations under this Agreement. Member acknowledges and agrees that the Security Deposit will not be considered an advance payment of the License Fee or a measure of Member&#x2019;s liability for damages in case of default by Member. Industrious may, from time to time and without prejudice to any other remedy, use the Security Deposit to the extent necessary to make good any arrearages of the License Fee or to satisfy any other covenant or obligation of Member hereunder. Following any such application of the Security Deposit, Member will pay to Industrious on demand the amount so applied in order to restore the Security Deposit to its original amount. To the extent of any unapplied Security Deposit after the termination of this Agreement, Industrious will only refund the same to Member, unless an authorized representative of Member directs Industrious in writing to send the refund to another person or location. If during the Term of this Agreement, Member changes the Office Space to one(s) carrying higher License Fees, Member will deliver to Industrious the incremental increase in the Security Deposit as required by Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Suspension of Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may withhold or suspend any Services and/or access to the Office Space and the Premises while there are any outstanding amounts due or Member is otherwise in breach of this Agreement, in addition to any other rights and remedies Industrious may have. In the event that Industrious withholds services from Member pursuant to the foregoing, Industrious shall not be liable for any claim of business interruption or for any indirect, incidental, special, consequential, exemplary or punitive damages arising out of such actions.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Form of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Payments for License Fees and all other fees hereunder may be made by ACH bank transfer, most major credit cards or debit cards. Member agrees that such payments for License Fees and other fees hereunder will be paid in accordance with the terms set forth in this Agreement and in the Recurring Payment Authorization Form, which is hereby incorporated herein by reference. All payments for License Fees and all other fees under this agreement must be paid in U.S. Dollars. Industrious may offer discounts off its regular License Fee and other fee rates for payments made by ACH bank transfer. Any such discounts will be reflected on the signature page of this Agreement. Any applicable ACH discount will be refunded to Member reasonably promptly after payment is made by member in full.</font></div></div>
  <div style="margin-left:9.463%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:5.450810166009475%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Stored Credentials; Recurring Payments; Cancellation. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a condition of this Agreement, Industrious requires Member, and Member agrees, to maintain a current bank account, credit card, or debit card on file to be used for automatic payments for all amounts due under this Agreement. Member must agree to the Recurring Payment Authorization Form. Member specifically acknowledges and agrees that amounts due under this Agreement will be processed automatically and on a recurring basis using the stored payment credential on file in accordance with the Recurring Payment Authorization Form (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Autopay</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member may cancel Autopay (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Autopay Cancellation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) with respect to a specific stored payment credential at any time online at </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">member.industriousoffice.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event that Member does not provide Industrious with an alternative payment credential to be stored and used for Autopay during that cancellation procedure, Industrious may exercise its right to immediately terminate this Agreement pursuant to Section 2(b). If an Autopay payment is rejected or declined, Industrious may terminate this Agreement pursuant to Section 2(b) in addition to any related fees as set forth in fee schedules published or posted by Industrious from time to time (i.e., late fees, fees for a payment returned for</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">non-sufficient funds, etc.). Notwithstanding the foregoing, Industrious shall not terminate any Member for opting out of Autopay or upon the rejection or declining of any Autopay payment, provided Member agrees to pay and promptly pays the Autopay Opt Out Surcharge, as set forth herein.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 4. Member Obligations</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Background Checks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious reserves the right to conduct a basic criminal and OFAC background check on any or all of Member&#x2019;s owners, officers, employees and agents who will be granted access to the Premises (particularly if Member desires after-hours access for such persons), and Member agrees to use good faith efforts to assist Industrious with the same, at no cost of Member. After-hours access may only be granted to those persons who pass such background check to Industrious&#x2019;s sole and absolute satisfaction. Member represents and warrants that neither Member, nor any of its owners, officers, employees or agents has been or will be: (a) designated as a &#x201c;blocked person&#x201d; as such term is described in Executive Order 13224, issued September 23, 2001 by George W. Bush, President of the United States; or (b) a person or entity described either as a Specially Designated Global Terrorist or a Specially Designated Nationals and Blocked Persons by the Office of Foreign Assets Control (&#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#34;) of the U.S. Department of the Treasury. The continued accuracy throughout the Term of this Agreement of the foregoing representation and warranty is an ongoing material condition to this Agreement and, accordingly, Member has the obligation during the Term to immediately notify Industrious by written notice if the foregoing representation and warranty should ever become false. Any breach of the representation and warranty or failure on the part of Member to so update Industrious constitutes a breach of this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious makes no warranty or representation to Member with respect to any security services or systems and Industrious expressly disclaims any liability related to the wrongful access, use or disclosure of any data or information that is processed, stored or transmitted through or by the Services, which includes without limitation, the Software. Member shall be fully responsible for the safety and security of its personal property brought into the Office Space, Premises and/or building. As between Industrious and Member, Member shall also be fully responsible for any liability related to the wrongful access, use or disclosure of any data or information that is processed, stored or transmitted through or by the Services, which includes without limitation, the Software. Industrious shall not be liable to Member on account of any loss, injury, liability, damage or theft to any business or personal property of Member, its owners, officers, employees, agents and invitees, other than as a result of Industrious&#x2019;s gross negligence or willful misconduct. Member acknowledges that all keys, key cards, key fobs, and other such items used to gain physical access to the building, Premises and/or the Office Space remain the property of Industrious, or its landlord or the owner of the Premises or each of their respective affiliates (as applicable, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member will not attempt to (or allow others to) gain unauthorized access to any computer systems located at or serving the Premises or any content or data of Industrious, other members, or any other person. Neither Member nor any of its agents, employees or invitees are permitted to enter any other office space in the Premises. Member will use its best efforts to safeguard the Premises and Industrious&#x2019;s property and will be liable for all costs and expenses should any such property be lost or damaged as a result of Member&#x2019;s and/or its employees&#x2019;, agents&#x2019; or invitees&#x2019; acts or omissions. Member is solely responsible for maintaining all necessary security and control of any and all user names, passwords, or any other credentials issued to or used by Member or its employees, agents or invitees, for use with Industrious&#x2019;s computer systems, networks, or other Services provided under this Agreement. Member will not allow (and will instruct its employees and agents to not allow) a party unknown to them to enter the Office Space or the Premises and acknowledges that such action may result in the termination of this Agreement. Member is and will remain responsible for the actions or omissions of all persons that Member or its employees, agents or invitees allow or invite to enter the Office Space or the Premises.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Complaints</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees that all issues and complaints relating to the Office Space or other members will be directed solely to Industrious. Member will have no direct access to or communication with the Landlord (if other than Industrious), and Member agrees not to send any complaints or demands to the Landlord directly.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Privacy Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees that the use of Industrious&#x2019;s online portal and website are subject to Industrious&#x2019;s Portal Terms of Use and Privacy Policy, which are available at </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.industriousoffice.com/portalterms/</font></font><font style="color:#1154cc;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.industriousoffice.com/privacypolicy/</font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> respectively, and which are subject to change from time to time in Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rules and Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Additional rules may be set forth in the Member handbook or other policy documents applicable to each Industrious location, which are subject to change from time to time in Industrious&#x2019;s sole discretion. Member agrees to abide by all rules and policies as determined by Industrious from time to time, whether communicated to Member verbally, by email, other written notice or public posting. Without limiting the foregoing, Industrious may require Member and each of its owners, officers, employees, agents and invitees who will be granted access to the Premises to agree to and sign Industrious&#x2019;s Anti-Harassment Policy prior to using the Office Space or Services.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Prohibited Conduct</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In addition to any other applicable rules and policies issued by Industrious, Member agrees to the following terms and conditions:</font></div></div>
  <div style="margin-left:7.731%;margin-top:6.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Assignment or Sublicense</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not sell, lease, license, distribute or grant any interest in the Office Space or any of the Services to any third party. Further, Member may not assign this Agreement in whole or in part, or otherwise transfer, sublicense or otherwise delegate any of Member&#x2019;s rights or obligations under this Agreement, to any third party.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Alterations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not alter the Office Space or Premises in any manner or attach or affix any items to the walls, floors or windows, without the prior written consent of Industrious.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Unapproved Items</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not store any of its property or materials in any area of the Premises, except the Office Space. Member may not bring any additional furniture, furnishings or decorations into the Premises or Office Space or install any satellite or microwave antennas, dishes, cabling or telecommunications lines in the Premises or Office Space without the prior written consent of Industrious in its sole discretion. Member acknowledges that carts, dollies and other freight items may not be used in the passenger elevator except by appointment made with Industrious, at Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Retail Use</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will use the Office Space solely as general office space in the conduct of Member&#x2019;s business and for no other use whatsoever. Use of the Office Space for retail, medical or other type of business involving frequent visits by members of the public, manufacturing, or for any other use prohibited by the Member handbook is not permitted. Regular use of the Office Space is limited to those persons subject to background checks as set forth in this Agreement.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Illegal Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not use the Premises, any Services, or any Industrious computer systems or networks to conduct or pursue any illegal activities, including but not limited to, downloading, distributing or viewing any illegal content, engaging in any activity in violation of OFAC regulations, and/or illegally downloading any copyrighted content, or any other activity that violates any intellectual property rights, and any such conduct using the Premises or Industrious&#x2019;s systems or networks may result in immediate termination of this Agreement.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Offensive Behavior</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not conduct any activity in the Office Space, Premises and/or the building that is harmful, threatening, abusive, harassing, tortious, defamatory, vulgar, obscene, libelous, invasive of another&#x2019;s privacy, hateful, or racially, ethnically or otherwise generally regarded as offensive to other people, including but not limited to, involvement in hate groups or activities involving pornographic or sexually explicit materials or obscenities, whether written, oral, or in any form or medium. Member will</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refrain from any activities that may be disruptive, a nuisance or an annoyance, including but not limited to, acts of disorderly nature or excessive noise. Member may not conduct any activity which may be hazardous to other persons in the building. Industrious may determine at its sole discretion what activities may be deemed offensive, disruptive or hazardous.</font></p>
  <div style="margin-left:7.731%;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Malware, Spamming</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not upload any files that Member knows or suspects to contain or may contain viruses, Trojan Horses, worms, time bombs, corrupted files, or any other malicious code, whether known or unknown that may damage or disrupt Industrious&#x2019;s or any other person&#x2019;s computer systems or networks. Member will take precautions to prevent the spread of viruses, including but not limited to, using up-to-date anti-virus software, enacting policies to avoid opening suspicious emails, and avoiding suspicious websites. Spamming other members or any other persons is strictly prohibited, and any such conduct using the Premises or Industrious&#x2019;s systems or networks may result in immediate termination of this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Personal Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member represents and warrants that it has obtained the necessary authorizations and consents for any personal information it processes through the Services, which includes without limitation, the Software.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Onboarding Process</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees to fully cooperate with the onboarding process (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Onboarding Process</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) for Industrious. Member represents and warrants that the information it provides pursuant to the Onboarding Process will be true, accurate and complete. Member acknowledges and agrees that should it breach the representation above, Industrious may immediately rescind or terminate this Agreement, in its sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Cross Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees and acknowledges that if they are in default on any agreement or understanding with an affiliate of Industrious, then they will be deemed to be in default of this Agreement.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 5. Intellectual Property and Confidentiality</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not use Industrious&#x2019;s name, logo, trademarks, service marks or domain names (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Marks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in any way in connection with Member&#x2019;s business, without the express written consent of Industrious, in its sole discretion. Member will comply with all standards established by Industrious from time to time with respect to the Industrious Marks. Member hereby acknowledges and agrees that all right, title, and interest in and to the Industrious Marks belong to Industrious, and that all usage and goodwill of the Industrious Marks will inure only to the benefit of Industrious. Member will not use, register, or attempt to register any trademarks or domain names that are confusingly similar to the Industrious Marks, nor use the Industrious Marks in any manner that would indicate that Member has any rights thereto. If consent to use the Industrious Marks is granted as set forth above, Industrious reserves the right to revoke Member&#x2019;s rights to use the Industrious Marks at any time in Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Publicity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may use the address of the Office Space as its business address, but only during the Term of this Agreement. Member may not use photos or illustrations of the Premises, or any Industrious Marks, in any of Member&#x2019;s marketing materials or in any other manner without the express written consent of Industrious. Further, no press release, advertising, sales literature or other publicity statements relating to the existence or substance of this Agreement or the relationship of the parties may be made by Member without the prior written approval of Industrious. Member grants Industrious and its affiliates the right to use Member&#x2019;s trade name(s), logos and/or trademarks in Industrious&#x2019;s materials prepared for its shareholders or members, or prospective shareholders or members.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member Directory</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may place Member&#x2019;s name and contact information in a directory of Industrious members; provided that Member will be given the opportunity to &#x201c;opt-out&#x201d; of such listing which it may do at any time.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Photo and Video Shoots</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that promotional photography and/or video recording (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Shoot</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) may occur in the Premises (but not within the Office Space) from time to time. Industrious will provide Member with reasonable advance notice of any such Shoot, and at such time Member may request that Industrious endeavor to avoid capturing Member&#x2019;s name, likeness, image, voice and/or appearance in the background any such recordings. Industrious will use commercially reasonable efforts to comply with Member&#x2019;s request. Subject to the foregoing, by entering that portion of the Premises in which a Shoot is </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">taking place, Member and Member&#x2019;s employees, agents, and invitees consent to such photography and/or video recording and the release, publication, exhibition or reproduction of such recordings in which they may appear for promotional purposes by Industrious and its affiliates and representatives. Subject to the foregoing, Member and its employees, agents, and invitees each hereby releases and discharges Industrious and its agents, representatives, and assignees from any and all claims and demands arising out of or in connection with the use of the name, likeness, image, voice, or appearance of Member or any of its employees, agents, or invitees, including any and all claims for invasion of privacy, right of publicity, misappropriation, misuse, and defamation. Member represents and warrants to Industrious that its employees, agents, and invitees will have been informed of and agreed to this consent, waiver of liability, and release before they enter that portion of the Premises in which a Shoot is taking place.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sensors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that Industrious does or may utilize sensors that record usage of the Premises, excluding the Office Space, and amenities (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sensors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and consents to the use of the Sensors. The Sensors monitor, among other things, the number of people utilizing a particular space or amenity, the times that a particular space or amenity is used, etc. Low resolution images may be captured, which will be processed by automated software, for the purpose of counting people and upon the completion of said task, the image will be deleted. No sound recordings will be made or captured and no high resolution photographs or videos will be taken. The data collected is anonymous aggregated data. Prior to the implementation of any sensors, Industrious will contractually prohibit vendors of any sensors used from combining any anonymous aggregated data with other data in any manner that could make it personally identifiable data. Industrious will use the data collected for improving or developing its service or products, or for any other lawful business purpose. Subject to the foregoing, Member and its employees, agents, and invitees each hereby release and discharge Industrious and its agents, representatives, and assignees from any and all claims and demands arising out of or in connection with the use of the Sensors, including any and all claims for invasion of privacy, right of publicity, misappropriation, misuse, and defamation. Member represents and warrants to Industrious that its employees, agents, and invitees will have been informed of and agreed to this consent, waiver of liability, and release before they enter that portion of the Premises in which the Sensors are being used.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may receive or learn certain confidential information about Industrious or Industrious&#x2019;s other members, including without limitation, information regarding its or their business operations, business and marketing plans, pricing, technology, finances and methods (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member agrees to hold all Confidential Information, whether belonging to Industrious or its other members, in strict confidence and to take all reasonable precautions to protect such Confidential Information. All terms and conditions of this Agreement (including, without limitation, pricing- related information) shall be deemed Confidential Information. Member acknowledges that any disclosure or unauthorized use of Industrious&#x2019;s Confidential Information will constitute a material breach of this Agreement and cause substantial harm to Industrious for which damages would not be a fully adequate remedy. In the event of any such breach, Industrious will have, in addition to any other available rights and remedies, the right to injunctive relief (without being required to post any bond or security). If an employee or agent of Industrious becomes aware of any Confidential Information of Member, Industrious agrees to cause such employee or agent to hold such Confidential Information in strict confidence and to take all reasonable precautions to protect such Confidential Information, except any disclosure required by law, court order or in connection with a breach of this Agreement by Member.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 6. Liability</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waiver of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will be solely responsible for maintaining the insurance coverage required hereunder and Member will look solely to such insurance for any and all claims, damages, costs, expenses, liabilities and rights it may have, except to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious Party (defined hereunder). To the maximum extent permitted by law, Member, on its own behalf and on behalf of its owners, officers, employees, agents and invitees, hereby Waives (as defined hereunder) any and all claims, actions, damages, costs, expenses, liabilities and rights against Industrious, Landlord, their respective affiliates, and each of their respective past, present and future principals, members, assignees, managers, directors, officers, employees, agents, successors and assigns (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Party</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; and collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) arising or resulting from (i) any injury or damage to, or destruction, theft, or loss of, any tangible or intangible property located in or about the Office Space, the Premises or the building in which the Premises is located, (ii) any personal injury, bodily injury or property damage (as such terms are defined by insurance regulations) occurring in or at the Office Space, the Premises or the building in which the Premises is located, (iii) the wrongful access or use of any data or information, or (iv) any loss of use or interruption of Member&#x2019;s business or any interruption or stoppage of any Service, except to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious Party. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; of Industrious or of Landlord include any person or entity that controls, is controlled by, or is under common control with Industrious or Landlord, respectively, including without limitation, any subsidiaries or parent companies; and the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waives</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; means that Member, and its owners, officers, employees, agents and invitees waive and knowingly and voluntarily assume the risk of.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Disclaimer of Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious expressly disclaims and excludes all warranties, whether express, implied or statutory, with respect to the Office Space, the Premises and the Services provided by or on behalf of Industrious, including but not limited to, any warranty of merchantability, fitness for a particular purpose, non-infringement, habitability, or quiet enjoyment, or any warranties that may have arisen or may arise from course of performance, course of dealing or usage of trade. Industrious makes no representations or warranties regarding the quality, reliability, timeliness or security of the Office Space or any Services provided by or on behalf of Industrious, or that any Services will be uninterrupted or operate error free. The Office Space, Premises and Services provided by Industrious are provided &#x201c;as is&#x201d; and &#x201c;with all faults&#x201d;.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The aggregate monetary liability of the Industrious Parties to Member, its owners, officers, employees, agents and invitees for any reason and for all causes of action, whether in contract, in tort, or otherwise, not otherwise waived as set forth above, will not exceed the total fees paid by Member to Industrious under this Agreement during the twelve (12)-month period prior to the date on which the cause of action accrued. Notwithstanding anything herein to the contrary, in no event will any Industrious Party be liable for any claim or cause of action, whether in contract, in tort, or otherwise for any indirect, special, consequential, exemplary, or punitive damages, including but not limited to, loss of profits or business interruption, even if Industrious has been advised of such damages. Member acknowledges that Industrious&#x2019;s obligations under this Agreement are consideration for the foregoing limitations of liability. The limitations, waivers, disclaimers and exclusions in this Agreement apply to the maximum extent allowed by law, even if a remedy fails its essential purpose.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitation of Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. To the extent not otherwise waived as set forth above, unless otherwise prohibited by applicable state or federal law, Member must commence any action, suit or proceeding against any Industrious Parties, whether in contract, tort, or otherwise, within one (1) year of the cause of action&#x2019;s accrual and Member, on its own behalf and on behalf of its owners, officers, employees, agents and invitees, hereby Waives any claims not brought within such time period.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:7.731%;margin-top:9.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except to the extent of the negligence or willful misconduct of any Industrious Party or their respective employees, agents, contractors or vendors, Member will indemnify, defend and hold harmless each of the Industrious Parties from, and against any and all actual claims, actions, proceedings, damages, </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.731%;margin-top:9.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">liabilities, costs and expenses of every kind, whether known or unknown, including but not limited to reasonable</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attorney fees (collectively, &#x201c;Claim(s)&#x201d;), to the extent resulting from or arising out of (i) any breach of this Agreement by Member or Member&#x2019;s owners, officers, employees, agents, or invitees; or (ii) any actions, errors, omissions, negligence, willful misconduct or fraud of Member or Member&#x2019;s owners, officers, employees, agents or invitees. If any such Claim is brought against any of the Industrious Parties, Member will defend the Claim at Member&#x2019;s expense, using counsel approved by Industrious in writing, such approval not to be unreasonably withheld, provided that Industrious will at all times have the right to participate in such defense at its own expense. The Industrious Parties&#x2019; refusal to consent to a settlement shall not be deemed unreasonable when the proposed settlement requires or results in the Industrious Parties, or any one of them, admitting to any wrongdoing or liability.</font></p>
  <p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except to the extent of the negligence or willful misconduct of Member or its employees, agents, invitees, contractors or vendors, Industrious will indemnify, defend and hold harmless Member from, and against any and all Claims, to the extent resulting from or arising out of any actions, errors, omissions, negligence, willful misconduct or fraud of Industrious or its owners, officers, employees, or agents. If any such Claim is brought against Member, Industrious will defend the Claim at Industrious&#x2019;s expense, using counsel approved by Member in writing, such approval not to be unreasonably withheld, provided that Member will at all times have the right to participate in such defense at its own expense. The Member Parties&#x2019; refusal to consent to a settlement shall not be deemed unreasonable when the proposed settlement requires or results in the Member Parties, or any one of them, admitting to any wrongdoing or liability.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Insurance Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member, at its expense, will maintain at all times during the Term of this Agreement the following insurance policies: (i) personal property insurance covering any and all personal property of Member and its owners, officers, employees, agents and invitees from time to time, within the Office Space, the Premises and/or the building in which the Premises is located, (ii) workers&#x2019; compensation insurance in the minimum amounts required under applicable state law, (iii) commercial general liability insurance covering personal injury, bodily injury and property damage of no less than $1,000,000 and (iv) business interruption insurance . All insurance policy(ies) required to be carried by Member must (1) name, as additional insureds, Industrious and its Landlord(s) (including any master landlord and their respective lender(s)), or other persons with responsibility for the Premises whom Industrious may designate in writing to Member, and (2) be endorsed to waive all rights of subrogation against Industrious and its Landlord(s). Upon request from Industrious, Member will promptly provide proof of insurance required to be carried above, and in the form required above, including without limitation, the inclusion of the required additional insureds and waivers of subrogation. Further, Member, on its own behalf and on behalf of its employees, agents and invitees, hereby releases Industrious from any liability resulting from, and agrees to waive all rights of recovery against the Industrious Parties, on account of any and all claims it may have against the Industrious Parties, and shall cause its insurance company to waive all such claims by way of subrogation or otherwise. If Member fails to maintain any insurance required hereunder, Industrious&#x2019;s failure to take any action regarding such breach, including but not limited to, requesting or requiring proof of the existence of any such insurance at any time, and/or providing notice to Member of any such non-compliance, will not be considered or construed in any manner as a waiver of any rights of Industrious for such breach, nor will such failure of Member to carry any such insurance or such failure of Industrious to take any action with regard to such breach impose any obligation or liability on Industrious in any manner. Industrious reserves the right, but will not be obligated, to purchase any required insurance on behalf of Member, at Member&#x2019;s expense. If Member fails to carry any required insurance and a Claim occurs that would otherwise be</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.972%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">covered by Member&#x2019;s insurance, Industrious, without imposing any liability on Industrious or waiving any rights Industrious has with regard to Member&#x2019;s breach, may, but will not be obligated to, make a claim under any insurance policy carried by Industrious to cover such Claim, in which event Member will be liable to Industrious for all costs and expenses of Industrious to cover such Claim, including, but not limited to, the applicable deductible and a reasonable portion of the premium as determined by Industrious. Industrious, at its expense, will maintain during the Term insurance in such amounts as required under Industrious&#x2019;s lease, management agreement or other agreement to operate and manage the Premises as co-working space with its Landlord for the Premises (as applicable, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will not, during the Term of this Agreement and for a period of one (1) year thereafter, solicit the employment of any officer, employee, contractor, subcontractor or service provider of Industrious, which causes such person, directly or indirectly, to decrease or terminate its employment or business with Industrious. If Member hires any employee, contractor or subcontractor of Industrious during the period described, Member will pay to Industrious an amount equal to such person&#x2019;s annual salary with or fees from Industrious. Notwithstanding the foregoing, nothing in this paragraph shall restrict or preclude Member from hiring any person who responds to a general solicitation of employment through an advertisement not targeted specifically at Industrious or its employees.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 7. General</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Breach of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event of a breach of this Agreement by Member, Industrious will have any and all rights and remedies available to Industrious as set forth in the Agreement, at law and/or in equity, including without limitation, recovery of all court costs and reasonable attorneys&#x2019; fees incurred by Industrious in pursuing such remedies, whether legal action is filed or not, all of which rights and remedies are cumulative and not exclusive of each other.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. This Agreement, including all schedules and attachments incorporated by reference, sets forth the entire understanding of the parties relating to its subject matter, and all other understandings, written or oral, are superseded. This Agreement will also be deemed to include all policies, procedures, and requirements published by Industrious from time to time, with which Member hereby agrees to comply. Except as otherwise provided in this Agreement, this Agreement may not be amended except in a writing executed by both parties.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Subordination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding anything herein to the contrary, this Agreement is at all times subject and subordinate to the Lease with Landlord and to any other agreements to which the Lease is subject or subordinate. Member acknowledges that Member has no rights under the Lease.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Governing Law; Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. This Agreement is governed by the laws of New York, without giving effect to any conflict of law principle that would result in the laws of any other jurisdiction governing this Agreement. Except that either party may seek equitable relief from any court of competent jurisdiction in New York County, New York, any dispute arising out of or relating to this Agreement&#x2014;including the breach, termination, and validity of this Agreement, and the arbitrability of any claim&#x2014;that cannot be resolved amicably by mutual agreement shall be finally settled by confidential and binding arbitration in accordance with the arbitration rules of JAMS then in force by one or more arbitrators appointed in accordance with said rules. The place of arbitration shall be New York County, New York</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In any action, suit or proceeding between Industrious and Member, including any appellate or alternative dispute resolution proceeding, to enforce rights under this Agreement, the prevailing party shall be entitled to recover from the non-prevailing party, in addition to any other relief awarded, all of its costs and expenses in connection therewith, including, but not limited to, reasonable attorneys&#x2019; fees.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Class Action Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Any proceeding to resolve any dispute relating to or arising under this Agreement in any forum will be conducted solely on an individual basis. Neither party will assert any claim (including counterclaim) against the other in arbitration or litigation on a class or consolidated basis, and neither party</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">will pursue or participate in any claim against the other in a representative or private attorney general capacity. No proceeding will be combined with another without the prior written consent of all parties to all affected proceedings. This class action waiver precludes Industrious and Member from pursuing, participating in, or being represented in any class, consolidated, or representative action regarding any claim against the other.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Neither party will be deemed by any act or omission to have waived any of its rights or remedies hereunder unless such waiver is in writing and signed by the waiving party, and then only to the extent specifically set forth in writing. No delay or omission by any party in exercising any of said rights or remedies shall operate as a waiver thereof. Further, one or more waivers of any covenant or condition by either party will not be construed as a waiver of a subsequent breach of the same covenant or condition, and the consent or approval by either party to or of any act requiring such consent or approval will not be deemed to render unnecessary future consent or approval to or of any subsequent similar act.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Relationship of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The parties to this Agreement are independent contractors and will not be considered agents, employees, servants, joint venturers, or partners of one another. Neither party has the authority to bind the other party except as explicitly set forth in this Agreement, and neither party will make any representation or warranty otherwise. Industrious will have no responsibility for any fee or expense incurred by Member in connection with either party&#x2019;s performance this Agreement, or provision or use of the Services.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event of any transfer or transfers of Industrious's interest in the Premises, Industrious will automatically be relieved of any and all respective obligations accruing from and after the date of such transfer. Following any such transfer(s), all rights, obligations and interests of Industrious under this Agreement will apply to, inure to the benefit of, and be binding on any such successors and assigns of Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Third-Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Except for third parties entitled to indemnity under this Agreement or third parties whose liability is specifically limited pursuant to the terms of this Agreement, the parties to this Agreement do not intend to confer any right or remedy on any third party.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Neither party is liable for, and will not be considered in default or breach of this Agreement on account of, any delay or failure to perform as required by this Agreement (with the exception of Member&#x2019;s obligation to pay any sum due to Industrious hereunder, including without limitation, the License Fees, which obligation will remain unaffected by the provisions of this paragraph) as a result of any causes or conditions that are beyond such party&#x2019;s reasonable control and which such party is unable to overcome by the exercise of reasonable diligence, provided that the affected party will use commercially reasonable efforts to promptly resume normal performance. For the avoidance of doubt, Member&#x2019;s payment obligations under this Agreement remain unaffected by circumstances beyond Industrious&#x2019;s reasonable control, including public health crises (such as COVID-19) and public health measures in response thereto.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. If a provision of this Agreement is determined to be unenforceable in any respect, the enforceability of the provision in any other respect and of the remaining provisions of this Agreement will not be impaired.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Unless expressly specified otherwise herein, all notices, requests, demands and other communications to be delivered hereunder will be in writing and delivered in person, by nationally recognized overnight carrier, or by registered or certified mail, return-receipt requested and postage prepaid, to the following addresses: if to Industrious, to: Industrious, Attn: Head of Legal, 215 Park Avenue South, 12th Floor, New York, NY 10003; and if to Member: to the address provided by Member upon execution of this Agreement, and if none, then to the Office Space. All notices will be deemed effective as of the date of confirmed delivery or refusal of receipt. In addition to the foregoing methods, notices from Industrious to Member may also be delivered by email to the email address provided by Member upon</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.972%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">execution of this Agreement. Notices of non-renewal by Member may, at the Member&#x2019;s option, be delivered by email to the Industrious email address provided to Member upon execution of this Agreement. Delivery of notices by email hereunder will be deemed effective upon transmission. Each party may update its respective address and/or e-mail address from time to time upon written notice to the other. Member must promptly provide Industrious with any change of address, e-mail address and other contact information (including phone number). Member agrees to accept community-wide emails sent out to all members by Industrious from time to time, which will be the responsibility of Member to review.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Updates to Agreement; License Fee Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding any other provision in this Agreement, Industrious may from time to time update the terms of this Agreement by providing at least thirty (30) days&#x2019; notice to Member; provided that such updates shall not materially interfere with Member&#x2019;s rights under this Agreement or impose any additional material obligations on Member. Member acknowledges that Member&#x2019;s continued use of the Office Space and/or Services beyond such thirty (30)-day period will constitute acceptance of such updated terms. In addition, License Fees are subject to change during the Renewal Term, if any, in Industrious&#x2019;s sole discretion upon eighty (80) days&#x2019; written notice prior to the start of the applicable Renewal Term, provided that price adjustments will not exceed 8% at a time. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Please</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">keep in mind that Industrious must receive a Non-Renewal Notice at least two (2) calendar months</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">prior to the end of the then-current term to properly terminate this Agreement. Therefore, Member</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">will have approximately 20 days to make a determination on whether or not to auto renew this</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Member acknowledges that Industrious may serve notice of any changes to Services, fees (other than License Fees hereunder) or other updates through community-wide emails sent out to all members or through notices posted at the Premises, and Member agrees to accept and review such community-wide notices.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Accord and Satisfaction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. No payment by Member or receipt by Industrious of a lesser amount than required hereunder will be deemed to be other than on account of the earliest amounts due hereunder, nor will any endorsement or statement on any check or any letter accompanying any check or payment be deemed an accord and satisfaction and Industrious may accept such check or payment without prejudice to its rights to recover the balance of such amounts or pursue any other rights and remedies it has under this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Time of Essence</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Time is of the essence with respect to the performance of each of Member&#x2019;s obligations under this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:35.347%;text-indent:24.862%;font-size:10pt;margin-top:10.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:36.176%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious: MEMBERSHIP AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Contract Date: March 12, 2024</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Membership Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) is made by and between the Industrious entity or entities (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and the member (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) set forth below:</font></p>
  <p style="font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.333%;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.062%;"></td>
    <td style="width:42.669%;"></td>
    <td style="width:15.063%;"></td>
    <td style="width:31.206%;"></td>
   </tr>
   <tr style="height:34.55pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:6.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.7pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Industrious</font></p></td>
    <td colspan="2" style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:0.6pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.6pt;text-indent:0;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Member</font></p></td>
   </tr>
   <tr style="height:34.55pt;word-break:break-word;white-space:pre-wrap;">
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:14.5pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:14.5pt;text-indent:0;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Name</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:97.75pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:8.05pt;text-indent:-89.7pt;padding-left:89.7pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">INDUSTRIOUS BOS 131 DARTMOUTH STREET LLC</font></p></td>
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:24.65pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:16.35pt;text-indent:-8.3pt;padding-left:8.3pt;font-size:10pt;margin-top:5.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.20972222222222223in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Company Name</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.45pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.45pt;text-indent:0;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.02361111111111111in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Adicet Bio</font></p></td>
   </tr>
   <tr style="height:46.1pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="background-color:#d9d9d9;border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:11.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.85pt;text-indent:-1.1pt;padding-left:1.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.09375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Location Address</font></p></td>
    <td rowspan="2" style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:53.65pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.7506944444444444in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">131 Dartmouth Street 3rd Floor</font></p><p style="margin-left:53.85pt;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7506944444444444in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Boston, MA 02116</font></p></td>
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.8pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Contact Name</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.7pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.017361111111111112in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:22.3pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="background-color:#d9d9d9;border-right:1pt solid #000000;text-indent:0.8pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.8pt;text-indent:0;font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.001388888888888889in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Email</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1.7pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:1.7pt;text-indent:0;font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.017361111111111112in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">nharvey@adicetbio.com</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">for access to and services relating to the following office space (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), at the following terms:</font></p>
  <p style="font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.22%;"></td>
    <td style="width:16.08%;"></td>
    <td style="width:20.54%;"></td>
    <td style="width:17.86%;"></td>
    <td style="width:22.3%;"></td>
   </tr>
   <tr style="height:43.2pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:0.9pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:11.1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Office No(s).</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:23.75pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:14.8pt;text-indent:-8.95pt;padding-left:8.95pt;font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1909722222222222in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Office Size (Seats)</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:43.1pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:7.9pt;text-indent:-35.2pt;padding-left:35.2pt;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.09097222222222222in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Monthly Licensing Fee</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:26.65pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:25.3pt;text-indent:-1.35pt;padding-left:1.35pt;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Security Deposit</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:31.7pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:13.3pt;text-indent:-18.4pt;padding-left:18.4pt;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.16180555555555556in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Conference Room Allowance</font></p></td>
   </tr>
   <tr style="height:65.5pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0020833333333333333in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">BOSCOP077</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.001388888888888889in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3933.00 USD</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:3.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5899.50 USD</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.4pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">9 hours per month</font></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Totals</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.95pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.95pt;text-indent:0;font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">4</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:0.9pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:0.9pt;text-indent:0;font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3933 USD</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:1pt;text-indent:0;font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5899.5 USD</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:1.4pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:1.4pt;text-indent:0;font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">9 hour(s) per month</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.38%;"></td>
    <td style="width:26.76%;"></td>
    <td style="width:17.7%;"></td>
    <td style="width:21.24%;"></td>
    <td style="width:15.92%;"></td>
   </tr>
   <tr style="height:78.5pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:17.15pt;text-indent:-18.85pt;padding-left:18.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.21875in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">License Start Date</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:7.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.65pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.002777777777777778in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Earliest Expiration Date</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:7pt;text-indent:-12.4pt;padding-left:12.4pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Month-to-Month Agreement</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;text-indent:8.05pt;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="margin-left:7.95pt;text-indent:-0.1pt;padding-left:0.1pt;font-size:10pt;margin-top:8.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.09791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">One Month Termination Option</font></p><p style="margin-left:12.35pt;text-indent:0.2pt;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1597222222222222in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(Month-to-Month Agreements Only)</font></p></td>
    <td style="border-top:1pt solid #000000;border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.6pt;text-indent:2.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.09375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Autopay Opt- Out Surcharge</font></p></td>
   </tr>
   <tr style="height:45.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:17.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">May 01, 2024</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.65pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">April 30, 2025</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="border-right:1pt solid #000000;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:5.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">No</font></p></td>
    <td style="border-right:1pt solid #000000;text-indent:27.6pt;vertical-align:top;border-bottom:1pt solid #000000;"><p style="margin-left:8.75pt;text-indent:-18.85pt;padding-left:18.85pt;font-size:10pt;margin-top:5.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.11041666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$45 per month (USD)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">* PLEASE NOTE THAT THIS AGREEMENT CONTAINS AUTO-RENEWAL TERMS AS SET FORTH BELOW AND IN SECTION 7(M). PLEASE REVIEW THIS LANGUAGE CAREFULLY BEFORE SIGNING THIS AGREEMENT.</font></p>
  <p style="font-size:10pt;margin-top:1.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Agreement comprises this signature page and the Industrious Membership Terms and Conditions, together with any attached or referenced authorizations exhibits, and schedules. Optional services are available, as set forth on the attached initial fee schedule, which fees are subject to change from time to time with reasonable advance notice to Member.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.981%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The initial Agreement term (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) will commence on the License Start Date and end on the Earliest Expiration Date (each as specified above). Upon expiration of the Initial Term, this Agreement shall automatically renew (each a &#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Renewal Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#34;) for an additional successive term equal in length to the Initial Term, unless Member provides written notice of non-renewal (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-Renewal Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) to Industrious at least two (2) calendar months prior to the end of the then-current term, or unless sooner terminated as provided in Section 2. As used in this Agreement, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; will include the Initial Term and any Renewal Term.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">If the Term is renewed for any Renewal Terms pursuant to this Section, the terms and conditions of this Agreement during each such Renewal Term shall be the same as the terms and conditions in effect immediately prior to such renewal, subject to any change in the Licensing Fees and other fees payable hereunder by Member during the applicable Renewal Term as set forth in Section 7(m). If Member provides timely notice of its intent not to renew this Agreement, then, unless otherwise sooner terminated in accordance with its terms, this Agreement shall terminate on the expiration of the then-current Term.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Month-to-Month Agreements Only</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: Notwithstanding the foregoing, if the One Month Termination Option has been selected by Member, as specified on page one of this Agreement, upon Industrious&#x2019;s receipt of Member&#x2019;s Non-Renewal Notice, the Agreement will terminate effective as of the last day of the first (1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">) full calendar month following Industrious&#x2019;s receipt of the Non-Renewal Notice. For example, if Member gives notice of termination on February 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">or 25</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">, the last day of Member&#x2019;s membership will be March 31</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <p style="font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">All Other Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">: For all Agreements with an Initial Term other than month-to-month, unless Industrious receives a timely Non-Renewal Notice, the Term of this Agreement will automatically renew as set forth above.</font></div></div>
  <p style="font-size:10pt;margin-top:2.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Simultaneously with Member&#x2019;s execution of this Agreement, Member will deliver to Industrious a security deposit in the amount described above (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;); provided that if the Premises (as defined hereunder) has not yet opened for business as of the Contract Date, and if the License Start Date is more than thirty (30) days after the Contract Date, Twenty (20) % of the Security Deposit must be paid upon execution of this Agreement by Member and the balance of the Security Deposit must be paid no later than thirty (30) days prior to the License Start Date.</font></p>
  <p style="font-size:10pt;margin-top:1.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This Agreement may be executed in counterparts, each of which will be deemed an original and all of which taken together will constitute one and the same agreement. Signatures to this Agreement transmitted by electronic means will be valid and effective to bind the party so signing. This Agreement will not be valid until approved and signed by an authorized representative of each party hereto.</font></p>
  <p style="margin-left:0.413%;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">[Signature Page to Follow]</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">By signing below, each party acknowledges that it has read and understood this Agreement and agrees to be bound by its terms, effective as of the Contract Date set forth above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Industrious:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Member:</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">&#160;/s/ Liza Greenberg</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">&#160;/s/ Nick Harvey</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Name: Liza Greenberg</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Company Name: Adicet Bio</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-family:Arial;min-width:fit-content;">Industrious Team</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Contact Name: Nick Harvey</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Title: CFO</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Membership Agreement Signature Page</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:37.867%;text-indent:1.626%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:39.167%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious OPTIONAL SERVICES</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(additional fees required)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Additional conference room hours:$25/half hour</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dedicated internet (100% fiber dedicated bandwidth):$10.00 per Mbs/company/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Public IP Address:$20.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone service (without phone):$40.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone service (with phone):$60.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone tree (basic):$40/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phone tree (enhanced):$120/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Call recording:$50/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Port in a number (transfer existing number to your new Industrious phone):$15/month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Port out a number (transfer an Industrious number to a new line/phone):$30</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Conference bridge:$20.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Fax to email:$30.00 / month</font></div></div>
  <div style="margin-left:5.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.5108231948175064%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Logo:$250 / logo</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font></p>
  <p style="margin-left:0.027%;font-size:10pt;margin-top:8.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.343%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">MEMBERSHIP TERMS AND CONDITIONS</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.361%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">These Membership Terms and Conditions are incorporated into and made part of the Membership Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) entered into by and between the Industrious entity or entities (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) and the member (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) set forth on the Agreement signature page. Capitalized terms not otherwise defined herein have the meanings ascribed to them on the Agreement signature page.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 1. Office Space and Services</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Subject to these terms and conditions and payment of all applicable fees, Industrious will permit Member to access and use the number and configuration of furnished workspaces and workstations specified on the Agreement signature page (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Office Space</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), located at the property, building, or space owned, leased, or otherwise controlled by Industrious indicated on the Agreement signature page (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will use commercially reasonable efforts to make the Office Space available to Member as of the date specified on the Agreement signature page as the License Start Date, provided that if </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Industrious </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">is unable to make the Office Space available on the date specified, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; will mean the date Member actually receives access to the Office Space. Member&#x2019;s payment obligations hereunder will begin on the License Start Date. Industrious reserves the right to relocate, reduce or increase the size, number, or configuration of the Office Space from time to time, in which case the applicable fees will be proportionately reduced or increased, as determined in Industrious&#x2019;s sole discretion; provided that no such relocation or increase shall result in an increase of the monthly License Fee by more than 10% of the then-current monthly License Fee without Member&#x2019;s prior written consent. Industrious will provide Member with reasonable advance written notice should changes to the Office Space or License Start Date be necessary.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Premises will include standard power outlets, common area restrooms and a common area kitchen. For common use within the Premises, Industrious will use good faith efforts to provide certain services (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), such as access to and use of shared internet connection and printers/scanners and other services as may be described in the Member handbook provided to Member. Any or all of the Services may be provided by Industrious, an affiliate of Industrious, or any third party service provider designated by Industrious from time to time in its sole discretion. All Services, other than shared internet connection and printers/scanners, that may be provided by or on behalf of Industrious may be added, deleted, or changed at any time at the sole discretion of Industrious, with or without prior notice to Member.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Business Hours</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Business hours for the Premises may vary by location&#x2014;the hours of operation in effect will be posted at the Premises or otherwise made available to Member. Industrious reserves the right to close the Premises on national holidays and on days with inclement weather at the discretion of Industrious. Certain Services may be available only during regular business hours, excluding holidays. The Premises may be accessible outside of business hours using the key card assigned to Member, in accordance with the procedures set forth in the Member handbook or other policy documents applicable to the particular Industrious location.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In order to receive certain Services (including but not limited to access to the network, shared printing, etc.), Member may be required to install on Member&#x2019;s computer device certain drivers or software tools (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member acknowledges and agrees that Software may be owned, controlled, or provided by third parties, and that the installation or use of any Software may be subject to separate licenses, terms, conditions, or restrictions. Industrious provides no warranties with respect to the Software (even if provided by or through Industrious), and as a condition of use of the Software, Member, on behalf of itself and its employees, agents, and invitees, waives any claim against Industrious, its affiliates, and any</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">person acting on behalf of Industrious or its affiliates arising from or in conjunction with the installation or use of such Software.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Specific Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will accept mail on behalf of Members. However, Industrious will not be responsible for any items received on behalf of Member. If Member expects a special delivery or package, Member must provide Industrious with reasonable notice and instructions, if necessary, in order for Industrious to accept such delivery. If Member&#x2019;s membership package includes a monthly allowance of conference room hours, such monthly allowance will not be rolled over from one month to the next. If Member has added Parking to its suite of Services, Member agrees to follow any and all rules and requirements for parking set forth by the Landlord or Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Maintenance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious will use commercially reasonable efforts to maintain the Premises in good functional condition; provided that Member is and will remain responsible for, and will indemnify, defend and hold harmless Industrious, Landlord (as defined hereunder), and their respective affiliates for any and all damage to the Office Space, Premises and/or the building in which the Premises is located, exceeding normal wear and tear, caused by Member or its agents, employees and invitees, and for the acts and omissions of Member and its employees, agents, or invitees. Member shall take good care of all parts of the Office Space, Premises and/or the Building, including any equipment, fixtures and furnishings, which Member is permitted to use hereunder. Member shall not alter any part of the Office Space, Premises and/or building or Industrious&#x2019;s equipment, fixtures or furnishings.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Access</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that Industrious and its designees will at all times have access to the Office Space, upon at least 24 hours&#x2019; notice to Member (except in case of an emergency, which shall be determined in Industrious&#x2019;s sole discretion, and for routine janitorial or similar access), for purposes including but not limited to the maintenance and safety of the same and any emergency situations. Industrious may temporarily move and/or replace parts and components of the Office Space in Industrious&#x2019;s sole discretion. Notwithstanding the foregoing, except in the case of emergency, Industrious will use commercially reasonable efforts not to disrupt Member&#x2019;s business in or use of the Office Space.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Only</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding anything herein to the contrary, this Agreement is a revocable license to access the Office Space and receive certain Services, upon the terms and conditions set forth herein. The relationship between Industrious and Member is that of a licensor and licensee only, and not a landlord- tenant or lessor-lessee relationship. This Agreement will not be construed to grant Member any right, title, interest, easement, or lien in or to Industrious&#x2019;s business, the Office Space, the Premises, or anything contained therein, nor will this Agreement be interpreted or construed as a lease. Member acknowledges that this Agreement creates no tenancy interest, leasehold estate, or other real property interest in Member&#x2019;s favor and Member hereby waives any and all claims and/or defenses based upon any such interest.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 2. Term and Termination of Agreement</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Term of this Agreement is set forth on the Agreement signature page.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:8.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Termination for Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may terminate this Agreement in its sole discretion, effective immediately if Member or any of its agents, employees, or invitees breaches any provision in this Agreement or violates any Industrious rules, policies, or codes of conduct. Provided that, if Member fails to pay any fee when due (or an Autopay (as defined in Section 3) payment is returned, declined or otherwise rejected), if it is Member&#x2019;s first delinquency in any twelve (12)-month period, Industrious will send Member written notice of the delinquency, and Member will have five (5) days from the date of such notice to cure the delinquency by paying all amounts owed (including late fees and finance charges, as applicable). Member is only entitled to one notice and cure period per twelve (12)-month period, and for any subsequent delinquency Industrious may terminate Member&#x2019;s license and membership immediately, in Industrious&#x2019;s sole discretion. Additionally, Industrious shall charge Member the Autopay Opt-Out Surcharge, in the event that Member</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">cancels Autopay and does not provide an alternative payment credential to be used for future Autopay payments as part of the cancellation procedure.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Termination for Convenience</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may terminate this Agreement (i) immediately in the event that Industrious&#x2019;s rights in the Premises terminate or expire for any reason; or (ii) upon thirty (30) days&#x2019; written notice to Member in Industrious&#x2019;s sole and absolute discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Removal of Property upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. On or prior to the termination or expiration of this Agreement, Member will remove all of its property from the Office Space and Premises, leaving them in the same condition as they were in when Member moved in, reasonable wear and tear excepted, it being understood and agreed that member has no right to continue to use and/or access the Office Space or any Services after the expiration or termination of this Agreement. In addition to any other rights and remedies Industrious has hereunder, Industrious will be entitled to remove and dispose of any of such property remaining in or at the Office Space or the Premises after the termination of this Agreement in any way that Industrious chooses, without notice to Member (whether belonging to Member or its employees, agents, or invitees), and without waiving its right to claim from Member all expenses and damages caused by Member's failure to remove such property, and Member and any other person or entity shall have no right to compensation from or any other claim against Industrious as a result</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Effect of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Following the termination or expiration of this Agreement for any reason, Member will remain liable for all amounts due or owing as of the effective date of such termination or expiration (regardless of the date Member vacates any or all of the Office Space or the Premises). Without limiting the foregoing, if this Agreement is terminated for breach pursuant to Section 2(b) above, Member will remain liable for (x) all License Fees and any other fees owed through the remainder of the Term, and (y) the full amount of any fees that Industrious paid to a broker in connection with this Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Broker Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). All such License Fees and Broker Fees will be due and payable immediately upon such termination pursuant to Section 2(b). In the event this Agreement is terminated for convenience pursuant to Section 2(c) above, Industrious will within a reasonable time following the effective date of the termination return to Member any pre-paid License Fees or other fees applicable to the post-termination period. This Section 2 and Sections 4 through 7 of this Agreement will survive the termination or expiration of this Agreement for any reason, as will all other provisions of this Agreement that may be reasonably expected to survive such termination or expiration.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 3. Fees</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Beginning on the License Start Date, and continuing during the Initial Term of this Agreement, Member will pay, in advance, the monthly license fee specified on the Agreement signature page (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">License Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). The License Fee is due on or before the 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">of each month during the Term, provided that if the License Start Date falls on a date that is not the 1</font><font style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Arial;min-width:fit-content;">st </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">day of the month, then on the License Start Date Member will pay the pro rata portion of the monthly License Fee for the remainder of that month. All License Fees must be paid in U.S. dollars. All amounts paid under this Agreement are nonrefundable and noncancellable, except as expressly provided herein. When Industrious receives funds from Member, such funds will be applied first to any past-due balances, oldest to newest, then to any current monthly fees due and owing. License Fees are subject to change during the Renewal Term (if any) as set forth in Section 7(m) hereunder.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Other Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Where permitted under state law, Industrious may assess an extra charge (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Surcharge</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in an amount that is commensurate with Industrious&#x2019;s cost to accept and process credit card transactions in the event the Member has opted out of Autopay. Such Surcharge will only be applicable to non-Autopay credit card transactions. Any such Surcharge will be identified on the Agreement signature page and on the Member&#x2019;s monthly invoice. Payments made by Autopay will not be subject to a Surcharge. A ten percent (10%) late fee will be charged on any outstanding balance existing on the 5th day of any month. Additionally, Member may be subject to additional fees for declined or returned payments due to insufficient</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">funds, as set forth in fee schedules published or posted by Industrious from time to time. Member acknowledges that all fees are subject to change from time to time at the discretion of Industrious. Any late fees or charges are in addition to any other rights and remedies Industrious may have for Member&#x2019;s breach of this Agreement.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security Deposit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The Security Deposit must be paid in the amount and at the time set forth on the Agreement signature page. The Security Deposit will be refunded to Member within forty-five (45) days after termination of this Agreement, subject to the complete satisfaction of Member&#x2019;s obligations under this Agreement, as determined by Industrious in its sole discretion. The Security Deposit will be held by Industrious, without liability for interest, as security for the performance by Member of Member&#x2019;s covenants and obligations under this Agreement. Member acknowledges and agrees that the Security Deposit will not be considered an advance payment of the License Fee or a measure of Member&#x2019;s liability for damages in case of default by Member. Industrious may, from time to time and without prejudice to any other remedy, use the Security Deposit to the extent necessary to make good any arrearages of the License Fee or to satisfy any other covenant or obligation of Member hereunder. Following any such application of the Security Deposit, Member will pay to Industrious on demand the amount so applied in order to restore the Security Deposit to its original amount. To the extent of any unapplied Security Deposit after the termination of this Agreement, Industrious will only refund the same to Member, unless an authorized representative of Member directs Industrious in writing to send the refund to another person or location. If during the Term of this Agreement, Member changes the Office Space to one(s) carrying higher License Fees, Member will deliver to Industrious the incremental increase in the Security Deposit as required by Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Suspension of Services</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may withhold or suspend any Services and/or access to the Office Space and the Premises while there are any outstanding amounts due or Member is otherwise in breach of this Agreement, in addition to any other rights and remedies Industrious may have. In the event that Industrious withholds services from Member pursuant to the foregoing, Industrious shall not be liable for any claim of business interruption or for any indirect, incidental, special, consequential, exemplary or punitive damages arising out of such actions.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Form of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Payments for License Fees and all other fees hereunder may be made by ACH bank transfer, most major credit cards or debit cards. Member agrees that such payments for License Fees and other fees hereunder will be paid in accordance with the terms set forth in this Agreement and in the Recurring Payment Authorization Form, which is hereby incorporated herein by reference. All payments for License Fees and all other fees under this agreement must be paid in U.S. Dollars. Industrious may offer discounts off its regular License Fee and other fee rates for payments made by ACH bank transfer. Any such discounts will be reflected on the signature page of this Agreement. Any applicable ACH discount will be refunded to Member reasonably promptly after payment is made by member in full.</font></div></div>
  <div style="margin-left:9.463%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:4.935%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:5.450810166009475%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Stored Credentials; Recurring Payments; Cancellation. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As a condition of this Agreement, Industrious requires Member, and Member agrees, to maintain a current bank account, credit card, or debit card on file to be used for automatic payments for all amounts due under this Agreement. Member must agree to the Recurring Payment Authorization Form. Member specifically acknowledges and agrees that amounts due under this Agreement will be processed automatically and on a recurring basis using the stored payment credential on file in accordance with the Recurring Payment Authorization Form (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Autopay</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member may cancel Autopay (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Autopay Cancellation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) with respect to a specific stored payment credential at any time online at </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">member.industriousoffice.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event that Member does not provide Industrious with an alternative payment credential to be stored and used for Autopay during that cancellation procedure, Industrious may exercise its right to immediately terminate this Agreement pursuant to Section 2(b). If an Autopay payment is rejected or declined, Industrious may terminate this Agreement pursuant to Section 2(b) in addition to any related fees as set forth in fee schedules published or posted by Industrious from time to time (i.e., late fees, fees for a payment returned for</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:14.44%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">non-sufficient funds, etc.). Notwithstanding the foregoing, Industrious shall not terminate any Member for opting out of Autopay or upon the rejection or declining of any Autopay payment, provided Member agrees to pay and promptly pays the Autopay Opt Out Surcharge, as set forth herein.</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 4. Member Obligations</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Background Checks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious reserves the right to conduct a basic criminal and OFAC background check on any or all of Member&#x2019;s owners, officers, employees and agents who will be granted access to the Premises (particularly if Member desires after-hours access for such persons), and Member agrees to use good faith efforts to assist Industrious with the same, at no cost of Member. After-hours access may only be granted to those persons who pass such background check to Industrious&#x2019;s sole and absolute satisfaction. Member represents and warrants that neither Member, nor any of its owners, officers, employees or agents has been or will be: (a) designated as a &#x201c;blocked person&#x201d; as such term is described in Executive Order 13224, issued September 23, 2001 by George W. Bush, President of the United States; or (b) a person or entity described either as a Specially Designated Global Terrorist or a Specially Designated Nationals and Blocked Persons by the Office of Foreign Assets Control (&#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#34;) of the U.S. Department of the Treasury. The continued accuracy throughout the Term of this Agreement of the foregoing representation and warranty is an ongoing material condition to this Agreement and, accordingly, Member has the obligation during the Term to immediately notify Industrious by written notice if the foregoing representation and warranty should ever become false. Any breach of the representation and warranty or failure on the part of Member to so update Industrious constitutes a breach of this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Security</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious makes no warranty or representation to Member with respect to any security services or systems and Industrious expressly disclaims any liability related to the wrongful access, use or disclosure of any data or information that is processed, stored or transmitted through or by the Services, which includes without limitation, the Software. Member shall be fully responsible for the safety and security of its personal property brought into the Office Space, Premises and/or building. As between Industrious and Member, Member shall also be fully responsible for any liability related to the wrongful access, use or disclosure of any data or information that is processed, stored or transmitted through or by the Services, which includes without limitation, the Software. Industrious shall not be liable to Member on account of any loss, injury, liability, damage or theft to any business or personal property of Member, its owners, officers, employees, agents and invitees, other than as a result of Industrious&#x2019;s gross negligence or willful misconduct. Member acknowledges that all keys, key cards, key fobs, and other such items used to gain physical access to the building, Premises and/or the Office Space remain the property of Industrious, or its landlord or the owner of the Premises or each of their respective affiliates (as applicable, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member will not attempt to (or allow others to) gain unauthorized access to any computer systems located at or serving the Premises or any content or data of Industrious, other members, or any other person. Neither Member nor any of its agents, employees or invitees are permitted to enter any other office space in the Premises. Member will use its best efforts to safeguard the Premises and Industrious&#x2019;s property and will be liable for all costs and expenses should any such property be lost or damaged as a result of Member&#x2019;s and/or its employees&#x2019;, agents&#x2019; or invitees&#x2019; acts or omissions. Member is solely responsible for maintaining all necessary security and control of any and all user names, passwords, or any other credentials issued to or used by Member or its employees, agents or invitees, for use with Industrious&#x2019;s computer systems, networks, or other Services provided under this Agreement. Member will not allow (and will instruct its employees and agents to not allow) a party unknown to them to enter the Office Space or the Premises and acknowledges that such action may result in the termination of this Agreement. Member is and will remain responsible for the actions or omissions of all persons that Member or its employees, agents or invitees allow or invite to enter the Office Space or the Premises.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Complaints</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees that all issues and complaints relating to the Office Space or other members will be directed solely to Industrious. Member will have no direct access to or communication with the Landlord (if other than Industrious), and Member agrees not to send any complaints or demands to the Landlord directly.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Privacy Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees that the use of Industrious&#x2019;s online portal and website are subject to Industrious&#x2019;s Portal Terms of Use and Privacy Policy, which are available at </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.industriousoffice.com/portalterms/</font></font><font style="color:#1154cc;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">and </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.industriousoffice.com/privacypolicy/</font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> respectively, and which are subject to change from time to time in Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Rules and Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Additional rules may be set forth in the Member handbook or other policy documents applicable to each Industrious location, which are subject to change from time to time in Industrious&#x2019;s sole discretion. Member agrees to abide by all rules and policies as determined by Industrious from time to time, whether communicated to Member verbally, by email, other written notice or public posting. Without limiting the foregoing, Industrious may require Member and each of its owners, officers, employees, agents and invitees who will be granted access to the Premises to agree to and sign Industrious&#x2019;s Anti-Harassment Policy prior to using the Office Space or Services.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Prohibited Conduct</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In addition to any other applicable rules and policies issued by Industrious, Member agrees to the following terms and conditions:</font></div></div>
  <div style="margin-left:7.731%;margin-top:6.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Assignment or Sublicense</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not sell, lease, license, distribute or grant any interest in the Office Space or any of the Services to any third party. Further, Member may not assign this Agreement in whole or in part, or otherwise transfer, sublicense or otherwise delegate any of Member&#x2019;s rights or obligations under this Agreement, to any third party.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Alterations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not alter the Office Space or Premises in any manner or attach or affix any items to the walls, floors or windows, without the prior written consent of Industrious.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Unapproved Items</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not store any of its property or materials in any area of the Premises, except the Office Space. Member may not bring any additional furniture, furnishings or decorations into the Premises or Office Space or install any satellite or microwave antennas, dishes, cabling or telecommunications lines in the Premises or Office Space without the prior written consent of Industrious in its sole discretion. Member acknowledges that carts, dollies and other freight items may not be used in the passenger elevator except by appointment made with Industrious, at Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Retail Use</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will use the Office Space solely as general office space in the conduct of Member&#x2019;s business and for no other use whatsoever. Use of the Office Space for retail, medical or other type of business involving frequent visits by members of the public, manufacturing, or for any other use prohibited by the Member handbook is not permitted. Regular use of the Office Space is limited to those persons subject to background checks as set forth in this Agreement.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Illegal Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not use the Premises, any Services, or any Industrious computer systems or networks to conduct or pursue any illegal activities, including but not limited to, downloading, distributing or viewing any illegal content, engaging in any activity in violation of OFAC regulations, and/or illegally downloading any copyrighted content, or any other activity that violates any intellectual property rights, and any such conduct using the Premises or Industrious&#x2019;s systems or networks may result in immediate termination of this Agreement.</font></div></div>
  <div style="margin-left:7.731%;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Offensive Behavior</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not conduct any activity in the Office Space, Premises and/or the building that is harmful, threatening, abusive, harassing, tortious, defamatory, vulgar, obscene, libelous, invasive of another&#x2019;s privacy, hateful, or racially, ethnically or otherwise generally regarded as offensive to other people, including but not limited to, involvement in hate groups or activities involving pornographic or sexually explicit materials or obscenities, whether written, oral, or in any form or medium. Member will</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">refrain from any activities that may be disruptive, a nuisance or an annoyance, including but not limited to, acts of disorderly nature or excessive noise. Member may not conduct any activity which may be hazardous to other persons in the building. Industrious may determine at its sole discretion what activities may be deemed offensive, disruptive or hazardous.</font></p>
  <div style="margin-left:7.731%;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Malware, Spamming</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not upload any files that Member knows or suspects to contain or may contain viruses, Trojan Horses, worms, time bombs, corrupted files, or any other malicious code, whether known or unknown that may damage or disrupt Industrious&#x2019;s or any other person&#x2019;s computer systems or networks. Member will take precautions to prevent the spread of viruses, including but not limited to, using up-to-date anti-virus software, enacting policies to avoid opening suspicious emails, and avoiding suspicious websites. Spamming other members or any other persons is strictly prohibited, and any such conduct using the Premises or Industrious&#x2019;s systems or networks may result in immediate termination of this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Personal Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member represents and warrants that it has obtained the necessary authorizations and consents for any personal information it processes through the Services, which includes without limitation, the Software.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Onboarding Process</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees to fully cooperate with the onboarding process (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Onboarding Process</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) for Industrious. Member represents and warrants that the information it provides pursuant to the Onboarding Process will be true, accurate and complete. Member acknowledges and agrees that should it breach the representation above, Industrious may immediately rescind or terminate this Agreement, in its sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Cross Defaults</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member agrees and acknowledges that if they are in default on any agreement or understanding with an affiliate of Industrious, then they will be deemed to be in default of this Agreement.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:6.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 5. Intellectual Property and Confidentiality</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may not use Industrious&#x2019;s name, logo, trademarks, service marks or domain names (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Marks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) in any way in connection with Member&#x2019;s business, without the express written consent of Industrious, in its sole discretion. Member will comply with all standards established by Industrious from time to time with respect to the Industrious Marks. Member hereby acknowledges and agrees that all right, title, and interest in and to the Industrious Marks belong to Industrious, and that all usage and goodwill of the Industrious Marks will inure only to the benefit of Industrious. Member will not use, register, or attempt to register any trademarks or domain names that are confusingly similar to the Industrious Marks, nor use the Industrious Marks in any manner that would indicate that Member has any rights thereto. If consent to use the Industrious Marks is granted as set forth above, Industrious reserves the right to revoke Member&#x2019;s rights to use the Industrious Marks at any time in Industrious&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Publicity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may use the address of the Office Space as its business address, but only during the Term of this Agreement. Member may not use photos or illustrations of the Premises, or any Industrious Marks, in any of Member&#x2019;s marketing materials or in any other manner without the express written consent of Industrious. Further, no press release, advertising, sales literature or other publicity statements relating to the existence or substance of this Agreement or the relationship of the parties may be made by Member without the prior written approval of Industrious. Member grants Industrious and its affiliates the right to use Member&#x2019;s trade name(s), logos and/or trademarks in Industrious&#x2019;s materials prepared for its shareholders or members, or prospective shareholders or members.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Member Directory</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious may place Member&#x2019;s name and contact information in a directory of Industrious members; provided that Member will be given the opportunity to &#x201c;opt-out&#x201d; of such listing which it may do at any time.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Photo and Video Shoots</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that promotional photography and/or video recording (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Shoot</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) may occur in the Premises (but not within the Office Space) from time to time. Industrious will provide Member with reasonable advance notice of any such Shoot, and at such time Member may request that Industrious endeavor to avoid capturing Member&#x2019;s name, likeness, image, voice and/or appearance in the background any such recordings. Industrious will use commercially reasonable efforts to comply with Member&#x2019;s request. Subject to the foregoing, by entering that portion of the Premises in which a Shoot is </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">taking place, Member and Member&#x2019;s employees, agents, and invitees consent to such photography and/or video recording and the release, publication, exhibition or reproduction of such recordings in which they may appear for promotional purposes by Industrious and its affiliates and representatives. Subject to the foregoing, Member and its employees, agents, and invitees each hereby releases and discharges Industrious and its agents, representatives, and assignees from any and all claims and demands arising out of or in connection with the use of the name, likeness, image, voice, or appearance of Member or any of its employees, agents, or invitees, including any and all claims for invasion of privacy, right of publicity, misappropriation, misuse, and defamation. Member represents and warrants to Industrious that its employees, agents, and invitees will have been informed of and agreed to this consent, waiver of liability, and release before they enter that portion of the Premises in which a Shoot is taking place.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sensors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member acknowledges that Industrious does or may utilize sensors that record usage of the Premises, excluding the Office Space, and amenities (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Sensors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;), and consents to the use of the Sensors. The Sensors monitor, among other things, the number of people utilizing a particular space or amenity, the times that a particular space or amenity is used, etc. Low resolution images may be captured, which will be processed by automated software, for the purpose of counting people and upon the completion of said task, the image will be deleted. No sound recordings will be made or captured and no high resolution photographs or videos will be taken. The data collected is anonymous aggregated data. Prior to the implementation of any sensors, Industrious will contractually prohibit vendors of any sensors used from combining any anonymous aggregated data with other data in any manner that could make it personally identifiable data. Industrious will use the data collected for improving or developing its service or products, or for any other lawful business purpose. Subject to the foregoing, Member and its employees, agents, and invitees each hereby release and discharge Industrious and its agents, representatives, and assignees from any and all claims and demands arising out of or in connection with the use of the Sensors, including any and all claims for invasion of privacy, right of publicity, misappropriation, misuse, and defamation. Member represents and warrants to Industrious that its employees, agents, and invitees will have been informed of and agreed to this consent, waiver of liability, and release before they enter that portion of the Premises in which the Sensors are being used.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member may receive or learn certain confidential information about Industrious or Industrious&#x2019;s other members, including without limitation, information regarding its or their business operations, business and marketing plans, pricing, technology, finances and methods (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;). Member agrees to hold all Confidential Information, whether belonging to Industrious or its other members, in strict confidence and to take all reasonable precautions to protect such Confidential Information. All terms and conditions of this Agreement (including, without limitation, pricing- related information) shall be deemed Confidential Information. Member acknowledges that any disclosure or unauthorized use of Industrious&#x2019;s Confidential Information will constitute a material breach of this Agreement and cause substantial harm to Industrious for which damages would not be a fully adequate remedy. In the event of any such breach, Industrious will have, in addition to any other available rights and remedies, the right to injunctive relief (without being required to post any bond or security). If an employee or agent of Industrious becomes aware of any Confidential Information of Member, Industrious agrees to cause such employee or agent to hold such Confidential Information in strict confidence and to take all reasonable precautions to protect such Confidential Information, except any disclosure required by law, court order or in connection with a breach of this Agreement by Member.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:4.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 6. Liability</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waiver of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will be solely responsible for maintaining the insurance coverage required hereunder and Member will look solely to such insurance for any and all claims, damages, costs, expenses, liabilities and rights it may have, except to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious Party (defined hereunder). To the maximum extent permitted by law, Member, on its own behalf and on behalf of its owners, officers, employees, agents and invitees, hereby Waives (as defined hereunder) any and all claims, actions, damages, costs, expenses, liabilities and rights against Industrious, Landlord, their respective affiliates, and each of their respective past, present and future principals, members, assignees, managers, directors, officers, employees, agents, successors and assigns (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Party</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; and collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Industrious Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;) arising or resulting from (i) any injury or damage to, or destruction, theft, or loss of, any tangible or intangible property located in or about the Office Space, the Premises or the building in which the Premises is located, (ii) any personal injury, bodily injury or property damage (as such terms are defined by insurance regulations) occurring in or at the Office Space, the Premises or the building in which the Premises is located, (iii) the wrongful access or use of any data or information, or (iv) any loss of use or interruption of Member&#x2019;s business or any interruption or stoppage of any Service, except to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious to the extent arising or resulting from the gross negligence or willful misconduct of an Industrious Party. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; of Industrious or of Landlord include any person or entity that controls, is controlled by, or is under common control with Industrious or Landlord, respectively, including without limitation, any subsidiaries or parent companies; and the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waives</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d; means that Member, and its owners, officers, employees, agents and invitees waive and knowingly and voluntarily assume the risk of.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Disclaimer of Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Industrious expressly disclaims and excludes all warranties, whether express, implied or statutory, with respect to the Office Space, the Premises and the Services provided by or on behalf of Industrious, including but not limited to, any warranty of merchantability, fitness for a particular purpose, non-infringement, habitability, or quiet enjoyment, or any warranties that may have arisen or may arise from course of performance, course of dealing or usage of trade. Industrious makes no representations or warranties regarding the quality, reliability, timeliness or security of the Office Space or any Services provided by or on behalf of Industrious, or that any Services will be uninterrupted or operate error free. The Office Space, Premises and Services provided by Industrious are provided &#x201c;as is&#x201d; and &#x201c;with all faults&#x201d;.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The aggregate monetary liability of the Industrious Parties to Member, its owners, officers, employees, agents and invitees for any reason and for all causes of action, whether in contract, in tort, or otherwise, not otherwise waived as set forth above, will not exceed the total fees paid by Member to Industrious under this Agreement during the twelve (12)-month period prior to the date on which the cause of action accrued. Notwithstanding anything herein to the contrary, in no event will any Industrious Party be liable for any claim or cause of action, whether in contract, in tort, or otherwise for any indirect, special, consequential, exemplary, or punitive damages, including but not limited to, loss of profits or business interruption, even if Industrious has been advised of such damages. Member acknowledges that Industrious&#x2019;s obligations under this Agreement are consideration for the foregoing limitations of liability. The limitations, waivers, disclaimers and exclusions in this Agreement apply to the maximum extent allowed by law, even if a remedy fails its essential purpose.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Limitation of Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. To the extent not otherwise waived as set forth above, unless otherwise prohibited by applicable state or federal law, Member must commence any action, suit or proceeding against any Industrious Parties, whether in contract, tort, or otherwise, within one (1) year of the cause of action&#x2019;s accrual and Member, on its own behalf and on behalf of its owners, officers, employees, agents and invitees, hereby Waives any claims not brought within such time period.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:4.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:7.731%;margin-top:9.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except to the extent of the negligence or willful misconduct of any Industrious Party or their respective employees, agents, contractors or vendors, Member will indemnify, defend and hold harmless each of the Industrious Parties from, and against any and all actual claims, actions, proceedings, damages, </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.731%;margin-top:9.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">liabilities, costs and expenses of every kind, whether known or unknown, including but not limited to reasonable</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.843%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">attorney fees (collectively, &#x201c;Claim(s)&#x201d;), to the extent resulting from or arising out of (i) any breach of this Agreement by Member or Member&#x2019;s owners, officers, employees, agents, or invitees; or (ii) any actions, errors, omissions, negligence, willful misconduct or fraud of Member or Member&#x2019;s owners, officers, employees, agents or invitees. If any such Claim is brought against any of the Industrious Parties, Member will defend the Claim at Member&#x2019;s expense, using counsel approved by Industrious in writing, such approval not to be unreasonably withheld, provided that Industrious will at all times have the right to participate in such defense at its own expense. The Industrious Parties&#x2019; refusal to consent to a settlement shall not be deemed unreasonable when the proposed settlement requires or results in the Industrious Parties, or any one of them, admitting to any wrongdoing or liability.</font></p>
  <p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.731%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:1.4468564740053536%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Except to the extent of the negligence or willful misconduct of Member or its employees, agents, invitees, contractors or vendors, Industrious will indemnify, defend and hold harmless Member from, and against any and all Claims, to the extent resulting from or arising out of any actions, errors, omissions, negligence, willful misconduct or fraud of Industrious or its owners, officers, employees, or agents. If any such Claim is brought against Member, Industrious will defend the Claim at Industrious&#x2019;s expense, using counsel approved by Member in writing, such approval not to be unreasonably withheld, provided that Member will at all times have the right to participate in such defense at its own expense. The Member Parties&#x2019; refusal to consent to a settlement shall not be deemed unreasonable when the proposed settlement requires or results in the Member Parties, or any one of them, admitting to any wrongdoing or liability.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Insurance Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member, at its expense, will maintain at all times during the Term of this Agreement the following insurance policies: (i) personal property insurance covering any and all personal property of Member and its owners, officers, employees, agents and invitees from time to time, within the Office Space, the Premises and/or the building in which the Premises is located, (ii) workers&#x2019; compensation insurance in the minimum amounts required under applicable state law, (iii) commercial general liability insurance covering personal injury, bodily injury and property damage of no less than $1,000,000 and (iv) business interruption insurance . All insurance policy(ies) required to be carried by Member must (1) name, as additional insureds, Industrious and its Landlord(s) (including any master landlord and their respective lender(s)), or other persons with responsibility for the Premises whom Industrious may designate in writing to Member, and (2) be endorsed to waive all rights of subrogation against Industrious and its Landlord(s). Upon request from Industrious, Member will promptly provide proof of insurance required to be carried above, and in the form required above, including without limitation, the inclusion of the required additional insureds and waivers of subrogation. Further, Member, on its own behalf and on behalf of its employees, agents and invitees, hereby releases Industrious from any liability resulting from, and agrees to waive all rights of recovery against the Industrious Parties, on account of any and all claims it may have against the Industrious Parties, and shall cause its insurance company to waive all such claims by way of subrogation or otherwise. If Member fails to maintain any insurance required hereunder, Industrious&#x2019;s failure to take any action regarding such breach, including but not limited to, requesting or requiring proof of the existence of any such insurance at any time, and/or providing notice to Member of any such non-compliance, will not be considered or construed in any manner as a waiver of any rights of Industrious for such breach, nor will such failure of Member to carry any such insurance or such failure of Industrious to take any action with regard to such breach impose any obligation or liability on Industrious in any manner. Industrious reserves the right, but will not be obligated, to purchase any required insurance on behalf of Member, at Member&#x2019;s expense. If Member fails to carry any required insurance and a Claim occurs that would otherwise be</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.972%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">covered by Member&#x2019;s insurance, Industrious, without imposing any liability on Industrious or waiving any rights Industrious has with regard to Member&#x2019;s breach, may, but will not be obligated to, make a claim under any insurance policy carried by Industrious to cover such Claim, in which event Member will be liable to Industrious for all costs and expenses of Industrious to cover such Claim, including, but not limited to, the applicable deductible and a reasonable portion of the premium as determined by Industrious. Industrious, at its expense, will maintain during the Term insurance in such amounts as required under Industrious&#x2019;s lease, management agreement or other agreement to operate and manage the Premises as co-working space with its Landlord for the Premises (as applicable, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Member will not, during the Term of this Agreement and for a period of one (1) year thereafter, solicit the employment of any officer, employee, contractor, subcontractor or service provider of Industrious, which causes such person, directly or indirectly, to decrease or terminate its employment or business with Industrious. If Member hires any employee, contractor or subcontractor of Industrious during the period described, Member will pay to Industrious an amount equal to such person&#x2019;s annual salary with or fees from Industrious. Notwithstanding the foregoing, nothing in this paragraph shall restrict or preclude Member from hiring any person who responds to a general solicitation of employment through an advertisement not targeted specifically at Industrious or its employees.</font></div></div>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Section 7. General</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Breach of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event of a breach of this Agreement by Member, Industrious will have any and all rights and remedies available to Industrious as set forth in the Agreement, at law and/or in equity, including without limitation, recovery of all court costs and reasonable attorneys&#x2019; fees incurred by Industrious in pursuing such remedies, whether legal action is filed or not, all of which rights and remedies are cumulative and not exclusive of each other.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. This Agreement, including all schedules and attachments incorporated by reference, sets forth the entire understanding of the parties relating to its subject matter, and all other understandings, written or oral, are superseded. This Agreement will also be deemed to include all policies, procedures, and requirements published by Industrious from time to time, with which Member hereby agrees to comply. Except as otherwise provided in this Agreement, this Agreement may not be amended except in a writing executed by both parties.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Subordination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding anything herein to the contrary, this Agreement is at all times subject and subordinate to the Lease with Landlord and to any other agreements to which the Lease is subject or subordinate. Member acknowledges that Member has no rights under the Lease.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Governing Law; Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. This Agreement is governed by the laws of New York, without giving effect to any conflict of law principle that would result in the laws of any other jurisdiction governing this Agreement. Except that either party may seek equitable relief from any court of competent jurisdiction in New York County, New York, any dispute arising out of or relating to this Agreement&#x2014;including the breach, termination, and validity of this Agreement, and the arbitrability of any claim&#x2014;that cannot be resolved amicably by mutual agreement shall be finally settled by confidential and binding arbitration in accordance with the arbitration rules of JAMS then in force by one or more arbitrators appointed in accordance with said rules. The place of arbitration shall be New York County, New York</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In any action, suit or proceeding between Industrious and Member, including any appellate or alternative dispute resolution proceeding, to enforce rights under this Agreement, the prevailing party shall be entitled to recover from the non-prevailing party, in addition to any other relief awarded, all of its costs and expenses in connection therewith, including, but not limited to, reasonable attorneys&#x2019; fees.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Class Action Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Any proceeding to resolve any dispute relating to or arising under this Agreement in any forum will be conducted solely on an individual basis. Neither party will assert any claim (including counterclaim) against the other in arbitration or litigation on a class or consolidated basis, and neither party</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.009%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">will pursue or participate in any claim against the other in a representative or private attorney general capacity. No proceeding will be combined with another without the prior written consent of all parties to all affected proceedings. This class action waiver precludes Industrious and Member from pursuing, participating in, or being represented in any class, consolidated, or representative action regarding any claim against the other.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Neither party will be deemed by any act or omission to have waived any of its rights or remedies hereunder unless such waiver is in writing and signed by the waiving party, and then only to the extent specifically set forth in writing. No delay or omission by any party in exercising any of said rights or remedies shall operate as a waiver thereof. Further, one or more waivers of any covenant or condition by either party will not be construed as a waiver of a subsequent breach of the same covenant or condition, and the consent or approval by either party to or of any act requiring such consent or approval will not be deemed to render unnecessary future consent or approval to or of any subsequent similar act.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Relationship of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. The parties to this Agreement are independent contractors and will not be considered agents, employees, servants, joint venturers, or partners of one another. Neither party has the authority to bind the other party except as explicitly set forth in this Agreement, and neither party will make any representation or warranty otherwise. Industrious will have no responsibility for any fee or expense incurred by Member in connection with either party&#x2019;s performance this Agreement, or provision or use of the Services.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. In the event of any transfer or transfers of Industrious's interest in the Premises, Industrious will automatically be relieved of any and all respective obligations accruing from and after the date of such transfer. Following any such transfer(s), all rights, obligations and interests of Industrious under this Agreement will apply to, inure to the benefit of, and be binding on any such successors and assigns of Industrious.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">No Third-Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Except for third parties entitled to indemnity under this Agreement or third parties whose liability is specifically limited pursuant to the terms of this Agreement, the parties to this Agreement do not intend to confer any right or remedy on any third party.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Neither party is liable for, and will not be considered in default or breach of this Agreement on account of, any delay or failure to perform as required by this Agreement (with the exception of Member&#x2019;s obligation to pay any sum due to Industrious hereunder, including without limitation, the License Fees, which obligation will remain unaffected by the provisions of this paragraph) as a result of any causes or conditions that are beyond such party&#x2019;s reasonable control and which such party is unable to overcome by the exercise of reasonable diligence, provided that the affected party will use commercially reasonable efforts to promptly resume normal performance. For the avoidance of doubt, Member&#x2019;s payment obligations under this Agreement remain unaffected by circumstances beyond Industrious&#x2019;s reasonable control, including public health crises (such as COVID-19) and public health measures in response thereto.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. If a provision of this Agreement is determined to be unenforceable in any respect, the enforceability of the provision in any other respect and of the remaining provisions of this Agreement will not be impaired.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Unless expressly specified otherwise herein, all notices, requests, demands and other communications to be delivered hereunder will be in writing and delivered in person, by nationally recognized overnight carrier, or by registered or certified mail, return-receipt requested and postage prepaid, to the following addresses: if to Industrious, to: Industrious, Attn: Head of Legal, 215 Park Avenue South, 12th Floor, New York, NY 10003; and if to Member: to the address provided by Member upon execution of this Agreement, and if none, then to the Office Space. All notices will be deemed effective as of the date of confirmed delivery or refusal of receipt. In addition to the foregoing methods, notices from Industrious to Member may also be delivered by email to the email address provided by Member upon</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.68in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.773%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.028%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">execution of this Agreement. Notices of non-renewal by Member may, at the Member&#x2019;s option, be delivered by email to the Industrious email address provided to Member upon execution of this Agreement. Delivery of notices by email hereunder will be deemed effective upon transmission. Each party may update its respective address and/or e-mail address from time to time upon written notice to the other. Member must promptly provide Industrious with any change of address, e-mail address and other contact information (including phone number). Member agrees to accept community-wide emails sent out to all members by Industrious from time to time, which will be the responsibility of Member to review.</font></p>
  <div style="margin-left:4.398%;display:flex;margin-top:7.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Updates to Agreement; License Fee Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Notwithstanding any other provision in this Agreement, Industrious may from time to time update the terms of this Agreement by providing at least thirty (30) days&#x2019; notice to Member; provided that such updates shall not materially interfere with Member&#x2019;s rights under this Agreement or impose any additional material obligations on Member. Member acknowledges that Member&#x2019;s continued use of the Office Space and/or Services beyond such thirty (30)-day period will constitute acceptance of such updated terms. In addition, License Fees are subject to change during the Renewal Term, if any, in Industrious&#x2019;s sole discretion upon eighty (80) days&#x2019; written notice prior to the start of the applicable Renewal Term, provided that price adjustments will not exceed 8% at a time. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Please</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">keep in mind that Industrious must receive a Non-Renewal Notice at least two (2) calendar months</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">prior to the end of the then-current term to properly terminate this Agreement. Therefore, Member</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">will have approximately 20 days to make a determination on whether or not to auto renew this</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Member acknowledges that Industrious may serve notice of any changes to Services, fees (other than License Fees hereunder) or other updates through community-wide emails sent out to all members or through notices posted at the Premises, and Member agrees to accept and review such community-wide notices.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Accord and Satisfaction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. No payment by Member or receipt by Industrious of a lesser amount than required hereunder will be deemed to be other than on account of the earliest amounts due hereunder, nor will any endorsement or statement on any check or any letter accompanying any check or payment be deemed an accord and satisfaction and Industrious may accept such check or payment without prejudice to its rights to recover the balance of such amounts or pursue any other rights and remedies it has under this Agreement.</font></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:7.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:3.4863287378925123%;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Time of Essence</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">. Time is of the essence with respect to the performance of each of Member&#x2019;s obligations under this Agreement.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>acet-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font></p>
  <p style="margin-left:34.96%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INSIDER TRADING POLICY</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.872%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.88%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This memorandum sets forth the policy of Adicet Bio, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d;) regarding trading in the Company&#x2019;s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the &#x201c;Insider Trading Policy&#x201d;) is designed to prevent the misuse of material nonpublic information, insider trading in securities or the appearance of impropriety, to satisfy the Company&#x2019;s obligation to reasonably supervise the activities of Company personnel, and to help Company personnel avoid the severe consequences associated with violations of insider trading laws. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is your obligation to review, understand and comply with this Insider Trading Policy and applicable laws. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors has approved this Insider Trading Policy, and we have appointed Nick Harvey, Chief Financial Officer, as the Compliance Officer (with his designees, the &#x201c;Compliance Officer&#x201d;) to administer the policy and to be available to answer your questions. Please contact the Compliance Officer if you have any questions regarding the policy.</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.88%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:1.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PART I.  OVERVIEW</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A.  	To Whom does this Insider Trading Policy Apply?</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Insider Trading Policy applies to all of our employees, consultants and contractors, and members of our Board of Directors, including anyone employed by or acting as a director of any of the Company&#x2019;s subsidiaries, as well as any other individuals whom the Compliance Officer may designate as Insiders (defined below) because they have access to material nonpublic information about the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:3.362%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:3.362%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition, all of our directors, executive officers (as defined by Section 16 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) and other designated employees must comply with the Trading Procedures included in Part II of this Insider Trading Policy (the &#x201c;Trading Procedures&#x201d;); we will refer to these individuals in this policy as &#x201c;Insiders.&#x201d; The Trading Procedures provide rules for when Insiders can trade in the Company&#x2019;s securities and explain the process for mandatory pre-clearance of proposed trades. You will be notified if you are considered to be an Insider who is required to comply with the Trading Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:3.362%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:3.362%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Insider Trading Policy and, for Insiders, the Trading Procedures also apply to the following persons (&#x201c;Affiliated Persons&#x201d;):</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">your &#x201c;Family Members&#x201d; (&#x201c;Family Members&#x201d; are (a) your spouse or domestic partner, children, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws who reside in the same household as you, (b) your children or your spouse&#x2019;s children who do not reside in the same household as you but are financially dependent on you, (c) any of your other family members who do not reside in your household but whose transactions are directed by you, and (d) any other individual over whose account you have control and to whose financial support you materially contribute. (Materially contributing </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to financial support would include, for example, paying an individual&#x2019;s rent but not just a phone bill.).);</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all trusts, family partnerships and other types of entities formed for your benefit or for the benefit of a member of your family and over which you have the ability to influence or direct investment decisions concerning securities; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all persons who execute trades on your behalf; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which you have the ability to influence or direct investment decisions concerning securities; provided, however, that the Trading Procedures do not apply to any such entity that engages in the investment of securities in the ordinary course of its business (e.g., an investment fund or partnership) if the entity has established its own insider trading controls and procedures in compliance with applicable securities laws and it (or an affiliated entity) has represented to the Company that its affiliated entities: (a) engage in the investment of securities in the ordinary course of their respective businesses; (b) have established insider trading controls and procedures in compliance with securities laws; and (c) are aware the securities laws prohibit any person or entity who has material nonpublic information concerning the Company from purchasing or selling securities of the Company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell securities.</font></div></div>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You are responsible for ensuring compliance with this Insider Trading Policy, including the Trading Procedures contained herein, by all of your Affiliated Persons.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="b__what_is_prohibited_by_this_insider_tr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">B.	What is Prohibited by this Insider Trading Policy?</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.841%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.704%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You and your Affiliated Persons are prohibited from engaging in insider trading and from trading in securities in violation of this Insider Trading Policy. &#x201c;Insider trading&#x201d; is (1) trading (buying or selling) the securities of a company whether for your account or for the account of another, while in the possession of material nonpublic information (see definition below) about that company or (2) disclosing material nonpublic information about a company to others who may trade on the basis of that information. Insider trading can result in criminal prosecution, jail time, significant fines and public embarrassment for you and the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prohibition on Trading in Company Securities</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">When you know or are in possession of material, nonpublic information about the Company, whether positive or negative, you are prohibited from trading (whether for your account or for the account of another) in the Company&#x2019;s securities, which includes common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities, except for trades made pursuant to plans approved by the Compliance Officer in accordance with this policy that are intended to comply with Rule 10b5-1 under the Exchange Act.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.92%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The trading prohibitions in this Insider Trading Policy do not apply to: (1) an exercise of an employee stock option when payment of the exercise price is made in cash or (2) the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with the Trading Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.92%;text-indent:7.317%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:7.972%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The trading prohibitions in this Insider Trading Policy do apply, however, to the use of outstanding Company securities to constitute part or all of the exercise price of a stock option, any sale of stock as part of a broker-assisted cashless exercise of an option, and any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.92%;text-indent:6.844%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prohibition on Tipping</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Providing material nonpublic information about the Company to another person who may trade or advise others to trade on the basis of that information is known as &#x201c;tipping&#x201d; and is illegal.  You are prohibited from providing material nonpublic information about the Company to a friend, relative, or anyone else who might buy or sell a security or other financial instrument on the basis of that information, whether or not you intend to or actually do realize a profit (or any other benefit) from such tipping.  Additionally, you are prohibited from recommending to any person that such person engage in or refrain from engaging in any transaction involving the Company&#x2019;s securities, or otherwise give trading advice concerning the Company&#x2019;s securities, if you are in possession of material nonpublic information about the Company.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prohibition on Trading in Securities of Other Companies</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Insider Trading Policy&#x2019;s prohibitions against insider trading and tipping also apply to trading in securities of other companies, including the Company&#x2019;s customers, suppliers, partners and other enterprises with which we are working (such as when negotiating an acquisition, investment or other transaction that could be material to the other company).  Whenever, during the course of your service to or employment by the Company, you become aware of material nonpublic information about another company, including any confidential information that is reasonably likely to affect the market price of that company&#x2019;s securities (for example, discussions of licensing a product or acquiring that other company), neither you nor your Affiliated Persons may trade in any securities of that company, give trading advice about that company, tip or disclose that information, pass it on to others, or engage in any other action to take advantage of that information.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If your work regularly involves handling or discussing confidential information of one of our partners, suppliers or customers, you should consult with the Compliance Officer before trading in any of that company&#x2019;s securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.92%;text-indent:6.813%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Duration of Trading Prohibitions</font></p>
  <p style="margin-left:0.84%;text-indent:6.94%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.102%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">These trading prohibitions continue whenever and for as long as you know or are in possession of material, nonpublic information. Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight. As a practical matter, before engaging in any transaction,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you should carefully consider even the appearance of improper insider trading and how enforcement authorities and others might view the transaction in hindsight.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Insider Trading Policy applies to you and your Affiliated Persons so long as you are associated with the Company. If you leave the Company for any reason, this Insider Trading Policy, including, if applicable, the Trading Procedures described in Part III, will continue to apply to you and your Affiliated Persons until the later of: (1) the first trading day following the public release of earnings for the fiscal quarter in which you leave the Company or (2) the first trading day after any material nonpublic information known to you has become public or is no longer material.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C. 	What is Material Nonpublic Information?</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.799%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.833%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Insider Trading Policy prohibits you from trading in a company&#x2019;s securities if you are in possession of information about the company that is both &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nonpublic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; If you have a question whether certain information you are aware of is material or has been made public, you should consult with the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;Material&#x201d; Information</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.803%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Information about the Company or any other company is &#x201c;material&#x201d; if it could reasonably be expected to affect the investment decisions of a stockholder or potential investor, or if the disclosure of the information could reasonably be expected to significantly alter the total mix of information in the marketplace about the Company or any other company.  We speak mostly in this Insider Trading Policy about determining whether information about us is material and nonpublic, but the same analysis applies to information about other companies that would preclude you from trading in their securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:1.107%;text-indent:6.803%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.898%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.803%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.898%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In simple terms, material information is any type of information that could reasonably be expected to affect the market price of the Company&#x2019;s securities. Both positive and negative information may be material. While it is not possible to identify all information that would be deemed &#x201c;material,&#x201d; the following items are examples of the types of information that could be material:</font></p>
  <p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">developments regarding any programs in clinical development, including recent regulatory interaction and/or data that have been recently generated from ongoing or recently completed clinical trials;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">developments regarding the intellectual property and/or freedom to operate for any of the current programs or product candidates under development;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">projections of future earnings or losses, or other earnings guidance;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">quarterly financial results that are known but have not been publicly disclosed;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">potential restatements of the Company&#x2019;s financial statements, changes in auditors or auditor notification that the Company may no longer rely on an auditor&#x2019;s audit report;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">pending or proposed mergers, acquisitions, tender offers, joint ventures or dispositions of significant assets;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">changes in management or the Board of Directors;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">actual or threatened litigation or governmental investigations or major developments in such matters;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cybersecurity risks and incidents, including the discovery of significant vulnerabilities or breaches;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">developments regarding products, customers, suppliers, orders, contracts or financing sources (e.g., the acquisition or loss of a contract);</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">changes in dividend policy, declarations of stock splits, or proposed public or private offerings securities;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">potential defaults under the Company&#x2019;s credit agreements or indentures, or the existence of material liquidity deficiencies; and</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">bankruptcies or receiverships.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.893%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.37%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The above items will not always be material. For example, some new products or contracts may clearly be material while others may not be. No &#x201c;bright-line&#x201d; standard or list of items can adequately address the range of situations that may arise; information and events should be carefully considered in terms of their materiality to the Company.</font></p>
  <p style="margin-left:0.92%;text-indent:6.893%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.37%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Nonpublic&#x201d; Information</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.815%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Material information is &#x201c;nonpublic&#x201d; if it has not been disseminated in a manner making it available to investors generally.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.92%;text-indent:6.815%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.815%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To show that information is public, it is necessary to point to some fact that establishes that the information has become publicly available, such as the filing of a report with the SEC, the distribution of a press release, publishing the information on our website or posting on social media if those are regular ways we communicate with investors, or by other means that are reasonably designed to provide broad public access. Before a person with material, nonpublic information can trade, the market must have adequate time to absorb the information that has been disclosed.  For the purposes of this Insider Trading Policy, information will be considered public after the completion of one full day of trading following the Company&#x2019;s public release of the information. For the purposes of this Insider Trading Policy, information will be considered public after the completion of one full day of trading following our public release of the information.  For that purpose, a full day of trading means an entire calendar day in which a session of regular trading hours on the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) between 9:30 a.m. and 4:00 p.m. Eastern Time (or such earlier close time as has been set by exchange rules) has occurred.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.819%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For example, if the Company publicly discloses material information of which you are aware before trading begins on a Tuesday, the first time you can buy or sell Company securities is the opening of the market on Wednesday. However, if the Company publicly discloses material information after trading begins on a Tuesday, the first time that you can buy or sell Company securities is the opening</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.315%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the market on Thursday.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="c__what_are_the_penalties_for_insider_tr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">D.	What are the Penalties for Insider Trading and Noncompliance with this Insider Trading Policy?</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.901%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.481%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Both the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the national securities exchanges, through the Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;), investigate and are very effective at detecting insider trading. The government pursues insider trading violations vigorously. For instance, cases have been successfully prosecuted against trading by employees in foreign accounts, trading by family members and friends, and trading involving only a small number of shares.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The penalties for violating insider trading or tipping rules can be severe and include:</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">forfeiting any profit gained or loss avoided by the trading;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">payment of the loss suffered by the persons who, contemporaneously with the purchase or sale of securities that are subject of such violation, have purchased or sold, as applicable, securities of the same class;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">payment of criminal penalties of up to $5,000,000;</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">payment of civil penalties of up to three times the profit made or loss avoided; and</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">imprisonment for up to 20 years.</font></div></div>
  <p style="margin-left:1.107%;text-indent:6.813%;font-size:10pt;margin-top:3.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company and/or the supervisors of the person engaged in insider trading may also be required to pay civil penalties or fines of $2 million or more, up to three times the profit made or loss avoided, as well as criminal penalties of up  to $25,000,000, and could under certain circumstances be subject to private lawsuits.</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.819%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Violation of this Insider Trading Policy or any federal or state insider trading laws may subject the person violating such policy or laws to disciplinary action by the Company up to and including termination of your employment or other relationship with the Company.  The Company reserves the right to determine, in its own discretion and on the basis of the information available to it, whether this Insider Trading Policy has been violated. The Company may determine that specific conduct violates this Insider Trading Policy, whether or not the conduct also violates the law. It is not necessary for the Company to await the filing or conclusion of a civil or criminal action against the alleged violator before taking disciplinary action.</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="d__does_the_company_have_any_other_polic"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">E. 	Does the Company have any Other Policies Regarding Confidential Information?</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.794%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.769%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company also has strict policies relating to safeguarding the confidentiality of its internal, proprietary information and the use of social media and other online platforms.  These policies include procedures regarding identifying, marking and safeguarding confidential information and employee confidentiality agreements.  You should comply with these policies at all times.</font></p>
  <p style="margin-left:1.107%;text-indent:6.794%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.769%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="e__how_do_you_report_a_violation_of_this"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">F.	How Do You Report a Violation of this Insider Trading Policy?</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.826%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If you have a question about this Insider Trading Policy, including whether certain information you are aware of is material or has been made public, you should consult with the Compliance Officer. In addition, if you violate this Insider Trading Policy or any federal or state laws governing insider trading, or know of any such violation by any director, officer or employee of the Company, you must report the violation immediately to the Compliance Officer. However, if the conduct in question involves the Compliance Officer, or if you have reported such conduct to the Compliance Officer and you do not believe that he has dealt with it properly, or if you do not feel that you can discuss the matter with the Compliance Officer, you may raise the matter with the Chief Executive Officer.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:-7.229%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="f__is_this_insider_trading_policy_subjec"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">G.	Is This Insider Trading Policy Subject to Modification?</font></p>
  <p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.107%;text-indent:6.857%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may at any time change this Insider Trading Policy or adopt such other policies or procedures which it considers appropriate to carry out the purposes of its policies regarding insider trading and the disclosure of Company information. Notice of any such change will be delivered to you by regular or electronic mail (or other delivery option used by the Company) by the Company. You will be deemed to have received, be bound by and agree to revisions of this Insider Trading Policy when such revisions have been delivered to you, unless you object to any revision in a written statement received by the Compliance Officer within two (2) business days of such delivery.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.37%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PART II.  TRADING PROCEDURES</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A.	Special Trading Restrictions Applicable to Insiders</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to needing to comply with the restrictions on trading in the Company&#x2019;s securities set forth above, Insiders and their Affiliated Persons are subject to the following special trading restrictions:</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Special Closed Trading Periods</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">There are times when the Company or certain members of its Board of Directors or senior management or support staff may be aware of a material, nonpublic development.  Although an Insider may not know the specifics of such development, if an Insider engages in a trade before such development is disclosed to the public or resolved, such Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute. In addition, a trade by an Insider during such a period could result in adverse publicity for the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Therefore, Insiders may not trade in Company securities if they are notified by the Compliance Officer that the trading window is closed because of the existence of a material, nonpublic development. The Compliance Officer will subsequently notify the Insiders once the material, nonpublic development is disclosed to the public or resolved and that, as a result, the trading window is again open. While the Compliance Officer will undertake reasonable efforts to notify the Insiders that material, nonpublic events have developed, or are soon likely to develop, it is each Insider&#x2019;s individual duty to ensure that they do not make any trade in Company securities when material, nonpublic information exists, regardless of whether such Insider is aware of such development.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	All Trades Must be Pre-Cleared by the Compliance Officer</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Insider may trade in Company securities unless the trade has been approved by the Compliance Officer in accordance with the procedures set forth below. The Compliance Officer will review and either approve or prohibit all proposed trades by Insiders in accordance with the procedures set forth in Part II, Section B below.  The Compliance Officer may consult with the Company&#x2019;s other officers and/or outside legal counsel and will receive approval for his own trades from the Company&#x2019;s Chief Executive Officer. If you are unable to contact the Compliance Officer, or if you do not feel you can discuss the matter with the Compliance Officer, you may contact the Chief Executive Officer, who shall be the alternate Compliance Officer.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	Prohibited Transactions</font></p>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No Insider may at any time sell any securities of the Company that are not owned by such Insider at the time of the sale (a &#x201c;short sale&#x201d;).  </font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Purchases or Sales of Derivative Securities or Hedging Transactions Without Pre-Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No Insider may buy or sell puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities or engage in any other hedging transaction with respect to the Company&#x2019;s securities, at any time unless such transaction has been approved by the Audit Committee of the Board of Directors. Any request for approval of such a derivative transaction by an Insider must be submitted to the Audit Committee in writing at least two (2) weeks prior to the proposed execution of documents evidencing the transaction. Any such request submitted by an Insider will be considered by the Audit Committee on a case-by-case basis and, if permitted, shall be subject to all of the other restrictions on trading in the Company&#x2019;s securities set forth in these Trading Procedures.  </font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Company Securities Subject to Margin Calls</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No Insider may use the Company&#x2019;s securities as collateral in a margin account.</font></div></div>
  <div style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.204685693290251%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Pledges Without Pre-Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No Insider may pledge the Company&#x2019;s securities as collateral for a loan (or modify an existing pledge) unless the pledge has been approved by the Audit Committee of the Board of Directors. Any request for approval of such a pledge by an Insider must be submitted to the Audit Committee in writing at least two (2) weeks prior to the proposed execution of documents evidencing the proposed pledge. Any such request submitted by an Insider will be considered by the Audit Committee on a case-by-case basis and, if permitted, shall be subject to all of the other restrictions on trading in the Company&#x2019;s securities set forth in this Insider Trading Policy.</font></div></div>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	Gifts and Other Distributions in Kind</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Insider may give, donate or make any other transfer of Company securities without consideration when the Insider is not permitted to trade unless the donee agrees not to sell the shares until the Insider is permitted to sell. In addition to charitable donations or gifts to family members,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">friends, trusts or others, this prohibition applies to distributions to limited partners by limited partnerships that are subject to this Insider Trading Policy.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">B. 	Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.78%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.833%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Insider may trade in the Company&#x2019;s securities, even during an open trading window, unless the trade has been approved by the Compliance Officer in accordance with the procedures described below.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> In reviewing trading requests, the Compliance Officer may consult with our other officers and/or outside legal counsel and will seek approval of their own trades from the Chief Executive Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Procedures.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Insider may trade in the Company&#x2019;s securities unless:</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.796%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Insider has notified the Compliance Officer of the amount and nature of the proposed trade(s) using the Stock Transaction Request form attached to this Insider Trading Policy.  To provide adequate time for the preparation of any required reports under Section 16 of the Exchange Act, a Stock Transaction Request form should, if practicable, be received by the Compliance Officer at least two (2) business days prior to the intended trade date;</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.796%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Insider has certified to the Compliance Officer in writing prior to the proposed trade(s) that the Insider is not in possession of material nonpublic information concerning the Company;</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.796%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Insider has informed the Compliance Officer, using the Stock Transaction Request form, whether, to the Insider&#x2019;s best knowledge, (a) the Insider has (or is deemed to have) engaged in any opposite way transactions within the previous six months that were not exempt from Section 16(b) of the Exchange Act and (b) if the transaction involves a sale by an &#x201c;affiliate&#x201d; of the Company or of &#x201c;restricted securities&#x201d; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended (&#x201c;Rule 144&#x201d;)), whether the transaction meets all of the applicable conditions of Rule 144; and</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.796%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Compliance Officer has approved the trade(s) and has certified such approval in writing (which may be by email). </font></div></div>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Compliance Officer does not assume responsibility for, and approval by the Compliance Officer does not protect the Insider from, the consequences of prohibited insider trading.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	Additional Information</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Insiders shall provide to the Compliance Officer any documentation the Compliance Officer reasonably requires in furtherance of the foregoing procedures.  Any failure to provide such requested information will be grounds for the Compliance Officer to deny approval of the trade request.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	Notification of Brokers of Insider Status</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Insiders who are required to file reports under Section 16 of the Exchange Act shall inform their broker-dealers that (a) the Insider is subject to Section 16; (b) the broker shall confirm that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any trade by the Insider or any of their affiliates has been precleared by the Company; and (c) the broker is to provide transaction information to the Insider and/or Compliance Officer on the day of a trade.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	No Obligation to Approve Trades.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer to approve any trade requested by an Insider.  The Compliance Officer has sole discretion to reject any trading request.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">From time to time, an event may occur that is material to the Company and is known by only by a limited number of directors and employees.  The Compliance Officer may decline an Insider&#x2019;s request to preclear a proposed trade based on the existence of a material nonpublic development &#x2013; even if the Insider is not aware of that material nonpublic development.  If any Insider engages in a trade before a material nonpublic development is disclosed to the public or resolved, the Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute even if the Insider was unaware of the development.  So long as the event remains material and nonpublic, the Compliance Officer may decide not to approve any transactions in the Company&#x2019;s securities.  The Compliance Officer will subsequently notify the Insider once the material nonpublic development is disclosed to the public or resolved.  If an Insider requests preclearance of a trade during the pendency of such an event, the Compliance Officer may reject the trading request without disclosing the reason.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5.	Completion of Trades.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">After receiving written clearance to engage in a trade signed by the Compliance Officer, an Insider must complete the proposed trade within two business days or make a new trading request.  Even if an Insider has received clearance, the Insider may not engage in a trade if (i) such clearance has been rescinded by the Compliance Officer, (ii) the Insider has otherwise received notice that the trading window has closed or (iii) the Insider has or acquires material nonpublic information.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6.	Post-Trade Reporting.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The details of any transactions in the Company&#x2019;s securities (including transactions effected pursuant to a Rule 10b5-1 Plan) by an Insider (or an Affiliated Person) who is required to file reports under Section 16 of the Exchange Act must be reported to the Compliance Officer by the Insider or their brokerage firm on the same day on which a trade order is placed or such a transaction otherwise is entered into.  The report shall include the date of the transaction, quantity of shares, the price and the name of the broker-dealer that effected the transaction.  This reporting requirement may be satisfied by providing (or having the Insider&#x2019;s broker provide) a trade order confirmation to the Compliance Officer if the Compliance Officer receives such information by the required date.  Compliance by directors and executive officers with this provision is imperative given the requirement of Section 16 of the Exchange Act that these persons generally report changes in ownership of Company securities within two (2) business days.  The sanctions for noncompliance with this reporting deadline include mandatory disclosure in the Company&#x2019;s proxy statement for the next annual meeting of stockholders, as well as possible civil or criminal sanctions for chronic or egregious violators.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C.	Exemptions</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Pre-Approved Rule 10b5-1 Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transactions effected pursuant to a pre-approved Rule 10b5-1 Plan (as defined below) will not be subject to the Company&#x2019;s trading windows or pre-clearance procedures, and Insiders are not required to complete a Stock Transaction Request form for such transactions.  Rule 10b5-1 of the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans, arrangements or instructions that meet specified requirements.  A trading plan, arrangement or instruction that meets the requirements of the SEC&#x2019;s Rule 10b5-1 (a &#x201c;Rule 10b5-1 Plan&#x201d;) enables Insiders to establish arrangements to trade in Company securities outside of the Company&#x2019;s trading windows, even when in possession of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company has adopted a separate Rule 10b5-1 Trading Plan Policy that sets forth the requirements for putting in place a Rule 10b5-1 Plan with respect to Company securities. Insiders should refer to the Rule 10b5-1 Trading Plan Policy for guidelines on establishing a Rule 10b5-1 Plan and obtaining pre-approval of the plan from the Company&#x2019;s Compliance Officer.</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	Employee Benefit Plans.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise of Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The trading prohibitions and restrictions set forth in these Trading Procedures do not apply to the exercise for cash of an option to purchase securities of the Company when payment of the exercise price is made in cash.  However, the exercise of an option to purchase securities of the Company is subject to the current reporting requirements of Section 16 of the Exchange Act and, therefore, Insiders must comply with the post-trade reporting requirement described in Section C above for any such transaction.  In addition, the securities acquired upon the exercise of an option to purchase Company securities are subject to all of the requirements of this Insider Trading Policy, including the Trading Procedures.  Moreover, these Trading Procedures apply to the use of outstanding Company securities to pay part or all of the exercise price of an option, any net option exercise, any exercise of a stock appreciation right, share withholding and any sale of stock as part of a broker-assisted cashless exercise of an option or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Withholding on Restricted Stock/Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The trading prohibitions and restrictions set forth in these Trading Procedures do not apply to the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with these Trading Procedures.</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">trading prohibitions and restrictions set forth in these Trading Procedures do not apply to periodic wage withholding contributions by the Company or its employees that are used to purchase the Company&#x2019;s securities pursuant to the employees&#x2019; advance instructions under the Company&#x2019;s 2018 Employee Stock Purchase Plan.  However, no Insider may: (a) elect to participate in the plan or alter his or her instructions regarding the level of withholding or purchase by the Insider of Company securities under such plan; or (b) make cash contributions to such plan (other than through periodic wage withholding) without complying with these Trading Procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any sale of securities acquired under such plan is subject to the prohibitions and restrictions of these Trading Procedures.</font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">D.	Waivers</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A waiver of any provision of this Insider Trading Policy or the Trading Procedures in a specific instance may be authorized in writing by the Compliance Officer, and any such waiver shall be reported to the Board of Directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:0.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PART III.  ACKNOWLEDGEMENT</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We will deliver a copy of this Insider Trading Policy to all current employees and directors and consultants and to future employees and directors and consultants at the start of their employment or relationship with the Company.  Each of these individuals must acknowledge that they have received a copy and agree to comply with the terms of this Insider Trading Policy, and, if applicable, the Trading Procedures contained herein.  The attached acknowledgment must be completed and submitted to the Company within ten days of receipt</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At our request, directors and employees and consultants will be required to re-acknowledge and agree to comply with the Insider Trading Policy (including any amendments or modifications).  For that purpose, an individual will be deemed to have acknowledged and agreed to comply with this Insider Trading Policy, as amended from time to time, when copies of those items have been delivered by regular or electronic mail (or other delivery option used by the Company) to the Compliance Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*	*	*</font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Failure to observe this Insider Trading Policy or the Trading Procedures could lead to significant legal problems, and could have other serious consequences, including termination of employment. Questions regarding these Trading Procedures or the Insider Trading Policy are encouraged and may be directed to the Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADOPTED: 	January 24, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EFFECTIVE:	February 27, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK TRANSACTION REQUEST</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Adicet Bio, Inc.&#x2019;s Insider Trading Policy, I hereby notify Adicet Bio, Inc. (the &#x201c;Company&#x201d;) of my intent to trade the securities of the Company as indicated below:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><img src="img110885244_0.jpg" alt="img110885244_0.jpg" style="width:672px;height:646px;">&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img110885244_1.jpg" alt="img110885244_1.jpg" style="width:672px;height:290px;">&#160;</p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">*NOTE: Multiple lots must be listed on separate forms or broken out.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.75in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I hereby acknowledge that I have read, that I understand, and that I agree to comply with the Insider Trading Policy of Adicet Bio, Inc. (the &#x201c;Company&#x201d;).  I further acknowledge and agree that I am responsible for ensuring compliance with the Insider Trading Policy and the Trading Procedures by all of my &#x201c;Affiliated Persons.&#x201d;  I also understand and agree that I will be subject to sanctions, including termination of employment, that may be imposed by the Company, in its sole discretion, for violation of the Insider Trading Policy, and that the Company may give stop-transfer and other instructions to the Company&#x2019;s transfer agent or any brokerage firm managing the Company&#x2019;s equity incentive plan(s) against the transfer of any Company securities that the Company considers to be in contravention of the Insider Trading Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.84%;text-indent:6.838%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	This acknowledgement constitutes consent for the Company to impose sanctions for violation of the Insider Trading Policy, including the Trading Procedures, and to issue any stop-transfer orders to the Company&#x2019;s transfer agent that the Company, in its sole discretion, deems appropriate to ensure compliance.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.102%;"></td>
    <td style="width:23.725%;"></td>
    <td style="width:17.784%;"></td>
    <td style="width:13.203%;"></td>
    <td style="width:37.187%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Send signed Acknowledgement to:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nick Harvey</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.37%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NHarvey@adicetbio.com</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>acet-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img18334421_0.jpg" alt="img18334421_0.jpg" style="width:113px;height:52px;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">KPMG LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">			Two Financial Center</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">			60 South Street</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;">			Boston, MA 02111</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos. 333-273834, 333-270560, 333-263588, 333-258763, 333-254192, 333-250033, 333-249275, 333-237123, 333-230363, and 333-222746) on Form S-8 and (Nos. 333-263587 and 333-256088) on Form S-3 of our report dated March 19, 2024, with respect to the consolidated financial statements of Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Boston, Massachusetts<br>March 19, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>acet-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, Chen Schor, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Adicet Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chen Schor</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chen Schor</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 19, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>acet-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="margin-left:66.667%;text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I, Nick Harvey, certify that:</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 of Adicet Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 19, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>acet-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Adicet Bio, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:</font></p>
  <p style="text-indent:5.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:5.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chen Schor</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chen Schor</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated: March 19, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:  March 19, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>acet-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted as of November 16, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), has adopted a Compensation Recovery Policy (this &#x201c;Policy&#x201d;) as described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Overview</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and the Nasdaq Stock Market.    Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	Definitions</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Recovery Period&#x201d; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Rules&#x201d; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Board&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Committee&#x201d; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Covered Person&#x201d; means any Executive Officer. A person&#x2019;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#x2019;s current role or status with the Company (e.g., if a person began service as an Executive </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Effective Date&#x201d; means October 2, 2023.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Erroneously Awarded Compensation&#x201d; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exchange&#x201d; means the Nasdaq Stock Market LLC.  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Executive Officer&#x201d; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation and received Incentive-Based Compensation after beginning service in any such role (regardless of whether such Incentive-Based Compensation was received during or after such person&#x2019;s service in such role): the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy making function or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">j.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Financial Reporting Measures&#x201d; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">k.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Financial Restatement&#x201d; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">l.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Incentive-Based Compensation&#x201d; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">m.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Restatement Date&#x201d; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	Exception to Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6.	Tax Considerations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7.	Method of Compensation Recovery</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or offsetting against planned future grants of equity-based awards; and/or </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any other method permitted by applicable law or contract.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#x2019;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8. 	Policy Interpretation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9.	Policy Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee; provided, however, that the Board shall have exclusive authority to authorize the Company to prepare a Financial Restatement. In doing so, the Board may rely on a recommendation of the Audit Committee of the Board. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy.  The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10.	Compensation Recovery Repayments not Subject to Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img18334421_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img18334421_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] (4# 2(  A$! Q$!_\0
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MJP_%MY]DT"90</.1$/QZ_H#51CS22$W97.)M-8^SZK<ZFR;KAMYB!Z!F[GV
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img104831930_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img104831930_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (I!-H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IICL]B
MK.Q9MS\DY/WC5NJ6E?\ (/3_ 'W_ /0S3K_5-/TJ)9=1O[6SC=MJO<3+&&/H
M"Q'-/J!;HJC8:WI.JNZ:=J=E>,@RZV]PDA4>IVDXJ]2:L 4444 %%%% !111
M0 4444 %%%% !50.W]KLFX[/(!VYXSN/-6ZI#_D-M_U[#_T(T 7:*BN;F"SM
MWN+J>."",9>25PJJ/4D\"LK_ (3#PQ_T,>D?^!T7_P 532;V VJ*165U#*05
M(R"#P12T@"BBB@ HIB3122R1)*C21X$B!@2F1D9';BGT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!4N'9=0LU#$*Q?< >#\O>K=4KG_D)6/U?
M_P!!J[0 45COXM\-Q2-')XATE'4E65KV,$$=01FM=65U#*05(R"#P13::W 6
MBF2S10*K32I&K,J NP +$X Y[DD "GT@"BBF2310E!+*B&1@B;F W,>P]3P>
M* 'T5%!=6]R91;SQ2F&0Q2"-PVQQ@E3CH>1P?6BYN8+.W>XNIXX((QEY)7"J
MH]23P* ):*9)-%% TTDB)$JEV=F 4*!DDGTQ6;;^)_#]Y<);VVNZ9//(<)'%
M=QLS'T !R:=FP-6BHOM5O]K^R>?%]I\OS?)WC?LSC=MZXSQFI:0!1110 444
M4 %%%% !1110 4444 %%%% %2P=G^T[F+8G<#)S@>E6ZI:=_R]?]?+_TJ[0P
M"BBB@ HK)G\5>';:>2"?7M+BFC8J\<EY&K*PZ@@G@UI6]Q#=V\=Q;31S0R+N
M22-@RL/4$<$4VF@)****0!1110 4444 %%16UU;WMLES:SQ3P2#*2Q.&5A[$
M<&I: "BBB@"I?.R?9MK%<SJ#@XR.>*MU2U'_ )=?^OA/ZU=H **;++'#$\LK
MK'&BEG=S@*!R23V%5UU.P>2UC6]MF>[0R6RB529E SN09^88YR.U%@+5%0O=
M6\=U%:O<1+<2@M'$S@.X'4@=2!D9K-3Q9X;DE6)/$&E-(S;51;V,DGT SUIV
M; V***R[OQ)H5A=/:WNM:=;7"8WQ372(ZY&1D$Y'!!_&A)O8#4HJM8ZC9:G
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M[GDD8*JCU)/ %/!# $$$'D$4 +1110 54OW9!;;6*YG0'!QD>E6ZI:CTM?\
MKY3^=" NT444 %%%% !16,/%WAHMM'B+22Q.,?;8\Y_[ZK4^U6_VO[)Y\7VG
MR_-\G>-^S.-VWKC/&:;30$M%%%( HHHH **KWE]::=;-<WUU!:P*0#+/($4$
M].3Q5=]=TE-,_M+^T;5[(DA9XY0ZL?0$9R>#P.:=F!H44R*6.>%)H9$DBD4,
MCHP*LIY!!'44^D 4444 5+%V=KK<Q;;.P&3G P.*MU2T_P"]>?\ 7RW\A5VF
MP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,!D'@D$=O2JB[23 YWQ%!JOBBTM-.BT.[L,7D4[7EU+!B!4;<641R,Q;C &
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M;_&KM%%P*6-3_P">EI_WPW^-&-3_ .>EI_WPW^-7:*+@4L:G_P ]+3_OAO\
M&C&I_P#/2T_[X;_&KM%%P*6-3_YZ6G_?#?XT8U/_ )Z6G_?#?XU=HHN!2QJ?
M_/2T_P"^&_QJ+[-J7VPW'FVF3'LQL;USZUI447 I8U/_ )Z6G_?#?XT8U/\
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M-3_YZ6G_ 'PW^-7:*+@4L:G_ ,]+3_OAO\:,:G_STM/^^&_QJ[11<"EC4_\
MGI:?]\-_C1C4_P#GI:?]\-_C5VBBX&;/;:E/Y69;0>7('&$;G'XU+C4_^>EI
M_P!\-_C5VBBX%+&I_P#/2T_[X;_&C&I_\]+3_OAO\:NT47 I8U/_ )Z6G_?#
M?XT8U/\ YZ6G_?#?XU=HHN!2QJ?_ #TM/^^&_P :,:G_ ,]+3_OAO\:NT47
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS7J.EV*:9I-G81XV6T*0C'HH _I7/^#/#-[X=T74K*[EMWDNKV:X0PL2 K@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\
M/S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HH
MT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _
M,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EF
MC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$
MU=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-
M_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_
M  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+
M_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\
M"6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\
MQ-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G
M_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT
MI?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#
M2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?
M\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=
MHHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S
M)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_P
MEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2_
M_$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9H
MW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\
M31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_
MX#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?
M\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@
M-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\
M/S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HH
MT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _
M,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EF
MC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$
MU=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-
M_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_
M  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G_@-+
M_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT I?\
M"6:-_P _,G_@-+_\31_PEFC?\_,G_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\
MQ-'_  EFC?\ /S)_X#2__$U=HHT I?\ "6:-_P _,G_@-+_\31_PEFC?\_,G
M_@-+_P#$U=HHT I?\)9HW_/S)_X#2_\ Q-'_  EFC?\ /S)_X#2__$U=HHT
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6H?]4*?3(?\
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MC-YUU-YF^3:JYQ(RCA0!T KI:X[X5_\ )-])_P"VW_HYZ[&L*BM)E(****D
MHHHH BN;B*TM9KF9ML4*-([>B@9)KD-+;Q1XGT]-7CUA=(M[C+VMK':I*?+_
M (2[-U)'.!CK73:U9-J6A:A8(<-<VTD()[%E(_K7/>#O$6G+X6L[*]NX+.\T
MZ%;:Y@N)!&\;1C;D@GH<9S5Q^&Z$4-;\1^(;#X=:M>SQ&QU>PF6$3B(%)AYJ
M+YB!@1A@35J^TWQGI=E+?6WB=-1D@4R?9+BPCC64#DC<F"#63XRU]?$7PP\0
M74%L\=G'/'%;SL>+A1,F7 P,#/%=1K/C+0M,TFYN1JEG-(J'RXHIE=I'QPH
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M.CHKG/\ A-M)]+C_ +]__7H_X3;2?2X_[]__ %Z/JM;^5A]>PW\Z.CHKG/\
MA-M)]+C_ +]__7H_X3;2?2X_[]__ %Z/JM;^5A]>PW\Z.CKD/$?BQK69[+3B
MOF+Q),1G:?0>]37?C:P-G,+;S_/*$1DH  W8]:X DL2222>237;@\&VW*JMC
MS<QS)**A0EONT2SW=S=.7GN)96/=W)J>RU:_L) UM=2*!_#NRI^H/%4J*]5P
MBU9K0^?52:ES)ZGIOA[Q#'K,)CD CNT&70=&'J*W*\BTN^;3=3@NE)PC#<!W
M7N/RKN?^$WTG^[<_]\#_ !KQL5@I1G^[5TSZ7 YG"=.U>5I+\3I**YO_ (3?
M2?[MS_WP/\:/^$WTG^[<_P#? _QKF^JUOY6=OU_#?SHZ2BN;_P"$WTG^[<_]
M\#_&C_A-])_NW/\ WP/\:/JM;^5A]?PW\Z.DHKFO^$XTK^Y<_P#? _QH_P"$
MXTK^Y<_]\#_&G]5K?RL/K^&_G1TM%<U_PG&E?W+G_O@?XT?\)QI7]RY_[X'^
M-'U6M_*P^OX;^='2T5S7_"<:5_<N?^^!_C1_PG&E?W+G_O@?XT?5:W\K#Z_A
MOYT=+5/4]2@TJR:YN#P.%4=6/H*QO^$XTK^Y<_\ ? _QKF/$VN)K-U%Y'F"W
MC7A7&"6/4_RK6A@JDII35D<^*S.E"DW2DG+H0ZEXDU'4I&W3M#$>D41(&/?U
MK+6:5'WI(ZMZAB#3**]R-.,%:*T/EIU:E27--W9TVB^+[JSE6*^=KBW)P6;E
MU]\]_P :]!CD2:)9(V#(X#*PZ$5XQ76^'O%=OINF_9;Q9G*,?+* '"GMR?7-
M>=C,&I+GIK4]C+<Q<7[.M+3HV=Y17,_\)SI7_/*Z_P"^%_\ BJ/^$YTK_GE=
M?]\+_P#%5Y_U6M_*SV/K^&_G1TU%<S_PG.E?\\KK_OA?_BJ/^$YTK_GE=?\
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M+ :]%9'V_6_^@)%_X&C_ .)H^WZW_P! 2+_P-'_Q-%@->BLC[?K?_0$B_P#
MT?\ Q-'V_6_^@)%_X&C_ .)HL!KT5D?;];_Z D7_ (&C_P")H^WZW_T!(O\
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M - 2+_P-'_Q-'V_6_P#H"1?^!H_^)HL!KT5D?;];_P"@)%_X&C_XFC[?K?\
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M $!(O_ T?_$T?;];_P"@)%_X&C_XFBP&O161]OUO_H"1?^!H_P#B:/M^M_\
M0$B_\#1_\318#7HK(^WZW_T!(O\ P-'_ ,31]OUO_H"1?^!H_P#B:+ :]%9'
MV_6_^@)%_P"!H_\ B:/M^M_] 2+_ ,#1_P#$T6 UZ*R/M^M_] 2+_P #1_\
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M_0$B_P# T?\ Q-%@->BLC[?K?_0$B_\  T?_ !-'V_6_^@)%_P"!H_\ B:+
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M1110 4444 %%%% %1_OM]33:<_WV^IIM, HHHH **** "BBB@ HHHH ****
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M.GHKF/[7\2_] 1/^^O\ Z]']K^)?^@(G_?7_ ->L_JTNZ^]&WUVGVE_X"_\
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M -E1]6E_,OO0?78?RR_\!9T]8OB37!HUD/+ :YER(P>WJQJE_:?BK_H#P?\
M?7_V5<EXAN[Z[U0_VA$L,\:!?+7H!U]3ZUOAL)S5%S-->IR8W,.2B^1--]TT
M9T]Q-=3--/(TDC')9CDU'117N)6T1\NVV[LO:7JUUI-R)K=SMS\\9/RN/<?U
MKU'3[Z+4K&*[A^Y(,X/53W!KR"NE\,W^LPVT\&F6D5Q&KAFWG&TD?4>E<&.P
MZG'G6C1ZN5XR5*?LY7<7T6NIZ)17,?VCXL_Z!%M_WT/_ (NC^T?%G_0(MO\
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MC'%1?VAK/_0#7_P,7_"ME_OM]33:JX&1_:&L_P#0#7_P,7_"C^T-9_Z :_\
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M3CDN'8J@VL%D(ZA7(VL?H36[0U;=#,C^T-9_Z :_^!B_X4?VAK/_ $ U_P#
MQ?\ "M>BE<#(_M#6?^@&O_@8O^%']H:S_P! -?\ P,7_  K7HHN!D?VAK/\
MT U_\#%_PH_M#6?^@&O_ (&+_A6O11<#(_M#6?\ H!K_ .!B_P"%']H:S_T
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MB_X5KT47 R/[0UG_ * :_P#@8O\ A1_:&L_] -?_  ,7_"M>BBX&1_:&L_\
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M@KGK-%>0W.A-\,?%6B3Z1J%U)INHSK;75O.P)8YQG@ ' ;(XR"#S@UK>!O\
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M;<W $G_/-1N;\AT_&LU?&^DL^TK<J/[Q08_0UHZ-X4LM.C$MRBW5XW+RRC<
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MH01TZ&MBN1\<$K=>%GC \[^VX5'/.PJ^_P#2NNK%K1,H****D HHHH ****
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M9&#TKS?2I]7L+S4[/2;2*XABN6!#G&WD@8Y'8?I7>:KJ4.E:=+=S$80?*O\
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M>>1G8]S@[?Z?K72UR/@R\-K]IT.Z(6XMY"4!_B4]<?S^AKKJG%)^VDWU_(K
MM/#Q2Z*S]5N%<UXYMDE\./,?OP2*ZGOR=O\ 7]*Z6N1\9WANOLVAVI#7%Q("
MX'\*CIG^?T%&%3]M%KI^08YI8>2?567J]C9L)FN-.MIV^])$CGZD U8ID,2P
M01PI]V-0H^@&*?6,K-NQTQ344GN%%%%(H**** +4/^J%/ID/^J%/I %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4?[[?4T
MVLVYOM4CNI4BT8RQAR%?[2@W#UP>E1?VCK'_ $ C_P"!:55@->BLC^T=8_Z
M1_\  M*/[1UC_H!'_P "THL!KT5D?VCK'_0"/_@6E']HZQ_T C_X%I18#7HK
M(_M'6/\ H!'_ ,"TH_M'6/\ H!'_ ,"THL!KT5D?VCK'_0"/_@6E']HZQ_T
MC_X%I18#7HK(_M'6/^@$?_ M*/[1UC_H!'_P+2BP&O161_:.L?\ 0"/_ (%I
M1_:.L?\ 0"/_ (%I18#7HK(_M'6/^@$?_ M*/[1UC_H!'_P+2BP&L0&4JP!!
M&"#WK#\+Z;=:+9W&E2Q_Z);3M]BEW [H6.X*>X*DE>?05-_:.L?] (_^!:4?
MVCK'_0"/_@6E/6U@+EOIMI:W]Y?0P[;F\*&X?<3O*+M7@G P/3%1:MHFFZY
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M 1_\"TH=V!KT5D?VCK'_ $ C_P"!:4?VCK'_ $ C_P"!:4K :]%9']HZQ_T
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M:.L?] (_^!:4?VCK'_0"/_@6E%@->BLC^T=8_P"@$?\ P+2C^T=8_P"@$?\
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MBLC^T=8_Z 1_\"TH_M'6/^@$?_ M*+ :]%9']HZQ_P! (_\ @6E']HZQ_P!
M(_\ @6E%@.AA_P!4*?5:PDFELHWN(/(E.=T>\-MY/<59J0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J/]]OJ:;3G^^WU-
M-I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM1*I$B8'S< YQZ9.,U?,G+?J(K>(=.^'EAH-W<Z/=V4>II&3:-8WQ>7S?X0
M'/>M=WOO$FNZ3X>U*6:&&#2X[W4HXV,;3RG"^62,$*#DD"NQ@T32;:59;?2[
M**1>CQVZ*1^(%8.NV=]I?BNU\36%E)>Q&V-G>V\('F;-VY74?Q$'@CT_2%.^
M@["CP9'I.JV%]X:*6"I*%O+<NWESPGK\O/SCC!XKK*Y)M=UG6]1L;;1]-O["
MV6827EU?VWECRQU15;DD^O:NMJ)7Z@@HHHJ!A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '+>,=:>RMTL;=RLTRY=AU5.G'UY_*O/ZW?&#
M,WB2<-T54"_3:#_,FL*OHL'34**MUU/C<QK2JXB5]D[+Y!3X9I+>9)H7*2(<
MJRGD&F45T[G$FT[H]7T+5!JVE1W)P)!\D@'9A_D'\:TJ\Y\,:U)I<5PBV4UR
MKLI_=_PGGV^GY5O_ /"7R_\ 0%O/R/\ A7@U\'-5&H+3Y'UF%S&E*C%U'[W7
M1G3T5S'_  E\O_0%O/R/^%'_  E\O_0%O/R/^%9?5:O;\4;_ %_#_P WX/\
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M] *\_7_XFCZK5[?BO\P^OX?O^#_R.GHKF/\ A*[S_H 7GZ__ !-'_"5WG_0
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M;2K,O]XP(3]=HJU6$E9V.J+YHIA1112*"BBB@"U#_JA3Z9#_ *H4^D 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %1_OM]3
M3:<_WV^IIM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%%% !1110!:A_U0I],A_P!4*?2 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@# N;_4X[J5(M%DEC5R%<7$8W#UP3Q47]I:
MM_T 9/\ P*C_ ,:V7^^WU--JK@9']I:M_P! &3_P*C_QH_M+5O\ H R?^!4?
M^-:]%%P,C^TM6_Z ,G_@5'_C1_:6K?\ 0!D_\"H_\:UZ*+@9']I:M_T 9/\
MP*C_ ,:/[2U;_H R?^!4?^-:]%%P,C^TM6_Z ,G_ (%1_P"-']I:M_T 9/\
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M_P"@#)_X%1_XT?VEJW_0!D_\"H_\:UZ*+@9']I:M_P! &3_P*C_QH_M+5O\
MH R?^!4?^-:]%%P,C^TM6_Z ,G_@5'_C1_:6K?\ 0!D_\"H_\:UZ*+@9']I:
MM_T 9/\ P*C_ ,:/[2U;_H R?^!4?^-:]%%P,C^TM6_Z ,G_ (%1_P"-']I:
MM_T 9/\ P*C_ ,:UZ*+@9']I:M_T 9/_  *C_P :/[2U;_H R?\ @5'_ (UK
MT47 R/[2U;_H R?^!4?^-']I:M_T 9/_  *C_P :UZ*+@9']I:M_T 9/_ J/
M_&C^TM6_Z ,G_@5'_C6O11<#(_M+5O\ H R?^!4?^-']I:M_T 9/_ J/_&M>
MBBX&1_:6K?\ 0!D_\"H_\:/[2U;_ * ,G_@5'_C6O11<#(_M+5O^@#)_X%1_
MXT?VEJW_ $ 9/_ J/_&M>BBX&1_:6K?] &3_ ,"H_P#&C^TM6_Z ,G_@5'_C
M6O11<#(_M+5O^@#)_P"!4?\ C1_:6K?] &3_ ,"H_P#&M>BBX&1_:6K?] &3
M_P "H_\ &C^TM6_Z ,G_ (%1_P"-:]%%P,C^TM6_Z ,G_@5'_C1_:6K?] &3
M_P "H_\ &M>BBX&1_:6K?] &3_P*C_QH_M+5O^@#)_X%1_XUKT47 R/[2U;_
M * ,G_@5'_C1_:6K?] &3_P*C_QK7HHN!D?VEJW_ $ 9/_ J/_&C^TM6_P"@
M#)_X%1_XUKT47 R/[2U;_H R?^!4?^-']I:M_P! &3_P*C_QK7HHN!D?VEJW
M_0!D_P# J/\ QH_M+5O^@#)_X%1_XUKT47 R/[2U;_H R?\ @5'_ (T?VEJW
M_0!D_P# J/\ QK7HHN!D?VEJW_0!D_\  J/_ !H_M+5O^@#)_P"!4?\ C6O1
M1<#(_M+5O^@#)_X%1_XT?VEJW_0!D_\  J/_ !K7HHN!D?VEJW_0!D_\"H_\
M:/[2U;_H R?^!4?^-:]%%P,C^TM6_P"@#)_X%1_XT?VEJW_0!D_\"H_\:UZ*
M+@9']I:M_P! &3_P*C_QH_M+5O\ H R?^!4?^-:]%%P,C^TM6_Z ,G_@5'_C
M1_:6K?\ 0!D_\"H_\:UZ*+@9']I:M_T 9/\ P*C_ ,:/[2U;_H R?^!4?^-:
M]%%P,C^TM6_Z ,G_ (%1_P"-']I:M_T 9/\ P*C_ ,:UZ*+@9']I:M_T 9/_
M  *C_P :/[2U;_H R?\ @5'_ (UKT47 DL))IK*.2>W-O*<YC+!MO)[CCWJS
M3(?]4*?4@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!4?[[?4TVG/\ ?;ZFL?Q-JXT'PUJ&IG&ZWA)3/0N>%'_?1%-*[L!K
M45XGX!CN_"7BG2!?.WD>(K/>2W:3<2H^N,?]]UI^.M$MO$?Q:T/2;QY4@GL6
MW-"0&&WS6&"01U [5LZ5I6OH*YZS17D-SH3?#'Q5HD^D:A=2:;J,ZVUU;SL"
M6.<9X !P&R.,@@\X-:W@;_DI?C3_ *[+_P"A-2=/2Z>@7/2**X7XL:A=Z?X-
M46DSPBYND@GD0X*QD,3SVR0!]#CO6'8Q6?@[XIZ9I.A3-_9NI6@,]OYQD7=A
MMKC)ZG:#]">QI1IWC<+GJU%>/^,/"6F^'/#E_J^KZM->^(9YU>SO-S1NK KA
M57<1@ 'GL,8Q@57\67TNJ+X'T_5K.[OI&MQ=WEM;(6FF&T=%!')"L3R._3%4
MJ2>S"Y[117&_#YO"SV=ZWANRFLG$@2[MKAG\Q&&0-P9FQWZ']1795E)6=AA1
M112 **** "N4;_DK47_8"?\ ]'K75UB'1[@^.4UO?%]F736M-F3OWF4/G&,8
MP/7\*J+M<""VU.\D^(%_I;39LXK"*9(]HX<L03G&>@]:YG5_%&N6^E^(Y;6Z
M7S[35HK:VW1IA4;9\IXYSD\GGGK70:GHNLQ>*?[=T.6Q9Y;46T\%Z7"X#%@R
ME03GG&*QO^$(UF32-5M[B]LY;J]U.*]\P;E7"E2PQ@XZ$ <]N:TCR[OR$2WD
MOBS3_$FEZ3_;T,XU6.7,KV:#[,8PK,4 ^]D' #9]3FJTGBO6M&3Q!ID]Q'J.
MH65S;06D\D0C#&<97>%P/EYZ=:ZK4M'N+SQ5H>J1O$(+!;D2JQ.X^8JA=O&.
MQSDBL34/!%QJ6I^);B2ZCA&HO:2V<D>2\4D*XRP( Z^A/'I0I1>_]:_Y .N+
MCQ%X:O\ 29-0U=-4M+Z[2SF1K9(C$[_=9"O49['-'AJ?Q!K.K:K<W&L^7866
MJSVT=JMM&?,1&X!;&1C( QSP<YJ4Z'XBUG4--;7KC3DM+"=;D1V6\M/*OW2V
MX#: ><#-:GAO1[C1TU1;AXF-WJ4]W'Y9)PCG(!R!SZ_SI-JWF!7\;:M?:/HD
M=Q9,8@URD=Q<B'S3;1'.Z39WQ@#\:P[6]OM7T+64M?%MIJ5M]DW)<1PHMQ$W
M)963&W:5&,D9Y/IFNH\0:?J5_:P-I-_]DN[>99EW$^7*!G*.!R5.?TK$L_"F
MH7&L7FK:G_9UK<363V:1:>K%2&Y+NS %C[8HBX\H'.Z9<Z]8>&/!UEI^KE6U
M)]I9[>-O*C\L':!CG;@D$\D]<BKVL>)KK3-;B\/W7BB.Q\B#SKC49K5#),S,
M=J*F-HP,9.*O:;X4UJ&'PU%>26&-&F;)AD<^9%Y>T'E?O9SD=,=ZTM4T/58O
M$?\ ;N@S6@N)8!;W-O=[A'*H.58%<D,.G3I5.4;@<Y;^-]2F\.Z\ME<0ZG=:
M9)$$OX(>'BD_C,8ZLH#9 XX].NIX7UFYO[]_LOBBSUVU\AF:)XE@N$<8QA0!
M\IZ'(XXJP/#WB&?2+\W.O-%JUS.DT9MV?R(-I&(U!YVD=>F<\Y[QVWAG5K[Q
M):ZQK']FVLEK%*B_V:'WREUVDN[ '@9('//>DW&S P]$\3ZIJ-S;^9XHM(-3
M,X6XT:\M1"J#=@HK8W%L=.3DUZ;7 7?A#Q%JNEQ:+JEWIEQ:1LO_ !,65VO"
M@;/&1@-VSNKOZFI;H""BBBLQA1110 4444 %%%% !1110!Y/X0_XE7B:'4,[
M8-2OKS3Y3V\P2&2,_4_,*-1)U'XAZ9K)YC.K_8;?O\D*G<1[%V?\JZ'_ (0[
M45\*7EA'<V\>H_VDU_:3!F*(WF;ESQGID'@]>]3-X/N8X?"D4$T)&D3>;<L[
M',C$?,5XY)8D\XZUT<\;W)L6_#VK7M]I^ORW,^][34KJ"$[%&Q$/RC@<X]3S
M7-Z??7FL7_@*\NK@F\N+2^+3!%'S;%&< 8_2M8>'?$EA-K%KI=YIPT_4[B2X
M,LP?SH&D^^% X/MD_P"%+I'A*_T]_"9EFMF_L>"XCN-C,=QD  V?+R..<XJ;
MQ5W_ %L,YC3[G6-"T'7;R#5W=QK[6[!H(_F8S*'?IU8'IT';%=(]QXCU;QOK
M6E66L+8V%G' X<6Z2.K.A.!N'0D$G.>@QC-5[GP=K<MIJU@DVGFUNM4_M&&0
MNX<9D5RK#:1P!QCK[4V)-<_X6/XFET62Q)6*T66&\W!6RC88,N2",'C'.ZJ;
M3N]/ZL(I7NKWVHV.FVNIF-K_ $[Q1;6LLD:[5E ;*N!VR#TJ34?&9N?$6IV9
M\46^@V]C)Y$:FV65YW ^9CN& H/&!R<=:TQX+O5L+/?=P37YUJ+5+V4@JK;3
MRJ#GH,  X_"K+Z'K^DZOJ-UX>FT][?4'\Z6"^WCRI<8+*5!R#@9!_.E> ]2Y
MX+\02>(] ^US&)IXIGMY'A^Y(5/WESV((-9^K:=K6E^+)?$6DV$&J+/;+!+;
M/*(I8]ISE&/&#GD5O:#IUWIFDQP7U_+?799GEGD).6)SA0>BCH!6/J.@ZW:>
M(;G6O#MY:"2\1%NK6^5O+<H,*P*\@XXJ$US.P%*R\1Z0+_5]3N-'NM.UVUL&
MEG@GRK30IELK@[6YXW8S^%5IKWQ;:>%E\52:M;R8B6ZDTS[,HB$1P=H?[VX*
M>N:T[7PMJ&I:A=ZAXFN+626:R>Q2WL581QQO]X[FY+'W'%4G\,^*KC04\-W&
MHZ=_98586NT5_M#PC^':?E!P,9S5WC<"A?:K-;ZSXNU6Q<Q3+H]O/"Q4$J=K
M$<'(K5?5-:UG6++1]/U!;'9IT=Y=W8@61V9N JJWRCN2<4NH^#KNXF\0?99+
M9(=0TZ*SME=VRA0$?-QTY'3-3S^'=6L]0L=5T:>S%['9+9W4-SN$4RKR"&49
M!!SVY%%X_P!>@%;P:E['XN\6IJ$L<MTLMJK21KM#@1?*V.Q(P2/7-:7BD?;K
M_0M'ZK<W@GE'8QPC>0?JVP?C3/"VAZOIFJZUJ&KW-K/-J,D3C[/N 7:I&W!'
M0< <G(':M!=*G?Q:^K3-&8([,6UN@)+ EBSL>,#.$ P>QJ&US7_K8#7HHHK,
M84444 %%%% !1110 4444 %%%% !1110 5FZAKVG:8VRXN!YG_/-!N;].GXU
MG^*]=?2[5;>V;%S,#\W]Q?7ZUYRS%F+,26)R2>IKT,+@O:KGGHCQ\?FGL)>S
MIJ[_ "/1%\;Z4S[2MRH_O%!C]#6U9:C9ZC%YEI.DJCKCJ/J.HKR"I[.\GL+I
M+BVD*2+W'?V/J*ZJF6P:]QV9PT<ZJJ7[U)H]BHJCI&I)JVFQ72  GAU_NL.H
MJ]7C2BXMQ>Y])"<9Q4H[,****104444 %%%% !1110 4444 %,FFBMXFEFD6
M.->2S' %.=UC1G<A549)/85R=E:2^,K^2ZNF>/2H'VQ1*<>8?\]3[XK6E34K
MRD[)'/7KNG:,%>3V7ZOR+D_C32(7*JTTV.\:<?J14]EXKTF]D$8G,+G@"9=N
M?QZ?K6]:V%I91B.UMHHE']Q0/U[U6U+0=.U2)EN+9-YZ2(,./QJ^;#O2S];_
M *&7+BU[W-%^5G^=R7J,BBN7TN:ZT'6?[#O9#) XS:RGT[#_ .MV/UKJ*SJT
M_9NVZ>QO0K*K&]K-:-=F%%%%9FP4444 %%%% !1110 4444 %%%87B/59[1(
M;*Q&Z^NCM3'51TS_ )_I5TX.I)11G6JQI0<Y="WJ&NZ=IAVW-P!)_P \U&YO
MR'3\:S5\;Z2S[2MRH_O%!C]#6CHWA2RTZ,2W*+=7C<O+*-P!]@?Y]:W'MX98
M_+DBC=/[K*"/RK5NA'2S?GL<R6+FN:ZCY6O][NC-LM0M-1B\RTG25>^.H^HZ
MBK-<YKGAPZ;NU?1,P30_-)"OW67O@?TK6TG48]5TZ*[08+##+_=8=14U*<5'
MG@[K\471KR<W2JJTM]-FO(NT445B=04444 %%%% !1110 4444 %%%% ",RH
MI9V"J!DDG %85UXPTBV<HLLDY'7RDR/S. :HR+/XNUB6SCE:+2K4_O&3_EHW
M^>GYUUECI-AIT82UM8X\?Q;<L?J>IKI<*=)?O-7V_P SA56M7;]C9175ZW]$
M8-KXPTBY<(TLD!/3S4P/S&0*W5974,C!E(R"#D&EOM)L-1B*75K')G^+;AA]
M#U%<G&L_A'6(K.25I-*NC^[9_P#EFW^>OYT*%.JOW>C[?Y ZM:@U[:SB^JTM
MZHZRBBBN8[@HHHH **** +4/^J%/ID/^J%/I %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!4?[[?4UY[\3K/4]=32?#^GVM
MP8KJY#W-RD+-'"HX&XCCN3C_ &17H3_?;ZFFU<)<KN!XSXD^&_B+3M*BU&W\
M17^LSV#HUO:F%RR<CE!O;I@< =![5;\27FM1>./#OB>U\-ZC>>7IH,MND$BE
M'82 H3M."-WI_/->MT5I[9]5<5CRL#Q'\0?$VD37^@3:-I6ES">07&=TKY!
M&Y5)^Z!P.,G)Y J?1/#<^H>*_&]MJ-K>6]CJ!")/Y93>-QY1F&#^M>FT4O:O
M9(+'G%YX#3PIX3UB/P]:'5I+P1^?::AB0.B;ON!-AW#=D<YXXYQ69X7\-)/X
MPL]7LO#5WHNF:= S/'=*PEGG*D' 8EB!GCG''OBO6J*/:RLPL>'12:CK'C-]
M<\5>&?$5S;0'_0[*#3V9%&> V[' ZD?Q'KP,'O\ 5/$^OV5SIM_;>'KJYT2Y
MC_?PI;DWL+\\%-V,=.WKR.*[*BB51/H%C@_ 6DZA_;>O>)+ZSEL%U.;]Q:S#
M$@4$_,P['GI]>V">\HHJ)2YG<84445(!1110!3U:ZDL-&OKR(*9(+>250PX)
M521GVXK+TK6+V_309I)M-C2^L!<3P%F$S.44_NUS]T9.<Y[5=\1_\BQJW_7E
M-_Z :XC36==4\#M$,R#0'*CU/E)BM(Q30CNY=;TF&[>UEU2RCN44LT+7"!U
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M7X?Y',?VGXJ_Z \'_?7_ -E1_:?BK_H#P?\ ?7_V5=/11[>/\B_'_,/JL_\
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MV2P@^S6Q\QCY<> -O7G@#DY-,^VZQ_T+T_\ X$P__%4?;=8_Z%Z?_P "8?\
MXJC4#@M1\*:A?QWD#^$+-=0N2ZMJ$5[MMLMD>:(2Q(;!ST)SWKLI_!NBWMO8
M)>VIFELH%@CF61XWV@8P2I!(]CZU;^VZQ_T+T_\ X$P__%4?;=8_Z%Z?_P "
M8?\ XJK<Y,5BL/!OA];.\LTTU$MKU$2XB21U5PGW> >#[C!/?-:5]IMIJ1M3
M=P^8;6=;F'YB-LB@@'@\]3P>*K?;=8_Z%Z?_ ,"8?_BJ/MNL?]"]/_X$P_\
MQ53=]QE?4/!^@:I?->WFFQR3OCS&#LHDQTWJ" WX@TK^$="DT>VTI]/4V=J2
M8%\Q]T9)R2KYW#KZU/\ ;=8_Z%Z?_P "8?\ XJC[;K'_ $+T_P#X$P__ !5%
MY=Q$FDZ'INAP/#IUJL"R-N<[BS.?5F8DG\36A67]MUC_ *%Z?_P)A_\ BJ/M
MNL?]"]/_ .!,/_Q5)W>XS4HK+^VZQ_T+T_\ X$P__%4?;=8_Z%Z?_P "8?\
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M?*BW#$DB0("%&"<#@GH.>]5_MNL?]"]/_P"!,/\ \51]MUC_ *%Z?_P)A_\
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M#_\ %4?;=8_Z%Z?_ ,"8?_BJ+ :E%9?VW6/^A>G_ / F'_XJC[;K'_0O3_\
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M;K'_ $+T_P#X$P__ !5<=CTC4HK+^VZQ_P!"]/\ ^!,/_P 51]MUC_H7I_\
MP)A_^*HL!J45E_;=8_Z%Z?\ \"8?_BJ/MNL?]"]/_P"!,/\ \518#4HK+^VZ
MQ_T+T_\ X$P__%4?;=8_Z%Z?_P "8?\ XJBP&I167]MUC_H7I_\ P)A_^*H^
MVZQ_T+T__@3#_P#%46 U**R_MNL?]"]/_P"!,/\ \51]MUC_ *%Z?_P)A_\
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MJ45E_;=8_P"A>G_\"8?_ (JC[;K'_0O3_P#@3#_\518#4HK+^VZQ_P!"]/\
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M*_3./Y&KFBZ"FF,]Q/*;B]E^_,W\A4GVW6/^A>G_ / F'_XJC[;K'_0O3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\*VAGT>329XAY4MJUL8%##J44@?*<YX]2.U;/V^R_P"?N#_OX/\ &C[?9?\
M/W!_W\'^-$ZCDK,$CP[3-#TB"?5/^$D\"^)-0NGOY7BFM;679Y1(P.'7/.X]
M.XYKV'PLUH?#EHMCIE[IMK&"D=K>H4E0 D<@DGGJ.>AK0^WV7_/W!_W\'^-'
MV^R_Y^X/^_@_QHG4<P2/*O!?B#4/"?AZYT^X\(^)+BY^TRRH8;!O+;/0%CR.
MG7!_&NR^'F@7OA[PL(-2"I>W$\ES-&I!$98_=!!.> /SKH_M]E_S]P?]_!_C
M1]OLO^?N#_OX/\:)3YKZ;A8L5Y;:>!;'Q!\1/%-QK^CSRVN^$VDKF2)'^7#;
M64@-T'KBO2OM]E_S]P?]_!_C1]OLO^?N#_OX/\:49.-[ 0Z1HVG:%IZ6.EVD
M=M;(<A$SR?4D\D^YYKS)/AY;^)_$OC-]5LKFWD>=/[/O&5U )#99>BN,A<]?
MPZUZG]OLO^?N#_OX/\:/M]E_S]P?]_!_C1&<HW:"QR/PS%Y9:!+HNH:,^GW6
MGRF-I%MRD=R.@D5L88\8)YS@'O5!UU3P3XUUC4ET:]U72=8*2%K"/S989%!X
M*9Z')YZ=._%=[]OLO^?N#_OX/\:/M]E_S]P?]_!_C3Y]6[;A8XGPU9:GK?CJ
MZ\7W^G3:;:"T^QV=O<C;,R[LEW7^'H>#ZCJ.3)XKL-3TSQGI?B_3K";488+=
MK2]M8,&41DDAD'\1!8\>P]21V7V^R_Y^X/\ OX/\:/M]E_S]P?\ ?P?XT<[O
M>P6/,=+BU_5O'UI?Z<GBVUTI9WFOH]9F\J(;MQ5(X\\J,8Q\V,KG'4[GQ5TN
MYU?P[I]K;V<]W_Q,X3*D,;,0F'!)V\@<]:[+[?9?\_<'_?P?XT?;[+_G[@_[
M^#_&CVCYD[;!8\PD\'Q>!/'EAJ^D:+)?Z1=?N98DA:>2R;C]XIY8#W_WAW%=
M'\3$U*]\-Q:-I=K<33:E<)!))%$66&/()9B.%'0<XXS76?;[+_G[@_[^#_&C
M[?9?\_<'_?P?XT>T;:;Z!8\JU?PGXE\,WV@:Y'J4NN#2Y4MA;6VG"-TMR,,!
ML)+#''/3/UKJ/BI97>I> +JWL;6>YG:2(K%#$SN1N!/R@9KK?M]E_P _<'_?
MP?XT?;[+_G[@_P"_@_QH]H[IOH%CR3_A$=4_X3V6(6EQ_8RQ-JB_NSM-PT(0
MC.,;M_..N*[7X8V=U8?#O2K6]MIK:X3SM\4R%'7,KD9!Y'!!_&NF^WV7_/W!
M_P!_!_C1]OLO^?N#_OX/\:)5')686/)O&ED]_J6L1ZWX+OKN\"DZ5J.CP.=R
M\[?.(8C<,*.03C. !C/I/A2WU2U\+:=!K4C2:BD($[,^]L]@6[D# )YR:T/M
M]E_S]P?]_!_C1]OLO^?N#_OX/\:)3;5K!8L457^WV7_/W!_W\'^-'V^R_P"?
MN#_OX/\ &LQEBBJ_V^R_Y^X/^_@_QH^WV7_/W!_W\'^- %BBJ_V^R_Y^X/\
MOX/\:/M]E_S]P?\ ?P?XT 6**K_;[+_G[@_[^#_&C[?9?\_<'_?P?XT 6**K
M_;[+_G[@_P"_@_QH^WV7_/W!_P!_!_C0!8HJO]OLO^?N#_OX/\:/M]E_S]P?
M]_!_C0!8HJO]OLO^?N#_ +^#_&C[?9?\_<'_ '\'^- %BBJ_V^R_Y^X/^_@_
MQH^WV7_/W!_W\'^- %BBJ_V^R_Y^X/\ OX/\:/M]E_S]P?\ ?P?XT 6**K_;
M[+_G[@_[^#_&C[?9?\_<'_?P?XT 6**K_;[+_G[@_P"_@_QH^WV7_/W!_P!_
M!_C0!8HJO]OLO^?N#_OX/\:/M]E_S]P?]_!_C0!8HJO]OLO^?N#_ +^#_&C[
M?9?\_<'_ '\'^- %BBJ_V^R_Y^X/^_@_QH^WV7_/W!_W\'^- %BBJ_V^R_Y^
MX/\ OX/\:/M]E_S]P?\ ?P?XT 6**K_;[+_G[@_[^#_&C[?9?\_<'_?P?XT
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MV^R_Y^X/^_@_QH^WV7_/W!_W\'^- %BBJ_V^R_Y^X/\ OX/\:/M]E_S]P?\
M?P?XT 6**K_;[+_G[@_[^#_&C[?9?\_<'_?P?XT 6**K_;[+_G[@_P"_@_QH
M^WV7_/W!_P!_!_C0!8HJO]OLO^?N#_OX/\:/M]E_S]P?]_!_C0!8HIL<B2H'
MC=70]&4Y!IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8\^CZ7-<222Z;9O(S$LS0*23ZDXJ/^P](_P"@58_^ Z?X5HO]
M]OJ:;3NP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\ X#I_A5^BB[ H?V'I'_0*
ML?\ P'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P# =/\ "C^P](_Z
M!5C_ . Z?X5?HHNP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\ X#I_A5^BB[ H
M?V'I'_0*L?\ P'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P# =/\
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MHHNP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\ X#I_A5^BB[ H?V'I'_0*L?\
MP'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P# =/\ "C^P](_Z!5C_
M . Z?X5?HHNP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\ X#I_A5^BB[ H?V'I
M'_0*L?\ P'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P# =/\ "C^P
M](_Z!5C_ . Z?X5?HHNP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\ X#I_A5^B
MB[ H?V'I'_0*L?\ P'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P#
M=/\ "C^P](_Z!5C_ . Z?X5?HHNP*']AZ1_T"K'_ ,!T_P */[#TC_H%6/\
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M?V'I'_0*L?\ P'3_  H_L/2/^@58_P#@.G^%7Z*+L"A_8>D?] JQ_P# =/\
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M]_!1]OL_^?N#_OX/\:.678/:1[EBBJW]H67_ #^6_P#W]7_&C^T++_G\M_\
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MD?G6M*ES2O/9:LPQ&(Y86IM.3=E\Q;?3=<\2*+B\NFL+-^4ACSN9??\ ^O\
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MC^I8?^1?<8/_  AVC?\ /"3_ +^&C_A#M&_YX2?]_#6]11]9K?S/[P^I8?\
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MN45E]8J_S/[SH^IX?^1?<C#_ .$0T3_GT/\ W]?_ !H_X1#1/^?0_P#?U_\
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M+[3]3.LZ-\TK?Z^W[2#OQ5FU\=::Z[+U)K.9>'5D+ '\.?TK6K2=5NI3UO\
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MQ6_VW&/M'EC?TQ][KTXIQQ:5]-+67K;<4L&W;76]WZ-WM^1<HHHKB.X****
M,^6Y@25U:>,,"<@N!BF?:[;_ )^(O^^Q3Y="TB>5Y9=+LI)'.YG:!26/J3BF
M?\([HG_0'L/_  &3_"GH ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\
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M ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\ P&3_  H_X1W1/^@/8?\
M@,G^%&@!]KMO^?B+_OL4?:[;_GXB_P"^Q1_PCNB?] >P_P# 9/\ "C_A'=$_
MZ ]A_P" R?X4: 'VNV_Y^(O^^Q1]KMO^?B+_ +[%'_".Z)_T![#_ ,!D_P *
M/^$=T3_H#V'_ (#)_A1H ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\
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M ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\ P&3_  H_X1W1/^@/8?\
M@,G^%&@!]KMO^?B+_OL4?:[;_GXB_P"^Q1_PCNB?] >P_P# 9/\ "C_A'=$_
MZ ]A_P" R?X4: 'VNV_Y^(O^^Q1]KMO^?B+_ +[%'_".Z)_T![#_ ,!D_P *
M/^$=T3_H#V'_ (#)_A1H ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\
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M ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\ P&3_  H_X1W1/^@/8?\
M@,G^%&@!]KMO^?B+_OL4?:[;_GXB_P"^Q1_PCNB?] >P_P# 9/\ "C_A'=$_
MZ ]A_P" R?X4: 'VNV_Y^(O^^Q1]KMO^?B+_ +[%'_".Z)_T![#_ ,!D_P *
M/^$=T3_H#V'_ (#)_A1H ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\
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M ?:[;_GXB_[[%'VNV_Y^(O\ OL4?\([HG_0'L/\ P&3_  H_X1W1/^@/8?\
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M1?\ ?8H^UVW_ #\1?]]BC_A'=$_Z ]A_X#)_A1_PCNB?] >P_P# 9/\ "C0
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M_0/M=M_S\1?]]BC[7;?\_$7_ 'V*/^$=T3_H#V'_ (#)_A1_PCNB?] >P_\
M 9/\*ST-0^UVW_/Q%_WV*/M=M_S\1?\ ?8H_X1W1/^@/8?\ @,G^%'_".Z)_
MT![#_P !D_PHT /M=M_S\1?]]BC[7;?\_$7_ 'V*/^$=T3_H#V'_ (#)_A1_
MPCNB?] >P_\  9/\*- #[7;?\_$7_?8H^UVW_/Q%_P!]BC_A'=$_Z ]A_P"
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M?B+_ +[%'_".Z)_T![#_ ,!D_P */^$=T3_H#V'_ (#)_A2T&'VNV_Y^(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img104831930_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img104831930_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )B!)T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3^\+995RK="2.W3OUHYG&=EKH'0\AHKTWXE>'M#7P_I'BK0;86<&H$+);@8
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MS/BKXA3^+O#=AIU_8@7MK)O:\$H_><$'Y HQG(Z'M4'C'QM_PENGZ-:_V?\
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M_!?C:_\ !>H33VL4<\%PH6>"3@/C."#V(R?S/%'+4?,]KV#0ZI?B9HMG<[=
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M6$A(##DEL?QGL.U<[12:3W ****8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
M[3_PH'_J9O\ R0_^V4?\*!_ZF;_R0_\ ME8_6*?<=F>+45[3_P *!_ZF;_R0
M_P#ME'_"@?\ J9O_ "0_^V4?6*?<+,\6HKVG_A0/_4S?^2'_ -LH_P"% _\
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M\6HKVG_A0/\ U,W_ )(?_;*/^% _]3-_Y(?_ &RCZQ3[A9GBU%>T_P#"@?\
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M (4#_P!3-_Y(?_;*/K%/N%F>+45[3_PH'_J9O_)#_P"V4?\ "@?^IF_\D/\
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M_P#ME'_"@?\ J9O_ "0_^V4?6*?<+,]HHHHKS2PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?5A;6FO^*IM0TNWD606XM5C:4KTWN#S70:GX4M+V^.HVEQ<Z9J1 #75FP4R
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MO;2(D#'RV7J6.,!>P)ZGI3Y9=@.AHHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M4?6'DOK@22-JD2QR,0H&X* .#[\\5UU%%9MW=QA1112 **** "BBB@ HHHH
M**** "O&;[3M)3QUXDN/$'A75]266YC:TEMK21UVA!GD$#KCUZ5[-151ER@<
M,L4U[\4-'U1+&ZCM#HCC=+"5\MBX(5O1L=NM<?J]I<VFGZZTEK=132>*DFLV
M$1)..0ZIUD&,\#K^%>TUDZ[X>M-?BMA<27$$UK+YUO<6TFR2)\8R#R.A[BJC
M.S%8X72;NVN$\4QS7%U+X@U2R>5H)+"2V#(D911&C9)Z^N:;X?TR^BUKX?O+
M8W");:1*DS/$P$3;!@-Q\I]C7;:5X7M--U)]3DNKR_U!H_)%S>2!V5,YVJ
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M0 4444 %%%% !14<X+6\@7.XJ0,?2L&""!H@#  ZX5@RX(.* .BHK!^RP?\
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MC)**** "BBB@ HJI>W,MN\/EQ^9N8[E'7 &>/>K$4J3Q+)&P96&0: 'T444
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M&D_0?^@USE='K/\ R+&D_0?^@USE"$%%%%,#>\(_\AAO^N)_F*S6_P"0V?\
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M_P!=3_*N.KL?&7_'E;?]=3_*N.IH1T>D_P#(JZG^/\A7.5T>D_\ (JZG^/\
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MNJ?C_(5SE,#>\(_\AAO^N)_F*[BN*\(1.VIRR@?(D1!/N2,?RKM:3&%%%%(
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M4 9GB'_D W?^Z/YBN1;_ )%5/^OP_P#H-==X@4MH5V "3M!X^HKD&_Y%5/\
MK[/_ *#30C+H/2B@]*8&S9_\C,/Q_P#0*QW^^WU-;-G_ ,C*I]1D>XV5C/\
M?;ZF@!*LC_D&-_UW'_H)JM5E>=+?':9<^WRF@"SJO^HT_P#Z]Q6;6EJO^HT_
M_KW%9M %G3_^0C;_ /7058T[_CPU+_KD/YU6L/\ D(V__70?SJUIX(L=3!&"
M(@"/QH S:*** +9^_8_[H_\ 0VI^L_\ (7N?]X?R%,8'-@W8J!GZ.:?K/_(7
MN?\ >'\A2 HU9MO]1>?]<A_Z&M5JLVO,-VHZF'./HRDTP+#_ /(N1_\ 7R?Y
M5G5HM_R+D?\ U\G^59U !6C<_P#(!L?]]_YUG5HW7_( L?\ ??\ G0!7OO\
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M=_U^A+DD[&_114<5Q#.7$4J/L.UMK9P?2MKK8HDHHHI@%%%% !1110 4444
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M?XI_Y]K?_P "%K;\)?#_ %[2O%%E?WL4$=O Q9V$H8_=(Q@?6O4_L$/]Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI\$<4LB/:O<,+N(*2 S(5P0<9X/0]376U#36C&%%%%( HHHH **** "BBB@
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M;Q:?!&C.LEJ;AOM<&TX&]"N.<=CCGJ:ZRE*Z>HPHHHJ0"BBB@ HHHH ****
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M%AG^(L"<M^0]JAL_"VH)J^E7^H:ZUY_9JR)%']E6/<&3;EB"<MTYZ<=!6O\
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MHHH **** "BBB@ K+L-'%CKFK:D)RYU Q$Q[<>7L3;USSGK6I11<#+_L8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]_X?L=8@U2X\G(,*M:70P,>9G[A4$@GY3QWKOQG SUI:*ENXPHHHJ0"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)U2VUK2[?4;,L;>X7=&67!(SC./PHMU NT444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)OAMK>DZ5?\ BI-1
MU2RLW?4W*+<7"1EAEN1N(S7K->1?#KP[HVMZAXIDU/3;:[>/4W5&FC#%02W
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M(?N2@,N' [9!''8YJU9:KXI\<75]<Z%JL&C:/;3-;PRFU6>2X9>K$-P!R/\
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MKF8['X.OH0U1HH%^3<;7[;+YX;'W=F_)/;/3WKH[GQ!I?A#X<VDVBZ=<6YO
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M['JWA8ZFWAC3Y-8N#/J$L(DF<HJX+<[<* . 0.G:MBBBLF[NXPHHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K33K&P:9K.RM[8S
M/OE,,2IYC>K8')]S5FB@ JNMA9I?M?K:0"\=/+:X$8\QDX^4MC..!Q[58HH
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M.- JCZ 5+112 SIM T:XO?MD^D6$MUG/GO;(SY_WB,U9BL+.&\FO(K2".ZG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *CGACN8)()D#Q2*4=3T8$8(J2B@#,T/P]I7ANQ:STBT%M;LYD90[-EB
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MC=-(T^*V\S[[ EF;V+,2<>V:UZ*7,[6N!RLWPV\'SZ@U])H<!F9MQP[A"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img104831930_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img104831930_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\!5 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHBES#(8W3N&!Q1&I&3LMQVTN5Z*].TOX3Q6^DQZGXLUN'1XI0"D+8W\]B2<
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MP,@FWEP<9_A&.1G\:%&<9*SN@NM4RAI'@O4=7\-ZCKZO%%86*,69CEG8 ':
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MR!<L!N)V@@'CWKU;XE:/X:U&RTO^VM;>P\F*3[-M&?-X7V/H/SJ'5Y5#K?\
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M//PU_P!<I/Y)7%?$OCXC:S_UV7_T%:])^*WA[5?$6CZ!<Z19O=QPQ,9/+(R
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M:0 .% 96QTRK @_E4>MZ_J?B._%]JMS]HN0@C#^6J?*,X&% '<UFT4^57OU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17UO_ ,(?X8_Z%S2/
M_ &+_P")H_X0_P ,?]"YI'_@#%_\37+]:78KE/DBBOK?_A#_  Q_T+FD?^ ,
M7_Q-'_"'^&/^A<TC_P  8O\ XFCZTNP<I\D45];_ /"'^&/^A<TC_P  8O\
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M];_\(?X8_P"A<TC_ , 8O_B:/^$/\,?]"YI'_@#%_P#$T?6EV#E/DBBOK?\
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MTC_P!B_^)H_X0_PQ_P!"YI'_ ( Q?_$T?6EV#E/DBBOK?_A#_#'_ $+FD?\
M@#%_\31_PA_AC_H7-(_\ 8O_ (FCZTNP<I\D45];_P#"'^&/^A<TC_P!B_\
MB:/^$/\ #'_0N:1_X Q?_$T?6EV#E/DBBOK?_A#_  Q_T+FD?^ ,7_Q-'_"'
M^&/^A<TC_P  8O\ XFCZTNP<I\D45];_ /"'^&/^A<TC_P  8O\ XFC_ (0_
MPQ_T+FD?^ ,7_P 31]:78.4^2**^M_\ A#_#'_0N:1_X Q?_ !-'_"'^&/\
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M /"'^&/^A<TC_P  8O\ XFC_ (0_PQ_T+FD?^ ,7_P 31]:78.4^2**^M_\
MA#_#'_0N:1_X Q?_ !-'_"'^&/\ H7-(_P# &+_XFCZTNP<I\D45];_\(?X8
M_P"A<TC_ , 8O_B:/^$/\,?]"YI'_@#%_P#$T?6EV#E/DBBOK?\ X0_PQ_T+
MFD?^ ,7_ ,31_P (?X8_Z%S2/_ &+_XFCZTNP<I\D45];_\ "'^&/^A<TC_P
M!B_^)H_X0_PQ_P!"YI'_ ( Q?_$T?6EV#E/DBBOK?_A#_#'_ $+FD?\ @#%_
M\31_PA_AC_H7-(_\ 8O_ (FCZTNP<I\D45];_P#"'^&/^A<TC_P!B_\ B:/^
M$/\ #'_0N:1_X Q?_$T?6EV#E/DBBOK?_A#_  Q_T+FD?^ ,7_Q-'_"'^&/^
MA<TC_P  8O\ XFCZTNP<I\D45];_ /"'^&/^A<TC_P  8O\ XFC_ (0_PQ_T
M+FD?^ ,7_P 31]:78.4^2**^M_\ A#_#'_0N:1_X Q?_ !-'_"'^&/\ H7-(
M_P# &+_XFCZTNP<I\D45];_\(?X8_P"A<TC_ , 8O_B:/^$/\,?]"YI'_@#%
M_P#$T?6EV#E/DBBOK?\ X0_PQ_T+FD?^ ,7_ ,31_P (?X8_Z%S2/_ &+_XF
MCZTNP<I\D45];_\ "'^&/^A<TC_P!B_^)H_X0_PQ_P!"YI'_ ( Q?_$T?6EV
M#E/DBBOK?_A#_#'_ $+FD?\ @#%_\31_PA_AC_H7-(_\ 8O_ (FCZTNP<I\D
M45];_P#"'^&/^A<TC_P!B_\ B:/^$/\ #'_0N:1_X Q?_$T?6EV#E/DBBOK?
M_A#_  Q_T+FD?^ ,7_Q-'_"'^&/^A<TC_P  8O\ XFCZTNP<I\D45];_ /"'
M^&/^A<TC_P  8O\ XFC_ (0_PQ_T+FD?^ ,7_P 31]:78.4^2**^M_\ A#_#
M'_0N:1_X Q?_ !-'_"'^&/\ H7-(_P# &+_XFCZTNP<I\D45];_\(?X8_P"A
M<TC_ , 8O_B:/^$/\,?]"YI'_@#%_P#$T?6EV#E/DBBOK?\ X0_PQ_T+FD?^
M ,7_ ,31_P (?X8_Z%S2/_ &+_XFCZTNP<I\D45];_\ "'^&/^A<TC_P!B_^
M)H_X0_PQ_P!"YI'_ ( Q?_$T?6EV#E/DBBOK?_A#_#'_ $+FD?\ @#%_\31_
MPA_AC_H7-(_\ 8O_ (FCZTNP<I\D45];_P#"'^&/^A<TC_P!B_\ B:/^$/\
M#'_0N:1_X Q?_$T?6EV#E/DBBOK?_A#_  Q_T+FD?^ ,7_Q-'_"'^&/^A<TC
M_P  8O\ XFCZTNP<I\D45];_ /"'^&/^A<TC_P  8O\ XFC_ (0_PQ_T+FD?
M^ ,7_P 31]:78.4^2**^M_\ A#_#'_0N:1_X Q?_ !-'_"'^&/\ H7-(_P#
M&+_XFCZTNP<I\D45];_\(?X8_P"A<TC_ , 8O_B:/^$/\,?]"YI'_@#%_P#$
MT?6EV#E/DBBOK?\ X0_PQ_T+FD?^ ,7_ ,31_P (?X8_Z%S2/_ &+_XFCZTN
MP<I\D45];_\ "'^&/^A<TC_P!B_^)H_X0_PQ_P!"YI'_ ( Q?_$T?6EV#E/D
MBBOK?_A#_#'_ $+FD?\ @#%_\31_PA_AC_H7-(_\ 8O_ (FCZTNP<I\D45];
M_P#"'^&/^A<TC_P!B_\ B:/^$/\ #'_0N:1_X Q?_$T?6EV#E/DBBOK?_A#_
M  Q_T+FD?^ ,7_Q-'_"'^&/^A<TC_P  8O\ XFCZTNP<I\D45];_ /"'^&/^
MA<TC_P  8O\ XFC_ (0_PQ_T+FD?^ ,7_P 31]:78.4^2**^M_\ A#_#'_0N
M:1_X Q?_ !-'_"'^&/\ H7-(_P# &+_XFCZTNP<I\D45];_\(?X8_P"A<TC_
M , 8O_B:/^$/\,?]"YI'_@#%_P#$T?6EV#E/DBBOK?\ X0_PQ_T+FD?^ ,7_
M ,31_P (?X8_Z%S2/_ &+_XFCZTNP<I\D45];_\ "'^&/^A<TC_P!B_^)H_X
M0_PQ_P!"YI'_ ( Q?_$T?6EV#E/DBBOK?_A#_#'_ $+FD?\ @#%_\31_PA_A
MC_H7-(_\ 8O_ (FCZTNP<I\D45];_P#"'^&/^A<TC_P!B_\ B:/^$/\ #'_0
MN:1_X Q?_$T?6EV#E/DBBOK?_A#_  Q_T+FD?^ ,7_Q-'_"'^&/^A<TC_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ J.<D0L02#[5)4=Q_J&_#^= %/S'_OM^='F/_?;\Z;1
M3$.\Q_[[?G1YC_WV_.FUS=WXUTVSUAM.D28NL@C:0 ; 3^.>*$KNR#S.F\Q_
M[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4
M.\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.
MFT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\
MWV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='
MF/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_O
MM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [
MS'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;
M10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?
M;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8
M_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^W
MYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,
M?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM%
M #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]O
MSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_
M -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G
M1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_
M[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4
M.\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.
MFT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\
MWV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_OM^='
MF/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [S'_O
MM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;10 [
MS'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?;\Z;
M10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8_P#?
M;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^WYT>8
M_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,?^^W
MYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM% #O,
M?^^WYT>8_P#?;\Z;10 [S'_OM^='F/\ WV_.FT4 .\Q_[[?G1YC_ -]OSIM%
M #O,?^^WYT>8_P#?;\Z;10!- [F9068CW-7*I6_^O7\?Y5=I#"BBB@ J.X_U
M#?A_.I*CN/\ 4-^'\Z *-%%%,14U2^33=,N+Q^D2%@/4]A^>*\I31I[[PY>Z
MXY8R+.#_ +P_B/YD?D:ZGXAZ@1!:Z7$27F;S' ]!P!^)_E5*'P]XOAT_[#'/
M"MJ5*F+>N,'KV]ZN.BN#Z(ZOPKJ?]J>'[>5FS+&/*D^H_P 1@UM5YSX(N9=)
MU^ZT:Z^5I,C&> Z^GU&?TKM+;7=/N]3ETZ&8M=19WIL(Q@X/.,436MT):*S-
M*BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 2V_P#KU_'^57:I6_\ KU_'^57:0PHHHH *CN/]0WX?SJ2H[C_4-^'\Z *-
M%%%,1FW&@:9=:DFH3VV^Z0@JYD;C'3C./TK2HHH S9M TR?4UU*2VS=J0PD$
MC#D=. <4ZWT/3K349=0@M]EU+G?)O8YR<G@G%:%%.[ ****0!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[R>2"%#$
MJM(\B1KO.!EF R?SIWV;5_\ IR_[Z?\ PJ+4/N6W_7U#_P"C%K=J[I13L96<
MIM7[?J8_V;5_^G+_ +Z?_"C[-J__ $Y?]]/_ (5L44N?R0_9^;,?[-J__3E_
MWT_^%'V;5_\ IR_[Z?\ PK8HHY_)![/S9C_9M7_Z<O\ OI_\*/LVK_\ 3E_W
MT_\ A6Q11S^2#V?FS'^S:O\ ].7_ 'T_^%'V;5_^G+_OI_\ "MBBCG\D'L_-
MF/\ 9M7_ .G+_OI_\*/LVK_].7_?3_X5L44<_D@]GYLQ_LVK_P#3E_WT_P#A
M1]FU?_IR_P"^G_PK8HHY_)![/S9C_9M7_P"G+_OI_P#"C[-J_P#TY?\ ?3_X
M5L44<_D@]GYLQ_LVK_\ 3E_WT_\ A44C7]K<VR7*VQCG<IF-FR"%9NX_V:W:
MR]7_ ./K3/\ KX;_ -%/51DF[6[_ )$SBXI--[K\QU%%%9FP4444 %%%% %6
M22[DOUM;58<^49&:4D=P,# ]ZD^S:O\ ].7_ 'T_^%%M_P C /\ KU/_ *&*
MV*T;44M#&,7)MMO<Q_LVK_\ 3E_WT_\ A1]FU?\ Z<O^^G_PK8HJ>?R17L_-
MF/\ 9M7_ .G+_OI_\*/LVK_].7_?3_X5L44<_D@]GYLQ_LVK_P#3E_WT_P#A
M1]FU?_IR_P"^G_PK8HHY_)![/S9C_9M7_P"G+_OI_P#"C[-J_P#TY?\ ?3_X
M5L44<_D@]GYLQ_LVK_\ 3E_WT_\ A1]FU?\ Z<O^^G_PK8HHY_)![/S9C_9M
M7_Z<O^^G_P */LVK_P#3E_WT_P#A6Q11S^2#V?FS'^S:O_TY?]]/_A1]FU?_
M *<O^^G_ ,*V**.?R0>S\V8_V;5_^G+_ +Z?_"C[-J__ $Y?]]/_ (5L44<_
MD@]GYLQ_LVK_ /3E_P!]/_A1]FU?_IR_[Z?_  K8HHY_)![/S9C_ &;5_P#I
MR_[Z?_"FV-PUU913.H5F'(!R :VJP-)_Y!<'T/\ ,T[IQ;M_6HDG&:5^C_0N
MT445!J%%%% %>]GDMX T2JTC2)&H8X&68+S^=.^S:O\ ].7_ 'T_^%1:C_J8
M/^OJ#_T:M;M7>T4[&33E-J_1?J8_V;5_^G+_ +Z?_"C[-J__ $Y?]]/_ (5L
M44N?R0_9^;,?[-J__3E_WT_^%'V;5_\ IR_[Z?\ PK8HHY_)![/S9C_9M7_Z
M<O\ OI_\*/LVK_\ 3E_WT_\ A6Q11S^2#V?FS'^S:O\ ].7_ 'T_^%'V;5_^
MG+_OI_\ "MBBCG\D'L_-F/\ 9M7_ .G+_OI_\*/LVK_].7_?3_X5L44<_D@]
MGYLQ_LVK_P#3E_WT_P#A1]FU?_IR_P"^G_PK8HHY_)![/S9C_9M7_P"G+_OI
M_P#"C[-J_P#TY?\ ?3_X5L44<_D@]GYLQ_LVK_\ 3E_WT_\ A1]FU?\ Z<O^
M^G_PK8HHY_)![/S9C_9M7_Z<O^^G_P */LVK_P#3E_WT_P#A6Q11S^2#V?FS
M'^S:O_TY?]]/_A1]FU?_ *<O^^G_ ,*V**.?R0>S\V8_V;5_^G+_ +Z?_"C[
M-J__ $Y?]]/_ (5L44<_D@]GYLQ_LVK_ /3E_P!]/_A1]FU?_IR_[Z?_  K8
MHHY_)![/S9C_ &;5_P#IR_[Z?_"C[-J__3E_WT_^%;%%'/Y(/9^;,?[-J_\
MTY?]]/\ X4?9M7_Z<O\ OI_\*V**.?R0>S\V8_V;5_\ IR_[Z?\ PH^S:O\
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MMOU,3[3<_P#0+O/_ !S_ .*H^TW/_0+O/_'/_BJVZ*7,NP^27\WY&)]IN?\
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M.3=<)%M."HP3C=C)'(%8>EZO9K9:W<:7XHN]2TV#3WDDMKB4_;+>0 G*EUW
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M^F:GX:M;:ROK.Y#N69@LL)!5T/7J#QQU%*.^O]?UI]P/;3^OZU^\H>']*O\
MQ#%JUY)XEUJVFCU.Y@B6&X'EHJN0ORE2"!Z5'IWB75;ZY\+Q7-P1<#4[NQO3
M%\J3F)'P<>^ <>M7M,TCQGH@U&WL(]!>"YOI[F.:>XFW*)&R,H(\$CTW?C4M
MIX)GL&\.>5=1S'3[N>ZO99,JTSRHP8J "/O-T)Z"B.R]%]^G_!"77Y_K_P
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M77V0W9E0A7+E =N=Q7=@9Q^=+!X=\17KZ-:ZQ<::+'2IDF$EJ7,ERT8(3<&
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MW0XSY?'S8SGMQSTYJU_PFVCMI5O?(;J1KB9H(K5+=C.TJYW)Y?4$8.>P]:+
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M;.U,A*G@D!>@!'MVK)U[QE<7LOAV'P]-=QP:H[LUU#9B1@J@Y0*_ 8$?-D<
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MO7\?Y5=I#"BBB@ J.X_U#?A_.I*CN/\ 4-^'\Z *-%%%,04444 5-0_U=O\
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MRHCN3+X69=A_R#K7_KBG\A5BJ]A_R#K7_KBG\A5BJE\3%3^!!1114E!1110
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M:GI=B6QU=%%%( HHHH *R]7_ ./K3/\ KX;_ -%/6I67J_\ Q]:9_P!?#?\
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M3$ZQN_ESQ.509. X)X^E6_[:B_Y];S_OP:TY6XJQCSJ-1W\OU-*BLW^VHO\
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M[==V(BM[A1%*SNTD>T >6P_F150A).[\_P B*E2,DDGU7YHMT445F;!1110
M4444 0VW_(P#_KU/_H8K8K",YM-86=H)I(S;E,QINP=P/-6_[:B_Y];S_OP:
MTE%M)HQC4C%M-]32HK-_MJ+_ )];S_OP:/[:B_Y];S_OP:GV<NQ?MH=S2HK-
M_MJ+_GUO/^_!H_MJ+_GUO/\ OP:/9R[![:'<TJ*S?[:B_P"?6\_[\&H_^$AM
M?M'V?R+OS=F_9Y)SMSC/YT>SGV$ZU-=36HK-_MJ+_GUO/^_!H_MJ+_GUO/\
MOP:/9R[#]M#N0W6A&^\06FI7-[+)!9Y>"SV*$64@KYA.,DX)P"<#-;%9O]M1
M?\^MY_WX-']M1?\ /K>?]^#1[.78/;0[FE31&@D,@10Y&"V.3^-9_P#;47_/
MK>?]^#1_;47_ #ZWG_?@T>SEV#VT.YI45F_VU%_SZWG_ 'X-']M1?\^MY_WX
M-'LY=@]M#N:5%9O]M1?\^MY_WX-']M1?\^MY_P!^#1[.78/;0[FE16;_ &U%
M_P ^MY_WX-']M1?\^MY_WX-'LY=@]M#N:58&D_\ (+@^A_F:N_VU%_SZWG_?
M@U4TM'CTV!9$9&P<JW4<U7*U!W\OU(YE*HK=G^A;HHHK,V"BBB@"IJ/^I@_Z
M^H/_ $:M;M86HAC;(R(SE)XG*J,G"R*3C\!5O^VHO^?6\_[\&M.5N*M_6QCS
MJ-1W[+]32HK-_MJ+_GUO/^_!H_MJ+_GUO/\ OP:GV<NQ?MH=S2HK-_MJ+_GU
MO/\ OP:/[:B_Y];S_OP:/9R[![:'<TJ*S?[:B_Y];S_OP:/[:B_Y];S_ +\&
MCV<NP>VAW-*BLW^VHO\ GUO/^_!H_MJ+_GUO/^_!H]G+L'MH=S2HK-_MJ+_G
MUO/^_!H_MJ+_ )];S_OP:/9R[![:'<TJ*S?[:B_Y];S_ +\&C^VHO^?6\_[\
M&CV<NP>VAW-*BLW^VHO^?6\_[\&C^VHO^?6\_P"_!H]G+L'MH=S2HK-_MJ+_
M )];S_OP:/[:B_Y];S_OP:/9R[![:'<TJ*S?[:B_Y];S_OP:/[:B_P"?6\_[
M\&CV<NP>VAW-*BLW^VHO^?6\_P"_!H_MJ+_GUO/^_!H]G+L'MH=S2HK-_MJ+
M_GUO/^_!H_MJ+_GUO/\ OP:/9R[![:'<TJ*S?[:B_P"?6\_[\&C^VHO^?6\_
M[\&CV<NP>VAW-*BLW^VHO^?6\_[\&C^VHO\ GUO/^_!H]G+L'MH=S2HK-_MJ
M+_GUO/\ OP:/[:B_Y];S_OP:/9R[![:'<TJ*S?[:B_Y];S_OP:/[:B_Y];S_
M +\&CV<NP>VAW-*BLW^VHO\ GUO/^_!H_MJ+_GUO/^_!H]G+L'MH=S2HK-_M
MJ+_GUO/^_!H_MJ+_ )];S_OP:/9R[![:'<TJ*S?[:B_Y];S_ +\&C^VHO^?6
M\_[\&CV<NP>VAW-*BLW^VHO^?6\_[\&C^VHO^?6\_P"_!H]G+L'MH=S2HK-_
MMJ+_ )];S_OP:/[:B_Y];S_OP:/9R[![:'<TJ*S?[:B_Y];S_OP:/[:B_P"?
M6\_[\&CV<NP>VAW-*LS7/^/*'_KYA_\ 0Q2_VU%_SZWG_?@U3U"_%]%##%:W
M0;[1$Q+Q$  ,"3G\*J$)*2;,ZE2+@TF7****S-PHHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\_D'_@.G^%<511[*'8+L[7_A:WBS_G\@_P# =/\ "C_A:WBS_G\@_P# =/\
M"N*HH]E#L%V=K_PM;Q9_S^0?^ Z?X4?\+6\6?\_D'_@.G^%<511[*'8+L[7_
M (6MXL_Y_(/_  '3_"C_ (6MXL_Y_(/_  '3_"N*HH]E#L%V=K_PM;Q9_P _
MD'_@.G^%=O\ #3QGK7B75[RWU.>.2.*#>H6(+@[@.WUKQ.O3/@M_R,.H_P#7
MK_[.*SK4XJ#:0T]3VRBBLB[\2Z?97+V\YE21#@CRS7#"$INT5<*E6%-7F[&O
M15>RO8+^V6XMWW1M^8/H:L4FFG9E1DI*ZV"N \?>/K[PEJ=K:VMI;S+-#YA,
MN[(.XCL?:N_KQ/XT_P#(PZ=_UZ_^SFM*$5*=F#V#_A=.L?\ 0,L?S?\ QH_X
M73K'_0,L?S?_ !KS.BN[V%/L3=GIG_"Z=8_Z!EC^;_XT?\+IUC_H&6/YO_C7
MF=%'L*?8+L],_P"%TZQ_T#+'\W_QH_X73K'_ $#+'\W_ ,:\SHH]A3[!=GIG
M_"Z=8_Z!EC^;_P"-'_"Z=8_Z!EC^;_XUYG11["GV"[/3/^%TZQ_T#+'\W_QH
M_P"%TZQ_T#+'\W_QKS.BCV%/L%V>F?\ "Z=8_P"@98_F_P#C1_PNG6/^@98_
MF_\ C7F=%'L*?8+L],_X73K'_0,L?S?_ !H_X73K'_0,L?S?_&O,Z*/84^P7
M9Z9_PNG6/^@98_F_^-'_  NG6/\ H&6/YO\ XUYG11["GV"[/3/^%TZQ_P!
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MYG11["GV"[/3/^%TZQ_T#+'\W_QH_P"%TZQ_T#+'\W_QKS.BCV%/L%V>F?\
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MUC_H&6/YO_C1_P +IUC_ *!EC^;_ .->9T4>PI]@NSTS_A=.L?\ 0,L?S?\
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M;_XT?\+IU?\ Z!EC^;_XUYG11["GV"[/3/\ A=.K_P#0,L?S?_&C_A=.K_\
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M^P79Z9_PNG5_^@98_F_^-'_"Z=7_ .@98_F_^->9T4>PI]@NSTS_ (73J_\
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MTCW_ *V'9WL<=1115B"BBB@ HHHH *],^"W_ ",.H_\ 7K_[.*\SKTSX+?\
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M:$@ ,<<'D_E0YQ6[_K</Z_0X>BN\/PU46MI?_P#"2Z7_ &9<-Y8NLMCS,XV
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M;L-P.>.#22>--.:;P8XANL:(H%S\B_/@J?D^;GH>N*(J>BZ:?E_F.3W?K_P
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MC>2ZMHNHV>)IO(:(*Z\\ANF.F?<5%%XTTZ3QCXKO;VZ\J"XL9;.SPC,&QA5
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M3_U]2?R6N?$_ ..YWU%%%>>6%%%% $MO_KU_'^57:I6_^O7\?Y5=I#"BBB@
MJ.X_U#?A_.I*CN/]0WX?SH HT444Q!1110 5XG\:?^1AT[_KU_\ 9S7ME>2_
M%CP_J^KZW8RZ=IUQ=1I;;6:),@'<3BML.TIZB>QY#16]_P (3XG_ .@%??\
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M^)_^@%??]^C1_P (3XG_ .@%??\ ?HT<\>X6,&BM[_A"?$__ $ K[_OT:/\
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M?;['[N?3ZUS22R1$F-V0D8.TXS79?\*I\6?\^</_ ($)_C1_PJGQ9_SYP_\
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M\^</_@0G^-'M8=PLSBJ*[7_A5/BS_GSA_P# A/\ &C_A5/BS_GSA_P# A/\
M&CVL.X69Q5%=K_PJGQ9_SYP_^!"?XT?\*I\6?\^</_@0G^-'M8=PLSBJ*[7_
M (53XL_Y\X?_  (3_&C_ (53XL_Y\X?_  (3_&CVL.X69Q5%=K_PJGQ9_P ^
M</\ X$)_C1_PJGQ9_P ^</\ X$)_C1[6'<+,XJBNU_X53XL_Y\X?_ A/\:/^
M%4^+/^?.'_P(3_&CVL.X69Q5%=K_ ,*I\6?\^</_ ($)_C1_PJGQ9_SYP_\
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M/:P[A9G%45VO_"J?%G_/G!_X$)_C1_PJGQ9_SYP?^!"?XT>UAW"S.*HKM?\
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M?SJ2H[C_ %#?A_.@"C1113$%%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_+_ (/^0EK;S_X'^9ZA17EL+Z89;(>&[N\$CV4_]J/ SR2(/*.&<$_ZT/C
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M-\:7$G6/3K18E_ZZ2G<WY*J?]]4[;$WW-VBBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 2V_^O7\?Y5=JE;_Z]?Q_E5VD,**** "H[C_4-^'\ZDJ.
MX_U#?A_.@"C1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/<06L1EN)HX
M8P<;Y&"C\S4E<E\0U9]"LE6WCN&.I6H$,IPLA\P?*3@X!^AH[ =%'JFG3!C%
M?VKA!EMLRG SCGFK=<!KMG)!X/U22?P_IVE.?)"FSE#EQYBYR0BX[>M6[_Q#
MJ-OH?BJZ2=5ET^[\JW)0?*NV,X]^6/7UH_K\O\P.RDDCAC,DKJB+U9C@#\:5
ME5U*NH93U!&0:\X\3W>K:OX>\1W"W\4%E9W#6HM#"#O52N6+YR&).1CCIUS4
MOB+Q3JEC/J5S8WLDD=C,J>3#8EH !MW++*V/FY/"GCBA:V'8[;4]..HZ<]DE
MW/9JXVL]OM#;>ZC<"!D=QSZ5-%%;:;8QPILAMK>,(N3@*H&!S7(_VQJH;Q'?
MRZK!;VFG3M#!%+!E!^[0@L5&XX+< <GI7/ZSK>ISZ9KFF7<]S-"^DO<(]Y9"
MV8,&"\ <[>>XSQ1^NOX7"U_R_&QZF\B1QM([JJ*,EF. !ZYJ*[MH[^PGM78^
M5<1-&S(><,,9'YUQ&K:EK&CV][8WEY;Z@LVCW%TA-LJB)XP,@KR&0[N^>G>H
MI]9U_P"R:]>VVHPPP:3'%)%;_9E(D_<([*Q[#DXQSS^%#2=_Z\A1OI;?_AO\
MSO+.U2QL;>TB+&."-8U+'DA1@9_*I))8X8S)*ZHB]68X _&O/;[Q3X@N;[5'
MTV&X$=@RHD<=M&\<C;%<^8[."H.['R]!SS6WXVE:?X=:A,Z>6TENC%,YVDE3
MBF[O5@K:)'553U;38=8TJYTZX:18;B,QN8R P!],@U4\0SW]IX=N;O33_I-N
M@F"[0=ZJ067GU4$5S%]XGU2_NEFT:\CBL9+VULHG:(.&9U+2-ZG 9!C/4&EN
M[ GI<[U5"J%'0#%+7GEQK'B.RM]9N'U:*5-'O(X@IM5!N%;83O(Z8#X&W'2I
M[[6->CC\2:E%J<"V^D7!$=JT"GS%5$8JS=1G) Q^O2C_ (?\O\PMT7I_7W'=
M)+'(7".K%#M8*<[3Z'TIU>:"]U:QB\5:U97J0PVU^LIM7@#>;^[BW!F/(X.!
MC'XUK7VK:W<'Q!?66H06D&CNR);/ '$Q2,.Q=B<@'.!C&.O-&RU[7_+_ #&E
M?;O8[.21(HVDD=411EF8X 'N:<"",@Y%>9ZUJNK>(_"OB.\BO([.SMH/+^R-
M"&+@Q*[%F/(/SX&/3O4MUXFU^2ZU(:;%<"+3=L4<<=M&\<C"-6/F.S@J#G'R
M]!SS1MN+M8]'IB/$9)$1D,BXW@$9&1QG\*X:?6/$$_\ PD%]!J,-K#I:)+':
MO K[OW*R,KMUQDD CGGKVK.N?$5Y9ZMJ4]A"XN=2GL8AMC#M&&@9CA20"V!@
M FC_ ('X[!_7W'IN<=::DB2%@CJQ1MK8.=I]#[\BO,]2O-<U"TBM+R:ZMO(U
M6S$4\L$22.';^) 6 *D9'0'CBM-=7U*36Y]'LYX;62YU2:,W0@4D)'!$QXX#
M.2W4YX'L*/Z_+_,=OZ^__([NBN .NZ])JD&AIJ$*W":D]I)>"W!\R/R/-!V]
M PZ<<9[=JZ/PQ?7MW!J$%_.L\UE>R6PF"!/,4!6!(' /S8X]*/Z_+_,3T_KU
M_P C<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"6W_ ->OX_RJ[5*W_P!>OX_R
MJ[2&%%%% !4=Q_J&_#^=25'<?ZAOP_G0!1HHHIB"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *JWVG6NI1Q1W<7F+%*DR#<1AU.5/![&K5% %:_L+;4[*2SO(O-
M@DQN3<5S@@CD$'J!69?^$-"U.YGN+NR+O<8,H$TBJY P"5#!2PP,'&:W** ,
M/4?!^A:K<RSWED7>;!E"S2(LA'0LJL 2.Q(S27G@W0;^6Y>YLF<7+;YHQ<2+
M&[?WM@8+N_VL9]ZW:* ,U]!TR2UOK5[17AOG\RY1F8[VP!GKQPHZ8Z52_P"$
M+T$^=OLY)6G@-O*\MS+(SQD@E2S,21P,<\=NIK?HH Q8/">B6\-W#'9DI=0F
M"7?-(Y,9_@!+$JO/1<"ISX?TLVU];FU_=7ZA;E?,;YP$"#OQ\H XQ6G10!BW
MGA+0[^X,]Q9%G9520+,Z+*%Z!U5@'Q_M U?U#3;35--ET^\A\RUE78\88KD>
MF5((Z=JMT4 84?A^'1X9[C1X)IKPQ[%CO-1G>-LD==Q<#Z@9[=Z9HGA6STWP
M_IVFSQI(UG(+C<A*CSLD[ACMDG /;%=!10!FS:!IEQ#?12VVY+Z19;D>8PWL
M H!Z\?=7ICI61;>"K*35M4OM2A2=KJ\$\:K*X4J%4 .F0K$%2>0>M=310M-0
MZ6,V70=,FM;^VDMLPW[^9<KO8>8V ,]>.%'3'2H;[PKHNI7CW=W9;Y9-HEQ*
MZK+CIO4$*^/]H&MBB@#$U+PAH6KS2RWMCO:5 DH2:2-9 .!N56 ;'8D9':EO
M?"6B:A<M<7-D6=U59 LSHLH7H'56 ?'^T#6U10!RJ>"K&XUS5;[48$FCNI8V
MBC25U&Q8U7;(H(5AE20#D5K77AS2;W[7]HLU<W1C:4[V!)080C!^4CU7%:E%
M'2P&(/"6B?V?-9&S8Q32+-(S3R&1G7&UC(6WY&!CGBI)_#&CW,,D4MH2))_M
M)<3.'$NT+N5P=RG"@<$5KT4 95KX<TFS%K]GM AM96FB;>Q/F,I5F8DY8D$\
MMFKEI86UBUPUO'L-S,9Y?F)W.0 3STX X'%6:* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** );?\ UZ_C_*KM4K?_ %Z_C_*KM(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK5:B@"S]K_V/UH^U_P"Q^M5J* +/VO\ V/UH^U_['ZU6HH L_:_]C]:/M?\
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M<GJ21Q6AIR^(1XDNC>Y_LOY_)Y3U^7IST]:):OY"6ESH:***@84444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !1110!/:_P"M/^[5NJEK_K3_ +M6Z0PHHHH
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MCRQ@L!N4@ CD@\CGUINE%R:ZW9%[1N>QT445REA1110 4444 %%%% !1110
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M18[5)'<#\NE5R+EYD#=F=?4,MW;6\L,4UQ%'),=L2.X!<^B@]?PK&\4>)?\
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M4,P/3 SDTE*71BLK%JBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M$]K_ *T_[M6ZJ6O^M/\ NU;I#"BBB@ J.X_U#?A_.I*CN/\ 4-^'\Z *-%%%
M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +\__94?7:'\WX,/[,Q7\OXK_,XZBNQ_X04?]!$_]^?_ +*C_A!1_P!!$_\
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MVREIG;"X[>]>SVL<D-K%'-*99%0!I",;CCDUSWA'P_\ V7:?:[E/],F'0_\
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M]:+?0LA0YQCGC.#Z]JW?B=_R3S5?I'_Z,6I_"/A >&A=W%Q?27^H7C;IYW&
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M0 4444 %%%% $]K_ *T_[M6ZJ6O^M/\ NU;I#"BBB@ J.X_U#?A_.I*CN/\
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M3BU_Y])OS%'_  G%K_SZ3?F*/JE;^4/[0PW\_P"9U-%<M_PG%K_SZ3?F*/\
MA.+7_GTF_,4?5*W\H?VAAOY_S.IHKEO^$XM?^?2;\Q1_PG%K_P ^DWYBCZI6
M_E#^T,-_/^9U-%<M_P )Q:_\^DWYBC_A.+7_ )])OS%'U2M_*']H8;^?\SJ:
M*Y;_ (3BU_Y])OS%'_"<6O\ SZ3?F*/JE;^4/[0PW\_YG(:C_P A.[_Z[/\
M^A&JU=:WB7178LVC(S$Y),:$DTG_  D>B?\ 0%C_ ._25ZL:U1*WLW^!X$L/
M1<F_:K[F;?A/_D7;?ZO_ .A&MJN2B\96$$8CAL)(T'14V@#\!4G_  G%K_SZ
M3?F*\VIAJTYN7+N>W1QN&ITXP<]DEU.IHKEO^$XM?^?2;\Q1_P )Q:_\^DWY
MBH^J5OY33^T,-_/^9U-%<M_PG%K_ ,^DWYBM[3+]-3L4NHT9%<D;6Z\'%9U*
M%2FKR5C6EBJ-:7+3E=ENBBBLCH"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* '1_P"M3_>%:%9\?^M3_>%:%(84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #9/]4_^Z:SZT)/]4_\ NFL^F 4444""BBB@ J];_P"H7\?YU1J]
M;_ZA?Q_G0!)1112&9NL:+!K<,<-Q/<)&AW;8F #'U.0:Q_\ A -)_P">]Y_W
MVO\ \37545K"O4@K1=D<]3"T:DN:<;LI:7I5KH]F+:U4[<EBS'+,?4FKM%%9
MRDY.[-HQ4$HQ5D@HHHI%!52Z_P!:/]VK=5+K_6C_ ': (****8@HHHH ****
M "BBB@ HHHH **** ,KQ+IAUGPUJ.GK]^>!E3_>QD?J!7"Z'IC^,?A$NBI,(
M+NV<PG?G"NC9 ;OC!%>GU2LM)L=.N;NXM+=89+M_,G*DX=O7'0'Z5<9637I]
MZ#L>9WO@3QIK?ARVTJ^O]+BALMHMXD# /@8RS!>,#.,#GO4'CJRO9O'GA:TA
MN$MK[[.BK,OS*D@8\^XR*]@K.N]!TR^U6VU.YM%DO;7_ %,I8@ISGH#CO5QK
M/F38K:->5CB[/P?XDUCQ79ZQXJN[,QZ?S!#:YPS Y!Y''.#^%<]%:ZS/\7M?
MDT*Z@AO85+A9U)25?D!4XZ=<_A7LU9UMH.F6FKW&K06BI?7 VRS!CEAQVSCL
M*(U;/7LU]X-77W?@<MX5\':I::UJ'B#7[J&;5+M#&JP_<C4X[X]@/IZU;^'W
MA6^\)Z1=6E_+;R237!E4P,Q &T#G('/%=?14.HW=?UH%CSF7P=XE\/:]?:AX
M3O+/[/?-NEMKH'Y&R3Q@<X)..G7O5WP[X.U70;+5=1-W;77B/4 299"1$A)S
MU R>>>G8#BNYHH]I*UA];GE)^$EQ)X?D>6^B;Q(]Q]H^U;VV=?NYQGWSC.:Z
M>_TWQG=:1I,=OJ=E;7T#?Z:Z.Q691C&,IU/?@=:Z^BFZLGN*P5Y1K'@#QGJ'
MBV;7H-4TR.7S#]G+2.3$G10 8R 0/US7J]%3";@[H?2QQ6D>&?$5UHNK:;XL
MU6&]CNXPD30DDQ]<GE5[[3^%<PGPY\675I:^'[_5;0Z#;3>8I3.\C)X QG/)
MX)P,]Z]<HJE5DG<5M+#(84MX(X8EVQQJ$4>@ P*\AUNUU*Z^-<HTBZCM[Z.V
M62)I5RC8C&5;V(R*]AK.&@Z8-<.M"T7^T2FPS[CG;C&,9QT]J4)\LKOS';2Q
MR7A_P=K,OBJ7Q+XGN;=[P1F."&VSM0$8STXX)XYZYK)TOP)XNT4:AI-AJ.GQ
MZ5>L2]PR%I0I&.!CKCWQZ5ZI13]JP/.;+P!JD7PUOO#5Q<6GVF2;S89(V8IU
M4@-E01R#V-0S^#?%.J^ %T"^ETU)H)8A;D.V/+0$?,0IYKTRBCVLG^8DK?C^
M)PGB/P1?W]MHE[I=W#;ZSI42(K/G8^ .,X]0>W>I] T;Q=)K_P#:OB+542)$
MV)8V<C>6Q]6'3OGO^E=I11[25K?UJ%CCO"OA2_T/Q1K^IW,ML\.HREXEB9BR
MC<Q^;( '7L35;0?!%]IUYXI>[N+8Q:QN$7E,Q9 2_P!X$#^\.F:[JBESO;RL
M/K?SN>=>%?"/BC2M%OM#N[^WMK-D8V]Q:.WFK(2#G.!\O!XXZUG7W@[QUJ^F
MIHNI7FDSVJL/]-D#/-M!SU(SG_.:]6HJO:RO<25MCS;X@6@T_P #Z3X6LV:6
M>YFBMH@>K!>I_/'YUZ#86BV&G6UFGW8(EC'T4 ?TJ*?2;&YU.WU&:W62[ME*
MPR,3\@/7 Z?C5VI<[QMYW86U7D@HHHJ!A1110 4444 %%%% !1110 4444 3
MVO\ K3_NU;JI:_ZT_P"[5ND,**** "H[C_4-^'\ZDJ.X_P!0WX?SH HT444Q
M!1110 4444 %%%% 'G7B[_D8)?\ <7^58=;GB[_D8)?]Q?Y5AU]'A_X4?1'Q
MN,_WB?JPHHKMM2UB?1]*T86T-NPEM@SB2,'. *=2HXM)*[9-&E&:DY.R7SZV
M.)HKOX+*U'BO2;R&!(TO;9I&B ^4-M]/QKAKOB\G _YZ-_.IIUE4=K=/U:_0
MJMAG2CS-WUM^"=_Q(:*["Q32_P#A%-36S5Y)U@1II9!_$?X5]A7-""T_LLS&
MZ/VOS-H@VG!7'WLTX5>9M6V=A3H.,8NZ=U<J45=TL6'VO=J32>0BEML8Y<]E
M]JZ+74B'C'2Q'$J1E8<(!QC<:<JO+/EL$*'-3<[[6.0HKTK4?[7COIA:OI*0
M _(LN-P&.]9?AY))='>:V2TBNFN\2RW*?*ZG^%3_ $K!8J\.:W;KW^1TRP'+
M4Y+OKT[=M3B:*U?$D<,7B"[2"$PQAN$*[>PR0/0UMWM\_A?3].@T^*$33PB:
M:5T#%B>WTK5UM(N*UD8+#I3FI/2.[^=CCZ*U[ZXCU[5;<6EFMO--M1PIX9C_
M !8[5TFNVUG>Z1=V=G&HFTDKR!RR[?F_K^5*5?EY5);_ (#AA>?F<9:+;SZV
M^Y'"45W^CQ7Y\)6)TR*V:<R.&\X#D9/K5#Q%:+>RZ=9@6@U=@PG$)"J.XS[U
M*Q*<^6W?KVZFCP35)5$^B>W?I?N<?175ZIX2EMM+MIX4C$B1,UR3+G)'I^'I
M7/Z982:GJ,-G$0K2'&X] .I-:PK0G%R3T1SU,/4IR49+5E2BMR]TK2UBD6PU
M)I;F*01F*5-OF'./EJ])X4MPTME'>R-J447F,AB_=GC.T'UJ7B()7?Y%K"56
M[*WWK[O4Y6BNSL(T.D^&R47+7C \=?F-1-H$6HZEJ]U*\PBAN6016T>]SSZ>
ME3]9BFU+I_G8OZG)Q3B[MV_%7.1HJ[JMG!8WIAM[@S1X!RR%&7V(/>J5;QDI
M*Z.2<7"3BPKT;PG_ ,B[!_O/_P"A&O.:]&\)_P#(NP?[S_\ H1KBS'^$O4]3
M)_X[]/U1MT445XI]*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .C_ -:G
M^\*T*SE.U@WH<U8^U_['ZT#+-%5OM?\ L?K1]K_V/UI 6:*K?:_]C]:/M?\
ML?K0!9HJM]K_ -C]:/M?^Q^M %FBJWVO_8_6C[7_ +'ZT 6:*K?:_P#8_6C[
M7_L?K0!9HJM]K_V/UH^U_P"Q^M %FBJWVO\ V/UH^U_['ZT 6:*K?:_]C]:/
MM?\ L?K0!/)_JG_W36?5AKK<I79U&.M5Z8@HHHH **** "KUO_J%_'^=4:O6
M_P#J%_'^= $E%%%(84444 %%%% !1110 54NO]:/]VK=5+K_ %H_W: (****
M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (0G3?\ GO=_]]K_ /$T?\(3IO\ SWN_^^U_^)KI**KZU6_F)^HX;^1'-_\
M"$Z;_P ][O\ [[7_ .)H_P"$)TW_ )[W?_?:_P#Q-=)11]:K?S!]1PW\B.;_
M .$)TW_GO=_]]K_\31_PA.F_\][O_OM?_B:Z2BCZU6_F#ZCAOY$<W_PA.F_\
M][O_ +[7_P")H_X0G3?^>]W_ -]K_P#$UTE%'UJM_,'U'#?R(YO_ (0G3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *O6_P#J%_'^=4:O6_\ J%_'^= $E%%%(844
M44 %%%% !1110 54NO\ 6C_=JW52Z_UH_P!V@""BBBF(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@">U_UI_P!VK=5+7_6G_=JW2&%%%% !4=Q_J&_#^=25'<?ZAOP_G0!1HHHI
MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "KUO_J%_'^=4:O6_P#J%_'^= $E%%%(84444 %%%% !
M1110 54NO]:/]VK=5+K_ %H_W: (****8@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )[7_ %I_
MW:MU4M?]:?\ =JW2&%%%% !4=Q_J&_#^=25'<?ZAOP_G0!1HHHIB"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "KUO_J%_'^=4:O6_^H7\?YT 24444AA1110 4444 %%%% !52Z_U
MH_W:MU4NO]:/]V@""BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@">U_UI_W:MU4M?\ 6G_=
MJW2&%%%% !4=Q_J&_#^=25'<?ZAOP_G0!1HHHIB"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KUO_
M *A?Q_G5&KUO_J%_'^= $E%%%(84444 %%%% !1110 54NO]:/\ =JW52Z_U
MH_W: (****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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93U:C[*GJU3T4 1QPK&V03TQS4E%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img104831930_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img104831930_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )*!&4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/I56@ HHHH **N7^D:EI8B.H:==V@ER8S<0M'OQC.,@9ZC\ZJ(C2.J(I9F.
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MY57I@%%7K#1-6U5'?3M,O;Q4.':WMWD"GT.T'%7/^$/\3_\ 0N:O_P" ,O\
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M29FC5=S?*Q"Y#<=,=Q7'WMJ]C?7%I*5,D$K1,5Z$J<''MQ7HGPO_ .2MR_\
M;S_6N&\1#'B?5@?^?R;_ -#-:Q;YN5]A%WQ1X1O_  G+9QW\UM(;J'SD\AF.
M![Y4<UMV/PG\0W>GP7=Q-IVG^?@Q0WLYCD;/3@*<'V/-=SXPLH;[XD>![:Y
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M.M3^&OB+!JEE>:)X\F^UZ=+$3%<-%NDC<8P!M&?<'J"/>O.+ZUEL=0N;2?\
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M((_[.M2+MH,?*?D1MN/3>XXZ8&*?;6NF?"+33>7K0WWBRXCQ!;@Y6V4CJ?\
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M$!3RPZ'O7"QVGA@^"YKJ34;H>(A+B.T"GRBFX<D[.N,G[W:N?HJ8TU%607%
MRP!( )ZGM7H?C_Q1H]UX;T+PWX>NC<6-E&&FD,3)ND VC[P'/+$\?Q5YW15.
M*;3?0!\,TEO/'-"Y26-@Z,IP5(.017I?CGQ3X>\3+X<UF"Z"ZM T:WL A?Y5
M^\?FVX(5@>G7=7F-%$H)M/L![1XLO?AEXPU=-2OO$U[#*D*PA8+:0+@$G/,1
MY^8U1T[6_AQX'+ZCHCWNLZJ%(A:="H3(QU*J!Z9P3R?6O):*S5%6M=V'<V8=
M9EO?&$&LZG-EWO4GG?!( #@G ZX ' ]!6Y\4=>TSQ'XN%]I5S]HMOLR1[_+9
M/F!;(PP![BN*HK3D5TQ!7H'A/Q3H<WA6X\)>*O.33VD,MM=1+N,#=>@&>N3T
M/WB#Q7G]%$HJ2LP/3[?Q#X2\"Z-?CPO?7.J:Q>QF$74D)C6!?8, ??'.2!TQ
M7.> ?%T7A75I_ML#7&F7L1@NH5 )([$9ZXR1CT)KDZ*GV:LT^H7/4].E^&?A
MO5_[=M-5OM0E@8R6M@;=AM;MEF4 X['/&.]>>Z[K%QX@UR\U6ZP);F0N5'11
MT"CZ  ?A6=13C!)WW"YW'PJ\0:7X;\5S7NK77V>W:T>,/Y;/\Q9"!A03V-<?
MJ$J3ZE=2QG<CS.RG&,@DD57HIJ*4G( KT;Q7XHT?4OA=X>T:TO/,U"T:,SP^
M4XV8C8'DC!Y(Z&O.:*)13:?8 KT#X5>)=(\-ZCJ<NKW?V9)[81QGRW?<V<X^
M4&O/Z*)14E9@=WX%\0Z5HWA;QA97]UY-QJ%D(K5/+9O,;9*,9 ('++UQUKG/
M"VNMX:\26>K+$)A QWQ$_?4@@CZX/'OBL>BCD6OF%STW4;?X8ZUJDNK-X@U"
MQ^TN9IK/[*[$,>6 ;:0,G/<CTXK.\9>/(-=\6Z5?64$BZ?I3)Y(<X>3:P)/M
MG  ^GO7!T5*II/5W"YZ)\2M1\+>))O[=TK697U!Q&CV4ENZ@* 03N(QGIW]:
M\[HHJHQY58#T+_A)M(_X4M_PC_VO_B:?:-_D>6_3S-V=V-O3WIOB/Q+I%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_X5-XW_ .@)_P"34/\ \77T[11]:GV0<J/F+_A4WC?_ * G_DU#_P#%T?\
M"IO&_P#T!/\ R:A_^+KZ=HH^M3[(.5'S%_PJ;QO_ - 3_P FH?\ XNC_ (5-
MXW_Z G_DU#_\77T[11]:GV0<J/F+_A4WC?\ Z G_ )-0_P#Q='_"IO&__0$_
M\FH?_BZ^G:*/K4^R#E1\Q?\ "IO&_P#T!/\ R:A_^+H_X5-XW_Z G_DU#_\
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MX5-XW_Z G_DU#_\ %U].T4?6I]D'*CYB_P"%3>-_^@)_Y-0__%T?\*F\;_\
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M_P"34/\ \77T[11]:GV0<J/F+_A4WC?_ * G_DU#_P#%T?\ "IO&_P#T!/\
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M34/_ ,77T[11]:GV0<J/F+_A4WC?_H"?^34/_P 71_PJ;QO_ - 3_P FH?\
MXNOIVBCZU/L@Y4?,7_"IO&__ $!/_)J'_P"+H_X5-XW_ .@)_P"34/\ \77T
M[11]:GV0<J/F+_A4WC?_ * G_DU#_P#%T?\ "IO&_P#T!/\ R:A_^+KZ=HH^
MM3[(.5'S%_PJ;QO_ - 3_P FH?\ XNC_ (5-XW_Z G_DU#_\77T[11]:GV0<
MJ/F+_A4WC?\ Z G_ )-0_P#Q='_"IO&__0$_\FH?_BZ^G:*/K4^R#E1\Q?\
M"IO&_P#T!/\ R:A_^+H_X5-XW_Z G_DU#_\ %U].T4?6I]D'*CYB_P"%3>-_
M^@)_Y-0__%T?\*F\;_\ 0$_\FH?_ (NOIVBCZU/L@Y4?,7_"IO&__0$_\FH?
M_BZ/^%3>-_\ H"?^34/_ ,77T[11]:GV0<J/F+_A4WC?_H"?^34/_P 71_PJ
M;QO_ - 3_P FH?\ XNOIVBCZU/L@Y4?,7_"IO&__ $!/_)J'_P"+HKZ=HH^M
M3[(.5!1117,4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(,.D"*P]"% -*<4E=#+56;3^/\*K59M/X_PK,"S1112&%%%% !1110 4444
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M:7%AH%A978B$]O D+>4Y93M&W() /(&>G'OUI244M!FA5NU_U1_WJJ5;M?\
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MRQACE@BDD(">H4"N!N].FDTZTDETB430VDL5M;/I\TT+8D)380WF6SG Y8X
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MG458HH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;E2T8 !//:IJ*
M,_RW_N-^5'EO_<;\JT** ,_RW_N-^5'EO_<;\JT** ,_RW_N-^51^8GVG[-O
M7[1L\SRL_-MSC=CKC/&:U*YO_FI?_<'_ /:U-"-3RW_N-^5'EO\ W&_*M"BD
M,S_+?^XWY4>6_P#<;\JT** ,_P M_P"XWY5:ME*QD$$<]ZFHH *KW2LVS:I/
M7H*L44 9_EO_ '&_*CRW_N-^5:%% &?Y;_W&_*CRW_N-^5:%% &?Y;_W&_*C
MRW_N-^5:%% &?Y;_ -QORH\M_P"XWY5H44 9_EO_ '&_*FR?N8GEE^2- 69V
MX"@=23V%:59OB'_D6M5_Z\YO_0#30!'^^B26+YXW 977D,#T(/<4[RW_ +C?
ME3?#W_(M:5_UYP_^@"M*AB,_RW_N-^5'EO\ W&_*M"BD,S_+?^XWY4>6_P#<
M;\JT** ,_P M_P"XWY4>6_\ <;\JT** ,_RW_N-^5.CC<2*2C=1VJ]10 444
M4 %%%% !1110 51DC<R,0C=3VJ]10!G^6_\ <;\J/+?^XWY5H44 9_EO_<;\
MJ/+?^XWY5H44 9_EO_<;\J/+?^XWY5H44 9_EO\ W&_*CRW_ +C?E6A10!G^
M6_\ <;\J/+?^XWY5H44 9_EO_<;\J/+?^XWY5H44 9_EO_<;\JCAD2X\SR'6
M7RW,;[#NVL.JG'0CTK4KF_"'_,>_[#%Q_P"RT^@C4\M_[C?E1Y;_ -QORK0H
MI#,_RW_N-^5'EO\ W&_*M"B@#/\ +?\ N-^5'EO_ '&_*M"B@#/\M_[C?E1Y
M;_W&_*M"B@#/\M_[C?E1Y;_W&_*M"B@#/\M_[C?E1Y;_ -QORK0HH S_ "W_
M +C?E5JV4K&001SWJ:B@ HHHH **** *]TK-LVJ3UZ"J_EO_ '&_*M"B@#/\
MM_[C?E1Y;_W&_*M"B@#/\M_[C?E1Y;_W&_*M"B@#/\M_[C?E1Y;_ -QORK0H
MH S_ "W_ +C?E1Y;_P!QORK0HH S_+?^XWY4>6_]QORK0HH S9/W,3RR_)&@
M+,[<!0.I)["B/]]$DL7SQN RNO(8'H0>XH\0_P#(M:K_ -><W_H!H\/?\BUI
M7_7G#_Z *?2XAWEO_<;\J/+?^XWY5H44AF?Y;_W&_*CRW_N-^5:%% &?Y;_W
M&_*CRW_N-^5:%% &?Y;_ -QORH\M_P"XWY5H44 9_EO_ '&_*CRW_N-^5:%%
M &?Y;_W&_*KD (A4$$'WJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!&!*D*=I(X.,XKRC7=<\1V?BFS2Z@@:\M&<6WEQ';*)!MR!G
MG/\ .O6*HZB+"W":C>Q FUR5E\HNT>>IX!.*J+L [2_M_P#9\1U-HC=L,N(E
MPJ^W6KE<_P#\)OX=_P"@A_Y!D_\ B:/^$W\._P#00_\ (,G_ ,34@=!17/\
M_";^'?\ H(?^09/_ (FC_A-_#O\ T$/_ "#)_P#$T =!17/_ /";^'?^@A_Y
M!D_^)H_X3?P[_P!!#_R#)_\ $T =!17/_P#";^'?^@A_Y!D_^)H_X3?P[_T$
M/_(,G_Q- '045S__  F_AW_H(?\ D&3_ .)H_P"$W\._]!#_ ,@R?_$T =!1
M7/\ _";^'?\ H(?^09/_ (FC_A-_#O\ T$/_ "#)_P#$T =!17/_ /";^'?^
M@A_Y!D_^)H_X3?P[_P!!#_R#)_\ $T =!17/_P#";^'?^@A_Y!D_^)H_X3?P
M[_T$/_(,G_Q- '045S__  F_AW_H(?\ D&3_ .)H_P"$W\._]!#_ ,@R?_$T
M =!17/\ _";^'?\ H(?^09/_ (FC_A-_#O\ T$/_ "#)_P#$T =!17/_ /";
M^'?^@A_Y!D_^)H_X3?P[_P!!#_R#)_\ $T =!17/_P#";^'?^@A_Y!D_^)H_
MX3?P[_T$/_(,G_Q- '045S__  F_AW_H(?\ D&3_ .)H_P"$W\._]!#_ ,@R
M?_$T ;=RL[6T@MG1)RI\MG&5#=LCTKRG^WO$P\9X-K -5\K['Y?EG;MW;L]?
MQSTQ7=_\)OX=_P"@A_Y!D_\ B:MVMWH]_NU>T\N>1$\LRQQEI O7;C&[\,52
MDEN)FA:K.MK$+IT>?:/,9%PI/? ]*EKGCXX\. X.HX(_Z82?_$T?\)SX<_Z"
M/_D"3_XFN?ZQ1_F7WHS]O2_F7WG0T5SW_"<^'/\ H(_^0)/_ (FC_A.?#G_0
M1_\ ($G_ ,31]8H_SK[T'MZ7\R^\Z&BN>_X3GPY_T$?_ "!)_P#$T?\ "<^'
M/^@C_P"0)/\ XFCZQ1_G7WH/;TOYE]YT-%<]_P )SX<_Z"/_ ) D_P#B:/\
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M$?\ 0;_\E9O_ (BC_A;/@C_H-_\ DK-_\11[.?9A=':45Q?_  MGP1_T&_\
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M,G_Q-'U>K_*_N8?6\/\ \_%]Z-VBL+_A,M _Y_\ _P @R?\ Q-'_  F6@?\
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M\28K]Y<%6'X$ UI4@"BBB@ HHHH **** "BBB@ HHHH **** "@@$8(R***
M/*O&WAU=(O%O+5-MI<,?E'2-^N/H>H_&N4KV_7=-75M%NK,J"[H3'[..5_6O
M$.AP: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+(Q:1V+,Q[D]:>#CSU'5Z+1'BYS72@J*W>K&4445Z9\Z%%%% !1110 4444
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M1Q2P-.3YI-W_ *\CRK_A!O$?_0._\CQ__%4?\(-XC_Z!W_D>/_XJO4M3U?\
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MK@!@K*&&<9YP:V^LSM>P<J/FS_A4WC?_ * G_DU#_P#%T?\ "IO&_P#T!/\
MR:A_^+KZ=HI?6I]D'*CYB_X5-XW_ .@)_P"34/\ \71_PJ;QO_T!/_)J'_XN
MOIVBCZU/L@Y4?,7_  J;QO\ ] 3_ ,FH?_BZ/^%3>-_^@)_Y-0__ !=?3M%'
MUJ?9!RH^8O\ A4WC?_H"?^34/_Q='_"IO&__ $!/_)J'_P"+KZ=HH^M3[(.5
M'S%_PJ;QO_T!/_)J'_XNC_A4WC?_ * G_DU#_P#%U].T4?6I]D'*CYB_X5-X
MW_Z G_DU#_\ %T?\*F\;_P#0$_\ )J'_ .+KZ=HH^M3[(.5'S%_PJ;QO_P!
M3_R:A_\ BZ/^%3>-_P#H"?\ DU#_ /%U].T4?6I]D'*CYB_X5-XW_P"@)_Y-
M0_\ Q='_  J;QO\ ] 3_ ,FH?_BZ^G:*/K4^R#E1\Q?\*F\;_P#0$_\ )J'_
M .+H_P"%3>-_^@)_Y-0__%U].T4?6I]D'*CYB_X5-XW_ .@)_P"34/\ \71_
MPJ;QO_T!/_)J'_XNOIVBCZU/L@Y4?,7_  J;QO\ ] 3_ ,FH?_BZ/^%3>-_^
M@)_Y-0__ !=?3M%'UJ?9!RH^8O\ A4WC?_H"?^34/_Q='_"IO&__ $!/_)J'
M_P"+KZ=HH^M3[(.5'S%_PJ;QO_T!/_)J'_XNC_A4WC?_ * G_DU#_P#%U](Z
MKJ,.D:3=ZE<*[0VL32NL8!8A1DXR0,_C6?#XE7[5:PWVE7^G+=-L@FN?*9'<
M]$S&[;21G&[ .,9S@4UB:CZ(.5'S^OPE\;E@#HP4'N;J'C_Q^O7? GPVM?!\
M)U"Z OM8*_>3&V/_ &4SCG_:./PKL/[<TC^TO[._M2R^W9V_9OM">;G&<;<Y
MZ<]*GCO[.:&":*[@>*X;;"ZR B0X)PISR< GCT-1.M.2LPL<)KNE>)]<O/-D
ML-D*<11"=,*/^^NM97_"&Z__ ,^'_D:/_P"*KT;4M933[FWM([.YO;NX#.EO
M;;-P1<;G)=E4 %E')SEA@'FJ0\66DUKI\MG9WEW-?^9Y5K$J+(OE\2;M[*HV
MMA3SU(QFNF&.JQBE&*M_7F>94RBC4DYSE)M^:_R.&_X0W7_^?#_R-'_\51_P
MANO_ //A_P"1H_\ XJO3=,U&WU?38+^U+&&9<@.NU@<X(([$$$'Z5;I_VE6[
M+\?\R/[$P_=_A_D>3_\ "&Z__P ^'_D:/_XJC_A#=?\ ^?#_ ,C1_P#Q5>L4
M4?VG5[+\?\P_L3#]W^'^1Y/_ ,(;K_\ SX?^1H__ (JC_A#=?_Y\/_(T?_Q5
M>L44?VG5[+\?\P_L3#]W^'^1Y/\ \(;K_P#SX?\ D:/_ .*H_P"$-U__ )\/
M_(T?_P 57K%%']IU>R_'_,/[$P_=_A_D>3_\(;K_ /SX?^1H_P#XJC_A#=?_
M .?#_P C1_\ Q5>L44?VG5[+\?\ ,/[$P_=_A_D>3_\ "&Z__P ^'_D:/_XJ
MC_A#=?\ ^?#_ ,C1_P#Q5>L44?VG5[+\?\P_L3#]W^'^1Y/_ ,(;K_\ SX?^
M1H__ (JC_A#=?_Y\/_(T?_Q5>L44?VG5[+\?\P_L3#]W^'^1Y/\ \(;K_P#S
MX?\ D:/_ .*H_P"$-U__ )\/_(T?_P 57K%%']IU>R_'_,/[$P_=_A_D>3_\
M(;K_ /SX?^1H_P#XJC_A#=?_ .?#_P C1_\ Q5>L44?VG5[+\?\ ,/[$P_=_
MA_D>3_\ "&Z__P ^'_D:/_XJC_A#=?\ ^?#_ ,C1_P#Q5>L44?VG5[+\?\P_
ML3#]W^'^1Y/_ ,(;K_\ SX?^1H__ (JC_A#=?_Y\/_(T?_Q5>L44?VG5[+\?
M\P_L3#]W^'^1Y/\ \(;K_P#SX?\ D:/_ .*H_P"$-U__ )\/_(T?_P 57K%%
M']IU>R_'_,/[$P_=_A_D>3_\(;K_ /SX?^1H_P#XJC_A#=?_ .?#_P C1_\
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M-S']FN+6YM9!'/;W 7>A(!!RI92"#D$$UHT.I)!8\4_X0+Q-_P! W_R/'_\
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M#$MLVN:*EEJ(U79I[QRJ>?[.&$.T8Y7)4+MDW/\ +][AL^A4442E=@%%%%2
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MEUC49((_+,0(A!C*,"I!$8S]T=<U*=&G@CO+BWO);G4YXO)2YNV4>6O; 10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#86L<4^?.1(5"R9X.X <Y]Z=Q'%06\,FO1Z5)#&VC+JDZQV[*/*W"!6V;>F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 5[V&2:VVQ;2XD1P'. =KAL9P?
M2F>9J'_/K:_^!+?_ !%6Z* *GF:A_P ^MK_X$M_\11YFH?\ /K:_^!+?_$5;
MHH J>9J'_/K:_P#@2W_Q%'F:A_SZVO\ X$M_\15NB@"IYFH?\^MK_P"!+?\
MQ%'F:A_SZVO_ ($M_P#$5;HH J>9J'_/K:_^!+?_ !%'F:A_SZVO_@2W_P 1
M5NB@"IYFH?\ /K:_^!+?_$4>9J'_ #ZVO_@2W_Q%6Z* *GF:A_SZVO\ X$M_
M\11YFH?\^MK_ .!+?_$5;HH J>9J'_/K:_\ @2W_ ,11YFH?\^MK_P"!+?\
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M_P 15NB@"IYFH?\ /K:_^!+?_$4>9J'_ #ZVO_@2W_Q%6Z* *GF:A_SZVO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;^W%Q97,-S Q($D,@=3CKR.*GHL!9^U_['ZT?:_]C]:K44 6?M?^Q^M'VO\
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M4;*QNH]3M1X;$LPDM"H\TM@C(.S/WL'[W;\*W?C1N_X0RUSO^S_VA%]HV_\
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M:I-),L-Q%&'D;<Q E8<GN:L:GHUIX:\'>&O%&ESSC5F>WWSF9CYH9"=A&<8
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MS++/Y8=QU"X5LXZ9.!GIFH_[?!CL&%I(K7-S]F=)#M:)AG/;GI19@;-%%%(
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M0.3_ *'#Q3_X'+_\11RQ[@=?17(?\(')_P!#AXI_\#E_^(H_X0.3_H</%/\
MX'+_ /$4<L>X$GQ!\/W>O^'4&FJK:E97"7=JK$#<ZG[N21C()_$"KVL>%-$\
M50VTFN:4DDR*" 9"KQYZKN0C(S[XK-_X0.3_ *'#Q3_X'+_\11_P@<G_ $.'
MBG_P.7_XBJNDDDP.DTW3++1]/BL=.MH[>VB7:D:#CZGN3ZD\GO5NN0_X0.3_
M *'#Q3_X'+_\11_P@<G_ $.'BG_P.7_XBIM'N!U]9&O>%]%\30Q1:Q81W0B;
M=&Q9E9?7#*0<'TSC@>E8_P#P@<G_ $.'BG_P.7_XBC_A Y/^AP\4_P#@<O\
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M-0N;7S+JPS]FD\QAY?X X/3OFM*6*.:)XI462-U*NCC(8'@@CN*Y+_A Y/\
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MAP\4_P#@<O\ \14IV=^8#KZ*Y#_A Y/^AP\4_P#@<O\ \11_P@<G_0X>*?\
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M[0W/EE+FXMWC)(:%ASD8P005/XCZ5!%!9Z.DUS<7>'F8&6XN752QZ =@,#H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *SY/]:_^\:T*SY/]:_\ O&@!M%5[Z*>>QGBMIO)G="J2
M?W3C@U1\/6&I:?8-%J=[]JF+EE;<6VCTR>33$:-U<):6DUS(&*0QM(P7J0!D
MXJI;:U:7>BMJL)9H%C:1EP-PVC)!&>O'K3M:_P"0#J/_ %ZR?^@FN5NHWT;0
MOMD2L;*_L!'<(HXCE,>%<?4\'\#5)7 [.VG6ZM8;A 0DJ!U#=<$9YJ6N7TAE
M37+-G8*#HL6,G'1N:R]+@M[Z30TF5986FO6VGE6YR,^HHY0.\JM!?17%[=VJ
M*X>U95<D#!W+N&/P-<?/8VR:#KTZPJ)+6[D6W;_G@ 58!/[HR2>,=:NV]GIM
M]K6N/J*Q2,J1$^9_ IB7<P]/J.F*+ =917#63WFHW>F17UO#=?Z#YD<=[*55
MVW$;L;6W-MQU'?--6)9Y-*MIGBGMUU&6-$1FD14"_<RRC<!R/3'%'*!W=%96
MMB2P\-78T]/*:*$B,1C&T=\?09K)EM;&VNM#_LQ(_P#2?DE"*/W\.SYBX_B[
M<GN:20&[I^IIJ8D>""80JS*LS[0KD'!P <]NX%0IK7G75S!;:?=SFVD\N1D,
M8&<9XW.#5+P;!#%HA>.)$9YI S*H!;#D#/TI^@?\A37?^OS_ -E%.RU LOX@
MLTTT7N)2GFB%X]N'C<G!5@3P03S_ %J]<SR0*ICM)K@DX*Q% 1[_ #,*XJ]_
M?6FJW<6#;3:G"(F!R'VD!B/;/>N\H:L!E:?K?]I_-!I]V(Q(8VD<Q@*1US\^
M?R!K5KC-/MC=^';B%;B")SJ3E%N#^[F8-Q&PSR#Z?I6MHCQP:E>Z>+"*TF14
MD<6TA:)LC&0,#:>.F.<=Z&@-VBBBI **** +-I_'^%6:K6G\?X59I#([C_4-
M^'\ZHU>N/]0WX?SJC3$4=1UBPTD1&^N5A\TD)D$YQUZ#W%75974,I!4C((/!
M%4M1T>PU81"^MEF\HDIDD8SUZ'V%75544*H 4#  ' %&@&9J]]/!-9V-F56Z
MO795D=<B-5&6;'<@=!5>]N+O1);:>6\>[M)95AE$R(&CW=&!11QZ@@U8U>QG
MGFL[ZSVM=6;LRQN<"16&&7.."1T-5[VWN];EMH);-[2TBE6:4S.A:3;T4!&/
M'J215*P#-/>]U*]U,-J5Q"EO=&*-(DBP%P#_ !(3WJA)K.H?V+*R769(M1%J
MMTB+^\3(YQ@C/..!CBK=MX<@N9M6.I6,3?:+AFBD(4OL('((Y'.:JS:5J<NA
MKI4MHDBVUU'Y<@*!980>I7/! ZCO[T] +VIS7FD2V,B:C-=>=<+$UO,D?S@]
M2-J@Y'6M^N>O-$_L_4(-4T:QA\U/W<UNBJ@=#U*YP P_#-;%O>+<75Q;B.1'
M@*[BV,'<,C&"?UJ6!G7$MW<>)S8QWTUO MFLV(DC)+;R.K*>U1'59]*N[ZUO
MI3<I#:F[BE*A6*YP5;  SG'('>I;B*[M_$YOH[&:X@:S6',3Q@AMY/1F':HO
M[)GU6[OKJ^C-NL]L;2*+<&95R26;'&<X. 33T DMHM7NM.2]_M#R[F51*EN(
MD,*Y (4Y&X^YW#K51-7N=4?0S!/):)>K,9A&J,0R < LI[@U<@EU>UT]++^S
MQ)<QH(TN%E40G@ ,<G</<;3TXJFGAORGT.VDACNK:U6;SVD"E=S $':>OS9H
MT M+<7=EXDM;!KU[N*XA=V614#1;>C951P>G/<5N5@VNE2:-KC2:?:H=/O!^
M^1-JF%QT89QE>>@Z<X]*UK*[6]M1.B.@+,NU\9!5BIZ$CJ/6DP,G3C>ZE/J1
M?4[F%8+QX42)(L!0%(^\A/?UK+&O7LEGIK37RVT<EU)!)=*J 2(HX<;@0,D?
M2M33M"MS/J4NH:=;2/+>/)$TL:.2A"XYYQSGBIM3T^66_P!':VA7R+68EPI"
MA%VX&!_A3N@".Z*V-Y<V.IMJLD41*Q!HF&[&1_JU!SQTJEIU_+?0VLMGKL5S
M<L0TMK,$0%?X@ %WJ1V)ST[YK=OH[F6RF2TF$-P5/ER%00K=L@@\5A:A976L
M10A]'%M?AT)O2Z8BVG.593O/L"!UH5@.EHJO%=I+>W%J$</ $)8XPVX'&,'/
M;OBK%2 4444 :$?^J3_=%.IL?^J3_=%.I#*UW_!^-5JLW?\ !^-5J8@K(UZX
MO(4L([*?R)+B[6%GV!L*58G@_0'\*UZR-?T^?44L(X=X\N[61W1@K(H5AN&>
MX)'K]*:W I76I7FF3W]I)>1R;+9;B&XN%P4RVPA@BC//(P/:H%U"^.HQV9N+
M\P7,,H\VYMXXVW( =R#:#CG^)?I6K)X?M)X+M+F2>>6Z"K).[ . OW=NT #!
M&>G7KFG#0XSJ,-]/=W5Q/$K(ID* ;6&",*H'?KUIW0&!I%]<:?IN@*)W:":*
M=Y$*KT5,@ XSC(^O-2VVLZC)96U^LEW/-(ZL]HMBWE>63R%?9G(!SG<1Q6Q;
M>'[:V^Q#SIY%L]XA60K@*ZX*G"C(_7FD3P];(L<)GN7LXY/,2T=E,8(Y Z;B
M ><$XIW0&6]]J;6.M7RZ@R?8;B18HA$A4JN#ALC)ZXX(_&FQ&]DU_4;FTD9K
MEK".2.)MNUF(.%)QG /3D>YK<_L6V^Q7]KOE\N^D>20Y&06 !QQ[=\TTZ'!]
MH,R7%S$S0"!Q&X7<HS@YQD$9[$4KH"GI%^\MY%#/J%UYSQ%FM;VU$;Y!ZJ0
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MR]<"NKKG/"-M/;?V[Y\$D7FZO<21^8A7>AVX89Z@^M='4S^(:"BBBI ****
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M)B&PGG^_S^%+#KINEF>VTR]FCBD:-F7RADJ<' +@_I5;0?\ D.:__P!?"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_0C_ /E6B_PKHJ*OF7;\_P#,1SO_  E/BW_H1_\ RK1?X4?\)3XM_P"A'_\
M*M%_A7144<R[?G_F!SO_  E/BW_H1_\ RK1?X4?\)3XM_P"A'_\ *M%_A714
M4<R[?G_F!SO_  E/BW_H1_\ RK1?X4?\)3XM_P"A'_\ *M%_A7144<R[?G_F
M!SO_  E/BW_H1_\ RK1?X4?\)3XM_P"A'_\ *M%_A7144<R[?G_F!SO_  E/
MBW_H1_\ RK1?X4?\)3XM_P"A'_\ *M%_A7144<R[?G_F!SO_  E/BW_H1_\
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M*?%O_0C_ /E6B_PH_P"$I\6_]"/_ .5:+_"NBHHYEV_/_,#G?^$I\6_]"/\
M^5:+_"C_ (2GQ;_T(_\ Y5HO\*Z*BCF7;\_\P.=_X2GQ;_T(_P#Y5HO\*/\
MA*?%O_0C_P#E6B_PKHJ*.9=OS_S YW_A*?%O_0C_ /E6B_PH_P"$I\6_]"/_
M .5:+_"NBHHYEV_/_,#G?^$I\6_]"/\ ^5:+_"C_ (2GQ;_T(_\ Y5HO\*Z*
MBCF7;\_\P.=_X2GQ;_T(_P#Y5HO\*/\ A*?%O_0C_P#E6B_PKHJ*.9=OS_S
MYX^*/%RG!\#?^5:+_"D_X2GQ;_T(_P#Y5HO\*Z67[_X#^5,HYEV_/_,#G?\
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MV_.<_='&,#\_:K-6;3^/\*3:ML!9HHHJ1A1110 5GR?ZU_\ >-:%9\G^M?\
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M4#M[>V@M8A%;PQPQ@Y"1J%'Y"I:X;5MVG3ZS;6"+!;LML76+Y%0$D,>/NY
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MK-W_  ?C5:F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJ*#3K*V21+>SMXDD&'6.)5#CWP.>IJS10!%]FM]D2>1%LA(,2[!A"!@;?3
M]*(K6W@EEEA@BCDE.9&1 "Y]21UZFI:* (Q!"L[3B)!,P"M(%&X@=B?2HAI]
MDMW]K%G;BYSGSA$-_3'WL9Z59HH KO86<D<L;VD#)*V^16C!#MZD=S21Z=8P
MJ5BLK= 4,9"Q*,J3DKTZ9[59HH J/I>GR6\=N]C;-#&24C,*E5SUP,8%2R6E
MM+;"VDMXG@  $3("H Z<=.*FHH AM[2VM 1;6\4(;&1&@7..G2IJ** "BBB@
M"S:?Q_A5FJUI_'^%6:0R.X_U#?A_.J-7KC_4-^'\ZHTQ!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7B*SO[&.2681SBU6XF#1LBA<?,REA@J#GD$T:UI5S?WEK/;F+$<,\+B1BO\
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M.WMI%-K+%++++)&Z8"XPREL K][GD<5+I>DW$.F7]M>O%YEY-+(Q@)(4/Z9
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MJ2RTJ>VU6"Z=XRD>GI:D G.\-G/3I5#4] U"8:I#9O:F#4'25GF=@T;+C(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img110885244_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img110885244_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +< OD# 2(  A$! Q$!_\0
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MK=8PI. 1(;0(<X.,$YP?0X .QHKG_P#A'M4_Z'/7/^_-E_\ (]'_  CVJ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<_9_P#)0]9_[!5A_P"C;NN@KG[/_DH>L_\ 8*L/_1MW
M0!T%%%% !7/^!/\ DGGAK_L%6O\ Z*6N@KG_  )_R3SPU_V"K7_T4M '0444
M4 %%%% !1110 4444 %%%% !1110 5#=6EM?6LEK=V\5Q;RC;)%,@=''H0>"
M*FHH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__
M (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\
M]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@N
MA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^
M$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0
MJ:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z
M'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH
M Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03
MP?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH
M?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\
MB:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'
M_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_
M ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XF
MN@HH Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__
M (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\
M]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z'_XFN@HH Y__ (03P?\ ]"IH?_@N
MA_\ B:NZ;X;T+1IVGTO1=.L9G78TEK:I$Q7.<$J <9 X]JTZ* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KG[/_DH>L_\ 8*L/_1MW705S]G_R
M4/6?^P58?^C;N@#H**** "N#\%W7BI? OAY;?1M&D@&F6PC>35I49E\I<$J+
M8@'';)QZFN\KG_ G_)//#7_8*M?_ $4M !]L\8?] +0__!S-_P#(M'VSQA_T
M M#_ /!S-_\ (M<#_8FDW/[1=[!/I=E+#)H9F>.2W1E:1G 9B".6()!/4@FN
M>O=-?P#I*M-9_P!H>"O$5JAN8&3>+"[9!M<#LI;!R.F!CE5R >O_ &SQA_T
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MBB@ HHK+U'P_9:I<B>XFU)'"A,6VIW-NN.?X8Y%&>>N,T :E%<__ ,(;I?\
MS]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\ X]0!T%%<_P#\(;I?_/UKG_@]O?\
MX]1_PANE_P#/UKG_ (/;W_X]0!T%%<__ ,(;I?\ S]:Y_P"#V]_^/4?\(;I?
M_/UKG_@]O?\ X]0!T%%<_P#\(;I?_/UKG_@]O?\ X]1_PANE_P#/UKG_ (/;
MW_X]0!T%%<__ ,(;I?\ S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\ X]0!T%%<
M_P#\(;I?_/UKG_@]O?\ X]1_PANE_P#/UKG_ (/;W_X]0!T%%<__ ,(;I?\
MS]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\ X]0!T%%<_P#\(;I?_/UKG_@]O?\
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M_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\
M\50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!T%%<
M_P#\)WX/_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/
M_P"AKT/_ ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_
M ,&,/_Q5'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5
M'_"=^#_^AKT/_P &,/\ \50!T%%<_P#\)WX/_P"AKT/_ ,&,/_Q5:NG:KIVL
M6QN=,O[6^@#%#+;3+*H88)&5)&>1Q[T 6Z*** "BBB@ HHHH **** "BBB@
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MKQ7%HK36T:2D6LP/\9EFD:-SN(V */DZ#'-.\U2X'C+4+%-9F=I_M/EFQO\
M]Y;%(#M\VVD4A%!#@2)\K,4W G:0 >G45XI8ZSJ7_"-:?>^'=>O=3U(Z#YNJ
MH\[7?D2;8MK;,X209DPHP7"DG<036A:7SVEB''B]M3\/7%_;_;+VUDF5+.-H
MY 5\]YI)$RZP;AN78'SQO) !ZM),Z3PQK;RR+(2&D4KMBP,Y;)!YZ< \GG Y
MK*L_$D5]K+6$&GW[0!I8Q?B-3;F2)MKID,64ALCYE )4X)KCY-6TRR\0^%K6
MU\73W.F3F\5O.U ,LJE25/F<,X5CM5MQP5QDL":Q-"BL8_"-QKNBZO>W,ND:
MQ<75S;0:O/*LML+F0D,@D(.8_G!(^<J,[@QR >LW&I0VM_;6LZR(;G*Q2E?D
M+CG83V8C)&>N#CFKE<+KL#1> I[HM<M=7M]!=P)/-([1RO<(8D4,3LQ\@VK@
M @\5UM@UDTU[]CN_/<3D7"_:6E\J3:/EP6/E\8.T8'.<<T 7:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y^S_P"2AZS_ -@JP_\ 1MW7
M05S]G_R4/6?^P58?^C;N@#H**** "N?\"?\ )//#7_8*M?\ T4M=!7/^!/\
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M* "H)K2&XGMYY Y>W<O'AV !*E3D X;ACUSUJ>B@"..".*661%P\K!G)).2
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M -%+0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_
M /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Y^S_ .2AZS_V"K#_ -&W==!7/V?_ "4/6?\ L%6'_HV[H Z"BBB@ KG_
M  )_R3SPU_V"K7_T4M=!7/\ @3_DGGAK_L%6O_HI: .@HHHH **** "BBB@
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MA6[\BUTZ>*T%L;95?]R<@C?D8(.?F. &P;BZ8!XYO9;G09[KPO+=0^38'2I
MD96UCC6;:5P50JR>61QNW ' P>QJ?RO[@YX]SUZJ]C>VVI6,-[9S+-;3H'BD
M7HRGH1[5Y3::%'>:K<ZMK-OKDMZ=0N$V-I@\J:U<L%W,(#(T?EL%\MFZKT
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MX3+2_P#GUUS_ ,$5[_\ &:QG_MBY\(W=_IOBK5 \I46LEY96ZR0LKLC!E\H
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M_P#QFC_A,M+_ .?77/\ P17O_P 9KF?$6K:W;?%_PWH=KK=U!INIQ32S0+#
M=IC1F 5FC+ $KSDD\G!'&/1J .?_ .$RTO\ Y]=<_P#!%>__ !FC_A,M+_Y]
M=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\ \9H_X3+2_P#GUUS_ ,$5[_\
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M*]_^,UT%% '/_P#"9:7_ ,^NN?\ @BO?_C-'_"9:7_SZZY_X(KW_ .,UT%%
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M_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\
MR51]C\8?]!W0_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\ R51]C\8?]!W0
M_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "50
M!T%%<_\ 8_&'_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "50!T%%<_\ 8_&'
M_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\
MR51]C\8?]!W0_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\ R51]C\8?]!W0
M_P#P33?_ "50!T%%<_\ 8_&'_0=T/_P33?\ R51]C\8?]!W0_P#P33?_ "50
M!T%%<_\ 8_&'_0=T/_P33?\ R56KIT>HQ6Q74[JUN9]Q(>VMF@7;Q@;6D<YZ
M\Y_"@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)..J@@U!_P )QXGU"RL[;1M)AN=6:TDN)MJ*8B5E>( !YXRH+)G.7(!Q@]:
M.\U#5],TGR?[2U&TL_.;9%]IG6/S&]%W$9/L*L6]Q!=VT5S;31S02J'CEC8,
MKJ>001P0?6O.KF35M1\57UQ*FE7%JWA^&Y_LZY@,B$,TA"&0.RGYU!+A2"
M!QN-K0-<U[6O$^@32WEK'9W?AZ._FM4MWQOD*;L'S.N>A(.!D=230!Z!42W5
MNUV]HL\1N402/"'&]5)(#%>H!(.#[&N2UG7/$P\4W^D:2FDQ1V^F+?12W2R2
ML[%G7:54J%!*XSDXQGG.!B:=JZR^(M6\06@L--EOO#VG7CR7S;8HR[2\RL,;
MMJX'49V@9'8 ]-HKS:#QSXAN((([>WTV>8Z[_93SRPSVRLAA$JN(FRRGYNY_
MA&.&R.HT'6KZ\T/49KY;=[RPN;FW9K=&1)?+8@$*2Q7(QQD\YYH WEFB>9X5
MD0RH 70,-R@YP2.V<'\J;+=6\$L,4T\4<D[%(4=P#(P!)"@]3@$X'8&N!@U;
M5]*\,>$'TV*QENM?GC-[<W9<GS986E+A5^]RIX+# 55& =RUY;ZYU/Q/X9;5
M+>U_M+3M>NK%KB",JLB?99'!4,25!!3*[CRO4X% 'I=%>=:3XU\2ZG:C5'TR
MRLM'N[.2>UNKZ6.%(7"[D#LLSLZE0Q)V(1MZ=<+;^-=;EM-2$:07AL[Z*+[;
M;:7<;?(>+?YGV?>7<;OEW(Q!5@X! P0#T2BO.)_'/B&_\J/PYIMGJ4D=A#>W
M#PNC0R>87 17DEB9 /+;YMKG)Y5<<]3XBU>_T_1K:\T^W+F25!*ZV[W7DQE2
M=WEQD,XR%7Y3QNW<@8(!O45Y_#XK\2:O?1VVD-H'ER:.NHQW.99T=RQ7:!\A
M R,9/(QDC^$58/B!XAUA8KK1=!5[6&"UGO!,T0 66-)6_>-,A3:C'!\MP2.U
M 'I549=:TJ#2QJDVIV4>GG!%V\ZB(Y.!\Y..O'6L32=5\0ZP3J=JNEG2W>XC
MCM9!(DRF-F12THW*=S)R-@VANK%>>974]>\3#P'J276FVSWT4LS1263RHLGD
M/DX\U<KM) '49)R>E 'I/VNV^Q_;/M$7V7R_-\[>-FS&=V[IC'.:E!! (.0>
MA%<7X<U35',&B?\ $JMKNPO)8+NWM[)HXTMD"E#&OF?+N$D1!.1ASQ\M6?#?
MVF"\UG1K*6"&TTO4U2)'A+!;=X8Y3$F&&W#2,%/(50 %P!@ ZRBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?L_\
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MP3@XQU /4 U:T_PMHVEWIN[.T:-]SNB>=(T43.26,<98I&3DY*@9R?4UL44
M<A>?#S1%L)?[-L(EOH[6:"R:[FEFCMQ(N"JJS'8O;"XQDX')!K6G@I[^.XM-
M<MI8]/EA,;V\?B.^NQ-D@X/F;-@&.V<YQP,@]Q10!DV'AO3=,U2;4K87?VN:
M!+>22:]FEWHGW00[D9'/.,_,W/S',;^$]&?4;B_%O-'/<G=-Y-U+&COMV[]B
ML%W@8P^-P(!!R!6U10!S5OX"\/VGV/[/#?1_8HWBMMNIW(\I7^\%_><9_H/0
M8Q3\/(XO$NG"U@\KP_:6,UL%35[I+A6=E?Y2.=OR8V^8!AB<<8/?T4 8G_"(
MZ']N6[^Q?,MI]A$/G/Y'V?&/+\G=Y>W';;3+;0(O#MD__"/V*3W.U(U6_P!0
MF($8Z*)&$C*HYPH&,^E;U% &%;^%-+'A>'0;FVBDM4^=EC!C DW;RZ8.4.\D
M@@Y'K1-X/T6XMK:&2"X+6LK2PW O)EN%=E*L?/#^8<J<'+<@ = ,;M% %.72
M;"?26TJ:UCDL'C\IH'&5*^AS_.L\^$-$;3;FPEM9)XKIE:9[BYEEE8K]T^:[
M%QM/*X;Y>V*W** ,#_A#-%^T6ER8[TW%H6:*4ZC<%\L,$LWF9<XPN6R=H Z
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M8Y.S@8&#CF33= CM+8_:)I)+N6[-[<30N\(DF/'(5N4"A5"L2,*N<D9K8HH
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M#V]_^/5T%% '/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@]O?_ (]7044
M<_\ \(;I?_/UKG_@]O?_ (]1_P (;I?_ #]:Y_X/;W_X]7044 <__P (;I?_
M #]:Y_X/;W_X]1_PANE_\_6N?^#V]_\ CU=!10!S_P#PANE_\_6N?^#V]_\
MCU'_  ANE_\ /UKG_@]O?_CU=!10!S__  ANE_\ /UKG_@]O?_CU'_"&Z7_S
M]:Y_X/;W_P"/5T%% '/_ /"&Z7_S]:Y_X/;W_P"/4?\ "&Z7_P _6N?^#V]_
M^/5T%% '/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@]O?_ (]7044 <_\
M\(;I?_/UKG_@]O?_ (]1_P (;I?_ #]:Y_X/;W_X]7044 <__P (;I?_ #]:
MY_X/;W_X]1_PANE_\_6N?^#V]_\ CU=!10!S_P#PANE_\_6N?^#V]_\ CU'_
M  ANE_\ /UKG_@]O?_CU=!10!S__  ANE_\ /UKG_@]O?_CU'_"&Z7_S]:Y_
MX/;W_P"/5T%% '/_ /"&Z7_S]:Y_X/;W_P"/4?\ "&Z7_P _6N?^#V]_^/5T
M%% '/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@]O?_ (]7044 <_\ \(;I
M?_/UKG_@]O?_ (]1_P (;I?_ #]:Y_X/;W_X]7044 <__P (;I?_ #]:Y_X/
M;W_X]1_PANE_\_6N?^#V]_\ CU=!10!S_P#PANE_\_6N?^#V]_\ CU'_  AN
ME_\ /UKG_@]O?_CU=!10!S__  ANE_\ /UKG_@]O?_CU'_"&Z7_S]:Y_X/;W
M_P"/5T%% '/_ /"&Z7_S]:Y_X/;W_P"/4?\ "&Z7_P _6N?^#V]_^/5T%% '
M/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@]O?_ (]7044 <_\ \(;I?_/U
MKG_@]O?_ (]1_P (;I?_ #]:Y_X/;W_X]7044 <__P (;I?_ #]:Y_X/;W_X
M]5W3=!L]*F>6WFU%V==I%UJ-Q<+CV$CL ?<<UIT4 %%%% !1110 4444 %%%
M% !7/V?_ "4/6?\ L%6'_HV[KH*Y^S_Y*'K/_8*L/_1MW0!T%%%% !7/^!/^
M2>>&O^P5:_\ HI:Z"N?\"?\ )//#7_8*M?\ T4M '04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %5-5OO[,T>^U#R_-^RV\DVS=M
MW;5+8SSC.*MUE^)8I)_"NL0PQO)+)93*B(I+,Q0@  =30!R,7C+X@3PI+'\,
M=R.H93_;T R#R/X:ZCPKK=QX@T);Z\T_^S[H3S036OG"7RWCD:-AO  /*GI^
MM<E9?$UK:QMX'\!^-RT<2H2-(XR!C^_6_P" 6GE\,O<W%C=V+7.H7MRMO>1&
M*5%DN)'7<IZ'#"@#J**** "LK4_$>EZ1=1VU[/(LKH9"(X))!'&#@O(44B-/
M]IR!P>>#C5K@/&$MG9^)UO[;Q-'X>UF"SC!DO@IL[V$R.5B<,1\P*ORI# .<
M9SP =S:74%]9P7=M()+>>-98G'1E89!_(U2T_7;74]5U33H([A9M-=(YFEC*
M*Q9=PVYY(QWQCTS7EOBSQ44T"SE,EUHVLII,5U';?VB;*WB^9ON1\-,YV_ZM
ME*A0,E2?FFU/Q'')JGBN;1]8MTBDNK 7-S$6D\FV\O;)(0CJX4$@%E8$9)R.
MM 'K]9,OB*QBUS3])'FRS7Z2O%+&F8@(_O OTS[#)]<5E^"X&E\.7=M+KS:S
M;-<2+#>PLZ@QL 2L<OFN[A6++OWY!!7^&O-_#TFC"+P1I\^N26TBI>_; =19
M9$?8H*!F;,8^7HA7!!Q@YH ]RHKQWPGK<'B#Q)X?L9?%5Q=#^R9]UK%J94O-
M',FS>4(=F,88G<3D*3TW9M:->76K-HWDZMJ$FN7+30>(---[(#;J4?<WE[OW
M&V14",FTD,.3G- 'K%9?B+7K7PSH-WK%['<26]JF]UMXR[D>P_J2 .Y%>8:/
MXG>2+PV(]>NCJ/\ PCUVE\Q>6X6&XC6(JTT8W .I,F21NY /516/>:E8W7@[
MQ/='6Y IT1(5L;KQ"+UC.2?,<*LS@ DQJ,\YS@+GD ][HKB/">IV;>,];TJT
MUYM2B%E:7<?F7OGLS/YGF.O.%4CRCA0%&]<  BL&Z\36L'Q)L$M]5NH\ZI+:
M7D-UJ9)?]R^U$M 2 FY4"OA69L8#;LT >@RZ]:P^)K;0&CN#=W%M)=(XC/E!
M$95(W'JV6' SCOC(SJ5P'C5;&/QKH-SJ^HRZ;I@LKR*2Z6Z-JI<F$JGF@@J3
MM+ !@3L/49!Q/#]W?WWB>TLM2UR_EO8M&%S#I\EZ;<F996,9D1"K%C'M+*_7
M<<C@8 /4=0OHM,TZYOIUE:*WC:1UBC+N0!GA1R32:9?Q:KI-GJ,"NL-W D\:
MN &"LH8 X)&<'UKRFTUD/IUG>0ZY<RSRV%R/$=M>7;,+63RFY:-SBW(F&P*
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MZB^1!XC:'PK-J<J0:O=3S2KL\F-E4SI*C[/-\U0QDQE<$D8%5WU I=7%E?\
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MV"K7_P!%+0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N?L_^2AZS_P!@JP_]&W==!7/V?_)0]9_[!5A_Z-NZ .@HHHH
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M6,*AG8X51E>220 .YHF\'>![>2&.?PWX>B>=_+B5[&%3(V"=J@KR< G [ T
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M2^\[[)X>\.7'D2M#+Y5E _ER+]Y&PO##N#R*G_X03P?_ -"IH?\ X+H?_B:
M.@HKG_\ A!/!_P#T*FA_^"Z'_P")JI)X9^'T.IPZ9+H?AE+^=2\5JUI )9%&
M<E4QDCY3R!V/I0!U=%<__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$T =!17/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-
M '045S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\30!T%<_9
M_P#)0]9_[!5A_P"C;NC_ (03P?\ ]"IH?_@NA_\ B:IZ#I.FZ-XZUNWTO3[2
MQ@;3+%VCM85B4MYMV,D* ,X &?84 =91110 5S_@3_DGGAK_ +!5K_Z*6N@K
MF_!9F7X:>'FMXXY)QH]L8TD<HK-Y*X!8 D#/?!QZ&@#@_%2W]AJOB[5]*DTS
M6=+3R_[>T340%=0D495HG'JF2-W *G 8\"#4'U+4OC;8RZ)-#8W4_A@/&;N$
MOL!9B 1D8;D<D,!C[IZ5V]WINKZA<17%[X-\*7,T+^9')-J#NR-Q\P)M,@_*
MO/L/2JMWX;N;^ZDNKSP!X,N+B4[I)9KPN[GU)-IDT <_\09K1_&/@Z"?R?\
MA&%U.5+T* (#=_>42=B=Q8G/??GG->C3:=HEQX@CN)K6TDU9+?Y7* R"(.K#
M/L' (ST()'>L6.PUJ+2CI4?@_P +)IQ!!M%U%Q"03DC9]DQR>>E+IMEKFC1/
M%I?A#PO8QNVYTM=2>(,>F2%M!DT <U\/(8KCX@_$>.:))$_M&!MKJ",C>0<'
MN" 1[BN18:F?#GQ?_L@R"Z_M5L^7][R_,/F8_P" ;OPS7I5AH5_I4[3Z=X%\
M'V<S(4:2WOFC8J>H)6T'''2G:;HVI:-<-<:7X(\(V,[(4:2UOVB8KD'!*V@.
M,@''L* .-\=#3Q\%?#8T+9]L$EE_8_D$>9YV1]S'.[[V>^>O-:'BCPGJ]U?W
M7BSP\ZQ^*]*N$RH^Y=Q_9XB\3#OR3CZD=P1T5IHVI6&H-J%GX(\(V]ZQ8M<0
MW[)(2W7+"TSSWJ>RLM<TZYN+FQ\(>%[6XN6W3RP:DZ-*<DY8BTRQR2>?4T 7
M/ ^J+K?A&SU1;8VPO'FG,+<E"TKD@GC/)/-<5I=]<:7XG^+6H6D9DN;6.":)
M ,[G6W<@8[\BNTCG\61*5C\/Z"BEBQ"ZQ*!DG)/_ !Z]223^-9EAHFHZ5=F[
MT[P-X0L[D@J9K>^:-\'J,K: T <I\+[V]LO$&GZ<EW]NM-6T%-9NI7A02)=-
M)AR9% 9P3N'SDGC@X&*]@KDM/LM<TDS'3?"/A>S,[;I3;:D\?F'U;;:#)Y/7
MUJ[]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0
M_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0
M!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'
M_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\
MR+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0
M_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0
M!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'
M_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\
MR+1]L\8?] +0_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0
M_P#P<S?_ "+0!T%%<_\ ;/&'_0"T/_P<S?\ R+1]L\8?] +0_P#P<S?_ "+0
M!T%%<_\ ;/&'_0"T/_P<S?\ R+5BQN?$DEY&M_I6E06ISOD@U.25UX.,*8%!
MYQ_$/7GI0!L5RGQ,_P"29^(O^O&3^5=7534=+T_5[;[-J=A:WMON#>5<PK(N
MX=#A@1GDT >.^%W,WC'P7;^*52-[;2(YM N;4>5'/NB4/'+DL2Z\8PP'&<?,
M!6[\.9$M/'/Q'%RZ0E=169A(P7:A#G<<]!CG-=S)X5\.RV$-A)H&EO90L7BM
MVLXS'&QZE5Q@$^U2WGAW1-1OX[Z]T;3[F\CQLN)[5'D7!R,,1D8/(H \S\0Q
M^5X_^%,>S9LBF7;C&,11\8JW\;=2MKKX<Z]80OOFLY+7S\8(0O("%/O@ X]&
M7UKO=0\+^'M6NC=:EH6F7EP0%,MS:1R/@=!E@3BH?^$,\+&V%M_PC6C>0'\P
M1?88MN[&-V-N,X &: (]!$]LEM'K5W8W&I3*WV1H(/+/D!4+* 2Q ! S\Q&2
MOJ .>\?_ /([> /^PG)_Z+KK=-\-:#HUPUQI>B:;8SLA1I+6U2)BN0<$J <9
M ./84FH^&- U>Y%SJ>AZ9>SA0@EN;2.1MHZ#+ G')H \?^)_B6\/C'1$N-%U
MX6^F:];-;>7:'R;H+\S;#D>9*QX5>P4X/S&EUSQ+>7?QA\,2WFBZ]#]FU&YM
MX(WM"L3Q;0@>/)^<]7=L#"E1SMR?;+O3[*_,!O+2WN#;RK-"9HP_ER#HZY'#
M#L1S1/86=U=6]U<6D$MQ;%C!+)&&>(D8)4D97(X.* ./\9S/<^-?!6AS1A].
MO;JXGN4/1V@AWQJP[C=\V/516!XJ\,:E!KE[XY\+*?[=TZY*SVP^[?6XC0M&
M1W;&<=^F.0N/1=7T2VU@V3S/+%/97"W-O/"0'1AD$<@@AE)4@CH?7!$MAHVE
MZ4\[Z=IMG9O<-NF:W@6,R'GEMH&3R>OJ: /-6\5ZE>Q^&+32[B72+35+"[U)
MIXXXW?*@NL8WJRX&[+<9/'([YGA[7]4\2^/?"&HZCJ,]D+C17N&@01K&7,HC
M( 93Q)M4]=W( (KUN^T32=4M4M=0TNRN[='WI#<6Z2(K<\@$$ \GGW-22:5I
MTUU:W4MA:O<6@(MI6A4O"",'8<97CTH X;XG^)-1T5((=(UB2SO39W5TL$=O
M&WF"*,ON:20,%48^Z%)8D#*C+# M_%GB/5]9TF$>(9;"&]\+C5)!%;P$+..#
MMWHQVG&2"3WQCMZIJ&B:3JTD,FI:797KPY\IKFW20QYQG:6!QG Z>E8DWPZ\
M,W&N6^I2Z9;M';V9LX[ P1FU"%S)GR]OWMQ/.>_2@#A-*\7>)=?U/PQ%)KDV
MF1ZGHLMW.L5O ?WL9(#+YB' 8#<1R,9QCK6;9Z]J7B77OAEK%ZQ@U">PU/=+
M&@!W+$ZB0 C&3M#8QCGIBO4]2\#:%J^NV>J7UHDXM+4VL=G)&C6Y0G(RA4\C
M QSQ5^X\,Z!=O ]SH>FS-!$((3):1L8XP" BY'"X)X''- 'D7@[Q1K>I:'X,
MT&VU.+17U*UOI?M=M8P -(DL@1%CV[ !C<P !/J"<F[XM\=:UI.N(-,\1I>1
MVDFGI=PQVD20'S@23N.YW+@;AM90JD<L<UZ:WA/PX]@E@WA_2FLXW,B6YLXS
M&KG@L%Q@'WIUWX6\/:A.\][H.EW,TBA'DFLXW9E&, DC) P./84 >0W^IZKH
M6L?$K6M)U/[-/8WUFXMS"CK<E@%V/N&[!!(&TJ<GK4>L>)K_ ,.>,OB'JMG'
MY-TZZ5&78!OL^^-0S8;"DC) W8&<9XXKV>30-&EO(;N32+![F!M\4S6R%XV]
M5;&0>!R/2FGPYH33W<[:+IQFO%*74AM4W3J<$ASC+ X'!]* ,[PA=ZS=Z;?0
MZTLT5Q!=/'#)*\#3-"0&1I!"3&K_ #8P  0 <<UXU')>:WX9\%2W-Z8V?Q4T
M#"WMH(E)+']X4$>TOUZC!W'(->]1VFD:%I,D45O8Z?IL2L\B*B10HO5B1PH'
M7)KFK>U^&-VCPVT'A&9;:-KIDC2V81)@;I"!]T8"Y;T H Q_B; ]E_PA5CI]
MY)I=BVM6\)BM$C1% Y4X*D?+C(&-OJ#@8?8:CXDU;XD^(-%MO$OE:?IZV5Q%
MNM(9&974,Z@@#Y6&1GDC((/!!ZRXU/PGKHM;*YO=%U$7 -Q;022Q3>9LW9=%
M).<;7Y'3!]#4>GW7@Y]2?4]-GT)K^ZC=GNK9X3+,BD;R77E@"!GG P,T >>^
M&?&VMZKXQM[$:_)?:7J5E>207'V2&$JT<C*KQIM)51MP/,9R>I Z54\&>._%
M-[-X4?4=9AG76+&_DD6>WCCCC>%GV.2@!_AYYQCMGD])KFH^"](L+'4]%\/^
M&]7M[C45L)9;3R?W33##'*HP)*]02,@BMR&P^'<.G+K,%IX62QB)C%\D=N(T
M)."OF 8')(QGO0!R,7BS6;/P[?VNK:]?VNNPW%G"VZRMYBQE)VFW=0L;)(%.
M"X)3# @G%4M.^(/B"?P[IEO>:B(+FX\2OI,^I)'&QCB7#<90)N.0H8H!@$[<
M\UZ!,G@&#0/.F7PU'HU[-OWN(!;W$HSSD_*S<'U/!]*F>Q\%P[=(>UT!/[3(
MF6R,<(^UD<APG\?3.<&@#B9!JD?Q6\,V6H>+);HQ6,Y>:&*&)))!+M*E"& +
M<(<'.1\NW.*R?"OB?7)O[)T6.Z^S+J6NZA#<:A;6D".HB0,!@1^7O<DDL5).
M#^'I.A?V+JQ$+Z'96NHZ')]F-L84;[&64']TV!A&4@@@+D=0""!>7PGX<2P>
MP7P_I2V<CB1[<6<8C9QP&*XP3[T >567CGQ5K,7@9EU1K(ZM'?Q79CMHF67[
M.ORRIN4[6//?;D#Y<9![_P"&^N7_ (J^&^EZIJ%P?MUS'(LDT:*IW+(Z;@,;
M<_*#TQGMVK9NO#'A^^\C[7H>F7'V>,10^;:1OY2#HJY' 'H.*L6>D:9I]@UA
M9:=:6UF^=UO# J1MGKE0,<]Z /';#QGXQ3X/GQK/K:7,QCDM_(^Q1@(QG"+,
M2,?,HW<<*<KD<$MM3>*?%$!TO1KF2>S?4=86WBU&8VLEPML4#C*Q;HA(QRH)
M&-HSM)YKT6VT+1[+39M.M=*L8+&;=YMM%;HL4F1@[E P<@8.148\-:"-+.EC
M1--_L\OYAM/LB>5N_O;,8S[XH \I3QOXG-S:(=79DA\:+H4A%O%BXM_E&6^7
MACM)RNW[QP.F(XOB%XC31[Q3?373/XL.DQW<<4 DCMQ@@)N"Q;VP0&?CDGZ>
MCZ1X!\/Z18ZE8+91W=EJ%\]]):W<4<D4;MCY43: %&!@<X]:T5\+^'UM;FU7
M0M,%O=,'N(A:1[)F!R"XQAB#SDT >>WGB3Q;8VEA<ZK=RV=M:!DU+[']EGN(
M_P!]MCFGC 8;"H^81$$'<>@ &-)XDU;PW'\2-8BU.>ZO;:\6"&&98RJKE$\W
M:%S\@8 #.WGD$G->NGPSH#"U!T332+3'V8&TC_<X.1LX^7!)/'K4QT72FFO)
MFTRS,M\GEW;F!=UPF,;9#CYACC!SQ0!YG-XI\503Z3H]U<36:ZCJRP1ZC,;1
M[C[.T8905CW1!F8, <<@#@G)K1^$0<#QF'F$SCQ+=[I0  Y^7YL#@9ZUV@\,
MZ NF'3!H>FC3V?S#:BTC\HM_>V8QGWQ4^G:+I6CF8Z9IEE9&<@RFV@6/S",X
M+;0,]3U]: /%;/Q-XAL]&:2QU1+>>7QR^ERNMC;@31NH):0*@W/D9+#!.3D]
M,7SXN\5-X'U/6DUJY9M!\02VEWLMH"US:*R Y^3 =0WWE &,Y!X(]-_X0OPK
MLV?\(SHVS?OV_8(L;O7[O7WJU;>'=$LK2YM+31M/@MKH$7$,5JBI,",?.H&&
MX)ZT <5J6LZVNO\ AS2X-8NH;37[B[N!>^3"6MX4C+Q1)F/;@C!^<%NV:Y#2
M]<U+QAXG^&.I7KM9W]S:ZDAGA1<[EC91(JL"O.,X((SVQ7M5_I.FZK:+::CI
M]K>6RD,(;B%9$!'0[6!'%1/H&C27=K=OI-@US:(J6TQMD+PJ.@1L94#/ % '
MG&B^*?$@\+ZO>7NH7%UJGAK[:E]"T$21W4B\Q<*F0H4$_*1GU(-1:9XA\<7_
M (;22&=WDNX[2XMIIY;*.XN 03/' J[D'3*^8N0-P/(&/5XK2V@>=XK>*-KA
M]\Q1 #(V ,MZG  R>P%9T?A3PY#9R6<7A_2DM96#20+9QA'8 @$KC!."1^-
M&78>($F^&K:X=4F4):2R->W=F!)&R[@2\*X!92""JX!(XZUSOPT\5:UK'B'6
M-,U2^>]A@M+.ZMY)HHDDQ+&'^81J%&00=OS;<XW-C)]$&GV2Z=_9RV=N+'RC
M#]F$2^5Y>,;-N,;<<8QBJVG^'=$TF?S]-T;3[*;RS%YEM:I&VPG<5RH'&><>
MM &E1110 5S]G_R4/6?^P58?^C;NN@KG[/\ Y*'K/_8*L/\ T;=T =!1110
M5S_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M '04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%9>I:!9ZK<+/<3:DCJ@0"UU*XMUQDG
ME8W4$\]<9Z>@H U**Y__ (0W2_\ GZUS_P 'M[_\>H_X0W2_^?K7/_![>_\
MQZ@#H**Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\ GZUS_P 'M[_\>H Z"BN(
MO[?P3I5VUIJ/BFXL[E0"T-QXIN8W /(RK3@T_3K/P;K%R;;3/$UU?3A2YBMO
M%%U*P48!.%G)QR.?>@#M**Y__A#=+_Y^M<_\'M[_ /'J/^$-TO\ Y^M<_P#!
M[>__ !Z@#H**Y_\ X0W2_P#GZUS_ ,'M[_\ 'J/^$-TO_GZUS_P>WO\ \>H
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M/;W_ ./4 <-XG\/ZQKWA/3H(?! M[L7UI-?PB6US,(E(?)W[67!"KDY/.54
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MBV[%%M_,5C^^QM4"(-&4)!; X.10!ZA14%K=QW:2-$LRB.1HSYL+QDD'!P&
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M(QG'6'J&);Z\?=XJ&U\ 16EOHL":_J[1Z/,9;4,+?C*;-K?N>1M+#U^8\\#
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M\4EO-!K&K0SI:BSN)4DCS=P@Y59 4(&W+ ,@5@&/-=/&BQ1K&BA44!5 [ 4
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MVSEU/4KFRL+26R2VF\G9)#(,.KE8PQX"C((/RCOG(!<\+^*;O7[JZ@NM$NK
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M), P";(G5F"DDAF3M@GG%RT^'T-G)"\7B#62T.GMIR;C;G$)  &/*ZC:N/\
M=YSELR6O@"SLXX8X-6U1$%JEE<J'BQ=PID*L@\O@A25W)M;'?/- '6T444 %
M%%% !1110 4444 %<_9_\E#UG_L%6'_HV[KH*Y^S_P"2AZS_ -@JP_\ 1MW0
M!T%%%% !7/\ @3_DGGAK_L%6O_HI:Z"N?\"?\D\\-?\ 8*M?_12T =!1110
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M@C\HN24*O)GY\Y<D$<  $\'CJTN+BS@32M3$L]\VGS*RQ#[).HW;9,R="HW
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MC"KGG87?YB2<G/.%X&* *%OXM@NX;N:VTS4YHH%E:-XH ZW'EOL*H58C<6W
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M:ZR@ KG[/_DH>L_]@JP_]&W==!7/V?\ R4/6?^P58?\ HV[H Z"BBB@ KG_
MG_)//#7_ &"K7_T4M=!7/^!/^2>>&O\ L%6O_HI: .@HKD=>^)W@_P ,ZM)I
M>KZO]FO8PK/']FF? (R.50CH?6I?#OQ&\*>+-2;3]$U7[5=+$93']GE3" @$
MY90.I% '4T444 %%%% !1144%U;W7F?9YXI?+<QR>6X;8XZJ<="/2@"6BBHE
MNK=KM[19XC<H@D>$.-ZJ20&*]0"0<'V- $M%%% !112.ZQHSNP55&2Q. !0
MM%5=/U.PU:U^U:;?6U[;[BOFVTJR)D=1E21FK5 !1144MU;P300RSQ1RSL5A
M1W :0@%B%'<@ GCL#0!+1110 445%<75O:1K)<SQ0HSK&K2.%!9CA5!/<D@
M=R: ):**B:Y@2YCMGGC6>56>.(N SJN-Q ZD#<N?3(]: ):*** "BBHI[JWM
MO*\^>*+S7$<?F.%WN>BC/4G!XH EHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JIJ<MW!IEQ+86XN+M4)BB) W-^) /T)&>F1U%NB@#F[G
MQ4NC3/)X@C_LZTD>"&S=@KM-*X^9 $=FW!CC&W  SN8'BQ+XOT6"2W2:>XB,
MQ109+.9!&SD!5E)3$1)(P'VDY'K4'C'2M4U>QL(M+CLWDM]0M[QQ=3M$"(I
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M:4RZ:8M2M;,LTJLP\^W<N$,>,>4QQD[B0 1@YR #HD\8:))92W0N9@(IQ;O
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MP%&:5MX5\41_V=YEOHX\CQ!/J\FV_E/R2>9\@_<#)'G-R<?<'][Y0#J&\9Z
MNGPW[7S+;RF0;C;R Q^6=LAD7;F,*<!BX !(!ZBM"_U>RTS3A?74CB!BBKY<
M3R.Y8@*%1068DD< $UP1\&^)'TV5'MM,2]:]O;J&>VU:X@DMS.^\%9%AY R0
M492K84\8Q78:U9Z[+H$5OI5]'_:"F,2S2$0^:HQOP0CA"W/(4X[8Z@ K'Q[X
M;$5FPU!V>\>6."W2UE:=VC)#KY07>""#D%15Q/%&D2:K%IHN9!<2L4C+6\BQ
MNX!)02%=A< '*YW#!R.#7'Z+X0\3:=JNDRRPZ7]DLM1NKMO^)E/-+MG# C<\
M67*[^K$;MO)&>+VC^!WTO7YYVTS0I(VOY;V+5#"#>@.Q<QD&,CAF8;P_W<?*
M#S0!N^)]?@T;3YD%V(+YX'>$_9GN @4?ZQU3[J D99B%&>35'3/&5A;^'-$F
MUB\?[5=65M+/*MN[(C2*H#2,B[(@S$X+%1UQT-+K>BZT^OS:EI#6,J7>G_8)
MXKR1X_*PS,LB%5;=]]LJ<9POS"N:M?AO?0"W%[8^&]5DDT^"TEGN[?+6CQKL
M#Q!D?S!MP=I*9*YRH.  6=8\7>;K&L*WB*^T"QT<QB:4Z66CD4CY_FDC/SDD
M!,'GJ%<&NCN?'7AJQO)[&?5E:YM0GVA4B>0Q!NC/M4A5Z98X"Y&<9&<+6/#7
MB?4H?%]O';:0L>MQ"*!VOY,IA!&"P\GNN6P"<'CG[U1:CX6\4:A%XE'V;1XS
MJ]C;VR?Z?*?+:,$$G]QR/G./]T>O !U\WB;2;?5XM,EN76XED$*MY$AB\P@L
M(S+MV!R!PI8$Y''(SB/XK^V^.-'T_3;\-8S+<"9#:LHE9%X9)6&UU!X.S.#U
M/(%4;;P/<+K]Q>7&E: YN[M+TZ@R[[NT?Y2\:%HOG&5PK[D*[LXR,%VC>%_$
MMC=>&H)Y=)6RT%)+=9HS(\EU$5V(2F%$;;5&?F<9)/;! .BU'Q!I&G:R+>\U
MH6TL-E)=RVIV[?)!4&1SM)&#P/F&<G@XX71O%FB:_.(=,O3.S0"X0^2Z+)&2
M!N5F4!L$X."=IX.#Q63XBT/7+_Q-'J&GPZ<]LFEW-E_I%V\;EY2IS@1,,#8.
M_P#$?3F+P]X?U[3M5T*:\ATT6]AH_P#9LS0W<CN6RA#*IB (_=KP2/O'KCD
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MMT?S(D(6YC._8<DL"-P)W D9!J1='\26]S;6\&A/*D'B.?5#<27421M#)YI
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M4 %%%% !1110 4444 %%%% !1110 4444 ,$,2SO.(D$SJJ-(%&YE4D@$]2
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MAG YKFO"G@V?7O NDVOB&:5;>#37M$L_L+VLT+.@1RY<DL5 (4A5'))W<$=
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M+K(2V-J^61OWDD +C<2<8SQ62GCKP_));1K=7'F7,LD$:-8SAA(@)9&!3*,
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MS/(6$20JQQN)."P !R,DA<B4^)Y_L8E7PSKK7'GM"UIY,0==J[B^XR>64Q@
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M8+* VTX)R,@%-_A_9NT=Q_:NH"_6\-Z;T1VV]I2@3)0Q>7D*!@A WOR:6P\
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MC5R'W[B<E20N.5/%8WB'7=5T_P 2:SIT7B?5H[H^2-)MUL8'BDGE#E86D,.
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M6+!24YWX+@[5Q@_Q<C"F@#JZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "N?\"?\D\\-?\ 8*M?_12UT%<_X$_Y)YX:_P"P5:_^BEH Z"BBB@ HHHH
M**** &+#$DDDB1HLDF-[!0"V!@9/>@0Q"<SB-/.*A#)M&XJ"2!GTR3Q[T^B@
M HHHH **** "BBB@ HHHH **** (;JTMKZUDM;NWBN+>4;9(ID#HX]"#P15?
M3=%TK18WCTK3+.QCD.YUM8%B#'U(4#)J]10 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(<X..3VS2T4 <?
MH7A>\?2M3L?$,$"1W6I27\?]GZA-N!:3S -X6-@5(&"#SC/%0Z5\/+2VNM8:
M]GOI(;J_6ZMC'JUT)$"Q*@+-O!W9W\Y/&WG@ =M10!RGACPW>>%K>]C@VW)N
M]3DG;S[^9]D#,2"-X;,@!&1QN/5N]=7110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<_9_P#)0]9_[!5A_P"C;NN@KG[/_DH>L_\ 8*L/_1MW
M0!T%%%% !7/^!/\ DGGAK_L%6O\ Z*6N@KG_  )_R3SPU_V"K7_T4M '045Q
M.K^+_$\'B"^TW0O!?]L0V9C62X_M2*W^9D#XVNN>A]:DT'Q9XBO?$<6D:_X1
M_L7S[:6XAE_M*.YW^6T8880<?ZQ>2: .RHHHH **QM.\5:1JWV];.:=IM/ -
MU;R6DT<\>5W+^Z90YR.F <]LU<TK5;36K%;VR\\P,2%,UO)"3COM=0<>^,4
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M@#R>\G\/R^+_  ]:#Q9-)8QZ=?NUTVIA9'C+QL!YX(8H-K88-DB(Y8@-GM/
M&J-K/@'0[Z6[%U.]G&)I0X8F0* VX_WL@Y]ZZ2B@ HHHH **** "BBB@ HHH
MH *Y^S_Y*'K/_8*L/_1MW705S]G_ ,E#UG_L%6'_ *-NZ .@HHHH *Y_P)_R
M3SPU_P!@JU_]%+705S_@3_DGGAK_ +!5K_Z*6@#H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ KG[/\ Y*'K/_8*L/\ T;=UT%<_9_\ )0]9_P"P58?^C;N@#H**** "N?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR?WYZO\ ZSDGGKZGU-7=-\,Z1H]U)<6%L\+.SL(_/D:*,L<L4C+%$R2<[0*
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MD8L IR5 (VDDC!.:M6WA_3+6PNK)8))8;M2EP;B>29Y5(VX9W8L1C@9/ Z4
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M>A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\
MXJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_
M /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\
M0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8
M?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_ /A._!__ $->A_\ @QA_^*H_X3OP
M?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,
M8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@
MHKG_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\
M'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_
M (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_ /A._!__ $->A_\ @QA_^*H_
MX3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ
M'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#B
MJ .@HKG_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\
M^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#
M7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_ /A._!__ $->A_\ @QA_
M^*H_X3OP?_T->A_^#&'_ .*H Z"BN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!_
M_0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA
M_P#BJ .@HKG_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*H Z"B
MN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJ@#H**Y_P#X3OP?
M_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ .@HKG_ /A._!__ $->A_\
M@QA_^*H_X3OP?_T->A_^#&'_ .*H Z"N?L_^2AZS_P!@JP_]&W='_"=^#_\
MH:]#_P#!C#_\55/0=6TW6?'6MW&EZA:7T"Z98HTEK,LJAO-NS@E21G!!Q[B@
M#K**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img110885244_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img110885244_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z M@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_
M^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA
M_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH**
M.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?
M_P!"IH?_ (+H?_B:C\#00VOAN2WMXHX8(M3U!(XXU"JBB\F   X  XQ725S_
M (-_Y =S_P!A74O_ $MFH Z"BBB@ KG_  ;_ ,@.Y_["NI?^ELU=!7/^#?\
MD!W/_85U+_TMFH L7WAJPU"\DNIKC54D?&1!JUU"@P .$20*.G8<]>M5_P#A
M#=+_ .?K7/\ P>WO_P >KH** .?_ .$-TO\ Y^M<_P#![>__ !ZC_A#=+_Y^
MM<_\'M[_ /'JZ"B@#G_^$-TO_GZUS_P>WO\ \>H_X0W2_P#GZUS_ ,'M[_\
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MK>\N8X6LDBE::!7A+JTLP)2-MW1"F2N2">< '>45YWHWBSQ3J<>CO.FCV_\
M:DMW:QJD<LOE/%YA5R2RY7]WM*8!_BW#.T:_AG7M7UK[ EQ)8I/ DZZO#';.
M#',K[%1"9#M&0YR0VX+G"[A@ ZVBJ&M7<ECHUU<PW%E;21IE9KYRL,?^TY&.
M!Z9&>F1UKB8/'.LOIE[-Y,4_V+4C;37<6FW&SRO)64.8-QD4$L%W#<!D-@B@
M#T6BJ>DWG]H:/97AEMY3/ DADMF+1,2 24)Y*YZ9YQ5R@ KG_!O_ " [G_L*
MZE_Z6S5T%<_X-_Y =S_V%=2_]+9J .@HHHH *Y_P;_R [G_L*ZE_Z6S5T%<_
MX-_Y =S_ -A74O\ TMFH M7/AS3;O7+?69A=&^MU*Q,M[,J*#C(V!PF#M7(Q
MS@9SBFW_ (8TO4M574[E;O[8D#VRR17LT06-OO *C@#/!SC.0IZ@8QO'FOO:
M:#K-CIXU'[=%ISW$ES8A,VBD-L9BQS\Q1A\@9@ 3\O!J*X^)&A:-<V6EWUR7
MN2D"3N)HLQ-(%V[D9Q(V=P)*JP .3CF@#2C\!>'(H[2..SG5;2#[-'B]G!,.
M[=Y3G?F2//1'RH!( P:L1^$-$CMM5MC:22P:LQ>]CN+F6596(QG#L=IQ@97'
MW5_NC'$76M?:M1UK5-:A\3V5OI>I):Q+8W86-D,<8\ITCD(R6E,A<@8&T;P1
MMKJ)_'^G0:E?V?\ 9^JLNGW<-I=7'V8+'$TA0*V6(++EP/E!./FQM(8@&@WA
M'1GT[[%)#<2()5F662\F:='7@,LQ?S%(&1PPX)'0D57U'PXLVEQZ!;:?9G1I
MVS>//.[2'YP[':5/F,QSEV<')W?,>#3'Q*\.?\))_8GVD>;YLD'G":(J)$!+
M*5#^8N-K#<4"DC@G(S4L=>N=6^(NEO$-4MM.N-)N98X+D(D4P$D.R954DY(8
M\/AE&/E7)R =Q)''-$\4J*\;J59&&0P/4$=Q6"G@G0%TV;3FM)IK25%C\N>[
MFE$:J<J(R[DQ@$ C9MP57T&*^M>+-*T/5;XW4.IO/8:6U[((8Y&C:(, 0JYV
ML^<?-CY1G+*,U<T;Q1;:U?RV:65]:RK;QW2?:H@GFQ.6 8 $D<H00P4].* &
MIX.T5+NRNO+O&N+*0RPROJ%PS;R,$N2_SG: OS9^4;>G%,OO!&@:B]RUQ:W&
M;FX2YE\N]GC!D7&& 5QMY"GC&2JD\@$<IXN\6:E+;^(K2&VU'3H]'NK,?:H&
M0F8-)'E2%8OAE?("@' P2"=M=#<?$#2K&RO)]1@N;"6VN4MOL]V\,;2.Z"1,
M,9-@!7)^9EQM(.#0!<_X1Z+2;N\U;1K:2?5+DCS%O-5N!%)SW!\P# Z83CH,
M"KVAZ3%HFD0V,*1KMW._EKM4N[%G('8%F.!Z51TOQ?IFL>%;CQ!9EVM;=93*
MF59E,>=PRI*GIP02#D$&LG28_%6M>&H-<37A;7U_;B>&Q-M&UK"'7*KG;YA8
M CYMY&[G:1\M &G?>!] U*YFN+BVN?-FN$N7,5]/$/-4 !P$<!3\JGC&2JDY
M(!"-X%T%KB>X\J^6>:X-T\J:E<HXE*E"RD2 KE3M(& 0%!^Z,)<>-;"VO_*>
MTO39"\%B^I*B&WCG)P$;YM_WB$W;=H8X)&#BA;_$K3;KR&ATG6C'<74ME"[6
M@7S+A-W[L*6# D(3N("C^(J0P !JV'@S0=-FLY;2SD1[,.(2;F5L!B"0P+'>
M,JI ;.TJ",$"K%WX<TV]UNVUB<79O;88A9+V9$49!(V*X4@X&01S@9SBLA?B
M#I\G]G1P:9JLUU?R3Q1VT<"EDDA)5T9MVP'*G^+'?..:)O'UI'H:ZO#I&KW%
MHD4TMT8X4!LQ$VV02;G W AN%W'"D],$@&KK'A;2=>F$M_#.S^2T#&&[E@WQ
MMR4?RV7>OLV1U]:S?^%=>&O(NH/LU\8[L(LZG5+H^8%.5S^\[4RY^(.F6][?
M6ZV&JRI820I<SK;;8XUDQM?+D%E^8?=!/< CFK47B])1J"C1]2%Q97D=F]N3
M )'9\%64>;C;A@<DCC/H< %[3O#FFZ5J5SJ%JMU]JND5)GEO)I=X7A<AV(R/
M7&>3ZFJ#^!- <3 Q7V)KM;U\:G<C,XZ/Q)P1QT]!Z#$UQJ%UH$=W<ZA)->K<
M7B16-M&T6\[\ ("1&HYS@,Q/'WB2 -"*9M7TDR0->6!F#!'>$)-'@D!MDBD#
MID!EZ$9% %2U\*Z-9:FVH6]HR3&5I@GGR&))&&&D6(ML5R"0650?F;GDYLZ9
MHFGZ/:RVUC 8X9'9V1I&<9/4#<3A>ORC@9X%<?X<\92VNA:!'J;:MK&K:Q ]
MQ'Y5K&!E0,IN4(BC_>/&?F(&*V;?QS87:636MAJ,YNH!.R10JSP*7*#>H;)^
M<%25# 8RQ P2 30>%X6\.S>&[\F?2 ODP+%-)$_D8P(G*D$@#Y>OS+P1US+<
M>'DFAT_30Q&DVCI,8Y97EDE=&W1J6<D[0P5N22=H' ZTK?Q7IBC4I+:WU.6X
M75#IXMGSOGN!$K8B61@%79SSL7Y6;ODX6D>-[?0M'OI];NKN2>75KB&"&]FA
MBE 7:2F79(E"Y[, >V<C(!VFKZ#I^N-:&_2=C:2B:'RKF6':XZ-\C#)'OGJ?
M6LV'P'H$"P".*^ @NVO8\ZG<G$[?><YDY)R<YS]YO4YJZ5\0]-UV\LK;2+#4
MKQKJV2Z+I$B)%&7*$LSLH)5A@A-QZXS@X;X[.MV.C:GK&GZ[<6,=G9[XH(88
M7#R MDOYD;'&-H !'0T /\1>&;W7/%^BWI6,:;903I*\>H36]QNE*<IY:@X
MC'\8SN/3'.A<>#M"N!:9LC";6 VT1MIY(#Y1()C8QL"R9 .ULC/:L^YU>X\(
MW5M::A<ZKKLFIS^58A;>$.K!"S*S*L<8!QQDYY/921</BQ(M7M;"[T?5+1+F
M;[/%=3I&(C+Y9D*<.6X"L-VW:2IP2.: ++>%](?4([W[/(LD;(ZQI<2+#N0
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MR$1L@*2J6,9&0/E7E1MX %;/AO3KO3;"1+PLKR2%Q$;^:]$8P!@2S .<XSC
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M"[,A_,W E0 <'D  YP*H6'CS2O(TN"PT_7+F34A<R6T31,[DQR$,&>1L+SG
M+ *, [1@5TVC:K;ZYHUIJEJLBPW,8D595PZYZAAZ@\'!(XZF@"Q:6D%A9PVE
MK&(H(4"1H.BJ. *FHHH *Y_P;_R [G_L*ZE_Z6S5T%<_X-_Y =S_ -A74O\
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M[^2]6TM]),2 R1F-U7$QVC:QQP<''7D&@]K='QM=7J13K=&_+1VT^C7CQ,5
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M8QA2,;>0,X]%HH \JTCP]J>GQ6"P^$9[4)XEGU%Q&]HNR!A($SMEZA95&!G
M4@=LR:3X>UBTU/PF+CPW(PTF[NQ+>"6W/[N3S K#Y]VW+J<=>#QD#/IA:X^U
MJHBB-MY9+2&0[P^1@!=N",9YW<8'!SD2T ><_P!G^)9/&^FWLNAO'9V6H7+
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M6ND'F[@S *%DW-DGD.<#C!]+J.<S+;RM;QQR3A"8TD<HK-C@%@"0,]\''H:
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MTES=3QP01*7DEE<*J*.I)/ %<^-/\,^)[HZE9ZBT\LJ!&FTO5I8A($/\7DR
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M*C P,8&]110 4444 %<_X-_Y =S_ -A74O\ TMFKH*Y_P;_R [G_ +"NI?\
MI;-0!T%%%% !7/\ @W_D!W/_ &%=2_\ 2V:N@KG_  ;_ ,@.Y_["NI?^ELU
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MM)[271M/>VN)C<30M:H4DE/5V7&"W Y/-7X88K:"."")(H8U"1QHH544#
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M.6:S01VT@M4#0*,X5#C*CD\#U-6=0TVPU:U-KJ-E;7EN2&,5Q$LB$CH<,"*
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M+=%99'&'<$#AF'!/4CK5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KG_!O_(#N?^PKJ7_I;-705S_@W_D!
MW/\ V%=2_P#2V:@#H**** "N?\&_\@.Y_P"PKJ7_ *6S5T%<_P"#?^0'<_\
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MM(2"P7+ .R+D#GD@' Z9XKG#:.NKZ\RZ=J$\-S!?&2;^S[JWN(RSC: Z?)<
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MEL3*CO'&TZG>"BM\G*L<@@[L$ ]!_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)JIX$TFUTC3[R.P.I?8I;CS(Q?6ZVQ!*@-LA$4?EKD=-HR<G
MOD]70!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_
M /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__
M *%30_\ P70__$T?\()X/_Z%30__  70_P#Q-=!10!S_ /P@G@__ *%30_\
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M+H?_ (FO*'T7[99:W!;>%)+>UGL+.6*SAT>XCCCDBE<R#,B#S90C ;PH+!L
M'#&MV;P^MYXLEEGM-:M1'):RZ&EI81K%'"$7]WYODLUN RON0L@(8<$DB@#N
MO^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]
M"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA
M_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\
MA!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T
M*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'
M_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH**
M .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$
M\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?
M_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B
M:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!
M_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_
M^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")
MKH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_
M .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]
M"IH?_@NA_P#B:V+&PL],LX[.PM(+2UCSLA@C$:+DDG"C@9))_&K%% !7/^'O
M^0YXL_["L?\ Z16M=!7/^'O^0YXL_P"PK'_Z16M '04444 %<_X-_P"0'<_]
MA74O_2V:N@KA_#?AJPU#3[RZFN-521]5U'(@U:ZA08O)APB2!1T[#GKUH [B
MBN?_ .$-TO\ Y^M<_P#![>__ !ZC_A#=+_Y^M<_\'M[_ /'J .@HKG_^$-TO
M_GZUS_P>WO\ \>H_X0W2_P#GZUS_ ,'M[_\ 'J .@HKG_P#A#=+_ .?K7/\
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MK7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\>H_X0W2_^?K7/_![>_\
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M  >WO_QZC_A#=+_Y^M<_\'M[_P#'J .@HKG_ /A#=+_Y^M<_\'M[_P#'J/\
MA#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\>H_X0W2_^?K7
M/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\ GZUS_P 'M[_\
M>H Z"BN?_P"$-TO_ )^M<_\ ![>__'J/^$-TO_GZUS_P>WO_ ,>H Z"BN?\
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M Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\ ![>__'J .@HKG_\
MA#=+_P"?K7/_  >WO_QZC_A#=+_Y^M<_\'M[_P#'J .@HKG_ /A#=+_Y^M<_
M\'M[_P#'J/\ A#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\ GZUS_P 'M[_\
M>H_X0W2_^?K7/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\ QZC_ (0W2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:?1TOEGTVWM#<2B9GCU6>^>9]NTEVF16& J@<G\._14 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7/^'O^0YXL_P"PK'_Z16M=!7/^'O\ D.>+/^PK'_Z16M '04444 %<_P"#
M?^0'<_\ 85U+_P!+9JZ"N?\ !O\ R [G_L*ZE_Z6S4 =!1110 4444 %%%%
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M7_R/0!T%%<__ ,(]JG_0YZY_WYLO_D>C_A'M4_Z'/7/^_-E_\CT =!17/_\
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MUH Z"BBB@ KG_!O_ " [G_L*ZE_Z6S5T%<_X-_Y =S_V%=2_]+9J .@HHHH
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MN"J*V2%BCMXV0$#G:"[N1_M-ZUUUCHVEZ7+<2Z?IMG:27+!IWMX%C,I&3EB
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M+/)* 5%NP! ?'4]* .LHKG_MGC#_ * 6A_\ @YF_^1:/MGC#_H!:'_X.9O\
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>acet-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-19T15:33:40.2657+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" id="DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" id="DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3">
        <link:definition>100040 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100050 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" id="Role_DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>100090 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombination" id="Role_DisclosureBusinessCombination">
        <link:definition>100110 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" id="Role_DisclosureMarketableDebtSecurities">
        <link:definition>100130 - Disclosure - Marketable Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100140 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" id="DisclosurePropertyAndEquipmentNet1">
        <link:definition>100150 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>100160 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements" id="DisclosureThirdPartyAgreements">
        <link:definition>100170 - Disclosure - Third Party Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>100180 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreements1" id="DisclosureLicenseFundingAndOtherAgreements1">
        <link:definition>100190 - Disclosure - License, Funding and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" id="Role_DisclosureCommitmentsAndContingences">
        <link:definition>100200 - Disclosure - Commitments and Contingences</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100210 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtMarketATMOffering" id="Role_DisclosureAtMarketATMOffering">
        <link:definition>100220 - Disclosure - At-the-Market (ATM) Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100230 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100240 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100250 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100260 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100270 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill" id="DisclosureGoodwill">
        <link:definition>100280 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100290 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables" id="Role_DisclosureBusinessCombinationTables">
        <link:definition>100310 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100320 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" id="Role_DisclosureMarketableDebtSecuritiesTables">
        <link:definition>100330 - Disclosure - Marketable Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100340 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100350 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>100360 - Disclosure - Accrued and Other Current Liabilities  (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables" id="DisclosureThirdPartyAgreementsTables">
        <link:definition>100370 - Disclosure - Third Party Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" id="Role_DisclosureCommitmentsAndContingencesTables">
        <link:definition>100380 - Disclosure - Commitments and Contingences (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100390 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100400 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100410 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100420 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Organization and Nature of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Business Combination - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails">
        <link:definition>100460 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" id="Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails">
        <link:definition>100470 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" id="Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails">
        <link:definition>100480 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails">
        <link:definition>100490 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
        <link:definition>100500 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" id="DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails">
        <link:definition>100510 - Disclosure - Business Combination - Schedule of changes in the Company's IPR&amp;D and CVR since the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" id="Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails">
        <link:definition>100520 - Disclosure - Business Combination - Schedule of Supplemental Unaudited Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>100530 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails">
        <link:definition>100540 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" id="Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
        <link:definition>100560 - Disclosure - Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" id="Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails">
        <link:definition>100570 - Disclosure - Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100580 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100590 - Disclosure - Property and Equipment, net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Property and Equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>100610 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" id="Role_DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails" id="DisclosureThirdPartyAgreementsAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Third Party Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails" id="DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails">
        <link:definition>100640 - Disclosure - Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails" id="DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - License, Funding and Other Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails">
        <link:definition>100670 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
        <link:definition>100680 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" id="Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails">
        <link:definition>100690 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" id="Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails">
        <link:definition>100700 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100720 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" id="DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails">
        <link:definition>100730 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" id="DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails">
        <link:definition>100740 - Disclosure - Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" id="Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100760 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100770 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100780 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100790 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100800 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100810 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100820 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100830 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
        <link:definition>100840 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail">
        <link:definition>100850 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100860 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail">
        <link:definition>100870 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100880 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100890 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails" id="DisclosureGoodwillAdditionalInformationDetails">
        <link:definition>100900 - Disclosure - Goodwill (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100910 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="acet-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="acet-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="acet-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="acet-20231231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="acet-20231231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="acet-20231231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="acet-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:href="acet-20231231.xsd#Role_DisclosureOrganizationAndNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="acet-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombination" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombination" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="acet-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" xlink:href="acet-20231231.xsd#Role_DisclosureMarketableDebtSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="acet-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:href="acet-20231231.xsd#DisclosurePropertyAndEquipmentNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="acet-20231231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements" xlink:href="acet-20231231.xsd#DisclosureThirdPartyAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan" xlink:href="acet-20231231.xsd#Role_DisclosureTermLoan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreements1" xlink:href="acet-20231231.xsd#DisclosureLicenseFundingAndOtherAgreements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentsAndContingences" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtMarketATMOffering" xlink:href="acet-20231231.xsd#Role_DisclosureAtMarketATMOffering" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="acet-20231231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="acet-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="acet-20231231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill" xlink:href="acet-20231231.xsd#DisclosureGoodwill" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="acet-20231231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="acet-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="acet-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" xlink:href="acet-20231231.xsd#Role_DisclosureMarketableDebtSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="acet-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="acet-20231231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="acet-20231231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables" xlink:href="acet-20231231.xsd#DisclosureThirdPartyAgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentsAndContingencesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="acet-20231231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:href="acet-20231231.xsd#DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="acet-20231231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:href="acet-20231231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:href="acet-20231231.xsd#Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:href="acet-20231231.xsd#Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="acet-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="acet-20231231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="acet-20231231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="acet-20231231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails" xlink:href="acet-20231231.xsd#DisclosureThirdPartyAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails" xlink:href="acet-20231231.xsd#DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails" xlink:href="acet-20231231.xsd#DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:href="acet-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:href="acet-20231231.xsd#DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="acet-20231231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="acet-20231231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="acet-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="acet-20231231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:href="acet-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails" xlink:href="acet-20231231.xsd#DisclosureGoodwillAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="acet-20231231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" xlink:href="acet-20231231.xsd#DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" xlink:href="acet-20231231.xsd#DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#axisDefault" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SaleOfShare" xlink:label="acet_SaleOfShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacwestMember" xlink:label="acet_PacwestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositAccounts" xlink:label="us-gaap_DemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RisksAndUncertaintiesPolicyTextBlock" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_Sec174CapitalizedRD" xlink:label="acet_Sec174CapitalizedRD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanCashMaintain" xlink:label="acet_TermLoanCashMaintain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillImpairment" xlink:label="acet_GoodwillImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="acet_StockIssuedDuringPeriodSharesWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantForfeited" xlink:label="acet_ClassOfWarrantForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="us-gaap_UnderwritingCommitments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WestportOfficeParkLlcMember" xlink:label="acet_WestportOfficeParkLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyOneLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidSoftwareSubscriptionAndLicensingFees" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LeaseCostOtherInformationAbstract" xlink:label="acet_LeaseCostOtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FairValueOfCommonStockPolicyTextBlock" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RentIncreaseAnnually" xlink:label="acet_RentIncreaseAnnually"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtTheMarketOfferingTextBlock" xlink:label="acet_AtTheMarketOfferingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PercentageOfCashFullyInsured" xlink:label="acet_PercentageOfCashFullyInsured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidProfessionalServices" xlink:label="acet_PrepaidProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalCommonStockNotSold" xlink:label="acet_AdditionalCommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwrittenPublicOffering" xlink:label="acet_UnderwrittenPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessAcquisitionsProFormaRevenue1" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PerformanceRestrictedStockMember" xlink:label="acet_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_JefferiesLlcMember" xlink:label="acet_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LossOnDisposalOfLeaseAssets" xlink:label="acet_LossOnDisposalOfLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchAndDevelopmentInProcess1" xlink:label="acet_ResearchAndDevelopmentInProcess1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseInConstructionInProgress" xlink:label="acet_IncreaseInConstructionInProgress"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" xlink:label="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedSalesAgreementMember" xlink:label="acet_AmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantMember" xlink:label="acet_InducementGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtmProgramMember" xlink:label="acet_AtmProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeaseProceedsPaymentsUse" xlink:label="acet_OperatingLeaseProceedsPaymentsUse"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BancOfCaliforniaMember" xlink:label="acet_BancOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment" xlink:label="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OrganizationAndNatureOfBusinessTextBlock" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OrganizationAndNatureOfBusinessAbstract" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BlackScholesOptionPricingModelMember" xlink:label="acet_BlackScholesOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanMaturityDate" xlink:label="acet_TermLoanMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DecreaseInConstructionInProgress" xlink:label="acet_DecreaseInConstructionInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TotalLoanAccountsOutside" xlink:label="acet_TotalLoanAccountsOutside"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DiscountOnUnderwritersWarrant" xlink:label="acet_DiscountOnUnderwritersWarrant"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MLimitation" xlink:label="acet_MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnsoldCommonStockValue" xlink:label="acet_UnsoldCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AvailableUnderTheLoanAgreement" xlink:label="acet_AvailableUnderTheLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateNetProceed" xlink:label="acet_AggregateNetProceed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseInConstructionBudget" xlink:label="acet_IncreaseInConstructionBudget"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementOneMember" xlink:label="acet_RedwoodCityLeaseAgreementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopment" xlink:label="acet_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PreFundedWarrantMember" xlink:label="acet_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockNotSold" xlink:label="acet_CommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ConstructionInProgressNet" xlink:label="acet_ConstructionInProgressNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockPriceDecrease" xlink:label="acet_StockPriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CombinedBalancesInDemandDepositAccounts" xlink:label="acet_CombinedBalancesInDemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgentCommissionsAndExpenses" xlink:label="acet_SalesAgentCommissionsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateFairValue" xlink:label="acet_AggregateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePrice</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SaleOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SaleOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SaleOfShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding capital stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID 19.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C O V I D19</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COVID-19</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacwestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PacWest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacwestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PacWest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacwestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PacWest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase of common stock at public offering price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Of Common Stock At Public Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase of common stock at public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Issued, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DemandDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Demand Deposit Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DemandDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Demand Deposit Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_Sec174CapitalizedRD_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sec 174 Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_Sec174CapitalizedRD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sec 174 Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities&#8212;related party, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, FDIC Insured Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, insured amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition date fair value of resTORbio common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock warrants issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options assumed as part of merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed As Part Of Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Assumed as part of the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, net of current maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanCashMaintain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan cash maintain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanCashMaintain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term Loan cash maintain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, fair value, settled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to financing, net of issuance costs of $823,940</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Two Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Conversion Shares In Connection With Merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Conversion Shares In Connection With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split exchange ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lawsuits filed against company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lawsuits Filed Against Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lawsuits Filed Against Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrant exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrant shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Rights Expiration Date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License funding and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Funding And Other Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average IBR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares of Common Stock Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended lease term from the date of relocation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnderwritingCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnderwritingCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Fee Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Fee Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise fee paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant as part of merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant As Part Of Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Assumed as part of the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualifying expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualifying Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualifying expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision for (Benefit from) Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of useful life or lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock [ Member ]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WestportOfficeParkLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Westport Office Park, LLC member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WestportOfficeParkLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Westport Office Park, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WestportOfficeParkLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Westport Office Park, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Merger Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost for merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research funding fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty One Loan Amendment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Loan Amendment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid software subscription and licensing fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid software subscription and licensing fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid software subscription and licensing fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease cost other information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Other Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities called</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen and two thousand fifteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen And Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 and 2015 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income tax provision (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Vested Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measure of Changes in Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Stock Incentive Plan Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Incentive Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RentIncreaseAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent increase annually</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RentIncreaseAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Increase Annually</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RentIncreaseAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in annual rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction In Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Separately Recognized Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities additions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash security deposit received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current and non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative revenue recognised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Cumulative Revenue Recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement cumulative revenue recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Backed Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market (ATM) Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Contingent Value Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual Contingent Value Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Contingent Value Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property, plant, and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposition of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under Employee Stock Purchase Plan, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of modified stock options and restricted stock units attributable to pre-combination services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Modified Stock Options And Restricted Stock Units Attributable To Pre Combination Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan and non formula ancillary service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan and non formula ancillary service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term loan and non formula ancillary service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company&#8217;s Marketable Debt Securities by Contractual Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfCashFullyInsured_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Cash Fully Insured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfCashFullyInsured_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Cash Fully Insured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfCashFullyInsured_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cash fully insured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston, Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Boston, MA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment from Regeneron for exercise of its option to license exclusive rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax basis difference IPR&amp;D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Basis Difference I P R D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Difference IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Related Party Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration, fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agency Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Minimum Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">resTORbio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Res T O Rbio [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">resTORbio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalCommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalCommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalCommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (Expense) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwrittenPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering Underwritten</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwrittenPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwrittenPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The pro forma revenues for a period as if the business combination or combinations had been completed at the beginning of the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisitions Pro Forma Revenue1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue - related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Available for Grant, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Available for Grant, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PerformanceRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance restricted stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of preferred stock warrant liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Preferred Stock Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of preferred stock warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 43,270,386 and 42,954,820 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Assets Arising from Contingencies, Amount Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options authorized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding balance under the loan agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Securities Converted To Warrants To Purchase Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Securities Converted To Warrants To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of warrants, Impact of converting to warrants for the purchase of common stock and adjusted for the Exchange Ratio and Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement grants member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_JefferiesLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of the combined company owned by resTORbio stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of outstanding warrants to purchase shares of common stock .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Outstanding Warrants To Purchase Shares Of Common Stock Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Warrants to Purchase Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock conversion in connection with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Conversion In Connection With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for (benefit from) income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment based on tax positions related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Issued During Period, Shares, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares withheld for taxes, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares withheld for taxes, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Topic 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of surviving stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Surviving Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of surviving stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability and TRDF obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability And T R D F Obligation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability And TRDF Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract research term period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research Term Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research term period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability (CVR)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax operating lease right of use asset liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Operating Lease Right Of Use Asset Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value included in other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares cancelled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CRO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued CRO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued CRO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LossOnDisposalOfLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss on disposal of lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LossOnDisposalOfLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss on disposal of lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LossOnDisposalOfLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LossOnDisposalOfLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchAndDevelopmentInProcess1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development in process 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchAndDevelopmentInProcess1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development in process 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchAndDevelopmentInProcess1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development in process 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of clinical milestones payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Clinical Milestones Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of clinical milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of redeemable convertible preferred stock tranche liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Redeemable Convertible Preferred Stock Tranche Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of redeemable convertible preferred stock tranche liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs granted (includes PSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill measurement period adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Measurement Period Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustment to goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs and Other Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Future Lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in estimated transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the offering, after deducting expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Summarizes the Purchase Price in the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment for research funding received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Additional Payment For Research Funding Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment for research funding received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant, shares granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Available for Grant, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Purchase Commitment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Of Options Percentage Of Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Of Options Percentage Of Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchanged during period shares in connection with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchanged During Period Shares In Connection With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock in connection with the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost for business acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License funding and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Funding And Other Agreements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Funding and Other Agreements Related to the CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised Investment Right and Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercised Investment Right and Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercised Investment Right and Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and other offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Other Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination of redeemable convertible preferred stock tranche liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Redeemable Convertible Preferred Stock Tranche Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination of redeemable convertible preferred stock tranche liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Change in Company's Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill Impairement charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of stock purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Description of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">qualifying expenses on cumulative basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualifying Expenses On Cumulative Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualifying expenses on cumulative basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows used for lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Pursuant To At The Market Offering Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Pursuant To At The Market Offering Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan availability end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Separately Recognized Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone closing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Closing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone closing liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares available for sale under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Available For Sale Under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for sale under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Unaudited Pro Forma Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Shares exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fees and expense incurred in connection with clinical trials.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fees And Expense Incurred In Connection With Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fees and expenses related to clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National Institutes of Health.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institute of Health</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of changes in the fair value of the unobservable financial instruments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Changes In Fair Value Of Unobservable Financial Instruments Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Fair Value of Level 3 Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights agreement [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Research And Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisory services annual fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advisory Services Annual Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisory services annual fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Period Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued CMO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued CMO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CDMO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Income Tax Refunds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received form tax refunds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Receivable, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate for term loan to finance leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Three Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Three Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Exercise Price, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net assets acquired:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of classification of company marketable debt securities in condensed consolidated balance sheets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt Securities Classification Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Two Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtmProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtmProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtmProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fourteen Stock Incentive Plan Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Incentive Plan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Shares exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments to CROs and CDMOs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments to CRO's</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments to CRO's</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of warrants, Outstanding and exercisable to purchase preferred shares as of December 31, 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Outstanding and exercisable to purchase preferred shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeaseProceedsPaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeaseProceedsPaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Proceeds Payments, Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeaseProceedsPaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease, Proceeds Payments, Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Funding Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Funding Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, estimated weighted-average period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of CVR liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of C V R Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the CVR liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Sublease Income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sublease Income Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Party Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BancOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Banc of California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BancOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Banc of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BancOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Banc of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entity date of merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Date Of Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity date of merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, temporary equity, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, temporary equity, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis International Pharmaceutical Ltd. (&#8220;Novartis&#8221;).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis International Pharmaceutical Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis International Pharmaceutical Ltd.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of commercial milestones payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Commercial Milestones Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of commercial milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in estimated fair value of cvr liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Estimated Fair Value Of Cvr Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in estimated fair value of CVR liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares upon accelerated vesting of rsu with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Upon Accelerated Vesting Of R S U With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class Of Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal and state research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchanged During Period Value In Connection With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock in connection with the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchanged during period value in connection with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional closing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Closing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional closing liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Loan Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxes withheld and paid related to net share settlement of equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes withheld and paid related to net share settlement of equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes withheld and paid related to net share settlement of equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Taxes withheld and paid related to net share settlement of equity awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock units outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options assumed as part of merger in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Assumed As Part Of Merger In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Assumed as part the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, RSUs forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Goodwill Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Goodwill Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value upon accelerated vesting of rsu with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Upon Accelerated Vesting Of R S U With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon accelerated vesting ofrestricted stock units in connection with the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount equal to pro-rated bonus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities&#8212;related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Nature of Business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BlackScholesOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black Scholes Option Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BlackScholesOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black-Scholes Option-Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BlackScholesOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Option-Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term loan Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CRO, CMO, and Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of Credit issued amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination acceleration of restricted stock units upon merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Acceleration Of Restricted Stock Units Upon Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acceleration of restricted stock units upon merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares authorized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For First Indication Approved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the summary of Prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo Park lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Menlo Park, CA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses and current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DecreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DecreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease in construction in progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Shares exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid maintenance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Outstanding And Exercisable To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of warrants, Outstanding and exercisable to purchase common stock as of December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Outstanding And Exercisable To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets recognized upon adoption of Topic 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets recognized in noncash investing or financing activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Exposure Prophylaxis in adults</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Exposure Prophylaxis Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Exposure Prophylaxis in adults</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value,Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination provisional information initial accounting incomplete adjustment tangible and intangibles assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Provisional Information Initial Accounting Incomplete Adjustment Tangible And Intangibles Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement prior adjustment in tangible and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adicet Therapeutics, Inc Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adicet Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adicet Therapeutics [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of early exercised stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Early Exercised Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period closing of the merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate value of common stock available for offering at-the-market price under sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Value Of Common Stock Available For Offering At Market Price Under Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate value of common stock available for offering at-the-market price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TotalLoanAccountsOutside_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total loan accounts outside</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TotalLoanAccountsOutside_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total loan accounts outside</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan amount drawn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Amount Drawn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount drawn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DiscountOnUnderwritersWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discount On Underwriters Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DiscountOnUnderwritersWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discount On Underwriters Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right of use asset obtained in exchange of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use asset obtained in exchange for operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">162m Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">162m Limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">162m limitation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease Agreement Description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issued Upon Conversion (1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock shares issued upon conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, fair value, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock warrants to common stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of weighted average ibr and remaining lease term table text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Weighted Average I B R And Remaining Lease Term Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average IBR and Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnsoldCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unsold Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnsoldCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsold Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnsoldCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsold Common Stock Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redwood City lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redwood City Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redwood City Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redwood City, CA (1000 Bridge Parkway)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable debt securities, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Grant Date Fair Value, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; none issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate number of shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events Considerations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants outstanding and exercisable, Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of net assets acquired in Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares withheld for taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Valuation Allowance Increase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of redeemable convertible preferred stock on exercise of warrants with loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted- Average Grant Date Fair Value, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Grant Date Fair Value, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount payable upon closing of merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Payable Upon Closing Of Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable upon closing of merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended lease Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended lease Agreement Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended lease Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AvailableUnderTheLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available under the Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AvailableUnderTheLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available under the Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding and exercisable, Weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinitely.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transition agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Pharmaceuticals Incorporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron Pharmaceuticals Incorporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AggregateNetProceed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">aggregate net proceed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AggregateNetProceed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Net Proceed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AggregateNetProceed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Net Proceed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preliminary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange ratio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, temporary equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, temporary equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options authorized in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Authorized In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options, authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Sublease Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, Rent Expense, Sublease Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of sharesaof redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional amount payable of option exercise fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Additional Amount Payable Of Option Exercise Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement additional amount payable of option exercise fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value included in research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Included In Research And Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value included in research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licence agreement additional revenue recognised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Additional Revenue Recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement additional revenue recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Limited Partnership Units Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customers percentage of total revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customers Percentage Of Total Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customers percentage of total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividends declared | $ / shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiplied by the fair value per share of resTORbio common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject to Ground Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office lease space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionBudget_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in construction budget.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionBudget_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Construction Budget</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redwood City Lease Agreement One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redwood City Lease Agreement One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redwood City, CA (1200 Bridge Parkway)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contribution in the plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) from the remeasurement of the redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From The Remeasurement Of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain from the remeasurement of the redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Shares exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares repurchased under stock purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Number of Shares Authorized to be Repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities additions (deductions).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities Additions Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions (Deductions)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options available for future grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Available For Future Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Share Consideration of Combined Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrants member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">common stock pursuant to at-the-market offering, net of issuance costs,shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">common stock pursuant to at-the-market offering, net of issuance costs,shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">term loan to finance leasehold improvements 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">term loan to finance leasehold improvements 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan to finance leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of deferred debt issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of deferred debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating cash flows used for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments, Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock shares of the combined company owned by resTORbio stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock from early exercise of options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock From Early Exercise Of Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Early Exercised Common Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value,Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Purchase Commitment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Taxes and Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Taxes and Tax Credits, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of contingent consideration liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Contingent Consideration Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock warrants into common stock warrants in connection with merger.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants In Connection With Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant into common stock warrant in connection with Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of number of shares of common stock reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Number Of Shares Of Common Stock Reserved For Future Issuance [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number of Shares of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockNotSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock not sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen and two thousand eighteen stock incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen And Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 and 2018 Stock Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Less portion of the fair value to be distributed as CVR.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less Portion Of Fair Value To Be Distributed As C V R</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: portion of the fair value to be distributed as CVR</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement cumulative revenue reduction recognised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Cumulative Revenue Reduction Recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement cumulative revenue reduction recognised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of trdf liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of T R D F Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of TRDF liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right-of-use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Operating Lease Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConstructionInProgressNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress remaining</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConstructionInProgressNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">construction in progress net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConstructionInProgressNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">construction in progress net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lump sum compensation payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lump Sum Compensation Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lump sum payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase of leased space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noninterest Expense Offering Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TRDF Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T R D F Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRDF Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockPriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price declined</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockPriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockPriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Price Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets for Financial Service Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets for Financial Service Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposition of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance price per shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CombinedBalancesInDemandDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined balances in demand deposit accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CombinedBalancesInDemandDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined balances in demand deposit accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CombinedBalancesInDemandDepositAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined balances in demand deposit accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership change plan description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Change Plan Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership change plan description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgentCommissionsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agent commissions and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgentCommissionsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales agent commissions and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgentCommissionsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales agent commissions and expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average remaining lease term - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Terms (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Other Income, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Outstanding ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Outstanding beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of changes in the Company's IPR&amp;D and CVR since the Merger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock warrants issued in connection with issuance of Series B redeemable convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For Second Indication Approved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan abstract [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock related to financing, net of issuance costs of $823,940, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering costs included in accrued liabilities at period end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Offering Costs Included In Accrued Liabilities At Period End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Offering Costs Included In Accrued Liabilities At Period End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AggregateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AggregateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacific western bank</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacific western bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pacific western bank [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" xlink:to="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SaleOfShare" xlink:to="acet_SaleOfShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_COVID19Member" xlink:to="acet_COVID19Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PacwestMember" xlink:to="acet_PacwestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositAccounts" xlink:to="us-gaap_DemandDepositAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RisksAndUncertaintiesPolicyTextBlock" xlink:to="acet_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_Sec174CapitalizedRD" xlink:to="acet_Sec174CapitalizedRD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockWarrantsMember" xlink:to="acet_CommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_IncomeTaxesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanCashMaintain" xlink:to="acet_TermLoanCashMaintain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LiabilitiesFairValueSettled" xlink:to="acet_LiabilitiesFairValueSettled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GoodwillImpairment" xlink:to="acet_GoodwillImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LawsuitsFiledAgainstCompany" xlink:to="acet_LawsuitsFiledAgainstCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="acet_StockIssuedDuringPeriodSharesWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOrRightsExpirationDate" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="acet_LicenseFundingAndOtherAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AreaOfSublease" xlink:to="acet_AreaOfSublease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantForfeited" xlink:to="acet_ClassOfWarrantForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderwritingCommitments" xlink:to="us-gaap_UnderwritingCommitments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExerciseFeePaid" xlink:to="acet_ExerciseFeePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_QualifyingExpenses" xlink:to="acet_QualifyingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_WestportOfficeParkLlcMember" xlink:to="acet_WestportOfficeParkLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementUpfrontPayment" xlink:to="acet_LicenceAgreementUpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResearchFundingFee" xlink:to="acet_ResearchFundingFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandTwentyOneLoanAmendmentMember" xlink:to="acet_TwoThousandTwentyOneLoanAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidSoftwareSubscriptionAndLicensingFees" xlink:to="acet_PrepaidSoftwareSubscriptionAndLicensingFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="acet_LeaseCostOtherInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FairValueOfCommonStockPolicyTextBlock" xlink:to="acet_FairValueOfCommonStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFifteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RentIncreaseAnnually" xlink:to="acet_RentIncreaseAnnually_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilitiesAdditions" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementCumulativeRevenueRecognised" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AtTheMarketOfferingTextBlock" xlink:to="acet_AtTheMarketOfferingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractualContingentValueRight" xlink:to="acet_ContractualContingentValueRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanAndNonFormulaAncillaryService" xlink:to="acet_TermLoanAndNonFormulaAncillaryService_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PercentageOfCashFullyInsured" xlink:to="acet_PercentageOfCashFullyInsured_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BostonMember" xlink:to="acet_BostonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxBasisDifferenceIPRD" xlink:to="acet_DeferredTaxBasisDifferenceIPRD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidProfessionalServices" xlink:to="acet_PrepaidProfessionalServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationFees" xlink:to="acet_ContingentConsiderationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAndCollaborationRevenue" xlink:to="acet_LicenseAndCollaborationRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResTORbioMember" xlink:to="acet_ResTORbioMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdditionalCommonStockNotSold" xlink:to="acet_AdditionalCommonStockNotSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnderwrittenPublicOffering" xlink:to="acet_UnderwrittenPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EmployeeStockPurchasePlanMember" xlink:to="acet_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessAcquisitionsProFormaRevenue1" xlink:to="acet_BusinessAcquisitionsProFormaRevenue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" xlink:to="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PerformanceRestrictedStockMember" xlink:to="acet_PerformanceRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:to="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_InducementGrantsMember" xlink:to="acet_InducementGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_JefferiesLlcMember" xlink:to="acet_JefferiesLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:to="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NovartisLicenseAgreementMember" xlink:to="acet_NovartisLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSharesOfSurvivingStockOptions" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractResearchTermPeriod" xlink:to="acet_ContractResearchTermPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedCroCosts" xlink:to="acet_AccruedCroCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LossOnDisposalOfLeaseAssets" xlink:to="acet_LossOnDisposalOfLeaseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResearchAndDevelopmentInProcess1" xlink:to="acet_ResearchAndDevelopmentInProcess1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseInConstructionInProgress" xlink:to="acet_IncreaseInConstructionInProgress_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GoodwillMeasurementPeriodAdjustments" xlink:to="acet_GoodwillMeasurementPeriodAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" xlink:to="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:to="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExercisedInvestmentRightAndPurchased" xlink:to="acet_ExercisedInvestmentRightAndPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_QualifyingExpensesOnCumulativeBasis" xlink:to="acet_QualifyingExpensesOnCumulativeBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetMember" xlink:to="acet_ContractAssetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MilestoneClosingLiability" xlink:to="acet_MilestoneClosingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NationalInstitutesOfHealthMember" xlink:to="acet_NationalInstitutesOfHealthMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:to="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmendedSalesAgreementMember" xlink:to="acet_AmendedSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_InducementGrantMember" xlink:to="acet_InducementGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentValueRightsAgreementMember" xlink:to="acet_ContingentValueRightsAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CaliforniaResearchAndDevelopmentMember" xlink:to="acet_CaliforniaResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOrRightIssued" xlink:to="acet_ClassOfWarrantOrRightIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdvisoryServicesAnnualFee" xlink:to="acet_AdvisoryServicesAnnualFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedCmoCosts" xlink:to="acet_AccruedCmoCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MergerMember" xlink:to="acet_MergerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:to="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:to="acet_TwoThousandTwentyTwoLoanAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AtmProgramMember" xlink:to="acet_AtmProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFourteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaymentsToCros" xlink:to="acet_PrepaymentsToCros_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementTerminationDescription" xlink:to="acet_LicenseAgreementTerminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeaseProceedsPaymentsUse" xlink:to="acet_OperatingLeaseProceedsPaymentsUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResearchFundingAgreementMember" xlink:to="acet_ResearchFundingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MarketableSecuritiesMember" xlink:to="acet_MarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationMember" xlink:to="acet_ContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EstimatedFairValueOfCVRLiability" xlink:to="acet_EstimatedFairValueOfCVRLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:to="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BancOfCaliforniaMember" xlink:to="acet_BancOfCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EntityDateOfMerger" xlink:to="acet_EntityDateOfMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantExercised" xlink:to="acet_ClassOfWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FederalAndStateResearchAndDevelopmentMember" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdditionalClosingLiability" xlink:to="acet_AdditionalClosingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandTwentyLoanAmendmentMember" xlink:to="acet_TwoThousandTwentyLoanAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" xlink:to="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnvestedRestrictedStockUnitsOutstanding" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NonRefundableUpfrontPaymentReceived" xlink:to="acet_NonRefundableUpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment" xlink:to="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OrganizationAndNatureOfBusinessTextBlock" xlink:to="acet_OrganizationAndNatureOfBusinessTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OrganizationAndNatureOfBusinessAbstract" xlink:to="acet_OrganizationAndNatureOfBusinessAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractLiabilityMember" xlink:to="acet_ContractLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BlackScholesOptionPricingModelMember" xlink:to="acet_BlackScholesOptionPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanMaturityDate" xlink:to="acet_TermLoanMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:to="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GrantTerm" xlink:to="acet_GrantTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MenloParkLeaseAgreementMember" xlink:to="acet_MenloParkLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DecreaseInConstructionInProgress" xlink:to="acet_DecreaseInConstructionInProgress_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfCustomer" xlink:to="acet_NumberOfCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RightOfUseAssetsRecognized" xlink:to="acet_RightOfUseAssetsRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PostExposureProphylaxisDescription" xlink:to="acet_PostExposureProphylaxisDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractLiability" xlink:to="acet_ContractLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="us-gaap_ConstructionPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdicetTherapeuticsIncMember" xlink:to="acet_AdicetTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_VestingOfEarlyExercisedStockOptions" xlink:to="acet_VestingOfEarlyExercisedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TotalLoanAccountsOutside" xlink:to="acet_TotalLoanAccountsOutside_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LoanAmountDrawn" xlink:to="acet_LoanAmountDrawn_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DiscountOnUnderwritersWarrant" xlink:to="acet_DiscountOnUnderwritersWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AtTheMarketOfferingMember" xlink:to="acet_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MLimitation" xlink:to="acet_MLimitation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SubleaseAgreementDescription" xlink:to="acet_SubleaseAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LiabilitiesFairValueExercised" xlink:to="acet_LiabilitiesFairValueExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationLiabilityMember" xlink:to="acet_ContingentConsiderationLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:to="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInLeaseObligation" xlink:to="acet_IncreaseDecreaseInLeaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnsoldCommonStockValue" xlink:to="acet_UnsoldCommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedwoodCityLeaseAgreementMember" xlink:to="acet_RedwoodCityLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LaboratoryEquipmentMember" xlink:to="acet_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncomeTaxesTable" xlink:to="acet_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilities" xlink:to="acet_ContractAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmountPayableUponClosingOfMerger" xlink:to="acet_AmountPayableUponClosingOfMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmendedLeaseAgreementDescription" xlink:to="acet_AmendedLeaseAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AvailableUnderTheLoanAgreement" xlink:to="acet_AvailableUnderTheLoanAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLossCarryforwardsIndefinitely" xlink:to="acet_OperatingLossCarryforwardsIndefinitely_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TransitionAgreementMember" xlink:to="acet_TransitionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RegeneronPharmaceuticalsIncorporationMember" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AggregateNetProceed" xlink:to="acet_AggregateNetProceed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExchangeRatio" xlink:to="acet_ExchangeRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementAdditionalRevenueRecognised" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:to="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CustomersPercentageOfTotalRevenue" xlink:to="acet_CustomersPercentageOfTotalRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseInConstructionBudget" xlink:to="acet_IncreaseInConstructionBudget_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedwoodCityLeaseAgreementOneMember" xlink:to="acet_RedwoodCityLeaseAgreementOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxAssetsFixedAssets" xlink:to="acet_DeferredTaxAssetsFixedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedResearchAndDevelopment" xlink:to="acet_AccruedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SalesAgreementMember" xlink:to="acet_SalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OptionsAvailableForFutureGrantsMember" xlink:to="acet_OptionsAvailableForFutureGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanToFinanceLeaseholdImprovements1" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdjustmentToGoodwill" xlink:to="acet_AdjustmentToGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmortizationOfDebtIssuanceCosts" xlink:to="acet_AmortizationOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PreFundedWarrantMember" xlink:to="acet_PreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RecognitionOfContingentConsiderationLiability" xlink:to="acet_RecognitionOfContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandEighteenStockIncentivePlanMember" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:to="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockNotSold" xlink:to="acet_CommonStockNotSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AgreementTransactionPrice" xlink:to="acet_AgreementTransactionPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SettlementOfTRDFLiability" xlink:to="acet_SettlementOfTRDFLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ConstructionInProgressNet" xlink:to="acet_ConstructionInProgressNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LumpSumCompensationPayment" xlink:to="acet_LumpSumCompensationPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TRDFLiabilityMember" xlink:to="acet_TRDFLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockPriceDecrease" xlink:to="acet_StockPriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CombinedBalancesInDemandDepositAccounts" xlink:to="acet_CombinedBalancesInDemandDepositAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OwnershipChangePlanDescription" xlink:to="acet_OwnershipChangePlanDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SalesAgentCommissionsAndExpenses" xlink:to="acet_SalesAgentCommissionsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesCommencementDate" xlink:to="acet_OperatingLeasesCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxLiabilitiesFixedAssets" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanAbstract" xlink:to="acet_TermLoanAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AggregateFairValue" xlink:to="acet_AggregateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PacificWesternBankMember" xlink:to="acet_PacificWesternBankMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillImpairment" xlink:label="acet_GoodwillImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="acet_GoodwillImpairment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_29"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_30"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_31"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_32"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_30" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LossOnDisposalOfLeaseAssets" xlink:label="acet_LossOnDisposalOfLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_AdjustmentToGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_RightOfUseAssetsRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_LossOnDisposalOfLeaseAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_AmortizationOfDebtIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_GoodwillMeasurementPeriodAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_VestingOfEarlyExercisedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_SettlementOfTRDFLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OrganizationAndNatureOfBusinessTextBlock" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="acet_OrganizationAndNatureOfBusinessTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombination" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_TermLoanAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="acet_LicenseFundingAndOtherAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtMarketATMOffering" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtTheMarketOfferingTextBlock" xlink:label="acet_AtTheMarketOfferingTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_AtTheMarketOfferingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RisksAndUncertaintiesPolicyTextBlock" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FairValueOfCommonStockPolicyTextBlock" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RisksAndUncertaintiesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_AccruedResearchAndDevelopmentPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_FairValueOfCommonStockPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="acet_MarketableDebtSecuritiesClassificationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_ScheduleOfSubleaseIncomeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtmProgramMember" xlink:label="acet_AtmProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OrganizationAndNatureOfBusinessAbstract" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgentCommissionsAndExpenses" xlink:label="acet_SalesAgentCommissionsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockNotSold" xlink:label="acet_CommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalCommonStockNotSold" xlink:label="acet_AdditionalCommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SaleOfShare" xlink:label="acet_SaleOfShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateNetProceed" xlink:label="acet_AggregateNetProceed"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwrittenPublicOffering" xlink:label="acet_UnderwrittenPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_AtmProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_OrganizationAndNatureOfBusinessAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AdicetTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_SalesAgentCommissionsAndExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_CommonStockNotSold" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_AdditionalCommonStockNotSold" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_SaleOfShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_AggregateNetProceed" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwrittenPublicOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_EntityDateOfMerger" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_ExchangeRatio" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopment" xlink:label="acet_AccruedResearchAndDevelopment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_NumberOfCustomer" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="acet_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_CustomersPercentageOfTotalRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_AccruedResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="acet_TransitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LumpSumCompensationPayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AmountPayableUponClosingOfMerger" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LegalFees" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AdvisoryServicesAnnualFee" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_ContractualContingentValueRight" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acet_ContingentValueRightsAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessAcquisitionsProFormaRevenue1" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="acet_BusinessAcquisitionsProFormaRevenue1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_MarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_ContingentConsiderationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_TRDFLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfContingentConsiderationLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_ContingentConsiderationLiabilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueSettled" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_MilestoneClosingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_AdditionalClosingLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidSoftwareSubscriptionAndLicensingFees" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidProfessionalServices" xlink:label="acet_PrepaidProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidSoftwareSubscriptionAndLicensingFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaymentsToCros" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidProfessionalServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acet_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseInConstructionInProgress" xlink:label="acet_IncreaseInConstructionInProgress"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DecreaseInConstructionInProgress" xlink:label="acet_DecreaseInConstructionInProgress"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseInConstructionBudget" xlink:label="acet_IncreaseInConstructionBudget"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ConstructionInProgressNet" xlink:label="acet_ConstructionInProgressNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="acet_IncreaseInConstructionInProgress" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="acet_DecreaseInConstructionInProgress" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ConstructionPayableCurrentAndNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="acet_IncreaseInConstructionBudget" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="acet_ConstructionInProgressNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfIntangibleAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedCmoCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedCroCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BancOfCaliforniaMember" xlink:label="acet_BancOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyOneLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositAccounts" xlink:label="us-gaap_DemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanCashMaintain" xlink:label="acet_TermLoanCashMaintain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanMaturityDate" xlink:label="acet_TermLoanMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AvailableUnderTheLoanAgreement" xlink:label="acet_AvailableUnderTheLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CombinedBalancesInDemandDepositAccounts" xlink:label="acet_CombinedBalancesInDemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TotalLoanAccountsOutside" xlink:label="acet_TotalLoanAccountsOutside"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacificWesternBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyTwoLoanAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_TermLoanAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_BancOfCaliforniaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyOneLoanAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyLoanAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DemandDepositAccounts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanCashMaintain" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_LoanAmountDrawn" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanMaturityDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_AvailableUnderTheLoanAgreement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_CombinedBalancesInDemandDepositAccounts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TotalLoanAccountsOutside" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanAndNonFormulaAncillaryService" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansPayable" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchAndDevelopmentInProcess1" xlink:label="acet_ResearchAndDevelopmentInProcess1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_NonRefundableUpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractResearchTermPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExerciseFeePaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementUpfrontPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchAndDevelopmentInProcess1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContingentConsiderationFees" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_AgreementTransactionPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchFundingFee" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExercisedInvestmentRightAndPurchased" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractLiability" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAndCollaborationRevenue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="acet_ResearchFundingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_NovartisLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NationalInstitutesOfHealthMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_GrantTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_GrantsReceivable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_PostExposureProphylaxisDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpensesOnCumulativeBasis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WestportOfficeParkLlcMember" xlink:label="acet_WestportOfficeParkLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RentIncreaseAnnually" xlink:label="acet_RentIncreaseAnnually"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acet_WestportOfficeParkLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_IncreaseDecreaseInLeaseObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AreaOfSublease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_RentIncreaseAnnually" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_SubleaseAgreementDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AmendedLeaseAgreementDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SubleaseIncome" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseAndRentalExpense_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_TenantImprovements" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_OperatingLeasesCommencementDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_LawsuitsFiledAgainstCompany" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementOneMember" xlink:label="acet_RedwoodCityLeaseAgreementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LeaseCostOtherInformationAbstract" xlink:label="acet_LeaseCostOtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeaseProceedsPaymentsUse" xlink:label="acet_OperatingLeaseProceedsPaymentsUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_LeaseCostOtherInformationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="acet_OperatingLeaseProceedsPaymentsUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="acet_StockIssuedDuringPeriodSharesWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_StockIssuedDuringPeriodSharesWarrantExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ClassOfWarrantExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_CommonStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_OptionsAvailableForFutureGrantsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOrRightIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantForfeited" xlink:label="acet_ClassOfWarrantForfeited"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantForfeited" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedSalesAgreementMember" xlink:label="acet_AmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgentCommissionsAndExpenses" xlink:label="acet_SalesAgentCommissionsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnsoldCommonStockValue" xlink:label="acet_UnsoldCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_AmendedSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_SalesAgentCommissionsAndExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_UnsoldCommonStockValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="acet_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateFairValue" xlink:label="acet_AggregateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" xlink:label="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantMember" xlink:label="acet_InducementGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PerformanceRestrictedStockMember" xlink:label="acet_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BlackScholesOptionPricingModelMember" xlink:label="acet_BlackScholesOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_AggregateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_PerformanceRestrictedStockMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_BlackScholesOptionPricingModelMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_MergerMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" xlink:label="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_CommonStockWarrantsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_CaliforniaResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="acet_IncomeTaxesDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarryforwardsIndefinitely" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OwnershipChangePlanDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MLimitation" xlink:label="acet_MLimitation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment" xlink:label="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_MLimitation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_Sec174CapitalizedRD" xlink:label="acet_Sec174CapitalizedRD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxBasisDifferenceIPRD" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="acet_DeferredTaxAssetsFixedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="acet_Sec174CapitalizedRD" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockPriceDecrease" xlink:label="acet_StockPriceDecrease"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="acet_StockPriceDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacwestMember" xlink:label="acet_PacwestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_JefferiesLlcMember" xlink:label="acet_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PreFundedWarrantMember" xlink:label="acet_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtmProgramMember" xlink:label="acet_AtmProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PercentageOfCashFullyInsured" xlink:label="acet_PercentageOfCashFullyInsured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="us-gaap_UnderwritingCommitments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DiscountOnUnderwritersWarrant" xlink:label="acet_DiscountOnUnderwritersWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacwestMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyTwoLoanAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_ExerciseFeePaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_JefferiesLlcMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_PreFundedWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dei_AmendmentDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_AtmProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_PercentageOfCashFullyInsured" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_UnderwritingCommitments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_DiscountOnUnderwritersWarrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LossOnDisposalOfLeaseAssets" xlink:label="acet_LossOnDisposalOfLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_AdjustmentToGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_RightOfUseAssetsRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_LossOnDisposalOfLeaseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_AmortizationOfDebtIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_GoodwillMeasurementPeriodAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_VestingOfEarlyExercisedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_SettlementOfTRDFLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtmProgramMember" xlink:label="acet_AtmProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgentCommissionsAndExpenses" xlink:label="acet_SalesAgentCommissionsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockNotSold" xlink:label="acet_CommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalCommonStockNotSold" xlink:label="acet_AdditionalCommonStockNotSold"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SaleOfShare" xlink:label="acet_SaleOfShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateNetProceed" xlink:label="acet_AggregateNetProceed"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnderwrittenPublicOffering" xlink:label="acet_UnderwrittenPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_AtmProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AdicetTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_SalesAgentCommissionsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_CommonStockNotSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_AdditionalCommonStockNotSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_SaleOfShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_AggregateNetProceed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwrittenPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_EntityDateOfMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_ExchangeRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopment" xlink:label="acet_AccruedResearchAndDevelopment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_NumberOfCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_CustomersPercentageOfTotalRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_AccruedResearchAndDevelopment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="acet_TransitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LumpSumCompensationPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AmountPayableUponClosingOfMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AdvisoryServicesAnnualFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_ContractualContingentValueRight" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acet_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_MarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_TRDFLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueSettled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_MilestoneClosingLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_AdditionalClosingLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acet_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BancOfCaliforniaMember" xlink:label="acet_BancOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyOneLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyOneLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositAccounts" xlink:label="us-gaap_DemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanCashMaintain" xlink:label="acet_TermLoanCashMaintain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanMaturityDate" xlink:label="acet_TermLoanMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AvailableUnderTheLoanAgreement" xlink:label="acet_AvailableUnderTheLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CombinedBalancesInDemandDepositAccounts" xlink:label="acet_CombinedBalancesInDemandDepositAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TotalLoanAccountsOutside" xlink:label="acet_TotalLoanAccountsOutside"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacificWesternBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyTwoLoanAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_BancOfCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyOneLoanAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyLoanAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DemandDepositAccounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanCashMaintain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_LoanAmountDrawn" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_AvailableUnderTheLoanAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_CombinedBalancesInDemandDepositAccounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TotalLoanAccountsOutside" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanAndNonFormulaAncillaryService" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LongTermDebtDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansPayable" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchAndDevelopmentInProcess1" xlink:label="acet_ResearchAndDevelopmentInProcess1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_NonRefundableUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractResearchTermPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExerciseFeePaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementUpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchAndDevelopmentInProcess1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContingentConsiderationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_AgreementTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchFundingFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExercisedInvestmentRightAndPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAndCollaborationRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractAssetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="acet_ResearchFundingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_NovartisLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NationalInstitutesOfHealthMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_GrantTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_GrantsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_PostExposureProphylaxisDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpensesOnCumulativeBasis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WestportOfficeParkLlcMember" xlink:label="acet_WestportOfficeParkLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RentIncreaseAnnually" xlink:label="acet_RentIncreaseAnnually"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acet_WestportOfficeParkLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_IncreaseDecreaseInLeaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AreaOfSublease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_RentIncreaseAnnually" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_SubleaseAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SecurityDepositLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AmendedLeaseAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_OperatingLeasesCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_LawsuitsFiledAgainstCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedwoodCityLeaseAgreementOneMember" xlink:label="acet_RedwoodCityLeaseAgreementOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_OptionsAvailableForFutureGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantForfeited" xlink:label="acet_ClassOfWarrantForfeited"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmendedSalesAgreementMember" xlink:label="acet_AmendedSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_SalesAgentCommissionsAndExpenses" xlink:label="acet_SalesAgentCommissionsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnsoldCommonStockValue" xlink:label="acet_UnsoldCommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_AmendedSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_SalesAgentCommissionsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_UnsoldCommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="acet_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AggregateFairValue" xlink:label="acet_AggregateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PerformanceRestrictedStockMember" xlink:label="acet_PerformanceRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" xlink:label="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_InducementGrantMember" xlink:label="acet_InducementGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BlackScholesOptionPricingModelMember" xlink:label="acet_BlackScholesOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" xlink:label="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" xlink:label="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_AggregateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_PerformanceRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_BlackScholesOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_MergerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_CommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_CaliforniaResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarryforwardsIndefinitely" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OwnershipChangePlanDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PacwestMember" xlink:label="acet_PacwestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TwoThousandTwentyTwoLoanAmendmentMember" xlink:label="acet_TwoThousandTwentyTwoLoanAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_JefferiesLlcMember" xlink:label="acet_JefferiesLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PreFundedWarrantMember" xlink:label="acet_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AtmProgramMember" xlink:label="acet_AtmProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PercentageOfCashFullyInsured" xlink:label="acet_PercentageOfCashFullyInsured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnderwritingCommitments" xlink:label="us-gaap_UnderwritingCommitments"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DiscountOnUnderwritersWarrant" xlink:label="acet_DiscountOnUnderwritersWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacwestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_TwoThousandTwentyTwoLoanAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_ExerciseFeePaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_JefferiesLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_PreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="dei_AmendmentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_AtmProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_PercentageOfCashFullyInsured" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_UnderwritingCommitments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_DiscountOnUnderwritersWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="acet_GoodwillImpairment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_GoodwillImpairment" xlink:label="acet_GoodwillImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_AmortizationOfDebtIssuanceCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_LossOnDisposalOfLeaseAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillImpairmentLoss" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_LossOnDisposalOfLeaseAssets" xlink:label="acet_LossOnDisposalOfLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="7" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="8" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" order="9" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="acet_PrepaymentsToCros" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="acet_PrepaidProfessionalServices" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="acet_PrepaidSoftwareSubscriptionAndLicensingFees" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidProfessionalServices" xlink:label="acet_PrepaidProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_PrepaidSoftwareSubscriptionAndLicensingFees" xlink:label="acet_PrepaidSoftwareSubscriptionAndLicensingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedCmoCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedCroCosts" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="8" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxBasisDifferenceIPRD" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acet_DeferredTaxAssetsFixedAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="acet-20231231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="acet_BusinessAcquisitionsProFormaRevenue1" name="BusinessAcquisitionsProFormaRevenue1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RightOfUseAssetsRecognized" name="RightOfUseAssetsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" name="TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_COVID19Member" name="COVID19Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_BancOfCaliforniaMember" name="BancOfCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenceAgreementAdditionalRevenueRecognised" name="LicenceAgreementAdditionalRevenueRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_IncreaseDecreaseInLeaseObligation" name="IncreaseDecreaseInLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_UnderwrittenPublicOffering" name="UnderwrittenPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TermLoanAndNonFormulaAncillaryService" name="TermLoanAndNonFormulaAncillaryService" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_OperatingLeaseProceedsPaymentsUse" name="OperatingLeaseProceedsPaymentsUse" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" name="StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" name="BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_NonRefundableUpfrontPaymentReceived" name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_StockIssuedDuringPeriodSharesWarrantExercised" name="StockIssuedDuringPeriodSharesWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_FederalAndStateResearchAndDevelopmentMember" name="FederalAndStateResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContractualContingentValueRight" name="ContractualContingentValueRight" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LiabilitiesFairValueSettled" name="LiabilitiesFairValueSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TwoThousandTwentyOneLoanAmendmentMember" name="TwoThousandTwentyOneLoanAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenceAgreementUpfrontPayment" name="LicenceAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OrganizationAndNatureOfBusinessAbstract" name="OrganizationAndNatureOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LicenseAndCollaborationRevenue" name="LicenseAndCollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LeaseCostOtherInformationAbstract" name="LeaseCostOtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_CombinedBalancesInDemandDepositAccounts" name="CombinedBalancesInDemandDepositAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_DiscountOnUnderwritersWarrant" name="DiscountOnUnderwritersWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_MLimitation" name="MLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_DeferredTaxOperatingLeaseRightOfUseAsset" name="DeferredTaxOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_GoodwillImpairment" name="GoodwillImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AdjustmentToGoodwill" name="AdjustmentToGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" name="StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" name="IncreaseDecreaseInEstimatedFairValueOfCvrLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_BlackScholesOptionPricingModelMember" name="BlackScholesOptionPricingModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AdditionalClosingLiability" name="AdditionalClosingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OptionsAvailableForFutureGrantsMember" name="OptionsAvailableForFutureGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PacwestMember" name="PacwestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" name="NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_MarketableDebtSecuritiesClassificationTableTextBlock" name="MarketableDebtSecuritiesClassificationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" name="StockExchangedDuringPeriodValueInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_NumberOfCustomer" name="NumberOfCustomer" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_ConstructionInProgressNet" name="ConstructionInProgressNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" name="SeptemberFifteenTwoThousandTwentyWarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_VestingOfEarlyExercisedStockOptions" name="VestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementTerminationDescription" name="LicenseAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_UnsoldCommonStockValue" name="UnsoldCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_InducementGrantsMember" name="InducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AtTheMarketOfferingTextBlock" name="AtTheMarketOfferingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" name="ChangeInFairValueIncludedInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" name="GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_StockPriceDecrease" name="StockPriceDecrease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" name="Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LumpSumCompensationPayment" name="LumpSumCompensationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_DeferredTaxAssetsFixedAssets" name="DeferredTaxAssetsFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TermLoanToFinanceLeaseholdImprovements1" name="TermLoanToFinanceLeaseholdImprovements1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" name="ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" name="RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_QualifyingExpenses" name="QualifyingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TermLoanMaturityDate" name="TermLoanMaturityDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AtmProgramMember" name="AtmProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MilestoneClosingLiability" name="MilestoneClosingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" name="TemporaryEquityStockConversionSharesInConnectionWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_CommonStockNotSold" name="CommonStockNotSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ResearchFundingFee" name="ResearchFundingFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_Sec174CapitalizedRD" name="Sec174CapitalizedRD" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AgreementTransactionPrice" name="AgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_SettlementOfTRDFLiability" name="SettlementOfTRDFLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" name="DeferredTaxOperatingLeaseRightOfUseAssetLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AvailableUnderTheLoanAgreement" name="AvailableUnderTheLoanAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_PrepaymentsToCros" name="PrepaymentsToCros" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ExchangeRatio" name="ExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_RecognitionOfPreferredStockWarrantLiabilities" name="RecognitionOfPreferredStockWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AmendedLeaseAgreementDescription" name="AmendedLeaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLossCarryforwardsIndefinitely" name="OperatingLossCarryforwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_GrantTerm" name="GrantTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" name="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AggregateNetProceed" name="AggregateNetProceed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TRDFLiabilityMember" name="TRDFLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ClassOfWarrantOrRightsExpirationDate" name="ClassOfWarrantOrRightsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContractLiability" name="ContractLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LoanAmountDrawn" name="LoanAmountDrawn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_AdicetTherapeuticsIncMember" name="AdicetTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AdditionalCommonStockNotSold" name="AdditionalCommonStockNotSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AggregateFairValue" name="AggregateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncreaseInConstructionInProgress" name="IncreaseInConstructionInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ScheduleOfSubleaseIncomeTableTextBlock" name="ScheduleOfSubleaseIncomeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PacificWesternBankMember" name="PacificWesternBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" name="TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_EntityDateOfMerger" name="EntityDateOfMerger" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" name="OperatingLeasesFutureMinimumSubleaseIncomeDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseFundingAndOtherAgreementsAbstract" name="LicenseFundingAndOtherAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" name="RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContingentConsiderationFees" name="ContingentConsiderationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AccruedResearchAndDevelopmentPolicyTextBlock" name="AccruedResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_CustomersPercentageOfTotalRevenue" name="CustomersPercentageOfTotalRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" name="MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_RentIncreaseAnnually" name="RentIncreaseAnnually" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_EstimatedFairValueOfCVRLiability" name="EstimatedFairValueOfCVRLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" name="ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_CaliforniaResearchAndDevelopmentMember" name="CaliforniaResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TermLoanCashMaintain" name="TermLoanCashMaintain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TwoThousandFourteenStockIncentivePlanMember" name="TwoThousandFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" name="TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_BostonMember" name="BostonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_InducementGrantMember" name="InducementGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ResearchAndDevelopmentInProcess1" name="ResearchAndDevelopmentInProcess1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ContractAssetsAndLiabilitiesAdditions" name="ContractAssetsAndLiabilitiesAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesCommencementDate" name="OperatingLeasesCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AdvisoryServicesAnnualFee" name="AdvisoryServicesAnnualFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TwoThousandTwentyLoanAmendmentMember" name="TwoThousandTwentyLoanAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment" name="EffectiveIncomeTaxRateReconciliationGoodwillImpairment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PrepaidProfessionalServices" name="PrepaidProfessionalServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LicenceAgreementCumulativeRevenueRecognised" name="LicenceAgreementCumulativeRevenueRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AccruedCmoCosts" name="AccruedCmoCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" name="StockExchangedDuringPeriodSharesInConnectionWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_SubleaseAgreementDescription" name="SubleaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" name="ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LiabilitiesFairValueExercised" name="LiabilitiesFairValueExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RedwoodCityLeaseAgreementMember" name="RedwoodCityLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" name="UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TwoThousandTwentyTwoLoanAmendmentMember" name="TwoThousandTwentyTwoLoanAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PostExposureProphylaxisDescription" name="PostExposureProphylaxisDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_FairValueOfCommonStockPolicyTextBlock" name="FairValueOfCommonStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" name="FeesAndExpenseIncurredInConnectionWithClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" name="RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedwoodCityLeaseAgreementOneMember" name="RedwoodCityLeaseAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LossOnDisposalOfLeaseAssets" name="LossOnDisposalOfLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" name="RedeemableConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" name="UnvestedCommonStockFromEarlyExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AmendedSalesAgreementMember" name="AmendedSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ResearchFundingAgreementMember" name="ResearchFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenseAgreementCumulativeRevenueReductionRecognised" name="LicenseAgreementCumulativeRevenueReductionRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" name="OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RecognitionOfContingentConsiderationLiability" name="RecognitionOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TermLoanAbstract" name="TermLoanAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_DeferredTaxBasisDifferenceIPRD" name="DeferredTaxBasisDifferenceIPRD" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFifteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_OrganizationAndNatureOfBusinessTextBlock" name="OrganizationAndNatureOfBusinessTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_DeferredTaxAssetsValuationAllowanceIncrease" name="DeferredTaxAssetsValuationAllowanceIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ExerciseFeePaid" name="ExerciseFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" name="CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_OwnershipChangePlanDescription" name="OwnershipChangePlanDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TransitionAgreementMember" name="TransitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ExercisedInvestmentRightAndPurchased" name="ExercisedInvestmentRightAndPurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" name="SeptemberFifteenTwoThousandTwentyWarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" name="FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" name="ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" name="OptionToPurchaseOfCommonStockAtPublicOfferingPrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantForfeited" name="ClassOfWarrantForfeited" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" name="ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" name="ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" name="RedeemableConvertiblePreferredStockTrancheLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_WestportOfficeParkLlcMember" name="WestportOfficeParkLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MenloParkLeaseAgreementMember" name="MenloParkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NovartisLicenseAgreementMember" name="NovartisLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" name="LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" name="IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AmountPayableUponClosingOfMerger" name="AmountPayableUponClosingOfMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_JefferiesLlcMember" name="JefferiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_IncreaseInConstructionBudget" name="IncreaseInConstructionBudget" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_RegeneronPharmaceuticalsIncorporationMember" name="RegeneronPharmaceuticalsIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" name="SeptemberFifteenTwoThousandTwentyWarrantFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PerformanceRestrictedStockMember" name="PerformanceRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenseFundingAndOtherAgreementsTextBlock" name="LicenseFundingAndOtherAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ClassOfWarrantExercised" name="ClassOfWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" name="ContractAssetsAndLiabilitiesAdditionsDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ContractAssetMember" name="ContractAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" name="NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" name="ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" name="StockIssuedDuringPeriodSharesConversionOfSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_UnvestedRestrictedStockUnitsOutstanding" name="UnvestedRestrictedStockUnitsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContractLiabilityMember" name="ContractLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContractResearchTermPeriod" name="ContractResearchTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TemporaryEquityStockConversionInConnectionWithMerger" name="TemporaryEquityStockConversionInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_SalesAgentCommissionsAndExpenses" name="SalesAgentCommissionsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" name="ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" name="LicenseAgreementAdditionalPaymentForResearchFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_QualifyingExpensesOnCumulativeBasis" name="QualifyingExpensesOnCumulativeBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LessPortionOfFairValueToBeDistributedAsCVR" name="LessPortionOfFairValueToBeDistributedAsCVR" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TotalLoanAccountsOutside" name="TotalLoanAccountsOutside" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_NovartisInternationalPharmaceuticalLimitedMember" name="NovartisInternationalPharmaceuticalLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" name="SeptemberFifteenTwoThousandTwentyWarrantThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_GoodwillMeasurementPeriodAdjustments" name="GoodwillMeasurementPeriodAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AreaOfSublease" name="AreaOfSublease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_ResTORbioMember" name="ResTORbioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PrepaidSoftwareSubscriptionAndLicensingFees" name="PrepaidSoftwareSubscriptionAndLicensingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContractAssetsAndLiabilities" name="ContractAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" name="ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_MergerMember" name="MergerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_DecreaseInConstructionInProgress" name="DecreaseInConstructionInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" name="CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantsMember" name="RedeemableConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SaleOfShare" name="SaleOfShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PercentageOfCashFullyInsured" name="PercentageOfCashFullyInsured" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_NumberOfSharesOfSurvivingStockOptions" name="NumberOfSharesOfSurvivingStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AmortizationOfDebtIssuanceCosts" name="AmortizationOfDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LawsuitsFiledAgainstCompany" name="LawsuitsFiledAgainstCompany" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" name="CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AccruedCroCosts" name="AccruedCroCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694767383024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,153,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Dartmouth Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">3rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text"> 503-9095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2024 annual meeting of shareholders, scheduled to be held on June 5, 2024, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680082096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 159,711<span></span>
</td>
<td class="nump">$ 257,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">162,272<span></span>
</td>
<td class="nump">261,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">26,777<span></span>
</td>
<td class="nump">28,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">17,424<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">207,295<span></span>
</td>
<td class="nump">330,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">4,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">13,441<span></span>
</td>
<td class="nump">12,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,287<span></span>
</td>
<td class="nump">19,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">17,703<span></span>
</td>
<td class="nump">18,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,120<span></span>
</td>
<td class="nump">38,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; none issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 43,270,386 and 42,954,820 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">550,943<span></span>
</td>
<td class="nump">530,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(380,772)<span></span>
</td>
<td class="num">(238,114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">170,175<span></span>
</td>
<td class="nump">292,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 207,295<span></span>
</td>
<td class="nump">$ 330,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681468224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694772727504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">106,043<span></span>
</td>
<td class="nump">71,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">26,533<span></span>
</td>
<td class="nump">26,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_GoodwillImpairment', window );">Goodwill impairment</a></td>
<td class="nump">19,462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">152,038<span></span>
</td>
<td class="nump">97,541<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(152,038)<span></span>
</td>
<td class="num">(72,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">9,978<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(573)<span></span>
</td>
<td class="num">(919)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax provision</a></td>
<td class="num">(142,658)<span></span>
</td>
<td class="num">(69,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (142,658)<span></span>
</td>
<td class="num">$ (69,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic</a></td>
<td class="nump">43,042,405<span></span>
</td>
<td class="nump">41,080,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted</a></td>
<td class="nump">43,042,405<span></span>
</td>
<td class="nump">41,080,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_GoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_GoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680785424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 303,129<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 471,449<span></span>
</td>
<td class="num">$ (168,324)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,736,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for cashless exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes, Value</a></td>
<td class="num">(3,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares', window );">Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,611,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts', window );">issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,value</a></td>
<td class="nump">43,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">17,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,790)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">292,338<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">530,448<span></span>
</td>
<td class="num">(238,114)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes, Value</a></td>
<td class="num">$ (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under Employee Stock Purchase Plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">20,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(142,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,658)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 170,175<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 550,943<span></span>
</td>
<td class="num">$ (380,772)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,270,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Pursuant To At The Market Offering Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>common stock pursuant to at-the-market offering, net of issuance costs,shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763295744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683715264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (142,658)<span></span>
</td>
<td class="num">$ (69,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Noncash lease expense</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,259<span></span>
</td>
<td class="nump">17,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of property, plant, and equipment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">19,462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LossOnDisposalOfLeaseAssets', window );">Loss on disposal of lease assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AmortizationOfDebtIssuanceCosts', window );">Amortization of deferred debt issuance costs</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,683)<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities&#8212;related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(2,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current and non-current liabilities</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(93,717)<span></span>
</td>
<td class="num">(44,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(4,464)<span></span>
</td>
<td class="num">(16,782)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,464)<span></span>
</td>
<td class="num">(16,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards', window );">Taxes withheld and paid related to net share settlement of equity awards</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">41,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents</a></td>
<td class="num">(97,945)<span></span>
</td>
<td class="num">(20,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents at the beginning of the period</a></td>
<td class="nump">257,656<span></span>
</td>
<td class="nump">277,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents at the end of the period</a></td>
<td class="nump">159,711<span></span>
</td>
<td class="nump">257,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">159,711<span></span>
</td>
<td class="nump">257,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of deferred debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LossOnDisposalOfLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on disposal of lease assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LossOnDisposalOfLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes withheld and paid related to net share settlement of equity awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676245424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OrganizationAndNatureOfBusinessTextBlock', window );">Organization and Nature of Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization and Nature of the Business</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The Company is advancing a pipeline of &#8220;off-the-shelf&#8221; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost-efficient manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. (when referred to prior to the merger, Former Adicet) was incorporated in November 2014 in Delaware. On September 15, 2020, Former Adicet completed a merger (Merger) with resTORbio, pursuant to which Former Adicet merged with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#8220;Adicet Therapeutics, Inc.&#8221; (Adicet Therapeutics). In connection with the Merger, the Company changed its name from &#8220;resTORbio, Inc.&#8221; to &#8220;Adicet Bio, Inc.&#8221; The Company&#8217;s principal executive offices are located in Boston, Massachusetts. The Company also has offices in Redwood City, California.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of the Company and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, the Company consolidated its operations, including research and development activities, in the United States and as a result, substantially reduced its operations in Israel.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant net operating losses and negative cash flows from operations and has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">380.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, public and private placements of equity securities and debt, and cash received in the Merger with resTORbio. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2021, the Company entered into a Capital On Demand&#153; Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as sales agent, to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock from time to time in &#8220;at-the-market&#8221; (ATM) offerings under a registration statement on Form S-3 (File No. 333-254193) (2021 Shelf Registration Statement) filed with the U.S. Securities and Exchange Commission (the SEC), which was declared effective on March 30, 2021. In August 2022, pursuant to the Sales Agreement and subject to the limitations thereof, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,611,723</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share resulting in net proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting sales agent commissions and expenses. In November 2022, the Company filed a new prospectus supplement to the 2021 Shelf Registration Statement for the offer and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock from time to time through the sales agent, which includes the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock not sold under the original prospectus and up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock (the ATM Program). During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were sold under the ATM Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to December 31, 2023, the Company raised aggregate net proceeds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through its ATM Program and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through an underwritten public offering (the Offering). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 19. Subsequent Events for additional details on these financings subsequent to December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects that its cash and cash equivalents, together with the proceeds raised subsequent to year-end through our ATM Program and the Offering, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements and debt service payments for at least the next twelve months from the issuance of these consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s revenue to date has been generated from a collaboration and license agreement with Regeneron Pharmaceuticals Inc, (Regeneron). The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercializes any of the Company&#8217;s product candidates or enters into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seeks regulatory approvals for, its product candidates and begins to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), the regulatory approval process, market acceptance of the Company&#8217;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#8217;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OrganizationAndNatureOfBusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OrganizationAndNatureOfBusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678743104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#8217;s incremental borrowing rate. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and determined that goodwill was impaired. For additional information regarding this assessment, refer to Note 16. Goodwill to our consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable and operating segment, which is the business of research and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allogeneic gamma delta T cell therapies for autoimmune diseases and cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds and treasury securities. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer, Regeneron, which represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s total revenue during the year ended December 31, 2022 (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, cash and cash equivalents consist of cash deposited with banks, investments in money market funds with maturities of three months or less from the date of purchase, and overnight treasury securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the lesser of the assets&#8217; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accumulated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. The Company performed a long-lived asset impairment test in conjunction with its goodwill impairment test in the third quarter of 2023 and concluded that there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets. There was also </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#8217;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s revenues for the year ended December 31, 2022 are derived through a license and collaboration agreement with Regeneron (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue under the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments or reimbursements for the Company&#8217;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#8217;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CDMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued CRO, CDMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various agreements with CDMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material adjustments to the Company&#8217;s prior period estimates of accrued research and development expenses.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2016-02), the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per common share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan (ESPP) awards and unvested restricted stock units (RSUs), are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Since the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events Considerations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements. Refer to Note 17. Subsequent Events.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-13 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. SEC filers that are eligible to be smaller reporting companies should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which enhances the transparency and usefulness of income tax disclosures. This amendment requires public issuers to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income, or loss, by the applicable statutory income tax rate. Additionally, this amendment requires issuers to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes as well as the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact the adoption that this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680952832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8212; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8212; Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Treasury securities (1) (2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (1) (3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents in the consolidated balance sheets.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. </span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681219520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software subscription and licensing fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid maintenance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepayments to CROs and CDMOs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683810000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Property and Equipment, net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.64%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful life<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_15175557-fa82-4f42-8860-de5b090ee079;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of useful life or lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_7c070633-44bd-4104-9d0e-d47392d30bc3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,292</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s property and equipment as of December 31, 2023 and 2022 is located in the U.S. Depreciation and amortization expense for the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in expense is primarily due to the completion and subsequent depreciation of the Company's good manufacturing practice (GMP) cell processing and vector manufacturing suite at the Company's office in Redwood City, California (1000 Bridge Parkway) which was completed in February 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Construction in progress has decreased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, compared to the balance at December 31, 2022, due to the Company's completion of the Company's GMP cell processing and vector manufacturing suite in February 2023. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in construction in progress as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is primarily related to lab and computer equipment not yet placed into service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680615120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Accrued and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CDMO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,390</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CRO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694774192544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Third Party Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Third Party Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Third Party Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regeneron</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#8217;s investment in the Company&#8217;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company received a non-refundable upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Regeneron upon execution of the Regeneron Agreement and an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of additional payments for research funding from Regeneron as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of option exercise fees, as specified in the Regeneron Agreement. Per the terms of the agreement, Regeneron must pay the Company high single digit royalties as a percentage of net sales for immune cell products (ICPs) to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#8217;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#8217;s license to use Regeneron&#8217;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve (12) years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from first commercial sale. No royalties have been earned or paid under the Regeneron Agreement through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta CAR T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement. In conjunction with the exercise of the option, Regeneron paid an exercise fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Company on January 28, 2022, and the Company completed the transfer of the associated license rights to Regeneron during the first quarter of 2022. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million option exercise fee, plus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of revenue recognized relating to the combined performance obligation, resulted in an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million recorded as revenue for the year ended December 31, 2022. The Company's obligations under the combined performance obligation were completed during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, there were no contract assets related to the Regeneron Agreement. The following tables present changes in the Company&#8217;s contract liabilities for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.643%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.643%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions<br/>(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Twist Bioscience</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into an Antibody Discovery Agreement (the Twist Agreement) with Twist Bioscience Corporation (Twist). Under the terms of the Twist Agreement, Twist will utilize its proprietary platform technology to assist the Company with the discovery of novel antibodies related to target antigens selected by the Company. The Company maintains the sole and exclusive rights to any program antibodies discovered under the Twist Agreement and has the right to patent, assign, license or transfer any work product under the agreement. Furthermore, the Company has the right to sublicense its rights to program antibodies to third parties. The Company may terminate the Twist Agreement at any time, with or without cause, upon a specified period advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per the terms of the agreement, the Company will pay Twist an upfront, non-refundable project initiation fee, a technology access fee, as well as a project fee for each project entered into under the agreement. Additionally, the Company will pay fees for development and regulatory milestones in the tens of millions of dollars and low single digit royalties on net sales to Twist for programs initiated under the agreement. In November 2022, the Company entered into an amendment to the Twist Agreement (the Twist Amendment). The Twist Amendment updates the language associated with Twist's audit rights as well as the amounts associated with technology access fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On a cumulative basis as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has incurred and expensed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to project initiation fees, technology access fees and projects fees as research and development expense related to this agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678469440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TermLoanAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Term Loan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 28, 2020, the Company entered into a Loan and Security Agreement (the Loan Agreement) as amended on July 8, 2020, September 14, 2020, September 15, 2020, October 21, 2021, December 2, 2022 (the 2022 Loan Amendment) and May 30, 2023 with Banc of California (formerly known as Pacific Western Bank) to finance leasehold improvements for the facilities in Redwood City, CA and other purposes permitted under the Loan Agreement. Under the October 21, 2021 amendment, Banc of California will provide one or more Term Loans (as defined in the 2021 Loan Amendment), as well as Non-Formula Ancillary Services which shall not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which each Term Loan to be in an amount of not less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 13, 2023, the Company and Banc of California executed a letter agreeing that, notwithstanding the covenants included in the 2022 Loan Amendment, until June 30, 2023 (i) the Company and its subsidiaries will not be required to maintain the lesser of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or seventy percent (70%) of its combined balances in demand deposit accounts, money</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">funds and/or insured cash sweep (ICS) accounts with Banc of California and (ii) the Company must maintain its combined balances at Banc of California or its affiliates, including Pacific Western Asset Management (the Letter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 30, 2023, the Company further amended its Loan Agreement with Banc of California (the 2023 Loan Amendment). Pursuant to the 2023 Loan Amendment, the Company must maintain the lesser of (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or (ii) all of the Company&#8217;s combined balances in demand deposit accounts, money market accounts, and/or insured cash sweep accounts with Banc of California. If the Company&#8217;s total cash and investments drop to less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the 2023 Loan Amendment permits the Company to maintain cash and/or investments in one or more accounts outside of Banc of California up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available under the Loan Agreement. Additionally, as of December 31, 2023, the Company is in compliance with such covenants as stated in the 2023 Loan Amendment and had no indebtedness outstanding under the Loan Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term loan abstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694679313072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingences</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office and laboratory space in Redwood City, California, and Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redwood City</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, Adicet Therapeutics executed a non-cancelable lease agreement, as amended in 2022, pursuant to which the Company leases office and laboratory facility at 1000 Bridge Parkway and a portion of 1200 Bridge Parkway in Redwood City, California (the Redwood City Lease).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2023, Adicet Therapeutics entered into a third lease amendment with Westport Office Park, LLC (the Third Amendment). The Third Amendment further amends the Redwood City Lease and increases the tenant improvement allowance as of January 1, 2023 by an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company fully utilized the allowance for the continued buildout of office and laboratory space at 1000 Bridge Parkway in 2023. Per the terms of this amendment, this additional allowance will be repaid through equal monthly payments of principal amortization and interest on a monthly basis over the term of the lease at an interest rate of eight percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) per annum. The Company received the allowance on February 21, 2023 and increased the operating lease liability accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2023, Adicet Therapeutics entered into a fourth lease amendment with Westport Office Park, LLC (the Fourth Amendment). The Fourth Amendment amends the period over which the tenant improvement allowance received in the Third Amendment will be amortized and identifies the monthly amortization payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 1, 2023, Adicet Therapeutics amended its letter of credit with Westport Office Park, LLC. The amendment reduced the amount of the letter of credit associated with 1000 Bridge Parkway by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million resulting in an updated letter of credit amount of $2.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Boston</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2018, the Company entered into a lease agreement, as amended in 2019, for office space at 500 Boylston St, Boston, Massachusetts (500 Boylston Lease). Under the terms of the 500 Boylston Lease, the Company was permitted to assign, sublease or transfer this lease, with the consent of the landlord.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 19, 2021, the Company entered into a sublease agreement with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,501</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rentable square feet of 500 Boylston St. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected undiscounted cash flows to be received from the sublease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:28.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized rent expense, net of sublease income, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the Company remains liable for the remaining lease payments under the 500 Boylston Lease, totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is included in the future minimum lease payments table below.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments under all non-cancelable operating lease obligations as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:28.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,015</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,090</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,776</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, net of current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.16%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:21.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Locations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IBR</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Terms<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1000 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.90</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1200 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.50</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Boston, MA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.60</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.70</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the operating lease cost and information related to the operating lease right-of-use assets, net and operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.63%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.124%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.124%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,991</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, operating right-of-use assets were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and operating lease liabilities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has no material finance leases.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains letters of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in connection with the Company&#8217;s office leases in Redwood City, CA and Boston, MA, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; liability insurance.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694679680416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stockholders' Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Certificate of Incorporation, as amended, authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value common stock as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stockholders are entitled to dividends if and when declared by the Board of Directors of the Company subject to the prior rights of the preferred stockholders. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends on common stock had been declared by the Board of Directors.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units available for future grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,473,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,871,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,310,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,272,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694775476256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below (in thousands, except share and per share data):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.747%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.934%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.295%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.934%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.455%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,293,442</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited or cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,112,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,984,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions used in the Black Scholes Model to calculate stock-based compensation are as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:23.195%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:23.195%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.15</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.97</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83.25</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">92.87</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">77.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free rates</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.86</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.22</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions are as follows:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#8217;s industry peers.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend yield.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money at December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2023 and 2022 was less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of options that vested during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The options granted during the years ended December 31, 2023 and 2022 had a weighted-average per share grant-date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.07</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the total unrecognized stock-based compensation expense related to unvested stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of RSU activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">513,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">194,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">513,700</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSU's in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t grant any RSU's in the year ended December 31, 2022. The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option repricing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 8, 2023, the board of directors approved a stock option repricing (the Option Repricing) to be effective on August 14, 2023 (the Effective Date) in accordance with the terms of the Company&#8217;s 2015 Stock Incentive Plan and 2018 Plan (together, the Plans). Pursuant to the Option Repricing, and subject to a one year cliff period, the exercise price of each stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">previously granted under the Plans, totaling </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,431,910</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options, was amended to reduce the exercise price of such options to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on the Effective Date. Under the terms of the Option Repricing, a repriced option will revert to its original exercise price if, prior to the one year anniversary of the Effective Date, (a) the option holder&#8217;s employment is terminated by the Company with cause or by the option holder or (b) the option is exercised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The repriced options otherwise retained their existing terms and conditions as set forth in the Plans and applicable award agreements. The stock option modification resulted in an incremental compensation cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was calculated based on the difference between the fair value of the stock options before the repricing and the fair value as of the Effective Date, using the Black-Scholes option-pricing model. Of the incremental compensation cost, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized in the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, and the remaining amount, less any employee terminations, will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of the Effective Date, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,418,042</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to purchase shares of common stock under the 2018 Plan to eligible employees who held inducement awards as of August 8, 2023. These new options were issued to eligible employees because their inducement awards granted under Nasdaq Listing Rule 5635(c)(4) are not eligible for repricing. The prior inducement awards remain outstanding under their original terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683797440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.854%;"></td>
        <td style="width:2.099%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.974%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.099%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.974%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">142,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,042,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,080,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's potentially dilutive shares as of December 31, 2023 and 2022, which include outstanding stock options and unvested RSUs, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.44%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,837,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,400,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683874608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for (benefit from) income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax expense nor benefit for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">162m limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,601</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,641</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sec 174 Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,871</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basis Difference IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. IRC Section 174, as modified by the Tax Cuts and Jobs Act of 2017, no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. As a result the Company capitalized such costs in its 2023 income tax provision, resulting in an increase in deferred tax assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">294.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will begin to expire in 2036 if not utilized, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">287.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of California research and development tax credit carryforwards available to offset future taxable income as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  If the Company has experienced an ownership change, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. As of December 31, 2023, the ownership change analysis has not been completed, however no material tax attributes are expected to be limited for full use </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">before their respective carryforward periods expires.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts and Israel. The tax years 2016 to 2023 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers. Additionally, the Company is currently undergoing an audit with California&#8217;s Franchise Tax Board (FTB) regarding the apportionment of revenue for the tax year 2017 and may be obligated to make future payments to the state related to this tax year depending on the outcome of the examination. The Company is evaluating the FTB's proposal and assessing its course of action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the federal and state research and development credits as a result of no formal research credit study performed.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,721</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694768768464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Regeneron owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">883,568</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing which was subsequently converted into common stock. For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from the Regeneron Agreement. See Note 8 for a discussion of the Regeneron Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683828768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. Defined Contribution Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, the Company made aggregate matching contributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678514464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. Goodwill</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the annual goodwill impairment analysis performed during the fourth quarter of 2022, the Company determined that the fair value of its sole reporting unit exceeded its book value, and therefore </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> goodwill impairment charge was recorded in 2022. During the first and second quarters of 2023, the Company concluded that no events or changes in circumstances had occurred that indicated goodwill was more likely than not impaired.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the third quarter of 2023, the Company experienced a significant decline in its stock price. As of September 30, 2023, the Company&#8217;s stock price declined </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% from its closing stock price on June 30, 2023, and the decline in stock price was sustained. The Company determined that this decline in stock price and market capitalization of the Company constituted a substantive change in circumstances that would more likely than not reduce the fair value of the Company&#8217;s single reporting unit below its carrying amount. Accordingly, the Company tested its goodwill for impairment as of September 30, 2023 (the Interim Testing Date).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the fair value of the Company&#8217;s sole reporting unit for the interim impairment analysis as of the Interim Testing Date, the Company used a market-based approach, and the primary input in this approach was a quoted market price in an active market. To determine the estimated fair value of the Company&#8217;s single reporting unit, the Company calculated its market capitalization based on its stock price. Based on the Company&#8217;s interim impairment analysis as of the Interim Testing Date, the carrying value of the Company&#8217;s single reporting unit exceeded its fair value. Accordingly, step two of the goodwill impairment test was performed. In performing step two of the goodwill impairment test, the Company utilized observable inputs and concluded that an impairment charge was necessary for the full amount of goodwill. As a result of the step two evaluation, the Company recorded a goodwill impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the three month period ended September 30, 2023. This impairment charge reduced the balance of goodwill to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694769396992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17. Subsequent Events</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATM Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were issued in a series of sales in accordance with the ATM Program, at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for aggregate net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting sales agent commissions, but before deducting any expenses related to such sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Underwritten Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, Adicet entered into an Underwriting Agreement (the Underwriting Agreement) with Jefferies LLC and Guggenheim Securities, LLC (the Underwriters) related to an underwritten public offering (the Offering) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27,054,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares (the Shares) of common stock of the Company, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the Common Stock), and, in lieu of Common Stock to an investor, pre-funded warrants (the Pre-Funded Warrants) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,445,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock (the Warrant Shares). The Shares were sold at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the Pre-Funded Warrants were sold at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per underlying share, which represents the per share public offering price of each share of common stock minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share exercise price for each pre-funded warrant. The purchase price paid by the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Underwriters </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the Company was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.256</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2559</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant, representing a discount to the Underwriters of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. In addition, the Company granted the Underwriters an option exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days from the date of the Underwriting Agreement to purchase, at the public offering price less underwriting discounts and commissions, up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,325,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Common Stock. On January 23, 2024, the Underwriters exercised this option in full. The Company received net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763447760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#8217;s incremental borrowing rate. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and determined that goodwill was impaired. For additional information regarding this assessment, refer to Note 16. Goodwill to our consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable and operating segment, which is the business of research and development of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allogeneic gamma delta T cell therapies for autoimmune diseases and cancer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds and treasury securities. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer, Regeneron, which represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company&#8217;s total revenue during the year ended December 31, 2022 (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, cash and cash equivalents consist of cash deposited with banks, investments in money market funds with maturities of three months or less from the date of purchase, and overnight treasury securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the lesser of the assets&#8217; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accumulated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. The Company performed a long-lived asset impairment test in conjunction with its goodwill impairment test in the third quarter of 2023 and concluded that there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets. There was also </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment of long-lived assets for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(i)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(v)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#8217;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the Company&#8217;s revenues for the year ended December 31, 2022 are derived through a license and collaboration agreement with Regeneron (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue under the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments or reimbursements for the Company&#8217;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#8217;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CDMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AccruedResearchAndDevelopmentPolicyTextBlock', window );">Accrued CRO, CMO, and Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued CRO, CDMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has entered into various agreements with CDMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> there had been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material adjustments to the Company&#8217;s prior period estimates of accrued research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with ASU No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASU 2016-02), the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per common share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan (ESPP) awards and unvested restricted stock units (RSUs), are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Since the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events Considerations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Events Considerations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements. Refer to Note 17. Subsequent Events.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-13 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. SEC filers that are eligible to be smaller reporting companies should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes (Topic 740):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which enhances the transparency and usefulness of income tax disclosures. This amendment requires public issuers to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income, or loss, by the applicable statutory income tax rate. Additionally, this amendment requires issuers to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes as well as the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact the adoption that this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763238416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Treasury securities (1) (2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.31%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.282%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (1) (3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents in the consolidated balance sheets.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694775496320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software subscription and licensing fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid maintenance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepayments to CROs and CDMOs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">492</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the summary of Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763340576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.64%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:18.32%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.54%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful life<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_15175557-fa82-4f42-8860-de5b090ee079;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lesser of useful life or lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,503</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_7c070633-44bd-4104-9d0e-d47392d30bc3;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,292</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">26,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680952832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.68%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CDMO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,390</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,356</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">674</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued CRO costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,811</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676185392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Third Party Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Change in Company's Contract Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, there were no contract assets related to the Regeneron Agreement. The following tables present changes in the Company&#8217;s contract liabilities for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.643%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:45.529%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.463%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.903%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.643%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>Beginning <br/>of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deductions<br/>(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at<br/>End of Period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763244928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Future Lease payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future minimum lease payments under all non-cancelable operating lease obligations as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:28.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,015</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,662</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,090</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,776</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,852</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,221</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, net of current maturities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ScheduleOfSubleaseIncomeTableTextBlock', window );">Schedule Of Sublease Income</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected undiscounted cash flows to be received from the sublease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows (in thousands):</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.22%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:28.7%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027 and thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock', window );">Schedule of Weighted Average IBR and Remaining Lease Term</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:47.16%;"></td>
        <td style="width:1.46%;"></td>
        <td style="width:21.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Locations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IBR</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Terms<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1000 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.90</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redwood City, CA (1200 Bridge Parkway)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.80</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.50</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Boston, MA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.60</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.70</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs and Other Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the operating lease cost and information related to the operating lease right-of-use assets, net and operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.63%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.124%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.124%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,508</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,991</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Information</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Sublease Income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average ibr and remaining lease term table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678429040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock', window );">Schedule of Number of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.44%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units available for future grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,473,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,871,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total common stock reserved</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,310,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,272,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of number of shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676048688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.236%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,878</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">176</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,126</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below (in thousands, except share and per share data):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.747%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.934%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.295%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.934%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.319%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.455%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term <br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,293,442</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.76</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options forfeited or cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,112,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,984,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.65</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.64</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions used in the Black Scholes Model to calculate stock-based compensation are as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.53%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:23.195%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:23.195%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.32</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.15</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">$</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.97</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">83.25</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">92.87</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">77.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk free rates</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.86</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% - </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.22</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary of RSU activity and related information for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is set forth below:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.18%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Units Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">513,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">194,455</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683468304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.854%;"></td>
        <td style="width:2.099%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.974%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.099%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.974%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss - basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">142,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,042,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,080,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:63.88%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.44%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,383,105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,203,020</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">454,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">197,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,837,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,400,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676083984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for (Benefit from) Income Taxes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for (benefit from) income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.040000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">162m limitation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill Impairment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred Tax Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,601</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,641</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,060</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals and reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sec 174 Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,871</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,803</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basis Difference IPR&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,676</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:64%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.56%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,721</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694772774864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of the Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,772<span></span>
</td>
<td class="nump">$ 238,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 43,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AggregateNetProceed', window );">aggregate net proceed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_UnderwrittenPublicOffering', window );">Public Offering Underwritten</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate number of shares sold</a></td>
<td class="nump">2,611,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 17.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_SalesAgentCommissionsAndExpenses', window );">Sales agent commissions and expenses</a></td>
<td class="nump">$ 43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_CommonStockNotSold', window );">Common Stock not sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AdditionalCommonStockNotSold', window );">Additional Common Stock not sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_AtmProgramMember', window );">ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember', window );">Adicet Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (380,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AdditionalCommonStockNotSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Common Stock not sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AdditionalCommonStockNotSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AggregateNetProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Net Proceed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AggregateNetProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CommonStockNotSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock not sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CommonStockNotSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_SalesAgentCommissionsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales agent commissions and expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_SalesAgentCommissionsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_UnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_UnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_AtmProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_AtmProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763277680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Customer </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_NumberOfCustomer', window );">Number of customer | Customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_CustomersPercentageOfTotalRevenue', window );">Customers percentage of total revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CustomersPercentageOfTotalRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customers percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CustomersPercentageOfTotalRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NumberOfCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NumberOfCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694763242704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694788279504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694677328480">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 115,143<span></span>
</td>
<td class="nump">$ 75,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">115,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115,143<span></span>
</td>
<td class="nump">75,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 1 | Treasury Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">115,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Treasury Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 3 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 3 | Treasury Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents in the consolidated balance sheets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680196800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="nump">$ 1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_PrepaidSoftwareSubscriptionAndLicensingFees', window );">Prepaid software subscription and licensing fees</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid maintenance</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_PrepaymentsToCros', window );">Prepayments to CROs and CDMOs</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_PrepaidProfessionalServices', window );">Prepaid professional services</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 3,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid professional services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidSoftwareSubscriptionAndLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid software subscription and licensing fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidSoftwareSubscriptionAndLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaymentsToCros">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments to CRO's</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaymentsToCros</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680203728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 41,624<span></span>
</td>
<td class="nump">$ 37,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(14,847)<span></span>
</td>
<td class="num">(8,753)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 26,777<span></span>
</td>
<td class="nump">28,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Lesser of useful life or lease term</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,165<span></span>
</td>
<td class="nump">7,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 26,643<span></span>
</td>
<td class="nump">19,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">9,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694675940592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 6,098<span></span>
</td>
<td class="nump">$ 2,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of fixed assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ConstructionInProgressNet', window );">Construction in progress remaining</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementTable', window );"><strong>Statement [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Decrease in construction in progress</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ConstructionInProgressNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>construction in progress net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ConstructionInProgressNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694773502048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 6,514<span></span>
</td>
<td class="nump">$ 5,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AccruedCmoCosts', window );">Accrued CDMO costs</a></td>
<td class="nump">5,679<span></span>
</td>
<td class="nump">4,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional services</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AccruedCroCosts', window );">Accrued CRO costs</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 13,441<span></span>
</td>
<td class="nump">$ 12,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedCmoCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued CMO costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedCmoCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedCroCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued CRO costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedCroCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680081136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 30, 2023</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AvailableUnderTheLoanAgreement', window );">Available under the Loan Agreement</a></td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_PacificWesternBankMember', window );">Pacific western bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TotalLoanAccountsOutside', window );">Total loan accounts outside</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_BancOfCaliforniaMember', window );">Banc of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TermLoanToFinanceLeaseholdImprovements1', window );">Term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DemandDepositAccounts', window );">Demand Deposit Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TermLoanCashMaintain', window );">Term Loan cash maintain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_CombinedBalancesInDemandDepositAccounts', window );">Combined balances in demand deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Banc of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TermLoanToFinanceLeaseholdImprovements1', window );">Term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Banc of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_TermLoanToFinanceLeaseholdImprovements1', window );">Term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AvailableUnderTheLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available under the Loan Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AvailableUnderTheLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CombinedBalancesInDemandDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined balances in demand deposit accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CombinedBalancesInDemandDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanCashMaintain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan cash maintain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanCashMaintain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanToFinanceLeaseholdImprovements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>term loan to finance leasehold improvements 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanToFinanceLeaseholdImprovements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TotalLoanAccountsOutside">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loan accounts outside</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TotalLoanAccountsOutside</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemandDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemandDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_PacificWesternBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_PacificWesternBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_BancOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_BancOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680956064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Third Party Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ResearchAndDevelopmentInProcess1', window );">Research and development in process 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">twelve (12) years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Payment from Regeneron for exercise of its option to license exclusive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_NonRefundableUpfrontPaymentReceived', window );">Non refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived', window );">Additional payment for research funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ExerciseFeePaid', window );">Exercise Fee Paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LicenceAgreementAdditionalRevenueRecognised', window );">Licence agreement additional revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc. | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees', window );">Licence agreement additional amount payable of option exercise fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ExerciseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise fee paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ExerciseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional amount payable of option exercise fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementAdditionalRevenueRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licence agreement additional revenue recognised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementAdditionalRevenueRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment for research funding received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development in process 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676061904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details) - Contract Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilities', window );">Balance at beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilitiesAdditionsDeductions', window );">Additions (Deductions)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,805)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilities', window );">Balance at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractAssetsAndLiabilitiesAdditionsDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities additions (deductions).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractAssetsAndLiabilitiesAdditionsDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=acet_ContractLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=acet_ContractLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678776528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Funding and Other Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">twelve (12) years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694677302544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 09, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_AreaOfSublease', window );">Area of Sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,424<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,424<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acet_WestportOfficeParkLlcMember', window );">Westport Office Park, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember', window );">Redwood City Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember', window );">Boston, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AreaOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AreaOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acet_WestportOfficeParkLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acet_WestportOfficeParkLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_BostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676084752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments And Contingencies - Schedule of Sublease Income (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent', window );">2024</a></td>
<td class="nump">$ 722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears', window );">2025</a></td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears', window );">2026</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDue', window );">Total</a></td>
<td class="nump">$ 1,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676037568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 5,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2025</a></td>
<td class="nump">4,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2026</a></td>
<td class="nump">4,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2027 and thereafter</a></td>
<td class="nump">12,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">25,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">4,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">20,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">$ 2,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current maturities</a></td>
<td class="nump">$ 17,703<span></span>
</td>
<td class="nump">$ 18,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694772863728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember', window );">Redwood City, CA (1000 Bridge Parkway)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementOneMember', window );">Redwood City, CA (1200 Bridge Parkway)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember', window );">Boston, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_BostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694775972880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Lease Costs and Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,510<span></span>
</td>
<td class="nump">$ 4,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_LeaseCostOtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for lease payments</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLeaseProceedsPaymentsUse', window );">Operating cash flows used for lease liabilities</a></td>
<td class="num">$ (99)<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use asset obtained in exchange of operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LeaseCostOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease cost other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LeaseCostOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeaseProceedsPaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Proceeds Payments, Use</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeaseProceedsPaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694775674576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock shares issued, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock dividends declared | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681051824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">12,310,790<span></span>
</td>
<td class="nump">9,272,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">9,383,105<span></span>
</td>
<td class="nump">6,203,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember', window );">Stock options and restricted stock units available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">2,473,485<span></span>
</td>
<td class="nump">2,871,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">454,200<span></span>
</td>
<td class="nump">197,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694678436960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>At-The-Market (ATM) Offering - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,943<span></span>
</td>
<td class="nump">$ 530,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_SalesAgentCommissionsAndExpenses', window );">Sales agent commissions and expenses</a></td>
<td class="nump">$ 43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_SalesAgentCommissionsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales agent commissions and expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_SalesAgentCommissionsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694773007072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 20,259<span></span>
</td>
<td class="nump">$ 17,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,143<span></span>
</td>
<td class="nump">7,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,116<span></span>
</td>
<td class="nump">9,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">18,060<span></span>
</td>
<td class="nump">14,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 2,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694789290880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,293,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,259<span></span>
</td>
<td class="nump">17,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,293,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value,Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 10.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, estimated weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value,Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, estimated weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.69<span></span>
</td>
<td class="nump">$ 7.69<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice', window );">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted', window );">Number of Shares Available for Grant, Options granted</a></td>
<td class="num">(6,431,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_InducementGrantMember', window );">Inducement Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,042<span></span>
</td>
<td class="nump">1,418,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions', window );">Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant, shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePrice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_InducementGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_InducementGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680639984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-Based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning balance</a></td>
<td class="nump">6,203,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted</a></td>
<td class="nump">4,293,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options exercised</a></td>
<td class="num">(946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, Options forfeited or cancelled</a></td>
<td class="num">(1,112,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending balance</a></td>
<td class="nump">9,383,105<span></span>
</td>
<td class="nump">6,203,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Shares exercisable</a></td>
<td class="nump">3,984,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Vested and expected to vest</a></td>
<td class="nump">9,383,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding beginning</a></td>
<td class="nump">$ 14.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options granted</a></td>
<td class="nump">5.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercised</a></td>
<td class="nump">4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options forfeited or cancelled</a></td>
<td class="nump">10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding ending</a></td>
<td class="nump">10.64<span></span>
</td>
<td class="nump">$ 14.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Shares exercisable</a></td>
<td class="nump">13.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 10.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contract Term, Outstanding</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contract Term, Shares exercisable</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contract Term, Vested and expected to vest</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Shares exercisable</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694677275648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">83.25%<span></span>
</td>
<td class="nump">77.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">92.87%<span></span>
</td>
<td class="nump">81.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.86%<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 8.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="nump">$ 19.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680443408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance | shares</a></td>
<td class="nump">197,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | shares</a></td>
<td class="nump">454,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted | shares</a></td>
<td class="nump">513,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs Vested | shares</a></td>
<td class="num">(194,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">RSUs forfeited | shares</a></td>
<td class="num">(62,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, beginning balance | $ / shares</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value,Granted | $ / shares</a></td>
<td class="nump">7.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value,Vested | $ / shares</a></td>
<td class="nump">7.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs forfeited | $ / shares</a></td>
<td class="nump">7.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, ending balance | $ / shares</a></td>
<td class="nump">$ 7.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683814816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (142,658)<span></span>
</td>
<td class="num">$ (69,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average shares used in computing net loss per share, basic</a></td>
<td class="nump">43,042,405<span></span>
</td>
<td class="nump">41,080,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted', window );">Weighted-average shares used in computing net loss per share, diluted</a></td>
<td class="nump">43,042,405<span></span>
</td>
<td class="nump">41,080,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (3.31)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681469248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">9,837,305<span></span>
</td>
<td class="nump">6,400,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">9,383,105<span></span>
</td>
<td class="nump">6,203,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">454,200<span></span>
</td>
<td class="nump">197,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694787418608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxAssetsValuationAllowanceIncrease', window );">Increase in valuation allowance</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 65,601<span></span>
</td>
<td class="nump">68,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OwnershipChangePlanDescription', window );">Ownership change plan description</a></td>
<td class="text">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 18,462<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
<td class="nump">$ 4,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember', window );">California Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember', window );">Federal and state research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 294,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_OperatingLossCarryforwardsIndefinitely', window );">Operating loss carryforwards indefinitely</a></td>
<td class="nump">287,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxAssetsValuationAllowanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance Increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxAssetsValuationAllowanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLossCarryforwardsIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards indefinitely.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLossCarryforwardsIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OwnershipChangePlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership change plan description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OwnershipChangePlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681416032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683874976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(23.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_MLimitation', window );">162m limitation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment', window );">Goodwill Impairment</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Goodwill Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_MLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>162m Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_MLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694677292432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 65,601<span></span>
</td>
<td class="nump">$ 68,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability', window );">Operating lease right-of-use asset liability</a></td>
<td class="nump">4,414<span></span>
</td>
<td class="nump">5,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,285<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxAssetsFixedAssets', window );">Fixed Assets</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_Sec174CapitalizedRD', window );">Sec 174 Capitalized R&amp;D</a></td>
<td class="nump">27,871<span></span>
</td>
<td class="nump">15,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Tax credits</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">102,745<span></span>
</td>
<td class="nump">94,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(99,069)<span></span>
</td>
<td class="num">(89,490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">5,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxBasisDifferenceIPRD', window );">Basis Difference IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DeferredTaxOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="num">(3,676)<span></span>
</td>
<td class="num">(5,439)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxBasisDifferenceIPRD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax basis difference IPR&amp;D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxBasisDifferenceIPRD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fixed assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax operating lease right of use asset liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_Sec174CapitalizedRD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sec 174 Capitalized R&amp;D</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_Sec174CapitalizedRD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680627792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 9,759<span></span>
</td>
<td class="nump">$ 4,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Adjustment based on tax positions related to prior years</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Adjustment based on tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Adjustment based on tax positions related to current year</a></td>
<td class="nump">8,698<span></span>
</td>
<td class="nump">5,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 18,462<span></span>
</td>
<td class="nump">$ 9,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694681227296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">883,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Revenue from related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694680355440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contribution in the plan</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694676020384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill Impairement charges</a></td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_StockPriceDecrease', window );">Stock price declined</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price Decrease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140694683527232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,270,386<span></span>
</td>
<td class="nump">42,954,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Estimated offering expenses</a></td>
<td class="nump">$ 91.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,445,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,054,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre Funded Warrant [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderwritingCommitments', window );">Underwriting Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_acet_DiscountOnUnderwritersWarrant', window );">Discount On Underwriters Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre Funded Warrant [Member] | Jefferies LLC [Member] | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DiscountOnUnderwritersWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount On Underwriters Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DiscountOnUnderwritersWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderwritingCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481804/940-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderwritingCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_JefferiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_JefferiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_AtmProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_AtmProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acet_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acet_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH:5ETZF/"[7+O?H-/;?O7PU[91T+$J<P]5YEZCVS$R_SQE&2I& E\O%*!^B
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M[&;@U<PP%=G&GH1)!*%@=23\AES/02%^A_.7^3$MCF6^ZNE=K7J"0JEZ3DA
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M*KK,(*L<079SZ##@[+UZ2G@6,R$O=*^0KHR4ZO&B8Z3NE8O/"=5F_@GSJW"
M3B=*>%R5_BN=.,VVZOS\W1":O(S0Y-\0ZG0,CPO9EZKQ8O$EW8$Z;%@+7W.3
M:"OA; DM"+PMMY72P;YR6+MO=2;>O5YE^PKHN8Y'/*>W@1HLL3-QR&3@=$0Z
MN23C<OG_YV-D:I"^U YDQ&1ISHA]U+SF3&RJGEX"M&VAZBZP?=M^-[BINN6S
M][?X>E%W_UV8^F/$!RHV*;2Q&5M#2.<JA$DKZOZ^?E"\K%KD)5?0<%>W":.0
M#FT _Z\Y5X<'/4#[E67^#U!+ P04    " #8@7-8I/N&H84&  !,*@  &
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M<9-"LL#E19W31NJSTJ$P>AV .GF#BMQA<!J)_MUH$L;=/F(\YS1$@.Z-V-!
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M"1_;H*CDKNS\&T2A()UU,NH[/FQ5 60NX_5>.\&WG3"2*+A_P,F7[?59VX&
M59>P[ G2U;"B$!D:<R<F7!UYXK.?9I;HNFT3X.@ QV@O%GU#A97@E#0K8HBB
ML6TDCMO?3X;YD%L5>5M,C,&] W>+'B-J2%"C?B171+H7R$Y#=JV(CEL,2)$Z
M2G9!O)TH,8B1D_2?W#OW9ZCG&*EUD33YQ)FZNNCY9]/SB6]25CLP;>GB\,-3
M6NA,?C!V*^@V9$0G:/1)I5.^4^PP7;@GBJ?'/H.-0\[ 4XF]/L=,DS)=/:IF
M5Y3HZ/Z-"-O>*,BGQJ?](8^Z/+<II1X.!H*U&3U%9FGK JW0).-ZP>)8M9-
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M<K<#,T$KX+7!W&4;S@>>-[*[C2VWMK&#E:%2;F7J<5]PZNQ)'AL7I3OU!*$
M)@!SA?]=(ZPW=Z8;A13S"4RUQ[,;>SR;^!))!K"XJU&BJ]MD.Y0EP9*9'N5K
M*#_)>C?%Z,UN;& E=[RZ0P_>0#_P\>)N'Y#2#?)?/Y:-+^!0"I3^LH=):'N
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M081L2]R/*RH.SDJU"WY*V0^[B\_QF@C# S. _JIB2SN)<+G<W8$0^'F%@S(
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M]'4'@<EC6Q)N[9T!1]%%BM7W1)O/IZX3J0.G"*?/2CQWX!M808CUOA46MS7
M;YW<C6*K.GJZ_\AU(L"5&^)59I['A?"7B1Z@M +?5G3DD[K1I_ +)^50&+B^
M":1@N=+P@;NA<H.4CCU41JSH^8 ]:VIU$WTET8VA@C-*-6E9JGLB!(KJ]]1%
MOI,:'$Z8DE4EQ-UK7!=I8CY^1*7<@8M0Q[K>H^';3);JM"?QR=/*>=P"^V?E
M%!&A*AE\&BS=L5-+GMJ79 ]=GV\NN[ATRB8IK'+@ %FL20W^^4)Y7EG_"MZ
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MZO/3KXJ?&+-08"Y_$C3&<C^?6,5P^>)T$=YJDW$U?DS@KH!@",@CG1=SI$F
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MPW?ZQ^ .]!N76S<,KJ5_WIH2N!D?@.]W#D)Y^0,G"#]Z^MW_ E!+ P04
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MQ U9W71-2FRC9!Y'%E>AML+W,HX:<ONND%"7D*V6M?2%W [H0]F4@>#4$/'
M)H#$,4L#T'+"(J9!*&\^A)IIW0ZF,+2'P:$[?/V_T7H&A5W?KZ/>/:,$NPJW
MJ:9WQRM'M]I=V,[C/65[/-[VKKE=2>VP0I<H.AZ>GB38[\,-*KYX4X5;2V8\
MWH'"8X&73K!T />7!EDW+Z2@N\8N_@502P,$%     @ V(%S6,IO#?CM @
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M?SVH'8#.,Z7L;N$2M']FD]]02P,$%     @ V(%S6*XJJ):*!   FPH  !D
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M"YH>45D!^IY+:38;:V [CT[_!5!+ P04    " #8@7-8)@NGS\X"  !V!@
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M!N6O>9:Y1E5OFO>U 1D$!:*GB OM#6N5 ZBC67(L-B ='[U8:.<YUPH"%=1
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MMKWA2XBG>\F6BVUCS5J7:(3#$VXWT=TN"%DW6/)+%!68DC][[0W0.Z,PQH!
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M"[;$#K##UT7*^L&HTZF.D:62B<.VEW7/,BOD<*&HKF"61R06LG!SNK>[NY9
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M+<#O"X5,J6YH@^:_L9O_ E!+ P04    " #8@7-83K\;T'0#  #E!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6R554USVS80O?M7[#"=],(105*R
M9$?2C.VDDQR2\<1)>^CT )%+$34(,  HQ?WU78 20V=D37N0B(_=M^\M=H'E
M7IM'6R,Z^-Y(95=1[5Q[G22VJ+'A=J);5+13:=-P1U.S36QKD)?!J9%)QMAE
MTG"AHO4RK-V;]5)W3@J%]P9LUS3</-VBU/M5E$;'A<]B6SN_D*R7+=_B [JO
M[;VA63*@E*)!98568+!:13?I]>W4VP>#WP7N[6@,7LE&ZT<_^5"N(N8)H<3"
M>01.GQW>H90>B&A\.V!&0TCO.!X?T7\+VDG+AEN\T_(/4;IZ%2TB*+'BG72?
M]?X]'O3,/%ZAI0W_L.]M\WD$16>=;@[.Q* 1JO_R[X<\C!P6[ 6'[."0!=Y]
MH,#R+7=\O31Z#\9;$YH?!*G!F\@)Y0_EP1G:%>3GU@].%X^UEB4:^RN\^]8)
M][1,'"'[_:0XH-SV*-D+*&D&'[5RM85WJL3R.4!"E 9>V9'7;786\2T6$\C3
M&#*6Y6?P\D%G'O#R_Z$3/FF'\.?-QCI#U?'7*=T]ZO0TJN^8:]OR E<1M81%
ML\-H_?I5>LG>G.$\'3A/SZ&O[W334.$&ZJ>XG?4^S2UE$SB9BG$L^%*C7VBY
M>GK]:I&E\S<6[M X48F"4\IT!1]4H4VK#?>]%0.WP*E5Z>QIW+E:&_$/EN!^
M ('3(*SM$-(9BQD+/[ U)VX>\!=@$UI)H>4&=ER28=%SLH$3#U94%MALT RE
M,3DRMR-50*" R@DG/0D-I=B)DNA9$!5P5<*^1D7-6TBR+&'S%)C>:F[*$$48
MNC2T"2''&FRW^9MV/*1?;HW0!HQO_,&4<EVA\:AC1A.X.<T?8E!C?J3DF>R:
M$SW\3V0GXW,C1QOL*BWIXA5J.\KULPB'VBC)TD#5N8YRYP^*JP*O+YX1'D\N
M^E+1K2\ &Y)*2,Z(PAVU0Z<$)8;ON)!\(W$<86NX<I#%TWD>3Q<S&BWF:3QG
MLY]P0\F4 9Z>%.MHX+5<Q?DBCU,V@\LX8WG,,G;Q5>V( +[(8SJ;DBV#]&H>
MSQ;LXHMV7+Z0BS2+\Y3%\RM&H;(YS2C4J99.1E=O@V8;'AA+J)UR_2T\K YO
MV$U_=?\P[Q_ C]QL!4F66)$KF\QG45];QXG3;;C(-]K1LQ"&-;W#:+P![5>:
M[K/#Q <87O;UOU!+ P04    " #8@7-8%GS/'TX,   A(@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6RE6FF3VS82_3Z_ C5QDIDJ#D>DJ,NQ736.
MG:-JD[C&<5);6_L!(B$),0^%($>C_/I]W0 O'6,G^\$>'D"CN_'Z=3>H%[NB
M_&@V2E7B,4MS\_)R4U7;Y[>W)MZH3!J_V*H<;U9%F<D*M^7ZUFQ+)1.>E*6W
MX6@TO<VDSB]?O>!G[\I7+XJZ2G6NWI7"U%DFR_UKE1:[EY?!9?/@7J\W%3VX
M??5B*]?JO:H^;-^5N+MMI20Z4[G112Y*M7IY>1<\?QW1>![PFU8[T[L69,FR
M*#[2S8_)R\L1*:12%5<D0>+/@_I6I2D)@AI_.IF7[9(TL7_=2/^.;8<M2VG4
MMT7ZNTZJS<O+^:5(U$K6:75?['Y0SIX)R8N+U/#_8F?'1N-+$=>F*C(W&1ID
M.K=_Y:/S0V_"?'1F0N@FA*RW78BU?",K^>I%6>Q$2:,AC2[85)X-Y71.F_*^
M*O%68U[UZGU5Q!]O7L.N1'Q;9-AK(\E=+VXK2*<QM[&3]-I*"L]("D+Q4Y%7
M&R/>YHE*A@)NH5:K6]CH]CI\4N(;%?MB''@B'(7C)^2-6UO'+&]\SM:-+)6S
M]9W< UJ5N"M+F:\57__G;FFJ$CCY[RGKK>SHM&R*G>=F*V/U\A+!853YH"Y?
M??5%,!U]\X3F4:MY])3TO[5+3THZK6<0^.+<$N[%\OC%VT>Z5N+7C1*K(D5X
MZWPM*KE,E6#9>66$Z<V.^[.5FRT-Q38%*4;H7%201LO(?/^UP93<%*E.)+TU
M%?YD++98"?!2R:*,N.)Y16UDGICKYQ?_5K*T*!3 D,J6JB0<71"."$SAQ3W4
MDV6\$9B!('X .6T9 \_$P@NB,?[.O#"<7'RO<BR3\CB9(  U08281 2!%P13
MC%^,@HM?BPJCSEK[#,MZX62!BV#F!>'T__3:<B^J_5:1'^1.ELD_< 'O*[QH
M70B]YMYH.J*+R!M-(G)15>K8.IZ&UKFNV-=Q6B>D-#: LT(>*Z?K_?L/YEJ$
M'B_BS6?SB[?9-BWV2ED8B7<UG(ZAXETJ<[AB*H)%Y)QW[",[YQ>GXEV3.<AJ
MT]/>4KNN]G!HR0#:D_7JR'HF$J'A7V0[C*TV8DEI:>@]#UZ.U;82AOB"=QZ6
MNCL@4<*]/]<L$XK\SKR/A9J+&W&W7I=J#:Q>_%)7 &U.WO*.- G%U M'8SC+
M>MV/(C'W(X+>?'316+T&/Y'XR L78R^*0KR?^.-I.T ]JC+6Y/TKL8BFXAH#
M(G_6#8"A*Z5)!KP3TVZE*8\F_(9>% 0\)QCYD\73&H\!]O%\[ 6CB9TP)8U)
MHVARJ \!^I2$L;>81]X\#$C"V)].Q(QMGE[\!L!!+_(WP9R15Q7B 8__GBH<
M6]( +4ZEVG3<\CJ5 ,[[>%.DRB!C)2JE56*9QG6*/3L?>PP&XX+6?$Z(?2=U
M*1YD6G.@0E@&,1:YT-D?A^*&",</R(:YOXCX/ECXB]G%V]8%JLS$%2$:H37Q
M)Q@S]0.&N#F\O_BM@ TZI5B8C_UP(K[$ZT7HSV>XFI&GZ<$\\'%_<:_-1[$J
M$9Q@-#AC[-OQD3^?XB+PI^X64/WRX@U"+$%,\6 Q\D=X:?]G*AN8JB2H=1"B
M.W@.&ZDS9G)9\5X0K=-PQCAVB4A%VAVZ:7;(SK_9@HKH=<8;9H=6 PKM;?CS
M(P0<[)WXZHMY&$Z_$:V7'UK'^3S9I2 !LA*ISCA\0/S,>QOD@*+$P#LP21UO
M/-9$'8MBJQ-%.X@TG!!KJT=)2<1I;R5I@*^;I16'+&-/EC8OU,M4Q^F>-7"P
ME#D-W.EJXX"]U$6EXDU>I,5Z;UD+C)4AU=<5KZ#S!/4DZ-,Y&HA^0&Y;\Q:<
MTP2O>AF9W!;,OC&=K*U2I?%;?Q*D;AA2&JR%=%8Q7*Q/R],OB9!MN!76D@\Y
MN_M]Q:C\%;V&J;'47JLT88L!$N"H+LG%ZL]:<@0/]H"#QNGN$ @WJ=4*KQOT
M 8P=^CH36ISS>E;S5F[2O(3.C"_+44LE_E)E01!K1AA !T5"CMH"?8-2N=A*
M;=D-BQ,<\2\'\=1E287'%@G1D*RMW/>$0/$^;_C'R"53#[1DZTO5EA-D+5*8
M+FAM9WV?YKB$L$'29UY8573IX-0:\$)+G$DO*HU&VM<KC8>90F+%MFTT*$$[
M+MYM5.[<H E,IEZM$-_DAQX0*=<*N80.;9*#=RJL3!%- "],=4/Y@=957&EP
M$6<#SK+V4F$?=%%:]8\5.P1?(\[YR^T7%:+<&C#8R'0*4:8YAH]'N;5]Y&3<
M8$8>,TF5C8\9OFL;QFZ8U2S3R<VV0&! XVJGU% ;9LI&%[1_.JNS@4[8%VW+
M83NV\;0T)P*C1M*B0@F#K!=\\=V!BAFZ6KU-U:$MQFMC!S15%EE#WCDHPVK7
M&&(ZA[A(;&3 @CVAR_$/@VU;%H1YHJ6"'J?I4.DA+>\TWI/].D?&P708*_ZH
MDS7O/X4ZY2)9-8 \0<[>.3Z"B<F  PY*$BCCB9J$_(5;LO%LR4!5 UEF:"[U
M#!BCC35%-E4BK5XB!G3L$N@PJMP.)AKD!::(U0 @76 @9E3C:-[@=$_6FT&9
MWT!HF*Y/,?R@6FF-; 4QC^PX@/,;S+_!8+4G:CVNU&A1JH<^9?=!6=\O;1.0
MO=M*6_C8XAX*GE^.LR]*"%:66K 1RJ0,P.%B#H.H!ALU3P 'U6Q3ZHJ BON2
MH:\&#GBP)>L9[3ZA&K4Y_N)0HS%JM"=4*@[:@K^_]$8"4]@ZUZTT-4#7XK#H
M&V:1H>G/4"&B1NU&.I51!<ZZIX=:WW$1<:R0(Q)V<9V7*B[6.4?4)YO?4MG(
MH+#/W18,@6/=.Z8RM_5EFX$.4EQO92(>UJI4=)Y)CCWRTT%^@&FA/[:^]T6O
M9[:]ZP?NF3GS=+TKNN2N924?-@;IW)ZRDK'_L)7MMZ9V\5Y'US6K=]::3S6H
MP6+F3>;4GLY\]*34WK?(FP1C;S:R[Z*9?><VXXJZ>B^:3+BQQ.NQ?=UUHE=B
M&GK3L!DPFGVJ\8PF:(#=:M/%(!<<*H2EOC9-N_>D^X8Y)4%YAH*L<AF-'GVN
M*$=M1V"QDDZ$TL"3!S%\5EV+:K;_;%AYKJRBL7*+U//(+1=ZAV< :DLM-'<0
M=(- BPM*A2>BC-5N2\C&<3:@N'AM)=I8DD]%4A=!0T7#IIOUW=$/E[*V_?LE
M%W?U&JV'F/?L%<N"SL @*='0 /6C,_Z!\N>P$>UD7=%,M\)]\_3:L8)M%2AE
M%^V20>0V@F>^;4>\@=[7A!(9QT69T F++:*8X% NG&VCPA%:?\L4/V)6SN+X
M:,S2=3"W=U=5L5:TL=9<>F:N?3I-,S4AS+4_A\9X+,;4RS^H[<$@"6L<R&*4
MP2NW!]Z94N*XC4=+@6*Z-FD7=DTQZ=3R+*63@Z=>!%@N@E'#RYZ%968!SG!)
M:BQU>G5JK;MT6S" @ZB?:+@P3PMN.P;USY/%C"OT?Y8FD7^*[]-BB0STDRP_
M@DG=N^'>^F#2QL;!=I[PM\,7)1-W\$&5:DE=(.\ ,3+:FS7:D_309KWRZ(J(
MW^YGNUDRSZ%,:5P".5;1$U?RNM_M;HH4*K<.Z#5'R!E-?V2/)/JAS+"-)573
M4,.]'(BDYU?+P5JZ5ZFY3G_H!)A,X-UI3MZ5Y,,0/ $CJD=M\ZEU+.$597VB
M7;G:SV^.AAEE]CQ^BUXNYA,2>P@N45G:#P2NV^M#-RM00F.X8P&#!L>>"DHZ
M&XA+GBC3$TQXQ%!TP#H]K"P(VKVR?=!4GBG>CZOP81FS5+!<N8JDH:T3);PT
MYU#1M>2?/E4#W5HA3WK#LT>7;2+9\0><-H]\1MKU6A.ZY""SHJ8NFLMUSBG-
M=X->+T_\0=%T4+3ESG.EI 1S0U^\;)]UJIX[+M^J$WBU\!GZP53VK(*^?EA#
MU^>_#;5?M[BZ._.MJ1GD+/BL;UT^$@46LP'B/;'S_:C6QM20&7@1?>2)PCZK
M;ILO,LRIYNB@NJ/W+AUAFDK!811YS4:AZ-X48D/M,AT.QO:3:G.RQ'*'F9M]
M;.B$;-?5[?9$B+4]O<A267:R['&\TC K.8[_E^.8^QJR)M/QY"J^OHJNW1%<
MU:U#17<;:18$EI"/%[*0ZA^0=:[29<?QS&N^./41^+;WV3Y3Y9I_G$#)"J%@
MO^"W3]O?/]S9S_[=</OC":0O+$?M[@I31_YL<BE*^X,$>U,56_X1P+*HJB+C
MRXV2T)<&X/VJ**KFAA9H?Q7RZG]02P,$%     @ V(%S6$T&1@S@ P  Q@@
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL?5;;;N,V$'WW5PS4HDT
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M/5)@@6"S;1^*/M#4V")"D5H>4=Q?WQGJB.THWF+[8HOBS#?7-^1H7AO[X H
MSYY*I=TB*;RO+M+4B0)*[D:F HT[:V-+[G%I-ZFK+/ \*I4JS<;CL[3D4B?+
M>7QW9Y=S$[R2&NXL<Z$LN=U>@3+U(IDDW8N/<E-X>I$NYQ7?P#WXWZL[BZNT
M1\EE"=I)HYF%]2*YG%Q<S4@^"OPAH78[SXPB61GS0(O;?)&,R2%0(#PA</Q[
MA&M0BH#0C<\M9M*;),7=YP[]YQ@[QK+B#JZ-^E/FOE@DYPG+8<V#\A]-_2NT
M\9P2GC#*Q5]6-[*GTX2)X+PI6V7TH)2Z^>=/;1YV%,['KRADK4(6_6X,12]O
MN.?+N34ULR2-:/000XW:Z)S45)1[;W%7HIY?_F),7DNEYJE'-'J7BE;SJM',
M7M&<9.R#T;YP[">=0[X/D*(;O2]9Y\M5=A3Q!L2(32<G+!MGTR-XTSZV:<2;
M?B$VQG7.;K7G>B-7"MBE<^ =NY%.*.."!?;7Y<IYBPSY>R@/C979L!7JF@M7
M<0&+!-O"@7V$9/GVS>1L_/Y(#+,^AMDQ]*/U.:XY.1NQ/@.WF@FC==L*M?0%
M\P5@8G3@BFTZ,5E67%KL.8];7&V==*P"2[T/.<N#E7H3%=<F6,3X'+CU8)E9
M4\VRD[AW;1!%;[$W< LIBYJ^X+[10WCVR%4 TI%8!6>P(A8J8SV!!RT]@R<!
M@)R* M31C<I)+"3"8.,:K)HV@YZ+@ML-L)H[Q!7&1B ='1RQFYT8I'4^0CH4
MP[\V&M>&,]T/!T6$"GD7#1J'1S2'TI9,Z@TX,B.D%:%T2#:!+PJ>,R-$L+;3
MDSJ7@GM<]KZ3IR4%I.0#J"W):<3W;5"0[[GM"VGS@\P?N I/6#0)Z$'..'-R
MH^4:C6)N<A#$$W(T)M\;\< J*P6,L"T([1XJ#^4*H:?CDY?8;]^<9Y-W[_=4
M.]2<S6;L6[:VIHSHU%WD]:XHLN^W@ X\@[<UW75M5X&2X_ <Y&1@Q#X=)1C2
M]148LH*WS@-><X)7TG,E_^&Q&3#F@S([+WWP3>["BDI)-T=;Y)<UCK9K$U0^
M7$4L8! P0/_!M&+"7C;$BB[/)J?<VBV]YZ4)VF/5!%&<M+;[)/#@?-M"/=.P
M;?9Z_)6*L^\("$],9%')/B$06<3[!;X?T5'2);[OI"^'-=#EY S)RM;.T.'3
M>/B:-_L!!Q=+UE3Y![JJ<5E5UG!1/-,,Z4#3!UJM G5CPYI.+M*-8W<9REU+
MF(9!*,J[*:+=03J:9Q9&>/*NC.W]E;4^.'2X$D'QKI###&Y"-0,M?=7M#)G_
MOWGOJ?@5A-X[X9\S=4!G)'#%?&TZ[*'3GF@>J];?4Y&B[:HY?OX;R@&;O,0$
M4_96=*=S&APB9URDTL%M@,P8OH'PR@7GB' =W=>!)I+8O>11YTT\?SGFR>$\
MV;G:NPZ4GECM?2_["XX?NPH1[1LV^7%TBA.D4D29?/<^L8"$IE&.LB9-SH &
MNH%S@8Y?),=+ \T1US38BBLZ%W=C8]Z@ V,V&AJ(TIWAM01$HQ$=#SI*4#/'
M]F_[KX#+9OA]%F\^(3Z@,U([IF"-JN/1N].$V68L;Q;>5'$47AF/@W5\+/!+
M!BP)X/[:8-^W"S+0?QLM_P502P,$%     @ V(%S6.5=PHKZ!   9@P  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULE5?;;MLX$/V5@?:"&M#*LF0[
MEXT-..EE6S1H4+?;A\4^T-+((DJ)*DG9R=_OD+I$CIV@^Y*((N?,G#,7T5=[
MJ;[K'-' ?2%*O?!R8ZK+\5@G.19,![+"DG8RJ0IF:*FV8UTI9*DS*L0X"L/Y
MN&"\])97[MV=6E[)V@A>XIT"71<%4P_7*.1^X4V\[L5GOLV-?3%>7E5LBVLT
M7ZL[1:MQCY+R DO-90D*LX6WFEQ>3^UY=^!OCGL]> ;+9"/E=[MXGRZ\T :$
M A-C$1C]V^$-"F&!*(P?+:;7N[2&P^<._:WC3EPV3..-%-]X:O*%=^Y!BAFK
MA?DL]W]ARV=F\1(IM/L+^^9L=.%!4FLCB]:8(BAXV?QG]ZT. X/S\!F#J#6(
M7-R-(Q?E:V;8\DK)/2A[FM#L@Z/JK"DX7MJDK(VB74YV9KFN-QI_U%@:>+.C
MO_IJ; C6;HZ3%N*Z@8B>@9A$<"M+DVMX4Z:8'@*,*9X^J*@+ZCIZ$?$U)@'$
M$Q^B,(I?P(M[DK'#BW^6)/RSVFBCJ"3^/<6W09N>1K-M<JDKEN#"HS[0J';H
M+7__93(/_WPAUFD?Z_0E])]+R(L0IP.<G 5PK,/JRRW<*;E5K(#W)7Q@94VM
M:76?^C#WXUGHAV$(.F<$!#*#1!8%-1/59?(=]J@0N-8UIL"IPX!\\>:<9H(>
M[,LDD2IE98)4V28'D^/0JP_, *-C.U0T!*!2G$X2P*\0!Y,8*E2-=Z !!&R[
M5;AE!J&D>54IF2"FSA^K:'7/J4U1/)#QY"*(J5^$H-8G'YDA'"K.FH9 N6VC
M(W^DA&5$'.B<]F%3&]@@N<+!:58^ -[3&-1DI%"0CQ2,I$&6Y U4 %^I]-5>
M<6.PA+MZ(W@"G[*,]"" 3P-E([]5=Y424P,4 JEH]2-$$J('LH8KHHN%C?*5
MU>WTWJ@1]@,Z=Q3BQX\WA)3"NWI+#'/D!:PQJ:T=$D>[?0B'2H^&Q"B,>LBG
M:OC(CH^S[MB-K/S1F1_.IOY\?M;5BCNS=L^CH\*AM=V^D45%XOI0,04[)FJD
MS(4!5=QDD/A7[5%KOK;F(]_2\VUU"8ZU11MNMPQXN4/RI@A=X1^9)93"GBG%
M;.$[T#O:>-ML?&LW1M:ZJE62TZB'<W\ZG?EQ' \ZX,"5@VEM.[8!?.FI-RVB
MI4A=G1\I.2CW*)B& ]8V@<_$^+] XXN+"P?K,BH>7/E;#S[L<TX%K- -"8MK
M_3U&\"PL,EOW[LS3Q-(7JFYP3B02[U$E7'=-;AO:01WGIY&P3T-SOF(\A<T#
M/"U=F[%!-1&&=LRCV=PY7_=Z-F]GC1['POJ/6KBVAY3K1-:4V=;#@5>B/@]"
M^"VP@Y.E*3=NU PCV5I43(]MJ3QEY6XEK29L(QI!XA!2]J A4[)P=JF==FV_
M/#,;!A7KQJE+X\GDT:C2CZUMWW<4M1/H8!;65=M)'3DF@)HAFCWY) P;(CB8
M=7$WZXX$Z$K!:L-U)P8U=%8+T62_$U%A@G1Q2P]'?J]/-X:.A[S=/<GU*56W
MEG2<ZE$;]PU)'Y7K)K]_ZC-S,0G.N\_,8=@%ZT.'4E)?D'I=]#2Z,G"#KZ?1
M]T:;ZA-M'\"IZ\5X</<K4&W=#5>#(]I< _NW_25ZU=P='X\W-_!;IK:<Y!"8
MD6D8G,T\4,VMMED86;F;Y$8:NI>ZQYQ^"*"R!V@_D])T"^N@_VFQ_ ]02P,$
M%     @ V(%S6+Y-]>XN)0  P'\  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&ULQ5UY;]S(E?\JA!<))* E2_+8GLQA0);MK(.9C"&-$RP6^P>;K&[5
MF&1U>$CN?/I]9QULDI(]LUA@$JN[6?<[?N^HQQ_N7?NINS6FSS[75=/]^.2V
M[W??/7W:%;>FSKM3MS,-_+)Q;9WW\+'=/NUVK<E+:E173R_.SEX\K7/;/'GU
M WWWH7WU@QOZRC;F0YMU0UWG[?ZUJ=S]CT_.G^@7UW9[V^,73U_]L,NWYL;T
M'W<?6OCTU/=2VMHTG75-UIK-CT\NS[][??$,&] 3_[#FOHO^SG I:^<^X8?W
MY8]/SG!&IC)%CUWD\,^=N3)5A3W!//XEG3[Q8V+#^&_M_1TM'A:SSCMSY:I_
MVK*__?')MT^RTFSRH>JOW?U_&EG0<^RO<%5'_Y_=\[//7SS)BJ'K72V-80:U
M;?C?_+-L1-3@V[.9!A?2X(+FS0/1+-_D??[JA];=9RT^#;WA'[14:@V3LPV>
MRDW?PJ\6VO6O;O@T,K?);NRVL1M;Y$V?71:%&YK>-MOL@ZML84V7'>E?QS\\
M[6%H[.!I(<.\YF$N9H8YO\A^=DU_VV5OF]*4:0=/8<Y^XA<Z\=<7BSV^,<5I
M]NQ\E5V<73Q;Z.^9WXAGU-^SF?ZF5OS?E^NN;X%P_F=JQ=S?-]/](3=]U^WR
MPOSX!-BE,^V=>?+JS_]Q_N+L^X79?N-G^\U2[Z]>YYWM\- ^8-]-GR.)3TWR
M*[K)?KTU6>&:#K:AS'M39AO;Y$UA\RKKX!$#3-EW6=Z4P)85/5#:KJA<-T O
MV6U^9[*U,4T&Z][E+?QL&^P/18CM]T#@_2UPH]_N76NA\UT%;;>F,6U>57O\
MW>QZ;MO#?#XV%C_=X/@TX\O:M$"KV5'ZRU\O+S]DKJ5_CT\7=OJYW^GGBUOT
M(<P.1KWRVS*SWU_=V2-W'=I70VEH3V0/J2_\?.7J7=[LZ60L?'U_ZW KW7T#
MO77#NK.ES5L@[-/LLJJ@J]ZTA;;1OK QT'S3Y20VX_,TE04)E/?^1,/L3VGZ
MZ5&4,'K>9D!@.+G-T%"'L!RFG)UKZ?B+H6U-4^SG5I%,?.% 7_@#?;%X!A\[
M@T.][7I;XSRG3O'+>J"U,['S4<*/CSG) Z8@XFW-OP:+C%3G#>A%?#CK'7SZ
M9#+CA\3=R3O0I3L^I?XV[[-\LP%E1[O(^PMCY[6G$7C>R E7-E_;RO96NHH9
MF&>/9X-#)T]RW[@H/:U'R D@1%"Z^._<Q%IS9YI!IF(^ ^+HD'Z&%NDC-")A
M 5SORM/L9BANH^U0M@!];%H4.7W^6=:[RH;.;(8*5G+'J]NU &K:GDD,=WN'
M,UTA#[1#7G49'$J& C%O81#:'IA@Y>@QQA&T'RN=./Q;.%">C#/@>5#;Q:<3
M1 MEAAP&"\K]CQ&1__D_OKTX?_D]S;^E_8*]6[L62!H7"^1D@%>+'F:%$P*D
MT4%_0X4'!F?=9IO6U="AZR+:6&*2EYY)7BZ2^%^=*^]M54TQQ^-:9OX/.#S6
M+DP YG-A.B^S=@/L,>P3:H$"J.H.%D7B(K=M=I=7 U%: _"TSYNM75>&!4,)
M_0%8(5$4?A$"+XB#2$KEV7KH8(H=;ER]1O%%XLK/#L13XWJD1B"P?T.C]=#C
MEP8')ZH&JJ],WL$S33.0<D+ZL'" MB6*@$_WMP;'@J4 U^"X&R 3IN?"ML50
M T,T!1%J"5JK-\RPARO%;[8ZMSK?@^2%_P [,[?E;;M'RJ#GTU7 R1,/IG/+
M^Q$##4"FL!Z@Y[ >T;$;-[0@A?XUY,"@[0K7!;L"WZ-(@L[@25HG$CTR;BOK
M95GVP#+I; #! DC&-?$4#7#RV\]YK1JQ(ZX.W8_Z)!Y?T0D!KJ!S0Y6$R^X=
M\&_611 V+X&6@+#"F51F"WP$_0:2J(AEH&GCGV_-=@!4X]I]QBH06PP@V'H
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MF^A#&Z!$5_V\'<EBE0TKXHC& 79LF3!1QT%/\)R@I/+Q<YH_#&J54D4- I_
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MEGV8C ,*$-#03^&ZGBD<-G&H!TEX0+L$33<-ZDG\2-#/F_AGR][7 =LY"@"
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MPZ!V!G1>*&4W"T?0_K/&?P!02P,$%     @ V(%S6.#*6BXJ P  SP8  !D
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MM-][<QH!-4.[V3A3A4&Y-([';E@6_)]#\@Y\OC+&;3<^0??GG/X"4$L#!!0
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M4[ .Z_7-K3HE@6,.<;(T&UW5&RYVC-EF)/,6D@ZF9,YI ZE(B)]'7?*^S-$
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M_Q$)^B-R_*:NR8ZW1V3<'\(>_(U _6)%Q1)%R /-2EJ=A4B6B@2"2&(P L*
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MCRNXFC.% K"_D-(T+VB@O>S/_@-02P,$%     @ V(%S6)&5EO8:!P  <3X
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MW?*8U/*8&.5!5BM.5^JJ+[*[*<72E5,CIF].(6$N),R#A/F3O9S:IX[U/*]
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MDI*E4!!8_CV2.4E3A23C^%&#6LTSE6/W^ 7]NDQ>)G./.9G3].]D)393*[+
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M1E4G@F[+#SKW5 B:E8<;@E>$*0-Y?TVI>#E1WXB:;X*S_P%02P,$%     @
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M'ZH%5RV[=<E( :4@K$0<UE/KRKV<C76]*?A!8"\.KI%.LF+L43>^95/+T4!
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M2S46>'EE6;Y(EIM+O 63DF7F,0$< ]<-U.]+QN3V13NH+XZGWP%02P,$%
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M*WD 9;.)S0Z<F0Y-Y7-AE_W.*'K+"6>B^XRK!&Z9,@^P3!4B+:G1\ KNZGT
M<@?KC(D4@0M8RZ)DXN%/32-A%"T:O.=LRW-N.&IXL4'#>*ZO"/\DX8&"G^XV
M\.+9%3RS9/>9K#03B9[[ABJQ>ORX4;VJ58<75 ]"^$#\F8:_1(+).8%/%K0^
MA$<?5F$OXP;C:Q@.7D(8A,,.0>O?AX<]<H;ML@P=W_ "'VWCG&VE8O94P%(I
MNP+UTBQ% G]+$5_*@'L::N:.E88O[XD9WADL]-<NGVL9HVX9]LZ9Z9+%N/#H
M4M&H]NA%S_\8C(/771[]3V1GCHU:QT9][-&*Y4S$",S %E,N!!>IW;PE*BZ3
MKM)KOHGCL[?C/@KF_OZTGJ<9HVEPTR:=Z;QI==[TZEPF":^7ADY+4M7+=-6E
MK^89]^A[FO'J3*#+VO3K^3+XVN/^N*UJ_+ON(^W/7M_'O_2]+^-,WL1[%)BV
M>J>_JAI^V@]&0GR\K_*3"TUAS@S:U]1*4"E,*+1'42$]8YD*_H-"3+?1I%)V
MWYG,)I12&3OKLJ)6[9]<W 6JU#5 35HJ8>HMU4;;'KMTK>51?$6]=] 17X>S
M35?^<C+;3+KBTZ:'^S_EU!\ 'YBB4Z4AQQU)"ZXGM*U4W53KB9&E:S-;::AI
MN6%&WR&H; *]WTEICA/[!^V73?0?4$L#!!0    ( -B!<UBLMHP*80(  "$%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;'U4VV[;, S]%4(#AA;H
MZDO2KN@2 TFS8@%:+&AW>1CVH-J,+526/$F)V[\?)3M>!J1YL46)/#P\(C5I
MM7FV%:*#EUHJ.V65<\UU%-F\PIK;<]V@HI.U-C5W9)HRLHU!7H2@6D9I'%]&
M-1>*99.PMS+91&^<% I7!NRFKKEYG:/4[90E;+?Q(,K*^8THFS2\Q$=TWYN5
M(2L:4 I1H[)"*S"XGK)9<CT?>__@\$-@:_?6X"MYTOK9&\MBRF)/""7FSB-P
M^FWQ!J7T0$3C3X_)AI0^<'^]0[\-M5,M3]SBC98_1>&J*;MB4.":;Z1[T.T7
M[.NY\'BYEC9\H>U]8P;YQCI=]\'$H!:J^_.77H>]@.3JC8"T#T@#[RY18+G@
MCF<3HULPWIO0_"*4&J*)G%#^4AZ=H5-!<2Z[$SDIC&=PNU&%4"5P5<!75Z&!
M66D027]GX0/,BD)X&;F$I>IZP8MZLD#'A;2GD\@1&X\9Y7WF>9<Y?2-SDL*]
M5JZR\%D56/P/$%$90RWIKI9Y>A1Q@?DYC)(S2.-T= 1O-&@S"GBC-_ >T"(W
M>04STF2!6^K@QNL!,V.X*H,V<$,U&.HM^*9AA<9+ ]0OG886?MT1*"P=UO;W
M(8TZ!N/##/Q$7MN&YSAE-'(6S199]OY=<AE_.E+?>*AO? Q]=_? =Q<-#@WU
M6'>U!=K<B,:O#Q$_#NU:E%N$DR0]A5<2T1ZB&^VU;8VF#,-I(=<;Y;H.'G:'
M^9]U;?_/O7L\[KDIA;(@<4VA\?G'"P:F&\C.<+H)0_"D'8U46%;TAJ'Q#G2^
MUMKM#)]@>!6SOU!+ P04    " #8@7-8N<*E([D%  "M+   &0   'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6RUFEUOHS@4AO^*Q8Y6,U+; /GNI)': -JN
M6DW5=G8N5GOA@I-8!9RUG68J[8]?&RB$0-TR.KU)@/@\_GC-P;SQ;,?XHU@3
M(M'/)$[%F;66<G/:ZXEP31(L3MB&I.J7)>,)ENJ4KWIBPPF.LJ D[KFV/>HE
MF*;6?)9=N^'S&=O*F*;DAB.Q31+,GR](S'9GEF.]7+BEJ[74%WKSV0:OR!V1
MWS<W7)WU2DI$$Y(*RE+$R?+,.G=. W>@ [(2?U&R$WO'2'?E@;%'?7(9G5FV
M;A&)22@U JNO)[(@<:Q)JAW_%E"KK%,'[A^_T(.L\ZHS#UB0!8M_T$BNSZR)
MA2*RQ-M8WK+='Z3HT%#S0A:+[!/M\K+CJ87"K9 L*8)5"Q*:YM_X9S$0>P&N
M^TJ 6P2X[PWH%P']]P8,BH#!>P.&1<#P(,"9O!(P*@)&V=CG@Y6-M(<EGL\X
MVR&N2RN:/LCDRJ+5 --4SZP[R=6O5,7)^8(E"95JJDB$TP@M6"IINB)I2(E
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MMUF61.-,LN^T--4TN R@Q!5IF'F0VUOL\DP<7R&9]D_8=GNC (I&&\D[L'7
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M4;D-=GTEI=D5KH'[ZS?_ U!+ P04    " #8@7-8T)/"16(#  "7"P  &0
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M\6C4;178=JRJFD)JK2R694USAY4S:#< WV^4L@\=5YOUM7CV/U!+ P04
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MG&W.& V8T W4\0GGZ<L/?8+UUZ##?P%02P,$%     @ V(%S6-N:.:?[!
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M);W>$$.2]2%?=[0H[3FY%!I/7=O,\%X$TAC@]Y40>M\Q$S0WK<D?4$L#!!0
M   ( -B!<UCHRDW'1P,  'X,   9    >&PO=V]R:W-H965T<R]S:&5E=#8S
M+GAM;,U776_3,!3]*U:0$$BP?+5I.]I*6P=B$A\5%?" >/"2V]::8P?;:;=_
MS[639LV65B!5@I?6=GR/SSGV=6[&6ZEN]1K D+N<"SWQUL84Y[ZOTS7D5)_)
M @0^64J54X-=M?)UH8!F+BCG?A0$B9]3)KSIV(W-U70L2\.9@+DBNLQSJNXO
M@<OMQ N]W< 7MEH;.^!/QP5=P0+,UV*NL.<W*!G+06@F!5&PG'@7X?DL#&R
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M6@L";%8$P"6"8@3T;J-.A,(FY:MG G30K@0'[52V5/]7+)U"3>!:3F"SGOC
M0ET#0@D80LU%%=/%79G1^E%89S3Z_I&E<R:ZX]"2,J@8MHGFVT)K,ES+%NR=
M)K4M"8Z*4IMHOBVT)J6U&L)F[?*:U!ZU!2YN"=P;<\='TW0*C8!KD8 MJ@3<
M%@!X-&H39.SR:((LH34)JI4'-DL/'Q)3*M">.J"N5BKB(N[6'F:@HY/1JOJP
MA=;\)EO+#W(:^4&LR@^K:+XMM":EM?P@9OGQZ<C/7!7<KBXGDT%;A)B[/9JD
M4X@04HL08A8A)I+.$'O(X^J;40A532=K9OSM]WY$''?4&7-6%8@MM":=M0(A
MQG+\59]7*\C=N!L-VU%G55780FO25*L*8E85IJA#<59\,8T52SIW$=+6%V0\
M:E<AYC$<S=@I% :I%08Q*XQ[]5S^6=4,5M%\6VA-SFK-0$ZC&8A5S6 5S;>%
MUJ2TU@SDP$\HQZYMH_9G<X+;J6I5,-A":W)4"P9B%@S_?TLUXS>VU&%GR%F5
M%[;0FG36\H*8Y<4'+EB\S ZK"S/.T6EK55W80FN>D:C5A7L:=>%:51=6T7Q;
M:$U*:W7AVE47;EM=8*^]$II[/9JC4X@+MQ87[H%?.#Y]N_7?XTDG'U9_QK"*
MYMM":]*V<Z3I1&>:[!YJLGNJZ12"PZT%AVOG8)-[^&33X2:^>3#'.MO?.;>8
M,K$LSG_"BJ,_TI;'_K9/MV=,KXJ3E7O/K_'%37E2M(8I#ZY^I&(99Q(E; &0
MSOD("G=1G@4M;Q3/B].1<ZX43XO+B-&0"=T WB\X5T\WNH/MB=S9?U!+ P04
M    " #8@7-8:Q4X\!,#  !+"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6RMEEUOVC 4AO^*E553*VW-!Q0H@T@MK%HO*J'2;M<F.2%6$SNS'>C^
M_6PG!%(%4U6]@=@Y[YOG.#GVF6P9?Q$I@$2O>4;%U$FE+,:N*Z(4<BPN60%4
MW4D8S[%40[YV1<$!QT:49V[@>0,WQX0ZX<3,+7@X8:7,"(4%1Z+,<\S_W4+&
MME/'=W83CV2=2CWAAI,"KV$)\KE8<#5R&Y>8Y$ %811Q2*;.C3^>^3TM,!&_
M"6S%P372J:P8>]&#^WCJ>)H(,HBDML#J;P,SR#+MI#C^UJ9.\TPM/+S>N=^9
MY%4R*RQ@QK(_));IU!DY*(8$EYE\9-M?4"=TI?TBE@GSB[9UK.>@J!22Y;58
M$>2$5O_XM5Z( X$_."((:D'P5M _(NC5 K-R;D5FTIICB<,)9UO$=;1RTQ=F
M;8Q:94.H?HU+R=5=HG0RO*<1RP$]X5<0Z#M:JL\D+C- +$$SEA>, I5"CQ:<
M;8AY>>K;0><KH) 0B1+.\@O4<CF?@\0DNU!VS\LY.C^[0&>(4/24LE)@&HN)
M*Q6Y?KX;U92W%65PA-(/T .C,A7H)XTA;ANX*N4F[V"7]VU@=9Q#=(EZ_C<4
M>$&O VCV?GE@P>DUKZ%G_'I'_&8EYVJEQUU+4RG[W4I=YF-1X BFCJIC 7P#
M3OCUBS_P?G2E]4EFK23[39)]FWMX!S%PG'7E6 F'1JAWGDWH3=S-(;@MHD5S
MU=!<66F6$DOH8JED PN++:+%,FA8!O:585SM-[2+9G"2QA;1HADV-$,KS1.3
M.%.;C_DDNYB&)YEL$2VF4<,TLA;('!)0/'%GA8P^LT(^R:R5Y763Y?5'*^3Z
MY)K;(EHTOK<_'+R/U4BML^%80]H\!X>5_]$ZJ956(EM(FRC8$P7OJ)6X_CH[
MP8+38+:0-MC^0/&M6WEH/:])=5Y+?5YW,O=.[L?6D(K9/6A+<N!KTZT)%+&2
MRNJD;F:;CO#&]$%OYF]UIVC:G;U-U68^8+XF5* ,$F7I70[5ULRKSJT:2%:8
MYF?%I&JES&6JNEW@.D#=3QB3NX%^0-,_A_\!4$L#!!0    ( -B!<U@J+'X^
MFP,  "L,   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;*U7VV[C-A#]
M%4)%"P?8U<WQ):DM(':ZNP%VT2#IY:'H R.-+"*4J)*4G?W['5*R8F=U*8KZ
MP18IGL-SAD-RO#H(^:PR $U><EZHM9-I75Y[GHHSR*ER10D%ODF%S*G&IMQY
MJI1 $PO*N1?Z_MS+*2N<:&7[[F6T$I7FK(![2525YU1^W0 7A[43.,>.![;+
MM.GPHE5)=_ (^O?R7F++:UD2ED.AF"B(A'3MW 37VR T #OB#P8'=?),C)4G
M(9Y-XRY9.[Y1!!QB;2@H_NQA"YP;)M3Q3T/JM',:X.GSD?V#-8]FGJB"K>!_
MLD1G:V?ID 126G']( Z?H#$T,WRQX,I^DT,SUG=(7"DM\@:,"G)6U+_TI0G$
M"2"8]P#"!A"^!5SV *8-8&J-ULJLK5NJ:;22XD"D&8ULYL'&QJ+1#2O,,CYJ
MB6\9XG1T5\0B!_(;?0%%WI-'3).DXD!$2B;W4NR972],EPNR@0)2IDDJ14[.
M<+<L34&J^LT'2$!23AXUU946\BMYH!J(%D1G0#X+I9 )"8_@R2UHROC%RM/H
MQZCRXD;[IM8>]F@/0O)%%#I3Y)<B@>2<P,- M-$(C]'8A(.,MQ"[9!J\(Z$?
M3CL$;?\]/!R0,VT79VKYIJ.+@R%6,1>JPK#]=?.DM,3\_[LK9#7C93>C.12N
M54EC6#NXZQ7(/3C13S\$<__G+KO_$]F9^<O6_.40>W3,(]7F$:O#H3$<$E/J
M'2E!QE#HKC#4W(%OR<U9MH]\-PQ6WO[4W]BH,^&S5OAL4+A9KEA"PK3J4C;K
MF/.-K&'^2>C._!\O!D(\;Y7.!YG,%H63L$*GX&&.R=*=?J>FME$#@^ LNOYR
MYI]^>H*]:"TL!J??9K38&0]D3WE%ZZN!X^5$BQBZW S331:NW^-F!!A.W7!X
M59:MI>4@53 /<\)9SK2UTV5B.9Y#PW-,@K$<NFK57HWDD(B?WYN;-"&81UA>
MJ%[9PTR8UXN>V(\"OT_!,S.!_WH=^H-<'X5(#HQS<I>7E,F\YW@984%%5SU6
M&F3/VIVK/KG$@\'Y?L6K59KC,*<%*B:)O9 !MT#GCAYAF_ANT*=^%#FR"8+P
MU5,XR'56?8P>4B-D**QO7_\79&W).RF[<I [6XTJW 55H>N:H^UM*]X;6^>]
MZ=^82MB6<Z\T=1G]A<H=*Q3AD"*E[R[P:I!U95HWM"AM<?<D-):*]C'#:AZD
M&8#O4R'TL6$F:/\?1-\ 4$L#!!0    ( -B!<U@?9.JNFP0  (81   9
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MF>H7#0CCH.?GG*OUP"Q0OY&BWU!+ P04    " #8@7-8"$D250$#   %"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RU5M%NVC 4_14KJZ9.ZDA(
M((0.(K5TTY!6"4&[/4Q[<),+L1K;S':@_?O93LB 0K9.["6QG7N.S[FVXSM8
M<_$H,P"%GFC.Y-#)E%I>NJY,,J!8MO@2F/XRYX)BI;MBX<JE )Q:$,U=W_-"
MEV+"G'A@QR8B'O!"Y83!1"!94(K%\S7D?#UTVLYF8$H6F3(#;CQ8X@7,0-TO
M)T+WW)HE)128))PA ?.A<]6^'/5-O WX2F MM]K(.'G@_-%TQNG0\8P@R"%1
MA@'KUPI&D.>&2,OX67$Z]90&N-W>L'^RWK67!RQAQ/-O)%79T(D<E,(<%[F:
M\O5GJ/QT#5_"<VF?:%W%>@Y*"JDXK<!: 26L?..G*@];@'9X!.!7 '\?T#D"
M""I 8(V6RJRM&ZQP/!!\C82)UFRF87-CT=H-86859TKHKT3C5#R%'"M(T00+
M]8SN!&82VP1+]!Y=I2DQ;9RC,2MWC$G]^0TH3'+Y3H?<SV[0^=D[=(8(0W<9
M+R1FJ1RX2FLS,[A)I>.ZU.$?T='VT2UG*I/H(TLAW25PM:G:F;]Q=NTW,MY
MTD)!^P+YGA\<$#3Z>[C?(">H$QU8ON"UB4;?O^A0-%9 Y8]#B2MY.X=YS2F_
ME$N<P-#1QUB"6($3OWW3#KT/ATR?B&PG!9TZ!9TF]GC$*=5^]9Y.'B^0S+">
M A$IB_WU+GV79*$E,S^C5=P)_)X71.' 76U[.A#H][N=R/?JP!V]W5IOMU'O
M1/]10 B]:+-2\JR4/#XJN?M"B;>GM2EB1V18BPP;14YA 0R$SNM$JZ-Z[0I%
M$IS+"WUFD]8AE8V$K]U0)R+;\=ZKO??^TYGJG3(%)R+;24%4IR ZY9F*7FR_
M* JZ8;2W2QOG_$='_=I1_P\;>@6L #07G.HZH5SAI5GA0X9*KE[#B6N<[;5>
MW*V;EH)8V )$HH073)67;CU:USA7]FIW?X>7!=(M%@NBK]D<YAKJM7KZUR#*
MHJ/L*+ZT]_8#5[H*L,U,UVD@3(#^/N=<;3IF@KKRBW\!4$L#!!0    ( -B!
M<UC=B?);;0(  ,P%   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;*U4
M36_;, S]*X)7#"VPQ5]I5G2)@7QL: \%@A;=#L,.BLW$0F7)DYBD_?>C9,=+
MNR3881=;I,CG]VB2PZTV3[8$0/9<265'08E87X>AS4NHN.WI&A3=++6I.))I
M5J&M#?#")U4R3*)H$%9<J" ;>M_<9$.]1BD4S VSZZKBYF4"4F]'01SL'/=B
M5:)SA-FPYBMX 'RLYX:LL$,I1 7*"JV8@>4H&,?7T[Z+]P'?!&SMWIDY)0NM
MGYQQ6XR"R!$""3DZ!$ZO#4Q!2@=$-'ZUF$'W29>X?]ZA?_7:2<N"6YAJ^5T4
M6(Z"JX 5L.1KB?=Z>P.MGDN'EVMI_9-MV]@H8/G:HJ[:9&)0"=6\^7-;A[V$
M>' D(6D3DK<)_2,):9N0>J$-,R]KQI%G0Z.WS+AH0G,'7QN?36J$<G_Q 0W=
M"LK#; 9+\A1LJA4:L5C[VLXE5^PC&Q>%<#:7[%8U#>-NSV> 7$A[02&/#S-V
M?G;!SIA0[$Y(20%V&"(Q<_AAWK*8-"R2(RSBA-T1@=*R+ZJ XC5 2)(Z7<E.
MUR0YB3B#O,?2^ -+HB0]0&CZ[^G)"3II5^;4XZ5'\.X!A0'J?F034%1SM.S'
M>&'14!__/%2P!J]_&,_-]K6M>0ZC@(;7@ME D+U_%P^BSX?$_B>P5]+[G?3^
M*?1LJJN:JQ>6[W<8=0N6P&IJM$/B&\1+C^CVT":+>_0;-ON:_HZ)>E==3$,U
MW!N,"LS*[PM+5-8*FU[JO-U*&OM)?..?T*IJ-LL?F&;/W7&S$LHR"4N"C'J?
MB)%I=D=CH*[]^"TTTC#[8TGK%HP+H/NEUK@SW >Z!9[]!E!+ P04    " #8
M@7-8=H&?^JH"  "I!P  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6RM
M5=]OFS 0_E<L5DVMM 5"2+MU!"DM^]&'2E6C;@_3'ARX!*O&9K83NO]^9T,H
MJ5+627T!GWW?=_?=P3FNI;K7!8 A#R47>N85QE3GOJ^S DJJ1[("@2<KJ4IJ
MT%1K7U<*:.Y )??#(#CU2\J$E\1N[T8EL=P8S@3<**(W94G5GPO@LIYY8V^W
M<<O6A;$;?A)7= T+,'?5C4++[UAR5H+03 JB8#7SYN/S=&K]G<-W!K7NK8E5
MLI3RWAI7^<P+;$+ (3.6@>)K"Y? N27"-'ZWG%X7T@+[ZQW[%Z<=M2RIADO)
M?[#<%#/O@T=R6-$--[>R_@:M'I=@)KEV3U(WOJ?HG&VTD64+Q@Q*)IHW?6CK
MT ,@SV% V +"IX#H&<"D!4Q>"HA:0.0JTTAQ=4BIH4FL9$V4]48VNW#%=&B4
MSX1M^\(H/&6(,\E7*?.:<4Z.YWG.;"LH)U>B^9[0.B''*1C*N#XA[\G=(B7'
M1R?DB#!!KA&&'CKV#29BZ?RL#7K1! V?"?J17$MA"DT^BQSR?;R/ CH5X4[%
M13A(N(!J1";!.Q(&X>1 /I?#\!0RA(^?A:<OAX<#:B9=3R:.;_*OGE"18R\,
M%6NVY$#F6H/1)&4ZXU)O%)"?\Z4V"O^=7X>:T$2)#D>Q\^1<5S2#F8<#0X/:
M@I>\?3,^#3X=JN!KDJ6O1+97W:BK;C3$_EC=J[*B3 '.,$.R@JHU'/R4&[:I
M8[-#=)N,/XZFL;_M5Z=Q.NLY!?L>Z9#'GHYIIV,ZJ&-A9'9/*L4RP$&7V>/\
M4/X-RSCH1QY%T1,!@['^M[VO1-:4Q>\-MQ*P2_:2T"23&V&:.=?M=O?0W(U?
M_]&]N<2NL<E,:,)AA=!@=(:)JN9B: PC*S<JE]+@X'7+ N]24-8!SU=2FIUA
M W2W<_(74$L#!!0    ( -B!<UBV^[4W%@<  +=#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<R+GAM;+6<76_;-AB%_PKA%4,+9+9$R8[=)0:2B,12-&C0
M+.M%L0O%9FRA^G!).<F _?A1'[%$5V&LXNS&EF2^#RD=ZA5U3.GD,9/?U%J(
MG#PE<:I.!^L\W[P?C=1B+9)0#;.-2/4O]YE,PERORM5(;:0(EV50$H^HXTQ&
M21BE@_E)N>U:SD^R;1Y'J;B61&V3))3_G(LX>SP=N(/G#9^CU3HO-HSF)YMP
M)6Y$?KNYEGIMM*,LHT2D*LI2(L7]Z>#,?<^]21%0EO@K$H^JM4R*7;G+LF_%
MRN7R=. 4+1*Q6.0%(M1?#^)"Q'%!TNWX7D,'NSJ+P/;R,YV7.Z]WYBY4XB*+
MOT3+?'TZF [(4MR'VSC_G#W^(>H=&A>\11:K\I,\UF6= 5EL59XE=;!N01*E
MU7?X5!^(5H#KOQ! ZP"Z'S!^(<"K [Q#:_#K /_0@'$=,#XT8%('E&*.JH-5
M'ND@S,/YB<P>B2Q*:UJQ4,I51NL#'*5%S[K)I?XUTG'Y_&9[I\3WK4ASPA[T
MIR*_D;/E,BID#V-RF5:=M^@$;P.1AU&LWNDBMS<!>?OF'7E#1D2M0RD4B5)R
MFT:Y.M(;]?)5%,<Z2IV,<MW,HK+1HF[21=4D^D*37'*5I?E:$98NQ=*,'^G=
MV^TC?=['<VH%?@C3(:'>$:$.];O:<T"XY[X8'AQ2.WTQG-G# ['8U>YUA//#
MPZGE6'J[_N*5/._ _D*^?M0ER&4N$O5W1_/.*YS?C2ORYGNU"1?B=* 3HQ+R
M00SFO_[B3IS?NX1"P@(DC"%A' 0S!/9W OLV^OQ2J6V8+@3)[LDB2Q)]XNLD
MM/C6I:V5U%=;)"Q PE@%FY2PXDK],/<]>NQXT\G)Z*&M6T=!.AO[4^KL"AJ:
MC'>:C*V:7+1T(!L9:74V0E:)MTL7*ZVO+DA8@(2Q"C9M'6YGZ#B.NZ?*J\4,
M328[32963?8389<.5D)?'9"P  EC2!@'P0Q-CW>:'F,O;L=(@9&P  EC2!@'
MP0R!ISN!I]:3EJD\TJ-9L=17MWLAHW1%Q).^25.B:YQZ7L'&K<PQ<X=3,[U<
M6&OL*QL2QI P#H(9LLUVLLUZY5KR+_D@2@'U?<?'CQ?DZY5([H3L/$>MZ+[G
M*!(6(&$,">,@F"&VZS2WI XV#=<\D,906@"E,2B-HVBFSBWKP;6?UI5Q4-QQ
MB.41N2X'MM=Z8'OSTL#6#NPM-)(6U#37:UTNZ)".]VX2&+16CJ*9$M)&0MHW
M,Y_]>:6ES%8R3*QYV4[NK262%D!I#$KC*)JI>./_N& #R(4Z0%!: *4Q*(VC
M:*;.C0WDVGV@L]5*BI4>*Y-4Y&0CLX40R\Y1LAW46V#_AT&W.QMZ9A(-H'4R
M*(VC:*9PC5?DVLVBCI1<^T<WI7]DS<E0YPA*"Z T!J5Q%,V4O+&BW DX)T.=
M*2@M@-(8E,91-%/GQIYRK>9(+V_>CNHM,=2<JFEMHWSLT;'C./MC9:CSA**9
MZC7>DVLWGPY-S+W<#7N=O66&FEE0&H/2.(IF]H7&T')GX(P-M;&@M !*8U :
M1]',B0>-E46M%LJ</0FYB)2H_K7K$M8.Z"LLE!;4M/98G []O1P-K9*C:*9>
MC25%[9;4EU#*L)@%DVUSE8?I,DI7G:I!C2@H+:AI[:OKU/?'GN?M*P=UHE T
M4[G&B:)V)ZK/V,B.ZJT>U'JJ:6WUZ+$S]B>3XWWYH+82BF;*U]A*U&IG])[B
M8,?UEM [:"I! *V506D<13,%;/PB:O>+>HQN#W6([37VUA@ZP0A*8U :1]',
MGM 84'2,'=M2J.L$I050&H/2.(IFZMRX3M0^ ZK7%1=J.-6T]C5RXA7V@;.?
MKZ%>$I3&4313O<9+HG8OJ?<%%^HGU;192T%OZ.Z[_- Z&93&4313OL9,HKW-
MI&LI"-\6<^9)?1OS<Y:2O>;>2D,M)2B-06D<13-[1&,I4;"E1*&6$I060&D,
M2N,HFOG\16,I>79+Z5:?X?)11GDQ>['(XE&>% _N=$EL1_5^^L+>,,_I4A+:
M! :E<13-5+(QFSR[V11$:I%M]9GZJ7ATJE952/6<OCL5A1I/4%I0TXI99>W;
MZ/T)4-!*.8IF:MC83MXK$Z!ZSV&S WLK"#6?:EK;!RFFL(UG^Q)"K2<4S92P
M]42;W7IZW:.W WI+AGV*K:*YOJ&9-YO]H!GV$;7_PVWR&K?)Z^TV_<SP5_]P
MF>HK:1B3Z^U='"W(I_JY@,YN /6CH+0 2F-0&D?1S+[2^%$>V(_RH'X4E!9
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MC3B".0 /&!+'S7MPYWT4KMY3X?K_N,/?4$L#!!0    ( -B!<UB7BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ V(%S
M6#^BQ[V5!0  V2\   \   !X;"]W;W)K8F]O:RYX;6S%FEMOXC@4@/^*Q<MV
MI.D"N3%3E4JTG<Y6Z@45U->524RQFL2,[?3VZ\=.ANU)"4?[<LI3FPOFX\0Y
MW_'E^%GIQX52C^RER$LS[JVL71_U^R9=B8*;O]5:E.[*4NF"6W>H'_IFK07/
MS$H(6^3]8#!(^@679>_D>-/65/?A@;(BM5*5[J0_<2_%LWF_[@_9DS1R(7-I
M7\>]^O]<]%@A2UG(-Y&->X,>,ROU_(_2\DV5EN>S5*L\'_>&S85[H:U,MT[/
M/.2<+TQ]QO+%'7<@XUXR< TNI3:VOJ-NGSO&)^%N;HXJJRYD;H4^YU;\U*I:
MR_+!-^-^11_\C#H.F[]-$(_T_PFC6BYE*LY56A6BM$T<M<@]8&E6<FUZK.2%
M&/<VMS!>9NQ':5V0V&79-.7N];_4??5EUOQJZW!!#/61=!?T95:#TT&>N6.5
MR\Q]>\9.><[+5+ ZN 8 !@A@L#= =C#E #)$(,-/A)QY"/\!P]22W:Z%!I 1
M AGM#?).9 ) Q@ADO$?(?P, F2"0R=X@S[A9 <@1 CFBA;S5#[R4;_6%.@7=
M<%MIX2%/*R,!Y#<$\ALMY*PJ"JY?/=1,/I32?8R[C#E)4U6YC D@OR.0WVDA
M+[C4[)[GE6#7@AL7Q/IQPP0^P#+X@!9OJL6:2Z>8%]>($:9^V+=V)30[JS1,
M/D-4-,2F<?6$2X7.@;4.?U5R[3_PE97"0D1,-4-BU[ANIROW2K<#Z!5^)?D"
M]L8A)ILAL6WF*ZDS-N4^F),'+;:[(V:9(;%FYD(7[$KQ5H&#&65(KI2BD+;)
MT/[)NNQM74TH7"'1"AHFE"&Q4696I8\KE6="F[_JM\.^0C;,(T-BD=1LAZ?<
M"!^[PB>9K0(64\B0V"$WKMTK90R;NA=VMN(:EC)#S!M#8G%<EJDJ!)OSEU9/
M"S!;!,2VN/,GQ29]S#5W3[,>Y;4(,5$$Q*(X%TM9BN8]U7)1U07,-&\EE  =
MD1!KXJ=2V;/,<\B#^2 @]L&L6ACQJ_*>^O'T004!IH* 6 5H==<JY@-,$ &Q
M(';4=^Q@SAU(*YJ8(P)B1Z!U7CN:F"X"8ET@=9Z/*,3$K!$06P.M]=K1Q!02
M$"NDN];;=,TO</H#LTI(;!6LQG*P$!-32TBLEJXRJS.6F%Y"8KWLJK?^@$),
M=,J+V#K;95=G)#'_A,3^@?57)QQFG9#8.LC\C$M'#&)BU@FI1R:HPT.(B5DG
M)+:.G](JA>N-[HU9R+*)ZB&;9)G\,%8),>N$Q-;9@3ES36=5^]W&K!/N9\9K
M0PKGLS'K1/N<^6KUS0BS3K2_F2\?48B)>2<B]@Z..8&8F'<B8N_@A5OKH:.+
M+9\U#0:R$,__6P"$F)B%(F(+[:@O-\P0$[-01&RAG9B-GB F9J&(V$)7[C:7
MB+ZRBZK,7/T+.JFGAIB8A2)B"[U7ZQ^*=2E\3"$F9J&(V$)P4#'9YH0+EIB%
MXD\;^W1$LS62C#$+Q>0K_1@FS)LQ9J&8?+T?PXP@)F:AF'K.K6LDV5EOQIB%
M8NH9N&[,CGHS1A?]B2TTL8?SE3B\YOK1SQ)-YM=?V.UR*;3/H:V$%&,6BC]C
ME:9K9-YX"&)B%HKWM&#SIW]"3,Q",?7:/Q;-=M[$+!036PC#=,W#'2F8A1)B
M"^'1A.D]P2R4$%NH8];H/1TQ!3$Q"R7$%D(QV]N0, LEQ!9J37!MCS,@)F:A
MY#/GX>#C7M9=%6)B%DJ(+81@'KC!,<1$-Y\16PC!/!?+5D+"+)006PC!O!-I
M*YJ8A1)B"^U>#Z]?*(B)62@AMM#.1?'FM8=;#C$+C8@MM%D:=S7<]IR'A ]]
MA%EH1+T.]''%O)T\(29FH5%MH7Y]LSDYSIIG=..^PKCS*<_3J6;^3[.S+8K]
M;I1EE>=G[MQM>:5XMMF9OME5?_(;4$L#!!0    ( -B!<UBL;5!7/ (  *\J
M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VLUJHU 8QO%;"5Y
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M.X'>CGH[@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=XQ^=F$0.]
MO8- [T"]@T#O0+V#0.\&]6X(]&Y0[X9 [P;U;GY2[S)^'7*Y]GRO\?H_2?5X
M/C=?+W]9?N^<W)<+SO5M17GZ"U!+ P04    " #8@7-80&L7N@ "  #&*0
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M<F]P<R]A<' N>&UL4$L! A0#%     @ V(%S6*0Q<X7N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ V(%S
M6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #8@7-8'X70$A$)  #7-@  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ V(%S
M6&>)]+)\!0  XA8  !@              ("!5!$  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( -B!<UAQ=4;6G (  -L(   8
M      " @087  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #8@7-8:->V\9@$  !Q$0  &               @('8&0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ V(%S6*3[AJ&%!@  3"H  !@
M             ("!IAX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( -B!<U@$YT%^)0(  $X$   8              " @6$E  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #8@7-8D((ZU6$'  "C
M(   &               @(&\)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ V(%S6(9;M,&<#   7B   !@              ("!4R\
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -B!<UBFUJV.
MQ",   !U   8              " @24\  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #8@7-8=;VY;H@%  #2#@  &0
M@($?8   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -B!
M<UC*;PWX[0(  -@&   9              " @=YE  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ V(%S6*XJJ):*!   FPH  !D
M         ("! FD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #8@7-8)@NGS\X"  !V!@  &0              @('#;0  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -B!<UAS%@.23@D  / 9
M   9              " @<AP  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ V(%S6%2DD_7 !0  8 X  !D              ("!37H
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #8@7-8/<;9
MHAD*   G&P  &0              @(%$@   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( -B!<UA.OQO0= ,  .4'   9
M  " @92*  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MV(%S6!9\SQ].#   (2(  !D              ("!/XX  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #8@7-8309&#. #  #&"   &0
M            @('$F@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( -B!<UA-8'[&[ L   H@   9              " @=N>  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ V(%S6+[>+Y'1 @
M; 8  !D              ("!_JH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #8@7-8W3[5 O\"  ":!@  &0              @($&
MK@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -B!<UC[
M%U!)YP0  "<-   9              " @3RQ  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ V(%S6.5=PHKZ!   9@P  !D
M     ("!6K8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -B!<U@A)\01V@(  &(&   9              "
M@4WK  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ V(%S
M6#>4<Y$8 P  10<  !D              ("!7NX  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #8@7-8PI<2. $%   "#0  &0
M        @(&M\0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( -B!<UA>H)NNV0(  $T&   9              " @>7V  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ V(%S6/,ANPJ?!0  6 X
M !D              ("!]?D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #8@7-8!TLP+[P#  #,"   &0              @('+_P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -B!<UA/6+\M
MYP4  /@/   9              " @;X# 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ V(%S6)&5EO8:!P  <3X  !D
M ("!W D! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #8
M@7-8#.H,Z0D#   D"0  &0              @($M$0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -B!<UA%A=>\*@(   X%   9
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M970T,BYX;6Q02P$"% ,4    " #8@7-8GME)(3\#  #V"P  &0
M    @('-)P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M -B!<UBA;#OR^0(  !0)   9              " @4,K 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ V(%S6-WN"]5_!   :!X  !D
M             ("!<RX! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #8@7-8YI9-HYP$  !$%@  &0              @($I,P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -B!<UCB]9.H/ ,
M .4(   9              " @?PW 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ V(%S6*RVC IA @  (04  !D              ("!
M;SL! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #8@7-8
MN<*E([D%  "M+   &0              @($'/@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -B!<UB:<+W?3P(  (H%   9
M      " @?=# 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ V(%S6-"3PD5B P  EPL  !D              ("!?48! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #8@7-8)X/6CH0#  "@$0
M&0              @($62@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( -B!<UA1PJ..TP,   8-   9              " @=%- 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ V(%S6$\1,&(E
M P  _ L  !D              ("!VU$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #8@7-85_FBBTP#  #I#0  &0
M@($W50$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( -B!
M<UC;DX+\6@,  .,,   9              " @;I8 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ V(%S6,YC%K?] P  :A0  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( -B!<U@&"T@2*0,  '4)   9
M  " @:=U 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MV(%S6.C*3<=' P  ?@P  !D              ("!!WD! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " #8@7-8XY.,K'X&  "=*P  &0
M            @(&%? $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( -B!<UAK%3CP$P,  $L+   9              " @3J# 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ V(%S6"HL?CZ; P
M*PP  !D              ("!A(8! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " #8@7-8'V3JKIL$  "&$0  &0              @(%6
MB@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( -B!<UB]
M!R>7$0,  "\)   9              " @2B/ 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ V(%S6 A)$E4! P  !0H  !D
M     ("!<)(! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M  #4%0  #0              @ %ZH@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( -B!<UB7BKL<P    !,"   +              "  ?BE 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( -B!<U@_HL>]E04  -DO   /              "
M >&F 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #8@7-8K&U05SP"  "O
M*@  &@              @ &CK $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #8@7-80&L7N@ "  #&*0  $P              @ $7
LKP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4 !0 .<5  !(L0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>359</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Third Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements</Role>
      <ShortName>Third Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments and Contingences</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences</Role>
      <ShortName>Commitments and Contingences</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Accrued and Other Current Liabilities  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Third Party Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables</Role>
      <ShortName>Third Party Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingences (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables</Role>
      <ShortName>Commitments and Contingences (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Organization and Nature of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Nature of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Property and Equipment, net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Property and Equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Third Party Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails</Role>
      <ShortName>Third Party Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails</Role>
      <ShortName>Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100650 - Disclosure - License, Funding and Other Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Funding and Other Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails</Role>
      <ShortName>Commitments And Contingencies - Schedule of Sublease Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails</Role>
      <ShortName>Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100750 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails</Role>
      <ShortName>At-The-Market (ATM) Offering - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Goodwill (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails</Role>
      <ShortName>Goodwill (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="acet-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100910 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:CommonStockDividendsPerShareDeclared, us-gaap:OperatingLossCarryforwardsExpirationDate -  acet-20231231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="acet-20231231.htm">acet-20231231.htm</File>
    <File>acet-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img104831930_0.jpg</File>
    <File>img104831930_1.jpg</File>
    <File>img104831930_2.jpg</File>
    <File>img104831930_3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="540">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acet-20231231.htm": {
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "acet-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "acet-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 292,
   "keyCustom": 67,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 22,
   "hidden": {
    "total": 12,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 8
   },
   "contextCount": 136,
   "entityCount": 1,
   "segmentCount": 53,
   "elementCount": 852,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 540,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100050 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_119167b2-4bd2-41bc-bc2b-7272a38298f7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_119167b2-4bd2-41bc-bc2b-7272a38298f7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_6266d910-cfeb-4c96-8052-2f53133c7cdb",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6266d910-cfeb-4c96-8052-2f53133c7cdb",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness",
     "longName": "100090 - Disclosure - Organization and Nature of Business",
     "shortName": "Organization and Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:OrganizationAndNatureOfBusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:OrganizationAndNatureOfBusinessTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "100140 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1",
     "longName": "100150 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities",
     "longName": "100160 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements",
     "longName": "100170 - Disclosure - Third Party Agreements",
     "shortName": "Third Party Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan",
     "longName": "100180 - Disclosure - Term Loan",
     "shortName": "Term Loan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences",
     "longName": "100200 - Disclosure - Commitments and Contingences",
     "shortName": "Commitments and Contingences",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "100210 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "100230 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "100240 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100250 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "longName": "100260 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "longName": "100270 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill",
     "longName": "100280 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "longName": "100290 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100320 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "100340 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "100350 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "longName": "100360 - Disclosure - Accrued and Other Current Liabilities  (Tables)",
     "shortName": "Accrued and Other Current Liabilities  (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables",
     "longName": "100370 - Disclosure - Third Party Agreements (Tables)",
     "shortName": "Third Party Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables",
     "longName": "100380 - Disclosure - Commitments and Contingences (Tables)",
     "shortName": "Commitments and Contingences (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "100390 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "100400 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "100410 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100420 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "longName": "100430 - Disclosure - Organization and Nature of the Business - Additional Information (Details)",
     "shortName": "Organization and Nature of the Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:AggregateNetProceed",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "acet:OrganizationAndNatureOfBusinessTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
     "longName": "100450 - Disclosure - Business Combination - Additional Information (Details)",
     "shortName": "Business Combination - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
     "longName": "100500 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)",
     "shortName": "Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "100530 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_14728681-e228-429d-9c6d-e288fc904418",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_14728681-e228-429d-9c6d-e288fc904418",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "100580 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "longName": "100590 - Disclosure - Property and Equipment, net - Summary of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, net - Summary of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100600 - Disclosure - Property and Equipment, net - Additional Information (Details)",
     "shortName": "Property and Equipment, net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_af925b6c-d225-4763-b22a-b3974a3e23db",
      "name": "acet:ConstructionInProgressNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "100610 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
     "longName": "100620 - Disclosure - Term Loan - Additional Information (Details)",
     "shortName": "Term Loan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:AvailableUnderTheLoanAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:AvailableUnderTheLoanAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
     "longName": "100630 - Disclosure - Third Party Agreements - Additional Information (Details)",
     "shortName": "Third Party Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:ResearchAndDevelopmentInProcess1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:ResearchAndDevelopmentInProcess1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails",
     "longName": "100640 - Disclosure - Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details)",
     "shortName": "Third Party Agreements - Summary of Change in Company's Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_40665ebd-fd67-4d04-97c7-45124e5c850b",
      "name": "acet:ContractAssetsAndLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e30421e9-e302-416b-8491-76859aa72b91",
      "name": "acet:ContractAssetsAndLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
     "longName": "100650 - Disclosure - License, Funding and Other Agreements - Additional Information (Details)",
     "shortName": "License, Funding and Other Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:LicenseAgreementTerminationDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
     "longName": "100660 - Disclosure - Commitment and Contingencies - Additional Information (Details)",
     "shortName": "Commitment and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_9574821a-e3a7-4169-a889-41b0f5866c4c",
      "name": "acet:AreaOfSublease",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9574821a-e3a7-4169-a889-41b0f5866c4c",
      "name": "acet:AreaOfSublease",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails",
     "longName": "100670 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)",
     "shortName": "Commitments And Contingencies - Schedule of Sublease Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
     "longName": "100680 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)",
     "shortName": "Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails",
     "longName": "100690 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)",
     "shortName": "Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0d8568b6-257d-4933-9f8c-8954426bbed7",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails",
     "longName": "100700 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)",
     "shortName": "Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "100710 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
     "longName": "100720 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
     "longName": "100750 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)",
     "shortName": "At-The-Market (ATM) Offering - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "100760 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f58078b6-76be-474e-a1ef-f5d1e47368bb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "100770 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_6266d910-cfeb-4c96-8052-2f53133c7cdb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6266d910-cfeb-4c96-8052-2f53133c7cdb",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "100780 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
     "longName": "100790 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "longName": "100800 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_2309e372-c3fc-40f6-a3a4-dd00f686d78e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2309e372-c3fc-40f6-a3a4-dd00f686d78e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "100810 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "100820 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100830 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "acet:DeferredTaxAssetsValuationAllowanceIncrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail",
     "longName": "100840 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail",
     "longName": "100850 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "100860 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail",
     "longName": "100870 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "100880 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10e00936-04f7-40bc-8922-30c108c241ea",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "longName": "100890 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a9b5d182-d438-4385-8651-fad8f690a69d",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails",
     "longName": "100900 - Disclosure - Goodwill (Additional Information) (Details)",
     "shortName": "Goodwill (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_1127a611-ccab-4753-9b4a-ad14202f612e",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1127a611-ccab-4753-9b4a-ad14202f612e",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "100910 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_734eb96f-caad-4eb8-9771-349750199d0f",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8b4a7d79-358a-4bf6-8b1a-17f8afc3527a",
      "name": "us-gaap:NoninterestExpenseOfferingCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r865"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r301",
      "r302",
      "r831"
     ]
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses",
        "terseLabel": "Amount equal to pro-rated bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "acet_AccruedCmoCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AccruedCmoCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued CMO costs",
        "label": "Accrued CMO costs",
        "terseLabel": "Accrued CDMO costs"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AccruedCroCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AccruedCroCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued CRO costs",
        "documentation": "Accrued CRO costs",
        "label": "Accrued CRO costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "acet_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development",
        "label": "Accrued research and development",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AccruedResearchAndDevelopmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AccruedResearchAndDevelopmentPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development Policy [Text Block]",
        "terseLabel": "Accrued CRO, CMO, and Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r210",
      "r696"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r129",
      "r218",
      "r692",
      "r714",
      "r718"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16",
      "r42",
      "r544",
      "r547",
      "r617",
      "r709",
      "r710",
      "r923",
      "r924",
      "r925",
      "r932",
      "r933",
      "r934"
     ]
    },
    "acet_AdditionalClosingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AdditionalClosingLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional closing liability.",
        "label": "Additional Closing Liability",
        "terseLabel": "Additional closing liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AdditionalCommonStockNotSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AdditionalCommonStockNotSold",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Common Stock not sold",
        "label": "Additional Common Stock not sold",
        "terseLabel": "Additional Common Stock not sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r732",
      "r932",
      "r933",
      "r934",
      "r999",
      "r1026"
     ]
    },
    "acet_AdicetTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AdicetTherapeuticsIncMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adicet Therapeutics, Inc Member",
        "label": "Adicet Therapeutics Inc [Member]",
        "terseLabel": "Adicet Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AdjustmentToGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AdjustmentToGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Goodwill",
        "documentation": "Adjustment to goodwill",
        "label": "Adjustment To Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r253",
      "r254",
      "r255",
      "r256",
      "r267",
      "r303",
      "r304",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r375",
      "r482",
      "r483",
      "r484",
      "r511",
      "r512",
      "r513",
      "r514",
      "r527",
      "r528",
      "r529",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597",
      "r598",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r662",
      "r663",
      "r664",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r444"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance cost",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r153"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AdvisoryServicesAnnualFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AdvisoryServicesAnnualFee",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory services annual fee.",
        "label": "Advisory Services Annual Fee",
        "terseLabel": "Advisory services annual fee"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AggregateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AggregateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Fair Value",
        "label": "Aggregate Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AggregateNetProceed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AggregateNetProceed",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "aggregate net proceed",
        "label": "Aggregate Net Proceed",
        "documentation": "Aggregate Net Proceed"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AgreementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AgreementTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement transaction price",
        "documentation": "Agreement transaction price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Expense related to options granted",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r490"
     ]
    },
    "acet_AmendedLeaseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AmendedLeaseAgreementDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended lease Agreement Description",
        "documentation": "Amended lease Agreement Details",
        "label": "Amended lease Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AmendedSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AmendedSalesAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Sales Agreement [Member]",
        "label": "Amended Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "terseLabel": "Amendment description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "acet_AmortizationOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AmortizationOfDebtIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of deferred debt issuance costs.",
        "label": "Amortization Of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred debt issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AmountPayableUponClosingOfMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AmountPayableUponClosingOfMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable upon closing of merger.",
        "label": "Amount Payable Upon Closing Of Merger",
        "terseLabel": "Payable upon closing of merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Increase of leased space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "acet_AreaOfSublease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AreaOfSublease",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of Sublease",
        "documentation": "Area of Sublease",
        "label": "Area of Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset Backed Securities",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r213",
      "r246",
      "r286",
      "r296",
      "r298",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r533",
      "r537",
      "r577",
      "r686",
      "r769",
      "r865",
      "r878",
      "r958",
      "r959",
      "r1009"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r221",
      "r246",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r533",
      "r537",
      "r577",
      "r865",
      "r958",
      "r959",
      "r1009"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total fair value of assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "acet_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering Member.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AtTheMarketOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AtTheMarketOfferingTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtMarketATMOffering"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Text Block]",
        "terseLabel": "At-the-Market (ATM) Offering"
       }
      }
     },
     "auth_ref": []
    },
    "acet_AtmProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AtmProgramMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program [Member]",
        "label": "ATM Program [Member]",
        "documentation": "ATM Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r358",
      "r685"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Total, Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r358",
      "r679",
      "r940"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term marketable debt securities",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r358"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Long-term marketable debt securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r306",
      "r358"
     ]
    },
    "acet_AvailableUnderTheLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "AvailableUnderTheLoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available under the Loan Agreement",
        "documentation": "Available under the Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99"
     ]
    },
    "acet_BancOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BancOfCaliforniaMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Banc of California",
        "label": "Banc of California [Member]",
        "documentation": "Banc of California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "acet_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black Scholes Option Pricing Model [Member]",
        "label": "Black-Scholes Option-Pricing Model [Member]",
        "documentation": "Black-Scholes Option-Pricing Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_BostonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BostonMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston [member].",
        "label": "Boston [Member]",
        "terseLabel": "Boston, Massachusetts [Member]",
        "verboseLabel": "Boston, MA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r855",
      "r856"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r525",
      "r855",
      "r856"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares of the combined company owned by resTORbio stockholders",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Unaudited Pro Forma Information",
        "documentation": "Tabular disclosure of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Summarizes the Purchase Price in the Merger",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Multiplied by the fair value per share of resTORbio common stock",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r524"
     ]
    },
    "acet_BusinessAcquisitionsProFormaRevenue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BusinessAcquisitionsProFormaRevenue1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenues for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisitions Pro Forma Revenue1",
        "terseLabel": "Revenue - related party"
       }
      }
     },
     "auth_ref": []
    },
    "acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination acceleration of restricted stock units upon merger.",
        "label": "Business Combination Acceleration Of Restricted Stock Units Upon Merger",
        "terseLabel": "Acceleration of restricted stock units upon merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction cost for business acquisition",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAssetsArisingFromContingenciesAmountRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Business Combination, Assets Arising from Contingencies, Amount Recognized",
        "documentation": "The amount, measured at acquisition-date fair value, of all the assets acquired that arise from contingencies and were recognized by the entity."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r14"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r93",
      "r530"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r526"
     ]
    },
    "acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination provisional information initial accounting incomplete adjustment tangible and intangibles assets.",
        "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment Tangible And Intangibles Assets",
        "terseLabel": "Measurement prior adjustment in tangible and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedLabel": "Accrued and other current liabilities",
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets acquired:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Other liabilities",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Purchase price",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions",
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions",
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in the Company's IPR&amp;D and CVR since the Merger",
        "label": "Business Combination, Separately Recognized Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Acquisition date fair value of resTORbio common shares",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Percentage of outstanding capital stock",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "acet_COVID19Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "COVID19Member",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID 19.",
        "label": "C O V I D19 [Member]",
        "terseLabel": "C O V I D19",
        "verboseLabel": "COVID-19"
       }
      }
     },
     "auth_ref": []
    },
    "acet_CaliforniaResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CaliforniaResearchAndDevelopmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California research and development.",
        "label": "California Research And Development [Member]",
        "terseLabel": "California Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash payment",
        "periodStartLabel": "Cash, Beginning Balance",
        "periodEndLabel": "Cash, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r688",
      "r743",
      "r764",
      "r865",
      "r878",
      "r915"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r207",
      "r830"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r166"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents at the end of the period",
        "periodStartLabel": "Cash, cash equivalents at the beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r137",
      "r241"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r137"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1022"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeDuringPeriodFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeDuringPeriodFairValueDisclosureMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes Measurement [Member]",
        "terseLabel": "Measure of Changes in Fair Value",
        "documentation": "Measure of change in fair value."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ChangeInFairValueIncludedInResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value included in research and development expense.",
        "label": "Change In Fair Value Included In Research And Development Expense",
        "terseLabel": "Change in the fair value included in research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r214",
      "r215",
      "r216",
      "r246",
      "r272",
      "r273",
      "r276",
      "r278",
      "r284",
      "r285",
      "r342",
      "r383",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r408",
      "r409",
      "r412",
      "r415",
      "r423",
      "r577",
      "r722",
      "r723",
      "r724",
      "r725",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r756",
      "r778",
      "r801",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r891",
      "r929",
      "r937"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r284",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r421",
      "r423",
      "r722",
      "r723",
      "r724",
      "r725",
      "r850",
      "r891",
      "r929"
     ]
    },
    "acet_ClassOfWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantExercised",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants, Exercised",
        "label": "Class Of Warrant Exercised",
        "documentation": "Number of warrants, exercised.",
        "verboseLabel": "Class Of Warrant Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ClassOfWarrantForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantForfeited",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Forfeited",
        "label": "Class Of Warrant Forfeited",
        "terseLabel": "Warrants forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Issuance Date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants outstanding and exercisable, Weighted average exercise price",
        "terseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "acet_ClassOfWarrantOrRightIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantOrRightIssued",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Issued",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Number of warrants, Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares of common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Number of Shares of Common Stock Issuable",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "acet_ClassOfWarrantOrRightsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantOrRightsExpirationDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Rights Expiration Date",
        "terseLabel": "Expiration Date",
        "documentation": "Class Of Warrant Or Rights Expiration Date."
       }
      }
     },
     "auth_ref": []
    },
    "acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Outstanding And Exercisable To Purchase Common Stock",
        "periodEndLabel": "Number of warrants, Outstanding and exercisable to purchase common stock as of December 31, 2021",
        "label": "Class Of Warrant Outstanding And Exercisable To Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares",
        "periodStartLabel": "Number of warrants, Outstanding and exercisable to purchase preferred shares as of December 31, 2020",
        "label": "Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares",
        "terseLabel": "Number of warrants, Outstanding and exercisable to purchase preferred shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Third Party Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r186",
      "r196"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "acet_CombinedBalancesInDemandDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CombinedBalancesInDemandDepositAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combined balances in demand deposit accounts",
        "label": "Combined balances in demand deposit accounts",
        "documentation": "Combined balances in demand deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r114",
      "r687",
      "r755"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingences"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingences",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r377",
      "r378",
      "r825",
      "r957"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration Liability (CVR)",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r826"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock dividends declared | $ / shares",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r871",
      "r872",
      "r873",
      "r874",
      "r932",
      "r933",
      "r999",
      "r1024",
      "r1026"
     ]
    },
    "acet_CommonStockNotSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CommonStockNotSold",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock not sold",
        "label": "Common Stock not sold",
        "terseLabel": "Common Stock not sold"
       }
      }
     },
     "auth_ref": []
    },
    "acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering costs included in accrued liabilities at period end",
        "label": "Common Stock Offering Costs Included In Accrued Liabilities At Period End",
        "documentation": "Common Stock Offering Costs Included In Accrued Liabilities At Period End"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock shares issued, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Pursuant To At The Market Offering Net Of Issuance Costs",
        "label": "Common Stock Pursuant To At The Market Offering Net Of Issuance Costs",
        "terseLabel": "issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,value"
       }
      }
     },
     "auth_ref": []
    },
    "acet_CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "common stock pursuant to at-the-market offering, net of issuance costs,shares",
        "label": "common stock pursuant to at-the-market offering, net of issuance costs,shares",
        "terseLabel": "Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million,shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r756"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r123",
      "r756",
      "r775",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 43,270,386 and 42,954,820 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "verboseLabel": "Common stock issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r690",
      "r865"
     ]
    },
    "acet_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants",
        "verboseLabel": "Common stock warrants issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r226",
      "r228",
      "r235",
      "r681",
      "r703"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r188"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r837"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction In Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "acet_ConstructionInProgressNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ConstructionInProgressNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress remaining",
        "label": "construction in progress net",
        "documentation": "construction in progress net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction Payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "acet_ContingentConsiderationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContingentConsiderationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration, fees",
        "label": "Contingent Consideration fees",
        "documentation": "Contingent Consideration fees"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContingentConsiderationLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContingentConsiderationLiabilityMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liability.",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContingentValueRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContingentValueRightsAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights agreement [member].",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "Contingent Value Rights Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractAssetMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Asset.",
        "label": "Contract Asset [Member]",
        "terseLabel": "Contract Asset"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractAssetsAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities.",
        "label": "Contract Assets And Liabilities",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractAssetsAndLiabilitiesAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractAssetsAndLiabilitiesAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities additions.",
        "label": "Contract Assets And Liabilities Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractAssetsAndLiabilitiesAdditionsDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractAssetsAndLiabilitiesAdditionsDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities additions (deductions).",
        "label": "Contract Assets And Liabilities Additions Deductions",
        "negatedLabel": "Additions (Deductions)"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liability.",
        "label": "Contract Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractLiabilityMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liability.",
        "label": "Contract Liability [Member]",
        "terseLabel": "Contract Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ContractResearchTermPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractResearchTermPeriod",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract research term period.",
        "label": "Contract Research Term Period",
        "terseLabel": "Contract research term period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Change in Company's Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Increase in estimated transaction price",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities\u2014related party, current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "acet_ContractualContingentValueRight": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ContractualContingentValueRight",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Contingent Value Right",
        "documentation": "Contractual Contingent Value Right",
        "label": "Contractual Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock warrants into common stock warrants in connection with merger.",
        "label": "Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants In Connection With Merger",
        "terseLabel": "Conversion of convertible preferred stock warrant into common stock warrant in connection with Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock warrants to common stock warrants",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common Stock Issued Upon Conversion (1)",
        "verboseLabel": "Number of common stock shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r71",
      "r122",
      "r151",
      "r418"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r854",
      "r1023"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r394",
      "r410",
      "r623",
      "r834",
      "r836"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r931",
      "r997"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r931"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r510",
      "r518",
      "r931"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r931",
      "r997"
     ]
    },
    "acet_CustomersPercentageOfTotalRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "CustomersPercentageOfTotalRevenue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers percentage of total revenue.",
        "label": "Customers Percentage Of Total Revenue",
        "terseLabel": "Customers percentage of total revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r243",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r406"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available Loan",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r108",
      "r393",
      "r593",
      "r848",
      "r849"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, End",
        "terseLabel": "Loan availability end date",
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "acet_DecreaseInConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DecreaseInConstructionInProgress",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in construction in progress",
        "documentation": "Decrease in construction in progress"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs, gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r931",
      "r996"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r161",
      "r194",
      "r517",
      "r518",
      "r931"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Income Taxes and Tax Credits",
        "totalLabel": "Deferred Income Taxes and Tax Credits, Total",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue related party",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r996",
      "r997"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r995"
     ]
    },
    "acet_DeferredTaxAssetsFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxAssetsFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed Assets",
        "label": "Deferred Tax Assets Fixed Assets",
        "documentation": "Deferred Tax Assets Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r995"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r995"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r995"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r995"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "acet_DeferredTaxAssetsValuationAllowanceIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceIncrease",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Valuation Allowance Increase.",
        "label": "Deferred Tax Assets Valuation Allowance Increase",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "acet_DeferredTaxBasisDifferenceIPRD": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxBasisDifferenceIPRD",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax basis difference IPR&amp;D.",
        "label": "Deferred Tax Basis Difference I P R D",
        "terseLabel": "Basis Difference IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "acet_DeferredTaxLiabilitiesFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities fixed assets",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "acet_DeferredTaxOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use asset.",
        "label": "Deferred Tax Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DeferredTaxOperatingLeaseRightOfUseAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax operating lease right of use asset liability.",
        "label": "Deferred Tax Operating Lease Right Of Use Asset Liability",
        "terseLabel": "Operating lease right-of-use asset liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company contribution in the plan",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_DemandDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DemandDepositAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Demand Deposit Accounts",
        "label": "Demand Deposit Accounts",
        "documentation": "The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r64"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r747",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r796",
      "r797",
      "r798",
      "r814",
      "r815",
      "r816",
      "r817",
      "r867",
      "r869"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r101",
      "r745",
      "r747",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r796",
      "r797",
      "r798",
      "r814",
      "r815",
      "r816",
      "r817",
      "r836",
      "r867",
      "r869"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r446",
      "r477",
      "r478",
      "r481",
      "r858"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_DiscountOnUnderwritersWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "DiscountOnUnderwritersWarrant",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount On Underwriters Warrant",
        "documentation": "Discount On Underwriters Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable",
        "terseLabel": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r168",
      "r875",
      "r1020"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885",
      "r887"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r269",
      "r272",
      "r276",
      "r277",
      "r278",
      "r282",
      "r561",
      "r562",
      "r682",
      "r704",
      "r840"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r272",
      "r276",
      "r277",
      "r278",
      "r282",
      "r561",
      "r562",
      "r682",
      "r704",
      "r840"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r279",
      "r280",
      "r281"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r499",
      "r519"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r998"
     ]
    },
    "acet_EffectiveIncomeTaxRateReconciliationGoodwillImpairment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationGoodwillImpairment",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairment",
        "label": "Effective Income Tax Rate Reconciliation Goodwill Impairment",
        "documentation": "Effective Income Tax Rate Reconciliation Goodwill Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r992"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r998"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r998"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "terseLabel": "Other permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r998"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, estimated weighted-average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options Issued and Outstanding",
        "verboseLabel": "Stock options issued and outstanding",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "acet_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "acet_EntityDateOfMerger": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "EntityDateOfMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity date of merger.",
        "label": "Entity Date Of Merger",
        "terseLabel": "Entity date of merger"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation date",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab and computer equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r201",
      "r230",
      "r231",
      "r232",
      "r250",
      "r251",
      "r252",
      "r254",
      "r264",
      "r266",
      "r283",
      "r346",
      "r352",
      "r425",
      "r482",
      "r483",
      "r484",
      "r513",
      "r514",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r560",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r617",
      "r709",
      "r710",
      "r711",
      "r732",
      "r801"
     ]
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "terseLabel": "Fair value of common stock shares of the combined company owned by resTORbio stockholders",
        "documentation": "Fair value of equity issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "acet_EstimatedFairValueOfCVRLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "EstimatedFairValueOfCVRLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of CVR liability.",
        "label": "Estimated Fair Value Of C V R Liability",
        "terseLabel": "Estimated fair value of the CVR liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ExerciseFeePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ExerciseFeePaid",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Fee Paid",
        "label": "Exercise Fee Paid",
        "documentation": "Exercise fee paid."
       }
      }
     },
     "auth_ref": []
    },
    "acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of redeemable convertible preferred stock tranche liabilities.",
        "label": "Exercise Of Redeemable Convertible Preferred Stock Tranche Liabilities",
        "terseLabel": "Exercise of redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ExercisePriceOfOptionsPercentageOfFairMarketValueOfCommonStock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Of Options Percentage Of Fair Market Value Of Common Stock",
        "label": "Exercise Price Of Options Percentage Of Fair Market Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ExercisedInvestmentRightAndPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ExercisedInvestmentRightAndPurchased",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised Investment Right and Purchased",
        "documentation": "Exercised Investment Right and Purchased",
        "label": "Exercised Investment Right and Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r570"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r570"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r566",
      "r631",
      "r632",
      "r633",
      "r848",
      "r849",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r102",
      "r401",
      "r848",
      "r849"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r571"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r848",
      "r849"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431",
      "r436",
      "r566",
      "r631",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431",
      "r436",
      "r566",
      "r632",
      "r848",
      "r849",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r566",
      "r633",
      "r848",
      "r849",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in the fair value included in other income (expense), net",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r631",
      "r632",
      "r633",
      "r848",
      "r849",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r571"
     ]
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of net assets acquired in Merger",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "acet_FairValueOfCommonStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "FairValueOfCommonStockPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock.",
        "label": "Fair Value Of Common Stock Policy [Text Block]",
        "terseLabel": "Fair Value of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of modified stock options and restricted stock units attributable to pre-combination services.",
        "label": "Fair Value Of Modified Stock Options And Restricted Stock Units Attributable To Pre Combination Services",
        "terseLabel": "Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services"
       }
      }
     },
     "auth_ref": []
    },
    "acet_FederalAndStateResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "FederalAndStateResearchAndDevelopmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal and state research and development [Member]",
        "documentation": "Federal and state research and development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "FeesAndExpenseIncurredInConnectionWithClinicalTrials",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees and expense incurred in connection with clinical trials.",
        "label": "Fees And Expense Incurred In Connection With Clinical Trials",
        "terseLabel": "Total fees and expenses related to clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liability",
        "totalLabel": "Finance Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r612"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r405",
      "r421",
      "r550",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r702",
      "r845",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r944",
      "r945",
      "r946",
      "r947"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r661",
      "r665"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from the remeasurement of the redeemable convertible preferred stock.",
        "label": "Gain Loss From The Remeasurement Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Gain from the remeasurement of the redeemable convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "negatedLabel": "Loss on disposal of property, plant, and equipment",
        "terseLabel": "Loss on disposition of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnSalesOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Disposition of Assets for Financial Service Operations, Total",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "terseLabel": "Loss on disposition of assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r780"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r364",
      "r678",
      "r847",
      "r865",
      "r952",
      "r953"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r61"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Impairement charges",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r368",
      "r847"
     ]
    },
    "acet_GoodwillImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "GoodwillImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill Impairment",
        "documentation": "Goodwill Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r365",
      "r367",
      "r369",
      "r847"
     ]
    },
    "acet_GoodwillMeasurementPeriodAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "GoodwillMeasurementPeriodAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill measurement period adjustments",
        "label": "Goodwill Measurement Period Adjustments",
        "terseLabel": "Measurement period adjustment to goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "acet_GrantTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "GrantTerm",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant term.",
        "label": "Grant Term",
        "terseLabel": "Grant term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment charges",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r954"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r145"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax provision",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax provision (benefit)",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r130",
      "r171",
      "r286",
      "r295",
      "r297",
      "r299",
      "r683",
      "r698",
      "r842"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r376",
      "r785"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r785"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r494",
      "r500",
      "r503",
      "r508",
      "r515",
      "r520",
      "r521",
      "r522",
      "r727"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail",
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for (benefit from) income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r195",
      "r265",
      "r266",
      "r288",
      "r498",
      "r516",
      "r705"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r496",
      "r497",
      "r503",
      "r504",
      "r507",
      "r509",
      "r721"
     ]
    },
    "acet_IncomeTaxesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncomeTaxesDisclosureLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50"
     ]
    },
    "acet_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current and non-current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities\u2014related party",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r926"
     ]
    },
    "acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncreaseDecreaseInEstimatedFairValueOfCvrLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in estimated fair value of cvr liability.",
        "label": "Increase Decrease In Estimated Fair Value Of Cvr Liability",
        "terseLabel": "Increase decrease in estimated fair value of CVR liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_IncreaseDecreaseInLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncreaseDecreaseInLeaseObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in lease Obligation",
        "documentation": "Increase Decrease in Lease Obligation",
        "label": "Increase Decrease in Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "acet_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "acet_IncreaseInConstructionBudget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncreaseInConstructionBudget",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in construction budget.",
        "label": "Increase in Construction Budget"
       }
      }
     },
     "auth_ref": []
    },
    "acet_IncreaseInConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IncreaseInConstructionInProgress",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in construction in progress",
        "documentation": "Increase in construction in progress",
        "label": "Increase in construction in progress"
       }
      }
     },
     "auth_ref": []
    },
    "acet_InducementGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "InducementGrantMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Grant",
        "label": "Inducement Grant [Member]",
        "documentation": "Inducement Grant."
       }
      }
     },
     "auth_ref": []
    },
    "acet_InducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "InducementGrantsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement grants member.",
        "label": "Inducement Grants [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest income",
        "totalLabel": "Interest and Other Income, Total",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r174",
      "r233",
      "r287",
      "r592",
      "r786",
      "r876",
      "r1025"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Company\u2019s Marketable Debt Securities by Contractual Maturity",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Debt Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r175",
      "r176",
      "r198",
      "r305",
      "r307",
      "r572",
      "r573"
     ]
    },
    "acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of redeemable convertible preferred stock on exercise of warrants with loan agreement.",
        "label": "Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement",
        "terseLabel": "Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "acet_JefferiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "JefferiesLlcMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment Member",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office lease space",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "acet_LawsuitsFiledAgainstCompany": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LawsuitsFiledAgainstCompany",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuits filed against company.",
        "label": "Lawsuits Filed Against Company",
        "terseLabel": "Lawsuits Filed Against Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense recognized",
        "label": "Operating Leases, Rent Expense",
        "totalLabel": "Operating Leases, Rent Expense, Total",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r864"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LeaseCostOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LeaseCostOtherInformationAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease cost other information.",
        "label": "Lease Cost Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs and Other Information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "acet_LessPortionOfFairValueToBeDistributedAsCVR": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LessPortionOfFairValueToBeDistributedAsCVR",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less portion of the fair value to be distributed as CVR.",
        "label": "Less Portion Of Fair Value To Be Distributed As C V R",
        "terseLabel": "Less: portion of the fair value to be distributed as CVR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Future Lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Amended lease term from the date of relocation",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit issued amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r246",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r534",
      "r537",
      "r538",
      "r577",
      "r754",
      "r841",
      "r878",
      "r958",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r170",
      "r694",
      "r865",
      "r930",
      "r948",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r206",
      "r246",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r534",
      "r537",
      "r538",
      "r577",
      "r865",
      "r958",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Settlement",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total fair value of liabilities",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "acet_LiabilitiesFairValueExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LiabilitiesFairValueExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, fair value, exercised.",
        "label": "Liabilities Fair Value Exercised",
        "terseLabel": "Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LiabilitiesFairValueSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LiabilitiesFairValueSettled",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, fair value, settled.",
        "label": "Liabilities Fair Value Settled",
        "verboseLabel": "Termination"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount payable of option exercise fees.",
        "label": "Licence Agreement Additional Amount Payable Of Option Exercise Fees",
        "terseLabel": "Licence agreement additional amount payable of option exercise fees"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenceAgreementAdditionalRevenueRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenceAgreementAdditionalRevenueRecognised",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licence agreement additional revenue recognised.",
        "label": "Licence Agreement Additional Revenue Recognised",
        "terseLabel": "Licence agreement additional revenue recognised"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenceAgreementCumulativeRevenueRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenceAgreementCumulativeRevenueRecognised",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative revenue recognised.",
        "label": "Licence Agreement Cumulative Revenue Recognised",
        "terseLabel": "Licence agreement cumulative revenue recognised"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenceAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenceAgreementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Licence Agreement Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementAdditionalPaymentForResearchFundingReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment for research funding received.",
        "label": "License Agreement Additional Payment For Research Funding Received",
        "terseLabel": "Additional payment for research funding received"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementCumulativeRevenueReductionRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementCumulativeRevenueReductionRecognised",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement cumulative revenue reduction recognised.",
        "label": "License Agreement Cumulative Revenue Reduction Recognised",
        "terseLabel": "License agreement cumulative revenue reduction recognised"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of clinical milestones payable.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Clinical Milestones Payable",
        "terseLabel": "Aggregate amount payable upon satisfaction of clinical milestones"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of commercial milestones payable.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Commercial Milestones Payable",
        "terseLabel": "Aggregate amount payable upon satisfaction of commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For First Indication Approved",
        "terseLabel": "Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For Second Indication Approved",
        "terseLabel": "Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAgreementTerminationDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement termination description.",
        "label": "License Agreement Termination Description",
        "terseLabel": "License agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseAndCollaborationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseAndCollaborationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and collaboration revenue",
        "label": "License and collaboration revenue",
        "documentation": "License and collaboration revenue"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseFundingAndOtherAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseFundingAndOtherAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License funding and other agreements.",
        "label": "License Funding And Other Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LicenseFundingAndOtherAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LicenseFundingAndOtherAgreementsTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License funding and other agreements.",
        "label": "License Funding And Other Agreements [Text Block]",
        "terseLabel": "License, Funding and Other Agreements Related to the CVR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "acet_LoanAmountDrawn": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LoanAmountDrawn",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan amount drawn",
        "label": "Loan Amount Drawn",
        "terseLabel": "Loan amount drawn"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balance under the loan agreement",
        "label": "Loans Payable",
        "totalLabel": "Loans Payable, Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r169",
      "r1021"
     ]
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansReceivableBasisSpreadOnVariableRate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Receivable, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate for term loan to finance leasehold improvements",
        "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Description",
        "label": "Long-Term Debt, Description",
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r71"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Line Items]",
        "terseLabel": "Long Term Purchase Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment [Table]",
        "terseLabel": "Long Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r67"
     ]
    },
    "acet_LossOnDisposalOfLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LossOnDisposalOfLeaseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on disposal of lease assets",
        "label": "Loss on disposal of lease assets",
        "terseLabel": "Loss on disposal of lease assets",
        "negatedLabel": "Loss on disposal of lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "acet_LumpSumCompensationPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "LumpSumCompensationPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lump sum compensation payment.",
        "label": "Lump Sum Compensation Payment",
        "terseLabel": "Lump sum payable"
       }
      }
     },
     "auth_ref": []
    },
    "acet_MLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MLimitation",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "162m Limitation",
        "label": "162m Limitation",
        "terseLabel": "162m limitation"
       }
      }
     },
     "auth_ref": []
    },
    "acet_MarketableDebtSecuritiesClassificationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MarketableDebtSecuritiesClassificationTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of classification of company marketable debt securities in condensed consolidated balance sheets.",
        "label": "Marketable Debt Securities Classification Table [Text Block]",
        "terseLabel": "Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "totalLabel": "Marketable debt securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r917"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "acet_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Debt Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate value of common stock available for offering at-the-market price under sales agreement.",
        "label": "Maximum Aggregate Value Of Common Stock Available For Offering At Market Price Under Sales Agreement",
        "terseLabel": "Maximum aggregate value of common stock available for offering at-the-market price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r440",
      "r658",
      "r706",
      "r746",
      "r747",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r827",
      "r828",
      "r844",
      "r850",
      "r857",
      "r866",
      "r960",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "acet_MenloParkLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MenloParkLeaseAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo Park lease agreement.",
        "label": "Menlo Park Lease Agreement [Member]",
        "terseLabel": "Menlo Park Lease Agreement [Member]",
        "verboseLabel": "Menlo Park, CA"
       }
      }
     },
     "auth_ref": []
    },
    "acet_MergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MergerMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger.",
        "label": "Merger [Member]",
        "terseLabel": "Merger"
       }
      }
     },
     "auth_ref": []
    },
    "acet_MilestoneClosingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "MilestoneClosingLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone closing liability.",
        "label": "Milestone Closing Liability",
        "terseLabel": "Milestone closing liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r440",
      "r658",
      "r706",
      "r746",
      "r747",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r827",
      "r828",
      "r844",
      "r850",
      "r857",
      "r866",
      "r960",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "acet_NationalInstitutesOfHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NationalInstitutesOfHealthMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Institutes of Health.",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institute of Health"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r139",
      "r172",
      "r204",
      "r224",
      "r227",
      "r232",
      "r246",
      "r253",
      "r257",
      "r258",
      "r260",
      "r261",
      "r265",
      "r266",
      "r274",
      "r286",
      "r295",
      "r297",
      "r299",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r562",
      "r577",
      "r700",
      "r777",
      "r799",
      "r800",
      "r842",
      "r876",
      "r958"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r257",
      "r258",
      "r260",
      "r261",
      "r269",
      "r270",
      "r275",
      "r278",
      "r286",
      "r295",
      "r297",
      "r299",
      "r842"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "acet_NonRefundableUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NonRefundableUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront payment received.",
        "label": "Non Refundable Upfront Payment Received",
        "terseLabel": "Non refundable upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated offering expenses",
        "label": "Noninterest Expense Offering Cost",
        "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "acet_NovartisInternationalPharmaceuticalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NovartisInternationalPharmaceuticalLimitedMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd. (\u201cNovartis\u201d).",
        "label": "Novartis International Pharmaceutical Limited [Member]",
        "terseLabel": "Novartis International Pharmaceutical Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "acet_NovartisLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NovartisLicenseAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis license agreement.",
        "label": "Novartis License Agreement [Member]",
        "terseLabel": "Novartis License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "acet_NumberOfCustomer": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NumberOfCustomer",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customer.",
        "label": "Number Of Customer",
        "terseLabel": "Number of customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Securities Converted To Warrants To Purchase Common Stock.",
        "label": "Number Of Securities Converted To Warrants To Purchase Common Stock",
        "negatedLabel": "Number of warrants, Impact of converting to warrants for the purchase of common stock and adjusted for the Exchange Ratio and Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares available for sale under employee stock purchase plan.",
        "label": "Number Of Shares Available For Sale Under Employee Stock Purchase Plan",
        "terseLabel": "Number of shares available for sale under employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "acet_NumberOfSharesOfSurvivingStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "NumberOfSharesOfSurvivingStockOptions",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of surviving stock options.",
        "label": "Number Of Shares Of Surviving Stock Options",
        "terseLabel": "Number of shares of surviving stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r295",
      "r297",
      "r299",
      "r842"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Less: current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current maturities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments",
        "verboseLabel": "Operating cash flows used for lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r608"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating cash flows used for lease liabilities",
        "label": "Operating Lease, Payments, Use",
        "terseLabel": "Operating cash flows used for lease liabilities",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r608"
     ]
    },
    "acet_OperatingLeaseProceedsPaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeaseProceedsPaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows used for lease liabilities",
        "label": "Operating Lease, Proceeds Payments, Use",
        "documentation": "Operating Lease, Proceeds Payments, Use"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted Average IBR",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average remaining lease term - operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining Terms (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r864"
     ]
    },
    "acet_OperatingLeasesCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeasesCommencementDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases commencement date.",
        "label": "Operating Leases Commencement Date",
        "terseLabel": "Operating leases commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 and thereafter",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r180"
     ]
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDue",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "documentation": "Operating Leases Future Minimum Sublease Income Due",
        "label": "Operating Leases Future Minimum Sublease Income Due"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "documentation": "Operating Leases Future Minimum Sublease Income Due Current",
        "label": "Operating Leases Future Minimum Sublease Income Due Current"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Three Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Two Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesRentExpenseMinimumRentals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseMinimumRentals",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Minimum Rentals",
        "terseLabel": "Annual rent",
        "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Operating Leases, Rent Expense, Sublease Rentals",
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Operating loss carryforwards, expiration date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "acet_OperatingLossCarryforwardsIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OperatingLossCarryforwardsIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards indefinitely",
        "documentation": "Operating loss carryforwards indefinitely.",
        "label": "Operating Loss Carryforwards Indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OptionToPurchaseOfCommonStockAtPublicOfferingPrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase of common stock at public offering price.",
        "label": "Option To Purchase Of Common Stock At Public Offering Price",
        "terseLabel": "Option to purchase of common stock at public offering price"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OptionsAvailableForFutureGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OptionsAvailableForFutureGrantsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options available for future grants.",
        "label": "Options Available For Future Grants [Member]",
        "terseLabel": "Stock options and restricted stock units available for future grant"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OrganizationAndNatureOfBusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OrganizationAndNatureOfBusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Nature of Business.",
        "label": "Organization And Nature Of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_OrganizationAndNatureOfBusinessTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OrganizationAndNatureOfBusinessTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Text Block]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other prepaid expenses and current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r865"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Total other comprehensive loss",
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r582",
      "r583",
      "r588",
      "r680",
      "r701",
      "r923",
      "r924"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r26",
      "r225",
      "r228",
      "r234",
      "r582",
      "r583",
      "r588",
      "r680",
      "r701",
      "r923",
      "r924"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable debt securities, net of tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r338"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Expense",
        "terseLabel": "Noncash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "acet_OwnershipChangePlanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "OwnershipChangePlanDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership change plan description.",
        "label": "Ownership Change Plan Description",
        "terseLabel": "Ownership change plan description"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PacificWesternBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PacificWesternBankMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pacific western bank",
        "documentation": "Pacific western bank [Member]",
        "label": "Pacific western bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PacwestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PacwestMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PacWest [Member]",
        "label": "PacWest [Member]",
        "terseLabel": "PacWest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForMergerRelatedCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Merger Related Costs",
        "terseLabel": "Transaction cost for merger",
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "terseLabel": "Shares withheld for taxes, Value",
        "negatedLabel": "Shares withheld for taxes, Value",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "acet_PercentageOfCashFullyInsured": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PercentageOfCashFullyInsured",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Cash Fully Insured",
        "label": "Percentage Of Cash Fully Insured",
        "terseLabel": "Percentage of cash fully insured"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PerformanceRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PerformanceRestrictedStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Restricted Stock [Member]",
        "documentation": "Performance restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]",
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "acet_PostExposureProphylaxisDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PostExposureProphylaxisDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Exposure Prophylaxis in adults",
        "label": "Post Exposure Prophylaxis Description",
        "terseLabel": "Post Exposure Prophylaxis in adults"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Preferred stock, liquidation preference, value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r412"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r756"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r756",
      "r775",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; none issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r689",
      "r865"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid maintenance",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r362",
      "r363",
      "r832"
     ]
    },
    "acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the summary of Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r846",
      "r951"
     ]
    },
    "acet_PrepaidProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PrepaidProfessionalServices",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid professional services",
        "label": "Prepaid professional services",
        "documentation": "Prepaid professional services"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PrepaidSoftwareSubscriptionAndLicensingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PrepaidSoftwareSubscriptionAndLicensingFees",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid software subscription and licensing fees",
        "label": "Prepaid software subscription and licensing fees",
        "terseLabel": "Prepaid software subscription and licensing fees"
       }
      }
     },
     "auth_ref": []
    },
    "acet_PrepaymentsToCros": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "PrepaymentsToCros",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments to CROs and CDMOs",
        "documentation": "Prepayments to CRO's",
        "label": "Prepayments to CRO's"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received form tax refunds",
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r138"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r722"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from related party",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payment from Regeneron for exercise of its option to license exclusive rights",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r23"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Employee Stock Purchase Plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r224",
      "r227",
      "r239",
      "r246",
      "r253",
      "r265",
      "r266",
      "r286",
      "r295",
      "r297",
      "r299",
      "r342",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r532",
      "r535",
      "r536",
      "r562",
      "r577",
      "r683",
      "r699",
      "r731",
      "r777",
      "r799",
      "r800",
      "r842",
      "r862",
      "r863",
      "r877",
      "r925",
      "r958"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r189",
      "r192",
      "r193"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r209",
      "r697"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r684",
      "r697",
      "r865"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r189",
      "r192",
      "r695"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lesser of useful life or lease term",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "acet_QualifyingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "QualifyingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualifying expenses.",
        "label": "Qualifying Expenses",
        "terseLabel": "Qualifying expenses"
       }
      }
     },
     "auth_ref": []
    },
    "acet_QualifyingExpensesOnCumulativeBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "QualifyingExpensesOnCumulativeBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "qualifying expenses on cumulative basis.",
        "label": "Qualifying Expenses On Cumulative Basis",
        "terseLabel": "Qualifying expenses on cumulative basis"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r430",
      "r440",
      "r472",
      "r473",
      "r474",
      "r634",
      "r658",
      "r706",
      "r746",
      "r747",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r827",
      "r828",
      "r844",
      "r850",
      "r857",
      "r866",
      "r869",
      "r956",
      "r960",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r430",
      "r440",
      "r472",
      "r473",
      "r474",
      "r634",
      "r658",
      "r706",
      "r746",
      "r747",
      "r810",
      "r811",
      "r812",
      "r813",
      "r818",
      "r827",
      "r828",
      "r844",
      "r850",
      "r857",
      "r866",
      "r869",
      "r956",
      "r960",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "acet_RecognitionOfContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RecognitionOfContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of contingent consideration liability.",
        "label": "Recognition Of Contingent Consideration Liability",
        "terseLabel": "Recognition of contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RecognitionOfPreferredStockWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RecognitionOfPreferredStockWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of preferred stock warrant liabilities.",
        "label": "Recognition Of Preferred Stock Warrant Liabilities",
        "terseLabel": "Recognition of preferred stock warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability and TRDF obligation.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability And T R D F Obligation [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability And TRDF Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant liability.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrants.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedeemableConvertiblePreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedeemableConvertiblePreferredStockWarrantsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrants member",
        "label": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability",
        "verboseLabel": "Redeemable Convertible Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedwoodCityLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedwoodCityLeaseAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redwood City lease agreement.",
        "label": "Redwood City Lease Agreement [Member]",
        "terseLabel": "Redwood City Lease Agreement [Member]",
        "verboseLabel": "Redwood City, CA (1000 Bridge Parkway)"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RedwoodCityLeaseAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RedwoodCityLeaseAgreementOneMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redwood City Lease Agreement One [Member]",
        "label": "Redwood City Lease Agreement One [Member]",
        "terseLabel": "Redwood City, CA (1200 Bridge Parkway)"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RegeneronPharmaceuticalsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RegeneronPharmaceuticalsIncorporationMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regeneron Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Regeneron Pharmaceuticals, Inc.",
        "documentation": "Regeneron Pharmaceuticals Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r621",
      "r622",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r774",
      "r776",
      "r809"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r1008"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r782",
      "r785"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r621",
      "r622",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r774",
      "r776",
      "r809",
      "r1008"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r622",
      "r624",
      "r728",
      "r729",
      "r730",
      "r783",
      "r784",
      "r785",
      "r806",
      "r808"
     ]
    },
    "acet_RentIncreaseAnnually": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RentIncreaseAnnually",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent increase annually",
        "label": "Rent Increase Annually",
        "terseLabel": "Increase in annual rent"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r394",
      "r410",
      "r623",
      "r835",
      "r836"
     ]
    },
    "acet_ResTORbioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ResTORbioMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "resTORbio.",
        "label": "Res T O Rbio [Member]",
        "terseLabel": "resTORbio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r991"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r991"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r991"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r492",
      "r1017"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research And Development Expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "acet_ResearchAndDevelopmentInProcess1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ResearchAndDevelopmentInProcess1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development in process 1",
        "label": "Research and development in process 1",
        "documentation": "Research and development in process 1"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ResearchFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ResearchFundingAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding agreement.",
        "label": "Research Funding Agreement [Member]",
        "terseLabel": "Research Funding Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ResearchFundingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ResearchFundingFee",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research funding fee",
        "documentation": "Research funding fee"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Measurement Period Adjustments"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r263",
      "r264",
      "r282",
      "r560",
      "r561",
      "r895",
      "r896",
      "r897",
      "r898",
      "r901",
      "r905",
      "r906"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r282",
      "r347",
      "r348",
      "r514",
      "r556",
      "r560",
      "r561",
      "r562",
      "r598",
      "r616",
      "r617",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r282",
      "r347",
      "r348",
      "r514",
      "r556",
      "r560",
      "r561",
      "r562",
      "r598",
      "r616",
      "r617",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r916",
      "r928"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r153",
      "r693",
      "r713",
      "r718",
      "r726",
      "r757",
      "r865"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r250",
      "r251",
      "r252",
      "r254",
      "r264",
      "r266",
      "r346",
      "r352",
      "r482",
      "r483",
      "r484",
      "r513",
      "r514",
      "r542",
      "r545",
      "r546",
      "r549",
      "r560",
      "r709",
      "r711",
      "r732",
      "r1026"
     ]
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r829",
      "r838"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating lease right of use asset obtained in exchange of operating lease liability",
        "terseLabel": "Operating right-of-use asset obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r864"
     ]
    },
    "acet_RightOfUseAssetsRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RightOfUseAssetsRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets recognized upon adoption of Topic 842",
        "documentation": "Right-of-use assets recognized in noncash investing or financing activities.",
        "label": "Right Of Use Assets Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "acet_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties policy text block.",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "acet_SaleOfShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SaleOfShare",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share sale",
        "label": "Sale Of Share",
        "documentation": "Sale Of Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from the offering, after deducting expenses",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the offering",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of stock purchase agreement",
        "label": "Sale of Stock, Description of Transaction",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r164"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares sold",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Aggregate number of shares sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "acet_SalesAgentCommissionsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SalesAgentCommissionsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agent commissions and expenses",
        "label": "Sales agent commissions and expenses",
        "terseLabel": "Sales agent commissions and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "acet_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement member.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r441",
      "r936"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Preliminary"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r250",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r266",
      "r282",
      "r514",
      "r556",
      "r560",
      "r561",
      "r598",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r901",
      "r903",
      "r904",
      "r905",
      "r935",
      "r949",
      "r950",
      "r1000",
      "r1006",
      "r1007"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r441",
      "r892",
      "r936"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Estimated Share Consideration of Combined Company",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89",
      "r525"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r89"
     ]
    },
    "acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the fair value of the unobservable financial instruments.",
        "label": "Schedule Of Changes In Fair Value Of Unobservable Financial Instruments Table [Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Level 3 Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureThirdPartyAgreementsSummaryOfChangeInCompanysContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision for (Benefit from) Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r339",
      "r340",
      "r341",
      "r342",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r246",
      "r339",
      "r340",
      "r341",
      "r342",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566"
     ]
    },
    "acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of number of shares of common stock reserved for future issuance.",
        "label": "Schedule Of Number Of Shares Of Common Stock Reserved For Future Issuance [Text Block]",
        "terseLabel": "Schedule of Number of Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of outstanding warrants to purchase shares of common stock .",
        "label": "Schedule Of Outstanding Warrants To Purchase Shares Of Common Stock Table [Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants to Purchase Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r781",
      "r782",
      "r785"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r991"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r445",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r150",
      "r152",
      "r153",
      "r214",
      "r215",
      "r216",
      "r284",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r421",
      "r423",
      "r722",
      "r723",
      "r724",
      "r725",
      "r850",
      "r891",
      "r929"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "acet_ScheduleOfSubleaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ScheduleOfSubleaseIncomeTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Sublease Income",
        "documentation": "Schedule Of Sublease Income.",
        "label": "Schedule Of Sublease Income Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r993"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Vested Restricted Stock Units",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of weighted average ibr and remaining lease term table text block.",
        "label": "Schedule Of Weighted Average I B R And Remaining Lease Term Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average IBR and Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "acet_Sec174CapitalizedRD": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "Sec174CapitalizedRD",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec 174 Capitalized R&amp;D",
        "label": "Sec 174 Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash security deposit received",
        "label": "Security Deposit Liability",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r300",
      "r843"
     ]
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantFourMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Fifteen Two Thousand Twenty Warrant Four [Member]",
        "terseLabel": "September 15, 2020 Warrant Four",
        "documentation": "September Fifteen Two Thousand Twenty Warrant Four."
       }
      }
     },
     "auth_ref": []
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantOneMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Fifteen Two Thousand Twenty Warrant One [Member]",
        "terseLabel": "September 15, 2020 Warrant One",
        "documentation": "September Fifteen Two Thousand Twenty Warrant One."
       }
      }
     },
     "auth_ref": []
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantThreeMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Fifteen Two Thousand Twenty Warrant Three [Member]",
        "terseLabel": "September 15, 2020 Warrant Three",
        "documentation": "September Fifteen Two Thousand Twenty Warrant Three."
       }
      }
     },
     "auth_ref": []
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantTwoMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Fifteen Two Thousand Twenty Warrant Two [Member]",
        "terseLabel": "September 15, 2020 Warrant Two",
        "documentation": "September Fifteen Two Thousand Twenty Warrant Two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock [ Member ]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r920",
      "r961"
     ]
    },
    "acet_SeriesBRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock",
        "verboseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "acet_SettlementOfTRDFLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SettlementOfTRDFLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of trdf liability.",
        "label": "Settlement Of T R D F Liability",
        "terseLabel": "Settlement of TRDF liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value,Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted- Average Grant Date Fair Value, beginning balance",
        "terseLabel": "weighted-average grant date fair value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock",
        "verboseLabel": "Fair value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r445",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Number of Shares Available for Grant, Ending balance",
        "periodStartLabel": "Number of Shares Available for Grant, Beginning balance",
        "terseLabel": "Number of shares of common stock available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant as part of merger.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant As Part Of Merger",
        "terseLabel": "Number of Shares Available for Grant, Assumed as part of the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized",
        "terseLabel": "Number of Shares Available for Grant, Options authorized"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares cancelled.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled",
        "terseLabel": "Number of Shares Available for Grant, Options forfeited or cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Exercised",
        "terseLabel": "Number of Shares Available for Grant, Options exercised",
        "negatedLabel": "Options exercised, Number of Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant, shares granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted",
        "negatedLabel": "Number of Shares Available for Grant, Options granted"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options assumed as part of merger.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Assumed As Part Of Merger",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Assumed as part of the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Authorized",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Shares exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Shares exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options forfeited or cancelled",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs granted (includes PSUs)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "RSUs granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Outstanding ending",
        "periodStartLabel": "Weighted-Average Exercise Price, Outstanding beginning",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ]
    },
    "acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options assumed as part of merger in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Assumed As Part Of Merger In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Assumed as part the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options authorized in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Authorized In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options, authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price",
        "verboseLabel": "Weighted-Average Exercise Price, Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options forfeited or cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options granted",
        "verboseLabel": "Weighted average exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r450",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r485",
      "r486",
      "r487",
      "r488"
     ]
    },
    "acet_ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options",
        "label": "Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options",
        "documentation": "Share-Based Payment Arrangement, Incremental Cost, Amount Recognized Over The Remaining Vesting Period Of Repriced Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period closing of the merger",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term",
        "verboseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Shares exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Shares exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs forfeited",
        "terseLabel": "RSUs forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, RSUs forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted- Average Grant Date Fair Value, ending balance",
        "terseLabel": "Weighted- Average Grant Date Fair Value, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "RSUs Vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value,Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "acet_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted",
        "documentation": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase price per share",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Issuance price per shares",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning Balance, shares",
        "periodEndLabel": "Ending Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares withheld for taxes",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r864"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r242"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r214",
      "r215",
      "r216",
      "r246",
      "r272",
      "r273",
      "r276",
      "r278",
      "r284",
      "r285",
      "r342",
      "r383",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r408",
      "r409",
      "r412",
      "r415",
      "r423",
      "r577",
      "r722",
      "r723",
      "r724",
      "r725",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r744",
      "r756",
      "r778",
      "r801",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r891",
      "r929",
      "r937"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r40",
      "r201",
      "r230",
      "r231",
      "r232",
      "r250",
      "r251",
      "r252",
      "r254",
      "r264",
      "r266",
      "r283",
      "r346",
      "r352",
      "r425",
      "r482",
      "r483",
      "r484",
      "r513",
      "r514",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r560",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r617",
      "r709",
      "r710",
      "r711",
      "r732",
      "r801"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r283",
      "r660",
      "r720",
      "r744",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r776",
      "r779",
      "r780",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r801",
      "r870"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r441",
      "r892",
      "r893",
      "r936"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r283",
      "r660",
      "r720",
      "r744",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r776",
      "r779",
      "r780",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r801",
      "r870"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Redeemable convertible preferred stock warrants issued in connection with issuance of Series B redeemable convertible preferred stock, net of issuance costs",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "acet_StockExchangedDuringPeriodSharesInConnectionWithMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockExchangedDuringPeriodSharesInConnectionWithMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exchanged during period shares in connection with merger.",
        "label": "Stock Exchanged During Period Shares In Connection With Merger",
        "terseLabel": "Exchange of common stock in connection with the Merger, shares"
       }
      }
     },
     "auth_ref": []
    },
    "acet_StockExchangedDuringPeriodValueInConnectionWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockExchangedDuringPeriodValueInConnectionWithMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Exchanged During Period Value In Connection With Merger",
        "terseLabel": "Exchange of common stock in connection with the Merger",
        "documentation": "Stock exchanged during period value in connection with merger."
       }
      }
     },
     "auth_ref": []
    },
    "acet_StockIssuedDuringPeriodSharesConversionOfSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfSecurities",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of sharesaof redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares",
        "label": "Stock Issued During Period Shares Conversion Of Securities",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock under Employee Stock Purchase Plan, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122",
      "r123",
      "r153"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cashless exercise of warrants, shares",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock related to financing, net of issuance costs of $823,940, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of common stock shares sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122",
      "r123",
      "r153",
      "r722",
      "r801",
      "r820"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r153"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Issuance of common stock upon exercise of stock options, shares",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122",
      "r123",
      "r153",
      "r456"
     ]
    },
    "acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares upon accelerated vesting of rsu with merger.",
        "label": "Stock Issued During Period Shares Upon Accelerated Vesting Of R S U With Merger",
        "terseLabel": "Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "acet_StockIssuedDuringPeriodSharesWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercised",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Warrant Exercised",
        "documentation": "Stock issued during period shares warrant exercised.",
        "terseLabel": "Exercise of warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r40",
      "r153"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock under Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122",
      "r123",
      "r153"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cashless exercise of warrants",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock related to financing, net of issuance costs of $823,940",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r122",
      "r123",
      "r153",
      "r732",
      "r801",
      "r820",
      "r877"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r40",
      "r153"
     ]
    },
    "acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value upon accelerated vesting of rsu with merger.",
        "label": "Stock Issued During Period Value Upon Accelerated Vesting Of R S U With Merger",
        "terseLabel": "Issuance of common stock upon accelerated vesting ofrestricted stock units in connection with the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "acet_StockPriceDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "StockPriceDecrease",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price declined",
        "label": "Stock Price Decrease",
        "documentation": "Stock Price Decrease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares repurchased under stock purchase agreement",
        "label": "Stock Repurchase Program Number of Shares Authorized to be Repurchased",
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r126",
      "r127",
      "r141",
      "r758",
      "r775",
      "r802",
      "r803",
      "r865",
      "r878",
      "r930",
      "r948",
      "r1001",
      "r1026"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r245",
      "r407",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r551",
      "r804",
      "r807",
      "r824"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split exchange ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Reverse Stock Split",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r805"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "acet_SubleaseAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SubleaseAgreementDescription",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Agreement Description",
        "documentation": "Sublease Agreement Description.",
        "label": "Sublease Agreement Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "negatedLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r864"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events Considerations",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r627"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "acet_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TRDFLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TRDFLiabilityMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRDF Liability.",
        "label": "T R D F Liability [Member]",
        "terseLabel": "TRDF Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "acet_TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxes withheld and paid related to net share settlement of equity awards",
        "label": "Taxes withheld and paid related to net share settlement of equity awards",
        "terseLabel": "Taxes withheld and paid related to net share settlement of equity awards",
        "negatedLabel": "Taxes withheld and paid related to net share settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance, temporary equity",
        "periodStartLabel": "Balance, temporary equity",
        "terseLabel": "Carrying Value",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r489",
      "r691"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance, temporary equity, shares",
        "periodStartLabel": "Balance, temporary equity, shares",
        "terseLabel": "Number of shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "acet_TemporaryEquityStockConversionInConnectionWithMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TemporaryEquityStockConversionInConnectionWithMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock conversion in connection with merger.",
        "label": "Temporary Equity Stock Conversion In Connection With Merger",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TemporaryEquityStockConversionSharesInConnectionWithMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TemporaryEquityStockConversionSharesInConnectionWithMerger",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Conversion Shares In Connection With Merger.",
        "label": "Temporary Equity Stock Conversion Shares In Connection With Merger",
        "negatedLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "acet_TermLoanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TermLoanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan abstract [Abstract]",
        "label": "Term Loan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TermLoanAndNonFormulaAncillaryService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TermLoanAndNonFormulaAncillaryService",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan and non formula ancillary service",
        "documentation": "Term loan and non formula ancillary service",
        "label": "Term loan and non formula ancillary service"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TermLoanCashMaintain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TermLoanCashMaintain",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan cash maintain",
        "documentation": "Term Loan cash maintain"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TermLoanMaturityDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TermLoanMaturityDate",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan Maturity Date",
        "label": "Term loan Maturity Date",
        "terseLabel": "Term loan Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TermLoanToFinanceLeaseholdImprovements1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TermLoanToFinanceLeaseholdImprovements1",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "term loan to finance leasehold improvements 1",
        "documentation": "term loan to finance leasehold improvements 1",
        "terseLabel": "Term loan to finance leasehold improvements"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TerminationOfRedeemableConvertiblePreferredStockTrancheLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of redeemable convertible preferred stock tranche liability.",
        "label": "Termination Of Redeemable Convertible Preferred Stock Tranche Liability",
        "terseLabel": "Termination of redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TotalLoanAccountsOutside": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TotalLoanAccountsOutside",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total loan accounts outside",
        "documentation": "Total loan accounts outside"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r405",
      "r421",
      "r550",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r702",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r944",
      "r945",
      "r946",
      "r947"
     ]
    },
    "acet_TransitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TransitionAgreementMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition agreement.",
        "label": "Transition Agreement [Member]",
        "terseLabel": "Transition Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandEighteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandFifteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Stock Incentive Plan Member.",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen and two thousand fifteen stock incentive plan.",
        "label": "Two Thousand Fourteen And Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 and 2015 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Stock Incentive Plan Member.",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen and two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Seventeen And Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2017 and 2018 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandTwentyLoanAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandTwentyLoanAmendmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Loan Amendment [Member]",
        "label": "Two Thousand Twenty Loan Amendment [Member]",
        "documentation": "Two Thousand Twenty Loan Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandTwentyOneLoanAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandTwentyOneLoanAmendmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty One Loan Amendment Member",
        "label": "Two Thousand Twenty One Loan Amendment Member",
        "terseLabel": "2021 Loan Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "acet_TwoThousandTwentyTwoLoanAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "TwoThousandTwentyTwoLoanAmendmentMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Two Loan Amendment [Member]",
        "label": "Two Thousand Twenty Two Loan Amendment [Member]",
        "terseLabel": "2022 Loan Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r253",
      "r254",
      "r255",
      "r256",
      "r267",
      "r303",
      "r304",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r375",
      "r482",
      "r483",
      "r484",
      "r511",
      "r512",
      "r513",
      "r514",
      "r527",
      "r528",
      "r529",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r574",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597",
      "r598",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r662",
      "r663",
      "r664",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agency Bonds",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r852",
      "r1018"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r852",
      "r854",
      "r1018"
     ]
    },
    "us-gaap_UnderwritingCommitments": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnderwritingCommitments",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Agreement to purchase",
        "label": "Underwriting Commitments",
        "documentation": "Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions and other offering expenses.",
        "label": "Underwriting Discounts And Commissions And Other Offering Expenses",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "acet_UnderwrittenPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "UnderwrittenPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering Underwritten",
        "label": "Underwritten Public Offering",
        "documentation": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r501"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment based on tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment based on tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Adjustment based on tax positions related to prior years",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment based on tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "acet_UnsoldCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "UnsoldCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsold Common Stock Value",
        "label": "Unsold Common Stock Value",
        "terseLabel": "Unsold Common Stock Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnusualRiskOrUncertaintyByNatureAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual Risk or Uncertainty, Nature [Axis]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature",
        "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnusualRiskOrUncertaintyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnusualRiskOrUncertaintyNatureDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureLicenseFundingAndOtherAgreementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual Risk or Uncertainty, Nature [Domain]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature",
        "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost."
       }
      }
     },
     "auth_ref": []
    },
    "acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "UnvestedCommonStockFromEarlyExerciseOfOptionsMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock from early exercise of options.",
        "label": "Unvested Common Stock From Early Exercise Of Options [Member]",
        "terseLabel": "Unvested Early Exercised Common Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "acet_UnvestedRestrictedStockUnitsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "UnvestedRestrictedStockUnitsOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units outstanding.",
        "label": "Unvested Restricted Stock Units Outstanding",
        "terseLabel": "Unvested restricted stock units outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r185",
      "r187",
      "r190",
      "r191"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r864"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "acet_VestingOfEarlyExercisedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "VestingOfEarlyExercisedStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of early exercised stock options.",
        "label": "Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "auth_ref": []
    },
    "acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
      "http://www.adicetbio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term",
        "label": "Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Warrants outstanding and exercisable, Weighted average remaining contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageLimitedPartnershipUnitsOutstandingDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageLimitedPartnershipUnitsOutstandingDiluted",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Limited Partnership Units Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted",
        "documentation": "Weighted average number of limited partnership units outstanding determined by relating the portion of time within a reporting period that limited partnership units have been outstanding to the total time in that period. Used in the calculation of diluted net income or loss per limited partnership unit."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r278"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r278"
     ]
    },
    "acet_WestportOfficeParkLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adicetbio.com/20231231",
     "localname": "WestportOfficeParkLlcMember",
     "presentation": [
      "http://www.adicetbio.com/20231231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Westport Office Park, LLC member",
        "label": "Westport Office Park, LLC [Member]",
        "terseLabel": "Westport Office Park, LLC"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481804/940-20-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481155/840-10-25-5"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-70/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0000950170-24-033482-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-033482-xbrl.zip
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MZF']AU8V&DXX_TO[N7WNX]S^+-\N-^")3SET9Z.@ \<.J! $'04<CCF>D$'
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M:G,TY#V<AG33%<7!,MOSO0AD)JJ AI(8J G0F%!',BR^[BB[<PD5RV2F-'^
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M0E3H8AU!&I(DCGW"J.^BW4<QWMF:_X\RG>N$)A#4Q<%@6!:7QOJP+H@,.E)
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M8*9&6P=8><\5?CJNT-LC&[X0]'QA??C"BV/\_]LNV#P'"EXEX%Y6LKR4X@&
MO[J7_G\]*^A90<\*-"L(>U:P/JQ@'J##LVD!XDJ[ID95!0AX!M]FXRJMSM3K
MJ CM("9ZP>YD+%KNWV[&@_+^_J3*[,Y<E=GC:=WCHTG=X][1]?-A=6SW6/U4
MK.Z36-<7K-E9<X>TOF[L3-^TV_S=1!6\!EC_WYDQ:-S]O]-QS(886-M),:JM
MQOR#:;$]%O]\6.S8/1@_%8RC'HO7%8NCL\E=!Y@46S<2M+[P5/_-RM? XJDH
M?#(9A,;DDYF!C*U=5K,>?']&\'5Z\'TB^,8]^*XK^,9G_(+EY[(Z2W.4?-EY
M*1L QAM4SQCGKY)$:P:!-THAY.[.#L1<Y;K->3'*\1(G?5E.\Q%OA<('IN ]
ME9I[E.Y1ND?I&93N[17K"]/L#.=;%EEELLG$:R4][#2OU3#[;?+J'EQ[<.W!
M=09<^WI<ZPNNR5E1@ORKBG*@8?$U</5(7W-Z,'UICZ@_(Z+2/E;Z:7CZ:U?A
MZD#&T#2Y=OY"*J#35P'(J2*/L<[F_=:^>;_U'Z,RK43*S16[IQ>L!ME47L*3
M *EXF58?L-!#:I^:VZ?F]JFY?6IN-Z6EQ=3<U\S-[9-S?QIYK9]8+Q[-B4</
MOJBSM^$M5GZV?VF=<ZUM>(Y])M)2ZJM"SN2UY",=RZE2+DO,TBV'Q>LHK<T8
M-JR]=A#6D3+#T"Z4'1P*]">M/PM88'1;]Y[J'HA[()X%XOYZO?4%8F<&?GDQ
M&,J\>C6GRA1S=V;>W,-K#Z\]O,[ :U^6?WWAE9ZU=XV<%5<Y2)47Z? ,I,N:
MI?E9(G/Y*EFF36V8L774C@%317?,,*S/.(Q4AV.:W[7D.\U,;5),;RU/TP-V
M#]@]8,\ =G\'P/H"MCM!YQ(1#_W2 )>5^23%6?TJV4TM-!_/CF$.AT]+!O*R
M<9QO-%'XQIAA'4#W($W#@O:VBAZ;>VR>P^;^-H'UQ6;O;%BF.4^'+,-,IR;!
MZ$Q)69UA):ST59*?OK5CF$ERLO9A#";]5(^CC[CO@;</9NJ#F?I@ICZ8J8,2
MU4(PT^7KQ3+]9Q_*U$?\]!/[*84C[[$(2C=IKY8:M;2_;&!]U5+_3%Y?I$E:
MOTJ&]U[SKH5"&I,J2-8)OY!BE/4J:(^R/<K.HVQ?NG]=4=8)SD9#@9Z/U\#8
M_:+$^&+R5^MD-("ACGLH_0FAU WN@E+X+TLRJ?_LQ"8NO/O.USUTOW%R(KV<
M3"^3U\0$9N-!@<4=#?)/(JV&&1MOX:\3"&BGLNFGYGT-N[$W0_CB'Z.J3M6X
M?;5^E,A<?$J*:YP#] !T5,(YA(ZN'T@Y4\!Y_"I/2?21U+."54_3.3J#]=;K
M?C'AU$-V+@UK)DS!,+=8=L7&U:=W'Q<WJ%U]37'+E_XY*_RJ1'SO;CX<M-HE
M[=H45WI.'S"Y%1P0*Q6_O\.4?*SOFA?U0CF!*_@S*XH?^+&JGWB<K@R])D4F
M5K%:)]_V=@ZVOUB'1Z=[UO'>G]O'NP>'?UK[1\=_@S_)EZ.C=B4[,-B_XM!.
M3K=/][[N'9Z>6-N'N];!X>[WD]/COUN[VZ?;M^WZK#3F;KJN^Y<[A*_G0.43
M)>\5K,WI15I9VWD^ GWV6 Z+LL;:D5-A#%NR-*^LAA!)0XG6M ZQ56-QB32_
M++)+:56CI$+W+"K(95K],$KS*&]"?/"RO$UK.\MF.MBP"EWJ!_K)9_LME 6C
MJXL2)2%+,8Y-FP%)@94PZ[M'OP%M>#82"^.=G"ZK&"%#P%RC\_&&I48UUM(H
M)M=Y3+Z:E%^VAD6E[P"9_*1K:HSDAC4LBW\ $Y?H::MPI/"%KK.!?V8L-PM1
M)-@HO327"0[F S[E]=#T,#!E[,_+XJJ^L!B.X-;EW[1.+Z2%FF5EX84FU/Z$
MRX_N\EINZ&^<3^TOB<Q2&/#BU[BH*<[BQO>C3"Q^*4'.&"SIVXQ^\=L4*>U&
M'P,V7OP*U^C&=P62*:S[C1]*B;5-;GZM]V#QZ^IBV3QJ.(_R1MLK;-I^AYM2
MI7"@6(F;4TI]1TRE=\1,##:K+@# <9AJ?,<V;5@LJV$<YQ<60#Q\R.XZ4@V5
M X'+2DZZQT9ZHS=_:<3");EC[<R9AQ/)!@6>\09;H!5LPDP[AC=&;#V'3SUO
M(M;M2D&S\%KG]S9]&OUE7B.8V41TZ2X5_6&F9?U)[Q9!=;[:2E@EC0Z^L*_3
M$<++W/ O;[71WF;H4R>, B^F;NB%U)_..\UQZ$1/_X[YHB '9S>82'(SJVI>
MXMCV8J]O0\A EQ8@J>9#RC '8$<L23-,&P!4,5EB4G_-89R:#=8EP*%FQ];V
M[@&Q;4>7A![513H8C'+$)4!&P[]TIWF1DW\OQ#D<D\E]5]EX,+R P5GO#__]
MRX=9-HF#FAE"->(<0$^-LFQL8:Y:)IL!?<,;<2UG86 X%NA2OQB^!^B&YNR.
MQMEH.*JL7 XO\"+=RGK_Y?"#?AJU+IR$YKD-%[AEFE.I'962J6K2'ZA?ZT A
M61HAI"'_>4%OAJ*0=Y?XQSD;P"D0,JN9=6IQ"5P9V04;CE%\.R_90%=<AU%.
M2%> _)050^0ALP<'#R,-[8UE![EYI&%%T+$8\=KBT#)%^ZI^!3X"\H5D);^P
MANG0$%9/V3UEWTW9&K O&8BHAMXV6IZB033/"U2]M(8!3 :HC5FJ+ 9W0/@<
M;^D)L"? I038T@A GL5 T #:D:S6=(8_E1+15>,I!T1+<RUL'._L&.9N@'!G
M-[3_MU4560I*U&@ C^%O%Q*42YC4N2;)@=Y95+YES^=[8KP/#:>7RC:7HB \
M?M\\V;3VBT*8G*UR!-Q:0.>I-OW@A:[O]W>W#65B^[U160PES.HK&AE@FI6U
M?2YS/K;>[WV%=BBMSPBE0X;O05EYJ"U0GU-#O97U)>4R!XC='@ZS1EBUWG_^
MTKSJJS;R:-EA5%\49?K?IL5<ZZ_;T!I/%$[ZIN30'XG^2+2ZY-3J)V;T2FWB
M'"6#U%QO#-\<Y)=HPCMGC3",O>M#\?[@<!=(<TI^E06$)_\Y2B]9AL@.YVR4
M 3B78TN!L)&?5[.*7M-]8Q==$"H6=<SI !>'7IJ+E7O*[BG[ :)O.H W:MEV
ME%<Z>J UGFN#.O13#%*.]E2C_,T1HGE86^+37)FTW\;X<"E+ .X970](72DT
MW3<OGKH$JB;]#$T2L.0EB."%T>>2487< ]Y93F\+G[H7\'1-NYD.L2?]GO0?
M9" L$NTDP%\&Z%O##S,8#4A>%I>M1M<+$#VMW4UKNN8B$I.0>+6@)CK.Y;#&
M"HSZAPE3']6&"#5=CENZ,H0&0^07UA6Z1KG$2F-+2+(GNY[L'L#=X=$1^OU'
MY8PTN\1^:FQ=3Z!#*QE;(\V(X0_LO+Y(2T$P1V^L%;HL!4&@I]:>6EMJY<5@
M($N4V!I]?:,1.%N;ZSS-<C8T##MMR+0--^EIJJ>IEJ;0'95E ((8QS1$XQ/"
M3QMJU)--3S9+R69&$Y@$(,VZS6_R26T2K6!G4@5B7%[/H-G4H-F36$]B+8F9
MP$6,14&/.0)5@85$,I84Y8PG"&6U&5N)T146&27*;[T"VE/;[0KHU*>BR[2F
MQF"&@CT?E65+6*V!>98,>RKJJ6@)6\0?2K0/-[[ );K=@LS>?@/DF,YU!3(9
M7D0+#%;^<P3 E?6B6$]S$^1JXB01KG1%_]9- *] Q4]G2&#0./#* 1L#O$&K
M2=Q.UL=Y]:2D26G.WV2*X2(=%59C>4#"PKMS)LZ UN74$U!/0$OX7RG;+!*K
M3?$1K;^R-:?^D-INJDQN"WJ+-/^;ZI0;%O!-:0);FPYGM$Q@AAEHD]#O7"<]
M0?8$V1+D3/:<$:+0G]032$\@MWB 3+5U0"#$K5&ED8JSZL*8%?"/:4Q2#S0]
M'4WIJ,E,G74C(FWEE:QN)NQRD,UKS%)&:BK;I$#,F))2&+O6#)]K0"P_?P#!
M]34]7F*'YPM!]R4]7JRD1P^=OQYTSB@-DU R:0(>+^4T7TX;U(K,PHM99^2Z
M4M=>>!@X]B3U"Y#4?&CNN;['5WN&,G95-9JD#L;1\:[X14\X/>$@%NG,L%L*
MQ\PG$12@&61IA;J"+B]HS!QLJ'V-336/8^C(VF?ZPNG-IJK'+93V*]70^)O4
M9FA=B$1'G61C^.,"2\/H5=1NWPU3XF2:"#*KI6&B508[(-K<Y3LKG\!&CHN1
M9>JPZ-?"&[C$?1NA1)ZE.L2TN*^K36O;!,E,XNEA6)=-Q13L6J3 L]#&#OPJ
MU=/2V:[+YS0MN;-L4CK(__8J(U>XA#_DI@5K><$TC]1E1P3B'C!#C*Y0AO#:
MWC@;:66B'"\I5_*P>D;HO$HY &<)4VNZ74+J;?V:RF@@&\8!898(1@$'A]VV
MCIBN?OLBWE<%:K(J1W?NHR4*306E5!CV9,T[?Z>, UV_C=K&.&AI59O#,9#E
MN<0[Y!&SBLG7\Z$)&]8_"MAN"R<&7>A9ICKY:7'$8SUJO0J3.(=?N<;.WZ>'
M%?0I<1]=3C(G1<%'\VL+.RQ+O!7/ ER73;*"/B\JS8#H]9;PHASBIL'G9#SS
M"*NLMLRW?EQ[=$T-$@0LZ&F2XZDY !8>:Y@#O%V+M8;,)ZJ_H7;C@ILE<$/R
M.GL92?VJ&;U!!WW&&XIE535"SQT09I%D31(='AI3*M=0[!U0>'4A-8?3.=-F
M/$CH.6Q)FFO;Z%QUL>908OH&/G:55G(#1H5!^=A%8[K0RP:2U:],LO<5LFM@
MMM*[ 5*#3F.8YJ*WCK0F'$!GD.EJ"2TAFUP;6&I-()/FPU&2S97;:6MX;%C5
MJ+R4XS;J%Z06J>MZ8?R3V3$=CV @'8OB'=S:YVS@PMW]G\M<EIJBF_HXTDS
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MKK9>HQ^-,U)N+9IB7BHWN6K*TY<PHWH!R01:/QSIPY&^!VXHBJJ^025;5A,
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MZAK(OKK'N$AZ&%7 P1<KI@Y-3@KPKJNF 4=6S*'K?RV!8Z/=\^*#:4G#CS(
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MHC-%U3; G&NZV#__Y:+*+IT*?QLO&W+9'L0,V#E::I;5''GNG70K ,W&8.'
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MH%;<5)/]U_0X^W"HGUDX857KK5J()FW%PWM@=H/&?Y'9R&,V-!ZE)LT\-VX
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M:6I+A(S'CY[2';<U! %<]K$H<^996!1C+ARG^AQ8IQX @0D1DN/8,1QOLS-
MO?\/G>&37,,@5W!:&]*_?-9//F;?O\S/^!)_7Q;T!EB-'>4C>2EWV1U\$U'1
M125\3Q26+T%J6M6>#:+HRLJ'SDON;DM9]N:,7:ZY,Z"<")K:,,K6PBOMH@SC
M[R=_$GD)#YEP'$",=D$4'9RWQ$CU1UG]Y+:50L>'I2M]9O%S&.4=[1;M0(C$
M[87=+'1U&P6"/0SVX(1##0%YLLIOGC4KL+[5$:J\C^KL#JZZ#BUJC&X%HIY)
M%H5[ G$OD"/"[%+L+-1$U#<%;*6]VS"@33YCN5CT- M A^R>KMN9N\0K@A8L
M.K&AV(K%/+5O-F*#^;<LF%1R4S^@@+63'V$QEXTH/^7E-;WC/W:>0Y24P*$G
MS*^ >GF"D(@)/D$ARG[T-^+!&2K9%GQTS>2WUC41>AU-P@"O(*SU[H3[OFK%
MGPF4639:)'8ME"#*K6!$"NRZ:WLF?Y^[,S[N)D)TFE?"%*D$0ME'%R7I+IPG
M?,GE71H?I9+L"J@I:OUDB39Y79JW$#D",#3D$SJ;L3Z,WJZBC6LG)OU65"K\
MBT?,NZZ+"2/IBM48HB:>Q&X"60&6>(WLT5W>[L)Q$B\BGWFX*$P&HC&^[*KB
MEQ8UAGER6,M[&4/ )E_R^4"+SJ#F G_, D&1N'L[AX5IAH,!!=U<R!KO2#LG
M%0JA &%\.Y,3<:*)_ Y::_C#K%):3%MIOZ*'YH]7S]WWRE_Z9@"D6(PKBMU:
M1?:>J3&Z\7WQ.]=?.EEA-+WM:[O0S*IR;??3AXS,QC;M^">E0U%=D L7D4#H
MB9,0&AG/C7Y+N-AH,%CP$W2?:.]=(UQMGM9BU$,9K VD":\%7[]TJMLW07\<
MNWGHSV3R5R4E,%2LMOS'E!?"O1"&]$%1T#@5YA5:<9ILT4+KA*,7;,D-$_UJ
M@!@X-AK/?4N68,6,R/2S8JU/CI-(B*#I6OU?P>I%)\'4B8@.QY_YYMK?^3'4
MCCQ*9KY+C)'$8"O6;4.-UK#OT7%D9Y3GMJ.WO:+G])QLSUZ?661N(/'@^U)H
MN\!<10LA9>*C6Y.G@S?R.7.@%$?R+(ZV<.L%NKM/UC-<=JW-$?%C#_X"6+;5
M.Z!?KHX8I%1+ &Y$8YS:Y^ W6AW&SRT_9J9E?2XA2<DW>33-1DJC)#"CWME>
MH>ME'+2L8/+G-!L_&_-4CIE>T1KP21VNU.3<VQE\-IE_O@LF8K-1H@I5& I3
M$J#^?3^_>1_B1FUE=*;8E!1[K&)V3YF29FXJJJHLIRO'_K+""EW"W3Q0/T#]
M[*!0YDTH,TZ)>1QI8*?))#C S4A?ED2NHS1L]:%J)S+MD!&-_'X89120 D$P
MAQ+9Y&,^YW\J2QM\39 "'7YT;BW?J:M5)18YGUYP),U_GZ(!OABW2K9,_NBA
MWW+T"(6R4@IU'K/QR2B]P9#0G#Z0^5GQ/]% O'-2>4-B&3%)W.R0JB5F)Z;:
MLCW6U^L2R/FW08UMKD9)=OE^$5F]#E^7?'7M(8JYD7ASH5%Q^[EWL@OXA9*8
M)Z9@1U#I%V9W6=F)&QW6X8CVS6OF"M,%2N8)%$8$%B'(-9[$.VFBQV=M-M^<
M+CWM:A#E]:$]W-I$)[NY36Y<CY(W=".PJW$8%0TQ$JW!L*93%)A->T%2($(O
M<8E);$WT;WOH#61T,5$T0$C9:/P/<7;X/:IIK0>^T3YPV.I93J.7&*U<ZTZ*
MCQXC3^TZ&,G2Z!@*,1(QH18^:&UQ1>Q:_BCDTODGU@TU>CG<'#./9V.!-Z/)
MZ"3#[D2L\/D8G8X<HAJ-YU&"X*TLB;M](.[H,D8"AG2!_@9W]I5BPQVT U_(
M'LA>5!6Y.L_A7TF:O%DY-+5!3O">W.?\[$!N^59ZN[]SL#W9>U=?@'#<?_/M
M=^_Q3=V,10UC)$%TM(5%X"7>Z8@D^C;Z'W5[9R_R8LGD?R)*N=Q&],J!#"Q=
M]WICU?/8,"$EWR62K.P34M!)#&Y%F-9:]6J"PX'#SDXC$0U;BOWO$+9><!7@
MIW9:B))57D[TO6'1^?_4]*'O (P])F'C%FKHMI$>6SWUO=IR+ XC.M?3.K_4
M2*&,QIV'6$-$5R[SFE<+^A:X'&%30TY3SN3F=72]2,]2#H_P_<85/XM8BHI@
MUD(B&E(5 ]+C3X_T.+D_(#W^%$B/&SV@F[99!SWC.%-6)S$:V<N?VM+,XPQ<
M9MY*\F$8N%4\<29_PW.G<,PWKVI-C".G36$(&Z])S?6S)6PL'=(<M$"[2B.?
MV*JKG)B$V*:= 'LN>E">@E*BS<;Y-O=2F?K#":Z'5U\XE_>X(19T71W6!54Y
MK[',0;X1W'<[R_< _M4CW ?XY^7VVR'^]6XWMR9/CQX\>/3D^,GQ@V^/[S\\
M??+HSP#XW[?EE*A=MUQ9E=Y-T%H_W$@D9L310TDQYT0G#;-E1(PP+[.#5='&
MJZ;Q+]<JJ=-D]UZ^?MNH:QNY<(G39D CSE +MSX-*KJ<W+H)E=[D2MX'??K+
M&EJ&]?WG7=]1)CW*]XMW_.J'Y[$#[6G,FSC?E).G7 AS.2M"X+>G]Z%0[\"U
ME4W)BQE95HY%_#Q4P@RX%EPZN7ZQX+1(AM4ZK%9=K3X"'6\92QI4(+-7@?B-
M/G\GE9!G%=C>[KUZ]^R H3^;!=J;4&U$T<2%ZHI??"C]QR*NO!A94Q0ERG+B
MIL-R'):C+D>R>%RO0XJ(&;-4X%343Y?+0ZW(+,GE[#=RB7.@UM<C6^.L$98?
M*\5W-)K8H?!7C=V)<W(GO/!(U$W5ZU%$RK3T(#)6CY_T'& A[;:0_%Q12KU2
M1)2K .:27%I/"51)H5FU"8G^'M?=T&1>'X#\G&'3#9ON6H\%J'\!=F2O17D6
MJ""OVWWOV>NS@RZ4P?/SJ;*8"+3$B5AWH:+(2-#RBAX!.L_E=X:( 6U**YL3
M@*8<UHD5M'(K<+[4! PK>UC9MK)IG38SI?M, \]<$+QGTXNBP:?GWH41S,<(
M6.80[ V+:EA4G[VHBI*+XY%D0]H*[J5^JCI&V+&8)7^]YPP7Z4VO]PAEUJ;I
M1>2-]/-$D"S<AD)'\MHA-"A0:/:G&D4+J+O%@I+DK-07^\;C72IAT&?DU*9V
MY7RS"/ 9H9:N]9^='37:\<Y,*)D], $)QO[7Y.4'.&#F8&FN)F +6R RV*&R
MGTK]=-BZP]:U\,+WL3"5<$LNO.W0V+E HG';XUHHC)TWE62Z-]+B*-A%5I-<
M&Q(+?R;_Z"FN,ZS 807*"A0 2 =4BG(Y&IO8Q2:S/8K63Z3.6FYC6'=PN>GC
M)E\Z^Y&'VT;(LUM#[W*CU;YGFH7RL<.V[Z3UT,>XVW6?.!W-,9] BC/=947G
M$KD)*^\T20+4,G='3,D5?\0Z-DW5S4UTC501="1<7+4(F.\FJFMFDX5;H:BY
MA8OPJ9C8&8V4@^9%D@Z;3MTEN!W\--Z61ED)!5?&68ET/J0&"9[S=N+-)&H\
MW<E1W&F,Q5&(4)+%$2Q0E'\)KPSE'Q12NUEWT3'"C^@VIJX0X/<!=X*]&H%L
MN,]?6Y**N7$G10K!LA"D!>H+LO,Z19V3![W]"+1%8 @8=0,V6WC<M\08(S-W
M&R\'GCJB2;8II\?9"A(-Q]E(TEQ>#,Q?E\\Z-E<;5<E6T12?@HJR9]6FF@!
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M9Y- 3!\M;F^"=7WWC'6\Z<TS9)YUVO)4#PU?4%ZHW7/07K6?0/%%Z;*H?2_
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MY+N6"A4%GB]T7%I&S ZM!&$S\L@)>C\"@M@SJP$A.&L11_N)>R[X".P2#9-
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M_:2;I[$[@.6!)>OI,^F9Q"$;Z*VT1LFUI&XM,Z=#%MH\I3-0KY-.5U]11OL
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M.;,-K(L57(Y,D\1A]C<U%2N%J4O$K2T;%;$$/@F$=DLX5%'+EPN$9U1;8NM
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M[@&*G6+=(;$CZQ/Z1FIJ9W73]+O.25$1S^$W9Z^A!JK;!W .EY*+9/($8 8
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M[\@F\LY40$%XP(""2S0%GPQH#Z3 *MIFM&TN:O:JW&UH;)Y8Z7CQ(^TP'=1
M%L7 ,/8<.&Q)4JN#-6%]$*$'+:H026S$DYMB\=4/<J<?/HBAD+ SJ\C%W8X_
M6 %:)DX08:J34H+O*%QKXY\M'S9#)6!W%3V#B4FG.J4P&CUUGFJ]3RVCOU[:
M;[8[OY_=P5 ???44UN<AG]9?W7Q:*S&M.:>G*^BI A3^FDX\K+EZIYPG+$W?
M=L5.&$F8J(^0W5\+!CS&P$F+R,,'<U9Q6H*D<?PU#F Z;.$6T<%$_F&Z*9D0
M ](W8XR(P=/9J_4IEP.R[K?"F9B.29.,&J2 .2'</+U9FJ H*^*"E\[H,35F
M\E#<XKT7L0RB59D^]\ZI:8$X'4@C!!0[U9(ZP/T391)K)=1%$ZU\0TT4YDT4
MDDIAKH9"P7G177.2-?(MI5U,TOS@]'XHG8O2^@1A])#*K@CGTHI2[Y+8HN'=
M\?[GU^%]$09Q\37^P^0E;=LC"8C$$>3;B@_%LN]8"I5BV.BRM'#-)?*EM3!Z
M_]PL3QWPWQ3G#5FH8)Z"N7SQXJU(0_#]<DFOT[JF#146!AO-:O'#LJO!P!2^
M^G X((ZIAT]"@XQ9R9B['P_1]*=0 N0O4AZ+ZH=*\MJ!KJN;R"PL\A5>H<*'
MD',TZD,&L2/^N0+[X4@"6UT^E"C6)1 B2/F)-[6.#75*?*K!4/"<C$02CM.&
M",!6D6HA[)7+ZWP/80"X8Q?@?*UZ(K$R&H'(>6MS8XE?3\8E>J[_%I9*&8++
MFOI<*/4D$?N3(50C?SB_&<^C3HPZN!4!8DV<B+K4A;2&!ZLCRZ*6\^35<"LU
MDKQ&A1)6ZT7AF_LQ#P]YNW#.O<FTV6 &-LJANS5]MRT'0J>7U5I>^QM+=<=,
M\D.B_7WYYC1N0SW;'-F!X)[VZ!//A0_>B-_#Q%\%BT%@J0(M? D0=7@5=QZ%
M" 2M?;MZB?;O9;Y+L0/25)AVZX6;_<?#+,S9*%O]5.5KL$*2,RD6&6/#E)/A
MGCH!Y>:9^(+*"S+()%H#XN![7],*E_%S7V]XNC:)1\&G=D0G\KB9OK4 33M_
MPQ?#'U4NP,E\1 VUA.IN1_N5NYQ]7<>/P,RJ MN,YVJ=BY(+==>OM:P@'!KY
M7OP"ZN>)*:YK*O(R^S0+:.B%)1+<:UI)"+H:#F*#"0E6VW'PQN SK$NLSQT&
M(M/4T%G'HI%6+K'GB\]D+Z<D2CAI006_'[$H,C.99,:8(8OO(BIE:J8B5PZM
MV&JSCX8^\E@C!.9D<WC:$/?0+!(UFA2UCQ>+EYX17!BWVGB C^]/Q PXZ^TS
M$W?&7HL4P,1QLXY4X6[J9-:$=-O1<IGVB4PXGB7R+3H]BV"P*8\1]H\&^D-F
M;E!@4@,%G3G",2?7M;/PEB^+A\D'5.O')T3$B?#$@)K)J'J@4B(JMB6S,N^#
MJ2&"\YFG^%-#,4]F*.;,4_R[<,=9040*+ <X'TE4IZT7";&IX)2\?TQU1D=;
MZ.6;7&1N_N8T1W&,P;TW1+3&,4Y.X]\E,_R71''@V Z4'8Y/A>BZF(8=YV53
MY3%V+DSM3<7O8JX@NNNY*(PP+2M "5GRH.'CP>0B!2:<5YVI0@WXGMF/Z3?O
M%[N^65[2)".P_)EO:)#YD=>4Y("&[VD@+GN;%S6M[#B_-WUO=SMX^@E3+XIG
MA<6E24SN7 Y)<2GMWRAXE9J%(WV#DMD477/"\!JYT-G'CF2M:Y&;&PJN:%\J
MG'$ CQJG>>W]IN/%:;5W\*<1,3@MDP1A/52VBW1<G!^P)S1AL^3R!K80%4?F
MVF,NR4-.*6T&87B4%*'$^Z:1/'H)/!PEX^SE?DQ7K94E]@H) !<^U2/_T>G6
M)/Y,"A.S1<)OC/20EU(!V(P@8WQ71;E>L80&BZA9R;URJVFEMS5!RR%'I[YM
M)E,F,['N\1Y%:6,0G,@G#ZM:B8U)%-UHG85E>@B$ZUA%]:[CD=YM%M]W'VND
MO=LFE*;G[/6I"::V9++24]_A66H7UO$I!28H5J7-]Z).6V_+5O@#PR]9MDJR
MGW142\87RDXAL-^++"<53DQ%/>.4]1XU[Q:YC3 #P3 @,.18%N7[#0TH!.W,
M:(@O,\!%+YM>TW"5-.@BG,P _50LL(!!XU<<56[VJIG._[+A*-%Q3<EIT#F"
M?%?<2F(/AT'RT@BI;,;P^\2E6W(F@=+*\FN((R_)P"%4/O1E;/R:#"WE=.A?
ML&RLYYP(I[J;;/+K8*H6JU[L)V5NE^S)[)F0%^#AW,JJ7N4*7E[;#7%.?EW@
MTP9;H-X#_8>=;/.FHTU'GK3 ,HK6)0BOB6J67DK4((8$2:1H3[>H5D%$;EW=
M6'!Y]E4W2/-&\>N!]-1Y7;]7NGB0@*H6[C*,(]QFPPIF$#+>P)M8;W!081>2
M]YNK&ZTZ+*RM.M /IS*PR;L (%VN.'5LXLWA+"O%B[.A><$PX?4&P2]?;.,?
M5$*)%DS_(S%6GO>R=>)NW!^,'46:&I$PFLI.S@$W=KPEGR.25LQILBZJL"3(
MQ0O^RW8@?=!%*TMBVZVGI=8478RY#M!:9Z@)Y7U+:O;(T.Z]0(=UU=-:"6ZK
M--B(K UQ6*=06\D7UTOJBG8^LUP)B@V;>E_(\G.:<4,[U%H^,\0F2/';(A#X
M;W@7AO(2%W,;7B?/;U6)3C8OW8.:YH08BQ7^%01Y329:C9;'"SL_.(Z4Z;ZA
MZ,-?IO?B<0JRC(\7_QE69=VWPMSA(U>"-@SKN;29C24>#]^WNKK:X+&K0%W=
M=YC'25T9-L>8M[ $5"+%=C,$AM-MK_N(^!:3_OCE!H::"(*)W<,V'-N4O;VI
M1/)]$/XJ<</RDE\)Z;4SW$#I@;W&TATWZZ=*G QW@36G&9<G(0FV_K+XR/N_
M%B]%Q2A7!===4]WK-EQQZ<V^K97N4K3/G8("K5FTR^3!>'F%AFC2@O? :.$H
M'BW@0>QUTI*UH(U5135JD\"#7+]8U*-_DNXJPQPG%]9$5/61R7$2V%S&PLQ>
M-/4UZ$:4\R[I0J!/./'#CU2=_\++\O8QT>M\^3Z_4'30,^7&D 4QFO>[O:M?
MIN*L=!32V97@8#6^ 0Z_E4X\.O4%3?:VW\$Y>POI,=1CY<__D-+76U&P79PF
M.(Q$[=[M:B]VC^L>@U9/5.C U;LMBL[S["Y#[+0Z K2'U!C"(:D+(+E6+.NF
MI\SKN@PA&+!!R-=@F<05= H-U%?IOB>E[4QU0R17P6=XE$CA\Y(00(ZLTE4S
MQT \U>_#E3OQ&?#7OH)+ZHON-%EW_#A"E+'R>_L&K<:R]3.?'#5^K:5'BO?J
MJ7FS98DJG()'[XN"SP1NY>=U$1Q-39N:'Y+<@63N5GSR:7J0/*G*;3!BFC[\
M,)RHA%X9B?NF@1&<9H-NT8Z*S?'(QB6CD2D)!UV)["'&5 >G"CMJ4UQPU.LS
M>4LNWC\KM-=7E. 'G0)N:,.->F@D0&'$[.VR*;>$APZ/W)(7"E.Q)GU$2[H:
MNQM>T[_Z2B69B@_AG;569=!=-JG_CC$4K8B1A1<;MBCDFLI_4R+<=)) /$ND
M]E1^:>@,;ON6 BQ9=_Q!&F?8=B5_%F]DU>37J>B2"5EG/+_KON5,!R-]<GH;
M7#L!!H;:4%HVKQ3ZY2*AK4O310'V=TZM2V=R?H%^8LY#ASLF69.X4,+,B=1;
M<-$&"=\UA!_U,F4(K-A%H6!-8NPPGG"*>(DE7D(<AQ9*4W4%X42<-PS P:@C
M1+'KQ/P:K,:H%U1#/-8.7DM"3W$JPTH7&>GQ6V#E-Z]J*DJF(7SLVW'5PF6K
M?0+(I=<!H)R1')\8R?%P1G+,2([?86&=106XQ!.0/$^K^0M*S.V0^57K1/K3
M0P@ FY,IS&HB1 GC8TG+C*RTR(W]?7&OO&\<,PA>V79&=S0AIGP:/AX^KPY.
MR[*;*S+)QK&A!U%P[M$I=D%?"M]B3.52J@X$(J#J<6* U7 ^Q6?NE5?W4V_*
M^T;)$7],\,-JSP4,?:#KHBEBAJNF @6A(GGBQ,1&,WSSF7"G@][8PK1X8ROP
M;D<(+X?Z=EQA(A!I)C&7;XDB?SD2;Q;55=G4JLXWB,DN\W^'CR%]*AJ RQ1U
MCIO]L%SV.TU,OLW7!8L_+EAYE1N.J7]4\EUH20#C7 Z,#3[XAHDBJ*G4P!CO
MZ@_EDDAF^*Z>N">;\E<H8$A0(_2@[#?2)RGG'K;D:F-*A<%!H28;JBURGC@"
ME8(#>%EL#<'4Y*M25:CB;."J*Z,IOP:BNS74 _RMC#$ D5WK;J_6Y]']5C]>
M4YXE #H(/(I8B?!O2)I?Q&MMXX2[" :7S2L D+6=*)C58D.15L?EUZ9LWYN>
M:<SG-Q1@-8JO\31!_JYDX=,WZF.Z])IK45JP';9@152DVV/9E8ZKZ9U&LR1$
M;VBJ4)6&?)NKD&XBKDG1H\C6AE,H]F'P54+4B(0TAF_9Y^/%3P(&E&-\%.*P
MEGW>MO625:"XG!%&3T>HQ;$<NE)*..$D/Q#$TQ$YE>2F$5G)$/4BIW-"Z:&J
ME78 4':H,"BSS<A@J;0C,9D ]_G!5JHUC@QZ=#:L2,:]"QW3>.G5%?=_@VRZ
MA(TQ?:US7V**7]37Z/:A%[JJZ5KV@/$VY!$EYM@UTJ!L#Y/8U2&V7&[R<NOZ
MA<+R +RVH;XWBV ']4L!+\D+CIJN,F<>'I!4H;E) 2,0/RX98Z9<)I0/8O,_
M_5;/;K[0=,%#NZ'*1I>MB#OX:D#=N-R$8@,'3W]@%;H<TM2MX];V$R;;+"YS
MR]>TN:1H[KB9_PGEW4U97$5 I:B.JB5=+ =U?9= .[ NA..2P9XK?P'J&Z>K
M<-FMEI[</-YNC!-,O8>?[.0(\X#*&HKQLFO##UXUVZV9 =1/UO4M3ON_\#N_
MO;?^O$<Y?_$9?#]"BOU4-^&(^4?,Y<U._*03/RCY:E]D+"R?%TFJG[S7@OO
M!M]EN^3KQ>H44WPP27TY =Y@G(HB="7OF)#R3X3/85=)QSA)DY 9$.RLY^0A
M/<F(J\8YA?J7?)(#]A!CMV57Q+PR>V<^<<^U!9$-,G1+1/Z0K)"&2/0LE8!%
MX T.GKEN7*N .'*:4J!!P8>S:T=D3+S=345PM4Z*WPY7I@X%:=VEA (SH(2W
MK&1!-$M#$B0VFMP\3@Y5^9[=W)??/[OYB2_[;3ZB+:)#$Y]^_F.2H<D^=FM(
MZ<IHNTZZ(G(N\X?YV%OZVR LZC7(6]O+*H-?3)47C#*L'73I8N2X:AA%^HRT
MB,+77K[Y.I7K/5[\H%#-&T9=MK[54R2SW8$T&KQ/]0RW2>*0,,:BAK=]O/B:
M\5XNLD2)E+QO1)77/J1IDGW=5^5_]<4@JD#\PB*!)<6TZ@!J:8 ?AEM5;'W>
M;>OZ3DV(KX'JGC-CJ*VUM,?')B&+*<58#/4$+6E;!WKUV4;)*F+/DWYDUQ2=
M*]Q+-%ZGK6TI&=#T$OW'V6O+F-RB *D?I7U%V9X0#)11<D7Y"^%L-^5%:4B2
M9T6(.&(^\D6Q"8__OKSCR^JE\E,^?'#R.!.S:5SH^"<X$L[TQ;[C%QM=GL6]
MYS_>7WQ?+SY_],5GN,;B7OSC_<R8DHGCD2\XO-@SKKF%U_;PP8.3<)'/GI\M
M[MEOPT7";90-ZQ'383WDVCK&YL:"77"9]QL^=C3HBR!==_ BZ!^LUE)/C0E&
MI\&=]+F"]364OEN[)>^,,)';@CA:I)/QWK;(*VL:J.IXDB2MB;YO4<%R@VOA
MSLJW&2:((NEPR1;7"6M)MW,+PK_MIC33X-V5&Y[_W25G+XAP >3W#4HF2P,3
M.1)_X0+Y.SP!O1LSU]@9159JA:#BJLS)8Z@N-L5101:%9+N-A69J?;QT8-*W
M_"[OG;U[^?;^4[L6^% QME6][ UT>T[T1>B$7"D%MASLFIGS@W384YG%,I$:
MLX>86CP+(C>JF_8INP#40E<;$%N>WF[;!HO9J@_C!C&Y+H__G_/FL__UQVD/
MC$J.=]!*OJMOZI<CIW:+@%NQ,'3$,H@M;%SW';9%;0P0>%'":7QU>LH;#^7Z
MACH(_>(Q]E)CJFYR64"Z":*SGU(\"=Z>(]D<W6=;]<?O/3^[+XPN+5J32A!W
M-C4:C3>:L"8_FI&LO'QC_2HU;_IQO<_S,('UMEPN3H-=6-Q[N2PVU(7\75DL
M+X'2ZHJ2:S3?U\UUOK_/S]\2U1;,[Z) MY0=V6&&^/&)9A''R3NA47QEDR_P
MP\6]TW>O7K^]O[BG2-UM..6"HXFR!J5:PM<R>)CAZLLPY6@=D8N1AT$D9@OB
M*RFHTT#>;]'>QU2%BX79+C?4%0;SQ+B47-D"&1X6'\3<_P7.%#T([9?^H?Z4
M*B,S..9W <<\FL$QGQ@<\]_Q<"*[A73-O;/3=V)$PT_J_: Q;-6$];- <P39
M4C;D1 &%SLLV5KP+M">!?TN,.<QH='8EF_,O(8;'/X-1=MXPBX#4C=#DVA$I
M^9O4XHVL-EOW%Y34^3$8ZWMG+UZ]U@<*/Q)L!1F@E24_PE4KOJO<XOF9#H>"
M&'KX8)+IM#LO*^G\4__\%1]@G-%2O_=#N>VWX0C8%L0/;B=N>AKQD2W<"CQ/
M83P/3QXL5F&+:FIO690[.:7Y>*7Y(N@K#66YJ9?O@4?>H=>R2"@??!<5X)$-
MIHY^K!L&;(;S-,Z$>+SD)EB3G7B7Q'J;D' 2GI9[R-KW\?-8-V$=?!9N@AD_
M#MYX'""R-"R.0Y^-,P14U=3D:*=>B(J0W]G7X9LZ0Y18;3C!12^7=0_00]V6
MW,[&RU6BTE>GT0=B=!$OYJZ^X/RL5&1WZK%K,&!$EG%Y"*4XX4QH =H20;,>
M.5;Y(7?*K79A.L6-P^Q^\83?/.6O[;W+V%W^S2_AX\6II_N,@8$DQ&@L[NU@
MGA 2?E@6.UDEDG_AQ3/AAI8THFW^+U08062]U+RE\B /6DT-TPM>7P[/^#F"
ME2&(NVDP8OPOUW%DX*C9$5P=VT]!V]EXL<1=@MT3GUKK JKZ$M[&R>?RT7N3
MF^8^%[M+>DX#Q2L#"P_+&$G-2* *N@*9"D8E#5RZRZ?=[W*->ZR*#L3WE2:;
MAD$DT]MOZNH"'28P?L%1E.Y[S<I15_S4.Y= ;X[V_N@#U4XC:=28(GRT9(ET
M1##1#LPSR?_PEH/]T#:'*SII5XP$%9I(+#[BQW_P-"P;+:2,MC!]Y.2IK= 6
MN\@Q2HJMD!2;'.Y\]V!?] X?O3R26<6:LS?MI"D1<ATRB3;<(9R,FBTCM@R]
MO/PU2?]6OD5-9G9T*X&BF:'5;IQD"E*3I-.!C@J]KNOK5(J#V,-OYVQW7=_T
MUMR[OJ83"]\&>2U 0JNPO1NZOU?LP,',PC?V@;8+MHNJ9D)6SZ5_.3XD\@\G
M/*HH#)#2U4:Y/'V+AR;,7J*-E>HP\HZHWU7RY+%;>JK%4K5%3G$@A \_PIPD
MZ=ZS^XN3QTC3/GB03:X268XZ?EE.U<%W+;85'4BM0#_17T.&7B;D[XM[)_?%
MR(_60ICABRKX#%3=L,9 _-'43LC_VI3KX@A276%,R@BRO&SJ2LI9JX)P2KER
M-_#ZX(S>O8?W%T5);L8] 6#C7OF&&ZF%[25R(E%N!]7B,!',O(]')WFP,.LG
M#XB6F EEVG1]55.'"MH\,\9QA[LKXR\^:.I+X:655TIT*U--6'BA?9523%^A
M\KC9Q_-K5"+63(>P]!K]5:1!!Y%*WW@C&-:4F&P!W6,WT-2C?5Q>%@_3*HPR
MLX_N,_2%<?ET@ (:UP(WCY09$_U3=O=6+WKP)IRQ62<%\3(6B3&VM7HM<C\>
M3984S2-K3P(N5*IBVUB,IHENFXV&* [4R);5:&-]^?@);:SCQ0\'-HO0&JO8
MC89:E3#X,#=]H2Y8ZUC5T%)5,,XK_'=QG:/%2X 1:*SO0VC@DXH'W5_<HA/.
MBH\<>#[3KHSWTS;[W6#1KRG*&1V[XR+].?$"C#9-^JZ3)TANIDZGGN Y34Z<
M-7T 1#-,!#TU+#/JXJ^S4XK]+]])7 >(N^&>VIPI&Y'<@71'IGE<[HWEY[85
MXJ^\J@MF+@X+[JK8,^>?XTYB(H1PQ4[,S*JW@FCF"SM<=25=#UH?)D/ ]6:>
MP9,'1WCU4Z_=ROGFQK?E!UDHY3K3)T8@*49G7:Z#K\7RL&SGO6*\&2O=B='+
MCL=&<GJ.7]( "U(.\#!M*O.@W'YACV%"G7TCT&M1Y6+XQT\OVM/0/,@&AYY_
MMY/S=56_)Q>.&7^HHZ MB-Q(PCS=U^6:&XYR]"_7U<JM9S@[-GF2W.]:YUFI
MA(1X!QD]?+X&2I#.*E-Z&.@W2%V*FN-)-K.1+J:;%NUEO5F92L6$Z^=\RU8K
M=_90!UT&M]6EO^DW&P<#**6/MZAHI@Z-X_@/3-8/L_5W+$C[QO#*!^%J.-IU
MOR3D6<])M*"22E6V^ X^G^K28CF=MF6N!M%A3_X$,!M"QL]HF[_HHGU)34,U
M]P'$/HMP\TU^#HHZ\)\!Y3]BBXBO2D&A!UZ9]4@D\-IID*ST 'B&A&$7_D2]
MVRUO;D)M#U Q"(2<^DM=RS]Q#D\01\PX<ZJ:_TA9;>7C>0:BL]>QHW$&FT^"
MS2/*0KK9-KD@>!/4$]-=1X[FR8;IZ1TD)XKE\3_^@A;W_O'L]1LI7^%'Z9R&
M^X\L( ?2SMBN608&+:(;#<W$XZXYPN*,@?+?V2]:'\Q:9^O X277KJG/^X0R
M7BA!8A\?XY< Y:HN4%P3"1EA5V7>/125J?\VO"S$@ZWTMPN3R'G>,L6KB\)A
MO_AFXG7CJ23ID#Q51C)!;4+NQ_V"X<XHA8?S/#AHL5$^2^3< 2XNE)TD92+,
M%E$0/IGW'>/>Y6:"X%B Z^ZB9K]B+4-3;T(**/Q+FK&838SBME+1<VVBK>L3
M/6*27O>")S@HQY-%O_$3YM87*U:X10833;,I26%B1UVS&SQ82WVL5OVHKRG%
M^UM7\HQ0N3L(E<<S0F5&J/S:5<1]\:[3:,1)3.;+E?=#:#%"3^-(UK(]XHWK
M:K%F';CIWE<Z%C18N_'$<11=X<#KRF6&1I=MT8F>GC/W=SR B4>-'.AA7"@.
M-$T98H22\?)4NCOD0M&WA3Y:/2\Z@=P;<MR,HC9X56\XT!R[0-YYV=2L#.K<
M(4N8C0]7W!H%W&'[V#<'VZQ3OT&I,VD^QC&U@?OU\=1%9+8_.VS'JSQV; N5
MWGK1[S"<X'T^^N+QTX=4/Z(:4EB=_*?'?]-+,@/>-=I4KZG3OZK@NJ%B0_0"
MU@E8+ M:]+& P/E7*KL"+X'$(,0GD1ETS)F.&?2JB!WDQSP3$YWO5!-)6(,!
M0RJ%%@!7CB0!!%.*XK/C5ZZ]V-K[E*XV;8H@^J2>YI#JXBEJ&8W09<M,BN2^
M%J-6[DZ:/H8OC_RI.VX%4E("J]8ZE_';\.]5O;5HZ=Z/W]Y'2:V+Z")L3OK&
MM_:I00Q\[R=+1=PG8IV'#TZ^A+$6/G^!4?_XK417X%\,_PC;BWUB_8/NS?#O
M8;1F5Z4&$JFINA&-WK[$/ Z9$%L]63NHAQ"!R6H-HL;IZQTOOJ^KHZD5J(^0
M6@6HBG1(&CKVAF@B3KYX]/3DR?'GB_!.-Y+48>L0;8))&4WL=2<R+4,HE6Q)
MH2'^0-\[MEX?'X=A"W+OC.IC57T=I<$-;Z>*!;9^OL4=V!.@HT!I2MRD^?O9
M&\ZXBBPDX1+G3 7-E*;,TQ*P!3S?A@%1XU-?Q5[4X\5WVJTK-\R2EZ.?;(>6
M*HY"$M/R+4OOEE*OL]F5@O$M9L&6N&,5O62P#6A)M6AV:$2V#7DXW0U]&\^?
MG][7:5DWP.[R?O\CBQ]WV_Z^PZG%A-\?"^J3>LCS4V5%_/';S*F8Y.MP9N=0
M6=$:@I>T+*O1X6A+!:8UK* I#P?]ZXM_]E6Q>$PMFR=F#<0*X'1E-33@*121
MJ:D2N"S+#;S$-N9_!NO7)\OJ9I!*X>WZ&1[Z7E+'G'!([SOEQXFK^5*TW\IZ
M><P"%PW'5[9]*J+"PXSB6:05"/-QXS3@:,$6)Q0O#4:!_4!R&+W"C]\>M=*_
M&M>&^3QZ=A'J05?1I%FXA_^^3$1RZ/A\I]<\785]MNJW]XEY)F)WHP=FRPC7
M%+UUM]HH/2;E*E\F"%\>O.[$Y,NBL[-]15K3;:U(#A8Y]P@=IE.2]&_;W7'W
M;4*-2$@'B92<G?P8QY#ZHO <TFLQQO1I>0\2(BHOZ@9,<-Q,MRV."#1!O.RR
ML89QXL_TW"WK_/,<]P67X"9K;,IY.F!CYR2S#'2-$?FE-<48)R1/D\2HGK$I
M.ZBGR+X>6<8)(J8_T8'[%]X>MZ_-@;=(0P?>"]_EUW?;AN!0.POC"':U*G/B
M0R5!#)T@!%;WSLY>GQH'Q'5!34B(N(V^3%D=F-3A0;98$CJ7>=&:XE(LABM
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MW[O$]<6G*7&=_)4*7+^9;_JS"ER_^!'-]5J4J__W?P"5\/\QWV;[YW!87^+
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M'21HG7R &U1VT^'C#OS;'CYN=N53TM9*Z6773#P>"IV])-]LL4]?R:NMG)%
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MA0UQ%]Y4P6>@=>N$8T\2!IP^V]95&89&&LTU:DT6'$X^=SX8WD*"?RJPASV
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M"R$9Z:%0BR[XOA) -6!=L)LV73G$!S">9=4 O-;B*P<%OQ$W]-ES:),!(XO
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M%<CK=#3G+04$$I46[98%"OSA2>FS&-9,H"^&2F*XJ*@-8SU-NG/V@E*=7;#
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M_?;Q/YWZ^+];'__/&W"_K-?;"%X&+GT6E=D$%&1(,_$>6QG^(7X\T+A5)DZ
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M,!27!XT&W<,11\"*59W(&A%S65^SPQM-\8?"!1SLX47I(%(RGM&1I!JK2H(
M^TR%V=>SM',Q?$[^;,F95ARXGMS*QQ?^+;HC'^7*_A#1:5M**"_2$S$SP%\
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MQ]6R24K.$HYT&-:)XR4)0Y?#@8P)4P\W7)]#)WKO2'G%H:7P%5YFV(IU@';
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M7/L(@I%\ N&0%6?OMA.I.!GYAM\[:)5NPQ(-IA72XC=>2K62V="P0IJ*H-J
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M?QHY/OSMLS_%W('4:N6W%)96Z_/LPE-<93^@(T4/ #^>RX\%_EQ48V=.2CK
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M_:\.Y9_Q=^:[*#;PXO.+P=G,1LU)O_:F+#HU*#:=\(S>'S$&@AU6=_:I8',
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M:Z:H+#OD")[>I$Q*^D^MJ# )6=J6YS'##?K;LMT]8=4YA#HE!0#-6)O;U'5
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M8 <"$W#^W#.UCP\FX-&Y=$RG-C?-M)\Z^UL;;#I\?CK/C87)?/J#+<<0&8N
MJHF4YF=&8ADBA870I@J LWA8>-<O*!#V^^9A^9QTOP]5N0]L18]K_+"8LS.H
MPF.6"5V_UCF>+:.XFTIZ0# 5-S=H3.+?GU /7*,3Q.:P52KD 0$5M8$A28E;
M*EP/&"41F:^A<N%^7X/5JX&^5P/U?NNVW(@B:)UBYT3'7L!ZI[:DT0D&T-2]
MEHFE_*W,-54U<PU"+&84.=2(K+W%NMXP#_Y^&916XWROQBFV=0A= AE]50-B
M,;L4&>MSG:I"W\GGDILSERMNBY+Z.*F+3$&;_'.EVT\!N;GP7!:,O)2\#;.A
M#261]0"4+#4)A_[6_\"_W"Y>>K7HU:+5HG=W:";ZD[O$*&\P;T[9K>>,@%P>
MG5%!(?Y)A1X'J>>)1:]FMYK=LB.M&PD;]0R>"52E7,AI\(Z+O^P19Y-G]Y:Z
M_+#.;3%T3MB#8XL[L*:C('K7]&$'H"_H<[\\&XX"\;&@>/JSWL7_D>+>BNJC
M_DWJ[(O/_D-_ABYIXI#)$YX4_$ #H+U4A[<%$.L8 JMKHJD->VO=3NMVNG<[
M-?O$5F>-DZTQCMS())ML/1G D?&*AFLCV"E2$*')NFE<WK3QAQ$7[;G6KV4(
MK8%<*,7\_JB25L-^SVQ)$L'&$'>N4M:P"@^5X/:N)?\M#"NU + ,98N$X#.7
M(885PK#/S6OQR"$2S/%-F&T&)381^J&6"="'BJ.6OYX>';9.?"^KT^.HY"88
MM(WCH_OD9*HK##N >T<+^;G^ &/5XU=.W<]K.4>?/_U$OT5H!?Q%@%DOPC3%
MW^C\CQP,6IC(%#QLVJ*'30B&0=.3G/+-"7#39^1Z4^3<S-0C6P+AA1&P+#0X
M#)+.EGFYM?@>ZM\4I@ ]2TC:! \[3A,$]@M*"]HUF*N6/2I2R:.:^,Q&1#?>
M6P#Z(U*P"3S$S=&G(?$+^_^KGV@[9.9:HQYLJ-:7AZ/; 8XITXV]XZX1C1J*
MA,E;0%=['B&\:ZH[!9I*'5^_D_D(]E9QR#&YEO91%Y>3AAD-BG;4$&)F [-8
M>YYTW-XV32=#&+QI& #: _4L<^UJV[JJ=*N=Z_S%:%[_/&EF*%O]3$O##'D^
MK)_!2\./]J"^&; %F%#ZW32)/QR:\=*&%00N;QJ?P]0( $].2Z7TD:AZ"N@$
MGU"=33(H]:AZHCU#U<G;Y'#@@M0+_Y$08KZXI<)!&T[EUSJ5$1RJ%OQQ]48P
MMSXGJ[S;U(O"W \$J6 %QUB=942Z\.F,$Z=\IA,[_AF959J1:B\,PN+'88>Q
M=?,X0?@/GIPU92!L&TMS<2Z>I^(<,T70*%<_ 32L>,KWBZ?\9,53KGC*]X(G
MN.1B)<']O?C8C\J/D<![FRWO^([QZ/;'Q=8Y1*'*%JISZ.ZVJ/:Y_W7Y??DE
MZ@ZW/5.';JNBI#I<1GO,.V6$"_MR-WB_2G-5 Z5NISA ICKAXDZ#-XW01'6J
M+"VA_C<] /P3W?=(A> XCT/;#314).6^$*W=FP/0S_@L@,>JW .CZ>:BX:!U
M\U%Y=]^S1T*Y<4H#6"K-/A?[?5%2_[[9]BUA+3\*+_(U/OPK?=&/_Z0AP2[W
MV>>)!M;S.%&Y]&MQ=+  JE76#Q$<XDY]?%GHR)/U.O*K7F][7;^OWDH4Z?].
M>$%\T"K1']MJ_#8"NN$\;S&OD=WX7A^4XF*68\5\()5JS\IS)?$V[/9$.$Y.
M>'2\,$"(_3ND-3;%>W*DZ_^--_+.N8. A FY*GT9N(OXM^)A^.>F6>Y]BQ49
MIXN-MZUEVT@RCRT)6O61>4EXQT8/?"HP]JTY4E6FU+68P=8I>4O"2\\5 .A#
MY73\"2+?DO_YE<2'>^1(MV0FNNS,EF$6)I]?#BC1\F=E)+L"H($;Z_R5MH$A
MV:A9)V<+82,W@++[3UA5#?@/S$BUI=( )W,G"7+,,C64SFG$T<?90,?M0)+1
MM^&.6Y!,T/;D9)@NO -U01C7 \<P>.0:A:^3NV K\>_9R[FJ;A,%OL%':+PC
MP+_PA#U,I J^ROX:S=ULHDC5@IE  6WO8SY/+TD6.Y2&^O,!*0+J+#>,0NUT
M*)FS%TQ6Q^T6B!9,]K)I[0&!/&:4O?"F)3B6K6#N_8[H3,KSB^0X8)-PM;_6
MUAGHN&I"+;IUK@^D)'N:J8E[:I(603<]8(G@'-3F6_*:SOMI&"!GD#&6$:JR
M$ER<S"!2.8G6N I5B]5@$7 <\U; (#K_TY@]G537B$&=(C3./FEY!:NQ^,[O
M=):QNE99FX?Q2S+48;5!&2,C,<*Q]7(?GDKG.>Y_KO?R6$)=B:$6IZ5QNK3A
M; '#MX]Y: 2>[H#UC_[#O%FTEA_]4=$130"/?MC\_^)8TSR#$L#4OV>2W/<Z
MC*!AL%6@^+TLS(<IP/V#NPU%]OJ[%V9PCOF8Z)RH&A"M)H :LW/\9O*_V1E6
MBG'M$]EDT?MC<JL'7UG?.6*27;;21Q, %3S?!P@\^2M\!X[JOZ-XX=GSS9/G
MFMZET;S\-L+)/<(-@[T C1=Y1FGQW/-)\S"82+P%;VF.@[P+@"DQ^NH4\AP]
MT:[H"\G5%=I'QZ$/5Y3Y!3P/2J!(/89P>0V-QT\62N^OOWKA;U4!CK@;@N("
MN?.A8Q:1[D G)U08FE;9-C&9@,[%P15R(/@ @[LHH@41\#%8K+O2?RP6(96<
M-*%<M1*3>A^=A='VAT^*=AS.1?OF_*VHSO]RHA4QQX*03J/ZY::23,]Z()*L
M"+,,S57&BR-[P>EX[Z8SW4=Z9K6.?O1!</Z"NSW>Y6$W,)0NRK>A!#SRLP^G
M3R[F;HCF2F2,('M7HAXL%!;#6S/7Q9?-@N[H'Y:XQ^C_4SG)M'#NBFJ8;^%
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MG;URC%JA?\?=] N%M33Y'YV)]WQA'#_"H26?S#$7(]_="=$"5VC]O_ME\C^
M#[3ZU=^27Y6]%MD/28]7Z^'X[CQO2#M"3#>MA:L4BH]5.L=U!6;T&)&]IU.Q
M XY\B=Z5F^'H7W];*@F)2$OOA?74.Z"AK26>*S7\7$>IP^%84VT4;@+L%C5U
M"HMR]Y"/R$$X@[+\-R%V.<X8&(!1!?"7<+7XB*SFDET0 &_$)[(G"WXEGU"=
M"%^>HLG$#4ZY[*)N'G/>XL;*^J@\FS>MDVQ=!O89UNGS)D[JV)3#RWN3M!'\
M9<.;\\/:P 6""QW<SO\7.VTJ.<):%[;#BC/YH#B33U><R:HN]]Y/4*HDQ+XH
MJB)!6[JHSE0YEQ,6,IL="N?>?1+PH@U_1[I+_B+ )U"1/G9_PD\S77L:.091
M(\,IJJ6'.W(BRM=Z'RSS<1R4E ,\I#*C3CY(S@0L1_P:*.E1U45"__#9F]8:
M1# "_=+\&6,'SYQ_^S%9*[J]>H'3+;%:TPD_=#P]@2JF)A?-L:Q1RPAF(J6@
MW,@PL96<!(7Y!AH(8AGSM^_, VQ97" L 1Y&E)[X?2B_$@Z<&VDZ1Z/GM6IJ
MM.1.:IB4%F34WMH$QE6<GE/F8.X@T;]3%&BQR>/WHQ,XW00K,'G9>VFV2(+!
M_ UBJ[QULPW5I%%H%3CU&J6+M9:-2XK0W#ZG[>9:^L"B:70A=WW</NL?5+:
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MG7_JG/V1?R3["/_[VEOR?N'6'^?L!T2'7H4Q1CO9FE4^5MK(>5PS&G>N4&2
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M-:&P)#S/-12DE&Y3%;G,&?O*$/97B)9982"!-5XW(WUJA!=<"="M;;RB5XY
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MIA.7"6+/I DH:U.-$(@4/CN03SAP+GZAX0A_,51[36<G"P58&\VU@1>SRHK
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M(F,=/@O5 !F6;7<S"OJU.,').AA15D?7*5B#LF5=V;(9+R,NB0.<>NL'Z+<
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M#I'-4:E/"*2J[S1J<.OL<0ARW'#TQ.V)F\MU+H"OQ >8(I5+HEAK 05OD@6
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M$1X]@#2N C2?!@[Z,4)94E< A N!J^'&VR)#+RUS&"3?GDT.O]\9W5N#77!
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M+2WX-:,NY;<Y<7,G6<6#[?Z41,#V&!FBG^DVSW1O.>0]T_>WI@^UW&SNJ);
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MGEO?61!/X68S1LF"]@N9RLN876:FJ0W8+;G'ODQIWH"W)"8,DE2V0^4:%-N
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MU+U5F->,H5] 35MG?0]G=&0MZWU)JP'K,6/VDSB(DS6R^IP6TYZ$CQUW(EU
M1)'D"+6;BA I-M <U%D:L^NMMS3F)T@W@\G=9) .#.>.^23QGJ[#69*[N!A%
M6:BO8A/IC7+TB"XK$Y4TS>I59+Z#TL;<O$UA];.4\ER.0>>"$[LPU"*1C46;
MXKKMVJV.<:39<NJ]_0>5AO+O3&R*3M5S]WP5UIC"E*&:1)ZX]KM<=M+R'0<7
MIO1[YYU'L9X!\8&PU4>=?';2+RA:!#K7HE%8@H I76 Y#*7HZBA(/E%]]B(
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MG.4&A[5BW+V,:5-?W0TM)-F *CQ@6N[$/L^[]QDVI^+4A4 #"D:F1<%$):L
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M0W)20/.YYV.'-L-1@*:U"G/B+7)8YO/28) !JI$UA@H*D0G72WV>K8$F-73
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MJ6@%L>G%Z/4V1OMK!LRMC96=L)OJ[!5F4.RVHJN*KCH8766!4I&C< T#@3@
M(.-(,L082,ZU#9ZM5;W;Q&[;#5VEM'&&@$<>.X.XTRX-U&LD7%",6F:D[*6E
MP]/J*G*B;C):BZXJZ33;M&+_NYL@",BFD=@OD.3F["R)6F?0MM6LA5#5H_SJ
M9-;U<AL5L[=0B>>*#-EE!K%E'<\PUB0F4U0IF70\=1(92*K/&!,])I39L%8
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M]WZIBQ@?[MH6,2Z1Q[L3>?S--HT=34O0\2'+4'&2WNXD]<Q'J2 BH[U 7)B
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M?BR&V2%OF((-!1L*-A1L*-A0L*%@0\&&@@T%&[:&#:7P].WNLR@C-9$A1EA
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M;-%K"7Y:&A>E94AHYQ-!%18Y%2SB4>,8K)=6B3[Q]V%^9<KT@) CI*KEJ*^
M= 'IYZ6QT8%AVBJD@]6("XV188G&*L6=YD (-6PM3YIQZV."4> A?2=]#EGL
M,$H6/I9.1^*"?3(:2PT=,%9H[ ,0HV00;2 VMS8,F4VZ<E;0^'K>N7O^\GB2
MMU]).#KD5+R2N7J'7X0QSIEU*)%I0)P!1\9:0)(QP@-VAK.U$S4N?4C?,DA&
MC!'GVB(KA4<A"J6 6BGYS3[CV_IR=V]^F$OBVX6(AGN.W/ ]BL;P(T] +9R[
MK.TNKNT.I3&4I2YB?,!KN]?$Q KN#%"#/(-DM:8K(1N]0<X)%7TP@"F]3DQ\
MH%Y*8I$&DZL\!XHLCS+] ]Y'IY/9>[.E>TN+S/MYR4Z>=9>M7V"MK&UA)V6I
MBQCO[MKN-3OA#FS .I$,HG/!+Z*045(AL)J#T49XNM;-UQHG M$4A9S;F/X7
MJ(M(B3;H* VVTJS5*RWL9#]<[\>4"K.9Z_TKM-.T?_.;3?JUJ?T4POP#Q?E^
MP*)4M,@=SG=IE0&-D;52YPALC)P7#@D2/';,@9?K5:_[=K[_<2&-W<=>?;--
M^*_F>D+FCSO@B>$#+L1Q*Y+"C\O:[N+:%C/W:):ZB/'AKFT1XZ-9ZB+&A[NV
M18R/9JF+&!_NVA8Q+O'-VW:RSGTVU;=Z>GH*PY!=,-74?H<2P7S(HK+73M2]
MSEL4%HC@E"-E2*ZI@7/>>.2(2!6)LMI'L=;99R,7;2?7N9'/;^/FL_W^WUG
MQ\-<>RB]T+W[Z_6>/O<[:!^6T:CE@/"#<M265,4"HP>VMH5<'LU2%S$N;&@W
MV9#JRO\R@CCC,;$AXY#5$!'5/E@> P.^EGZ\25#V1WO>-3G\ X9V"N'S>!-&
M](C^A6*+51H+&RHP>@PP6MA06>HBQGN_MH4-W<J&< 1KA=&(8R805UPA9WU
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M;7$'PU5.&= 2$9NUA0T&:2H$B@H'X8ST@JUY0WIAN%GJ^BH3R+8937/ .[Q
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M?[/4%S:T@@5]LBX+9P#XY[S:T3[*[T)TYK5[>A2>6-_16P,18-S5RQ_LWB7
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MDD6U(+7&HF57KKBZ(/ ]S-)HO>4H;Z?ZN6W(U7Z!2-0#;7I\N>Z0C;HO4$_
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MUDK\H6L^N(RRO*"D2%)&>&)"4M!0HPTFDBS.<I;2?1AJ@^/BI\%I 9_G&C^
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M;KKDIM_929[<]QE/,8P;\N6RKZ\3V\I^VY?H/FA^V;>8*O4UH?U]3? Q0OO
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M_"HLS2,C<Y)0PP@7VI"BD!0!D4VD!4N3> ,#[,Y9$O5>XXLL?F#,XV?.WY/
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MQ/%ZO+U@'XXUZ\$:.E#:%]A!XL5EY8>RD-;%O!AH1VN&Z5;W1UO&?7<7B$M
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M"%)0JU&,#H+HZ".R)'$DJ%-$"2*490?7I?WF/\4P'\7;/02G:'(5?\\/OJ_
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M,]_.,&]P7MY-JEGI'=PUL[ONYJN;_.I6.;A^%>N![I^V)W-[6,6Z-7 X;MS
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M]I(H*HFB_1"99.)2*(HB]@QQQB1RUGG$?+):./@CWRI0.C-$GC@_) M!6 F
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M(V7KD1DJSP52'$4EL:8R<&VWNJR>;?8.[HMI$O&+2L;JX(0\[W.Q?Q;?"]7
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MR5HK7VHW 1>\3X]=LG2O])TQ*"F%35T%WHN/1KH,P>W71$6C8FY6H%)(Q!W
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M=.2YFG'XO.;4%]P'W^I4QY?<H[O@3_D/B- G^>6A'8UNFL \$ZTLCG3M[HE
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MT"8O?_DX9S2;Q=(/<K82ZNBV]. EU'ZT:JDY39(T(I[T0)=F;@P2STU(Q)+
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M )IB"TU68![.YEJ!N84$0,Q$][V :.J#9BY$0$3@^?"K#B45L=31H\Z([D'
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M[&1]UW5OZ#^VK?23#,,V?]V1)GGTS2QM,^J;JV<[4-L.U#WATE,10K:CKNU
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M2>'A^C2A_9.& W>/#%7D_:2"5- @37W83('_T0$G0M.41#QA01@G4K*E3(6
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M)U.)/L.0#AK8Z*3!1J%%\4?]R*!M#EK6'<SZAH Z2&/- ?)$+ /"51"1A*J
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M?FSDCD!W;Q%2N#E7#P3=#BCQIX)>B[Q'S:]V7A9Y#P%Y;2SU2)"7/T&-P\<
MK_]$P,LM\!XUN]IY6> ]!.#UMT89-B5XKRG!W(_F*<'4W5\64UT/R?F$=?P-
M$-'EVDA-RS6ZA*KK@1/O.OOLO,.J^^,R,YW.S 7U(GDA\!)VTIZ4T[K1V+UQ
M=O<94W7B<9,OQ2S&6BPZ@7E9C-T 8P.+L4>!L?LK=W@38UF+L<TIESI2RWJ
MK[L/W5I\M3AT<O.R^+H!OH867X\"7_<6M5W"5Z^W^+K[ *W%5XM#)S<OBZ\;
MX&MD\?4@\972F 9/X2->F16E1:5O)AWGN@U.(M;>#;*5\U7G L.YB+?_T-7$
M(-^G-(5'G,^B_&/@?/QX-L [/\(M,#?5)U^QF3'ZQ2W46D@ZD7FUQ S_Q][R
MYD>5?9O/9:1_$)65VBC&V!A^>I6_4EDU'HG92[SZ:BR4RO*+3M?H+#<#:1 ;
M+$#XPS^GU21+9^V8S*,$!-"KI/B!BX7][>?MIW\\!2*O7- ;W[[U<_=?>UA@
ML]"7<_DQ%A>ZEA]$I&"DO!2C[V)6O?KIQ<T=:9?;S'_U6I_RDAHJ;K_?#-=T
M)A?32=$V.,<1X>K !/!V K1<3($FLQ\:A+;Y('7=H?MS^P#0_4B,*_VRTF.!
M2-6N1&F6W;S[IYN8\"VK +M&V63VLGU^A?"O/Q<-PY^;S5YQE0XIO^5R#. 8
MS*];Y7D#Y3G^5ZL]'Z3VS#SFN4^A/;_.)UE2J)GS-JMD :NX-H^Q<=VLR[98
M4;_TZW?XS7F3%97,C 9\UNF(M15%^?]-10GP,IJM*.CV_S;1E>=E62.K+ENU
M\F3F9<%UDTHT[O;0]0!HHQ];N05T]5PWHHOHNK\R;,O'Y.^/N#=!:8^8>QOH
M[J"$JF?QUN+2"<S+XNTF>$NM-7N(>$M=P*HP7K)FV]$3>!_\'4!%3E[J&G3V
M@L7%M 0,>M@IOD]R4IC3!G1N_]XK36/MT;X>!8KF<ZO!F%HPMJ!U O.R8+P)
M&-L:<8>(Q2#. ^:QI_ LO\_2!Z/M=7^I#?(U#@1MYW.SKF:+2J<S+XNVFZ"M
M;9YU2&A[2XF:L!>F[V\YYDAF>+<8U>@+R/37J4!\FRV?J6\KU=P?-T-;8N90
M)+&=UV'-RR+G)LC)K=/XD*!SO=.8]0(Y7Z=I5E[5X5.Q<,P S,R; 'J7JWA%
MO/;Q%NON#\5;_[#%IQ.<E\7=37#7_Y/%W0/$W1O]GO>:'-4]N8?H"3]_T=7$
M !YS:=2T@/XTGJ,O(",\"M-R/H\:5S* YI6!7?%=E/"2UJ%<(8*5VHRB3^Y?
M<RIO*>MIP[5>VS3: K,%L*.?EP7F38 YL,!\2,#<^))I""@24O9"\="/8F:<
MR?W(HP)H#AMH?E(\;O]DM(-S5!MJN[S!Y7-"S=%\4:L7@PY(>YY'&&->Z-W5
MF;IV-=/H>1=8M\2HP_O*-@O41PYHQSHO"]2; '5H@?H @7I5T)=Z?0%J?V]
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M":OE'<\.6BW/:GGKM;R_BTFFG<\ZO[#Z7>\EH]7O#E\26OUN+_K=H^3:T7+
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MJEE=4$5?JW?WA+O?O5K;8XK_L2.+</72"9BR%8&:C5=$A^?4$2/_F__ X7_
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MUR^=33*I14*C;EE\JJ@;I'?W-^GL,&*23 ;N>YYH4ZY(:S[JS?I:APC89O1
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M/92-!U(^=R (B@AA:MZB4K5)[=1UF4*L2%'"T?_[+LT4&6@-.[E/*Y43:$R
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MJ8?M+WJWV7C)GGP>)KSB&TU 22<2H\;#_12'9!YD>M=!B!,]",IA._MX;8H
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M$+UZ6U%3C"(QLCGZ7T=*4PQE:A^XY%[XDV3=.C.FL<N4&)%$40[+H8JT[D#
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M=)IOUQS?$1)\R5.!4Q#IGW$(82Q@\.5^JF5,7E0JO-[C+ MY2@9'L515CK)
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MDMY+OU(H<PT[#E/;3FUW-P//M>_O\)AG&4Y2HA@1L3(HP82::[?5='.'V=7
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M5#;_!1.9FGH1#WK9OB.$GYS"/RV?<:T=HZ:'ZVHJ\RC=)88 J$JS";G]&[J
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MOP[C5Y[%5TBHD:_XP!J71.Q-UKIYF ; ,]-+72%YM6FX#8'IWD-UUH>KMVW
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M[,O[7^+1+VBB%3."K61+Z*"R]<7BI_GEQQ^Z/: 'TC6EA3[^\.UT9RQD(+1
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MSO%3$$4C+!I]ZWZ,8_\U",/Y9NL%25_('D$-!3FYB<\^/)CX_%@F?B!CCLA
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MKO5]Z+G8-4&V&O;F \%/WMXP(Y\I!5MU4[&6B%#>.MC5VRYOV,>JS"+? C3
MC"OI+N4@G2%.R;ZGA<ZU@'B_D>Y7TX&J/@"I9:S>.C@2\0B J2<1IJFJ%.J\
M8"EE?Z,6%@V3<A GG*FQXTDT9'Q3A^ U_W6ZD4ABM.EN,&_<"S6J#Y%M6(A#
MOVZ;-L&&Y=&XY%8#W3BM#KEQK0KOFJ0Q;^;3V5U>#5+.5RMI8<L^/(W6AXV&
MS=F4@: XY7">=MMO@XYT6*A 2=R%#!S+JL3A>E6U-U7A6^-M1#.2+:>JLFI9
M(\2/QB\YFEZ-/WW$;;&=TGLM0$>XJDI=>G!1IM62J_V6S]M/P NV;$;"V1LI
M_H=HZV4(-YVE$WT]F'OZ4"NQ*VX>.&]_JJOU2KA*-[AY4AAPGX26P\LAV&I-
MBF"BH#,8ZF?*@ G3)C!M U-&1"6UC1VH8H0Q,L!;S;R"?!KTS/$KWM+P!L2&
M>05]+M=U]9AGT+5UV_#LHM3G-HF2"$1!?J"CEBE0I*V-8<(:_;81'HCX-;;]
M**,@L?4&[&)Y^8/%I&1LBXA7>@PA=5<=)ZZUCFLIXEH )(?X%'[&IJ,U1=$J
M3TNT-7^+]\9N/O,$^I[ [/.:_W,-^1</@#5+'-/R(N&L!?#* 6[H<RT\*.]=
M081A,*;]RF])DAAT(.I(#>_%[M&F7QRSZ5UHY[@V[YNZ!Z 70EE(\4^0J4Z"
M0'?H"_VO 9^Y D5Z>-N0";-,00K([S&&/;=.QQH^N!DP&''8LG&SJGF23<N?
MDSJ'#G"X =H7A0TO08S\B>QQ(16 =J64X)W96)VUWYF+4OR+-RVK SIDV.!.
MB05RQE=5#1L2V#&O]]T'2$(X*9-IH8RDCL6;'HZ[V"ZI$6>E2"1(^[I]J&K@
M?-V[GLWD1B8:DUY+'9%#;LFA@7Y3N&XLB>;5C#<\J=.'DS([XX^\J!!+4"8O
M]D_YHDQ,L5M2U67BJ'QR>9^>=RP:X=.0_CD%-)9_F1$=\234EY-!X)<!LBYW
MFQV)%PE]$_9:XA9@'9_JO&UY>2UVVWFJ:'O\4"1!DN$WLK6,Q!WYI&R!K./6
M2#SI7+X<PB-[PW<*",=U@UMY^*F%;)+: Q(7O=?NULB?,*W!V?/&(;P/Y6NG
M,T#*AX;@FF><+W'WGI*Z''X6.VK9U$[P WG95@ZV:_A(D'[H^LOO2SK+SY,O
M<FWXR$N^V)M^4W?L2^DJ^0H-_%(!>R-5!"?A#.-IMW-22 Z>%D9\8]\<.0J)
MF<SVLGJ+ZSELZ\9.I&+_.[]#,-:%\*GXNCMQBC<&]JNS(A\+P: FWUY8I\KA
M@'!RS;W=@19?K6OX30M7.PD1279X/B=XY0/02$I&6C5Q(9 &"4[1%Y<+*RYV
M-B$L.M>ZR4O>-"?I/]<YH=LWPBQ .TUDQ\(W[TRZ>*X/L/>H$.$T47U(#:)=
M)8PX-EC2L'R!S*YWTB!F@_B*KUK_;-A#DK$[+O:MXM-5P6%CEQ Q[)TFR:A(
M'BD(#"H7((ARB"C1S)8-5\@,I3,E?G3^];7&O(W;=KSW%04QLDP7,M/VF.0%
M[+9%/'X2?SO$M<2>S3!D&(("R02DL@U?-[3N>XEJEU'I);'1U$=W1TY]%"16
M-M/1RZ)E*(F^LX#9LY<)E<R/=_<UB1.Z^Y O(4[7VQ$P\7%N4QN9>Y MB?_B
MV?01"+3XC$/SA'BN/_.FU<PJT\6,K^H\%5^CHJ^@=]C=&U>5KV'&6@;F(I&Z
M-IA)BR4W"V M*Z,5NN3W&?N>1>;WL(</>V<O_$K#+]3B[EZL #.73<3KP&^)
MW>98B7+@']JQ;9![[6#=X3<)=F0Q_ 94$2%&%L\?87V2M_%[LSK("@LC<*(N
M^$?C2W_)B)8:N#5((P-,%]<J6X^C[9<$)HG68B'V''F6+B+O<^\&GDB?1H7+
M0Y,_!?6]4,=,X[.8(;46.:%(/<Q2-%Z7W>/UMS[KB-4J>/L]7(G*O[_[KW?O
MWKV'! *Q2DW8^S^^FXC/X'_;%2R0>1(Q.1-O..[B?WP_81_>??A1%E&XGWZ8
MP"P-@ GY(R\V?V=_^''RX<_O)C_^Y4_X_3]\F/SUCW^8_.6#5M3?S>FC]-@?
M3>$\%5D.)4L<J&WWV#VP:VJ><2-2.8VO-]M'^V=]BDXR/(Q_)LWSK'=QB:U]
M77/;Q.UY3LXKH1U0>5^+_$]>K=9Y ^UH=;74F'> 9](]6WEW[>$4_NK<[.;V
M+<4321+-I&ZZ&G*T]QP)@R,?+!:T_NA*!JC'5FUB.17D/\ I]J*TB O(%1C[
M%-2BJ)[@Q=OW_E=98==V@"',M42<.M 6Z ASB!QD:+5!3%LT89+*ZI5'TMDX
MZ2 ]ZH D2G#P$@TB*FBNDPV<J\0_:S&A61O>DS+#EF7KH[.\28L*VL;DX<X7
M:DX9P:05$R;ML,\ 1&1.[=/6Q\Q8HT^Y43DF#AM!ITA&!LW$2<4CUE%J[VL!
MQ8*[=[%\7WZ/$4!C:M_A)>X=7F-];R7S@ D89"AOM4EA#]Z'"YV=D69?N?;\
M**\]6<^UIZ%B#MZ7<."(]=\ZR0LZK.<M-K!GL#"15' F.DKQNC> /%=-3U[0
M%98[\IZ1K<%;+/ @%MW[FO,8S0 ^/LD!CR+4DG/,]MH'8<?H:$=?HK/])6\?
M3M?BX+,TB]G&Q6KU?)E4 4H=;4<=UC>=A"$E[$EH84J-0Y'10:6-X/GYNB[S
M5FQ!Q/[D//\"/_GA?&J!N %1(N,AVPSFCW/Z[74J?*&CG86^S/^YSC-<W>@7
MP!;GDQ3L9-QA(&H-S*B0:9NQ.MLA<K%S[1-66!ZO+(^#)CIPVZ(K8#3>K.Y%
MF5?RPJ&95ZKJV*.ZM;,GECN5Z<)&W34=.?-*W;PT\+.N>K83>6&WP/$B4SA[
M-Y^(C#T@O= D9D\K[Z3$MO5BN8(5#&NJJ)=)[ +;2G\#:ZJPT%>%::O\2DR@
M"<()B=BJ;W_ZDE+Z8P:C%+\#2Z%X<^5MX,U*+) 'R#R:A?@B$^]0OD#X YF/
MA/I;,9F(E<8^YP-,N#B,) WTW )JK9A,^/Y<Z/UI2:O^Q#9,IRNE:1A).TTB
MK9L0]A7\UK+P^XJODWQ3T4#\*AX^) #F(-,RYWF3)L4_>%)_*K,S\?[MN[V4
M61Z2QT @W+"PL\ (&T.YX3R/ _CR?%%KJ *_JZK$,1<)[F 8YYS*49B?W_;D
MV/BH/+(.UU^E=>D\L\#G;WC'3M99WE;U5>*'DR;%,)!SI.86\2S%S=5%F:U3
M?*Y8>;[G6;&SQS9"J;Z\84L4&W;C/(PK\@%8+I"T.!6>P_A@C_D/[][_A1VL
M]?9_<^R5Y,UED7H]#RV(75Z>QGD6_K9W7HNX/FRQ@QCL5&_:$P=*=@0.N+GC
M1K:X2GS6@.7HW9V_U;)(?!ZJJ+>AFJ!IC6VWX@C@=@C1;P=LVIPPR2>BJXHE
MB858<Y0)VPU\KS-,7^N>@@,Z]?O*+5Y2;ECU5!)F<JUH#^A\#QSN0E[8*[_T
M@6?K@D\7UEW4=B*$8N)TAB-TT]ZW[-W;96D&Q,@N)]6YD+8R:9 =S6B!;Y,/
M%"AU^%$!FBZ<2]#>=)J\-YVZW?8,#8E2R7'0B#DG*FM<]8:MW0Y;3)"".5^N
MJCJI-S0WH4(#>70!H$HE5%55)5RG?>;UO??.0:O$W(R8MNGM20W04@[H THO
MW; M47/8-RQ&+.3;9&(@ERYZ02RPJ8N2&7T,%#+2./H0[$;7,O/J"W&VQ,NS
M8R[N&4*P](4-H4%U_?0%Z&)IU:?&03]\VD]?F!$H6Q''X$4/+FU,5YY)5CLL
MXF@0C2QO-!$GM>]RE5MJQNRQ"T,IURYLB1VU5]:QZAL?9J2B'56T' C=[QA0
M_8:"\[.>)3X:EO$X[UT /$+Y7%KQ7%; $ .KY4C<*!P/#C*R HRH:_44\,K[
MS1U)Q#3,#Y*U!)Y6^!2#QL)$]B@.H ;-3_7^.3&B+E!8:2ANPE#@:#RQ7QQT
MQX6SF[#[&.Y\1FP]V+Z:.H]+3QHQ(].AV+Z,QPTVJ%<.8]'!79L]AZSN2X/Z
M+'1\M-1Y !=[(>1/^OT,_L[=EJ;$6$SW<IYOSGA:2R;Q9EVTLN?P6IPZ:CI[
MB.]>5Q)Y;QA:-=E\(M8'7+.5<(W !ZE$T,\V(F*O,BYR[-NJ<?57RB=,J6=:
M/5UCH $*:P?^1-OPJN+46Z-W;".("A:KQZ1N<S'1I_ :GZAND$$N$95P5I!T
MTVP2N"QU4*?D:-?.2*E,BXUSQ3NL4\Y%TD[/@O=R),W#OB5TXD^/T;RM4D79
MI'B,MO8@7 @IAX"RV-MX"[X"38^+4W')FX;S2UQ KBLQRVU\[^%(XH213/8K
M2641NZ,'],E^%TA@8%@H=:MP:BX5W%X5R.JE#URW<0VRS,U>>)M!NC5:U"8T
M+EBD:.B3D(Z"I7 +*TSJ-)UT<5;/:-%P#TW[A>08H#3Z:W4_?4G%]&#VSQ+[
M(S@L26]N<=(/Z.WPD1X/-DG0@+ZDRCLXK$8AU@@XO^SRU(=[\*M/.E)1?A@G
MG7M4.<RMPZ!"ML "Y?"7'&%\=#&YZ-JF.<J&A!< 4FAF0VQQHL<#<0$0VI\K
M\>"H&UT$\7/R)5^NEX=C-C!,B<PREEX8Q,PU]N+<.V'2Y.\W^-W7$</TJ"5/
MV#)2A.#UH$+1LW6MH;5E11O@!>T[K'#?(<MH2;1,RBD"W@GA$8W/PZV5\!C<
ME*.WF=&</J_$@@\55E"!"RG'JAZTDTVJHVV3I>>K&Z;7$H<MNH0&:\0>>"'[
MF.'Z-A980FB?>Y/-A_8:"@Q7PZ0GQ7^HWU<$9RU^@76E4?B+/9U0IQPE)=I=
M8-]-K@_9\HX+W+#DRH,[\X(KZ3@>2?Q!\?+?0+VXV-$TMZM,O+P?WKW_T[L/
M7H/-R&9:."/I#,2_??<AVC ,XJ?]%.?5*D_97_[P(5;]BL1\\BW%DV*.W&JW
MUF9<IEOE7%W3 U=SNC PLO?D9ET_YH_X(H@=Z3"$.'WM7XW2(U/.,G$0"01H
M2&?E*V/A_>B>(RU?ID]CT/0$\?%KS7P[GF:TDDK>7"?YOIT-)J/+ ?TPCU>:
MNY_9/?>V.6V;8Y9\ F937L-;/JW/\F95-4DQ75Q6Y?UE_L@S ML9YJ;1J()&
M6J4,QAVH>XOZ)$;1A,EKR -<1\:(B%..;86E)Q3'=DEU4F;SV=GY]*[([W%A
M..B-)I[3P!Y6:8..[I9SH)#Y7GM"(>6<S=@9.V?&EJ.]#1TH:D-<CU+H8)09
M:X*&2Z'!JB+8.:^7^S7,==XS#3-;J_):$9]E%.;MX7R2+X+V19<*@\C '8 #
MN]+I7=W]; Z:%Y^Y?(IX)^+3%_*2-/FL2R(I;Y>BM(_$B8:S"U!M)=W&X_5*
M_/@H.4.QD]GEGCS:2S-Y1K% "B[$^,[+)D]]@(D'N* T./O&-J!SE=;%R5<?
M35R=GH/[^QJS^MUH.+&*49P)_[/P.\T[)[$]W0^L;Y[<-3B+>E3Y2@!42Z@S
M'=%7"(;6^=#^"_:K,B3X@>4@X>J25IJR(YS!,$1=O%2,F35_P>__%CZQ=]=>
ME$(G;H/.Q?I-E%Q>KXEFB0>NA;%XH)/"T)2IY4&]AEAV2&3P^ZVDABKO1BRG
M.+D-DUA04F$/0?/^(?,' _OHY.QXRQ"A;:4<92>M>)ONUG2SU%8.T$]@N"W-
MJJ"J8SYN/O,$&*MP^4J:O#GYDN_=GFI$,90E9E0A+3Q'Q+#>.'> 79>.H4I4
M?'@JCKZY'T8VU'VD)&;<3JDIY9L*A4G7417_>CQ6ZRK+*PP167=S['($&CV'
M?G.8Y<52@#N8#L/GX5::<)YWTQ(HM^T UICTV)O3GV?AD4ZA;NZJ*BL7\72
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M902B0:>:%J@"6AGOP;B6C4CVD9=\D;<Q[W1]B10)X19VVU]6/!4_SBOXR,)
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M-\'!@Y,:DFC--:<QYKN55O( _YC>L"AHYH.[XQS?Q8P)>!'0<T\^!=V2OJ!
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MZ&C@X,526X=8S8V2$?K9F5=>[&K8E'P87XONX\0^>D<\NXCP./6^)7W@V;I
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MWS:D7W+4VO[80AE)#0V3]%15V6G>;ER^BVFYYWC<QL\"!0PTT(1I74 +);&
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MHH M380(PA709964\^H\+\$4+*Y\J(KL8KFJJT="J-OW7A#XQEDAQ$,L%J2
M"O)! P J:!7L_1C][$PMK]Y?AT+OY<[&Z@*B/2P^#+_F67WBL"4>L"-V. ?M
M)]CG97#FFN3+J=AOY*U-]>Y1=PKULR30(8^/5'4ZF#?.B]7O4MBB-0U6.J\4
MX(U7K9J6A\UD4N+1N["%L6Q[<3\6+XJM9S"/]0R6@%WR+PS?=''&[UIGU^7[
M."SIL%G*U.$E$XHZFZFPB="!_50/S/9ONF @E^E])DH>DU?.?/ -CR[TI U<
MRTN.F&J$#Y:B65XH-B23::%,28V&8C.H5\Y!9Y=K!^HI?3G_%27L0[./?:7N
ML7EIX:.\X\@5]UA/]6,<\K$1Q'\?[C&Z.0F/*7'$87-S@K\\3R\8=*FYKODY
M5'AE,N/HRV#-2)I.XD;)8@_C1&>3<P!G,I[_WS-I!6">[=M$)44PD'&LMMHS
M1Q2#^YG)5/',[3=@W??62ADJLM3 ^R+6,]P9$_B%53-W_%X^RR\W4:NG6"]O
M(S!@#^5-/WG<43PQ8A FQJ^+LB?1U(-TN>?#)%6*\TQL=/H24!/6"_SY&L*P
MA6Y*:$+="P3#: :]2*FZET]E8V[U5!(HD0$>PK^#K*M0<#R8Y=\<'@ XD^$!
MW'9\/11L_2' RL.Y6A@OOQ&=/NB&YA85XL95W:M!B]ZGI"XV:N.I^*J&*<Q0
M&MTW +OS.&@U>U+-514XM1,A!O+I:]_MKA!JW$1MYB"CZ<LBE6=$B($]%^I
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M"? <*V4*>O'\Y?^#B7QA,SGZPOMB62TLJ8MO=TV^+;SQC?M=:TX 4'NV4*\
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MET:XOX;Y^W61Y?1>*1]V>XL?RZ4?#@*#[/WN9GX]C^'27\]8FJ&6(EU#_U*
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M)_)!XH*4_R--T-KG>&<G%*2I!O)XK=91XL:"CIM>V\>[QX5[P&?K-7TH9\^
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M('I\IQ=D.Y)?]SN*53'"OMW;JJ5T]T)!''UO9>$Z#-*]@GABU'5,C?W+-44
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MM;ACP "D)X*R76")E\_S4GA:1>PH Z-@D8*0RS.QVO(5_'X,AXJNLHX9/8=
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M75P0 2BEAU=V[HMB>S?T'5:1 %2E-!=8A"]Q6+,6WD 4H#Y6?^A8*!A!WZ.
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M+4:SK;>I7P?9^RQ>P_\ YO='$,%=/^-0H6'\5D/[:UX(3GV]D4;%^2X(9;E
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MD)-H+RQ"_R1K%2J3B2_7 S)\7.\LL9_MAR1.P<L*I3AFZW\4&0\,Z\6<,;Z
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M<!7$^6S%_)]P>A-ZE$."!PW6E%SO1$5KU]02\'L.X0^&9[L+PI1I\O0E2=6
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MT&D/#E7J+_B %3[@;A<Q-@712QP4:[JY(?;P+DFWP3S>P/] C[/T^6 QP'4
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MS@S,;4)Y'G<[-BGRXBB+13/ZP?0JAL?8?6^Q>%XX.#OL8;OLC1E!)BZ$ "^
M,D\JVM*,4N_O7TO($_"!XZI6T$N!2HL/>,F1W267*)M5OU<FG\H#"&&QR?<
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MY-6PK2(%[=3QP@!KY&:0(DRD]J9E];Z(\VH*Z715;TYF]G8GM[%<1H/[ M<
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ME!Z-K\$/)&V'852N[B'9I?! OF?",X6AKFU-M9D_R[@JT\.8OOX\+YRR/LG
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MVD:,9-FR;](DCY(B2CXJ3[\T&4:9J0/8P=@/%"J5,#1>*),U -MFB;S0RFG
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M!'UZDN4U]'QYA9Z-3K^N+X;I?Q%C=1-.@_"$;^$30/\?MWU*LX@7HZ=D:-N
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MU#*P_<M'^OF?(8C*F:'_:":%_O'M+)7>@FP+(Z)7[<V-V4SQ;E[EAR>8?L"
M#A&]C5$BVR:6.:F $"4?.$\X2QP5=#*ZF/O;AYN'!"NC0ZYMFMY6]<TN2S('
M'XAG)1\LXOA4?9%ZOWGMC<'Z-4VB!/$%Z-VI<F!N"$E,/CB5LP2=#&8*"@'\
M#J.<S.1PB'),#]B9@NBM55>VBC+B?;5)SA\$,*N(/.V@\#N88Y-;3G?$#H8.
M-/D;BU5FMC<=O5Y!N8$DTW\M*I$YGG_,JE^SGU@T9M18=BU]4^19'B0AN@!#
M5MGN9H,1P<E$"LV$G@*X@40S%9(W5G"O9'I:$4^.(<8U2!X21&*#^*EXCZ-M
M_5 P%B??WPZ? H'IN!.IP3;3>N%^(1'OU[.]>@$+UX[+B*K5"9!-ONY\J^OY
MV$A;0KTX4"+;*8\FK8'MED72VG ;&=93# ?%@KGHPT,UB]9 =#!:- R#3+#M
M:\-X[)9Z<Z3MNQV:+&%)]>-T":ROY_?_PA[J!SS2%O?VZ6K98_U 2>0<RV&'
MO **9TIN8\3BR7V@X2R//H&8[U$Z$+%=O\M%3S&@+_W$J7 O:*/-LM)[<3 E
MM$\TEP$=$3XVG3&A]HGKQ+!4=$02;]=+PHL\.S+,.-M9PT>(Q"F;Z%+S4B_5
M $I\Z6;C18X<F3LFZ]OC(V#,&\?C2A>?\&O@H:+X6'E14D;V+(W( +G87%32
M&CJ^KYP7Z:=DSQ==#Z,#(M=.DJS+XGPYNNP!C*N.8I@>?,2)>["8[J,Z*L!;
M?/LN#E//[*D##B</CHQ_;P76WWT].V(\=2#DY'&2\+2NL/J')Z>)+ZV,\^:N
M(/QU/6[2KN&U2FK9)H)!F E*G/RD5'WW">![N@BPV+[N-7!>::RXL WPI:_!
M4ZII8)TZR5QT(4Z.&O4RT?4ROE5_G9"?KLEGGR99&D<A/EK708S!>MD#@-AW
MXPE*+G:9E97DT7Q]TO-<N"F+NHU,!S6Y58WT&80 '#!PS/SV@A0!LOW-'R)W
MBS%..%K?$.4+BMA@J&:9U%20-*W7R/!DJUH$4G/NM[4MBXETG+VXK\EBI,<@
M"BL%*YKH)M\#V,&?L3"9GG8<-IE#9C24\HBH^PEGE,\1C/B4'#&1_ HXI7G9
M78PM9(/F%&"=ZB/.FEQ*E[NWK$R]S%@)OX_Q7.B,69]_MB0ET=<TV7*/.K.Y
MN</2$ OA[.EM#=,6+E$QF"DL"MZC&(EC0/*IY70P7F7Y*3@1_E>JNG*OL<G*
MV 2^/Z)\?U-D>7H L ;YQ%^*5%>3NP(+$+8.3/WHM_[$WB2)OI8\79*[)>AD
M$0F0OOK6[8#X;1#V,_O$M3"6>^?H'6PX3.)39#;-2F7&Q\(6HJ/H2(!DRYXV
MKX=!A4JZ_7.?QB& 6>DU+,J(SNY@4J1LZ:AXLC&MI0V9>KCR?+^9N??X7)@%
M1\,^)#?!,<J#N#5!UF,L[FA0L,D#7&OM+H )NI!9JY@1KL*VC=@BCK"C2<ZI
MG@NA\3@4 ((]2++H$^ B]P> ZS,AZ7VS>PU^L'FH0:-81,6DJ9<5#QUZ#Z27
M(.Q&65!C,:-:(YO $+R8,/__<&$F$/Z?_Y5#0I6J/Z(7"_S([V*B4/\__RL#
M'X<6:]$W9I[M?E&2_V<8'<ZVS*#1<C"2/CQR?5AZ=B2.67(T$G^]0&(7Q$V5
M-^FEAD1M_Q^'CM6E%]?*- =T?<.E33M6XQ$=,/%(D_\(.TM57$G<$0@J8XX.
M#,Z6(JNQV*.1X;9X!_]Q1D6 ACCT[1(OFQ&0(!!R5+%OF-.QZ,OWP8I%7V@=
M=:S]9]O6+FDAU('%WVS#0LJDJ .)_[(-B1G6_+]M6S/?G*D#@E]L@T!@"-6!
MP=]MPZ"QH.I8[C]L6R[;'JMC^;_:MGR&-5<+VV,ILZ=IM=9Q>3P#LQ8$K./U
M6-9I+:NWCKN3,V]KP<(^_D[.(JX%#.L8/Y$-70L*UO%^-..[EI5;Q_%)6/"U
M &$=+\BS^VM!P#IV4#OU^]DZ)I#K@* % NLX0Y[S@A8$K.,,J9X/6I9N(5O8
M]Y[0LF[[6$ ))PPM2%C'_\EX;FA!PCH><+"[AQ98K&,0:3X56E9N'4<H]BV1
MPZ&*R.Y&7-L:C_U$@N3W((^V:!7&0U0O-F@-SC8>0;L&9Z_!V1X6S[Q(*G-5
MY'M$_O\M7]:TU<.>93A;F;6<D$257%X72_SM!UX4R<Z6+$[RN@@Z6;48[J7A
M=+!J$>*K(^IER7(>(\20AR374?D#0/RL? @+I_OJ!^Z2F^?J!\X^!TOT U]]
MGW5H@MF\B!<.T5P^WP^W:):(X(4C-%_"\,(#6E8V\<0UFB_+>.$<S9.!O/",
M%LI/7CA,RXM=RS"-G/^(.$()L8%J)JK-J,8URA<[N]I25EO*:DNQVI;"K0#;
MFSZ]K0V:>NY!NFQG_L#0:W_R#PVUC[L'QWR>9"<3DC \R[@W@-_'V%)> 3H0
M,("G$E-9FX&PFS59B@3O&[6Q+;M1AZB754"O\AQ&[T6.G^/7M/3AD=L>B7%L
M3L#$OU?2_<W1.,E+9=$M(M2VE/UO"US@Y D@6:]4#9'?-D30R^I:3RPKZ?!Q
M;%MRN2D*ULP;R+9%D_WY"KZ37]A,D4Q?VY96;L/(M?4[V[8X@GWYY_L4O@#X
M&6U'[=_E&+8MM:V>'+U6UB!V+K;)9% *K=\#&/X&TVS4HMF#&7XG,7N,]N(U
M^('CF#''CV:.-P?_>AT@<HF?>/2^$YTD]RD=.)0Y1Y?@1/2/5?GRUW3:XD</
M9]NQ)Z3H[G",TQ,HV86G F[W:-XXA<T(LL8>R[:EEP>8.=]15YXSVMCEX_*[
M_U%KW,FZ2$'>MJ-! 7'=O/PUO<I?]^!+ /_$P35EV3P29U,7UL.EP[-RIKW5
MJ1G3FC6J79U)-<@_BZP,K$5SI>LW"/;O?4KS#)!<FD4YJ%[<\I0^@VWZ41J!
M>'Y]VC]K&RT@LRH5\-C[:;-K*>-?P+: O!SPT\94?&?Z:B,\MV82%3>6H+\D
M8(OW []:7P#\N)#^IXXVZ[I4K6B>M7"?D/:)81Z]T</H6,G=#_3,)1\T&4=Z
M6\8---MJAMZ;D2/-<\X(HF_'-+G:;D&,\Y: \'<DJZ &F]WSRYO$TB8-.N=M
M4KW,(:.:+,+4W'TB>A*M=/7^@/ GI@E1U,_8DA!3UL2.,Z;?;6.V\LVX(@=C
M*QNLL136NHVOL13L<[#$6 J)(\'U*6"X4"]P]WG.(6T4&' Y@H14885)4/A;
M7X$.F\TH.)=.9L:P(FFR*/ -LAD&=R/MK(LO$[M5.1YD)GT?6/Y8CJ]_U#&0
M\>=R//Q.GD[*^WTY#HGDF^EI&.((3S,O(A+'N*-Y$:4HZ;+F1<"BK(^;%W&+
M WWBO*C^,M1YSH^R,&.][/PH(S/.#<^/ C/C/?7\*$$STI'/CYHTHUW]EEVE
M1I''X+*+V$QV.?2CTHU^ET0_"N5,]$1<=BV=R:Z,RZZ[,\$C<MG5>,:[5RZ[
M1L\49\UEE_"9Y/BY["H_JGQ(EUT!2)D/JA_E@21\4_TH"-3S:/6C%I#*BE >
M);U;JPFM&?!T9<!C156@!PQDUV/3VXT;P_PI<3?%G91>IF%3>.&R2H9<PQ1<
M\CKEARF,I A68[*&*KCKC&J-(DX-\5T>OWL39/O[./V>K<SJRJRNS*I:X)'(
M#$&0@5M0_N]#LCEBU5*4?%2DIBD]3]V0 0-8M$BT"4=$3V^KK;C[@0V+ (G-
M1*EPE66 R<B.',P<'2B.QY*_#>*:E#XDNQ0>B"%5L+VRO0U6G4NW (39/7II
M2_W/:_#C&>R*)&3M(+>+>7J]$+$1V^*3;12#CG+R-<6G".W 9X38A^O3&^*X
M6B3C:IM'GV5Y;_ZYU/(I8\#=@B,$VZB\4DEX=4C16_%O7M(X7@]SKSC"&_\?
MUC=^!G'I>5>[9^(?T$R[?VBU%&RXFK$-YKEN3^TK.JX%Y&2$9C8WF31#S<T=
M,9#)QV47Y9PT(:T&MNW,?90@L5#!SO &LN/9KR1@[-]T]KB3>?NI_6QX/>]3
M^!5\O]INL3D36X ADIH+--6#H/+%L#',)<Y'8V]V5V&IFN FC*<V-9G^OH+S
M!<?]!3#,WHY88_'S7W_ZY:\_BU+?2_1U=4_,UR9AD*\')'EG*EXHWD#&<Q&_
MIE=;Q.] @&:-7M+\A'W1<\0382[H>&!S&@,&,,I78L$3\T'H/YN-2$+*XW0;
M95B36T @P5).&M8@($2S0C0-8907Q*V,L(CA=9%_3?/_ 3G6%S,7+MG=(HT-
MT:4TC/! %0V]M\GEE5J',G"+O8Q.*[-9Z*I;4FFW&%.FM713'-4AAMK%+C]@
MVTX0/Q7O<;2M8U$&L,WT_@X\_Y.??8-JA.ACGV]V:&:$A&W>RVPM#TGM<(RX
M_K,D_8AIWV,4O$<QNU#;E!$M>AXJYAH1RA/'W"7N9[::QJ!Z&185A&B3AR&U
ME\3]]%4!J"D6L9NC@Q$7(3[VZ$#  H3U(<=,?EXZ8-\E_64H&=*B2W23)H2Q
MQ9[D-T66(^X#BNC'T%&,+?<W1->PHFZ3($[^F&;$L0%)L8059&4Q%G2R[;&C
M*%$G:V$MHBJ\4BJ,QFXRGR5UN+Q:F**@S:F?YN<@!W>(YN@QF@R?A&)BW2@S
M7]/?TC3\'C5NEFT*3&VG>"X<-X<.4\0HKS"DNSD*66'W<#@&$21N3&S+!Z.Q
MZDH=6/@E&3M '*+#BN7@<S(/1,,((_0"\KST4=CLRE 'D@6&NA'3!E2\NA[O
MG57AZ_^^X)=$K2WB(2C,3N4(TYQXYEU1-JSBC6JS $&\V9$[2U5!"9L;UQ1O
M=K?@/9=QV>?U,%MT">W]'P&$ 9H<(YST(AZJ;L_TIIDXK.JWK^70(=XQJ2ZV
M,:L4'?MDP[1)%Y[WO(E'/8>@/B2(NRKP-2IC4UF"AG3WM1",NB7=(\Z%7.M:
MHJM,8"QU!;N]XMM?,U=?T,-10,*)E$2H9=^GD0"I?JHYX[,7A82[\R:I53N;
M74TZ,3?VF ;)U0<$@&*IU/45Q3B<0_'O AB?SAJLMEJ+MC"9;HIGVH C@>4K
M0F^[%\DW4X=47N /'M#C4+Z$PV?4UW6I&5-YG$(CI+P^W]YS)\]NO(96NA1!
MYE]HI1B3X2$L[0,R-C;$<= &1H5TDJIR(RZLQF6-TY4X&CJC.-K0<8,>',=0
M:21$MSX+*X[ <<3&QQ?T:-/987^9@$BX]3.)-=U/WF:<%*85&.A>;S,J*O.&
M#;YTC@/#<W/O%3R2\?2W&@TI=F=4V$FG:A8544> X974U(*,&Q4VQ[]/$N$6
MM H-,O$+C@.F*HJA(WY(!P(X7L=1M9#/""=P'*4)4OU%2(+C4,PEQ5)C(QS'
M3IOT.C$BPW%8U8BX>@[V,J%5("PSHF1LQLO=7'S6U'Z8PN0Z#HP:OGY(-);C
M@.G@ZR?%>3E>JULUJW\1&N8X/G-QMG.61IP1/C5<V)!#NDS )O!6,];#GA&G
M21P%%TW'@5'Y0*J)XM0!Z(Q5J%2_D(*X3\?1FNN]% 68.@ZCFG=S2.#J,@&;
M^FYJ+#)L32$]4T&TCH.J_*&E1^#J0&G&0H7C7L_A4<".PS3;L\F(.G8<OFG4
M7T7PL^, *B=FO&AK'5C-6%54@\IL4!"WX_#I)G7B&'+' 53$ZO(BU!U'2(>1
M8'HHO Y09ZP2/,N]%4;B.PZBFKL[),;?<<!F$%WUJGYGQ$H'V9//M* #/.MJ
M?TO[_#F.AA;W63,%Y*TKI3X=6\=ATG&X.-E%=*#UJYMH#<AWHL5/R-$  &VI
M5[2 [*@WEGQ>%RVHN6RBGYQC1@NB+MMBIN>TT0*IRQIA3@H=Y\IH-\O=P(\@
MJ106")JO 0X+V^RNBPRQ@%G65!1O20FW( ^BV&"%;712PR(&M0WC"\CWV':+
M=YB\_A?L:S]_H_P YE)7BN;(K=0MU]E<933,47Q4\;#HU*$#UOP%TZ(,W4#\
M6/)KI T<175.K2 &V9D9XM3WIK4S6.'Y/0/_*M!,[CXQ3.A3O+K!C-8V39];
M I[=WOTEF*^B5\6L-[>.<Y3H;?TB0>9WK'()> I@?N*>.DI#U5F+\\,33#]@
M<&#3SHLV5@#7WMCK4_L7SOD?,( 5BQQX.C0=[0SFK8FC?S631O_X]HSO&O7X
M]'^==5I?@A_1H:"?Z\O?YT>,<DR[O]FYB>;))WZ+HS *X ES=91T?Y2WF][>
MW!*:B7P-#N@_6\2(SX>(.RYQ4>8/W3,H SKO IA$R4=VM=T6AX(0X%NPB[81
MJZ*/1$?E57BP"N)U#V!P!$4>;7&8#>=YYS2WA3_G\G_TMO.^-5'"?VLZOYLM
MQ7'I=$3<4K.OX#OYB5MP0]S97&6;IPWWF#2_FRT967E]/4%T[1"$Y&\LR)GM
M%9.,MR0$\#N,L'(6ZR5)^#62I7#<7I1A<WOC3UK%[U6I<ZC)Y:<,9T7QNH56
MW)7(+2J]M&X_*YB. M]N](_6K7E(6KR$!/LA',*&A4J1#E9S/0I8G'"F<[EY
MY$'81U\-V:]I_I+&HK*P=2OEC%EMR)&;$;>]AGVLSCUKR^J?5:/R\0'!!^*'
MOX*\(C14,"C-=+V".4BX)%_46@F1R,#V+Q_IYW^&("KI _J/ABR@?WR[2_(H
M/V'7:7A,86D61 !M=IT_]>8^H*/J*C;DJ^6'O@#X01='**V,T5RZX6[S/0$P
MVT='1%.WV(OS@T6$Y?N;%0GVB*"@*973?0;8PQ*0'UZ.,5.PE>FIO [2.0(X
M2JF'I]/ 8.6U,[DN.8E-D6<X*36;>^1VL:DF,GJG7_8IS+%W2\N8S5J6_ "*
MSTKIZ?6:/A40G8FLRZ]>Y5V*35@DVH$:,8KQ>J'W*7P&1]J$6>R]N*-9^M3,
MJC)$=?GTJP(16(CC0E_3:] T9E4%G#:FN_6W!KOL=*(6)'UA',_Y/=(DW7BH
M41U2K 9%KL82WV6E&]_"]*UP! =>C0$50#A24D#J8'#=3SIID(?>+$>PX1T6
M7> X<H#$Y);M[-"$\UZXJ%B]9JE+,]R1I5M2[!(T1S#A71;5H#A_21A^&7C5
M% <7JQ?)O154EYAZE1T '%DC[93++M*-4RN?L7Z0"WV?>V*X^=B,C#P[S?5A
MZB AX5CC""0BSEHA)FY<))F(\$ERNXSCDNL 23N>M?(D<GRD7(=#%-O D5%U
M0C!#3+&(8^JZ:=F\2(T/;(\3L1D%[=11UB/.=9 &44B*1YW-">UGXD6I2C^;
M<=%_>=CNC#;G99[AO Q19=@,E;8C--WKU.9DN3.<,(9FV694M-,CP]4 9TQ.
MJAZGGI^ XUD,)[YK@WR*'<_2IPRJ&3B .=/PC7_6Q"[1CF>3FX -S?'9]2QQ
M$^#@>X2[GMEMXATZNZ.[GJMMR@&A.<>[GFE-A<A <=%W/5O:.%B&! )H0<AZ
MMI<9?* %#F>XW '!#5J <H?'E0F1T *1&_QN+RI#"Q+6<[=RH1]:U,76L[IC
MHDFT(.4&[SLF<D4+7-:SR$,B7[0@9#W3K"B,QN'DNB_%X1# $UID])%$NV@;
M)/G5EM@:\/5)T5W"E7(TY-AE15I+3>AB-SO1V .'4!TK+O5Y6F[<P=W-99,Y
M%[?$4A1ZP#]PPNZR+,1#4AUB$$>?($3\3UF@MBFXVEFTDB'- 4$J<S552?!'
M,%EDYUOC];!M&=R\9/P^RUF*#=G5,H#>0EQBZQ;)5G%ZQ+.L%.;<K$XR/163
MO_K5O"FR'(%*S6)PT49U2I-JW*P1TS>[US0/8BR;)@65\(H[&3L -5Z(ZT#2
M ";]+V7X*XO(<#JHSD]2EE:E'S0:S/P.SH4/3V%:&GW^$);!4?_;J4"I83VL
M!D\J-D*"X^@50^8]AX[@P0N,4 G(8J(BI+B@KD^>!(]A,RA"K[*QPIG$X7':
M55S)"W;)]3GJ^ZL$#0G^TU&_5E6O.(^C==1+4\G)$;#3#FL:ZWI=-^GAO:K[
M9F7IKG-=,5S=-*L!XA;KXG:QH#P797[9]:GU+[E"79+#&%LP97X</1RKM>%T
MBNAZ'-,$77:NPHK>UH:,?EQUU&4[*^K(R%9BX/=1K%@A'RB/I;B &[NQP=1T
M%9/<.ZL9KQ8)MX]M9V5X)24KES'^R)O7C%\Z'WU-\Y;G45E-%LN"Q/WF)^:Y
M&SB,56]<68:=7Z%/W$\Q^4(<[.OF&;&(;*+5;[(\4,U?$ K7_9*#8VO&Y7E_
M2'( 098_G%<@3-^L9&B+*(?%F9V[GBCH?POX&7TB@;);M9UM:.-W5)XH'GO=
M$"$VA]$VKPIXOR%IDY/J>5#7M4:0_'90[ND33#^CK"]Y5\&@C;J":#N/,<C!
M5?C/HG2D>JT-+DG86%^RTOQ"V]$9OV[L4 @\6\Q[J;0\ $OO_HJMNTDSI@F9
MW\>F!ZWUXDBL:\  1A/+LT1H_)/9$EWOV.L1RV8 B0.EXO4<9W]]:II4)^CJ
M>P!Q=&=4QMF4-(]%(96-;PRB2H-[G29%!K*; D(\1Y*T=EO^@[%VB8Z*7X;'
MXG!\*0YMJ"M,:92<TUJU3\D!/P%H<*Q/?#NFR4V<HDO[P2N,(NQC[$ \@H\@
MO@=,KJ#Y77E!)?3,IO#T A#3MT7/9)(4Y$M4_)B-E9>;2G(8;/,"1_62AQZ=
MH-^#N #/T<>>>O)$79QS&AIB:Z!7&9!5Z3MML9]JR6A#QS0.V(R0A*,'UVK
M"+URP9UC8'9T<4Y+CC[=:ASD$N;**-LOPULOCHW[2$CHZB52D3F&QXB\\:,
M68Q[W."'=["=87D T57B9_IZH?"W&@$I6B)P*!"Q%SV\',&#1TM4 J*7EAA,
M-#R>1Q6\XC;CI('FJC%=V>R&.NOAXO(!-J,TRW,^4\Z2&2/B93$98F!TU#-W
M%"325DS'DZ6.NCN&<L+/F#UJT%F9T\3J>$+5H<=-;^C>C"FDABY<8+-U/$FJ
M F:0:?9U/6/J4&Q*:['KZ5 'OT/J3-&N9U ="IV,B=KU+*J#WF^>(=SUO*F#
M@!!;WEU/DCKTKK2L]ZXG1!UV$MC. Z[G.QV$@]!=85DAF8VFJ8QDC?X-LJ=S
M6KP(5PPI*<$:IKF&:7H<IEG7.J%<H?L@@H1 -!>-L;910UFU;VOHD7IWYN:9
M0?^51>AY#$I2%;Q',3HO IB'C&39LILI$@/%#B!9)&3%[ T:8O409+XF-INE
M5P]! Q+/N =N>2"M_B[V^;M8K(\<]9)[9G<?]NPO5;*^R_+H@.T51#_= 8!D
MY4<]2J5VD)Q6,7L5L[T4LRD3ZKI[5>5&-Y#4:$50TXJ1RJ]VS. V@;.*XAI
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MANL1?P0_]VQH>3UL6P;WUO+[&%O*)M\#B$AA>B2ZA>2CG&?%P7$]KZ6Z*KX
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M1"_>0$)B$?30Q/;WW:'%3#ZCA^KY!;7B*\NCO,A!MMG]-PCB?,^9H:B//QF
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MD^.E'Q+U,I=XJ7C/P+\*-)&[3SP;?K QJ[5-T^?&O;+;SQK?>(,+SP)XQ.K
MK\&!E4J#VFS>1!_@6)W8IMA*;U)4O(?U7=Z2S&?2> 2$S)3/*'H9,?7A7@U.
M!\5Q*%] $J=/ ?R3?%(B?)K?8<T5-%? ]!)S!>$G8+.["DLVD H@MZFQB5]M
MMYCT(";P)0^2,(!A]G8,@QS\_->??OGKS]R5R/6UY57G+H7>UBJRRV&HF,VM
M6L#(=\/\(]@4@<R0 /D5?&\./A*M$_2?VRI;+'N+AHVA^*G\ V3Y,87Y9K=#
M B-Y N,M^Z'D-=>>)8,<A,U[''T$K)A7<2?EJ63"[VD:WB")7Y;9$'598 Y
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M>H7>+*U^.D0?-8WJ65IU=""W*"."EA;X',0=FN"CI=4V!W*%-(!I\>N41Q+
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MT5<S:,%*>QZ)/VCG&[J2P\%/6?,6"18RZ+$+^?H)BQ!MPNJ#)$X*(2]B%/6
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MPP2?@5_7CWD<>8D\B"=B(,\FD3QXC,3D?>'9]N/.(T_X]$*/GIN,SH9><C"
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M16D:M;(FH*1\#S1*BP^*LW2L;L8'FXU"+6@?<P_)+#%+PR!GU"/#.LZK4C5
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M=;(ILL 2W <L'I7%SXR<OA(GVJ3FI)S5GH):SS<=A804A9)YQJV5N"@:12V
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M2L/CK;BJBO*WX*TI+>>-)P(U4'W,-G?,_-=SS*Z(J&P++M0/SI_)GQ@9C3'
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MEX#4?=M7$E/QQOX>=<-Q,!/'0_3>QUKD3T^8@MN;Y*M'9))+KG<QPC >$5H
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MJ.IBO#5MZ)R0RKE3-/6$7Y^*_K6 D^K]?1B4QAN.2G5KYED![QB/<3E 7*<
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M-B2OL8DB+;GMHNBI*03T@C#^>M$(&L$5E<#?D$S?0(5$M2ZC)G+&FN:C UO
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MTO;[$B-/;7P(\OC1=^&4%/U<2='_^&I>+W?_^7_^XZMUMRG_\_\#4$L#!!0
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M#?W\-C2;ZKF,D.BB8"K15&;YPFS.229E@-9EXN$/V&W>Y*6T]@!=2!V1[+E
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MG!3I8M];PD&& R(-8!A)QUI9@!Y]57MBH!XX]: '"H[01(:Y0P:$'9M0I,O
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M0/<QKX>O$IA<7H:*-+-3$D#GDL-<BTN.G7=5;_]U^.)"@9??+I4^E6FGWY+
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MH>0#08\UXHH/+CD^$VY&TP2]TOK)2!3=!]G H!U$%8;:K-0@R4?9.$?"PQA
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M%QW1(V@!$B?"0&L3E*/&28A%25M:2<^QI+5?L?9X&A5]#7WVS7>9&<\2:5Y
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M9ZO3Z;QYI@E0=S[Q4RHRMNG=?<##5^_;6Y-!FQNMH++=:MU6^#RSF65\",S
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MA!C(N8=_'=7/(-RH Q1Z*#&80%NLSJ7@SAL:6RDD-Y(<D"'W\&&1(DV5I7S
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M^-AZ8CK<IO\V\/ZGPVW_?PK^!U!+ P04    " #;@7-8R--$H<P(  #</P
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M,OIV,0(LOVQ4?(G.I5K\0R^7%;B>9FX)ZFXGMVZ67BU=L?_Y6M+N6//^L#-
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M,O7G,(K50YVOT6SEK3MX^_NY[DEJ/AL]^LBO@"9<,33ONO'C82/DCI+1^9P
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M%[A/4Q'(W04,S4Z*ZU)F6\F/L]()F@<PT[9 =.,/"=QNK*N)7 31FA2_ 'V
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MXK_6U['.75'O+8 !1-G$CT)A %+.OPHH&Y=I!T6K/GKK!RQC/?+\C0"CW,A
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M\S9<N@H,826YH->68N_,FHB)>\7>+7T_"0C9FIWH/5-M)O2N2W^1-F)EU*]
M7H)SF(&9Y;SCK:[";_Q1:Z*9"6R=11/J8_)\>6F7C82([S8CWPLCMJEBQ9[\
M[/PHB\N?U99K]]A:8)K#;5_/L=-(V8J%-KSRC"JE#%E5^AQLQ*UT NH+M[_
M\M&I")J <I58@<+F.$65;H+KD(7NS!C83T;#>.V!.Y,[IWHO1S*](:;&W)_>
M-P>>!JG20C\]G,]CAQ(%EXMPNZ\)$"F=M(77*H'DWMGYB$0_C_Z.)RT+U^LB
MN!_QZ^(!X<Z;4>/.1&NR.9_!(]-U(V74<F5#VS\%!D#;OOPB#H4!CJ,?@AF&
M[QBRM]91R#R=9RE\=-0T^(^,X$4@J]K97J4V?$O4;2>$32(GHS1^:4H38P((
M""YQ"OM9+1+EZF4&JU>AY2(,J^:3')M!"MVC]#O$21V]0A\#%/>L"X\83.70
MUOQDCV2O$U<_0T_=)CG4E?2^G<E'^F//L&18L0J>$PQ<V_4*@=LB'-S]5 X]
M)WCM[!I^Y29KSU$E=!\7% Q^<HZI7;B7/LZ<C:PA9BNE#\68]PE)8[*P?/L*
M5:20SGU4I;/R7NMX:5W[V/CS=YO$^2ZO?$95+FT+.?6OB3D,K$X!0A-X8<RJ
M8_IIRYCI;],[""&-F0M7_/PQ9X=94IN:&8PD.Z_@^EI<_'&O8T$V:<8E=FM8
M+NL'RX[9@\]9J^(I 6^)$0+C@,/>,2GOTRP3K=Y1\AE(Q45Y,R+<ZHBOC&(N
M77O*3)66;4*\V,LMZZ4Q\.#K 0AQ@FL%:1RIE4G^^,M&>V+P-0VMC5E['LEO
M+;*D?DFXQJCRQN89[&4_*[\P4MSN)LU/+=!?; &!RM+%$_P-+3)6M@4I?+9S
MRK+;C2F:CB&?#LY+=JD3@(L_:S 55[_&#P >DQ)$V-8<L?=FSZX5K][88=PH
M=]=Y)PR$?Q<8D,K(N%L'8+?8++HJMBNO^!FHD[9"5C.U?RT-?Z]Y3U9G*!)?
M==(V_;%/5$7%5ICEKN]ZNO G[\+6,$\\S7PJ3G)YJ_A7=N<L5;&+@E4<#.4<
MC/T#V7/CO=O$4H@K\\%;B57- #?SLU[@BEMIID:7,7-8WZP8W=C+\?"L87M%
MDYIFS"(&5%%-3Q"P05Q"&+KJBQ'@Y;F632+MZBDR;K#\*>1E7%5W@S_^\_85
M)Q;06 #D<8#AGDY\+MOF3-SS(7OKPUS@;(#@2(#B^H$O[[H]3K?0P64T1]@2
MELK.:&3OUZJH#+\QP-W2!:?BL"%V6W>:5F]MSL*<WO*"KE'58>@:FCY7C)!Y
M^4M5*5&<,I81M^& ;DK^IHE[ >,KY6R5H?V49_WO7=XFH1)3@J.R7?L6R]].
MM-6T5;]X_'G','_LNUQY>-J88;\X^L;]**WS>#:TG,<1_SI=HSX9.5@SC8E:
M]V?RVZ:S)FJXJS IFUX%^NQ^[!Q, #+P0K#4A-C.!>C9J9]<@H>2C-KF099_
M^4(SVU2>%Z+)"Z:?-QHO.V]J69+Y84%<M.F'>H6"<ERZ;E<2M9+2N41-22AT
M!AS2?9R_$Y^'1PN;\S3S'V4A[A4X/XJ9G@9Z:J;WM"+6M5KRS1+5_8@ZX32*
M'234F')!HTP:A@$ZN==A@%\FUW(!=>>QOX:SK>X\DQB@S5E?YZ]<8X2VET5F
M'7-W^:"$T38@J,,I6QXJ*)9M3[5!4#S:C@_<FBL7R_#9_<"DG93OLUF AXBD
MZ*]C!>8?G?:5\!N$*()=#/[3)?G -!B@>_81KKJNM3XZC:%^"M/U%=>-"<=H
M3,[7^>!9=P>@S^KYK7BWJ&HWWC""GN)$RW?&X4;^N*#NH%<"B$ZJQ-^//;OF
M[KG7*72TDZWI:E.-A>FTWX_GB:VA4L.-8:/MV2Y\LW+<6YL*7EN\K+2Q^=:7
M:[0PO[A@@AHG^4*5,_Q&\Y)68.5$+W)=[UYZ31Q1U<Y5M")+8:VM)D96ZPR?
M72M%),:%^^>LQ=HRMK'=["-EUHP\KMN!K'##IU))<W4TC(\NP*.(KJ9K1^9[
MY9H3L4RV9H\LQTQWA&2LK6?27!]1!5<RXD=LI-YN*AP57N!$ZD?=>F3G5MEZ
MIOGB[:&G<.LK]J^Q4BQ[EJ&(XDR47$N==1$9OZPSXNBCI)UF3S)*GCCUTF<@
MDQ<._MWO[B$Y L^ZO O"<R;2%9*'V5DYM'?\P%]?0 6H&!G*1)F-N!^?'QTP
M!M0&K)+>80?X79J(#_>*AWE2.,\DV"5T3 U<Q[Y<WVLEG#RH9=DG/G*,XA;-
MV&)@]KBB,KXIAKS=,T8Z,0ZJV(=F%1380N G@+Q,]UNRXN[Q%9Q7#92+=_;
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M#X_-$S\"F)T3!PY5 <Y&JD'-'#  :FQ8RAM^J=T?8)9^VI]</U<PLY"9IFS
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M#-_+K0[4#(750Z0N'5Q0J?8>8B$MWJGN;N4J1JHH@IV#VF"DNJCMPMPO\-T
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M$G@ZRA'IFJ4WCGPJD/=$^ GE(SY& +PGXG--X-@=I!4D?1(\NAI=!-\)=E)
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M_S#\,\-78@GDV-_9VF-%,O>M'@=V,%;F<G^'%DG]RP#P(5#_\>2Z%74KK'+
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M7"KB YCLJ]AH^C[9[R!AAY\>ZY64A+%+#)I6Q(]Z%889/%!Z-Q<"GZ X)BZ
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MPA9GL"/[5%$G1(N7]W,ZE<0MII7!M_2Q+U5VEWI%$DT_-;<JY.E"BYJ6GHJ
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MZ+I62)$9X(0&!$:Y233K:1W8>QCUH*P'\SYTK?.:\^!L]*$!5WD&>P6UL*=
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MO;%5R<IC*+L:([RB+DT$GF#M0EGVDV]:*8/L=6DGY!SR/X-=D8S)MIE?==
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M8]MYPH,'#+WA<O(Z4R8;E:9&\XP$E/EY@BO44P]( [Z-&H[]ZS:JU(TQ*^.
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M3O6#*9IQ:Z,^<PJA<AUE+B!CEO$VZ#5_Y6B[X -JPNR"^D^)=ZR(G34&5=S
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M5K^77.# X0Q3@4.Z]\-F/UCN;KA79E2IZ>@)I%Z3HOE Q^W)3KKZT%F]YO&
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MB]]?OQR<=(#LQP N689@ (*&V'F$'VPE'UVJ>9@T!=IC 6ZS5S1@ &]XQ#&
MQ(?@Z4:)D]M5/"=;46@TQ71J6/XPVN0@#*$&7M"U\<$Z<3QS0G_F) SU!&IU
M.'O6EEHQ6G7(2>\F8<Y+#"#"HX7PY/88SPGRS 5PE@#;A#?8)@SO$7D8PW:
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M_#V+^WU_\Q+_,PRN'$AE3-\;+RSIP)5=N"'L7_9<^VKCV^,WCPX/WD4<WM3
M 'XRZ(C3S3N8^J/$%5/D++<#K?H,%;]\(@LE9YT7Z5=X=PZEA/Y/1550IFDT
M5.3O)@DHV7<5_Q.#G0+P/Z?^$^"^18\@!E B$W:X6E:?((L!7-H(P  >NQ&>
M7)1'_C B905>W8M2,>0 &X^;M!W3JV, B6ZJAR^F_Q.7Q)^VEKIK^%WC_I4H
M?W(]&1'_OY=/%9+_9@)62":%3!J^5B=[^''&)V(X(QNRG@Q]K5?NQZNOM2X)
M9PK>Z7L!_5N[*/YS_/T#,_J_ %!+ P04    " #;@7-8<?.,F< I 0!-30$
M$@   &EM9S$P-#@S,3DS,%\Q+FIP9^R\=5"<W[8MV@2"!0GNDN#NKH'@ 0($
MMR0XC3N--!(@P25 0G -#L'=W;6A<0L.W6@':2[[U)5][CO[['U>W7JOZM9O
M=8T_NKZOU]=CKC7'''-U53\L/*P#GJLJJB@"4)X  "B/+\##$D >@(F.CH'^
M%!,# P,+"Q,;AQ@7Y]DS' I"(GQB&DHZ6AI*:FIZ1FX6^I><#-34K")LG+Q\
M@H*"="QB4J+\DMP"@OQ_FP0%"PL+YQD..2XN.?\+ZA?\_^7QT D@P'SR$2T#
M%>4EX D!"BH!RD,O@.[Q>SY%^;<!^.\#Y0DJVE-T#$PL[&>/-]0]!SQ!045]
M@H;Z]"D:VN/5@,?K #2"IX0O^%ZA$VE]P'CI2LP?G)"#R2!7W46B/05C%/CH
M%H*%34I&3D')Q,S"RL8N*"0L(BHF+O]:05%)6455YYVNGKZ!H9&%I96UC:V=
MO;N'IY>WCR\H]%-8>,3G+Y&)25^34U*_?4_+S<LO*"SZ65SRJZ:VKKZAL:FY
MNZ>WKW]@<&AX>F9V;AZRL C=V-S:WOF]N[=_ #\[O[B\ND;\N?D;+Q0 *LK_
M&/\A+X)'7D_0T%#1,/[&"^6)]]]N($![^H(/G?"5%L8'5Z*7_,&8Q'().=5=
M6 P"VC"2CVY3V*2,@AM,\+]1^S=F_QJQD/]7S/XGL?_%"PK 045Y7#Q4 H ,
MX S*FML6RIL;R0KX"W_A_R!0IUHM-@+H5!'.&^5&PQ/#[:T&8[WMP/J[@4:8
M"FJ6+,<X$!)(_P 8HH-YW\8_ /:2S!0,M1T'WGY0\,P$3 O2Z)O$(V*1J]!N
MS.NO*6#6T96OM*('&G@@_3>!+Q'"'#TX9H"9U5YAM(J$/P4!+F_/CUO@16RU
M1\G= RE39E%P\QY*C2_N!?;B@LS/'#58DH:&NA-JMU%G7@S0B%;,]%8C-+O-
M**?J?L3A+*R:#CU1('["^-IMF"(#J9-N48Q1V6[GIVLYO>PE21EY:8YO1\D2
M=Z?F6SZ6WY-O*^[XJ_8*EE%R&J*A&CR (=K5:6ZD")\(JN3YH9'5I5>UK^%?
M[4O(/IIWNZ"[\H=/QNRKGY(?(P>MO@(HKN\8X\UD>:N(8P&TB_R,43%%=,XL
M()>78A#553+]-JW-L\C'8B,PRKJY/0&OH7*5Y=O46"BU1>/V<X 81;\*1O8>
M>W'^]#*G[U.2(W$3:2)$CIUW$73/Q=9HF8#B/=#E">\@]3& U@6307*;MFY;
M0)ZI]>P5/W&*,.L!* 0/LR3Z3^UB6+A^B9T9)JPCHE7 I@(!_>UV7=K\C+6!
M!\W2QGE4@U>3'F>KW-?43]O$QWDS->RB]-F]H<>84Y=D+9XLCC(@'@LE&(J'
M,CBP*V2L=SQK.S&S@5#?!'Z:<2R[I&$^\,+"21Q<KMY#X3X\'G,)Y(6U#7R2
ME.=.E0S1A3*&O^7[K>@>&CM '_>SHD$'P;%IC#-6I D,+ W7Y+IKPI\4H4-<
MN@6RSODKE=D?XG].L^-9OY_NAY4Y-$D)_Z2QTZF[7S1%Y66MM)QU:&6!M:C4
MA+Z=RIF_7/K6,UBSD:#D/DB/LXV#D^YN"$F5QH!G?:JLL*BIAITTV!;D?C'5
MLCYY5/#%?G$K%=K6.KV;I5<&9\,<4ZUL=*&",A@=GX4*ZN?J]./+Q.V^6J$K
M4R6MH26^ A $9[:L4L#I0N]L2@M#O=>CGI$VX[Q,6=07PS;8+BFFQLN>/! *
M$'QE,7&'4F (#!2=\3A6I!.?MG9E](O<Q>QUPY22+?0Y?%,SU0HLWK]Z_D>X
M2IE4])H4*APZFPA*V[_CR*N,0(J]*F!(C5W]K:LHI?KM6T4 3-&N_07LHIT-
M,0?.[T4:I+A8)E$LA/"JW$70;FOO7I\&<$I'I$^9-93YI'9)XW<$$&G  C)+
M'+%B_7[\RD^ED>4LTQ3#R$9[CZ/+0^+C]PIR1^IOM1&E8_DB::3M%PWQ-DZ0
M*)J5)CD:-<RNI,74D,_@G/(B[E,FV92_NG=)19W-U=>&2.&XZXH?;L8R'M$7
ME2*5I@BR!P"=^ /@WF_@#AHY]E,XV,EMC:B5QW$#3()9BX@&!8QR"#YKK#(;
M%2%4V;9!HG&D30DV"96[#;R)DC@I-#A#]PKQE0D:NN.8EE1_ )"8=V70F=!)
MK28^ *P;/[IYP2*D=Z\=)\IM_!EJ(M>TYR35O9KJIHYI95WO'/ U$9C.H]K1
MT,+39IHZX79V!$M/(!6LH/PD[L.VB=1!][3OF;2^Y:=H 8(YI1TS&;.>K98A
M3_R0M*='VQ05/+V_"&;<L;[<JUO9RL#"?"RZJH#B7X73?M>XN'"V[GQX+D;/
MGYF.IX*1%*RCH<$+T7?QR[11\-,,JP-C()!(=;S#KGHCCPDJ23=H&-I6Y6A)
M/MTHY>\[E!Q#ECZ_#,JK5:HE/^NF",=>^X,E+$"\HD"?>=WJX0>#\Q(.B.>*
M=U?@,XA3;8LY%O2@AG/TFG_Y&!H](/&<Y#T @QQ@0?-'2&U3,3B[(\PCCG1/
M+V188M=@NT$K[,_7A,YU@JK06%SL<FCS8\H'D.ROLDS7'H)#,FDZPKOG)8:<
MM"P;E=\I;SFTDJ*R9-^%6=ZQ5-7,MGH_;;O,)WM+SLC,MH67']S5M9E5:U)A
M&C(@LM'&<.O7FQ:88I*[//IS'%VUTDT&!^*W90R.R*0&WF,O*;0%F)'+%4#2
M=T@5W[X2<\%_&WC"OA8JI"ZCBB@MWNN1KTG8G;,Q]LLHH9Q[UX$I#./E"U(0
MV?1J*S)#1-[V@!=  75+FMCU5;?R07+IU4OI !??/0X1%O8O'G3R0[:5QG-"
M$R@^/$<W7LG9!C[AFIR2#>[*B6PLL?DBDI9! (KB4TY)OJW*"%!F2^&>J^U-
M>!K%]_< -B@JP5D0.<%RT*M[9^@E4+9ZJU8_]TX4EI( +K0W8X:3FJO.G*')
M9F4$X;C'*@,J,-S 4FITU#Y4NG-$ZFTPO2RKHM%5@Q84U$(?G%Y6=BEE)ZD]
M3R$[C@4]R>ON&P(XSQ>'6E?1T&/.5U\KCK/9+ 8"OV:R3.=.WJG_M'-1/E,
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M7."I'L,+9980EUX2*5"<70G4Z E'ESO,3RM]\=$S'(@';M4YY2=<[18&WEI
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M2NFWV@7<4(Z$;NZWS.36P7G"CX3JHT[4V#!!GO2E.+?1>LZ1TLQFA\UR>]#
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MV[3L.T4/7J]WA;]/OP*5#6R\@WJK#&C+2'%E];'HO.1\Z1#)A0X]6;PPI>B
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M_04/^:QQLPV7#N_0YE,6CC1X,[ZY/53Z"<8XN>9%Q@\YB@X()?5Z0_#Q*\-
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M_JR:-1\$R6%$/$J4ZNI"JI-U-BH&U,P#YN_OTT=R-*>9\JR*6SQB6LKZ,:C
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MJOQI]U,-R,!=1^OOP1@QKLB(*#M;>ZV7UU6833:S;=.YXY#A&ABIP*Z)47U
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MO?E;WGTF,9I$:LC\\J/A.U35^1= 0M'KQ'Q>YYS#_P)X6'O=>>$U!ZN BYV
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MM@0\L:L.@[Q<Z.7.L/4VD3XJ\ />[LG5.E!;M%#X?T#P'U$T[$FO'-&/XF6
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M''6XP\BYOWL!S.^]V5-3EOCXKZ]5E8U<[]##W]:9IKYJ7X;QTNNKBFF<A$B
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MD.$8H*FSXBI)HN:_N\!#X]J&1@]/HQBR,>UD+X[ [/]UDA4NC@]]O]K1#]F
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M= -=RC0I&2_8L?=]F^)-8E. 8>*B)NS+IR^;N=I$]:A72:NF(O"9G%IQ(P&
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M4[JQO7YGGV#Y#,@LY2@ZW+^=331SPRXGH?I&,1>&I/6!;%&JX5=\T?=\X6?
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M> -*+F3GSH\K3%*A-7QAK P8I]:=9%R@I_%ZU,D>,+ONGUE_X/_56<GAT7A
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M)2B>SI:#J,]N/O*^86A*^FQ0>\E '6(W(WSYWS=73I^!/$D>1N=9NK\V,)#
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M?"UA.1KKX+G2OOF@?E6IH!1K-.V*BZLM9U$J;EGO_ +>@URW8? ,8+%P=_]
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M3\:IN4XS')MY2MT\JKR/I-.Q!M<8,U+H3-^J.A9OFSU#''(=> [F  _.7K_
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M2PPLK9FO36@>WC;6S\[;:B*FI1?WEI2VE$=,=?9\V.5P\D/S6=:(+M&NE;5
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M^M,F>@,(IA*7^8OWK8850J/F1U#!_+X>+)[N[KF)*Y"[%=_4)9T]4F%F K0
MRL 7VPS)5%Z?J(5,MYZ2XA7E?:N1L*#91K7W9F5S1F9QB&I&3BXVRKN1=PG4
M[/2)CY96?=(D INSB:+<EZ@FI44*^;HU/3^FB"4$M&/]_6@E^P"XL]H5UB^+
M>6[$G7F?7.P055IB9++$G5'2%&Z-O1/OL$&5A>2*85!__#E,HY[0X>9@=L#T
M[5)I_V! [_L4:I=E5?^4>+[U,@KU\.C'SY3? .G80OKAMIBPWA;F\/O1NWJ_
M2Z>&P]-.]Z-61Z$K^?ZE9P%@)GYHQ^,41<592@IG0N!@_AE/B$&^:%4B=:3>
M);6KA;+_9;S(NIJ.5$0T';FF%@,=]C_,*+L5@%)3XY?,0#.)BV_EH:"/!MX#
M$@Q&T=%,WN745V2+P'X7)VYU(B@=NQ)1!>E;@CT=O<7HHC2#3'JS M^ LL)5
M*]?R)R$2G]<[F45=W;*:2X#(%K8&7I1HUC!6^)=TO1>O)7'70LXKN;E: 16K
M.?9#?I?C!4:$;8=GO75.HU7[M@WVA7Z +W@X9 329& !?Y&<O-_E>:"R^F@U
MW#+2UW9R8HQGHR)@G2F(<(RDW\V.?[D1C7M<0^/X.2!1L[XU]+YOZ7+Z=L@O
M:L8H&\?1@ X?'_;S2%._A':)O?D$-SRYS9QN G*X6,_@E&QEA(<W UAC\255
M"PJ[E9466BV'2&1:-]$EH!49I:-=^W?F_!X!X09;VO7US?#&IN98B<., O+:
MOP4LUBM^) V'!]:X9<5!A2!4'K<#-34"6LS]ZKDQX!^3FQ4_=.DA)LYOU,-<
M()9@HCX!\@1Q?>#'[69L\<NBY6V4>8G>+CTD<]6<YK]1O%51JH:U$8ZH#_D(
M#^5Z;M'*J$*E//:D4"RR03V]$SZ:OW.ZL"7K-L\F&^!%GC;QKQQYS$&7)C&(
M/]45!X<Y [)Z)_BFL9$XGYJ=:$&2Y]>91?F%BB2%#K#O50U^I5B]K]<C'G68
M+5S(AL)%.NF]O9")!!YF.EPOV&2U#+RPI\I"%35R,>4*)RQ!^S%J/"GR*?+)
MSC)J-?C,X3J;<>T0'%?ZH AX@)7%1%5U R$IR8Z):1%:2@I$OF3L1Z&%"["2
M6YOON!^MNPF:O^]WNES,LD!)UVY"[@_W[9BF;:$ZZ5:U)A#90?0A8?/^P49S
MF.S[45J[.!G/6CKF<([+'Y:E/:R=M8VMT:[4:(YXTBXH_'V:_<%*@@_PLTNI
MUV<[ %&:X4=%F^(_H+&_HJ(IE[5V4BS1K/=O] Q1LC_**"4C,D&>NH<!>;B)
M3I,LZ%3U:=Z+2M%G"IKI(_#O3QG3U0X!L+%@WS!#KNG7W/,[C:*I%*9 8Z""
M<%DY.ZRG;(324I[%.EB<*=FA'L[G]F%\JS;T?NM7PK6EDV,K'6) !>!,(AG[
M ==^[*@5*\E$Z0=>SM7QS@QLZ5?FU6.LKPPRKEW64U[T>#%>7I>MF2^ZP1E;
M(PE_Z!X 1WE"'YIG&FXT/@VI9JW97&Q[(KY9/5O% \:_?HWORGU'8P\ X.%C
M0;D*\.QNV5J84?>S=S'% <429QV#Z6=[K73E8O20F.DI&D-J@TE38 :2%\8C
M;7>7H*2\:CK<W\N/AS(=@LC6UQEE].U=&L?2,I+'9\%S\S!K2//GS3>B/\H5
MA-<I6&WL_]1NTV(%/4'0'4Y21[1?9MN4SM]EW8\L'3[[V=:,-J9AZR#H \>G
M(L7<;O4@'\ $Z^/IZC<"=EQZC8&'W6[1?I]:H2]?"@M6QOZP+'KW:7(?4LG&
MR<&'-OHI]P97T2]W1S)I2.0^U<:#.YIGU#$6N:U2?J[3NO D_WT-L*0JI6_.
M5($YE;*;8^GKW;3X &,6KB2J>V10=1W>$(K?Y,8^3&GY/M:WGDQ"=K-"6W&.
M:JVF/N(2/'? HMX<3#%2&\(>[(PM*N@2,CN1VS(NG'Z3U-PVR5OUZNGAD$B+
M%/\8#&98DK?_Y+*1VE/)"@3"P;,35/L4S?E]JUQ4\I_L_;-%1INBL!+E$]<;
M,S\MX1WW<2S-=I]$5Q>$5 OV"$]M@G"*:.P[0R5:&\MXY5S*7>Z,=*SPE/ "
M4+WPC*1^3$7E] KBG14FQ' [K[ UQ)R00=UX*VUIAL"FZ>.DM$LXB&#;*+9X
M[U\_P73" J;R[$_[$I"L2=Z+"CPO:5G"ILA1Z1 (;F8+$/63D4SI-:PGY#_7
M/)WQ-[AZG1,-!]I4(H2$0+BYON-_10="$:#H!,'-(,1M(/_YA(C7A47?(H=1
M7ZJ:=!LQ*P=JG>!]Q;FW.?0Y=OD'727]R\40G$N#5 .(G0N8:*8"Z[MUM""9
M)'%QM//+.M",8'O]+SO' P<WQV&*1%*GQ+C4G!T#^T+GE\O_=+:DK"4B&^Q9
M?J78P\/"_#Y,U^0/:FZ^@MIS;+Z[G2T<B^L6GTJ$\O 2FQ39PF!_NILXP#>C
M?M.7/=2H4?(MN$R2J)8PP2\![&"4G\8)U3-F\^#>7GL>LA(J!?6@%)UO(C,Q
M1LV9%%8F-XC.[&3"WH:0N[HZXV,G:*[ICBNR\,S/&:,TI&=FXA7XD$X_T-$\
M:DL5;]9/?8136P)2"DD3@^R</*C=ZKR39^7><@]3FCZY]*3V=6=2C"F@KMF2
M-27_8C%@R+#Z 'CRON/EB?OUS ^<EL!<%Z*4;N>$BA"O]8,MV@7)D)G6,NZD
MM,[O9"@4T.C?T%).@-V=GN+QK'$YC+J?]WG/,4M2/"I\"<J"DDC:-R.^M0!7
M;\8;?2BWX_]4T$5P-\/R=X6^'C6D,Y1&JG+^IVB94.JV/H(I,@KP:K/VTT=S
MEW1AS^FK:S"HU_ADC6K4(T!]'/8?]02#VD-&=6>J_XFH'<I>4B8<:6J\(TH]
M*>JE2ES'QGCQ"ULXZ./VU@?ZH$N-N#D%IQNQ/Y-#BWL(VF'[_Q#ZM Q$#0A!
ML3,SY.']]7N.%P'CM:,,3]IQRK?R9TXZ)_Q1?*N-4T[D+% 4)PE+N!\U(\4'
MTE4,23?4P<  \#]_/?G_3O",Y&EBE (%6^(2AGH,>B.+LS*#F(IW+[;A/;>:
MDYNI2.T]:JL[,:5,_D]L5=-RKZ^M$N\/0!I[CFAK"\JJXE3%VN.+='*O2C..
MEK6&CZ%;.U=N^QK_),J\?1(NY83OK:R):&J#-QJDJ!?Q$#=\!.0VGJJNG.Q*
M7N;GF"FOR7T5 H_;-!QP_V*%<^:FZ"_T[SYBN:?Z*@LCZJ3U*-=0,)T6CFR'
M2E1RU+6<2A]38A7$NT4SDEJ9<%6'GQN2SX)DN6<@_NJDD6VZ5B#<Z0FA/XO&
M4K2V\]/."V%Q%KO<,LJ]OINY:' E87<*M:[J)YH#K]3?W5QSYZ;\[!>W<85V
M<408S_X^DW=B6;RS_'#OC"$0Q,-C:XTQXS:;B\4W>@V5N>*#GO3W6B-^=:H8
M>XJ^.M JSZ"S@O1 +KK8S@KM#U/E$Y'H('*+^3U?XN&8\.JHBA6*? %/>!JK
MTB:._Y^?XDP%=NTVMR+3(L1/5^MV?<N-8IZ@Z,Q)V26:^#8;%>PV-NKP9)3
M)0^ +W5\FA;3YSQ2+KRB!K:JU12F)6[]J=$>MW[,:JL5E053<K:S"#B3=4GL
M?OFO1X[JV;?NMFF&!@ZS]B01RST69"+/7H,-3*B36OR*TZDRZCI1UA]R0F5-
M8=$N!G!^YDB,C0NZG8GK]_B^+NX .]L/*CH@SM.8?L;K !X[A1/J1+&P Q%M
M'QQ/E_F7L&_!K,]]=+>5"'I]3+4&.Q])*WJ>U"GZE=SED2&9GZ=Q,)>EL5$N
ME:%RI,HMGF)2EE73>R2G(S))H'S$OYV[#AU]B:%__OJ,KBZ5<49UL'3$,;4R
M?<M?,!KX)OA'GCW&5>OT=>".^/D6JH6AM9R!/[)[3;<Q8;/W,YDF);BIC@IP
M MO+@G?_6IUK""+L_.K_?(UPB($C<E0=_!4']C1ZO__-8HV\1"&3X1C)#?"$
M^#)]];L'D._)Z3U:DS>=BJBN:#4QGBI6.9 GL'F9% -[Y4]3M&>R,#/#YT+Q
M@\F.O.C#&Y;:H^B0(S,J&PX(K]!P!UM99VP;3D5NTM(  1O+[;BA786)O?:.
M&*=!Z(C44SJ*AI(<*^;1G6'G(*K/?!>:5)@7W3OJP 73(48HR6.=3_@PX.M;
MUF-KP8I(C83W;O!#QK@AD?*-C9CE"Q?&_G"1 V6D!<XKN)^[,?W2^AW,49[;
M"J3MBT5J$'@'KIB45D2+U ;XF<,G><_YZQB2C8Q1JTJ/M/[\=97?EDVFZ67P
MALA2[GI>GK!K]=5P*X4]R=%@ E!Q0@\X.S"*+K@M-$D[)^):@BI:%2X8;,4I
M>./^$]$L]I/#VF)B\/MQX:3)#*<(%-KPYEWI7*BL=K9OL]O:4<.M:-N);"I6
MY7 '^<&A/*L$-I?-O^POC3HNJTT>=T8)EV?C&#D0>N%XCIGD_3;N(J?2(G!Z
M_ZEM9$0L**SC]91G'7!YN6%F)=I&NH?N]E3NB</+=GTX=NF_U.QNO6-B@8\U
M((L(ON0MJ3*:#@9;MZP< "ZP$^-,$&CF* V[%3ZIGNMW H.IN@40RJZ$G,.%
M-O(SK )?@Z)4-(1)#@!T./!X7!\QK!"*C'@<QB37#HLV3#4S&K4Z%GM' RC7
M*"T8+*ZK]0^TRNZ+ZA4KVV5KG1;1I#+!:!IWSIZW$\T7EB0P:#&9JY,F:'T@
MP2_VK75;(\_'""$G@3OCPZ6[*<<<F>%-IVM+ \78-R7-S#E7-!UL0;^D9QX
M>\O7T+-."I.2B7N&9;,E,V/0D!VCX"+J5^V*[=?7/VM<QLZVB<G45"TZMT4]
M4@.Y3[PBI+\=48):@#N"*J6\+6[-?I!^0(UC_HYQH)03F5R/Q1-XR 0TY?M.
MGRXGYR>G,Y?YHL7.&'4TZ6.,YZCRF<@R(R;F_.]@<+T#JWYJO!+E\\41T@\"
M:7"T$;K^I!K9I*,DH.3(IIP:P384370L(>W).!E3[;'UEV!ZUE^S8FZ7WCRD
MR AH!D8X^TP*U?.UL3@/9Q58,Y*TRSAD(J#^F@68X@_CM]J6Q;1PUE].'L5"
M!R0 \>=_#V4DKXJ\(RUFCOQ]2,.% Y2657H1*/;6-([D O:[*8.5!\!%7+%T
M5?/GZZ >S<>H!4S6EE$'3<Y@'-P =R''OWPL*XA;.]1AV!V[=,H?B 9)^P6L
MQE#T?X#EAK]0K4*$QZB%]EYF^7P$ #S*4[)>S/+>VA5MFURT?P$%64\H<]0X
M<EJT_; :Z#H_Y(Z%/0 XAGKD+DF^/0! T]E0ZH3^/&-,Z+B;5]XBQ\1:BS4^
M\X<O=R^-S93F<]-,1J.J(6TV>?;T[EI29I%9!X4Z[YVK/7XR)A!LR:GM['TY
M5N>/DM:L]J[Q'U/9L_K4?^_#PA!UR1?V=];+>!CX1CEVA[XQ<964;F\/?6.H
M/C34F+)T;T04-4[A_ @0+^G.U%_H\7K[GOF$YFO#,H6WFWX]U(]U&014U'$D
M>P 0!LN;W\;[WCQQBF@S Z%%.L=O=4FR\4K!SN/M&258DK'A"HFMG=M^LV)H
M,Z&WX[?@U?YC&)3X$[#7N')_F=ORGG60A-)*]@?=>27"\\\]EN0#@ Q3K1/9
M\QKCA$PA,]NM),T66A @!Q:_ 3)F+7^_*-KNX)Q!G[S%>/7,B,+,1A^GS6SV
MU$9H"<'.7$GQ;]'U?)S?5#'SY80[U,]+YWH@3 K!O6]#<ZXW5/OA3@ZR@M#1
M7FU[@YF(4\UZ53?7DU\/ *;=?!;RL 27V/R2BQ*P.L>8K4@Q5-H2'00WP]A]
MF,B;M$S.@YJI%BQ+F!>^76..VS(XMZ TQ<1U7Y_[AL?73[F?B,!_J_TQ^ZG)
M'2!Y?;YG9(*[]54:G*]:I8'&N/L]92.M0W5]Z<Z!G0TLA,4&D3G$(4M9$T;[
M(Y9.P0->C4,_TOFYYCE'-#M-$%1VZVP6R$!63<);NHD+:H3?#ZSOZ'#)UH:8
MD*SI%Z5HN2AZO.\>F>JJX^PU<<0R[6T)/B<O65Q5Y_O\;.MXVS1]5K/#LI[Y
M/:)8-%>#)/@\ *:1J:[&G?QGT7J!TI-P'E(",U-PED36P>:;YPVAE.$O/BGA
MT:28/P#"9?6'JPUPC[ZFY5@?&U1"G-A7EGO=&'F0JE=&7%<R/&^O>K->'0\@
MIJ35"T'9?R@&2GF,!C;5S?I#_ZYVDLC\I0I'$VX+'Y'X"W:T?I8G!*JR,3GC
M@!(Q'E5QZ*)RFP<  55OAINR3%^>5>P$UYQ TI%N,G;)6G65# BX&M-9'IS%
M8A/T+8O0AJ4T8C^4%,='J<*!B6<&3DJ^:!_XM+8^"T@F^\?+__?SF+AWCWPX
MJ]<#>$2OE]3EOC(!&I,V53Y7L5EEK$<1B(3E;3LOWLJ??$CW0Q/;J;8G7%2Q
MQ Z>#3SM6Z^1#FL*5EX!<96_N.:?LG-:/:+<%0*?>7OU>+Y&.?RBR7XZ7_MZ
M07DL>90E;.Z:66VO?-0]FQ3CB>R?0=Y3!%CIS$(L76O,%GQ6M4()K.ICF_M6
M1V1\SKD'019OE+_[\R!"_9:IZ2QCWXHH]UW@,\*%T)]-_"5G(Y2^U[YH$Z'M
MY@7@G]X<]G\^Z NXVZ/Y:?YX[-:P%),&,5E2-2=6'7^B]BO8.,[A/ "_2Y;^
M>'&@9=)]6CV>X*G*_K[03E-&(%5#(>W(%8T"@\&)5U1_G-UQWS>KXM\/ %OC
M!&#"+MO]F00^; R YU-.C_@&SWS!QZER/P)O/5'*;;TBDR)@T](<4=VB9<X]
M+_/\[RX\"9DW?5/!#.<YB/5^JF^93)N06 XW5A#X*=-Q&M=7-+@#+.PSDN4]
MX8P48>"ZM; L)F3X@_/2KU@H&:HP)AX8X',IXV+HKX!N5V,F0_ZK R-YK[(&
M6?]1YQY%Q\Q'GUW] JUFZF1?+2#]<HRV/2=XTY(OUM\2:&W4C@['(F&C[9(3
MW@W9,2TU';!/])G12N/KXD1Z7-RD57H9?EIY:9L(9^%SBZ=[+MZY_E)H,(-*
MU=:78;#;)R,D%]W WV;\L'L7/?2)W==;=2_/)?*:2;EZB,WKNVIMKUXD22N6
M^S,)N3O+VB#TER!J^54PU[NS42?VQ)&$%9-@\06 C&;3K@QXY)[1VW%99^(5
MK\V);&?1KJA;FQ>U:.J]6A'ITN.&F_7KL+=0A- ;KS3FF([98K#</+7MD,ZX
M?M;E(H,SBK+&6N8GX &0:$S=P7%R69A7U6F5OSU:W$)G57_&#DZ5WU8>U$18
M.#A^M5F%,!WU>%VB^DJK%A3 &[NJSFA7+9+TQN!^0+2C-):4@3XBXK,NLK@G
MD.C$YC(1O$'7,2J<BU:8RG_E+=.\B)E4$YM3-J["C&QIC#7\.#@OQ2LO&ZR1
MMW/W[^0;-=L:"Z0;=8 N&Y]T9);/_:S<GJ$Q\'+U@<@F;@H@.%LC#G9]@[B[
M$LTF_#56GCUJ T&X1?.EE)]-L;#VL]9J/Y?X*\_4X[%6*%^.K+B5RE9/?W^B
MV%<,]G"/CQ$]_DHWW9K[ "!R59X(QX7#Z?;<M17=HO]?[L;^3P2WQ&KLYF.6
M']B]K$D>,K3DH=QJ7-A""L>7R:NMU/43?+CP5@E8DI2H4;!0"OLY5GHE!JQT
MPLA#76U)-5&\R!<_=/Y1GCG385SSQ](5-JG"L5?DK1B;:L$.##B(!"7R'L5I
M_/ZWNDB9'<>&H75BRG=J35N(>']8.\N(O<1G^E-9]O),[:HCQ\X>19VZ>B-7
M!S+0-NG^H/(^H7\J\=>MAM[X[?.<;9I9FC3SK,9)TU=_/%4V5$9<&C+SL^6!
M23J; 5T;-ACPRDYUS-JVP3T(TL,C612T@.^T S1)^5JTBY+:H4DINR2A>D_P
MWNJ)/ #"$DTF:1!.N5!P'4+I.=;KT%A.>TJ%8TG*9D_;+^-=]=%?\-B^[<;P
MDI+)UBWFJ/X>LX@X[O5(TM$!V^*+K$$ >_=4B:J(!E5Z)<4X_HT*<;F@V%;E
MXZNJ%"A71PJVF/:8\+#) T"SHZ/QS-']2M"D\_O01NU/3D!PX/9>5G*A(J59
MB+K!Q&>/14&(F$[8:$.ZTP^F2]/5,!*]L"F2"P=:*T2H.*M9;5\NN5L&X/7+
M<YW.-Q+ N(@ETI9.L;IM9[IOCE+&TX\? ,YDG85B_==N0\=[NC63G__,#RI"
MEU"\&?CF5'J^OH;&BCKI+4XY1FCWN$ASVC3D^X[V,<L;[\:H06;7F%4\+^7,
MYE'3N$KWEHZP(O",]I]=@SRP][HQ.7:=96KN7Y6+'1-AK:T71\[<NR8>1=7%
MFI8!-.E@R0.8&-6";$XH]XMQX3_"1N<^O&N)FK$<X1\3MQY16BI+'P.V*BWR
MDN<8.[*/M[I-S':73.QK*G;GDPN\XE]>//J*U7"Q3&Q__Z(Q=MFH3KUD#?(K
MQ88[ !H?9#*=ERU<[1<RNAOX^'BSU@X$+@%]E?:$56@]98M\A_W(*ZPIKK1(
M?D6.R*2P;'Y'0.'2N+='@Z&E)MZ=(V0HX#%KBR375LHL(=W8MJ\[_48?G*IQ
M\2U:@++>R:I9Z;7H%G;.-@]VOV15X;.,EA?IJS?M2F9*BWG&TT(X-G7%/@<A
MHR)SVF^3,Y=RK#%V[^*0'0PU$U8L=UDL5<A\B8TX=$_:3!Y48W$Q)+(2(X5<
M8HM7+]MQ7E##DUY(\O=UU'E<.';+O/H (&[]5_;Q\P-(O/?U'3)B IQ4"$59
MD,DL-C_P>!.&EK(),ZR![I!MJ%L+WM%^C.N:%.8GM,^BCYE4F40WGLG>8!FG
MS]53N!RDS>:E"L&K\'G$D$[XHR4BYVF,>+:0?I+5_YCW9YV%#L88.^7)]4X_
M=8[(@UWJ#>TYGF "P"OG-@I9+1X3J*.K7XT@?OBY]NKYV(=LAIVHUS4JZB&_
M9%0Y)3@S9B#%R" "HUYI9_OX$&D(0ZJ7)TJ)A.Y[\EH3RZRN(N/I(;6 W7%*
MI)M-L?'H1P[$9.VET9+R<_$^$LW? GT,(D#U8YKP<XCRP26]M( 9=K+K[QO2
ML@AV_E7H]G9^&M#T"8WDJVRO"F.'R?FCCCJ2QM,CRQIQI#,)B?PAL=ZL-$<.
M)CYW^GRNR@R/ZE2[ZWRA@-'/MK&DH&#F-U$,:?<U9\3XK,ID'GP96;?Q(S+7
MEAV&F6FGU)KWK1$2SB;=\658[$@'KXNL%X%&OP^WCP9]S_ X,''75H <XKG[
M,F52M[]J2IF;*HS</Q*]W)0.BVGNUV=<$WE1GK^#VH#53^VC6Q"<4NQT/R_P
M2V315>.*<XSWWU;BB#&>ZPL@7SVMT>C'QFE*S&][8!C]82=DFG+400JQ>3=/
M@4+R?X#.,E0.VR1)=].KO6M@K(TOS]M!3(--$SK_^V;_L:W3IW^<:W0HJE_1
M),*$;B\ZF+S7-66JXVG[O*SSQ>ZD"@J5*/1;>$)O\+7(WC/(>I(W%QZ<D1P3
M>'+!62IGTIWZSTZ+VL6<<N4W$YO"O?1&;T(:[Y-GM-\FI92&*%TI37H0\]\(
M[O8]_NQ,^48+5TOR(\GW ^BO"6GL50C)A9/['2M7E6$R+'.=.T )[1R8/*&M
MJEH(_E^^R/7_X_]^//SY+U!+ P04    " #;@7-8R/0;7LK9  "C. $ $@
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MQ#7'\\=RQ@WLJ8M0):H>:C2H.?/,WGL8\65;VG)E7[FC,6UN*3F%1_ZMX)V
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M19H]=LQK6?XAK$+?BRJ  :E[1U4DG;RRR"IR6$[D:FX;0WF,(4>R%RP1!>"
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M:F.<GOF,:>2,T.K(G96_OL[6]E,C#\L&2RAH'?S,DGWS#9<N]+W38ZZCW_N
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M9JS'X3\LJ&L4C_X"AN]27#'6-!GX*THQB&Z(5XS^GQ@+_QN<_M\H_&=0>+'
MHC:@R FW'ZTN8I@93&@('N98JBL1,<$!\=P0^";HBDQ/2?7W@\@B8OK:=-HH
M[M+!_]Z_XI->D]=TQ1JF>%^G#@>8M<4?E52'4VLK C3_UHFJ:B] "EU^78P0
M,G)G?_E+#8FS,^T4Y3WE@)_?=/$Y*X';@8,B^Q+@DUO-.* 7C"IV_HXM7\:V
M?KLFUFCC&C_N BNN09[JS-JKYUK5"SA@1/ 8!S#C@-7"2XWAJQN'8.0PEK=V
M.V^@B2+1?/""'FK7@ .^F6YA)7% M_99.A1-N 19@V+TG$:5A?>8$[$N?5W_
M\,GX_Z"SQ#E*,M5B/?4X2(EKSAFR3>>+ ^(@2-W _"ULB#<4M84#:(P]M >:
MB#G;TH^$9,?=<8!<TS#F^BTJOV4!F2-EEQJB>U>3JN#JU+B&? OC:P*9%L?J
M3F0O=;Y+--C$1%&J5#U-+/=J#&<X$4576.( -K@Y>A7:IQ?UE4^*CLXG_QH\
M]O\9#SZXF1:Q<%W 5!1"3EY/[5O:@]SFL:W?_Q54+9@Y>&0(W 5Y.+$A[>E:
M9#PS4_.]39W*/?:IAJ2$":>QYLT8JMB9W\PAK_S,*FQJC19[4E>C6]0UPK1\
M.6OK/U_]7)(C_9-JVDYYM?+.H11)E%FR*).\&1V4<JX?-V"149?PKO217N=Q
M[PO?CM);%3<=TA8'L=^+:U-=?-#64[3(.;HWLA:78U+<G#>( #/)TM.J"ZS2
MG&E F_ ?GYX5$^7\'?3]S9QW:0%T;V*VVSC"SK]6'KO.E_N_SC-G5O1WR8=8
MVZ5*G/N])W>KA26*4-N_ZYZ-(Q[L#4A+5T#L+WTM4_<7_23JDF]L&!RCNLRZ
MWYLPODF/U?O373"\TA]+0JZN&J&KSE"6&X=6CEMZBUF\,/1"_%%9B9.7_5J<
MW-!6 481E,P?7(%7TJRZQ^$2:+(4I,G.MF=D:;E%<OCF[*U$)F;/W@W]I-7[
M53]-(;;/1;TSY.HVWU[<KPT_.FZR.1")#WA=*7T_9QFN/V64,^S$KEQA:B8=
MW:#_=I;QD16])(.T]0F-0/RODA+"\$X9\*^'=M27X3D"G_RK6/?GU3[S&C,[
M+Q[&C#2:]Q\9,,%=X->$ 1R>\J$\6H1WL1NUOYRHU+9FE1QB$9I%I8K%LM"*
M!>DD>_&2HKD(')!B&<=Z#WOP,M[=>(E_5#! ,5\A7Y%3U4Y@P.;<_XX9H=17
M _PBMMNN/0X/CMMI]0W0-@6P$F,'/KC4IP/#+_P_/NF-G.Y2,'M2Y[2V39\6
M+% X@2O@YLW?85>\.*!+R'XZT2?5J#9-1G.3)(4I9".[Y%,;CPX):S)KYJJI
M/GJK$VFR0/E.3*J):9SN3]*7!(3K8; KW*!ZD*/'CVW":8]CQ.Q6^LZ!59I_
M9!UWPD_A4.F[,A)!8@(%H;8_7&[[&F@/>%PV'%2\2>(=ER[LB HFN1P<R0K]
MN-="MUR N9-J#H5?8S&!S"KRS$4Y&SJ:*'N+5AHKW&.8&7NL,7,8L]DPJ*XW
M(4WI[XMO+V&4W+0C8J9P-L8P]O8C@37>4>:ON)G5ZAJ*"#_PF>F>GUBCH?ES
MG6=?,Q>(E6\W$&1)< _Q2DH+%:/B#HZVNE1M'=HT$SM)G.[;N6Y:-'_X:C#Z
M3@@UMG..-0KB&,,!WEL5*PKVGJ;X>@CXHH.$]TY)$OF$-Y-::;XP+*>=24DW
MQJ.C1!P=WAQT7\$N"/'+\G[,D;S#+=K+GVRW]T-2V$Z8\>"*X1&KMP:UE +?
MO5)VR0D7JJDNW7?GT0CIXQ4'2!__7I]J1LMTM8I63>FM7HK2"L\+)WJGV"H1
MD%G1OUPJFT_O-_\]$^L;<')Y6+'B-&5VG39 1K97 1+8*+^)TA9SK&SU,!KE
M<D5]LG-X!$D0"P*E849VN;-S?_S;@U!O,+E<T!-?^4&OR/2[K>8A?>U@^ 0.
MV'Y=RULP/A(%<9C@ZS_-?-T#9H%[S4U'U0CPSBU)N;NP5&_0;3Y]E<%S&'5Z
ML_W'2'X=4JFE<(&>LV9"AT#E@HLDS_@=![WDJ1A1A-AWGW*GARH3@N6;;1,G
M9RWJ@:P.[TG%EC:8WX2&?MO:?+P"4IL WQ%P<CSEFBA]4--8&?G P3-%\MG'
MP1JUQLPV_[",US\/9$'FLIFRGY->#>;/+=\_2*:9^TKSY"!4D8-(5I.$,^9D
MM6P6I?PR?/ZE3RE&(M_$Y&FE F%R8O,S_)1C^NP4\G'Z=OCO' B\_[@>8AY_
MP4B^1KI_$JB)O51HJ*757[8S44M4?G+<V=? L)9PDM^]YA'U-KPBS]3NG8G\
M_>[J\2>//!47.D(3]6J/PPZ7HS;$P*2+VUD,2,UO"#NT!Y6="VC&8Y;SK>&%
MK"49-?X\$"16C:6=DM:F24.%^U-7UU4GL%^R'ATU)^PMS0??^L"UP;!^^GUO
M_\H%!^"C9_8A<"NU_AX7L1[HV?[=H\YA'8L4;^'&1UX<O"RZB1^"U\!YNC6H
MT&G:L^FQMP8)=NZF@9\6O[[XX+:!-Y_9[6UA"\KD9V5!TL"WIQJ[>]+X/8H2
M+>\7N=_O5R+1Z @FD?S=X=*9UDHQ0=<^-<>5Z7#VI2)E ^KN."<HO8!?)SG?
MJ]F6J9]ZU 8KP% ZN, #(2NTXSVQLB7N+K;9BXM&<XN!B;ZP!(;1(SP7/JFS
M4+^U?$TAC8D CY34Z5&C'?>EC@*6NJ3<T?R>GE7*5Z'K^$.RF0Y\1@C9DA+[
ML>$J957R]D06HT=(LZ?!874D]6Y ^_U&3^JTB.#R\))BK3<%/FZG8@S/.P-U
MY@.FAN3(Z];O3<<$JQW9Z_>C]W$ ,>:/?QL<C:T6.Q70@;^<..D:?< OVR&8
M#;PN$7SIR+O45?D8O%BNKCY)W1+CABHQ&,<\-Y6^U+!UD^>S=I'+\[(XHK,;
M5MLK;19Y!YWK%QO^Y"SP^F=MVOBY$[4=JP2W"8'4[$?\D.XWRS[>W8U+<8VT
M9:XY,@G</Y=Z.$4:BXCOD<R5NTZ[]MB5<%UYXP"!R\C=M@JX_\SXE+2Q9UX+
M)L$GZ&RS7XNIW#DZ5X%^(>!'%UW[R9KTS9YT@]:)(/;Y&],OMFO1;N;X-#.Q
M#*I< PER_;?%]\%&%64H?-U)P=/8G=RE6V/+-LVMOJSJBGS!T:PWD;,AQ!DK
M4QO0]P>*J,0C%8VF;>V=Q%)'=1>" PZV@'IIUM:)5 C<%CWC4G?:>"6H;+6V
M7;[UTTZT87]/C)1 /U5+U+I)8F$A^$!N,?*4H5L'@0-B3H6-+^V[4WA.OSIR
M9*CE/G/K>!'\Y,9W]X6TZ&>(^P?IKOE/T=[A.DP,-+$8?;E%S9)SMYN6],@4
M,JT\$<,QJ"("&FDQ6<%O65O?F'*N^=6:_:60%7N1#O$ /9D3E_2H1R8:TF$>
MMUIEOPA9 :.(;?/A/$6[1GFECW[$=>I]R.>*</O^!0\[) <V&B]]2+R39!?$
M6!-WB 47# [.GJ8I-+2QNZ+T]\7+OB6U?G_%J(4)74&#-AV"?HA"+P@[3L #
MDP]#T!430^9=9O_:N#T(^:MQTU"^>@XZ/27&QAHME@K\PZ 8<N,"^UX9%3\:
M=-WAZ3+^^U<?!DRK^^8OJI&LT?E&#H_L7IAV2_5+CW+$?#/-V63SEMF&6TCQ
M\H6/2BOZTT5MC#G7]+/8##JF[1RL1%J)=SUB,G>@Z6#@^+[ZUX.7&.V,8C>:
M25(_E4T%]<MTE_32]! %*7%D$2FY)HP%/^'ER_R)+$^&^!,VJ_I5+O2-SB^J
M.L()!D0^5<1X/3[MI3$;7[T=Z35*8[Q>EPBINBI6U[]3VE3[_N'(7<AM95&B
M7CU%=^^EQZ-[@@>6G\Q4:7+>-S:&SRXQ>9UXX^,S,/2X+E.;HY;5*R<$'=]+
M3+^<[TI2$1!(>\%A^>F"V0ITY3@Z!EOW^&P@X[ZFP4M3(P[W#9H67]VA_3.;
MQTXUVL="#-]7=UT3X.7FSZVC,ZCPI\LD$$_9YPR7W3, <3/T/MZ* K:YRVUU
MD.RF*+<E^+/ZJZO]":]/5<KAL?VP<[[;-X/70Z4,KBML4M:B0CAC7@7FOKZ1
MV&G9KVZGO 7C@D.]H#412<(ZSPO7X+?8MH?'%'#T9;QJ=L,%YKEHDX:L@.:8
MUV1Y]M*4OM#7&1I\7WKL'2T=_RGB2&E7_D:E+VCB>>U#%^QOSA+;5I6;6WZ.
MD N[A';9$\\?'@W+HR9=2Z+CHIO^_N&M];0A.D='4DIOOP>07<3D ,>)Q,^/
MH_)<U[HKD0\J'#S?N'G,WU(IN'SVX@ 6_29R>+&=?JWJ!;&=X@NGUZ.>_J9"
MAEFKF[3U&F&\'";D76>_+0BM?,8-)O:<2D^N2'K$_"_4VDV]"75U#KH" 1#B
MGL((;8&VHGO*TJ,?D)MVZ(55\Y/VA-([/69*7Q!6-R4Y[_Q"%#R,.:G8FSWD
M-*XW(DU9W,^MM02GS<R%""5J*@EUBY?ND6R_+0\",^QP:34WU5_J%<S,ZO@(
M.LW>UW>IO['&;RQM)9D;T9.FWN%_?WBNU&P()/O616!.DL VN$/E(MQG31JI
M<CL\:LL26?YYU$QFS&R&Z97L*+N9L;2CU9 $=Z\T,F3(7YLXYF3G=:N=T^&^
M=56MQ/_%WGM'-;6M_<)1%%0$%.E(D2Y5I7<1Z=)[5Y$:Z1V$*$AO @+2I88>
MJ0%"DRY(#;WW%EKH)21?W.=LMYZQSQGO^.X[QOM]]]X_UAC,Q<PSU_K-I\]G
MSN4DX_IZ /:4=Y]-W$L-3T;&R1I))!LC;V;H\ZR^U=<\\R+PV30A[S)RWTQX
MJT-<N-!T-]EJ*\=P]EYM= F+%4.EDAMO16'JM^7#*\]7OQQF-KEHZ0JR1KKH
MN92#.(S:\YVJ8IJ/-IE#==:*4GU$+(47^:5UD <//)SU8:7E,&-IE?>B!M.3
MCQYM]XZR.WZ<VR.RP8V;CNP-73%'%L=5.!15&<1.5597)UVSI9RY(DR=0ICX
MM0G1YD*6X& ZWN)N2Q]SO5^!^EU$EZP4^*5F#3^)NOS/?+9^$C; DL8 3!_\
M<%HJ$+\%L/"3@53[^5*KS-"8YO^^X!4;59W!0&=G_AB +)?="-EOL:KJ'#:L
M"L8 ;I_Q#'4@9;$TK^T$V54R!_7&/R@DT6\_I?3+.WL5V@GDH=:7N[JW<301
M/CG4!_9)9 C/EWP0L5]]2X2,5:C8E'0M:H&.8'J]O[-49=Z$DCJS,YS2>>L#
M!Y6M8;M(1(4.V<25)&W$HY"=E23*>R%2U(D IAI&H:MR)C9DV!<ZW+ ZXN,G
MHEHW<%WN@75X/ZCHF%B!5GHR5G7V]38Y=K!2-F77(ZL2K'U'U-N\O86@2I^K
MW+8$UI*%GLO92:J'CTCK>03)V?JV=\@9/Z'1\.2FKSU_(EN:2'*?F./NW.WT
MCW>C%$OG03=GU@RFTFR"JJ+D*\H5CHE2%V=AX4NN-')>(B#C] VBL_/1=6=9
M4ZIUAIEV0QE8H^"7Y."7Y5!KNNXKEUO= "G.,_&FE.OWS<T<\29*9D[UB[>V
MBL>7GS=ZQ+5KX7SM%2Z1D+QA\\$#).V'>)RTX*W'+,T<<38Y;5CS(3IHAO1#
MY+C84:;J=>#FA"RX8-((>*?%EJNRK4XDQ,]%DV6M[U/1N\Z[ O)])M98]OA$
M\WI&>.#%EPK8M O"U6$DG]BP-,Y"32$BEMK?,=RL>JO' F$B&3G;XNY^9IL*
M-S$TEK'EKVRKT7T/X^&LH=':=?:3+S  !=AO+0VP*M_C;+;9,S%ZRD/E%G'S
M66CO=H>SS]36XB'?EGN+0?TX$CAI<)U@:433(#].MW>O*OYN^D=4MG.H)*0;
M?0UDFH["J8<F]$$C[;GEC_-L8VX^6BVEB1#81XN52"*20>R&UDQ)(_<MWA4O
MN]S<+<=E<^QD(B84CV#^F4H8;7W60&8^!NH4&457@_=(7Q;^\G=* PL[Z/(-
MK(__^;_A0PF7<S..N1H1&W07%)4P/8-?\PF:)[I]![Q12+KN0^QHGX<XB-H?
M720T4Q7/A5(R5U7&6+T?"%+KRO;W;[/3D0SCM'.5O+9Q).!XFB!(%B-';(?C
M3$I_,PUO45-T#T:*[\R1V-$NH'.YJQGHW1UVRFE6N_=ZZ]G[_+D/Y)^O>+L5
MI7JWZY*7G;C1$2F[WZ7*@O$/";R4O?%Y^7+CI7=T G( G9+8+%-#CS+J]>*C
MR9(0@@R?#4?V&F8'0B^SM+C8S!.@;H4]?N*6 #YU][J=I$?0RV^-+^;V4UMR
M'6<JW.I1&(".14G6WH7D]S4,8)X#KOLX68_%#'AS9;JW+]DCMEO,RRZO! 7,
MT9]5MF<PJ7/;*Q(D5Y\4E<9/>5,TYW@<Z,/;X^2>1!>2T)* O@L=>)K/DCEZ
MW_LHKYG/PI'[<BS,_?4MO'JEDA-OHUB#QII!/EB8Z&D. 6&.6=ZUSX[OOB-Y
MW[0^7[WAK%%K>C:)OJX*.9Q:EYR_7_;%Q\(0L<X4.8+D&F2N.O4ONZ_7S_WL
M_:HXGNGK :SE;?^0Y)OAZ@!U*P9G?G.V=[P4J24K1%!QB#>D<W4TD+\1.KNA
M-BG'N8MXL$&&Y"O(7"8CC7@K+*HZT^[8F7<XC6.*9  :A*V;FL7;"G/:OI[Q
MF%"0]*))#!:5^TQYF&%[X69:\F[T; =MD&J1L% OJ3,4\=YQ1LKAY?Z"8:%%
M6&^4T%1R$&/T3H^=KJAKKHG"H@^=NKRSM;VY(TF9'1W'PRBK=B?GBH.#DM!T
M543U!W49DD#2A$(,H&,D$2N2!!A 9EHE!X\N5F,7\Z)_G 8I(VXLCE;=XRW<
M18VN!*G+D#('_--QN_5K:,I!.XF6O815UV ,0)JT5%LB[;WFN<D_'#V'JC3N
MQH3V%6&QQLWKVZ_@Q>GVDE81TG=@U:Q>4:XE4+V8,RXJY,$DJ,+TFN$FT@Z_
M!MG!]%:XA! 4Z"0U=_*Y?.B0=;A8W>Y%Q'9?[%&.Z'[%[J/QU9F ^IG9T<-C
M' -]D.GH::H >)&&H7E[97"!XUM6%3O46<9F4!IW[AIAD]<M52/+)+><12X>
M)5C:^&+])X/,^N_Q(\5,;ALM]#4XD<*+8KJL15:^]'7UU8T5_=NO78'!BU8[
MK_GY0[2K+E7-X]\Z5_'4?AVN-7-O%UTI !8?+HES<"7WXP_2@O-?>JT4\'4_
M^A/NI=H7AI%L!+U9:LC Y!>N1^:1>WO:P<IL9576=7E]LJ\)>;_A0+!.7[N7
MUN7)S84=-6 8J))A;+(B6P;NV2&5)NY3& O;C2^T+S:>G;;6I9I*J-HEB^G3
M!(K',KV@=@IZK!7]059^-=1G]?T.5S'?IZS=?5%# T^@0'0^WYU)>;U2XSVA
M63KQ;\)])"#33SR(79$0K'C(QA>_3H#V.-L?92N)6D;'<RXZWW3@;2<2H[T?
M>[(J'ZHD-&_87</#U3!L%U_5PRABB1?Y.?*TS5G0A&8TIV(P>YCOVR'-$VI-
M:E/KB;=5M2''Q*2?R@I+'O:)^3GVV)QX/QW=.KS@/M=G\&08I)WQCMA0_61^
MD^2 :>MNRO-HE8D+K&Y"77)!US7.)135^63:W-$OHGO]8$;^7NARL?'+?554
M.:?<S%RX%U+#Z&11KA*61DYN>[6N0;EMR:UW9+=1N6CNN1FC>- ;'1I(8*45
MZM[GL<I<;EO7@-I$L=93LSNB=KT.'O1SSOJ/3AC.B+9HQ$Y\C>6V!#442.>'
MET)GNZ.A+_7B'SL]DB55\;'&8H(!"!YCN=PTZI2G;I,'Y9QC?7Q<94N VAL+
M ,;:V@QRRFL]>"GWF@Z"%\F.LT@_\Q *-_.3@YO#&\:X1WBA5_RHW3R4&Z:5
M!?JDZJ$PY(OS![=-98@-/LR=)C\?1T3WT?%;6M>258)-UC1H'K)H]P>F.M9J
M35[QQUNE/$T(?U.3=8:B0SQ?OW WW57Q5T)&)A>:?+6]J=N?_/&1P3='&V1.
M\[L8]>!5_S3'-CNE*[Q;^YD* @_,9SYO,690[IAXSQ?C&<$KNW&KX"4'WM=:
M?*JF#V^+%Z5S P($>7EZ_'NG"#D&\F$NM_Z0ZW?9&$ G-U$&V@**P%'  #X8
MT4FC>@Q.Z HNGN6@9+!J]<D6B;J&U0_?2FL(-/05BXL::&VX>*+YMQ9XER=]
M[2DH^()\ ]M5ZO.?^^]TN2 >/I4@2BM=S3%I5["AM%/YZ5=*[4\LLW&U!^)X
MI$,#<H;OODJ^Y^%#7)@J#-H.2A(A=&)PQ[1]6X0U'I'3?WQ]0/GU@%1:>C=U
MR3U)S%V".@:OU-43PLT?8A%<QHTC0_%A3_7X(^#1 R"<+<.*2+/'I9$(.&(P
MG3RVGD#UI'C &T[VF:DT22QU\AZG'J]C)#F65M7((09PN>US6PZGFZ:)L.W3
M*9;A"#M\NM@=^TYZQ\A3B'Z)ZM<&9GBE8:JN?"F\H8FO.U"*5G;\DMO54=JB
M8F6)]-''/AA 2:Y6DFYPQ9:H27_1P?NZ(,TT3_H&0;9\BF3(I^SMKJ6+?N<.
MQ8'^-Z*>V1M)[2?'AM]>6-M>:0O:>>98!J7L7(ILJ/1^C+1M:"P"NMTRK+/.
M42Q-3 P<=ZXF%@>PR=C*@"S%B%4)IHBE:=T[8RX71M;0(S7K;)=/7&CS,0!C
M#&".]K481X%TEM5#U<]3RL[6X"(6'U%U0^]"STO+2O8WOIW.K8;JOV$NN0 _
M&^8'*D78S.GYQ&^(&C^=5 R_6U8UUTD7^'4UKQ,BI_RD2S9:8WLZB7F:7O\2
MF[BJV(W5+91K[LS7'".#B-T-<@U#.VL2"D6.E*KK&W?V&/)AC8AB#."[L61)
M^FZ[>Q!*V!/HD\-Y]E)OLNE8<% V@4>"Y0T#KOM+_:H$IDC>P<0\ R"\S14,
MI"6M1%)1TFV.1G#>C@A74-L88]<5ZO*'BP.K(H]&#,V<:;[SV%UBT?Y N@@1
MOS]R_,"XE;DJ33A+#"^B!><D5-68@HM(W)[H)%GE2W\1OJFIOL'XIVURY7I#
M3['-</.I?#;RR&MBEJ2TT?/&=J,J\/FDIO;=DPA(JG)_PNNKJCWUD88EPJ=1
M1KI*A2=5MB+;1Z*VQ'M'LZKA"IX.D<&W;L-N4$0L\;#2]=;B&WZ"<,[7OH-*
M\P$9!![&,=*C99.\]D&&LP?G[XJY+FSMA_8Y^G!-I=R+FOBN5SX$N3+M&D68
MR-_3CHTI:V?2_-HWC<=02VU/-&UXDKE-Z3+/'>V3(VVQEYWU6O;!7+Z.:/"]
M0"*)0S%?/FNP_N<!'O-!JM7-%K4GV6334(<HT5"[1??%<)V.8$MX<9TX2*+D
MW<%!0/AZ^+;I,Z^DU*QE#  '?>TX(1U%MR]W?W>D?2NK?LA^Z8["=2KCHK=+
M?+>(8>\P .OR4^WN/OQIQ QO[9#]2GUI1<4[KDW:042WM>";P8<33KANX7=]
M)DKG+UP9DCIDTQ\GR^AG\)A1/WHDDG<%TN6K UC%FTU:@T"*72;OV_-81N);
M)3A_N]>DKLVUC=78" U=\PLWL:TZQOSUD:2T\"35HX:HH[$=KKKS^M@W3:?O
MZ!S8YQN>JUR:\LQ_L8NNYPDZY #VB  1K-4A6RY;BB@%A^#&-R$?4<4II*>1
M#T>3UEZ_L7_A.0^<O761MB"J9/TJZH7JC,3(Q(/Z$*&YLWT-ZP:6ZG2](*5A
M/L^#[N1@ Z#M7G880XG@S?SY0#FZ8@X7=&/AO=G\#J5YHMLV(N)+A GYUJ0]
M]3UQ@1EYGC$Q[W=,A:^S7:,G^C07CM2U%7OH2C]L&=6\;O>J5&"@K<#&R:AB
MZ8N%9@BEMH1ZG]$<TG@$7*!O-4)L,CO%>8M5QRX[[2UA=EJ3$Y",A\I 82X/
M]6P$BG\3_-IM#H?QX8?VPK7K0F<648@#*N%"(D)$-VW6%9%7N^L:^GQF2L.'
MEYSOQL0\N%7X4*9]/L8KNH,D/HT&"2@?X2HN.L3G$O'AMF+\TC!$O.JR^:!!
M?\J-;<FI)6^A]H*Z5<.&*K4W 92K#+:Y];3\5)6A$T)-C(.K&?G9CUW9WL2'
M>Z6W"ZZ:A$;O>(9>FU:[JH;/R^L Z#Q;"8+TH8D.EYC!W>A+";1AOK6C[\'G
M$@SPS=S092AD>SSK,2YO'[N714UA^E6;"#[W/>M!HV!^P_6(%-V&IS$MO 0E
MD44/9"]-R,^EC#IG>802Z'3M6<]Y4Q:96Y7,IP9MZS\VV\?Q>R#5E\/;/,,"
M1>JD.WH#KY1*DW8W-5A>;9X+['CN/)@\HHNN="<>%$!762UE[*9B .-F231W
M-E592H%.N]_>C!*?/J0UD'-_D59W?SVR$M2:1CW,+XH!W*FLN*%Q+ALY,CTA
M<VF9X!['*&/>$K+'74L#W8A/((KM83BU7VPI/^QZ?\L^N44W>AI?)H+UR]#@
MS K>E66CG;'U_G"[=E72":M;&P)G5\-%ZA 2GS_D54=[\;J?70!E0]U)JWZ4
M:OU,+Y3S]YWL!:$;7F  _6W6(Q8U& "M&C8B_RYY1E$(1F:)S+:\'/C%K_W7
MBWCRSS*S_U+QX1^E7/Q$AVX8P(_,9_B/-*CTA7'CA8_4/RJWTIL:0!FWT8P'
MIOEQ"\JV;T3GS^OUBR?F#-^^R;'-*6MR10'I3YK/59,FS[U;1JE<<UH+;TP7
MMSHSB-YE\P&S7U\4:F-M'<'?W=&Q$+IDQH0!3,H4@4@]$N21%EC-< W]SI,V
M"^3-)$\V17Z;S=7"G3$ @#.286=U)#J^L[F5*V\)\[O_ZCR$Z9V2SR6$!A-2
M@2DZ.V]0+F*#@CAQZ94;A!II.YS:UA'Z&6C+,K.)&V6^7)<@"*4VHS:Y]^&V
MS[5."J:1-(BS=];77!LJ#VMF)&$<87JU<UAJ5I<3:-IR]2*)K%!UXQAZBMMG
MBK!'+'E]Y)5Q).Z^&<)D>VQ,<<OWO8X%K(2 DLLLM!<XV?WM3;*W1[#&EI\"
MIX<:@"DI?E+5A[5EP/I,[;V"K1T#=+^\W('B:FDO[RCI=Z )SQ"*,8OQY%U%
M_%#)RE[1R/2,D)?3(.\>8,-Q4[1_R^>231BXX];D^D1*;6"JLZTW6.&NQGB@
MKJ7U \:QIKG /I.'O39'$0OW^0E45I4:X2SPRFL,^BAP]"O=B)!+_O<[U*1(
MOYHHY1IY<&C$P_7]=:OKZJ BTP?7Z#K#JP09]BOHZ7B,GJ=5EL\A7Y!'0. R
M0TO#FTQ?9-/V]!OZS3X*D#WD<= JG8P-=^OAJQP]&YP[@I\-'5 %_DPC)&74
M82,KCJBSE=FNX.W_D#$H,+U#*OD.RTH::K^>>* M+O.F<VN1V>^;(U75"+L\
MYZ-'PH5Q&N?%X L?&0P@XT8MB)BW>/?1[!%9.@8@MH(!-(5(GA1(?JG  $Y7
M!=%7L%Y@FTZ<F4?5"E 2#R$H,%BAV6;.T<&00OK\O1^[L7Z.=UG<#=O).)]6
M#&#, (3:3\8Z4TP_RCK0S7 ,8#5E]N0V*P9 :D3H#_IL K+P7XQP4EI_ZOEV
MJFKDPR+'L8AE9"7,?7&<J[>8W4HP=MQ:D(!@NDOQ+1N N"O;;PR/R;=2Q5EE
ME%DC%]UU'AETCJ^* :0Y@^:>IJ.TZ7X;L/ ^ZKE*HRM8*E>)DRQ:1KQG-:D@
MNG7#T(V(%4"+ER-MO>C,JZ?JG#EC8.T5'D::LQGYGO>7%18>:XE-\3BN4]TI
M6PS@A34&L-]KC[H6BP&$9OTVJ*,(=V6^<IZ'CWE]XJ"MDD:DFN%.)OD8T9>F
M-F/H2133D9?/#HK1?0&N%MM9%?TJ/"$YA7O*[Q*[[.*[#C"?M\*QF8MUX7GA
MMDCZ)I<DVK,' WA'#$)J@7X;LHAWL?-Y69W@A&U;0X:M2WSZ2V)&OAB10.7B
MU&KZ5:;PYT-.J,>!<-5AY@:XN=^^:H =[=BSF.N,%A.4Q@IX:=<0<A7I#D=\
M&$"<3X?410 VQ.X3;MQE4$6S1_TZJG;P&U,/B[0NXQLKO<C-;%BY?FYX2)SC
M!WE6X$U_?]VZ._FF&V@B.$\EV]%4SV68P-R;[V_==P&4!UM8^NX7IJB 3:SS
MR7Y>+_D=]MLH^1-/JXZ/=V5-NQ7(K2RYPC-CO['6V^LP@?;(AQH1F:"UR@*-
MC[$P=$G(1T9*F39#TX%XJ\S0[V-_=ZY??IY/M_W96="?F=J_4EE::-+]BYN+
M*+F]BR>A;'G\/VIZ'XDIET016FELF)H#8Z*HKL4UQW//R[&"6<K)VT:KW*L^
M ">NMB<23&5>*Y%I=99EDG0UM.Y:_2S4;D,7LL<D@5L=+WLCQ/GU]X[/EU]]
M*^J[<Q*DB R(*PF8/V\=XM[FH7<'.N@_C[@K*BHH];;ZF"5X PT*?'MT2C,%
M/7(P8JX;=9#CO>B<>4S9\';/YFEU(-:3MAIK=:2_2=@2/G?F:,*Z,-DM^DE,
M)\PV>V(Z)/N[+MF>D6F7UDWY(,;N9S?]'I$X&Z(9O'M$3LE5IU1#BUY6$/.(
MVN&2>TH>?AM;O0@E*U1I+&GQ$@<5TB9!;]575^MG6=W8V<>Y#/-QAI.&S&,
M9'H>\1B )A3>4B? \O#([T&YW95E'SD:[Z-B;R4VSH.3UR_#\3U>ZL5=6[2B
MZ%@V6GF;\<9SH5+M<D Y@' 69N-E'/+:U45=AOZ/ NE_J8\UB/N7S$])&@;
M>DHY?.(+W)?.^R5%?\VV<>DYW>$&Z."A(6G4[Y6Q!>FJ3^Y?0-0R0]D)_K"W
M974*Q9"@-Y+NA?PP(WP'HH_%%55ZA(T1-J/,2'X_E.AP8B1 [YODT8#UP^(V
MB0<-\)4J],SN87NJM2-[,Q3H>+<SLN,&G767GT?O0V.FXR,W.!/O]%>2,I_6
MF,<Y#6\/2_#;3)@'Q?0_@YHE/YO(Y<W.?".^"KW:JDBCG]HY_QAP6.+<!M5Q
M)Z=E?U=<D>S]A4H\(7[/:&;*-MS6(_"QS $C_?-891@/HE/!Z.AIVGVF&+XX
M*GEDO?1E3;'PR.&KO6!K8(YROEC7T8?6P8KHU*:"\!0SB.*^L<G*L9S_LR&^
MW4&E!1IV&DF'57)1N8]+&$!M7]\Y_ZS_BWD>?)Y/,\:1R38X L(386>Q4=\'
MF%^A&B%[H =A,!/0Z"DD.OG%PBEXB)/KD(88H1*E?F6\FREOOM-X4N]^E\",
M8Y^B'[P#Z"J>TI-M+),],Y5L"#QRN3?+=/.S:)R"QB444L^$#LF2N%#L-:L#
M&RY*NE!OC\N6>V!&IK6<<OPA4IS$LM[Y3*]4":L!1C7C0<0@:XZ>S/(5(>.4
M$$=<23<2LGN[(I:L?(/#/ @0HE_5\L)%O"R4+?O!G]GE(@)6M)2##]$^?^//
M%5^;T:8+W0USG@4>N3-RK%C'/OXC!YV%SB7ZQX)+,5:,?VT-2[Y[@P$\843)
MK37^Q16_7G4V^#5UPB0-C)4AV>Y#E0023]53O^_Q2F, T0"Z79$C [8J*,U!
MZ6*"@5BM>6.PR]B(?J8?%\=6,[U2-]DJ[UU"%=^7/N4Z_-9\P.YBQ<7FZ";.
M.U(PI5,NQO'KV"D! RXOKAQ?KK<+534\G47JX&\MVS?M6_'YB*H,U>&.Q*L]
M.;ZM<'<S^JV%IIU>D&1;;!]_0+;!NNZ9ZON*#K\9V2##5!ZN+L*[G-]Q(E&V
MB(GZI-"J[9T+>R>-,FA<(ZZG0#%XO5]U89)!.>"]^P@O$<.0TLUG:L2#,DUL
M\M2%SO/30\XFB.M7&SXA_>]07W#1BGH'?J484[CT%D?48TG76T81?G:  =RK
M5\%IGZCRSS/<\&(IS9M>US1D.0E*7KXH>H2L]-R7]>#P[[/I'Z1KUUP_DZXS
M$"/;L26?R(QCTO\P9W>#?)FVI=*UF$J4XQ$'J;"&K.,!6-V6\R:2BUM4G+>E
MBFSD^%AI40DX#"7+G3]&<M_X5![%UA&;8M;@;+P" Y:86'M]IUH8:P@>V2.E
M\I*W>WLW_U+DH"QOE+JQ;^N^X);Q2?NF<Z@KD19_?1\G?-N^<I9T36/\Q*_#
M(%856IW@4U\3R09]JGYSS.)T//A4]L&E!5@/@[B3/+/IK9+XK9IG3[Z9VN%)
M"J!/VQ\:Y 4GCH76" M1? -K5M=%XDN-<J*$Y^ENV8Q^EZEO*/9HY=&1L 80
M.<F3:K9XM4&"7?5=U8NMW6D98\8'V[\R\Y FN=(OQIN]JPG*Q2-=)]$PS6G$
MQ[FP/YGJ&C0;,1G' .;IC?E7=:?)Q^*.WD6"0<*(P;IS;M\;X[*Z9&53F["/
M<G4MUZMM]R[Y=R+2IKUU"]6EJ?KWE0&>OJS#=YI%L@UJOX';^SQ]>(VRG?$N
MF3V",)%PNJWZB5I $&B^QMV&=&O+PK[LCN)9T6O&E(,3%.V2'LLUB_VN_--,
MUE1;$:2Z [)71=[1FM.\&T*)DD(#N;?X3YCK>!&/OKDN4X.;1!5NC&DXQG5,
M ]SY\W<7;&4F6SD\7UPM(] Q^U0B]EVA?:E]H&D1K\'KQK95;FKZX3+ZR?J%
M)P;PZ4<*[T=F[M>+-+$$U/%1\G"?"!W(H?);8&,L&4$Y@J8F"V7+Y_QW9^K&
MSUYXH26[2H8Y0(>($ZRIA_UCU?:?ZZE#/_>IJF>&W@_^A[4&%4)_+"])_J-<
M]5Y#'W6!Z&8:*[L_ZXT-%;Q^+;A'Z,B,Y",K[H%'N :7<545!V2Z[O,@S,B%
MFFV_3<J<)1WH6!Y-2>ZO>V, O@1TDPY8MR)GY^*$7Z+7..RH?]MZ1'SDO7V=
ME'6^T4PW$YFG!^<1F\Q'OX870M^$6 $I-X<:?_Z$#V3;@@%()#0>SPUL+H^)
M5X@FN?P]<3YO83<B6\*55'Y&^='75@4-H0\X1,_MZ$X/ZC& 1MRHK6K0ZN Q
M&D4EG@+#JPIR5OG%+\__:Y0A79%6)X/O8=9>^A_>BOF/D@P+F[XTUR'SBOB"
M 7QPA5PXJBZQMTE91-!$U JU<-I<$X]D]TJTZPYJ]L-JU=\]=Z7MJO3#0W+T
M>_9IS2'!:W/19IYBL.#I.%P5G)M(7=4%65=?7'L=R^"*]4H0P8:7*XRAQQ7(
MQ#9(3,)['T?HRF*ZHF05UB%(5YH]W[5"3P:A?7A .U_S7;*'B_A-KL^L<*>D
M"9:55U0 Z8CX'&2CR<C+7[T%](J5U&DR[^;LGX#:XB\;@@1UTSQMOUE,9 QH
MV2WZ1T_RPRZ@1*@S$PQ@UE_N+R %KXM.V]TNO@H4#R^DP_^><#9I_.UVU=#K
MN<K+ J*!G>/4PG1;COK]'J:M@F1)LM'Y4^NSXTFO!N19_$&I#@P8@,Z-Z$J1
MFW-I<?!?9NROD51CW.L#MJPG1H5[!+].!*3.1'/&&L25U3=4QP(%%'M@5G0\
MZM66X$65\MW #/OY6?SU'?[29,5ZPY!.BXDNG-U&'M85&L<9J&IPL8[K^Z]N
MS,\5(1^<'B,T?N6/E6*P?9-XI:"/-UIR=Y6K^(1P5:=^N"1L#*;L8^\))&VF
M9#2[:TC);.0B=M!GIO9MSO;)JNS(<T,Z(NMRD\<?6@C3<8>-'KSL8VGJ$%H/
MOZEK^K=(,:LH@0^_7%2(?G2EP5TY;JVB\OM&_/5J1%NYG\K6X.NO.!0=7=Y#
M,[?AK@1T+0)>%CE'FES9+TF\+2UT90"7W2_Y;T@:E/XMY1LI":H(W;.PB9;&
MPPM&E5)&+,<UY&  QG<P )EBO9\<4! ?"9^9-?+4:(^1SQ%KFU"Y+:>:5Z#N
MJ((!C.0EJCSZZ.F-#J^1(=&Q^/HWF^FN*DMO&X)&AR3/'@+=OE3>FGFF4@H[
M=6Y=5GLU)\0:E6.(G@A#^]A+[GPM%C8,+8T2B9 #\0P-9I:#JC*QS&C8]X,9
M_^R2?^2T:8J5)L70GI_WLLYM>$X/Z_Z0.DONKUL94__FQUGCW5^\K=SY"FF-
MKTV=Q! 8K!SIFU5I'AD^"25F?5&93F\>^4A8[-70[*0ZJ*]X]0]M@ UY):#I
M?VD#+1W[HR'3?83G/[3!GQW_J0SB2&/)@VTM;[[TVVI^*-O*ZB<2&OO7TP6I
M #_'V=AK];!S"/[RS%MYC:LC^__0%$23TC4Y^EZ-*!_K],/=V;/[ZS\?AE]C
M8W]KU(V!PSO@MF+O%I/W8UI#HA49K7M,VR@,@(%=*SQ&X= TB6O@URUH!%!4
M. ZZ7A6KRU]^"5^!Z^E/7,\.G_SXW1J&YR VW/AS[$%U6Y9P,XV'MH+_C=#;
M2)[(V_H.'($8=GK&&RUCG*%"?:MRY>DO1(9&-0W^+9T6K,Z6=LV@WKEE8*,K
M6/;M:IH)OGCH;7-ZR">51RK7FUAQ^$OU&__3) U07;_YCD28@BM2=5$? _A?
MF,_DBTIRU-D,Z(?@_.Q'VVOL_V.B9"PP@+\H_M6S/.'Y#[.C@XN-S.FK)8).
MDV __ZG-5^%Q,$;V]-7KNX6N=X>=*O&PW!YISAXZG;YFF!G*P?O\;WS?3(I)
M1@;>CUB;F,6*SQ ;U:3]U\S!XZH+0884^WE#[IN-FO]F=L#CW:6^$S3_@?/P
M_E>E*J]H]B<]R;_Z8;F&]O\._'_&P-]')1>[Z,Y.@S  :9*? LJOJM9(/B!]
M4P<JU3!PAQAY"W#SNC"*/>/Z?9;O&UIA_@H)6#?P^]1_GT?)P=J:OG=-\G!$
M\N*:3J5SP_TOC34!M+T*^NZ W?L[:12^_%4TK#J";L*EM@7$90U!,C+:\+FT
MB2ZA;4OKW';CL>,#VF&;,IO>SK4P6Y9AOU^CU__BA<.PBI8-HSN;9STH]EKF
MX4O51RG<D7$7_"#%(0 :AKAB $3H2E=%@3Q*5AQ*<:#7-V9JT36G^1S6^S,"
MHP=/L"K\W="_.N;_M4O-1)JY+3NZC5?Z'AUGV!C<H%1@L);W@.A0</;PG&>_
MV&NECA>\H:;DR+59QNX9$1PR/W9HG^-267*/67U\:K598*VP\"J)NE[JO?^T
M1UZ?.@C%O!B- =#B83643KTS:[-:JOL6'<]8PVG8!405#!JLROH&X:T*$F"=
M\*Z+;@ K8]T#5OG_\>-\__ZZQ-5X=H@"Q1D7Z/RY\?\?:SM_+KOD_[D0 \B2
M(=&\]4=E0B)*"9E6.5]LTCO[+$UH,9Y@DXI^7#1XYP#R#'+G!(X!,!*F_J@M
M/1<NSF-:M6 MQ<*%;]B6OG^*A\8!GZC_UM(EE7'W9G-CV-P"S0,]RM$@>@R@
MR04#N"'Y>W,A+VM<^HMQ*@3%94\&ZENB.R%,GY?[M6&D38(EA%]>B0$$%"_T
MG:*P-N02',7V>Y,C-#/*G/"KFUOC;F4=UD)*?@#-B8 "Z'YK.6JI;V:,<?>.
MHLF@89*K>T0H/-7=K%\;)>RAXA]%KXY/8 #-(TA+%%H* WB[CB8!_=HB;5.7
M*PMZ#A,U/3&8X<3JC$[)71K)YJC?6M4%;$=JF^26P/\,$FT7C=__,$9N& "!
MF&6Q1X)N'71H-5)^P=\K()B;<$[4!]B*@$O@@SI;\GY4%Z-[.42&%CY/2*MJ
M3K)EEG&CE,#C1O5U*UK1A-?V>AR:B9,KM)MS]#1UDTLA,KIE]7[H<3NN61?;
M4_\UFS:6)#=S645%Q/,2G(X9B8;=># 0"+2V?]1#].D9K(QP093.9@?1BN;#
M #I;P* ?@P$5;VND?A+W1Y.KE&( C[OI>C" ]J@38Y&."QQ.D" &0+4OP@$;
MT]Q4'E]/WZUUC3K#U4/;H_E S>LCDFN49J>-)Z.) W)?P&/<?<^P0,"+0/V/
M.O9!R*S?*-;UAHH'2'QU\[)$<:>:H=_%2R9C !%T?Q'D7W%1W[Q_A%\.EYQW
M0= =W"Q%S:*L?B4(X<V,>J'ZQ3@M$3N[8#T,X+-YU H&L"CW*T7/5!+O&SY^
MFP=]O[["+R2!W]>RL&]#;IG[RQL,_$[1Q%*&MCG].4R<]S^APG9$<G[U?P 4
M8/$N412DSC!_VF#:P+#Y2\L*#MEF;#7AZDP=53WO'-9S%XFZ\,( -A?*"Q5O
M$&1?AZ6-RY!&."Y$"(S,SWWZ'G.O!8>R1$CSXT%H=8%V +\GC)I/2P"J-F/(
MW$I(*TB)FYMG#;8PL"[\#'F$3&^MEVLQ84I^!BVMC!<:H! +*'/B'1O-'>U+
M)VU<\H5A "7JH+7+T)8V19WG/:!_#WI)WPO54L'__Z+^OQTKEB#F,8!P.Y2I
MK0_7<,4#:G<9=3+/3G$GG\+5I"-)/U/D?!%H%/L@L3K:^4\>V-[+W?8J)M%A
M2N. WXO.BL[5U0S4I.SD_W;#.;VY1%EQ:!UEUSY->O>.G.-EY3NX$>W++Z:T
MX@CT!OB&^W43/?H63++F(<3*N89C$]UWK<)IGXP+4VX"X<#5OM#9/4ECK.)C
M:SRX9#B_D,/QD-?T/RJC\O^KC/Z_(Q; VA/0(G4C^:2IDJOM3=SI 2V9-"<B
MHW2;TY7ZJ+D$E >0#NM/+PW'V:B%4\M;P](*9>X)79E+<2,-GN$:C.LJ[RHB
MO/8PC2.&9%4RP"@I+A]^,AW1=3]OG1/(\.#5B[@7_:&N4I]U8T[\%]K!V1Y^
M&(!*F&JYQU:NU7!*E3Q>(S]">Y\GHG');02$6,< 4EU>S%,J3&F([&#A:?P%
M\0T,X"]5U/A3%0UC +^ KOOWH$-^ [WQ;T$'_07Z3YJ_HUZ( ?P%.^3O83?]
M%7;0W\#^\S6L?B/Y.S?J_L:-IG_+C?\.F[_8\7\"&HC\KF3PMICF_'[>U%>2
M1YX]M&/[X0!QW\I]8^_19J)38M4+'P54?"E$Y7; ()57ZB&)NI',_\M"J*L>
MZ>WIIQ0N.V>'/[[!Z&W^>]L^"$V?4XK%7L:+Z9?]H+DH\8&B'3&>/)/Q=3*1
M7MC=>9U!9)-V&,[*#0^QU3W4BM.R+F&56%?H=IUYSN2,S81V3E!0"5_$R]5C
MY_&/D_C"]#B4O=<0*8[:A_8 @60S;TZ#[61W]^>78!41G587#JHS;8IYQ6ZB
M0+.(3)BMTGQ];T*NG*L Y+D=:Z1@586.Q.OE3@HUGT?".4,2U,;Z^C.>!I4!
M(QEFMY*VVUDD7EF'QQ!)1QYXRQ\3*V\ZDNC:@E&"M76E99Z'0'S1K2>\S*D?
MO[MW57>N5GEK*[,V0;WB$WU CB @N.6%\Y%W>D6, .WJNSY6BFWK<WE$GMXR
M&T0:+D8D$+>82MLSJ3IL:S_O^=E3T%.CI-F3HB\#5?BHNVG/QLMGNY0EQPP\
M+N5UM)>H!/BT_4!X T!C[2V/C6.J\$&F(1T#QBE8]_?P*5(Y-\S>V=8!JN:3
M*YK#)+?L;H:5VE&2:;DFEE&IQI'7AS"")UT]<92?69G# +*B9O3GH;Z#XAA
M<9"E]UU7$G4=^C_#9<BS$ZX?P5+6'\&2$(3W7VX48;F*(,+.V_SY2<)3JE1(
M^@T,(.>IA.E1!_A$YY!T%9[/[J017*@1H2>D:N'9$509/VCOIJ@ZGBWT 80-
M![SJ*?5$ C5N1'^0<S0R#7.1O-^;\SJ=D6Z6;1-4?S*41CPJL9WLA $<MD6A
M_=&DL\%@JMVC [1EK'\A)Y=IP?!D%AJ&MC0S846"T;(THEBF/'(V&?^M:?0)
MM$#[O4JL-Y0-\O1M9NA6G4*NW@1*:+=RDZQ4SM7)?#]'NT7!OUWY64ZWO>!S
M ]A=95(H7B"X9C>N+_A>=<A"98HT'X7HJ%"+EUFT8=7L35?\D)=0=']%Y/P!
M!@"M<'KE:24/>-B!%WNJMDH*0T.)$ ="7AQUD@1:!A.FV-!+*0<#L# 2C.<N
M&]OGC7AKQIJRWR&MUK8+U_ QU(,OU9<''%0H,,7+WJ.D>"7@V(03FY0.))RW
M<.33M13TBTSPS)AEWLHMS)Z9SI9PH9R$.71]D1A'%7JW8@"$+V%(LC*^L L1
M2EMX7]2S9T&W RBWWBIL;8M8!.EP(%&XL98)ZL9VT7.Z#0-SPZXT)AV*E;7.
M-*4UK"[9CA_PI-(.SNV##"K2&.H'2W*A%4H4=>=A-=3'2G06> T@PL#D%,WR
ME_M"9QR#E:9X$Y,H,6S<7-Z3EN7C6G#M15W5W<XBBJNKT9UK/ARLVB>NCN Q
MDV[[0KU98^L-VJ/!R^[-HFE>B_7,.HSE0K4<U94G#GOZZ^ZZ7D>IKY)2%$<0
M]VV_=V0N(N^>AY;GGACS[1"=3,QJEP?L'"P%R]VC'%,0RS]@)!$I53@%I;Z/
MVUKQ/"2=,D#QUE575NKS&^+[:.S124RJ1 ='PRGO'EQ9!&/YL8C'GV_HQ$R@
MG'_S]L:3N?Q]F@;CS^@EHIU8Z4*2ZT;[9QS]KE&X)C9)Z(C<L0D] [Z)5^[$
M8D\+KJP^$F:$P"?*^"%7)5*S:$Q5AU\?&EY;VLN-&4MIG2XCL@=YV62#(-5<
M(,2*4X5N!D]S<A2T#=P-L2Z=F7K"7/4V?IJM795BS@'T8\,RL:%1MSW;)).*
M>E &'FY2RJM-OPFCR%"V@O^Z-#FGW1^0F+8_ZG;% !2"WS2!J'Y\E#0R="Y'
M0VLIAQ@X$&$EI&3AN1/(W[@Y"2GOG5TK2U- XQZ>>8UFZ.(MU!-M.B<C7"]:
M@U;5401HW(HZUA*?S(=@(\$=-=_U*"0/> C$D^.V8-U>)%XOF;@\!U0,D LH
MWA,I.-U?@**B1D&'73P7 -U^U_W5-OM3NA(, /'1] Q0\IJGW9MX;*%P3 QO
M87)+3F8D9F&B-8)'^9%AM!UOC=:B.T3*1-)8];V8@N5G?6#_M(QH5<;+$23%
MQUM%4LME<G>/>MRTH_BH[KV1GRJ%9R /(S,65&_9J%N7KJ\(90L<S=Y7J<<3
MK6D3F&SRNE46BCXW@$4.HI?GX1,<MM\["<4Z#FAGEUZLFS!6E.ZR0#.^W5W9
M.--+$]2F!FA<GW).FWY7$M8R(P'/W.T)C"TP!@JH/E_*6H^Y>B=#> P5!3[,
MBXEIY)[P&1E%4KDKHD&[-\- 5R<,3K(T!OF+9?5Z/ETE'IS.B5\5BP@5<9!:
M':F-X)D_BL[U0#P-W-/?YH3,>69 :Z$3RT,^W_#L"$$W7Y:[@.C6HS=H[P%+
M"PQ8LF])N=KS)#O>@ #LG=/DZI4%6Y7I$6B*QE :A<5!';U<P:LF"J2!.';3
MW>[";<H; @D):UASZ5:.AI%T^+N(JRRV0M>+E*X&)CZ*F;5 (T4_<GO?>HQB
M'S]QGV^##;I[^*T9(JY)-&>.V4^!&GL!2[Z^P\F2H2[4QCQM!KYIM>]#"OGL
M<7JH"(HHRNU:'(07_158(_A6DK]&WJMM#_YLA K;G\L_E;#SHJW.9/?B3O(U
M71$6GX6@ *6[!'6FDX(&(QF<(KZ)+K:"AM(-"NGB02_\B!9UGI]8WIWA4.:T
ML3WB2,;Q ;HN/R]#ONWR<ETIUGLC T==>(TL*.MT]:G5";H="SPK%'NZ2!^^
M>.72%)S^)"!G\J1U0Y1?_[79%V^][_N4N6ZOS2-7FOTCWP[6&[YI5-TGX-F_
M '7VU>RZ^;T1I86"$>YW)J0]XJ%%1^?R5\++;IY'$B@@-14&7"+L1@@XCE6X
M1K]#]:H*2H1>'[.FC"BGAW!N-=!N4.'("<.JZQ0&FJ,XV2:_"O=Z'!32BB-Q
M(Q:\NY45FTR8YP/,JB/-U<(J'"O\8V=*X"NZ$QA YH4=LWT+U@UAS!S@3T2)
M[OKP<PAQF2QM*-_F;;YKRX@UARI#Q/#6M+N[QZ%)S1.C:N@A)2R?)VNHP_RC
M3/!6@'322,E O'=R0:[G/MI(-SM!_6M(.$Z\/<0F2@>9]NGH3" V<VS*T&K"
M9W *FO(U)^[=-U8\FC[?BWRG!N_)@M%.4\LE#,#0][WDG2>3;^2&WF3+7!NX
M]?FY3YLX1_D "I@W@Q(?=<VWQ1K*RG$E*NFPY^0WM>Y&7@")C)%X+9!;B#L;
M"54-C.1WS!S"GY"_!31-^7#@*2.Y J+>'6Y=:W.R:$RDQ;V1HZW][C32.86P
M:2@/JB!3K-W([S1= U][OC&1<M:;+Y#A5,H)OZ7W-%GW+1X.5/$8L?9&OK8W
MEC N<QV^!KEB:A/C 0^_V :+/QP;[8T;.5EL*_6(4J],5A5T^$J:]'C]/GX\
MY;<F)K.DP6R>KFCJJMG#TOH\#U&9(3&9!7%E[I[<=R_8P6=,OF9\X;C:>,]P
M60I86SZ9(^WB<MOR.L_L\NU&R8XE=.X"LN/,Q3OH4K5W5<.+*\1YU 9YEAJA
M53#S:.XBBNLO' \W"/%.^;/3) ?GD.T)^7G#8/CF/8_NJ>_F23KF]%64524J
M0E= BLDJ/'&O$];19G;KC0C0'N>Z 6'BRS=2MIF()\BY00O!".9<+9$4TF>+
M-*>414 >W+6J6H%D[P5E&^!]5ZG:";;GLY6BHNDJ<J?KJBV^;&4#2TAJ(QF'
MV0FWF*]$\05NY7?\QAEQUI,&_5O1%",NR@RCK55GH5/K',OM1]Z*?704.E,>
M:WB'&?>+49 3#*")NJIJ_^(R4>#"J.Z(V4@E7?EZ[3,@9\)MN9H<G66W*%!'
M&OMJ&&?%I&J P3TXM\2PW?$@2>K"V-*M60XB-0_4_7PD68?6<.702#&K,H=.
M",/E*7^F>Q+KJ_X;0)Y67^;^;10U^ 0D!VV0*:^Q%NO^T%AWA5:%R"CM$\K:
M%SF9W(V^QF&Z@XKD_BU,7(S;!%UI7&S!AK\EV-"4I: 51! JFE9H! GCDY3@
MS9ODV;GE>RB'Y('\,!.N6JXE[-KFBC;JC+>?\*]7R\^A.$I\(AW-'&;7]NBB
MHW8%3ZAV./K>*&>"+*9],J]B #(?=_%V!<'P06@=5XE/[25+A]GUVT0?TQ=-
MD:23H3E4T3]<N.2W$'9-#X/)XD9(YSK'[QD*4ZE_R7S5?&FD1'2;A6:&<O3_
M\A7R^J"6,T[3W9**L'.Z:_H(7;@"PW?SY@\9DWBLD,?LK!(R#H9CR V.ZMK=
MZ9V0.GU7(&V<^?QAV5O^B816M;Q51\8:O(.\G%UUN-V!SQ,.A+*A?&U=)&[:
MS3F!>2PS/N)]DN2FFB?.L^3X4;?(Q(KJ"9#N%H.QQ!1S1&9]P?L%LO$42(ZS
M@7W+N%T%@CKYPJ)%.5:-LLQO+G4OLG7QLYBOZ\-",LCZ242AZ%US4OBT!YUF
M.9R?(S_IH4"Z2Q5\\F8\=6GENS6MI9<5=A(4-E4S3-"!G%HHKJ%.K?7NY&U=
M8;Q(K#SH5@2!-D91 987/AU$,L 3NPGJ=#)K-SA[SY6$Z*Q"0AJEMT[BB (1
MV51L! DYY]ETN/#?@DGT09<FH;GW:_2SB9[.FO7EE2RC;DXTY"PHP8#='/@T
MHFHQ+'>("T+J%BEH %MZ:);=%#1-9.^R/7W#E_HG(\=JED"S//H#OCAY& ^B
M6F\U+S/TR\_/&OR6N-*-U"U%$6, 401FZ-H.5-(7+#-%_F F4)B+1&U<&79*
MS>G.R$]&7\AWT2A^N2K_%:_><:!@7361<L$!"5%NEB.?YW+N<LR=@G9V''-Z
MTVVC^2=&4SR"9&T9CM\\ODB2_C1Y#CZO'/8 &E*E@F-Y0=CXPOZHX[BQO1;I
M\C$!"BZ?VM^E"'FBBF_H"CT\I:[\+57APV_ZZ&02+6=KB6Y(/QT1,@U)*PJG
M8LN$A?Q\'8ZJ4CCGJQ.I_ U5X!V3CCPF:V'35-WK31(I285SJ;HJT$9_Y89^
MSLH[GJY4UTLD#EX$FTBFJO)OQXRIRCC'9M9KMMY9\^_XXO&2Z.;ZKFS2^VNC
MUQIY\]D5H]><0X>1$BEG3R="JDY<P0I@PT+2.LZL99SX#NA!47U5R*33J6OI
MPI"N;?%Z_(,WG+O;&:1%"I[BK86<7WTM 567) ,$VR9LX]+]Z^XYVP))-*<-
MN^"=8?[WKCY0A6@:.!=.]K8>87WK 0DJJR.JB$B($'R+7]P"T&A>!G/(Z_)%
M?IU#2TSSZHA)9ZU#SP)#K#TS! ,/A5?WMMUR)RU5M5Y$PS[/@<CY4I^"N_"!
M:98R7A*PW>T9T[M&:V?\AQ6.':\M'_+R\DEI.U&<I:PB2S1&6P0%?4FJ1[/B
M>4D$.6R7YG8L7C^/G%Z+D/]F#-+MM^6_>/-=A&,8Q;4[,]/1YB9P5H].='5@
MM.;F:U9PU0BB;?63ZE@T<BN>%PWFZ^0/LV9(FMC>4S(/?>#^=#[XAF_U0H .
MM\Z3J@3A) ZSUHDK:90CIL^25NZO1)!F/[2\(=\[X[U(EVHVG)M4BUOTQU?1
M?TS?,>0]W1Y3^ME9["F7!]>O&8P:I"1@L696789T-?[' JS2/[,6-G'_7%'\
MQ]+Q/X\+WU#\Y_GA;]D&9$A:_RBW7 !1@99>P!L1HQB )?]6W._M!KH3O_B.
MQ $9TK4//RLT)SQ>H+C<,\33,KQ9PHKD!!,)<ZA$MTVW/X CT:DU)=RA&KHZ
M.$.'Z7>MW7A/3/ -3P^A@Y:/IDP5 PP>>[ +.GD<'MQ-^H:\2XN?>ACQDLO)
MN[MPQ-J6BR$@ZZ'HW=3EP&M7SG6ORECD,Y?3].ZWF;##?V1RIE55DK?4UX^J
M%F3&NO>SB'57</;7C07*%[E(.@HVXDWH-8X_D 3VTCSB^\1[DS1&5CH.!;IC
M(BI#^-$ "EFX/CX+WQ6/A+<G,5]$1GE*0&F3^0/*VL1KX!K6B1\=7D9_7&1%
MA2YG(V4"1M^A%*RYL'&@E0U5S%0;=;N[R+:& KN _]>#$K)0\8_V((2WGQOT
M<+"C8,RC12I(;_?9GND"ET#;/,R>N2]^^0'>]&KZLQ&"]L9<R98>546EHIF^
MPN1/"WN3*U%1R4(=\RFCMV4D7T'^((.N*_(FBUU(IFZ\LW8=G'V\EL0S!B&;
M(9N]O<AT&7?SN4N/MH^DPF #F4<FS:.S%21!JU1NTE2SH+WI!PXG^6T?Q'=.
M?OQZ[B/1;NH0KFU&805&(8:*RG1R!)H>JN2CJ1F_0"+Z_A5[B8^\&N_)D&)L
M0_H(]!I,W L4%Z[(E@F]]7.?>^X;,@P@.DC]1_KK(D4W<?3W&SK:&$!@.U2\
M+)1#T& X:Y#S&1A7Y_2EJB;Z<MU:6Z_BPREV%;Z%5:[HN(4>*T/#JG0<'+["
M\Y:+8?&&W%(45V8R(L/S4;0]_BM05<O9C3[X9HGKM%K^2Z74O4YOPI5Z]HD9
M#B6KK7FUTL_-H0= A1?YWFQO5)W;6YKU)M SX.8JT]$%I?^8 O$ +=!._9D"
M@2B1I]T>?7/]\[I!>O"D:LT78G+M\A@3_2A*')J',W6#H8D=B7IDD:L%'H23
MBK3L#;N'$4NU56%YXPO6=8'!'!"QP/7(Q&-2$A,^>#8R*G3'WJXNCYO3O+R\
MF1>WG?3Q!"%O^'X'?XOU#.M(1:K HBK\\+KMEMWU1YD 0>('GNURM(%E0$&E
MQ*IS/>O)G9KQ'H@U9'=19E!G5;!JPE^9TY!Z61J6LHB7MP9L\-<>J)/.]UC8
MX^@0>57KPG9\_<[ESQR7GWRXWH$PH='E/ 1>2$QL3PPN+P1NB=4,.(:0]Z,M
M4M;OL]IO'&$ ]"JSHZF]VPC#?A=;_"?]?!>:YU+WAF+.-C:?=.9=6KNT"@;G
MZ%<BW8+HV@C<];PW]8P-Q!RZER6_MZE=BJBA(5(W,94AC'&'S6  $8V==ZIF
M3 /!&7)Y'LYM$L0#+ENZ>K8L.PI3[RL(&'HH&:.A&7.NQ6[(F8!"Q-ETW/>R
M"6O=H^MF!).R>B4]8Q;JO=?-3F_LV;"YQ/XXV>8VJ]D0>>L,[>Y.8(6/I,I0
MLD8U_-"\-N&8@"+:P4E7S"S%R3G-9KM^88M"#R'H)D&O8*H6$4.MY/-(*)NZ
M83?^22)CNAJP,R][#=QX>($%TAYQ5K-)59SF[SR/ 5SY5@0D /.1 >F_$]#'
MX0X^9LQRD!3I:40VQ.:#(Y:LD\B&L@)%V28$6!Z_#4^Y263B.%)W=*S3.&2[
MQ;6];:)7?*?[G2%%A _>$GLJ;=<Q;.<$AI7I[EWQ5#''C-F2]$*%$I9TKLJ\
M2*!Z;G8"[7,\6J,B,& 5 QA.6B$W''0%!7FEI7KFAQE+G\LJ+2DP<%ITSDNI
MOU60#,KQO""Y"'=%UT[=J6PLB1<'HN_47Q63?FFPH,#)TC^J4ALO](F/IU?E
MVI7%27$@\;%Z_QOAN52Y)X.N9H5&&\Z,"NQ- ]GRV;>/:V.C1B>J;[ =*9T=
M5K/:([HZ\HP]8-*Q"VDA13E'+N? IY'Z=>!3/0X_@:UO2Y%^=3NZ::+%-N@%
MLFD2*+&(P+6N>"9:FU12=;^P6G1MZ(6X)" SE+V)X_<2@>__4C+ C@&TF!G^
M6.B-A2#PL\=BLJE#A$) ^4>DJT\(G=0C-]FU(H2$NU^9G< ,;@0]>^O7X\_K
M1=BM_88Y,W&%*GSCJ7KZ--&.(*0?)-(]4%%362\?9/'0O\&:R!0#T(<HA#+Y
M,84RWP@6*(ALKJ?:U_/R;:>N[Z/#5]'KFM7/WRU..+PP\GESBC1$RR$:SY;)
MT6\YUD1^S]BPD"^*Y[]VU%*7\;KR,Z&N:FG-?[%)%H^HM5[2&_#12[GA5VL:
M-"A#'E6ADTPM,8@GD7U+TDCMOBA'-)#V+MD,MP3=8)K2M^&1RZU$248$8P>
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M0\.*V[>(5DO7U7?6H\?MH\\E6ZR97A$\BK>_'&*NDEK5Y:'%OU WWS_(&[,
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M7^!;JJ$-S;!^"##SS8GS\TB=H><>A74NY@E.=#Z3HP7->#8282WO&9^2JCH
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M,]Y.A#GV*7"H*[^@:.T8C<H"MIZ8TS_YP";DPU#C_ D/<8:9:ZQ>]JKO,Y,
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M?M^LFE75W:M?EUXW >^EQ:7$ 5#O  "HMQ?@=04@"D" @X.'@T6 AX='1$1
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M0MB_#T="&7L6\_+J*D9K,W/&L[WF=,]A6BP#"(DEFT2*6"R;F>M'-57C1$\
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MA-K#/GZP^9D# Q'&:?A6P*^OU;)$1883R=*.-U6/^<?/LM#E<J/?]=9I@G1
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MKTL8\QK])>@]-G=K\*;@\8;+X3JZ^WS):R]/%Q7\MA[Y#4S5D)J%)>/P=TV
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M##I!XRJK=M@IT<N:&.NX09H.N<JVW\(\H^V6#2&40M#^4D>+V,7E2T]T\^S
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M:9%(C6OHA2X*R+4H6#_@YM$+?Z3[45F!O3QF./6Q&?7Z/=95?_Z%#KUK#IX
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M;++$Z$:@$,[6;A>L?1[&OK F?7Q&$4K*$+N'BD%E3RBQ9EO::&610W'9'"Y
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MX'00R8ZBV5\/MTC)_PT#_NYPBZN-J12(.I*7$\0':T  VQ8:WAKPQC>E=&'
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MZKAQF!0RWGZN1+O[3=SO</PW<_>O0-%/@_PU?A @->A$Y C;!PI;,5Y0S2#
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M(K+WZY,O8;;[%-IR+<2L5^]/##GGWKES54RVJ=AK#VM<\AME1(]E.HG*%^;
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M9G(MYT'PN6M1V/-;/2F0'.9@EJI@:__*BL BR<Q\F)\R0KH+@J0E1P<&6U"
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MM.D" 6[S!?ZHGSL%%LA(#BH6[1SM\%YKY>J<UQJ,;HT! 4:A4436 P&ZY"#
M"PY_"+ +W9N(#0BP7C!C5;Q>X6,8%UY$;HN"\CB\AGOU16'L*5ZRX5&@5Z!B
MSQDTTWO6\F>]1!])E\F@X>4,%@V# ($E!AEA_T^K.4>=^< 2YGP+"O\WSVV
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M6_)7FE^:=,":X\76G48V)EHZ9'Z*F^_7=Q@<VPPGH'&%3\((S2(,G*F?>-/
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M$8O(N8Y:0SHP5T-%2TVC^!-!<Q)^(LR>NACL0<#8NAKM%,N*'#6"3,GH-S\
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M8AA)XS*^%W^OL!YFM&5(1G$O\&&Z]@?7XF%N;3SM6,J[XQB9O9,B&51_9%J
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MA($T?H=J#!5_4>ZO:_V7J23O71ALE9*UK'P.8A\G%'(X^(TO*B]V1:X)_ZV
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MFD"M:EE[L%(<-R%Z_BS#B7N'9#3.MM139?S(9CC=Q(O(K9#TYR7A;3HC54#
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M*AT3F5H<BWJ9T(?N_ETB&J%-OXCWR_7!5(TI:@)Q8?(WH4%F.6_ECJ@<4+;
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MZP01K3D:J#J1(ZM18L$EW, &C#/<EGMEL-'E+Y$DJ-FP1.VM0*14=2!LKOU
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M*V?I^X\D2L:+<NQS#C5$\^EB/XR.F6.^1C\V,N@1YZ)A)>7E/L17?'.6VB>
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M;D5R\H(5K5MY]JY!RURTU\S)8:S;7F%?;RN*TG'/E\O"_<PVXEH?N]1P+Y-
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MJ>^V.:,)#A!N^:'T_I?O?"YUIY7U"]-+K;(>.][^@F!7VN$W[%E99<GN-_>
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MO;$8W#LL?"$.LTFDH6\*J.XFRK]XY?&<^GV6W'LK"7#OND!=BFR3E=K3S7N
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MS/";"[O[38*\@)&S:8=8Z\2!(SBJ^AS!UHO[VN1\20Y,%FX(PV*5_E3((Q?
M\XV?,>J[*>VV.BF?&MJ EL..["[L@!LTF'3/!*RGKKC$7V;R7.^P4[-[5"DF
M)$$YF=B4O>\6$5D2"U%556'7>3VQ73GI)F+8/;KXBBDB6"P0@8)N]J1A8\S"
MA._IM("7Z\#B*RK!X&D;F5JB<DN%V0^?EP.<"+^?EW"*:?G<:OP$/.P-%@:&
M!CP-<0-NGY EDT<5]>09VX1?\ ?OV>@N8"<U9%<P8U>AK\1<%DZ*NG_)MZUU
MF9.Q$6@:ZWA<7(M/Q=7%4"GH/7KP=*8A'9E08H<FD)K;N<9?(]UMFB02*[*#
MU4>ET+JOX\8^QRD+YWY@%Y[\4;'.'"5(+P3=_ 'F6:'^I^#\P@?5:7JY91G4
MWYSYO$)(@Q&D$58,5)7"4NXYT_(Q7KE[^'>%2\Z5L$"MR=+U ^RWK2D R_0U
M [$C.#;:/%R5&_4EN)Z!CGQ37CQ(IZ!(:K[!"LITK7%EN6!XB%C>ZVN5$(WM
M%MVN-EWPM+RPSI6%/N#TY?]26SN$5[^4 UI9N3[+S\ =GFX(2EX_-5XUK][3
M(J;N+5B:L\2DZ4GA"%BJG.2L1H\IR>$P T%*(R(^CQ8!Y#?U$N\8@JGF#93E
M2)0NPQVY=C*L:3O1G'(_4YNOCY?8N MQ&[]=6KQ2%IAG/EPU[0\K"CPEPI;P
MP1DP0E,/18+,?#0M'/TOJF.2F[K1$Q!R"^;DXMMI!''L*&4$]7DC/*%<TG1B
M&.86<EA.7;H!)9 ?S*2SY[>\"DRIR <,P3SLR::>PQUIW'@H=.M!?"D#E=_/
M-Z1,:N.1K[_!JCA4!Y(]@K*]30  9CJ>D6KI]WS^@JENEA9ATX^"!2!8AQ8I
M4CRT3N_JT"A6\)Z9'?QR+"[7'JHG-)K\'\S#J>1&ZV)=7&GTJ$(98.F\/EJI
M=KV.)9)CUNVR(FA.[*=H05@,##&0^"!Q*2>3>O<:.)\ROPKQX79,B,KG86;G
M<N#*I_5\D=[I\9)GG/R785LKXEV+L2[P+ 'F3:,>O!_GPOS\P9;^[3(N5H*9
MB9$VSIR<DF-/JQ^\=(R]S@/"5(3%7<4UJ3J%:MP3]ST3CCS0>5[3QN42-XW$
MH6(S!^^Y]#($JC:,'KDEZYWSV:&0.QNPUG!LSATGB* !3(B:3E0EB_T)C9?T
MEJO7Y^6]Q+F[:!.4LZ[\N8'1A)SSU #1B5$Y6*(O6&+H/'TNM)03J&9,RE9<
M_"6P#?AAT@WYRI]D5WUP3*#CB 0N+O,40V8*!3=HJ>-7[YDX:Z0*X7(LX^I4
M!GO00Z/K+;2T<# 4T&'Y^=Z9#?CC\)=]A'U%S<<;]X"BI^6BOD=)/C[CHQA[
M?DS$!JF1DG8V1 :J+(IFT2*>O10]%(!MNI6S+L&93B'-/?K%H1R[BYR/J&7U
M;>%>:)24(Z48$GNY(Q^/MGPJJPP(A8U! T(T+JCUZS4B=]6\GL9'R'V^ <S$
MB^HDI%EZ%BW'.J0^_S"P@C:$OUY?K59J;VP#V-W*6[;$IM 1>#=L:_#$M$<]
MK@O$7G5EJD;#_+K7F_<0S>F2LACX??%:7\8&F- N)J:'7'&S',R=L>80O*E[
MXF20,EXQ;E4]B70P6F<E3ZLI)DU+Q".0?R*<,XYR8KQL9#M#KHWOB(/(2K:
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M1UJ<EE-;00F$=Y?"Z43%E =\KL$2\-1U8,1*$)8PW8=>AM$IX?<RN<-5_![
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MY/UG^1\7J?NY_P)02P$"% ,4    " #;@7-8[.4DQS\%! #!-R8 $0
M        @ $     86-E="TR,#(S,3(S,2YH=&U02P$"% ,4    " #;@7-8
MM,VV_W\F @!=V2  $0              @ %N!00 86-E="TR,#(S,3(S,2YX
M<V102P$"% ,4    " #;@7-8R/%TB_"Y  ! N 4 $               @ $<
M+ 8 86-E="UE>#$P7S,Y+FAT;5!+ 0(4 Q0    ( -N!<UC*.759-CP  ,G\
M 0 /              "  3KF!@!A8V5T+65X,3E?,2YH=&U02P$"% ,4
M" #;@7-8.CS32QL#   I$   #P              @ &=(@< 86-E="UE>#(S
M7S$N:'1M4$L! A0#%     @ VX%S6.<Q@W3:"   KD    \
M ( !Y24' &%C970M97@S,5\Q+FAT;5!+ 0(4 Q0    ( -N!<UC(TT2AS @
M -P_   /              "  >PN!P!A8V5T+65X,S%?,BYH=&U02P$"% ,4
M    " #;@7-8>2+;$T<%   *(   #P              @ 'E-P< 86-E="UE
M>#,R7S$N:'1M4$L! A0#%     @ VX%S6#YR-\4\$@  'XH   \
M     ( !63T' &%C970M97@Y-U\Q+FAT;5!+ 0(4 Q0    ( -N!<UC-P* _
MC\$  #8F 0 2              "  <)/!P!I;6<Q,#0X,S$Y,S!?,"YJ<&=0
M2P$"% ,4    " #;@7-8<?.,F< I 0!-30$ $@              @ &!$0@
M:6UG,3 T.#,Q.3,P7S$N:G!G4$L! A0#%     @ VX%S6,CT&U[*V0  HS@!
M !(              ( !<3L) &EM9S$P-#@S,3DS,%\R+FIP9U!+ 0(4 Q0
M   ( -N!<UCI__C9> 0! ,Q$ 0 2              "  6L5"@!I;6<Q,#0X
A,S$Y,S!?,RYJ<&=02P4&      T #0 J P  $QH+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>acet-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acet="http://www.adicetbio.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acet-20231231.xsd" xlink:type="simple"/>
    <context id="C_8c149222-bc5e-4c16-ad97-efbf7c1789f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36cb52c2-306e-4caa-b3ac-f865a14de66a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5962f55e-c424-4534-bcc2-208837c6f318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_42ffbc28-8797-4c9a-88db-e5d89d2b4738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ec965417-7244-4e77-bb2e-c305534384cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-30</instant>
        </period>
    </context>
    <context id="C_06b4ae69-f76e-476a-824f-b50f46053d25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_7e25f46c-a94c-4ebc-b2ae-28925638d603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="C_521621f6-cd1f-43e6-8b46-e9d3d9f8d92c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9348b37e-6b12-4d6f-ae6c-a16de43632b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8c7df557-b405-497e-9c20-e9d91070c1c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_4e336b74-cdf0-4074-a710-6ea06894b567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_9574821a-e3a7-4169-a889-41b0f5866c4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:BostonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc080d41-4d34-4968-8ee6-17defa00e2d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_58d02c2b-7ab3-4be5-b6e6-472220ca82b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0fd947b-427a-49bf-b248-d4fd92ea0354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a623b912-7fdc-45eb-b768-963c9acc0e80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_347a9bbd-5136-4186-a21c-9d1306e004b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="C_6dce953e-d2b7-435c-8ac4-abae82da8350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_861cf2db-c8b6-4b71-8308-dd9637a42ef6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_10c7a5a5-e785-4aa8-b13b-b70c7914a426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_bf683366-266e-49d4-80ac-b860fd1c30bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_03b04d41-2a70-46cc-b31d-d9c911eb2cda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0c69718-cc5e-49e4-a0e8-bdc77ac5c987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="C_733a8089-51c5-4d2f-ba06-56a474b671db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5315a26-1d42-4c2a-88a8-f9074dbbcfc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ebaf029a-2dfd-4e74-9c11-5aaa7f157e14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_567c498c-9118-465c-999b-374820f503df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="C_dc363f47-13e1-4ded-8501-89b95420f66d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9d5312ec-a7ba-4ea9-806a-0f9c38c43ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8b31a2fd-9ce2-44b0-ae61-2ba25f62ea40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_b3211074-499b-46e0-bac9-fdef2d5b6a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AdicetTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_241fa14f-5fcb-4423-8601-15153c2f69e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_84848db9-118f-4390-b78f-e0b308c9a192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b4e3d6b0-f801-44dd-b98a-08f6aee1758f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:InducementGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57f55a55-f9b7-41ed-98a9-192b9feeae13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f44dae87-630e-4f43-926e-3a7d2b0185c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3839044c-67c3-4761-9d07-88d8d945f812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_46cd3449-6f00-448a-a65c-df577e2a664f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4a819e95-0893-45bf-809c-89c052bcc2bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_af2ebdd0-26c4-43a6-a4ca-3aa3d01aa585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="C_50941431-c7dd-4f38-8678-4027d202f1e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f148e6a6-cf77-4216-bdf2-c79ea3d192a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e7c9f079-510c-48e3-b00d-988277978714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_e2934718-edb2-47e5-ae88-69ff951335ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_941f1480-af5e-406b-8c0f-c6265ac70511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_da045486-c2fe-4b90-ab00-21eab7441f0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_af925b6c-d225-4763-b22a-b3974a3e23db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_120ea2d3-27e2-495d-b032-85ee8a4225d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e485415b-bfa6-4e68-b402-10c45a238a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4cbd04fa-00ff-47cb-b761-f69bdbaecf25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0981498-005c-4ad0-9192-bd130ea10fe8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e885ea3-80a2-45de-abec-f29848bb6275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_869bf6a3-58bc-465a-b7da-4f80fdac6a75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_530cfa2e-3440-4246-a577-8979ecb76ea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e312fee1-4691-4e86-92c4-5ce4a346c5df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28bf845e-d84a-43e5-867a-584ae32a962a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fe26f58a-9036-43d0-abc5-d86be0b9ef22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ff7e4a68-2391-4c50-aaba-76ac9387247f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f218b6be-cd0a-49e1-8525-a5eb02ac8f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_311e49e6-e6fe-465d-83fb-e37ac0ea7ce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1d264861-044d-454d-9a46-2ea594afdb73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-28</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_c4019755-11ed-4ad5-8299-f0d1cfdef0eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_596f1ec4-c26f-47d8-873a-09b6b3910e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8c4301bd-829f-4113-9dfb-fc7cb0d08261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1caa1e3e-b49b-4099-b413-9f91f7e43341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c123cd80-5380-4099-a3a4-c9250a72e19d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b4a7d79-358a-4bf6-8b1a-17f8afc3527a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-23</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="C_dd112089-6f8c-421a-b580-9551aa752b5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_40665ebd-fd67-4d04-97c7-45124e5c850b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_91bff28d-648d-4207-9e94-2523616823eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bcd33f2a-27fd-406a-827c-58b453fc673e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6266d910-cfeb-4c96-8052-2f53133c7cdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3e7400b2-991e-4baa-bd6d-1b6d5cc20a11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="C_11fc1a2e-6bbc-4957-8f50-7b077832e3e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_747dc985-0918-4eea-aab1-03ff0d433f81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3230b6d3-1bf9-4181-a9f1-7031157a8914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ac9c8951-310f-4055-8d6a-dd9b592bf973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_f58078b6-76be-474e-a1ef-f5d1e47368bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b7944d0b-f730-4427-b995-a253e5c8fac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bd6622b0-707b-4b92-a039-abb383da1129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_301d7c2e-336e-4386-a679-d09592f8589f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_254f47ef-7aad-45a0-af9a-05ffb52efd9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_119167b2-4bd2-41bc-bc2b-7272a38298f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b748401-3bad-4b8b-a340-f66ff9129682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_916c0314-0614-4526-9283-d8a045dc95a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:WestportOfficeParkLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-09</instant>
        </period>
    </context>
    <context id="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-30</instant>
        </period>
    </context>
    <context id="C_0a65afde-d201-475c-b3b9-224c530f5ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d422142-c5e5-4b57-97a3-51fb1b8cf885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cecd4cc3-7caa-450f-a101-f3b58059d74a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:FederalAndStateResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9dde8aec-c602-4c92-b003-83bf44a811d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25598d97-d78f-4397-9197-66cd5cdbf8ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_edc6bfee-a0a7-4dbb-a2f0-2d9cb5654b09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0e5442b4-b4a0-4661-aeb9-e32534abdac2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b17d8234-ba90-441b-b4a7-b13d05bda5b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_84de4e02-9bcb-4587-b4c2-9ad91bf61ddc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:AtmProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_14728681-e228-429d-9c6d-e288fc904418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_10e00936-04f7-40bc-8922-30c108c241ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9b5d182-d438-4385-8651-fad8f690a69d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a8e06b97-dcd0-4935-82a5-621e10a35a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_54fb6a03-848a-42a9-a84c-0292032c99c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_f239a655-77af-476f-8413-e0d33ef6a09e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_017e9e60-0f49-41f5-a465-41847cfbef4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ace4969-2a3a-4174-850a-95de252b6cec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="C_1127a611-ccab-4753-9b4a-ad14202f612e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_57732136-14ea-4518-80b2-de77d352b723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b2ca41eb-0eab-49bb-971f-56952843d4a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_734eb96f-caad-4eb8-9771-349750199d0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4cf6be1-4f2c-4f83-bfd3-9d9edf02216a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dbf4e63c-86b1-47fc-8dda-dad71e1a42cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8dfe4ff4-baa6-4df7-adb9-4800a2eebae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8f65238a-1a42-43ff-a87b-7cac1f995a5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_897945e8-d886-4a9a-afe5-8e849b01fa66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:BancOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_e30421e9-e302-416b-8491-76859aa72b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d8568b6-257d-4933-9f8c-8954426bbed7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2b3a4007-846a-4910-997b-c91ad41987d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_20687195-6562-483c-b3ff-ff5be6c897ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a1f48c1-61ea-48ac-83cf-0496c0da44fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_62d1c290-a6a5-4ca0-a3ab-96d98d887372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7d48a06f-dbae-4fc5-8ffb-b637076720b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_516b6271-7ed7-4039-97f5-4296694a6d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88454f42-8fdc-4021-91ce-b4d6b6330c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2bbcb4a0-03ec-4fec-b751-f0405cc986d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Customer">
        <measure>acet:Customer</measure>
    </unit>
    <unit id="U_Segment">
        <measure>acet:Segment</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_78e26d3a-28ba-443c-9f3a-713342ae37b0">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_4e336b74-cdf0-4074-a710-6ea06894b567"
      decimals="INF"
      id="F_b105355c-88f2-4bb0-9587-2ecb45059c3c"
      unitRef="U_USDollarShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <dei:EntityCentralIndexKey
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_49ae315d-b10b-4413-bf96-d7282eb25f7e">0001720580</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_bf683366-266e-49d4-80ac-b860fd1c30bd"
      id="F_f30c709a-76e3-4145-b103-2ca8c4ebcfe6">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_1fe11b76-4e54-4945-809b-fff21b239652">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_861cf2db-c8b6-4b71-8308-dd9637a42ef6"
      id="F_02c8489a-6506-4289-ab9f-6643a1cc30cf">2035-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:AmendmentFlag
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_af856426-4501-4430-80e2-08edda63f4be">false</dei:AmendmentFlag>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_25598d97-d78f-4397-9197-66cd5cdbf8ef"
      decimals="INF"
      id="F_8355ddf8-e507-406d-9614-b01702d73d24"
      unitRef="U_USDollarShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      id="F_3f165358-ac84-4432-ab5b-1a2e7c4a487f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      id="F_6a2aed98-a0c1-4bfc-9ae8-b9b0b7443017"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      id="F_15175557-fa82-4f42-8860-de5b090ee079">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2"
      id="F_7c070633-44bd-4104-9d0e-d47392d30bc3"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_b52f8333-ac77-4d14-a73d-eda21bab3138">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_01f65c5d-2a08-4622-bd3a-4830f7d431c9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_237ec7de-955c-4e3b-904a-58f391d9d8df">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_85ced808-82c3-45f8-ae78-abf8dbd9ec63">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_fc6174bc-19f5-4396-94e4-1660c15c5604">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_5487efb0-e011-4dfe-a731-92d399b589a1">001-38359</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_895f722b-a426-414d-b53e-281fc85757da">Adicet Bio, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_4370ed9a-8447-4403-8142-2026be019dea">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_1d279dfc-a083-47ec-96d2-257c22438ff7">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_0c8097dd-1b13-4984-bdea-4e6b6155dd40">131 Dartmouth Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_6ff46ed4-4537-453e-89ac-d080a2b2fee2">3rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_06ee9583-5e64-47b7-85a4-d7f262e08d63">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_9a5e1c41-d8ec-4c7d-923b-446353b27acd">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_f2e8b506-fe70-4438-b7db-bd9d66208c00">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_9bb7696a-e9d9-4e8e-bd0f-938c4bd7b19c">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_22fd7ddc-a223-47e2-97ce-7ce438cbd0fc"> 503-9095</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_0fa302e5-e4d1-4a85-b711-f6b489c648de">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_f79caa2e-8782-4e69-8014-d05a2f6868bb">ACET</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_6abf3361-7415-481d-b9c1-8d10969bd5d4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_f777f323-b717-4618-b14f-97c869220884">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_fd08f763-07dc-40a8-a1b9-6b1e120e377f">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_34f4f070-4b65-42e3-9318-2b62a1879d16">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_5d4c1616-7a92-4e66-9379-2576438e83a7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_ea21a242-d382-4052-9f27-6e8640851e69">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c293ff81-e895-45f1-831b-bcc2e75011d4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_ef2c22f6-c502-4035-953a-d9c217b44dd9">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_7a1d0098-bdb0-4eb4-a77a-d7006cfb6b21">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_998e3a19-8fb8-4880-bece-ff08b3f24ec5">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_469ca882-3f02-4a2f-8635-8b93ec42fc7d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_42ffbc28-8797-4c9a-88db-e5d89d2b4738"
      decimals="-5"
      id="F_9a11ddc0-4832-4843-aa6b-464274af95f5"
      unitRef="U_USD">76700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_28bf845e-d84a-43e5-867a-584ae32a962a"
      decimals="INF"
      id="F_9c32cab7-4008-4ae6-90a2-8ad047812ef4"
      unitRef="U_shares">82153984</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_9fbe7d63-cd48-4daa-9100-a687e3e8a302">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#x2019;s definitive Proxy Statement for its 2024 annual meeting of shareholders, scheduled to be held on June 5, 2024, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_bca20154-3a7a-4a90-92fe-7c0d5222cc9d">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_57d911dd-5f8c-4998-b332-25c680ab7913">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_29245981-29bc-4e39-b52a-ddc74853e198">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_530d0756-2ac2-4372-a443-ef42e84da6ad"
      unitRef="U_USD">159711000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_8d4af636-37bb-4148-953a-953b14bb7100"
      unitRef="U_USD">257656000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_89554672-39d0-4da9-856d-c65b04cf2f02"
      unitRef="U_USD">2561000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_4eecfa28-f48d-4504-9418-a7e25449f46b"
      unitRef="U_USD">3382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_7f57fa17-fa78-4a00-9b85-e69af5398f76"
      unitRef="U_USD">162272000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_854817e4-a5d6-4563-a346-6f00d2328c65"
      unitRef="U_USD">261038000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_ac91906c-4d9b-4bed-8ac6-85c760e66da3"
      unitRef="U_USD">26777000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_961dc87f-2e45-4a77-ba31-3fc828bb576d"
      unitRef="U_USD">28710000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_b1e1a035-c350-4d48-8e23-c23768451820"
      unitRef="U_USD">17424000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_56a66b60-3c8b-403e-9505-81373e9966c2"
      unitRef="U_USD">20269000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_93f7f135-1820-4fc9-bfb8-a9067e85ab15"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_aa9a9835-9647-4a19-844c-5b8935dab11b"
      unitRef="U_USD">19462000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_0b8dfcc2-386d-40ab-b80d-9525ddd05e6c"
      unitRef="U_USD">822000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_115bf040-ec2e-4133-a3b3-3fd0755cb92d"
      unitRef="U_USD">1211000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_1d2fff31-710f-48a2-90e9-5f7d5f079bb3"
      unitRef="U_USD">207295000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_1a126345-2bb4-447f-951f-5c841206b368"
      unitRef="U_USD">330690000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_2c4cc242-cbcb-46a7-9ca8-36921af7cc42"
      unitRef="U_USD">2625000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_17e180a8-8c4e-4891-85fb-8f0be1761916"
      unitRef="U_USD">4404000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_c2e78ab2-1b9c-4db5-ad3f-62c4d4c461c1"
      unitRef="U_USD">13441000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_25eeca35-3865-4d6c-9bce-e59c902ecbaa"
      unitRef="U_USD">12811000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_51d132e5-826a-4e1f-bd05-e604c3a787b5"
      unitRef="U_USD">3221000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_7f584735-72a6-4063-a5c4-b9c61fb1b17a"
      unitRef="U_USD">2492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_53f36560-c95e-4247-8993-be32231da942"
      unitRef="U_USD">19287000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_3c1efe05-e558-44b8-ab4b-ee033a20416d"
      unitRef="U_USD">19707000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_1e4d96a7-5f06-4ed2-9fce-e25c96f829c9"
      unitRef="U_USD">17703000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_1139f58f-b114-4756-9d88-c2a6c29aa5e4"
      unitRef="U_USD">18531000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_7e9a9b04-b85c-4132-b95d-7d3b7c126b32"
      unitRef="U_USD">130000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_cf625e61-878b-4277-a0a5-f03faa52e155"
      unitRef="U_USD">114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_8bda9113-600f-44e3-9550-3ecce2b29c05"
      unitRef="U_USD">37120000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_54ef1874-832f-46f8-b2cf-d1a7ddd50295"
      unitRef="U_USD">38352000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="4"
      id="F_c87772f7-cc0d-4a88-93f8-fb9d2cc50a7d"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="4"
      id="F_808c095c-00e3-4f9d-903f-55d5eac8a9fe"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_62069b0f-3356-4ac1-bf9e-b5b78dc3f060"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_70da6ea6-ac38-45a7-ab4e-c1ce7947711c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_edca7554-a9f0-41d8-9ba3-0eb65e63f3b8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_e64b9457-102b-4288-aa14-0cd818119013"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_78ecff4f-63d5-4913-bd82-51f0b19c1f65"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_39b49483-2f60-49bb-b8e9-e6d2d7bbda78"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_4ff08f3c-a0e1-4f36-891e-f91c2db42820"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_d135f376-ee5b-41de-94c4-db27b3d6bacd"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="4"
      id="F_1941e927-1783-42f5-b11f-466c84add8d4"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="4"
      id="F_82cd0326-f946-47a0-b72c-26bfe215f652"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_2c185c71-e951-4f20-ad0b-f1a8f57e3199"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_b93ae9bf-4446-4f94-98ba-b2da27e57b3d"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_457d5cab-1cbe-4db6-b4ac-171ee3ef59e4"
      unitRef="U_shares">43270386</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_fce7ca27-c3cf-4b93-bcb5-5a945ba490da"
      unitRef="U_shares">43270386</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_742bdd2d-d96d-4017-94e5-be6a0677f043"
      unitRef="U_shares">42954820</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_5651a4b0-5d3f-48e8-97ac-5b4d6c451c70"
      unitRef="U_shares">42954820</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_9f427be9-277d-48e2-baf3-da12fcccbef3"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_d9e35d1b-90ec-4f45-aafe-d4b283f08c1d"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_d982ec5d-e68d-4166-b759-43013c8440fb"
      unitRef="U_USD">550943000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_f85c8fbe-6ad9-45c3-93c4-10ed04b6c5a8"
      unitRef="U_USD">530448000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_443fe3a0-a13e-4fa3-9d27-6478e215896c"
      unitRef="U_USD">-380772000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_f1ef68ae-bb6c-40fc-90a1-37fc6acaba20"
      unitRef="U_USD">-238114000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_93fa33b4-bead-431e-b590-42cdc1353bce"
      unitRef="U_USD">170175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_aa7041ca-b069-43d9-9e28-a99252ef35bc"
      unitRef="U_USD">292338000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_903b4ca4-901f-4d13-b6fa-71c9be1de2f9"
      unitRef="U_USD">207295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_ab08bce2-cc43-4f71-b22c-ab9d67591bfc"
      unitRef="U_USD">330690000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_095a7c54-6207-42c6-8902-79e626a7c9a7"
      unitRef="U_USD">0</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_8c376a72-3e08-4451-bb35-294a2feecd93"
      unitRef="U_USD">24990000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_757a4c75-7da0-440c-8c23-34ba5acec58b"
      unitRef="U_USD">106043000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_6fa7807c-6995-4e63-89ca-78323e159465"
      unitRef="U_USD">71246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_678cffe5-8ecf-4142-b48e-c1523801f7c6"
      unitRef="U_USD">26533000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_ccdf3f48-cdeb-44ae-835e-3ba6895df26e"
      unitRef="U_USD">26295000</us-gaap:GeneralAndAdministrativeExpense>
    <acet:GoodwillImpairment
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_b1257019-a5f5-4642-9c3b-e945684e7d93"
      unitRef="U_USD">19462000</acet:GoodwillImpairment>
    <acet:GoodwillImpairment
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_ef798215-53d0-484e-9a6e-d5778c0d963a"
      unitRef="U_USD">0</acet:GoodwillImpairment>
    <us-gaap:OperatingExpenses
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_48bb6bdf-6108-4243-865d-420170166a6b"
      unitRef="U_USD">152038000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_3b5f7ef0-986b-457f-8348-7befd8143712"
      unitRef="U_USD">97541000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_e7e3a974-416c-4056-9617-076a13b27b95"
      unitRef="U_USD">-152038000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_8844c480-a16d-4617-abed-bb1c89bc98b9"
      unitRef="U_USD">-72551000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_297a96b2-d10d-4cb4-a847-81dc132e9a41"
      unitRef="U_USD">9978000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_dfcf1f68-17c4-4022-9805-388a3f0a9b9e"
      unitRef="U_USD">3760000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_9896ee8c-0809-4138-a990-fb73b48d2e0e"
      unitRef="U_USD">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_d19befe7-ca22-4b3c-8dd9-a7f1800c91e6"
      unitRef="U_USD">80000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_e1382a9b-5ff5-40da-8c54-0fa9eeda2385"
      unitRef="U_USD">-573000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_585209e9-f3dd-4d7c-9602-31cac30edd8f"
      unitRef="U_USD">-919000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_8455b887-18f1-4a4b-8d22-bf3e207ec890"
      unitRef="U_USD">-142658000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_e49f2045-aa04-4c2d-b663-541ef877b49f"
      unitRef="U_USD">-69790000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_dbe33acc-22fd-4845-8d92-7fdbf52ca865"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_a64d136e-6752-44a9-9398-33906e01fc3a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_2536bac1-3640-40d9-937f-1d87e2f41294"
      unitRef="U_USD">-142658000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_7e161ae0-db67-4933-8b73-6b003138acf4"
      unitRef="U_USD">-69790000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_5936ce69-9d3e-4091-8923-3e13d2a7390c"
      unitRef="U_USDollarShare">-3.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_020897d0-892d-460c-b3c4-7fa51a892fc8"
      unitRef="U_USDollarShare">-3.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_ae2258f1-93e5-4eee-9b16-83e6448adc31"
      unitRef="U_USDollarShare">-1.7</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_789b91ec-c0b9-4b8b-83c8-5bd732a39662"
      unitRef="U_USDollarShare">-1.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="INF"
      id="F_30081f3e-7765-42b6-9e8b-999fc0123ad9"
      unitRef="U_shares">43042405</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="INF"
      id="F_77b4c982-ccfc-491b-8bcc-142e89f25533"
      unitRef="U_shares">43042405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="INF"
      id="F_b7f9007a-0cac-42bf-92ae-ba0ca8333e53"
      unitRef="U_shares">41080286</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="INF"
      id="F_0344bd9d-1d17-4917-a748-2114fbf9294e"
      unitRef="U_shares">41080286</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_6dce953e-d2b7-435c-8ac4-abae82da8350"
      decimals="INF"
      id="F_1d21b79f-926f-4854-8e91-a3c447adf476"
      unitRef="U_shares">39736914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6dce953e-d2b7-435c-8ac4-abae82da8350"
      decimals="-3"
      id="F_0368a475-4978-4bfe-a074-2f062d36b976"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f218b6be-cd0a-49e1-8525-a5eb02ac8f27"
      decimals="-3"
      id="F_e57ab629-08eb-4efb-b867-6f94d904a848"
      unitRef="U_USD">471449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3839044c-67c3-4761-9d07-88d8d945f812"
      decimals="-3"
      id="F_42c98d5e-6dfe-452f-aa90-1c0b1d2fe085"
      unitRef="U_USD">-168324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7"
      decimals="-3"
      id="F_21f459a2-fbb6-463e-ab5e-ab54df069233"
      unitRef="U_USD">303129000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="0"
      id="F_1fd4065d-b2f8-472b-a339-0e3a1bf1e298"
      unitRef="U_shares">126176</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd"
      decimals="-3"
      id="F_344fb7a6-9865-4108-9a4a-42d37dfdcad8"
      unitRef="U_USD">1315000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_554f84c7-f279-47fa-ac78-cb6f174c74bd"
      unitRef="U_USD">1315000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="0"
      id="F_79df30e3-8c77-460a-a334-b2c8f24a419e"
      unitRef="U_shares">548580</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="INF"
      id="F_c3cf67ef-98c5-459d-8162-b00a5650e089"
      unitRef="U_shares">100731</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="0"
      id="F_f4e4054c-d77d-48ac-822a-68c8ba096e68"
      unitRef="U_shares">-215901</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd"
      decimals="-3"
      id="F_80a80f39-bd7f-4af6-9b48-174fdd3030b8"
      unitRef="U_USD">3234000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_c5902606-8abf-41a1-bee4-16c23feba29b"
      unitRef="U_USD">3234000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="INF"
      id="F_8ef92196-8655-40d5-ba5a-87beb8b0db5b"
      unitRef="U_shares">46597</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd"
      decimals="-3"
      id="F_b91d80d5-066e-4dfd-8d6d-9e3abbd8adfd"
      unitRef="U_USD">432000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_54521517-f0ed-4bf0-9c0d-0a738c2af6f4"
      unitRef="U_USD">432000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-5"
      id="F_6f8ab82f-d93e-4294-b703-48d1dfee797c"
      unitRef="U_USD">1600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares
      contextRef="C_a8b78d91-5959-4a0c-a95c-284e5c1bc2fe"
      decimals="INF"
      id="F_907d6a28-6cfb-4bdc-8d0c-7e1cc091be17"
      unitRef="U_shares">2611723</acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCostsShares>
    <acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd"
      decimals="-3"
      id="F_bb4d40be-e9a6-4ee8-9c8e-bfc11200d46e"
      unitRef="U_USD">43360000</acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts>
    <acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_a423d4fa-7664-4eb3-ac32-a7175af848de"
      unitRef="U_USD">43360000</acet:CommonStockPursuantToAtTheMarketOfferingNetOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4a819e95-0893-45bf-809c-89c052bcc2bd"
      decimals="-3"
      id="F_5377bdcb-e5d1-426f-8d0d-872d33c57c7f"
      unitRef="U_USD">17126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_e4dbde40-fbde-444b-872e-4ece18c86e8a"
      unitRef="U_USD">17126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_8ace4969-2a3a-4174-850a-95de252b6cec"
      decimals="-3"
      id="F_ef6f29f3-313d-4ddd-b438-a39350466cf6"
      unitRef="U_USD">-69790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_6bccfe20-1bb8-4ff2-8f02-d85f620fde35"
      unitRef="U_USD">-69790000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e312fee1-4691-4e86-92c4-5ce4a346c5df"
      decimals="INF"
      id="F_99795ac4-67d6-48de-91a5-03fc5d20db28"
      unitRef="U_shares">42954820</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e312fee1-4691-4e86-92c4-5ce4a346c5df"
      decimals="-3"
      id="F_63fe387f-7e0e-49c8-bff5-4813c9ed670e"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57f55a55-f9b7-41ed-98a9-192b9feeae13"
      decimals="-3"
      id="F_8ef38651-34e6-4c2c-a510-5d785ae5ef40"
      unitRef="U_USD">530448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_869bf6a3-58bc-465a-b7da-4f80fdac6a75"
      decimals="-3"
      id="F_a7f9748b-28ed-4e06-ba25-798a64aff08f"
      unitRef="U_USD">-238114000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_fbe938a7-8da8-4580-9310-774b84e11293"
      unitRef="U_USD">292338000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f"
      decimals="0"
      id="F_833443ab-6a7e-43e4-9aae-63314d0b9438"
      unitRef="U_shares">946</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba"
      decimals="-3"
      id="F_a54b9e29-c3e8-4ace-afc9-bb57fcd9e022"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_4bead084-418e-4417-9767-ea84e9895c2c"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f"
      decimals="0"
      id="F_86a79e80-aa68-4690-bc5b-51dc0b3bec6f"
      unitRef="U_shares">194455</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f"
      decimals="0"
      id="F_5ae15424-791e-490c-a5f4-167f17a8cf5a"
      unitRef="U_shares">-86145</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba"
      decimals="-3"
      id="F_7f620f31-434f-499b-a8ef-28cda4fd3e43"
      unitRef="U_USD">150000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_0feaa598-4035-4747-bacd-771bc67de378"
      unitRef="U_USD">150000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_46cd3449-6f00-448a-a65c-df577e2a664f"
      decimals="0"
      id="F_159b8c83-70e3-4958-a2c4-062b9b4ccec3"
      unitRef="U_shares">206310</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba"
      decimals="-3"
      id="F_40c6440a-8d37-433f-8526-599b40cc7e9f"
      unitRef="U_USD">382000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_284dc7a2-8489-48d2-8f08-bdc4678f950e"
      unitRef="U_USD">382000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cd2c661a-8e94-4ed2-a4f6-a4eccfb8a0ba"
      decimals="-3"
      id="F_4cadfe79-009a-4fdb-be8c-bbb2fd97ca0a"
      unitRef="U_USD">20259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_c8dc0197-cd12-412d-baf3-d7df0b34f938"
      unitRef="U_USD">20259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff7e4a68-2391-4c50-aaba-76ac9387247f"
      decimals="-3"
      id="F_c84d031d-7212-4c86-8d7e-48075bb6a386"
      unitRef="U_USD">-142658000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_89ad36d9-ad9c-4e47-b140-4b4f97e301a4"
      unitRef="U_USD">-142658000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20687195-6562-483c-b3ff-ff5be6c897ac"
      decimals="0"
      id="F_3923e7d4-cea4-426a-b7f7-8e684edd35b8"
      unitRef="U_shares">43270386</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20687195-6562-483c-b3ff-ff5be6c897ac"
      decimals="-3"
      id="F_66b8148a-d166-454e-94c1-d3966f038897"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fe26f58a-9036-43d0-abc5-d86be0b9ef22"
      decimals="-3"
      id="F_cba09608-b874-40c2-9b5e-3e91ea52724b"
      unitRef="U_USD">550943000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8dfe4ff4-baa6-4df7-adb9-4800a2eebae6"
      decimals="-3"
      id="F_69b2e9ea-76c9-42dc-bf09-520c98a7889c"
      unitRef="U_USD">-380772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_93574348-7503-49fc-91db-04b78fe9e0fb"
      unitRef="U_USD">170175000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_ef82b4b2-915f-4dd4-8277-701b2bbdc541"
      unitRef="U_USD">-142658000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_0dd93dfb-121d-4d75-ae93-c407b2aab607"
      unitRef="U_USD">-69790000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_9d016486-da84-45c2-a10c-2363601c5fb9"
      unitRef="U_USD">6098000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_eb335d83-202b-4640-8c69-256edc9546fc"
      unitRef="U_USD">2575000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_04c8740d-487c-4ca9-951b-1c7d234f6591"
      unitRef="U_USD">2844000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_54d0122c-f439-4a85-89d6-4a81844b4db8"
      unitRef="U_USD">2434000</us-gaap:OtherNoncashExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_5ae884d8-1165-4846-8572-60d47ce622b1"
      unitRef="U_USD">20259000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_cc0188ce-e5ad-42c5-9ce0-aff62f60ddb6"
      unitRef="U_USD">17126000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_d159cafd-8b50-4790-bf1d-388d5b88ec1a"
      unitRef="U_USD">4000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_821d76cc-38c1-4f68-8989-47f3b1af7ecf"
      unitRef="U_USD">-55000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_8a665040-24b3-4b67-b98b-58cc28340862"
      unitRef="U_USD">19462000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_07bae918-479f-47d9-b4a1-d59dca587895"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <acet:LossOnDisposalOfLeaseAssets
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_1427b788-01cb-465b-9237-0d849bc7fd03"
      unitRef="U_USD">0</acet:LossOnDisposalOfLeaseAssets>
    <acet:LossOnDisposalOfLeaseAssets
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_3243922b-13e4-4009-a9e7-12cd398e3f2b"
      unitRef="U_USD">1000</acet:LossOnDisposalOfLeaseAssets>
    <acet:AmortizationOfDebtIssuanceCosts
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_46852efa-935b-4337-9e5e-21c22a12b8e8"
      unitRef="U_USD">30000</acet:AmortizationOfDebtIssuanceCosts>
    <acet:AmortizationOfDebtIssuanceCosts
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_c050bbfd-080c-4337-8b51-1e087461e3eb"
      unitRef="U_USD">92000</acet:AmortizationOfDebtIssuanceCosts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_d71c98e3-78f4-477b-a68e-ee30be54c23e"
      unitRef="U_USD">-926000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_fd36ed37-8d71-4fec-aaec-294f7df837a2"
      unitRef="U_USD">-1343000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_61f4958d-7663-4125-8f2b-310fc112e9b7"
      unitRef="U_USD">-358000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_09c15454-9ddd-4b3d-86c6-0a0b6575a9bd"
      unitRef="U_USD">-929000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_9f2b9edf-d5b4-4d6c-9387-4d18df052bc5"
      unitRef="U_USD">-1683000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_cbbf747e-76ea-4693-b015-26fdf5812bfb"
      unitRef="U_USD">1710000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_7cb64f94-09ba-443a-9a98-4a022771f466"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_82d127f3-37a2-43ee-8c6e-dd841b0d0b0b"
      unitRef="U_USD">-4805000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <acet:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_af9585b0-7795-45a6-a103-7c30e0291dcf"
      unitRef="U_USD">-99000</acet:IncreaseDecreaseInOperatingLeaseLiabilities>
    <acet:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_c7c874ca-e7c9-4195-a6f9-e013cea1acdb"
      unitRef="U_USD">-2264000</acet:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_e92c8a52-d7f2-4861-88aa-c575c801edf1"
      unitRef="U_USD">750000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_cac94148-5962-40e9-af97-a28b760da3de"
      unitRef="U_USD">5831000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_29dd1ea4-dba0-4eb6-b921-37119b16c9af"
      unitRef="U_USD">-93717000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_c460ead1-35a6-4902-869d-810300636845"
      unitRef="U_USD">-44765000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_4c6397fe-254e-4c3d-b18c-55d34df45a13"
      unitRef="U_USD">4464000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_3dfbba70-8a4b-41e4-8d9f-686f1ba1e1bf"
      unitRef="U_USD">16782000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_11d41570-91ce-4a4d-8d0c-5b49073adcaf"
      unitRef="U_USD">-4464000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_820669ba-1e4e-4d74-9193-f03ef7ded340"
      unitRef="U_USD">-16782000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_4a2e903d-118a-403d-9eb5-4ba6976c87a5"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_e1b8273c-a92a-4292-be3b-2fd6f25ba8f7"
      unitRef="U_USD">43360000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_f28c8644-17e9-4f01-834d-c5c562eefd8f"
      unitRef="U_USD">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_b8903ee6-c139-4e22-af99-522478573e79"
      unitRef="U_USD">1315000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_f7b79e86-1a39-4ad9-8255-f70d5b96c537"
      unitRef="U_USD">382000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_9f93ee81-6b15-48ec-aa86-54b216e1762e"
      unitRef="U_USD">432000</us-gaap:ProceedsFromStockPlans>
    <acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_6633365e-04b6-4be8-8951-04e28908ec46"
      unitRef="U_USD">-150000</acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards>
    <acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_e45ec692-1b46-4104-a03d-585eb17de7f2"
      unitRef="U_USD">-3234000</acet:TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_f7022d4f-b392-47a3-a21d-f6040c8768ee"
      unitRef="U_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_2fa18cdb-e24d-478e-a206-71e522c9d4cf"
      unitRef="U_USD">364000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_f76ddc85-1773-47ed-8d6c-0d5c1089fad7"
      unitRef="U_USD">236000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_9cfa4337-d3c6-4b0d-8f6f-a587fe70a8cc"
      unitRef="U_USD">41509000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_bfb465e5-6c30-4d12-b323-5d276142b545"
      unitRef="U_USD">-97945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_0b100b8f-9c98-4915-8b52-eb08b641095b"
      unitRef="U_USD">-20038000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_dc5da96b-f0cb-402a-9c21-7cb26839d25f"
      unitRef="U_USD">257656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7"
      decimals="-3"
      id="F_a4f355ec-6cee-4c29-ac6d-1fa71ff17599"
      unitRef="U_USD">277694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_50e14436-576a-4f99-b251-412458d2ce5f"
      unitRef="U_USD">159711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_7ded5ccf-4bd7-472e-8089-8031a7d6c892"
      unitRef="U_USD">257656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_2bc81ced-a015-44b5-9628-9c9e1f41e833"
      unitRef="U_USD">279000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_73c7ffd3-4f2e-4789-97b6-786472126d45"
      unitRef="U_USD">565000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_a547734b-f269-44af-8585-a14a4bed6a58"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_345d5da2-8771-4cd4-be2a-91864593dd5c"
      unitRef="U_USD">2329000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <acet:OrganizationAndNatureOfBusinessTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_0a01d79c-a37c-4752-ae5a-01b9f5ec6abf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Organization and Nature of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The Company is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost-efficient manner.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adicet Bio, Inc. (when referred to prior to the merger, Former Adicet) was incorporated in November 2014 in Delaware. On September 15, 2020, Former Adicet completed a merger (Merger) with resTORbio, pursuant to which Former Adicet merged with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#x201c;Adicet Therapeutics, Inc.&#x201d; (Adicet Therapeutics). In connection with the Merger, the Company changed its name from &#x201c;resTORbio, Inc.&#x201d; to &#x201c;Adicet Bio, Inc.&#x201d; The Company&#x2019;s principal executive offices are located in Boston, Massachusetts. The Company also has offices in Redwood City, California.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of the Company and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, the Company consolidated its operations, including research and development activities, in the United States and as a result, substantially reduced its operations in Israel.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred significant net operating losses and negative cash flows from operations and has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;380.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, public and private placements of equity securities and debt, and cash received in the Merger with resTORbio. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 12, 2021, the Company entered into a Capital On Demand&#x99; Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as sales agent, to provide for the offering, issuance and sale of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock from time to time in &#x201c;at-the-market&#x201d; (ATM) offerings under a registration statement on Form S-3 (File No. 333-254193) (2021 Shelf Registration Statement) filed with the U.S. Securities and Exchange Commission (the SEC), which was declared effective on March 30, 2021. In August 2022, pursuant to the Sales Agreement and subject to the limitations thereof, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,611,723&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share resulting in net proceeds to the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting sales agent commissions and expenses. In November 2022, the Company filed a new prospectus supplement to the 2021 Shelf Registration Statement for the offer and sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock from time to time through the sales agent, which includes the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock not sold under the original prospectus and up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock (the ATM Program). During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were sold under the ATM Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent to December 31, 2023, the Company raised aggregate net proceeds&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through its ATM Program and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through an underwritten public offering (the Offering). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 19. Subsequent Events for additional details on these financings subsequent to December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company expects that its cash and cash equivalents, together with the proceeds raised subsequent to year-end through our ATM Program and the Offering, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements and debt service payments for at least the next twelve months from the issuance of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the Company&#x2019;s revenue to date has been generated from a collaboration and license agreement with Regeneron Pharmaceuticals Inc, (Regeneron). The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercializes any of the Company&#x2019;s product candidates or enters into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seeks regulatory approvals for, its product candidates and begins to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), the regulatory approval process, market acceptance of the Company&#x2019;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#x2019;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#x2019;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/p&gt;</acet:OrganizationAndNatureOfBusinessTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b3211074-499b-46e0-bac9-fdef2d5b6a7c"
      decimals="-5"
      id="F_4dc0ad4e-c334-43d7-b54c-ea6ba9c38d21"
      unitRef="U_USD">380800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f148e6a6-cf77-4216-bdf2-c79ea3d192a2"
      decimals="-5"
      id="F_2a7ac6ff-5b5b-4edd-8cc0-6a2d2e2eb52f"
      unitRef="U_USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7"
      decimals="0"
      id="F_718a5da2-d16f-4608-8593-04c017730b77"
      unitRef="U_shares">2611723</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e7c9f079-510c-48e3-b00d-988277978714"
      decimals="2"
      id="F_951ef926-56f8-49e4-867f-f66a1ffbef84"
      unitRef="U_USDollarShare">17.23</us-gaap:SaleOfStockPricePerShare>
    <acet:SalesAgentCommissionsAndExpenses
      contextRef="C_9875af4d-4bbc-4a71-b5c4-22c2833297b7"
      decimals="-5"
      id="F_39a3ee2b-1189-4709-adb0-8df69c7b8a90"
      unitRef="U_USD">43400000</acet:SalesAgentCommissionsAndExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5962f55e-c424-4534-bcc2-208837c6f318"
      decimals="-5"
      id="F_89a293d0-7317-4d88-b48e-903fe89d7972"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <acet:CommonStockNotSold
      contextRef="C_8c7df557-b405-497e-9c20-e9d91070c1c9"
      decimals="-5"
      id="F_58455675-68a5-4d1c-9e83-deb5eda8abea"
      unitRef="U_USD">30000000</acet:CommonStockNotSold>
    <acet:AdditionalCommonStockNotSold
      contextRef="C_8c7df557-b405-497e-9c20-e9d91070c1c9"
      decimals="-5"
      id="F_c328a700-0dba-43c2-8b9e-cd13649d3024"
      unitRef="U_USD">70000000</acet:AdditionalCommonStockNotSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_84de4e02-9bcb-4587-b4c2-9ad91bf61ddc"
      decimals="0"
      id="F_a6e34a87-4b80-4084-bd6e-00065e07b674"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acet:AggregateNetProceed
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-5"
      id="F_cef2a562-76be-4bc6-87ca-ae1b3b8af05d"
      unitRef="U_USD">19300000</acet:AggregateNetProceed>
    <acet:UnderwrittenPublicOffering
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-5"
      id="F_def8567e-01bd-4c50-935f-c9a78f06b67a"
      unitRef="U_USD">91800000</acet:UnderwrittenPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_24885e85-af31-4030-aec2-0857fe64182a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#x2019;s incremental borrowing rate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and determined that goodwill was impaired. For additional information regarding this assessment, refer to Note 16. Goodwill to our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable and operating segment, which is the business of research and development of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allogeneic gamma delta T cell therapies for autoimmune diseases and cancer&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds and treasury securities. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; customer, Regeneron, which represents &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Company&#x2019;s total revenue during the year ended December 31, 2022 (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, cash and cash equivalents consist of cash deposited with banks, investments in money market funds with maturities of three months or less from the date of purchase, and overnight treasury securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments of the Company, including cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the lesser of the assets&#x2019; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;accumulated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. The Company performed a long-lived asset impairment test in conjunction with its goodwill impairment test in the third quarter of 2023 and concluded that there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment of long-lived assets. There was also &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment of long-lived assets for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(v)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#x2019;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the Company&#x2019;s revenues for the year ended December 31, 2022 are derived through a license and collaboration agreement with Regeneron (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue under the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Payments or reimbursements for the Company&#x2019;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#x2019;s performance in satisfying the obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CDMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued CRO, CDMO, and Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various agreements with CDMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; there had been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material adjustments to the Company&#x2019;s prior period estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consistent with ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASU 2016-02), the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;net loss per common share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan (ESPP) awards and unvested restricted stock units (RSUs), are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders. Since the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subsequent Events Considerations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements. Refer to Note 17. Subsequent Events.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-13 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. SEC filers that are eligible to be smaller reporting companies should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which enhances the transparency and usefulness of income tax disclosures. This amendment requires public issuers to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income, or loss, by the applicable statutory income tax rate. Additionally, this amendment requires issuers to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes as well as the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact the adoption that this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_964165cc-9d0c-4ecd-9f45-c46e5f7c8784">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_ae49c962-8dba-48d8-8acf-a2be426f882c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_d7489c76-fa9f-4def-8e37-f6ef4be2bee4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#x2019;s incremental borrowing rate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_08c1ff5c-d043-4b44-94af-706a05526c8d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an interim test for goodwill impairment in the third quarter of the fiscal year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and determined that goodwill was impaired. For additional information regarding this assessment, refer to Note 16. Goodwill to our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_01131c88-8418-48df-87bf-4acde2b6fd97">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable and operating segment, which is the business of research and development of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allogeneic gamma delta T cell therapies for autoimmune diseases and cancer&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company&#x2019;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_ec8c61ab-2749-4021-9c08-e7912ce9ed66"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_6bd6eed2-c22b-4bbf-a5fb-f9d9217619d7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are held at two financial institutions in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds and treasury securities. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; customer, Regeneron, which represents &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Company&#x2019;s total revenue during the year ended December 31, 2022 (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <acet:NumberOfCustomer
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_3658ddc3-617f-4a30-8018-9b2563e092e0"
      unitRef="U_Customer">1</acet:NumberOfCustomer>
    <acet:CustomersPercentageOfTotalRevenue
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_b387d197-8816-4f4b-b586-84094d601137"
      unitRef="U_pure">1</acet:CustomersPercentageOfTotalRevenue>
    <acet:CustomersPercentageOfTotalRevenue
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_5a4b3dcb-a4c1-4918-8b1f-3d1512e51fef"
      unitRef="U_pure">1</acet:CustomersPercentageOfTotalRevenue>
    <acet:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_2fdb48d4-9d78-46c5-be1a-010259d21be0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;/p&gt;</acet:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_7b5b9586-f0e9-4fa5-b2c2-f991f40e11fd">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, cash and cash equivalents consist of cash deposited with banks, investments in money market funds with maturities of three months or less from the date of purchase, and overnight treasury securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_8f292a89-281b-40a6-a062-0b71c8814cab">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amounts of certain financial instruments of the Company, including cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_56628d6f-3a28-4299-b479-4bfefad37fec">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the lesser of the assets&#x2019; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;accumulated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_8eedb956-417a-4f81-8408-9b9602cf55f0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. The Company performed a long-lived asset impairment test in conjunction with its goodwill impairment test in the third quarter of 2023 and concluded that there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment of long-lived assets. There was also &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment of long-lived assets for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_19527f36-af6d-42f8-8fb9-10d9718f8816"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_28b08047-c46e-42a9-b325-fa69ff7fbf6d"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_f86015c6-a3b1-47c7-9d88-3587ba2d0972">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(v)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#x2019;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the Company&#x2019;s revenues for the year ended December 31, 2022 are derived through a license and collaboration agreement with Regeneron (see Note 8). The Company did not have any revenue for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes revenue under the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Payments or reimbursements for the Company&#x2019;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#x2019;s performance in satisfying the obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_b969bd3a-b9f4-404e-a244-eab0a151ab01">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CDMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <acet:AccruedResearchAndDevelopmentPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_dd0b4e60-43ac-4cf4-bb68-f82e31ee017b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accrued CRO, CDMO, and Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has entered into various agreements with CDMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CDMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; there had been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material adjustments to the Company&#x2019;s prior period estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;</acet:AccruedResearchAndDevelopmentPolicyTextBlock>
    <acet:AccruedResearchAndDevelopment
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_c2ba0302-37bb-4d47-aab3-1d47c6a9ea03"
      unitRef="U_USD">0</acet:AccruedResearchAndDevelopment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_829a7009-d692-498b-bbb9-10ad861652fb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consistent with ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASU 2016-02), the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c8847191-029b-4741-a44a-af8c61a7a2f9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_246e783f-33d5-4808-beb0-ddb75c156308">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_25d06cbb-5aab-4a02-94d0-e9642e5293ab">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;net loss per common share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan (ESPP) awards and unvested restricted stock units (RSUs), are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders. Since the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_6b3d7320-9530-471c-8a3e-00f4d1e2c1c4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subsequent Events Considerations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements. Refer to Note 17. Subsequent Events.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c12a6f87-ea99-4679-acef-c4264460b96c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2016-13 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. SEC filers that are eligible to be smaller reporting companies should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company adopted ASU 2017-04 in the first quarter of 2023. The impact on its consolidated financial statements and related disclosures was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes (Topic 740):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which enhances the transparency and usefulness of income tax disclosures. This amendment requires public issuers to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income, or loss, by the applicable statutory income tax rate. Additionally, this amendment requires issuers to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes as well as the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). For SEC filers, this ASU is effective for fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact the adoption that this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_3ef1c869-365b-4ce0-9ef3-3ab245399dcf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2014; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2014; Unobservable inputs which reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Treasury securities (1) (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (1) (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_f8c20c02-8d00-4c72-b4d5-aabfec8d198f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Treasury securities (1) (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.31%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.14%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.282%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (1) (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_516b6271-7ed7-4039-97f5-4296694a6d53"
      decimals="-3"
      id="F_32cc67c2-c20b-4110-8ee5-573adde35339"
      unitRef="U_USD">115143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9348b37e-6b12-4d6f-ae6c-a16de43632b1"
      decimals="-3"
      id="F_fad817cb-52dd-4a37-aa97-a437d3c1006a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dc363f47-13e1-4ded-8501-89b95420f66d"
      decimals="-3"
      id="F_162cb483-d00e-4d08-84e7-64fe8ccb19fc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dbf4e63c-86b1-47fc-8dda-dad71e1a42cf"
      decimals="-3"
      id="F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"
      unitRef="U_USD">115143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_530cfa2e-3440-4246-a577-8979ecb76ea6"
      decimals="-3"
      id="F_167fe1f9-4f4c-4c5a-879c-32bf788d2134"
      unitRef="U_USD">115143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e0981498-005c-4ad0-9192-bd130ea10fe8"
      decimals="-3"
      id="F_289c2d77-3f07-48b1-b05e-14aa2a3b8ff3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c4019755-11ed-4ad5-8299-f0d1cfdef0eb"
      decimals="-3"
      id="F_6afd780f-687b-487f-a47b-9e5865ac07f6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_14728681-e228-429d-9c6d-e288fc904418"
      decimals="-3"
      id="F_772ba258-d3cf-4fa6-876e-614691315b0a"
      unitRef="U_USD">115143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_301d7c2e-336e-4386-a679-d09592f8589f"
      decimals="-3"
      id="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789"
      unitRef="U_USD">75701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f239a655-77af-476f-8413-e0d33ef6a09e"
      decimals="-3"
      id="F_eb235763-2049-4536-89f0-a95a1e624a98"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_edc6bfee-a0a7-4dbb-a2f0-2d9cb5654b09"
      decimals="-3"
      id="F_a4cf4f7d-863d-4f43-b627-e3f1271563ae"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62d1c290-a6a5-4ca0-a3ab-96d98d887372"
      decimals="-3"
      id="F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"
      unitRef="U_USD">75701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_521621f6-cd1f-43e6-8b46-e9d3d9f8d92c"
      decimals="-3"
      id="F_264ec5a1-634e-4019-be8c-8b3a13b4fb14"
      unitRef="U_USD">75701000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a0fd947b-427a-49bf-b248-d4fd92ea0354"
      decimals="-3"
      id="F_1066aed2-2284-433a-b20e-fe482fc66b5c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_120ea2d3-27e2-495d-b032-85ee8a4225d9"
      decimals="-3"
      id="F_f24151e0-4a05-4fc7-a789-e1079a26dbaa"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8c149222-bc5e-4c16-ad97-efbf7c1789f9"
      decimals="-3"
      id="F_1443a2fd-5bd6-442e-a399-63df5ee36b1f"
      unitRef="U_USD">75701000</us-gaap:AssetsFairValueDisclosure>
    <acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_bf470113-99d4-4a03-b61c-d123b0688597">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid software subscription and licensing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid maintenance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepayments to CROs and CDMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_1e567a99-f0d2-460f-bcd3-21f26e545f1b">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid software subscription and licensing fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid maintenance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepayments to CROs and CDMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_20385f06-e2a4-4b4c-82a7-af66ccb64ce9"
      unitRef="U_USD">1014000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_17bcd837-cc00-4077-b2f9-44469abcd00f"
      unitRef="U_USD">1251000</us-gaap:PrepaidInsurance>
    <acet:PrepaidSoftwareSubscriptionAndLicensingFees
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_2da595be-c179-41e1-abaa-59ed5b7a9a9b"
      unitRef="U_USD">582000</acet:PrepaidSoftwareSubscriptionAndLicensingFees>
    <acet:PrepaidSoftwareSubscriptionAndLicensingFees
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_3b4f5119-30b5-499f-bc54-2dd99d5d4911"
      unitRef="U_USD">529000</acet:PrepaidSoftwareSubscriptionAndLicensingFees>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_ca001244-7609-473c-b629-d7d01dee5fb9"
      unitRef="U_USD">373000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_2388ecdb-b365-4191-9ca6-b5b63ffe020a"
      unitRef="U_USD">295000</us-gaap:PrepaidExpenseCurrent>
    <acet:PrepaidProfessionalServices
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_54c55ca7-a4a2-46a3-89bc-b45477cd2c2d"
      unitRef="U_USD">82000</acet:PrepaidProfessionalServices>
    <acet:PrepaidProfessionalServices
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_d83f2f54-8c86-416e-8480-ac4e2e208fa8"
      unitRef="U_USD">44000</acet:PrepaidProfessionalServices>
    <acet:PrepaymentsToCros
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_8a42c906-3fad-4ac6-9ed7-56d9d1c6e801"
      unitRef="U_USD">53000</acet:PrepaymentsToCros>
    <acet:PrepaymentsToCros
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_57e4581d-7bc3-4d3c-a94f-fce33bca8d1b"
      unitRef="U_USD">492000</acet:PrepaymentsToCros>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_b6503f15-3f49-412d-9f56-133db837bb90"
      unitRef="U_USD">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_20c63534-a916-4e2e-9e0f-4f1c904bf704"
      unitRef="U_USD">435000</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_77a9fc24-4326-4a76-ac36-2e3f6e8ef83b"
      unitRef="U_USD">457000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_a43e3001-2ae4-44b6-9ab9-48b3a27d2cc8"
      unitRef="U_USD">336000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_a7742b82-a74a-4e1f-83ba-a6249d8d291e"
      unitRef="U_USD">2561000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_1077d7e5-a823-4855-a911-0744f91fc9e3"
      unitRef="U_USD">3382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c2482fe7-734b-4227-b310-90be74589489">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="-sec-ix-hidden:F_15175557-fa82-4f42-8860-de5b090ee079;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lesser of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="-sec-ix-hidden:F_7c070633-44bd-4104-9d0e-d47392d30bc3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All of the Company&#x2019;s property and equipment as of December 31, 2023 and 2022 is located in the U.S. Depreciation and amortization expense for the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The increase in expense is primarily due to the completion and subsequent depreciation of the Company's good manufacturing practice (GMP) cell processing and vector manufacturing suite at the Company's office in Redwood City, California (1000 Bridge Parkway) which was completed in February 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Construction in progress has decreased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, compared to the balance at December 31, 2022, due to the Company's completion of the Company's GMP cell processing and vector manufacturing suite in February 2023. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in construction in progress as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is primarily related to lab and computer equipment not yet placed into service.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_9d261f10-1bef-4e36-987c-99f097c9b144">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.32%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="-sec-ix-hidden:F_15175557-fa82-4f42-8860-de5b090ee079;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lesser of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="-sec-ix-hidden:F_7c070633-44bd-4104-9d0e-d47392d30bc3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b7944d0b-f730-4427-b995-a253e5c8fac0"
      decimals="-3"
      id="F_e106f5f2-37b9-4b77-bb9b-d0b200fdc5bc"
      unitRef="U_USD">26643000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2bbcb4a0-03ec-4fec-b751-f0405cc986d4"
      decimals="-3"
      id="F_be59a930-45c8-4867-9bdf-f62415366700"
      unitRef="U_USD">19959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a8e06b97-dcd0-4935-82a5-621e10a35a16"
      id="F_d7e31791-88b0-4ba4-81f9-acc39b105225">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a8e06b97-dcd0-4935-82a5-621e10a35a16"
      decimals="-3"
      id="F_538b09da-5d3b-42c6-85fc-1f9203548da6"
      unitRef="U_USD">13165000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1caa1e3e-b49b-4099-b413-9f91f7e43341"
      decimals="-3"
      id="F_fe521b4f-7212-41f4-8928-919cac67f4df"
      unitRef="U_USD">7503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4"
      id="F_8d04f061-4eac-4921-b2f6-35fbdfaa97a0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_61d83ca4-bbbb-43d9-8738-fd8891eb69d4"
      decimals="-3"
      id="F_910d3ade-29a6-4ab3-8471-0df0e755727a"
      unitRef="U_USD">951000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_254f47ef-7aad-45a0-af9a-05ffb52efd9a"
      decimals="-3"
      id="F_5170f904-1863-4ec4-9a24-6b3841db53ae"
      unitRef="U_USD">184000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c123cd80-5380-4099-a3a4-c9250a72e19d"
      id="F_e938855e-ce4d-4a17-af25-5c2b3ea05a06">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c123cd80-5380-4099-a3a4-c9250a72e19d"
      decimals="-3"
      id="F_bd7e3e9c-294c-41f8-a362-3b414513254d"
      unitRef="U_USD">411000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4cbd04fa-00ff-47cb-b761-f69bdbaecf25"
      decimals="-3"
      id="F_531a1911-25f7-46e6-ad2f-1f05807ccffe"
      unitRef="U_USD">353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2"
      decimals="-3"
      id="F_a0ed4a04-ce81-4de3-8b09-5c0b432ff35b"
      unitRef="U_USD">265000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9dde8aec-c602-4c92-b003-83bf44a811d5"
      decimals="-3"
      id="F_c0bd065c-4d5e-47b9-a402-2142714fa2a4"
      unitRef="U_USD">9292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73"
      id="F_3f97280e-e8d6-40b0-9952-e733da209cff">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fd7ecd14-b8eb-4306-a5a9-00856d0eec73"
      decimals="-3"
      id="F_b1e0bb82-b8f0-4f77-ade7-777eadb5c74e"
      unitRef="U_USD">189000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b17d8234-ba90-441b-b4a7-b13d05bda5b4"
      decimals="-3"
      id="F_270cd59f-d75f-4cfb-a0c7-1ab11a3a2e40"
      unitRef="U_USD">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_fc1bc77d-5e76-487a-bf34-dd3af7be4490"
      unitRef="U_USD">41624000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_da3a541a-b480-4f6b-8ee4-6511f6b92ab2"
      unitRef="U_USD">37463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_54c389b1-b672-46f0-b10e-caaa68589271"
      unitRef="U_USD">14847000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_102654d2-8733-4221-933b-0f8b19e196fc"
      unitRef="U_USD">8753000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_862317cd-5182-4cd7-8f6e-26ece30cabb7"
      unitRef="U_USD">26777000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_22209d40-9789-4558-9d37-80bb46a4230e"
      unitRef="U_USD">28710000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-5"
      id="F_75701812-f4b6-4b0e-b1e3-a6070ff21480"
      unitRef="U_USD">6100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-5"
      id="F_64e2ed1a-69be-40e6-af57-cfc4ee1ba11d"
      unitRef="U_USD">2600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_0a65afde-d201-475c-b3b9-224c530f5ff2"
      decimals="-5"
      id="F_621af8ad-d633-4054-b999-679a0da35bf2"
      unitRef="U_USD">9000000</us-gaap:ConstructionInProgressGross>
    <acet:ConstructionInProgressNet
      contextRef="C_af925b6c-d225-4763-b22a-b3974a3e23db"
      decimals="-5"
      id="F_f5b8fc17-fd89-41b0-824b-755e84338e0f"
      unitRef="U_USD">300000</acet:ConstructionInProgressNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_16499ac8-2664-4e73-9706-802226079cda">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued CDMO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued CRO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_a67de1f9-c93c-44aa-a57b-7aca1d1177e1">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.68%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued CDMO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued CRO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_1dccefd1-3ac8-4642-af9a-b5241ab3e064"
      unitRef="U_USD">6514000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_51e74b17-e2ff-41c6-a6c3-80b15ce2b4d3"
      unitRef="U_USD">5703000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <acet:AccruedCmoCosts
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_f0f87815-813b-4f15-8674-6a2d69f59856"
      unitRef="U_USD">5679000</acet:AccruedCmoCosts>
    <acet:AccruedCmoCosts
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_05a7e9a1-5cdc-468b-aee2-593279913a48"
      unitRef="U_USD">4390000</acet:AccruedCmoCosts>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_0df86ba1-e3c9-485c-9502-09e302f06489"
      unitRef="U_USD">625000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_19efcf3b-ecec-4f22-8ac5-2986bb3997f0"
      unitRef="U_USD">1356000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <acet:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_77b291b1-9533-4658-92b2-dd750fbb6717"
      unitRef="U_USD">354000</acet:AccruedResearchAndDevelopmentExpensesCurrent>
    <acet:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_b51caaa7-bd39-469c-9424-6466056910f0"
      unitRef="U_USD">674000</acet:AccruedResearchAndDevelopmentExpensesCurrent>
    <acet:AccruedCroCosts
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_12793fc9-61f2-4aef-bbc1-4cdf3ea2765d"
      unitRef="U_USD">257000</acet:AccruedCroCosts>
    <acet:AccruedCroCosts
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_1a582ecd-769e-482c-87d7-b3d9de2f121a"
      unitRef="U_USD">657000</acet:AccruedCroCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_1ffb083f-863d-4f3a-8ea4-870dc2e120f4"
      unitRef="U_USD">12000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_e3d98bb6-6899-4038-9038-26759c640e42"
      unitRef="U_USD">31000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_0aed0691-3091-4a8d-a757-1f20dd677f8f"
      unitRef="U_USD">13441000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_955654ba-7f97-48a7-8c59-79f6e306935b"
      unitRef="U_USD">12811000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_8d60cfe7-0b19-418e-b596-00f6187417e9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 28, 2020, the Company entered into a Loan and Security Agreement (the Loan Agreement) as amended on July 8, 2020, September 14, 2020, September 15, 2020, October 21, 2021, December 2, 2022 (the 2022 Loan Amendment) and May 30, 2023 with Banc of California (formerly known as Pacific Western Bank) to finance leasehold improvements for the facilities in Redwood City, CA and other purposes permitted under the Loan Agreement. Under the October 21, 2021 amendment, Banc of California will provide one or more Term Loans (as defined in the 2021 Loan Amendment), as well as Non-Formula Ancillary Services which shall not exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which each Term Loan to be in an amount of not less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 13, 2023, the Company and Banc of California executed a letter agreeing that, notwithstanding the covenants included in the 2022 Loan Amendment, until June 30, 2023 (i) the Company and its subsidiaries will not be required to maintain the lesser of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or seventy percent (70%) of its combined balances in demand deposit accounts, money&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;market &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;funds and/or insured cash sweep (ICS) accounts with Banc of California and (ii) the Company must maintain its combined balances at Banc of California or its affiliates, including Pacific Western Asset Management (the Letter).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 30, 2023, the Company further amended its Loan Agreement with Banc of California (the 2023 Loan Amendment). Pursuant to the 2023 Loan Amendment, the Company must maintain the lesser of (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million or (ii) all of the Company&#x2019;s combined balances in demand deposit accounts, money market accounts, and/or insured cash sweep accounts with Banc of California. If the Company&#x2019;s total cash and investments drop to less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the 2023 Loan Amendment permits the Company to maintain cash and/or investments in one or more accounts outside of Banc of California up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available under the Loan Agreement. Additionally, as of December 31, 2023, the Company is in compliance with such covenants as stated in the 2023 Loan Amendment and had no indebtedness outstanding under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <acet:TermLoanToFinanceLeaseholdImprovements1
      contextRef="C_8b31a2fd-9ce2-44b0-ae61-2ba25f62ea40"
      decimals="-5"
      id="F_d3c94a60-ddc1-4c1a-b778-3bd7668ca0ca"
      unitRef="U_USD">5500000</acet:TermLoanToFinanceLeaseholdImprovements1>
    <acet:TermLoanToFinanceLeaseholdImprovements1
      contextRef="C_897945e8-d886-4a9a-afe5-8e849b01fa66"
      decimals="-5"
      id="F_516e8dc9-c542-492c-bd35-1a5d19d5f8fb"
      unitRef="U_USD">15000000</acet:TermLoanToFinanceLeaseholdImprovements1>
    <acet:TermLoanToFinanceLeaseholdImprovements1
      contextRef="C_54fb6a03-848a-42a9-a84c-0292032c99c7"
      decimals="-5"
      id="F_3137f882-27d6-44d6-aa44-22f742edde03"
      unitRef="U_USD">1000000</acet:TermLoanToFinanceLeaseholdImprovements1>
    <acet:CombinedBalancesInDemandDepositAccounts
      contextRef="C_7e25f46c-a94c-4ebc-b2ae-28925638d603"
      decimals="-6"
      id="F_4a418351-d317-45c7-9c81-cad1d59b1e11"
      unitRef="U_USD">200000000</acet:CombinedBalancesInDemandDepositAccounts>
    <us-gaap:DemandDepositAccounts
      contextRef="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8"
      decimals="-5"
      id="F_133ab3fd-d960-46a9-ba9a-80d98988bb6f"
      unitRef="U_USD">35000000</us-gaap:DemandDepositAccounts>
    <acet:TermLoanCashMaintain
      contextRef="C_4857a09a-d95e-4b3b-b26a-546fe2e885c8"
      decimals="-5"
      id="F_e3268abd-9660-4aaa-a11d-a3e341d08d99"
      unitRef="U_USD">35000000</acet:TermLoanCashMaintain>
    <acet:TotalLoanAccountsOutside
      contextRef="C_ec965417-7244-4e77-bb2e-c305534384cf"
      decimals="-5"
      id="F_11f7fe30-a287-4d08-bc11-0cf0511c8362"
      unitRef="U_USD">2500000</acet:TotalLoanAccountsOutside>
    <acet:AvailableUnderTheLoanAgreement
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-5"
      id="F_362eb9ab-e791-4a67-9fb5-618f63852fd0"
      unitRef="U_USD">12700000</acet:AvailableUnderTheLoanAgreement>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_07d5ed00-b085-46a6-bf9b-1869257c4e7d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Third Party Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Regeneron&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#x2019;s investment in the Company&#x2019;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from Regeneron upon execution of the Regeneron Agreement and an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of additional payments for research funding from Regeneron as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of option exercise fees, as specified in the Regeneron Agreement. Per the terms of the agreement, Regeneron must pay the Company high single digit royalties as a percentage of net sales for immune cell products (ICPs) to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#x2019;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#x2019;s license to use Regeneron&#x2019;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve (12) years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from first commercial sale. No royalties have been earned or paid under the Regeneron Agreement through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta CAR T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement. In conjunction with the exercise of the option, Regeneron paid an exercise fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the Company on January 28, 2022, and the Company completed the transfer of the associated license rights to Regeneron during the first quarter of 2022. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million option exercise fee, plus $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of revenue recognized relating to the combined performance obligation, resulted in an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million recorded as revenue for the year ended December 31, 2022. The Company's obligations under the combined performance obligation were completed during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, there were no contract assets related to the Regeneron Agreement. The following tables present changes in the Company&#x2019;s contract liabilities for the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning &lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;End of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning &lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deductions&lt;br/&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;End of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Twist Bioscience&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, the Company entered into an Antibody Discovery Agreement (the Twist Agreement) with Twist Bioscience Corporation (Twist). Under the terms of the Twist Agreement, Twist will utilize its proprietary platform technology to assist the Company with the discovery of novel antibodies related to target antigens selected by the Company. The Company maintains the sole and exclusive rights to any program antibodies discovered under the Twist Agreement and has the right to patent, assign, license or transfer any work product under the agreement. Furthermore, the Company has the right to sublicense its rights to program antibodies to third parties. The Company may terminate the Twist Agreement at any time, with or without cause, upon a specified period advance written notice.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Per the terms of the agreement, the Company will pay Twist an upfront, non-refundable project initiation fee, a technology access fee, as well as a project fee for each project entered into under the agreement. Additionally, the Company will pay fees for development and regulatory milestones in the tens of millions of dollars and low single digit royalties on net sales to Twist for programs initiated under the agreement. In November 2022, the Company entered into an amendment to the Twist Agreement (the Twist Amendment). The Twist Amendment updates the language associated with Twist's audit rights as well as the amounts associated with technology access fees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On a cumulative basis as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has incurred and expensed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to project initiation fees, technology access fees and projects fees as research and development expense related to this agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <acet:NonRefundableUpfrontPaymentReceived
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-5"
      id="F_379fa577-a723-45f0-9545-15f1d31ef4ac"
      unitRef="U_USD">25000000</acet:NonRefundableUpfrontPaymentReceived>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-5"
      id="F_c40c5404-c7ba-4c9c-9673-509fa76dac80"
      unitRef="U_USD">20000000</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees
      contextRef="C_a623b912-7fdc-45eb-b768-963c9acc0e80"
      decimals="-5"
      id="F_53e85266-8917-4001-a71c-7a462da83a78"
      unitRef="U_USD">80000000</acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees>
    <acet:LicenseAgreementTerminationDescription
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_487441de-56a2-4f98-9f87-18069e8ea7fb">twelve (12) years</acet:LicenseAgreementTerminationDescription>
    <acet:ExerciseFeePaid
      contextRef="C_1d264861-044d-454d-9a46-2ea594afdb73"
      decimals="-5"
      id="F_40e7f430-e8cb-4df2-8b72-91d63a5ecf3a"
      unitRef="U_USD">20000000</acet:ExerciseFeePaid>
    <acet:ExerciseFeePaid
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-5"
      id="F_2398b078-be33-4228-964b-fc5b8f27a9fa"
      unitRef="U_USD">20000000</acet:ExerciseFeePaid>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-5"
      id="F_0348938e-2426-40fb-bed6-37d24831b216"
      unitRef="U_USD">5000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <acet:LicenceAgreementAdditionalRevenueRecognised
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-5"
      id="F_36cf082f-9cd2-4fef-ae77-7307e80c878f"
      unitRef="U_USD">25000000</acet:LicenceAgreementAdditionalRevenueRecognised>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_4d982ae9-6d89-4791-9227-b07b37ea2cb2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, there were no contract assets related to the Regeneron Agreement. The following tables present changes in the Company&#x2019;s contract liabilities for the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning &lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;End of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.529%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.463%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.903%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;Beginning &lt;br/&gt;of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Deductions&lt;br/&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance at&lt;br/&gt;End of Period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_40665ebd-fd67-4d04-97c7-45124e5c850b"
      decimals="-3"
      id="F_5f8e9191-ba39-4d05-a2df-1b8307466686"
      unitRef="U_USD">0</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilitiesAdditionsDeductions
      contextRef="C_50941431-c7dd-4f38-8678-4027d202f1e1"
      decimals="-3"
      id="F_8cfed16c-3f5a-4ca3-85a5-e8dec2ce67ea"
      unitRef="U_USD">0</acet:ContractAssetsAndLiabilitiesAdditionsDeductions>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_8f65238a-1a42-43ff-a87b-7cac1f995a5c"
      decimals="-3"
      id="F_98ea76df-a187-491a-8a38-47443cd457ce"
      unitRef="U_USD">0</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_e30421e9-e302-416b-8491-76859aa72b91"
      decimals="-3"
      id="F_b98d36a4-e09f-4d8d-8e93-484bd6ae61ba"
      unitRef="U_USD">4805000</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilitiesAdditionsDeductions
      contextRef="C_bd6622b0-707b-4b92-a039-abb383da1129"
      decimals="-3"
      id="F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6"
      unitRef="U_USD">4805000</acet:ContractAssetsAndLiabilitiesAdditionsDeductions>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_40665ebd-fd67-4d04-97c7-45124e5c850b"
      decimals="-3"
      id="F_9e46f4c1-bcc0-426b-81d4-81778adabcb9"
      unitRef="U_USD">0</acet:ContractAssetsAndLiabilities>
    <acet:ResearchAndDevelopmentInProcess1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-5"
      id="F_eac18e41-3a0a-43c5-a21f-b8046170bba1"
      unitRef="U_USD">1000000</acet:ResearchAndDevelopmentInProcess1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_bb55f8b4-9672-4095-a4be-46cbc31c6067">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office and laboratory space in Redwood City, California, and Boston, Massachusetts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Redwood City&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2018, Adicet Therapeutics executed a non-cancelable lease agreement, as amended in 2022, pursuant to which the Company leases office and laboratory facility at 1000 Bridge Parkway and a portion of 1200 Bridge Parkway in Redwood City, California (the Redwood City Lease).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 9, 2023, Adicet Therapeutics entered into a third lease amendment with Westport Office Park, LLC (the Third Amendment). The Third Amendment further amends the Redwood City Lease and increases the tenant improvement allowance as of January 1, 2023 by an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company fully utilized the allowance for the continued buildout of office and laboratory space at 1000 Bridge Parkway in 2023. Per the terms of this amendment, this additional allowance will be repaid through equal monthly payments of principal amortization and interest on a monthly basis over the term of the lease at an interest rate of eight percent (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%) per annum. The Company received the allowance on February 21, 2023 and increased the operating lease liability accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 7, 2023, Adicet Therapeutics entered into a fourth lease amendment with Westport Office Park, LLC (the Fourth Amendment). The Fourth Amendment amends the period over which the tenant improvement allowance received in the Third Amendment will be amortized and identifies the monthly amortization payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 1, 2023, Adicet Therapeutics amended its letter of credit with Westport Office Park, LLC. The amendment reduced the amount of the letter of credit associated with 1000 Bridge Parkway by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million resulting in an updated letter of credit amount of $2.1 million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Boston&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2018, the Company entered into a lease agreement, as amended in 2019, for office space at 500 Boylston St, Boston, Massachusetts (500 Boylston Lease). Under the terms of the 500 Boylston Lease, the Company was permitted to assign, sublease or transfer this lease, with the consent of the landlord.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 19, 2021, the Company entered into a sublease agreement with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,501&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; rentable square feet of 500 Boylston St. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected undiscounted cash flows to be received from the sublease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized rent expense, net of sublease income, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Further, the Company remains liable for the remaining lease payments under the 500 Boylston Lease, totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is included in the future minimum lease payments table below.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The future minimum lease payments under all non-cancelable operating lease obligations as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, net of current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Locations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;IBR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining Terms&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redwood City, CA (1000 Bridge Parkway)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redwood City, CA (1200 Bridge Parkway)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Boston, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the operating lease cost and information related to the operating lease right-of-use assets, net and operating lease liabilities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.63%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.124%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.124%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows used for lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, operating right-of-use assets were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and operating lease liabilities were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company has no material finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains letters of credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in connection with the Company&#x2019;s office leases in Redwood City, CA and Boston, MA, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; liability insurance.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:TenantImprovements
      contextRef="C_916c0314-0614-4526-9283-d8a045dc95a2"
      decimals="-5"
      id="F_d5597909-80a6-4c0a-9788-812824c63676"
      unitRef="U_USD">3000000</us-gaap:TenantImprovements>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_af2ebdd0-26c4-43a6-a4ca-3aa3d01aa585"
      decimals="2"
      id="F_0b5d0385-ccbe-4557-86e3-21f74e5b11a7"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_e0c69718-cc5e-49e4-a0e8-bdc77ac5c987"
      decimals="-5"
      id="F_0c2ee79c-47e0-4fcd-84ba-672809e49c30"
      unitRef="U_USD">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <acet:AreaOfSublease
      contextRef="C_9574821a-e3a7-4169-a889-41b0f5866c4c"
      decimals="0"
      id="F_0cd698f0-6f38-4614-892f-b3b0e250de14"
      unitRef="U_sqft">9501</acet:AreaOfSublease>
    <acet:ScheduleOfSubleaseIncomeTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_55d652a8-eeb0-4ece-a1f4-52b7175157a3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expected undiscounted cash flows to be received from the sublease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfSubleaseIncomeTableTextBlock>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_dc8da30e-76f7-4e62-bb0d-3b0131917c1c"
      unitRef="U_USD">722000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_57712be8-0d19-42d4-8d4f-8897ea20fc04"
      unitRef="U_USD">736000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_6cd84adf-02c8-4952-8ba0-384976127ee2"
      unitRef="U_USD">438000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_62d99ac0-4b03-4406-9366-b5719a94e649"
      unitRef="U_USD">1896000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDue>
    <us-gaap:OperatingLeasePayments
      contextRef="C_03b04d41-2a70-46cc-b31d-d9c911eb2cda"
      decimals="-5"
      id="F_8514bc7a-03b4-4c34-a3fd-2206b44d308f"
      unitRef="U_USD">4000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_91bff28d-648d-4207-9e94-2523616823eb"
      decimals="-5"
      id="F_11559be6-d4e0-47d8-9f6d-d3e8ad7d2a88"
      unitRef="U_USD">3900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-5"
      id="F_8b7a8f2d-0868-4611-826a-1257ce0eaf10"
      unitRef="U_USD">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_3c5b295e-ece9-474c-9ad0-75f00c5923d6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The future minimum lease payments under all non-cancelable operating lease obligations as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:28.7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, net of current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_f60cac49-8322-4690-99d7-6f11c6573d00"
      unitRef="U_USD">5015000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_31369049-acb8-4f9f-8c58-163f37122872"
      unitRef="U_USD">4662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_dd3a384a-5ad0-4c32-ba53-8d64d961699f"
      unitRef="U_USD">4009000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_190a4f01-6b70-4b11-aa14-5136f505ebc0"
      unitRef="U_USD">12090000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_092929f7-9e07-4f12-ab62-3692341228f2"
      unitRef="U_USD">25776000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_157e2ed9-916d-4d7b-a3d1-e07a109331d6"
      unitRef="U_USD">4852000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_c820531d-4c0f-4640-afcf-2df0ba7bc665"
      unitRef="U_USD">20924000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_664c8645-a570-48ae-b674-fd3b51a1ee18"
      unitRef="U_USD">3221000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_276b8e67-dab4-4860-b2ea-bfaeb3cb38d3"
      unitRef="U_USD">17703000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_b66bb551-cc38-482f-9e40-01e32e3735f7">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Locations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;IBR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining Terms&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redwood City, CA (1000 Bridge Parkway)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redwood City, CA (1200 Bridge Parkway)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Boston, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7"
      decimals="4"
      id="F_07f26da0-7483-4ebc-98f7-2bf3e3d185c3"
      unitRef="U_pure">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7"
      id="F_83388a2c-0dcc-4da7-a847-7b91085cd296">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_2e885ea3-80a2-45de-abec-f29848bb6275"
      decimals="4"
      id="F_1dbddaec-0755-490b-a409-25b4e82d372f"
      unitRef="U_pure">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2e885ea3-80a2-45de-abec-f29848bb6275"
      id="F_08580194-e1c5-49a3-b928-9c0f1d8cbfe4">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68"
      decimals="4"
      id="F_b88be579-1a0a-4db2-81a1-14ea3ba5b5e3"
      unitRef="U_pure">0.093</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68"
      id="F_0fff927e-83b0-4d73-ad52-6f7c5289c8d5">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="4"
      id="F_57970bb9-9c9f-40e6-9772-110707908bbe"
      unitRef="U_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      id="F_9b58cf41-6ba1-45ff-9494-d05945a00514">P5Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_4695a3fa-6a87-4db8-be00-b3ff1c42c43c">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the operating lease cost and information related to the operating lease right-of-use assets, net and operating lease liabilities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.63%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.124%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.124%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash flows used for lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_fbdedbde-20ed-436b-b8d5-2e3c0249ab99"
      unitRef="U_USD">4510000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_05e1a57d-808a-480e-a2ed-3fe26fcc5922"
      unitRef="U_USD">4508000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_be82e5b6-aa89-48d7-a603-e3771928084e"
      unitRef="U_USD">195000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_a8ebcbda-d1e6-40d6-98f2-3232b1c0cfb7"
      unitRef="U_USD">133000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_33562ed6-6ee0-452a-8889-f5a2b1b10396"
      unitRef="U_USD">714000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_1d59edfc-fa65-4899-8666-cf5700f5cf98"
      unitRef="U_USD">704000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_c75c86bc-1fc5-4136-97b8-b9aeb656a3ab"
      unitRef="U_USD">3991000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_d06d0155-ef58-463d-bea7-3f5441a32661"
      unitRef="U_USD">3937000</us-gaap:LeaseCost>
    <acet:OperatingLeaseProceedsPaymentsUse
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_d76afb2a-c0eb-4494-88cb-0e79d8c37094"
      unitRef="U_USD">-99000</acet:OperatingLeaseProceedsPaymentsUse>
    <acet:OperatingLeaseProceedsPaymentsUse
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_60c03100-9519-48f9-ac08-aceb3d3d271a"
      unitRef="U_USD">2264000</acet:OperatingLeaseProceedsPaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      id="F_e3689723-aa18-4ed2-8d09-2934fb7999d4">P5Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      id="F_a793b8c4-35bc-4d52-b3cb-eba4d5d5d2aa">P6Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="3"
      id="F_7ee8e796-4d8a-4df6-b240-ab8f06c7fa8c"
      unitRef="U_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="3"
      id="F_4edf305a-19ab-427a-b075-524e3e9c8a30"
      unitRef="U_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-5"
      id="F_aeb4e8f4-d8ee-40f7-ab10-b91886cf453e"
      unitRef="U_USD">17400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-5"
      id="F_678d0123-51b8-40b4-836e-2d6c0db3bfad"
      unitRef="U_USD">20900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_0d8568b6-257d-4933-9f8c-8954426bbed7"
      decimals="-5"
      id="F_f7789f59-97a9-4301-8f26-8dc726cb223f"
      unitRef="U_USD">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_45937f8b-d5ca-46b4-8c1c-6b2f497a5c68"
      decimals="-5"
      id="F_c965289f-0760-49aa-87e1-bb10a22e68e0"
      unitRef="U_USD">200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_83afc251-8983-4efa-8d81-10b320e5b30b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Certificate of Incorporation, as amended, authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value common stock as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stockholders are entitled to dividends if and when declared by the Board of Directors of the Company subject to the prior rights of the preferred stockholders. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends on common stock had been declared by the Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has the following shares of common stock reserved for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units available for future grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,473,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,871,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,310,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,272,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_0e666c07-ba5c-46ad-b223-5926e994e897"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="4"
      id="F_9a3aceaa-63eb-4406-a04a-0856ef486eb6"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_6b0f4cdd-9ee5-4823-bb7f-8ab2ae153dd9"
      unitRef="U_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_1265920d-e9e3-4461-8320-889755b6fa57">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has the following shares of common stock reserved for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units available for future grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,473,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,871,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,310,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,272,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0e5442b4-b4a0-4661-aeb9-e32534abdac2"
      decimals="INF"
      id="F_357c8f11-b474-4983-884b-6e3f0ae7b4d3"
      unitRef="U_shares">2473485</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4d422142-c5e5-4b57-97a3-51fb1b8cf885"
      decimals="INF"
      id="F_df2f215f-6af7-4b62-8110-57bce3933451"
      unitRef="U_shares">2871705</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8c4301bd-829f-4113-9dfb-fc7cb0d08261"
      decimals="INF"
      id="F_f97094ab-9cf1-429e-a78a-af339dda4ee3"
      unitRef="U_shares">9383105</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_311e49e6-e6fe-465d-83fb-e37ac0ea7ce6"
      decimals="INF"
      id="F_0811e1f2-92aa-44ad-945f-e76722a27967"
      unitRef="U_shares">6203020</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"
      decimals="INF"
      id="F_3bf40953-0066-456a-9139-a8810b5b28c0"
      unitRef="U_shares">454200</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e"
      decimals="INF"
      id="F_0a66693a-064d-45b1-9124-6a4bd4a87cfb"
      unitRef="U_shares">197580</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="INF"
      id="F_b4541ee9-e384-49c6-a542-90716791d22d"
      unitRef="U_shares">12310790</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="INF"
      id="F_852981fd-f476-4c6b-9eb0-83c1f9295e52"
      unitRef="U_shares">9272305</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_5a18efdd-d7ec-4cfa-8a3a-1653e2d890f8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents stock-based compensation expense by type of award (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of stock option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is set forth below (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.747%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.934%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.295%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.934%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.455%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,293,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,112,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,984,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The assumptions used in the Black Scholes Model to calculate stock-based compensation are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.195%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.195%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The assumptions are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#x2019;s industry peers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Dividend yield.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money at December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2023 and 2022 was less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total fair value of options that vested during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The options granted during the years ended December 31, 2023 and 2022 had a weighted-average per share grant-date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the total unrecognized stock-based compensation expense related to unvested stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over the remaining weighted-average vesting period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summary of RSU activity and related information for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is set forth below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;513,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;513,700&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; RSU's in the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t grant any RSU's in the year ended December 31, 2022. The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, there was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Option repricing&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 8, 2023, the board of directors approved a stock option repricing (the Option Repricing) to be effective on August 14, 2023 (the Effective Date) in accordance with the terms of the Company&#x2019;s 2015 Stock Incentive Plan and 2018 Plan (together, the Plans). Pursuant to the Option Repricing, and subject to a one year cliff period, the exercise price of each stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;option &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;previously granted under the Plans, totaling &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,431,910&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options, was amended to reduce the exercise price of such options to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on the Effective Date. Under the terms of the Option Repricing, a repriced option will revert to its original exercise price if, prior to the one year anniversary of the Effective Date, (a) the option holder&#x2019;s employment is terminated by the Company with cause or by the option holder or (b) the option is exercised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The repriced options otherwise retained their existing terms and conditions as set forth in the Plans and applicable award agreements. The stock option modification resulted in an incremental compensation cost of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was calculated based on the difference between the fair value of the stock options before the repricing and the fair value as of the Effective Date, using the Black-Scholes option-pricing model. Of the incremental compensation cost, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized in the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, and the remaining amount, less any employee terminations, will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, as of the Effective Date, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,418,042&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options to purchase shares of common stock under the 2018 Plan to eligible employees who held inducement awards as of August 8, 2023. These new options were issued to eligible employees because their inducement awards granted under Nasdaq Listing Rule 5635(c)(4) are not eligible for repricing. The prior inducement awards remain outstanding under their original terms.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_1c1e949b-a96d-4fb2-9b49-9042d22de06a">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents stock-based compensation expense by type of award (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f58078b6-76be-474e-a1ef-f5d1e47368bb"
      decimals="-3"
      id="F_60d21f4c-b52d-41b5-9742-e67cce8e8396"
      unitRef="U_USD">9143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d48a06f-dbae-4fc5-8ffb-b637076720b8"
      decimals="-3"
      id="F_6c012c85-63b1-4544-bec9-ce2700d7c422"
      unitRef="U_USD">7225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88454f42-8fdc-4021-91ce-b4d6b6330c65"
      decimals="-3"
      id="F_858c1955-6150-4511-a917-bf576fecb570"
      unitRef="U_USD">11116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_733a8089-51c5-4d2f-ba06-56a474b671db"
      decimals="-3"
      id="F_f9cae74d-180c-4ed3-8735-7f9786c338a8"
      unitRef="U_USD">9901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_eed7ab63-313a-4c46-bc99-86bc3f9440cd"
      unitRef="U_USD">20259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_2267e981-c3fe-4974-896c-4e114ed8455f"
      unitRef="U_USD">17126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b4cf6be1-4f2c-4f83-bfd3-9d9edf02216a"
      decimals="-3"
      id="F_390ea28b-e174-4e16-8626-d99839c0e8f4"
      unitRef="U_USD">18060000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9d5312ec-a7ba-4ea9-806a-0f9c38c43ee2"
      decimals="-3"
      id="F_056f23df-1d86-41d1-9d63-fbe9cfd063eb"
      unitRef="U_USD">14054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_596f1ec4-c26f-47d8-873a-09b6b3910e9a"
      decimals="-3"
      id="F_1b7e45ab-9e15-449e-9164-e94a9ed3a5a7"
      unitRef="U_USD">2023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_241fa14f-5fcb-4423-8601-15153c2f69e7"
      decimals="-3"
      id="F_3f32bef3-80ab-430d-9ba2-56514901c9ef"
      unitRef="U_USD">2878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e485415b-bfa6-4e68-b402-10c45a238a24"
      decimals="-3"
      id="F_9c66c849-b540-43d2-ad25-77ef1abef579"
      unitRef="U_USD">176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dd112089-6f8c-421a-b580-9551aa752b5e"
      decimals="-3"
      id="F_6ad7f00d-3567-4982-9a11-35afa9a9dd21"
      unitRef="U_USD">194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_1549e207-823c-40b2-b050-924ffb9faf45"
      unitRef="U_USD">20259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_088fbb61-c944-4fc5-8993-a218ee2aed8d"
      unitRef="U_USD">17126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_3c3d2bb5-4962-47c2-8bf7-09d392bdfe44">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of stock option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is set forth below (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.747%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.934%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.295%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.934%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.319%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.455%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,293,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,112,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,984,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="0"
      id="F_a14d9d8f-78cf-4bd1-a29a-571141a58876"
      unitRef="U_shares">6203020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="2"
      id="F_6a4485a7-26f1-43af-8186-94f51d81b531"
      unitRef="U_USDollarShare">14.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      id="F_e1e33338-a1f3-4b73-b65a-2d5a1c725ffd">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_4a26b9ab-ee04-4a84-a194-52cc2210482f"
      unitRef="U_USD">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_92970713-8e97-49f5-a609-b452d128c5bf"
      unitRef="U_shares">4293442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_df324e7c-c7e7-4855-9dd4-101b8a88d56c"
      unitRef="U_USDollarShare">5.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_dbab6298-d834-470f-99fb-afa5bce6b74a"
      unitRef="U_shares">946</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_89ec1a99-3f7f-4bdf-add8-403a522a03c7"
      unitRef="U_USDollarShare">4.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_8fff9293-12a4-41d3-8779-efbb805a29d3"
      unitRef="U_shares">1112411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_70f46aae-f68b-41a7-ac6e-622a6e034ef8"
      unitRef="U_USDollarShare">10.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_7d182ffa-21c5-41ab-aeb8-579086ce82bb"
      unitRef="U_shares">9383105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="2"
      id="F_f6f46572-e0c3-4336-babc-3cfa85bf4647"
      unitRef="U_USDollarShare">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_bd774236-1e34-42a0-986c-7b95844f08bd">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_e9342299-e9ac-458e-8f3d-2c368a4c27d6"
      unitRef="U_USD">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_eca386bb-de02-401a-9b82-d3702d17857f"
      unitRef="U_shares">3984821</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="2"
      id="F_c126b5a9-b0c3-4ebf-b93b-667e342c5861"
      unitRef="U_USDollarShare">13.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_fea7fabf-1534-4009-9327-d450b5f49f33">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_c0fa659d-d446-4da8-9915-a3414c02c326"
      unitRef="U_USD">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="0"
      id="F_1cbe082b-107f-40d2-9af5-43e9cb84a2f3"
      unitRef="U_shares">9383105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="2"
      id="F_7c8808e6-fca7-4ea0-88b2-2edc70c0f26f"
      unitRef="U_USDollarShare">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_7692d494-dd21-4e6f-b4ac-d2c53547d294">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_a1ad513c-76e5-405b-b7a4-bf0b4b31a1e0"
      unitRef="U_USD">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_e818314f-42a6-45cc-98ac-bedcff5d9ed7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The assumptions used in the Black Scholes Model to calculate stock-based compensation are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.195%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.195%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk free rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_da045486-c2fe-4b90-ab00-21eab7441f0a"
      decimals="2"
      id="F_5d01ab6e-c8d2-41dc-8dea-90398039f502"
      unitRef="U_USDollarShare">1.32</acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9"
      decimals="2"
      id="F_6f695e4f-f278-4c04-84f0-4aa16ceba200"
      unitRef="U_USDollarShare">9.15</acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_cecd4cc3-7caa-450f-a101-f3b58059d74a"
      decimals="2"
      id="F_47927b0a-4dbc-4910-a716-becbb6f1c579"
      unitRef="U_USDollarShare">8.94</acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_57732136-14ea-4518-80b2-de77d352b723"
      decimals="2"
      id="F_82f6839d-fdc5-4a2a-a535-cad834625f3e"
      unitRef="U_USDollarShare">19.97</acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_da045486-c2fe-4b90-ab00-21eab7441f0a"
      id="F_407d48d9-8817-45c3-8b68-363c08455c41">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9"
      id="F_d8ad00b5-ee83-4bbd-a70c-b4f14913d511">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cecd4cc3-7caa-450f-a101-f3b58059d74a"
      id="F_abc27536-e0ad-4cfa-b65b-0dde5e9b6637">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_57732136-14ea-4518-80b2-de77d352b723"
      id="F_f416037e-e5f3-4451-a7ef-d261a13b646f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="4"
      id="F_37c9b69f-5907-4285-8c7f-a166d8625d62"
      unitRef="U_pure">0.8325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="4"
      id="F_5bf13a8d-a8b6-4e8b-b635-a022bf1b87ba"
      unitRef="U_pure">0.9287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_64e78d3e-7f86-4906-b9fa-7dd95e1cedd9"
      unitRef="U_pure">0.774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_fa1c12e7-db5c-48e8-9e72-13c65fe64d2a"
      unitRef="U_pure">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_6e747f30-f7f9-4e32-8a08-2cfde039bf8f"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="4"
      id="F_30b22238-24b6-4e5a-90a4-ebe3270ae070"
      unitRef="U_pure">0.0486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_22d723fa-c746-4bf3-ab42-d7bfa236a97f"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="4"
      id="F_ec0650a5-7eec-44f7-84f5-be118704f4ed"
      unitRef="U_pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_ab48b1f6-61c5-4859-90f6-86a89482585e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_99b6dfbb-bba7-4e05-9807-e7d1164d581a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_b2ca41eb-0eab-49bb-971f-56952843d4a9"
      decimals="-5"
      id="F_c8388e93-4f64-452b-aa6e-b75617b1201a"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-5"
      id="F_0194fefd-6cd7-4d5e-98e6-2601c80619da"
      unitRef="U_USD">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce"
      decimals="-5"
      id="F_ab65c3e8-c361-4762-9396-ac08bd3d651c"
      unitRef="U_USD">17900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192"
      decimals="-5"
      id="F_5dcbcdc0-557f-4ada-969d-a0873f07f495"
      unitRef="U_USD">13400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce"
      decimals="2"
      id="F_dc17a1c2-eafe-44ac-941d-1a3b3bfae57c"
      unitRef="U_USDollarShare">3.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192"
      decimals="2"
      id="F_2d0106c6-07b6-41b0-b8f0-516fc1b61ef3"
      unitRef="U_USDollarShare">10.07</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_747dc985-0918-4eea-aab1-03ff0d433f81"
      decimals="-5"
      id="F_cba97280-871a-4add-88b2-e49729bb5c20"
      unitRef="U_USD">31700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce"
      id="F_a9607b7c-1122-497b-96cb-f3e2979a2114">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_208bf39a-606c-47c9-9f33-e444df603ada">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summary of RSU activity and related information for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is set forth below:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;513,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e"
      decimals="0"
      id="F_77b94e07-46c6-45d6-bb66-753bfed1471a"
      unitRef="U_shares">197580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_2309e372-c3fc-40f6-a3a4-dd00f686d78e"
      decimals="2"
      id="F_11227600-a00c-4be6-8a0c-e7f050650e7a"
      unitRef="U_USDollarShare">7.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="0"
      id="F_ab547956-5dd6-42ca-a1e2-b2da566e161a"
      unitRef="U_shares">513700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="2"
      id="F_d544e8db-6b6d-4124-9a17-793ac9c0f3b1"
      unitRef="U_USDollarShare">7.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="0"
      id="F_c04e77d0-7ac5-4875-be74-e760826d48ac"
      unitRef="U_shares">194455</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="2"
      id="F_b9138131-9597-424c-9e1c-31d6eb5a6e44"
      unitRef="U_USDollarShare">7.43</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="0"
      id="F_38783f80-b772-495d-9d92-9c060d42f931"
      unitRef="U_shares">62625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="2"
      id="F_2558018a-de0b-4f7a-acec-452277a5e93d"
      unitRef="U_USDollarShare">7.07</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"
      decimals="0"
      id="F_c362d2b6-cd6f-4ed2-8a7f-723860705e9f"
      unitRef="U_shares">454200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"
      decimals="2"
      id="F_de97ea0c-2656-4bb6-91b8-366e5a3bd84e"
      unitRef="U_USDollarShare">7.69</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="0"
      id="F_80356415-15ba-4857-a3a2-3017bfdca160"
      unitRef="U_shares">513700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4"
      decimals="0"
      id="F_fcbc4e2b-d7af-4237-abde-b33c2346c68e"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"
      decimals="2"
      id="F_2468e4a0-ddc9-44d9-84fd-5efbd0d2688b"
      unitRef="U_USDollarShare">7.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_1b8d4dbd-fee1-4600-b11a-5058fabfaaa6"
      decimals="-5"
      id="F_5da0787d-2db0-4bcd-807c-71327f858be6"
      unitRef="U_USD">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      id="F_56ee6cdf-b471-4366-bc64-99e3c563a80c">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted
      contextRef="C_347a9bbd-5136-4186-a21c-9d1306e004b8"
      decimals="0"
      id="F_90c7a6aa-eb17-4504-9e63-08823c6440d2"
      unitRef="U_shares">6431910</acet:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted>
    <acet:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice
      contextRef="C_567c498c-9118-465c-999b-374820f503df"
      decimals="2"
      id="F_f9e98ba0-0a75-4c53-b6f8-a60aa85c3170"
      unitRef="U_USDollarShare">2.14</acet:Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodexerciseprice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_3e7400b2-991e-4baa-bd6d-1b6d5cc20a11"
      decimals="-5"
      id="F_653316eb-e0ed-40d8-a42a-d7a6843d8132"
      unitRef="U_USD">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <acet:ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions
      contextRef="C_dc080d41-4d34-4968-8ee6-17defa00e2d7"
      decimals="-5"
      id="F_2d25eae2-6d79-4a53-a315-ece6f4d73541"
      unitRef="U_USD">1300000</acet:ShareBasedPaymentArrangementIncrementalCostAmountRecognizedOverTheRemainingVestingPeriodOfRepricedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_b4e3d6b0-f801-44dd-b98a-08f6aee1758f"
      decimals="0"
      id="F_99facc77-3ab7-45d5-b428-49dd1aed47ab"
      unitRef="U_shares">1418042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_258c0ce7-9c4c-4a07-a222-0eaf43e7d0bb">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.854%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.099%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.099%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,042,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,080,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company's potentially dilutive shares as of December 31, 2023 and 2022, which include outstanding stock options and unvested RSUs, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,837,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,400,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_0114e57f-c5fc-4d5e-b42b-52ff484f5ec9">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.854%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.099%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.099%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.974%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,042,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,080,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_63bf2469-76df-4409-9339-1bc9fdaefeac"
      unitRef="U_USD">-142658000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_ca01993c-8fad-4c6c-bd2e-6d3c136e0d65"
      unitRef="U_USD">-69790000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_1424a39f-cc47-492f-a47c-0787c140b694"
      unitRef="U_shares">43042405</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="0"
      id="F_a254f150-00d3-4be9-a796-f56edb0f6034"
      unitRef="U_shares">43042405</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="0"
      id="F_0fee951f-6a8e-4ebf-b8c1-46097c0e2e9d"
      unitRef="U_shares">41080286</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="0"
      id="F_e8570035-8512-45d2-a0a4-4925e1d18afd"
      unitRef="U_shares">41080286</us-gaap:WeightedAverageLimitedPartnershipUnitsOutstandingDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_d60b5315-3d1e-4e93-89a6-70c43199642d"
      unitRef="U_USDollarShare">-3.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_8b0b794a-3213-495e-8b7d-ed8cb0728ed2"
      unitRef="U_USDollarShare">-3.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_9c39f2d5-4057-42f4-bcc0-6c2847e473a5"
      unitRef="U_USDollarShare">-1.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_1c751ad7-3165-4d07-aa26-0374d079a3f2"
      unitRef="U_USDollarShare">-1.7</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_98d5a8be-8e77-4df5-a22f-f79dff8508e1">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,383,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,203,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;454,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,837,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,400,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e2934718-edb2-47e5-ae88-69ff951335ce"
      decimals="INF"
      id="F_4a8c64b7-9dfa-40ab-9240-cdc1f771dddd"
      unitRef="U_shares">9383105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_84848db9-118f-4390-b78f-e0b308c9a192"
      decimals="INF"
      id="F_982ed2f6-6cb5-437e-b88f-e7a2b5fe34cd"
      unitRef="U_shares">6203020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be46b2fc-cc15-436c-aee3-78300a1a3a6d"
      decimals="INF"
      id="F_7b298e2c-493f-4980-b07e-c3cbb072eb4f"
      unitRef="U_shares">454200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0c2905bb-8931-4e2d-a1ca-b467daa53be4"
      decimals="INF"
      id="F_bfa01e22-d05a-47cf-aeea-00bd681abbcf"
      unitRef="U_shares">197580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="INF"
      id="F_6c28592e-a983-4ee1-9d15-9a70ed7ec5bb"
      unitRef="U_shares">9837305</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="INF"
      id="F_deb4a4af-fbc4-4248-ad3c-bc95b8b5cfd0"
      unitRef="U_shares">6400600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_52a5c437-ef37-4cc2-baff-11db01fb0103">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; income tax expense nor benefit for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;162m limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use asset liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sec 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basis Difference IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. IRC Section 174, as modified by the Tax Cuts and Jobs Act of 2017, no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. As a result the Company capitalized such costs in its 2023 income tax provision, resulting in an increase in deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;294.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will begin to expire in 2036 if not utilized, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;287.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of California research and development tax credit carryforwards available to offset future taxable income as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  If the Company has experienced an ownership change, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation. As of December 31, 2023, the ownership change analysis has not been completed, however no material tax attributes are expected to be limited for full use &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;before their respective carryforward periods expires.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts and Israel. The tax years 2016 to 2023 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers. Additionally, the Company is currently undergoing an audit with California&#x2019;s Franchise Tax Board (FTB) regarding the apportionment of revenue for the tax year 2017 and may be obligated to make future payments to the state related to this tax year depending on the outcome of the examination. The Company is evaluating the FTB's proposal and assessing its course of action.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the federal and state research and development credits as a result of no formal research credit study performed.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adjustment based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adjustment based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c30c5b4c-624a-4475-b349-f2369cc3fa40">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_d4920332-dd11-4e9d-acc0-0d93a5341fdb"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_578e1135-5d2d-4185-94a3-e8b7496fcc32"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_dd4bd504-44ed-44a6-82dd-24e57b774da0"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_1c6d6ad9-c7c7-451a-b145-5814d50364f9"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_54e184c3-78fd-4636-b60e-3abe5a5b9889"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_f094b1dc-9fae-4eb8-9c63-2b694c8f74a2"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_0e43394d-098a-4bbf-8e0f-44e1cdee6a8c"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_4d8c6413-7963-4858-b9ed-8c23e8789f42"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_8d0e6f1e-4170-46b0-b5af-00c758e8235e"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_4db91092-f032-4ba0-a066-925d739dd85b"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_65572815-9807-4e90-bc73-c7f8dce6044c"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_1025de46-1226-459b-a047-691e9053a091"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_24e8e8aa-4ab4-45bf-808d-93f4450ccf88"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_072f92bd-4d23-493f-b1ae-942115cacea0"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_d6ed073b-904b-4a9c-a889-8d403ee90187"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_ae967139-d036-49df-b28e-ce850748c881"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_36f359d1-66f4-412c-88c0-e4dc35c3a6a4"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_c308ea68-b602-4b11-89a2-7ca74445bf3d"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_58d02c2b-7ab3-4be5-b6e6-472220ca82b1"
      decimals="-3"
      id="F_a495cbba-c70c-46bf-b60b-29ce6fa6fae0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_bcd33f2a-27fd-406a-827c-58b453fc673e"
      decimals="-3"
      id="F_e98771df-5759-4a41-9fd6-e0c06c13772b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_4e9dcfd5-0efb-4fc9-9f73-cdbf40176152">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;162m limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill Impairment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_a8b81149-0c3f-4653-b6ed-9c0fef6a5336"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_7c36fbe4-7f79-44c8-b7c6-433c8095c432"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_622d8d12-f6fd-434f-a1ee-bd707bd33aac"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_6dded7af-078c-4572-a2b0-b3ad58a23073"
      unitRef="U_pure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_1e2a91cb-1819-4680-b332-e984ec76dbcd"
      unitRef="U_pure">-0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_58c02f2f-ecfa-4bc8-9f72-f55e5bbbe198"
      unitRef="U_pure">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_a96dcc1d-b152-4f60-a975-c03dd3f96f0b"
      unitRef="U_pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_16fa261d-4ace-4cf4-b48a-4f2860664804"
      unitRef="U_pure">-0.232</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <acet:MLimitation
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="2"
      id="F_c5f48a8c-2b3c-465c-832f-12ab3d114a3f"
      unitRef="U_pure">0</acet:MLimitation>
    <acet:MLimitation
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_ce41bbf8-3c3a-4209-830b-82b63ccd0668"
      unitRef="U_pure">-0.015</acet:MLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_f0256d7f-de04-4333-a12d-e9ef1f2feb90"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_4bda6d5b-ecbf-4cbd-a9df-818d0ea03d88"
      unitRef="U_pure">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_5cbb3918-798a-4bb6-8202-aee1e3a09af3"
      unitRef="U_pure">-0.029</acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment>
    <acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="2"
      id="F_a5bbb536-e15f-4aa6-a635-e1e7c1a9ce83"
      unitRef="U_pure">0</acet:EffectiveIncomeTaxRateReconciliationGoodwillImpairment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_9e8951bd-5043-48c2-a918-cad928cd27e9"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_52bd7f83-6ec5-4299-a7cd-ea02c6a5e4e8"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="3"
      id="F_ffce8181-b76b-4f3b-8267-5eec002d2875"
      unitRef="U_pure">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="3"
      id="F_e05f8dcc-199f-4a45-abbc-0c8ffd84176c"
      unitRef="U_pure">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_26471871-898f-439a-b6ac-12d2fa604fa7">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use asset liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sec 174 Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basis Difference IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_18ea3bb3-2476-4a3c-b711-71ceb930699b"
      unitRef="U_USD">65601000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_5316668b-b868-40eb-9b6d-8c9714ec254d"
      unitRef="U_USD">68499000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_7daf5bab-32ad-425a-a1cf-bffa78a17f74"
      unitRef="U_USD">4414000</acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability>
    <acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_29b8cd1f-6c00-482d-a547-5784963949cd"
      unitRef="U_USD">5641000</acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_60199e97-1836-4b22-91ee-0dbffdad0dc0"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_290542d8-6c6d-4fe0-843d-94d00f6041d2"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_335285d2-2834-4164-a9d3-96ec902f9f6b"
      unitRef="U_USD">2285000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_6a3ee984-1081-4705-b6b5-9803beef222d"
      unitRef="U_USD">1846000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_634038cf-ef7f-48aa-9612-92d8d7d7f2d9"
      unitRef="U_USD">704000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_034cd5c5-d2b2-4140-a903-8b6a092323a1"
      unitRef="U_USD">1060000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <acet:DeferredTaxAssetsFixedAssets
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_e6ad1579-b691-43db-91e7-643d5c2ac2e1"
      unitRef="U_USD">768000</acet:DeferredTaxAssetsFixedAssets>
    <acet:DeferredTaxAssetsFixedAssets
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_467cde21-17b9-4633-a8b1-7d472f64b526"
      unitRef="U_USD">574000</acet:DeferredTaxAssetsFixedAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_2abfa51e-c2d8-4988-8f80-2ac74aa17566"
      unitRef="U_USD">1074000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_02f3e559-7a32-4fd2-9746-d325ea48c3ec"
      unitRef="U_USD">1480000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <acet:Sec174CapitalizedRD
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_276386bc-9ffa-4b35-9693-0e5b7eb72a09"
      unitRef="U_USD">27871000</acet:Sec174CapitalizedRD>
    <acet:Sec174CapitalizedRD
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_7d21a204-2656-4e39-88cf-1afae86418f8"
      unitRef="U_USD">15803000</acet:Sec174CapitalizedRD>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_e1281dc0-fc5d-4d06-9bad-964e03e28e6e"
      unitRef="U_USD">26000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_8f099297-eddc-4a7c-aab5-68838dd74a14"
      unitRef="U_USD">28000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_aac7f75b-3c9f-4299-a591-3b7700445fc3"
      unitRef="U_USD">102745000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_119c82a1-db43-4ae5-a352-8651f301e5aa"
      unitRef="U_USD">94928000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_61ee369d-b588-455c-96f1-96c3677d1a4b"
      unitRef="U_USD">99069000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_fc701ae1-8c54-4ccf-b38a-1b6cbc98e37f"
      unitRef="U_USD">89490000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_fd883db6-f411-4708-86ba-c31dab85610a"
      unitRef="U_USD">3676000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_82658894-1f87-455d-ae84-166c9966ab13"
      unitRef="U_USD">5439000</us-gaap:DeferredTaxAssetsNet>
    <acet:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_92c9e49f-579e-40ff-876c-edc85025e01b"
      unitRef="U_USD">0</acet:DeferredTaxLiabilitiesFixedAssets>
    <acet:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_665cab43-911d-4253-a583-06e93bf6b6ef"
      unitRef="U_USD">0</acet:DeferredTaxLiabilitiesFixedAssets>
    <acet:DeferredTaxBasisDifferenceIPRD
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_303d38a4-0417-42c6-a345-fc8655a17412"
      unitRef="U_USD">0</acet:DeferredTaxBasisDifferenceIPRD>
    <acet:DeferredTaxBasisDifferenceIPRD
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_3e6a1d64-6df1-4a0e-9665-0b9314d6675a"
      unitRef="U_USD">0</acet:DeferredTaxBasisDifferenceIPRD>
    <acet:DeferredTaxOperatingLeaseRightOfUseAsset
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_4480f10b-39dc-4479-8867-72a80f3c7a36"
      unitRef="U_USD">-3676000</acet:DeferredTaxOperatingLeaseRightOfUseAsset>
    <acet:DeferredTaxOperatingLeaseRightOfUseAsset
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_996b0079-0811-4814-aa9a-059c322f47ca"
      unitRef="U_USD">-5439000</acet:DeferredTaxOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_cae59781-0c64-4e21-9702-b9b560dc9861"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_ca6ba3ac-9db3-4a8b-a9c8-9b55e21828bb"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <acet:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-5"
      id="F_97c8d497-8a6b-4921-b7be-cf2811ec2621"
      unitRef="U_USD">9600000</acet:DeferredTaxAssetsValuationAllowanceIncrease>
    <acet:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-5"
      id="F_fa16ff58-4a58-4e64-ae1f-84b2679bcc2a"
      unitRef="U_USD">16300000</acet:DeferredTaxAssetsValuationAllowanceIncrease>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914"
      decimals="-5"
      id="F_138c7da5-7ac4-4725-8d99-2d2da0bb7947"
      unitRef="U_USD">294800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_36cb52c2-306e-4caa-b3ac-f865a14de66a"
      decimals="-5"
      id="F_4ff0dd16-ed57-43d1-936b-07801c1a2d43"
      unitRef="U_USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ebaf029a-2dfd-4e74-9c11-5aaa7f157e14"
      decimals="-5"
      id="F_34ac8196-50ae-4e39-b93c-ae537403b2f1"
      unitRef="U_USD">16100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914"
      decimals="-5"
      id="F_0744e4d6-d148-4a52-9590-9041f7eecfb5"
      unitRef="U_USD">7500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acet:OperatingLossCarryforwardsIndefinitely
      contextRef="C_3230b6d3-1bf9-4181-a9f1-7031157a8914"
      decimals="-5"
      id="F_c517da68-d22f-458d-8924-9d8166c5fb74"
      unitRef="U_USD">287300000</acet:OperatingLossCarryforwardsIndefinitely>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0"
      decimals="-5"
      id="F_f30b300c-ccf2-4818-b80e-5c93a1af2d03"
      unitRef="U_USD">11300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d5315a26-1d42-4c2a-88a8-f9074dbbcfc7"
      decimals="-5"
      id="F_a9c34ce0-d6ec-4794-bb34-dd14c4888727"
      unitRef="U_USD">6400000</us-gaap:TaxCreditCarryforwardAmount>
    <acet:OwnershipChangePlanDescription
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_6c159000-a667-4be9-8b74-fbb1df252c21">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period.</acet:OwnershipChangePlanDescription>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_017e9e60-0f49-41f5-a465-41847cfbef4a"
      decimals="-5"
      id="F_d55c2a96-9087-465b-9226-d2423e985728"
      unitRef="U_USD">800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_cc989fe6-e502-4861-bd3a-7eea8aaba2c0"
      decimals="-5"
      id="F_ed46bc69-27a8-4812-9984-395ecacbefa5"
      unitRef="U_USD">17700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_3af2629e-0baa-489a-9ddd-7e7f35672538">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adjustment based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adjustment based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_4663ef72-cd00-4206-9f26-b614ddd8be74"
      unitRef="U_USD">9759000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_119167b2-4bd2-41bc-bc2b-7272a38298f7"
      decimals="-3"
      id="F_25193600-792b-47da-8b45-acc5d79945f1"
      unitRef="U_USD">4040000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_25306f78-d007-4ee5-8cec-1dcb88936cdf"
      unitRef="U_USD">5000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_a63dc3c5-2546-45b2-992a-89c93937742a"
      unitRef="U_USD">2000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-3"
      id="F_97b6271c-cc90-4641-802a-a3f482dbdc39"
      unitRef="U_USD">8698000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-3"
      id="F_501e6810-dc87-428a-8185-18fe3b6611d8"
      unitRef="U_USD">5721000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-3"
      id="F_32be0ae5-6d9b-426e-8571-c704d5dcfede"
      unitRef="U_USD">18462000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-3"
      id="F_244f47c3-7a97-45f2-b4e3-7f519e03c22a"
      unitRef="U_USD">9759000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_0adc0309-42f7-4702-8481-9f1f5ddeb255">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Regeneron owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;883,568&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing which was subsequently converted into common stock. For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; revenue from the Regeneron Agreement. See Note 8 for a discussion of the Regeneron Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_10e00936-04f7-40bc-8922-30c108c241ea"
      decimals="0"
      id="F_d7f4aac5-afe6-4cf7-8e50-40901e5c1b6d"
      unitRef="U_shares">883568</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_35dbf7eb-611d-41ce-bc2e-0e3d1326329f"
      decimals="-3"
      id="F_7e8a3478-c9da-4647-bf21-b703cce3cb55"
      unitRef="U_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_e45aaa00-c79a-478f-9c36-d27bdcc54ada">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. Defined Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, the Company made aggregate matching contributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      decimals="-5"
      id="F_2bda7b6f-0942-47d5-a227-fbde61ed4915"
      unitRef="U_USD">1200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_6266d910-cfeb-4c96-8052-2f53133c7cdb"
      decimals="-5"
      id="F_c1c5aeed-f9c2-4805-b54e-e9de12c91731"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_c2e5758d-c205-4b9b-97ee-5576f137dec8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;16. Goodwill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the annual goodwill impairment analysis performed during the fourth quarter of 2022, the Company determined that the fair value of its sole reporting unit exceeded its book value, and therefore &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; goodwill impairment charge was recorded in 2022. During the first and second quarters of 2023, the Company concluded that no events or changes in circumstances had occurred that indicated goodwill was more likely than not impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the third quarter of 2023, the Company experienced a significant decline in its stock price. As of September 30, 2023, the Company&#x2019;s stock price declined &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% from its closing stock price on June 30, 2023, and the decline in stock price was sustained. The Company determined that this decline in stock price and market capitalization of the Company constituted a substantive change in circumstances that would more likely than not reduce the fair value of the Company&#x2019;s single reporting unit below its carrying amount. Accordingly, the Company tested its goodwill for impairment as of September 30, 2023 (the Interim Testing Date).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In determining the fair value of the Company&#x2019;s sole reporting unit for the interim impairment analysis as of the Interim Testing Date, the Company used a market-based approach, and the primary input in this approach was a quoted market price in an active market. To determine the estimated fair value of the Company&#x2019;s single reporting unit, the Company calculated its market capitalization based on its stock price. Based on the Company&#x2019;s interim impairment analysis as of the Interim Testing Date, the carrying value of the Company&#x2019;s single reporting unit exceeded its fair value. Accordingly, step two of the goodwill impairment test was performed. In performing step two of the goodwill impairment test, the Company utilized observable inputs and concluded that an impairment charge was necessary for the full amount of goodwill. As a result of the step two evaluation, the Company recorded a goodwill impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the three month period ended September 30, 2023. This impairment charge reduced the balance of goodwill to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_434acfa3-e4d8-4b84-a0b0-ce406b8f1bda"
      decimals="-6"
      id="F_e6f9e44e-a9c6-4d68-b1d6-a4bad8785a0f"
      unitRef="U_USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <acet:StockPriceDecrease
      contextRef="C_9a1f48c1-61ea-48ac-83cf-0496c0da44fb"
      decimals="2"
      id="F_a59ed779-4cdb-4e51-8d93-37bf81a37e51"
      unitRef="U_pure">0.44</acet:StockPriceDecrease>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_1127a611-ccab-4753-9b4a-ad14202f612e"
      decimals="-5"
      id="F_65bea098-5ec4-4a59-8b78-4ebce3b9cd37"
      unitRef="U_USD">19500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="C_734eb96f-caad-4eb8-9771-349750199d0f"
      decimals="-6"
      id="F_5e35c9ad-c544-42d7-8290-2030f5dad4d6"
      unitRef="U_USD">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_a9b5d182-d438-4385-8651-fad8f690a69d"
      id="F_426c20fb-561c-4743-8b38-ccc80332ad8c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATM Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were issued in a series of sales in accordance with the ATM Program, at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting sales agent commissions, but before deducting any expenses related to such sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Underwritten Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 22, 2024, Adicet entered into an Underwriting Agreement (the Underwriting Agreement) with Jefferies LLC and Guggenheim Securities, LLC (the Underwriters) related to an underwritten public offering (the Offering) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,054,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares (the Shares) of common stock of the Company, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (the Common Stock), and, in lieu of Common Stock to an investor, pre-funded warrants (the Pre-Funded Warrants) to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,445,333&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Common Stock (the Warrant Shares). The Shares were sold at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and the Pre-Funded Warrants were sold at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per underlying share, which represents the per share public offering price of each share of common stock minus the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share exercise price for each pre-funded warrant. The purchase price paid by the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Underwriters &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;to the Company was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.256&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2559&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Pre-Funded Warrant, representing a discount to the Underwriters of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. In addition, the Company granted the Underwriters an option exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days from the date of the Underwriting Agreement to purchase, at the public offering price less underwriting discounts and commissions, up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,325,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Common Stock. On January 23, 2024, the Underwriters exercised this option in full. The Company received net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses, of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8b748401-3bad-4b8b-a340-f66ff9129682"
      decimals="INF"
      id="F_abd0cad6-1a25-4191-8c8d-c62c25d3bb60"
      unitRef="U_shares">6350000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8b748401-3bad-4b8b-a340-f66ff9129682"
      decimals="2"
      id="F_f316112d-3120-497e-bad4-856d2b3ed66c"
      unitRef="U_USDollarShare">3.13</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_941f1480-af5e-406b-8c0f-c6265ac70511"
      decimals="-5"
      id="F_a29b772d-f7f1-45c7-8d30-8cdf0f1cd646"
      unitRef="U_USD">19300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119"
      decimals="INF"
      id="F_2644e0ca-0d2d-48c8-bcd3-861e0f737f22"
      unitRef="U_shares">27054667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2b3a4007-846a-4910-997b-c91ad41987d4"
      decimals="4"
      id="F_962307c5-5df7-4032-9c4b-3fdecd96b376"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119"
      decimals="INF"
      id="F_b15ea346-317d-400e-9db1-881938fcd5d1"
      unitRef="U_shares">8445333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c44f0175-bd7e-48ad-9e8c-fa5116a69119"
      decimals="2"
      id="F_6661593d-512f-4a59-8a0f-d771c501eff1"
      unitRef="U_USDollarShare">2.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4"
      decimals="4"
      id="F_bd2171db-864a-4038-819f-3cde3d56cf9b"
      unitRef="U_USDollarShare">2.3999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_06b4ae69-f76e-476a-824f-b50f46053d25"
      decimals="4"
      id="F_9fa9436d-56dd-4297-a4d9-4b04ee133cc7"
      unitRef="U_USDollarShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ac9c8951-310f-4055-8d6a-dd9b592bf973"
      decimals="3"
      id="F_2fa696e8-e95b-4615-b704-5541fa09dad1"
      unitRef="U_USDollarShare">2.256</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4"
      decimals="4"
      id="F_a6a6e839-7223-4dc3-b696-269b6218a244"
      unitRef="U_USDollarShare">2.2559</us-gaap:SharesIssuedPricePerShare>
    <acet:DiscountOnUnderwritersWarrant
      contextRef="C_f44dae87-630e-4f43-926e-3a7d2b0185c4"
      decimals="3"
      id="F_e08e5dcc-9dee-4634-b310-f9b9bc40eea1"
      unitRef="U_pure">0.06</acet:DiscountOnUnderwritersWarrant>
    <us-gaap:UnderwritingCommitments
      contextRef="C_11fc1a2e-6bbc-4957-8f50-7b077832e3e6"
      id="F_0fc7fd52-4b4a-4bd1-9f56-75a93b717315">30</us-gaap:UnderwritingCommitments>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_10c7a5a5-e785-4aa8-b13b-b70c7914a426"
      decimals="INF"
      id="F_897531d6-7f2f-40a5-a1a0-8feca14524de"
      unitRef="U_shares">5325000</us-gaap:CommonStockSharesIssued>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="C_8b4a7d79-358a-4bf6-8b1a-17f8afc3527a"
      decimals="-5"
      id="F_74066459-ac2f-43a2-aca8-eebab634bbd8"
      unitRef="U_USD">91800000</us-gaap:NoninterestExpenseOfferingCost>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_fad817cb-52dd-4a37-aa97-a437d3c1006a"
          xlink:label="F_fad817cb-52dd-4a37-aa97-a437d3c1006a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"
          xlink:label="F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8b6ff166-6c4e-465a-adf4-cc3169cf1789"
          xlink:label="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a4cf4f7d-863d-4f43-b627-e3f1271563ae"
          xlink:label="F_a4cf4f7d-863d-4f43-b627-e3f1271563ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_eb235763-2049-4536-89f0-a95a1e624a98"
          xlink:label="F_eb235763-2049-4536-89f0-a95a1e624a98"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_162cb483-d00e-4d08-84e7-64fe8ccb19fc"
          xlink:label="F_162cb483-d00e-4d08-84e7-64fe8ccb19fc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_32cc67c2-c20b-4110-8ee5-573adde35339"
          xlink:label="F_32cc67c2-c20b-4110-8ee5-573adde35339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"
          xlink:label="F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"
          xlink:type="locator"/>
        <link:footnote id="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f" xlink:label="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents in the consolidated balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fad817cb-52dd-4a37-aa97-a437d3c1006a"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a4cf4f7d-863d-4f43-b627-e3f1271563ae"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_eb235763-2049-4536-89f0-a95a1e624a98"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_162cb483-d00e-4d08-84e7-64fe8ccb19fc"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_32cc67c2-c20b-4110-8ee5-573adde35339"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"
          xlink:to="FNT_2b5f6c65-ea44-4781-a1f8-3b455054da4f"
          xlink:type="arc"/>
        <link:footnote id="FNT_b8155da4-ace1-4e3d-9591-49c7404454de" xlink:label="FNT_b8155da4-ace1-4e3d-9591-49c7404454de" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treasury securities are included within Level 1 of the fair value hierarchy because they are actively traded and valued using quoted market prices.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6c4727fd-ddb3-437a-9f91-8f6d7cf195b6"
          xlink:to="FNT_b8155da4-ace1-4e3d-9591-49c7404454de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fad817cb-52dd-4a37-aa97-a437d3c1006a"
          xlink:to="FNT_b8155da4-ace1-4e3d-9591-49c7404454de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_32cc67c2-c20b-4110-8ee5-573adde35339"
          xlink:to="FNT_b8155da4-ace1-4e3d-9591-49c7404454de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_162cb483-d00e-4d08-84e7-64fe8ccb19fc"
          xlink:to="FNT_b8155da4-ace1-4e3d-9591-49c7404454de"
          xlink:type="arc"/>
        <link:footnote id="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1" xlink:label="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_66bfc669-7f11-4299-bdfe-2fa260b91fd3"
          xlink:to="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_eb235763-2049-4536-89f0-a95a1e624a98"
          xlink:to="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8b6ff166-6c4e-465a-adf4-cc3169cf1789"
          xlink:to="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a4cf4f7d-863d-4f43-b627-e3f1271563ae"
          xlink:to="FNT_85994e57-99b0-417a-8409-2d0d53c37bf1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6"
          xlink:label="F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6"
          xlink:type="locator"/>
        <link:footnote id="FNT_d612eae3-79b2-4c1e-bffb-1fef370f9dab" xlink:label="FNT_d612eae3-79b2-4c1e-bffb-1fef370f9dab" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a5bcf563-0fd0-472b-89bd-3dc86e9773c6"
          xlink:to="FNT_d612eae3-79b2-4c1e-bffb-1fef370f9dab"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
